# EDGAR Filing Document

**Accession Number:** 0002112446
**File Stem:** 0001213900-26-039468
**Filing Date:** 2026-4
**Character Count:** 1666649
**Document Hash:** 27fe0b6a17da9f07cb61645eb050282a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-039468.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001213900-26-039468

**CONFORMED SUBMISSION TYPE**: S-1/A

**PUBLIC DOCUMENT COUNT**: 50

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JATT II Acquisition Corp.
- **CENTRAL INDEX KEY:** 0002112446
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294294
- **FILM NUMBER:** 26835138

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD
- **STREET 2:** 71 FORT STREET, PO BOX 500
- **CITY:** GEORGE TOWN
- **NON US STATE TERRITORY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-1106
- **BUSINESS PHONE:** 201-688-0364

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD
- **STREET 2:** 71 FORT STREET, PO BOX 500
- **CITY:** GEORGE TOWN
- **NON US STATE TERRITORY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-1106

?xml version='1.0' encoding='ASCII'?

**As filed with the Securities and Exchange Commission on April 2, 2026.**

**Registration No. 333-294294**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**AMENDMENT NO. 1**

**TO**

**FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**JATT II ACQUISITION CORP (Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **6770** | **N/A** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(Primary Standard Industrial<br> Classification Code Number)** | **(I.R.S. Employer<br> Identification Number)** |

---

**153 Central Avenue C/O 56 Westfield, NJ 07091 201-688-0364 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Nicholas Fernandez Chief Financial Officer 153 Central Avenue C/O 56 Westfield, NJ 07091 201-688-0364 (Name, address, including zip code, and telephone number, including area code, of agent for service)**

**Copies to:**

**Alexandra Low**

**Appleby (Cayman) Ltd.**

**60 Nexus Way, 9<sup>th</sup> Floor**

**Camana Bay, Grand Cayman**

**Cayman Islands**

**KY1-9009**

**(345) 949-4900**

---

| | |
|:---|:---|
| **Mitchell S. Nussbaum**<br> **Giovanni Caruso<br> Loeb & Loeb LLP<br> 345 Park Avenue<br> New York, NY 10154<br> (212) 407-4000** | **Derek Dostal<br> Pedro Bermeo<br> Davis Polk & Wardwell LLP<br> 450 Lexington Avenue<br> New York, NY 10017<br> (212) 450-4000** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.**

**The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.**

**SUBJECT TO COMPLETION, DATED APRIL 2, 2026**

**PRELIMINARY PROSPECTUS**

**$60,000,000**

**JATT II ACQUISITION CORP**

**6,000,000 Ordinary Shares**

JATT II Acquisition Corp is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to as our initial business combination (the "Company"). We will have (i) 24 months from the closing of this offering or such earlier date as our board of directors may approve, or (ii) such other time period pursuant to an amendment to our articles to complete our initial business combination (such period, the "completion window"). We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us.

This is an initial public offering of our ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price of $10.00. The underwriters have a 45-day option from the date of this prospectus to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any. Unlike certain other special purpose acquisition company initial public offerings ("SPAC IPOs"), investors in this offering will not receive warrants that would become exercisable following completion of our initial business combination.

We will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares that were sold as part of this offering, which we refer to collectively as our public shares, in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account described below as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. As further described in this prospectus, our articles provide that a public shareholder, together with any affiliate or any other person with whom such shareholder is acting in concert or as a "group" (as defined under Section 13 of the Securities Exchange Act of 1934, as amended, the "Exchange Act"), will be restricted from redeeming its public shares with respect to more than an aggregate of 20% of the public shares sold in this offering, without our prior consent. Each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against an initial business combination, or whether they do not vote or abstain from voting on the initial business combination, and regardless of whether they hold public shares on the record date established in connection with our initial business combination.

If we are unable to complete our initial business combination within the completion window, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain limitations and on the conditions as further described herein. We may seek shareholder approval to amend our articles to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension.

Our sponsor, JATT Ventures II L.P., a Cayman Islands exempted limited partnership formed for the purpose of investing in us (the "sponsor"), acting by its general partner, JATT Ventures II Ltd, has committed to purchase an aggregate of 300,000 ordinary shares (or 309,000 shares if the underwriters' over-allotment option is exercised in full), at a price of $10.00 per share in a private placement for an aggregate purchase price of $3,000,000 in the aggregate (or $3,090,000 if the underwriters' over-allotment option is exercised in full), that will close simultaneously with the closing of this offering. These ordinary shares, which we refer to as the private placement shares, are identical to the ordinary shares sold in this offering, subject to certain limited exceptions as described in this prospectus.

AI Biotechnology LLC ("AI Biotechnology"), an affiliate of Access Industries, Inc., has indicated an interest to purchase up to an aggregate of $30,000,000 of our ordinary shares in a private placement that would occur concurrently with the consummation of our initial business combination. However, because indications of interest are not binding agreements or commitments to purchase, AI Biotechnology may ultimately elect to purchase more, fewer or no shares. We are also under no obligation to sell any shares to AI Biotechnology. As such, there can be no assurance that AI Biotechnology will acquire any shares in connection with our initial business combination or otherwise. Any investment by AI Biotechnology or its affiliated entities and persons would be made on terms and conditions determined at the time of the business combination and may be different from the terms and conditions on which shares are sold to other investors in any private placement.

Our initial shareholders, which include our sponsor, currently own an aggregate of 1,725,000 ordinary shares (the "founder shares"), up to 225,000 of which will be surrendered to us for no consideration after the closing of this offering depending on the extent to which the underwriters' over-allotment option is exercised. **See the sections entitled "*Summary — Our Sponsor*" on page 10, "*Summary — The Offering — Founder shares*" on page 15, "*Summary — The Offering — Voting*" on page 17, "*Risk Factors — Risks Relating to our Search for, and Consummation of, or Inability to Consummate, a Business Combination — The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares and the amount of deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us*" on page 38, "*Risk Factors — Risks Relating to our Search for, and Consummation of, or Inability to Consummate, a Business Combination* on page 37, "*Dilution*" on page 81 and "*Proposed Business — Our Sponsor*" on page 100 for more information.**

Because our sponsor acquired the founder shares at a nominal price of $25,000, or approximately $0.014 per share, our public shareholders will incur an immediate and material dilution upon the closing of this offering. Our public shareholders may experience additional dilution if we increase the size of the offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act") and effect with our sponsor a share dividend or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering. **See the section titled "*Risk Factors — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the business combination causes the trading price of our ordinary shares to materially decline.*"** Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor. We will also pay our sponsor for officer compensation and administrative services provided to members of our management team an amount equal to $20,000 per month. Our sponsor may loan us up to $300,000 under an unsecured, non-interest bearing promissory note for offering-related and organizational expenses. The loan is due at the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $900,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions. Our sponsor or an affiliate of our sponsor or certain of our officers and directors may loan us funds to finance transaction costs in connection with an intended initial business combination. Up to $1,500,000 of such loans may be convertible into private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender. The issuance of such shares may result in material dilution to our public shareholders. **See the section titled "*Summary — Our Sponsor*" for more information regarding, among other things, the amount of compensation and securities received or to be received by our sponsor, its affiliates and our officers and directors.**

The following table illustrates the difference between the public offering price and our net tangible book value per share, as adjusted to reflect various potential redemption levels that may occur in connection with the closing of our initial business combination, which we refer to as Adjusted NTBVPS, on a pro forma basis to give effect to this offering and the issuance of the private placement shares, assuming no exercise of the over-allotment option and exercise of the over-allotment option in full. Adjusted NTBVPS excludes the effect of the consummation of our initial business combination or any related transactions or expenses. **See the section titled "*Dilution*" for more information.**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** | **As of February 13, 2026** |
| **Offering <br> Price of <br> $10.00, <br> No <br> Redemptions** | **25% of Maximum <br> Redemptions** | **25% of Maximum <br> Redemptions** | **50% of Maximum <br> Redemptions** | **50% of Maximum <br> Redemptions** | **75% of Maximum <br> Redemptions** | **75% of Maximum <br> Redemptions** | **Maximum <br> Redemptions** | **Maximum <br> Redemptions** |
| **Adjusted<br> NTBVPS** | **Adjusted <br> NTBVPS** | **Difference <br> between <br> adjusted <br> NTBVPS <br> and <br> Offering <br> Price** | **Adjusted <br> NTBVPS** | **Difference <br> between <br> adjusted <br> NTBVPS <br> and <br> Offering <br> Price** | **Adjusted <br> NTBVPS** | **Difference <br> between <br> adjusted <br> NTBVPS <br> and <br> Offering <br> Price** | **Adjusted <br> NTBVPS** | **Difference <br> between <br> adjusted <br> NTBVPS <br> and <br> Offering <br> Price** |
| Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option | Assuming Full Exercise of Over-Allotment Option |
| $7.66 | $7.10 | $2.90 | $6.19 | $3.81 | $4.44 | $5.56 | $(0.28) | $10.28 |
| Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option | Assuming No Exercise of Over-Allotment Option |
| $7.65 | $7.09 | $2.91 | $6.18 | $3.82 | $4.44 | $5.56 | $(0.19) | $10.19 |

---

Members of our management team and board of directors will directly or indirectly own founder shares and/or private placement shares following this offering and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Further, each of our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors were to be included by a target business as a condition to any agreement with respect to our initial business combination. The low price that our sponsor, executive officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. If we are unable to complete our initial business combination within the completion window, the founder shares may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. Additionally, each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to another entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, there may be actual or potential material conflicts of interest between our sponsor, its affiliates or promoters on the one hand, and the investors in this offering on the other hand. **See the sections titled "*Proposed Business — Sourcing of Potential Business Combination Targets*" and "*Management — Conflicts of Interest*."**

Of the gross proceeds we receive from this offering and the sale of the private placement shares described in this prospectus, $60,000,000, or $69,000,000 if the underwriters' over-allotment option is exercised in full ($10.00 per share in either case), after deducting $600,000 in underwriting discounts and commissions payable upon the closing of this offering (or $690,000 if the underwriters' over-allotment option is exercised in full) and an aggregate of approximately $900,000 to pay fees and expenses in connection with the closing of this offering and approximately $1,500,000 for working capital following the closing of this offering, will be deposited into a trust account located in the United States with Continental Stock Transfer & Trust Company acting as trustee and held only (i) uninvested as cash, (ii) in an interest-bearing or non-interest bearing demand deposit account at a U.S. chartered commercial bank with consolidated assets of $100 billion or more selected by the trustee that is reasonably satisfactory to us, or (iii) invested only in U.S. government securities, within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the "Investment Company Act") with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations. To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer we hold investments in the trust account, we may, at any time, instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account uninvested in cash or in an interest-bearing or non-interest-bearing demand deposit account. **For more information about the risk of the company being considered to be operating as an unregistered investment company, see "*Risk Factors — Risks Relating to our Search for, Consummation of, or Inability to Consummate, a Business Combination — If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination or force us to abandon our efforts to complete an initial business combination*."**

Currently, there is no public market for our ordinary shares. We intend to apply to have our shares listed on The Nasdaq Global Market, or Nasdaq, under the symbol "JATT". We expect that our shares will be listed on Nasdaq on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq.

**We are an "emerging growth company" and a "smaller reporting company" under applicable federal securities laws and will be subject to reduced public company reporting requirements. Investing in our securities involves a high degree of risk. See "Risk Factors" beginning on page 37 for a discussion of information that should be considered in connection with an investment in our securities. Investors will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings.**

**Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. No offer or invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities.**

---

| | | |
|:---|:---|:---|
|  | **PER SHARE** | **TOTAL** |
| Public offering price | $10.00 | $60000000 |
| Underwriting discounts and commissions<sup>(1)</sup> | $0.40 | $2400000 |
| Proceeds, before expenses, to us | $9.60 | $57600000 |

---

(1) Includes $0.10 per share, or $600,000 in the aggregate (or
$690,000 if the underwriters' over-allotment option is exercised in full), payable to the underwriters upon the closing of this
offering. Also includes $0.30 per share, or $1,800,000 in the aggregate (or up to $2,070,000 in the aggregate if the underwriters'
over-allotment option is exercised in full) payable to the underwriters for deferred underwriting commissions to be placed in a trust
account located in the United States and released to the underwriters only upon the completion of an initial business combination.
See also "Underwriting" for a description of compensation and other items of value payable to the underwriters.

The underwriters are offering the ordinary shares for sale on a firm commitment basis. The underwriters expect to deliver the shares to the purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2026.

 

*Sole Bookrunning Manager*

**Guggenheim Securities**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2026

**TABLE OF CONTENTS** 

---

| | |
|:---|:---|
|  | **Page** |
| [SUMMARY](#a_001) | 1 |
| [THE OFFERING](#a_002) | 15 |
| [SUMMARY FINANCIAL DATA](#a_004) | 36 |
| [RISK FACTORS](#a_005) | 37 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#a_006) | 76 |
| [USE OF PROCEEDS](#a_007) | 77 |
| [DIVIDEND POLICY](#a_008) | 80 |
| [DILUTION](#a_009) | 81 |
| [CAPITALIZATION](#a_010) | 84 |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_011) | 85 |
| [PROPOSED BUSINESS](#a_012) | 91 |
| [EFFECTING OUR INITIAL BUSINESS COMBINATION](#a_013) | 104 |
| [MANAGEMENT](#a_014) | 120 |
| [PRINCIPAL SHAREHOLDERS](#a_015) | 129 |
| [CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS](#a_016) | 131 |
| [DESCRIPTION OF SECURITIES](#a_017) | 133 |
| [TAXATION](#a_018) | 150 |
| [UNDERWRITING](#a_019) | 159 |
| [LEGAL MATTERS](#a_020) | 169 |
| [EXPERTS](#a_021) | 169 |
| [WHERE YOU CAN FIND ADDITIONAL INFORMATION](#a_022) | 169 |
| [INDEX TO FINANCIAL STATEMENTS](#a_023) | F-1 |

---

We have not, and the underwriters have not, authorized anyone to provide you with information that is different from or inconsistent with that contained in this prospectus. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus.

i

**Summary**

 

*This summary only highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all of the information that you should consider in making an investment decision. You should read this entire prospectus carefully, including the information under "Risk Factors" and our financial statements and the related notes included elsewhere in this prospectus, before investing.*

 

*Unless otherwise stated in this prospectus or the context otherwise requires, references to:*

● *"we," "us," "company" or "JATT II" are to JATT II Acquisition Corp, a Cayman Islands exempted company;* 

● *"articles" are to our amended and restated memorandum and articles of association;* 

● *"Companies Act" are to the Companies Act (As Revised) of the Cayman Islands as the same may be amended from time to time;* 

● *completion window" are to (i) the period ending on the date that is 24 months from the closing of this offering, or such earlier liquidation as our board of directors may approve, in which we must complete an initial business combination or (ii) such other time period in which we must complete an initial business combination pursuant to an amendment to our articles;* 

● *"directors" are to our current directors and director nominees;* 

● *"equity-linked securities" are to any debt or equity securities that are convertible, exercisable or exchangeable for our ordinary shares issued in a financing transaction in connection with our initial business combination, including, but not limited to, a private placement of equity or debt;* 

● *"founder shares" are to our ordinary shares initially purchased by our sponsor in a private placement prior to this offering (for the avoidance of doubt, such ordinary shares will not be "public shares");* 

● *initial shareholders" are to our sponsor and any other holders of our founder shares immediately prior to this offering;* 

● *"Guggenheim Securities" are to Guggenheim Securities, LLC, the representative of the underwriters in this offering;* 

● *"management" or our "management team" are to our officers and directors;* 

● *"ordinary resolution" are to a resolution of the company passed by a simple majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the company, or a resolution approved in writing by all of the holders of the issued shares entitled to vote on such matter (or such lower threshold as may be allowed under the Companies Act from time to time and pursuant to our articles);* 

● *"ordinary shares" are to our ordinary shares, par value $0.0001 per share;* 

● *"public shares" are to ordinary shares sold in this offering (whether they are purchased in this offering or thereafter in the open market);* 

● *"public shareholders" are to the holders of our public shares, including our initial shareholders, management team and advisors to the extent our initial shareholders, members of our management team and/or advisors purchase public shares; provided that each initial shareholder's, members of our management team's and advisor's status as a "public shareholder" will only exist with respect to such public shares;* 

 

*●* *"private placement shares" are to the ordinary shares to be issued to our sponsor in a private placement simultaneously with the closing of this offering (which private placement shares are identical to the shares sold in this offering, subject to certain limited exceptions as described in this prospectus) and upon conversion of working capital loans, if any; and* 

*●* *"special resolution" are to a resolution of the company passed by at least a two-thirds (2/3) majority (or such higher approval threshold as specified in our amended and restated memorandum and articles of association) of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the company of which notice specifying the intention to propose the resolution as a special resolution has been duly given, or a resolution approved in writing by all of the holders of the issued shares entitled to vote on such matter (or such lower threshold as may be allowed under the Companies Act from time to time and pursuant to our articles);* 

● *"sponsor" are to JATT Ventures II L.P., a Cayman Islands limited liability company .* 

Any forfeiture of shares, and all references to forfeiture of shares, described in this prospectus shall take effect as a surrender of shares for no consideration as a matter of Cayman Islands law. Any share dividend described in this prospectus will take effect as a share capitalization as a matter of Cayman Islands law.

Unless we state otherwise, the information in this prospectus assumes that the underwriters will not exercise their over-allotment option.

**GENERAL**

We are a blank check company incorporated on January 13, 2026, as a Cayman Islands exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to our initial business combination.

While we may pursue an initial business combination in any business or industry, we intend to focus our search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, we intend to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of our management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. We expect to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process.

Our sponsor, JATT Ventures II L.P., is a Cayman Islands exempted limited partnership, which was formed to invest in us and is acting by its general partner, JATT Ventures II Ltd. Although our sponsor is permitted to undertake any activities permitted under the Limited Liabilities Partnership Act (As Revised) and other applicable law, our sponsor's business is focused on investing in us and directly or indirectly providing office space and administrative services to members of our management team. As of the date of this prospectus, JATT Ventures II Ltd is the sole general partner of our sponsor, and our Chairman and Chief Executive Officer, Dr. Someit Sidhu is a limited partner of our sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd.

**OUR MANAGEMENT TEAM**

Our management team is led by Dr. Someit Sidhu, our Chairman and Chief Executive Officer, and Mr. Nicholas Fernandez, our Chief Financial Officer, each of whom has significant experience building, operating and investing in the life sciences and medical technology sectors globally. They will be supported by a team of investment professionals and support resources as further described below. We believe our management team has complementary skills and experience relevant to our business strategy, as well as significant expertise in identifying high quality companies seeking financing as a stepping stone to public markets. With significant exposure to such opportunities and deep experience in investing in both private and public life science markets, we expect to have access to a large volume of potential investment opportunities, which we believe represents a competitive advantage.

**Dr. Someit Sidhu** serves as our Chairman of the Board and Chief Executive Officer. Dr. Sidhu has broad expertise covering various topics in the life sciences industry, and is a strategy consultant and serial biotech entrepreneur in the industry. Dr. Sidhu is the founder of Khanda Therapeutics, and has served as its CEO and director since December 2025. Dr. Sidhu served as CEO and a director of JATT Acquisition Corp from its inception until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. From March 2023 to April 2024, Dr. Sidhu served as the CEO and director of Zura Bio, and has since continued to serve as director of Zura Bio. Dr. Sidhu was also a co-founder of Izana Bioscience and served as its CEO from November 2017 until its eventual sale to Roivant in June 2020. He is also Co-founder of Pathios Therapeutics and Akaza Bioscience and has served as its CEO from 2019 to 2021. Prior to these companies, Dr. Sidhu advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on Pharmaceutical R&D and Portfolio Strategy. Dr. Sidhu has also been serving as director of GSN Estate since September 2024 and as director of Invictus Bioscience since May 2016. Dr. Sidhu gained medical experience during his time in Cardiology and General Surgery after graduating from the Oxford Medical School where he was a Senior Mackinnon Scholar at Magdalen College. We believe Dr. Sidhu's extensive operational and investment experience in the life sciences industry gives him the qualifications, attributes and skills to serve as a director.

**Nicholas Fernandez** serves as our Chief Financial Officer. Mr. Fernandez has over 20 years of experience across operations, accounting and finance. Mr. Fernandez has been with Athanor Capital, a hedge fund, from December 2019 to December 2025, most recently serving as Chief Operating Officer and Chief Financial Officer. From April 2024 to November 2024, Mr. Fernandez served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of EcoBridge Capital Management. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jefferies LLC, a global bulge bracket investment bank, from February 2017 to April 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez has previously served as a director of Iris Acquisition Corp from May 2023 until its business combination with Liminatus Pharma, LLC in April 2025, and has been serving as a director of Liminatus Pharma, Inc., the post combination company since then. Mr. Fernandez has also been serving as the CFO of Amanat Acquisition Corp. since January 2026. Mr. Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr. Fernandez holds an active Certified Public Accountant License in the state of New York.

**Verender S. Badial** is a Director nominee. He has more than 20 years of experience as an investment banker and is currently Managing Director of Cryfield Investments, which he founded in 2015 and is responsible for the corporate finance services and capital fundraising activities. He also serves as Chief Executive Officer of ME Asset Management, a UK-based investment platform backed by Cryfield Investments. Mr. Badial has also served as the Chief Financial Officer of Zura Bio Limited from March 2023 to July 2025 and was previously JATT Acquisition Corp's chief financial officer since July 2021 until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. Between 1997 and 2015, Mr. Badial held executive functions in the Equity Capital Markets departments of Rothschild (ABN AMRO) and Societe Generale, allowing him to leverage rich experience in structuring and executing equity capital markets transactions as well as building up an extensive network. Mr. Badial also held the role of Managing Director with Rothschild (ABN AMRO) and Societe Generale within the investment banks and is experienced in both buy- and sell-side advisory transactions incorporating leveraged and structured equity and debt finance solutions with a key focus on financial sponsor portfolios in pharma and healthcare. Mr. Badial brings unique capabilities for the target identification and business combination processes based on his expertise from acquiring and funding numerous corporates, raising capital for M&A and IPOs coupled with significant expertise in analyzing potential financial or management improvements to operational businesses. Mr. Badial graduated with an honor's degree from the London School of Economics & Political Science. We believe Mr. Badial is qualified to serve on our board of directors because of his experience as a seasoned investment banker.

**Christopher Staral** is a Director nominee. Mr. Staral is the Founder, Managing Member, and Chief Investment Officer of Triple Helix Investments, where he brings a multidimensional background across science, public and private markets, and high-performance decision-making. Before launching Triple Helix, Mr. Staral founded and was CIO of Allostery Investments, a specialized, low-net biotech fund known for combining deep scientific research with sentiment and technical overlays, from July 2022 to August 2025. Mr. Staral previously worked as senior analyst of Laurion Capital Management, where he played a key role in building and helping lead Laurion Capital Management's private and long/short public biotech strategy, expanding the platform and driving investment across emerging and established therapeutic innovations. Prior to Laurion, Mr. Staral was an Investment Analyst at Mangrove Partners, focusing on high-conviction long and short opportunities within biotechnology. Mr. Staral began his finance career in sell-side equity research, first at Canaccord Genuity and later at Goldman Sachs. His path to investing was unconventional: raised in Minnesota and initially pursuing medicine, he ultimately gravitated to biotechnology investing because it combined his scientific interest in the complexity of human biology with the mark-to-market competition he thrived on — first as a world-class individual performer, and then by building and leading elite teams in highly competitive environments. Mr. Staral received his B.A. in Chemistry from Carleton College and attended the University of Minnesota Medical School. We believe Mr. Staral is qualified to serve on our board of directors because of his background in medicine and years of experience in finance.

**Dr. Arjun Goyal** is a Director nominee. Dr. Goyal is a life sciences investor and entrepreneur and the Founder and Managing Partner of Vianti Capital, a therapeutics-focused investment firm. Prior to founding Vianti, Dr. Goyal was a Co-Founder and Managing Director of Vida Ventures, a U.S.-based life sciences venture capital firm with over $1.7 billion in assets under management. He co-founded Vida in 2017 and departed the firm in December 2024 following multiple realized exits and the scaling of the platform. During his tenure, he served as the originating and lead partner on multiple investments, including Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck), Asklepios BioPharmaceutical (acquired by Bayer), Scorpion Therapeutics (acquired by Eli Lilly), Halda Therapeutics (acquired by Johnson & Johnson), Homology Medicines (NASDAQ: FIXX), Kinnate Therapeutics (NASDAQ: KNTE), Alterome Therapeutics, Quanta Therapeutics, and Third Arc Bio, with active governance involvement across multiple companies. Earlier in his career, from 2014 to 2017, Dr. Goyal was an investment professional at 5AM Ventures, a life sciences-focused venture firm. There, he co-led investments in companies including Aprea AB (NASDAQ: APRE), Spyryx, Pear Therapeutics, Portal Instruments, Entrada Therapeutics (NASDAQ: TRDA), and Homology Medicines (NASDAQ: FIXX), and served as a Board Observer across multiple portfolio companies. Dr. Goyal has also been serving as a director of Centessa Pharmaceuticals Plc since January 2021. Dr. Goyal trained as a physician and brings a combined clinical, scientific, and business background to his investment work. He earned his M.D. from the University of Melbourne, completed medical research training at the University of Oxford, received an M.Phil. in Bioscience Enterprise from the University of Cambridge as a Commonwealth Scholar and Gates Cambridge Scholar, and holds an MBA from Harvard Business School. He completed postgraduate medical training in Internal Medicine at the University of Sydney. He has received several professional recognitions, including the Advance Award for Technology & Entrepreneurship for Global Australians (2021) and selection as one of Australia's 25 Most Influential Global Game-Changers in Business (2026). He serves on the Board of Advisors for the MS/MBA Life Sciences Program at Harvard Business School, the American Australian Association Education Fellowship Committee, and the Investment Committee of the University of Melbourne Technology Endowment Fund. We believe Dr. Goyal is qualified to serve on our board of directors because of his experience as a life science investor.

**Dr. Jonathon Kluft** is a Director nominee. Dr. Kluft brings more than a decade of experience in biotechnology investing and investment analysis across a broad range of therapeutic areas. He currently serves as a consultant to Atika Capital Management, LLC, a healthcare, consumer and technology-focused hedge fund, and also engages in private investment activities. From April 2016 through June 2025, Dr. Kluft served as Vice President, Special Projects and, prior to that, Vice President, Investments (previously Business Development) at Roivant Sciences, where he was closely involved in the sourcing, evaluation and execution of transactions that resulted in the formation of several Roivant subsidiary companies, including Immunovant, Urovant, and Pulmovant, among others. Prior to joining Roivant, from January 2013 through April 2016, Dr. Kluft was an Analyst at Atika Capital, where he identified and presented equity investment recommendations primarily within the pharmaceutical and biotechnology sectors. Earlier in his career, Dr. Kluft served as an intern at Gilder, Gagnon, Howe & Co., an asset management firm, where he conducted due diligence on biotechnology companies. His background in biotechnology investing provides the Board with valuable perspective in evaluating potential acquisition opportunities, drug development programs and strategic transactions. Dr. Kluft received his M.D. from Columbia University College of Physicians and Surgeons in 2013 and his B.A. in Philosophy, Politics and Economics from the University of Pennsylvania in 2005.

Our management team's efforts to seek a suitable business combination target will be complemented and augmented by the expertise and network of relationships of our independent director nominees. We believe that our access to and affiliation with our independent director nominees represent a competitive advantage. We also believe that our management team's expertise will be augmented by the other members of our board of directors, which will provide extensive experience in business and financial matters. We believe Dr. Kluft is qualified to serve on our board of directors because of his decade of experience in biotechnology investing.

With respect to the foregoing experiences of our management team, past performance is not a guarantee (i) that we will be able to identify a suitable candidate for our initial business combination or (ii) of success with respect to any business combination we may consummate. You should not rely on the historical record of our management team's performance as indicative of our future performance. For more information on the experience and background of our management team, see the section entitled "*Management*."

**PRIOR SPAC EXPERIENCE**

Our management team includes executives and directors with experience sponsoring, operating and advising public life sciences companies, including special purpose acquisition companies. We believe this experience is relevant to sourcing, evaluating, negotiating and consummating a business combination and to helping a target company transition successfully to the public markets.

**JATT Acquisition Corp**

JATT Acquisition Corp ("JATT I") is a special purpose acquisition company incorporated for purposes similar to those of our company, which raised $138 million (including over-allotment) in an initial public offering of units in July 2021. JATT I was sponsored by JATT Ventures, L.P., the general partner of which is JATT Ventures Ltd. Dr. Someit Sidhu, our Chairman and Chief Executive Officer, is the limited partner of JATT Ventures, L.P. and the director and shareholder of JATT Ventures Ltd. Dr. Sidhu served as CEO and a director of JATT Acquisition Corp from its inception until JATT I completed its business combination with Zura Bio Limited ("Zura Bio") in March 2023. Mr. Verender S. Badial also served as the Chief Financial Officer of JATT I from closing of JATT I's IPO until the completion of its business combination with Zura Bio. Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura's pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura's lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. In connection with JATT I's shareholder proposal to amend its amended and restated memorandum and articles of association to extend the date by which JATT I was required to consummate a business combination, which was approved at an extraordinary general meeting held on January 12, 2023, the holders of 12,111,022 of JATT I's Class A ordinary shares, exercised their right to redeem their shares for cash at a redemption price of approximately $10.26 per share for an aggregate redemption amount of $124,226,450.64. In connection with the extraordinary general meeting to approve the business combination with Zura Bio, the holders of an additional 1,506,480 Class A ordinary shares exercised their right to redeem their shares for cash at a redemption price of approximately $10.26 per share for an aggregate redemption amount of $15,456,484.80. Prior to the Business Combination, holders of an aggregate of 13,617,502 Class A ordinary shares exercised their right to redeem their shares for cash for an aggregate redemption amount of $139,682,935.44. Following the closing, Zura Bio's Class A ordinary shares and warrants commenced trading on The Nasdaq Capital Market under the new trading symbols "ZURA" and "ZURAW," respectively, on March 21, 2023. On March 2, 2026, the closing sale price of ZURA was $6.67. As of March 2, 2026, the aggregate market capitalization of Zura Bio reflects a market value of approximately $641.4 million.

Past performance of our management team is not a guarantee that we will be able to identify a suitable target or consummate a successful business combination. You should not rely on the historical record of our management team's performance as indicative of our future performance.

For additional information regarding our management team's experience, please see the section entitled "*Management*."

**INITIAL BUSINESS COMBINATION**

**Business Strategy**

We are a team of experienced life sciences executives, investors, physicians and entrepreneurs. Our business strategy is to leverage our network of relationships, therapeutic development experience and capital markets expertise to identify and complete our initial business combination with a company in the healthcare or healthcare-related industries, with a primary focus on biotechnology and broader life sciences. We intend to target a business that is well positioned to benefit from public-market access and from the operational, strategic and financing support of our management team and board.

Our selection process will draw upon the relationships, domain expertise and sourcing capabilities of our management team and directors across the United States, Europe and other key life sciences markets. We believe we are well positioned to identify a business combination partner that can benefit from our team's experience, including:

● Experience sourcing, structuring, financing and growing biopharmaceutical businesses and therapeutic assets;

● Experience identifying differentiated science and therapeutics targeting significant unmet medical needs;

● Experience evaluating and developing underappreciated assets and platforms within private companies, academic institutions and larger biopharmaceutical organizations, including through partnerships and licenses;

● Experience in capital formation, equity capital markets, strategic transactions and the transition from private to public ownership;

● Experience supporting companies through key development, financing, partnering and commercialization inflection points.

Our team is in regular contact with entrepreneurs, physicians, scientists, key opinion leaders, management teams, investors and investment bankers across the healthcare ecosystem. We believe this network should provide access to a meaningful volume of prospective targets, including companies evaluating crossover financings, strategic transactions or alternative paths to the public markets. Upon completion of this offering, we expect to use that network to define the parameters of our search and begin an active review of potential business combination opportunities.

**Business Combination Criteria**

Our acquisition strategy seeks to leverage our team's relationships, domain knowledge and inbound opportunities to source an attractive initial business combination.

Consistent with our business strategy, we have identified the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. We intend to identify and acquire a business that exhibits many, and perhaps all, of the following characteristics:

● Rigorous science and a differentiated therapeutic or technical rationale;

● Compelling preclinical or clinical data, or a platform with the potential to generate differentiated products addressing meaningful unmet medical needs;

● The potential for data-driven or technology-enabled approaches to improve development speed, decision-making or probability of success;

● Identifiable near- or medium-term milestones that could drive value creation through scientific, clinical, regulatory, strategic or commercial progress;

● Novel technology, know-how or assets protected by robust intellectual property or other durable competitive advantages;

● Platform or portfolio potential that can support repeatable value creation through additional pipeline development or expansion;

● A management team with the experience and judgment to develop, finance, partner and, where appropriate, commercialize its programs as a public company;

● An attractive valuation relative to the quality of the science, data, management team and development opportunity; and

● A business that would benefit from public ownership and access to incremental growth capital.

These criteria and guidelines are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general criteria and guidelines as well as other considerations, factors and criteria that our management may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet one or more of the above criteria and guidelines, we will disclose that fact in our shareholder communications related to our initial business combination.

**Sourcing of Potential Business Combination Targets**

We believe our management team's significant operating and transaction experience and relationships will provide us with a substantial number of potential initial business combination targets. Over the course of their careers, the members of our management team have developed a broad network of contacts and corporate relationships around the world. This network has grown through the activities of our management team sourcing, acquiring and financing businesses, the reputation of our management team for integrity and fair dealing with sellers, financing sources and target management teams and the experience of our management team in executing transactions under varying economic and financial market conditions.

This network has provided our management team with a flow of referrals that has resulted in numerous transactions which were proprietary or where a limited group of investors were invited to participate in the sale process. We believe that the network of contacts and relationships of our management team will provide us important sources of investment opportunities. In addition, we anticipate that target business combination candidates will be brought to our attention from various unaffiliated sources, including investment market participants, private equity funds and large business enterprises seeking to divest non-core assets or divisions.

In evaluating a prospective target business, we expect to conduct a due diligence review which may encompass, among other things, meetings with incumbent management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as applicable, as well as a review of financial, operational, clinical, legal and other information about the target and its industry which will be made available to us. If we determine to move forward with a particular target, we will proceed to structure and negotiate the terms of the business combination transaction. The time required to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of, and negotiation with, a prospective target business with which our initial business combination is not ultimately completed will result in our incurring losses and will reduce the funds available for us to use to complete another initial business combination.

**Process and Structure**

We are not presently engaged in, and we will not engage in, any operations for an indefinite period of time following this offering. We intend to effectuate our initial business combination using cash from the proceeds of this offering and the private placement of the private placement shares, the proceeds of any sale of our shares in connection with our initial business combination (including pursuant to forward purchase agreements or backstop agreements we may enter into following the consummation of this offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, other securities issuances, or a combination of the foregoing. We may seek to complete our initial business combination with a company or business that may be financially unstable or in its early stages of development or growth, which would subject us to the numerous risks inherent in such companies and businesses.

We will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares in connection with the completion of our initial business combination either (i) in connection with a general meeting called to approve the business combination or (ii) without a shareholder vote by means of a tender offer. If we seek shareholder approval, we will complete our initial business combination only if we receive the approval of an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company, however, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles. The decision as to whether we will seek shareholder approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirement.

We have until the date that is 24 months from the closing of this offering, or until such earlier liquidation date as our board of directors may approve, to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination within such 24-month period, we may seek shareholder approval to amend our articles to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of ordinary shares will be offered an opportunity to redeem their shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding ordinary shares, subject to the limitations and on the conditions described herein, regardless of whether they abstain, vote in favor of or vote against such extension.

If we are unable to complete our initial business combination within the completion window, we will redeem 100% of the ordinary shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest income to pay dissolution expenses), divided by the number of then issued and outstanding ordinary shares, subject to applicable law and certain conditions as further described herein. We expect the pro rata redemption price to be approximately $10.00 per public share (regardless of whether the underwriters exercise their over-allotment option), without taking into account any interest or other income earned on such funds. However, we cannot assure you that we will in fact be able to distribute such amounts as a result of claims of creditors, which may take priority over the claims of our public shareholders.

Nasdaq rules require that we must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the trust account) at the time of the agreement to enter into the initial business combination. Our board of directors will make the determination as to the fair market value of our initial business combination. If our board of directors is not able to independently determine the fair market value of our initial business combination (including with the assistance of financial advisors), we will obtain an opinion from an independent investment banking firm which is a member of FINRA or another independent entity that commonly renders valuation opinions. While we consider it likely that our board of directors will be able to make an independent determination of the fair market value of our initial business combination, it may be unable to do so if it is less familiar or experienced with the business of a particular target or if there is a significant amount of uncertainty as to the value of the target's assets or prospects.

We anticipate structuring our initial business combination so that the post transaction company in which our public shareholders own shares will own or acquire 100% of the equity interests or assets of the target business or businesses. We may, however, structure our initial business combination such that the post transaction company owns or acquires less than 100% of such interests or assets of the target business in order to meet certain objectives of the target management team or shareholders or for other reasons, but we will only complete such business combination if the post transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the "Investment Company Act"). Even if the post transaction company owns or acquires 50% or more of the voting securities of the target, our shareholders prior to the business combination may collectively own a minority interest in the post transaction company, depending on valuations ascribed to the target and us in the business combination. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock, shares or other equity interests of a target. In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our shareholders immediately prior to our initial business combination could own less than a majority of our issued and outstanding shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post transaction company, the portion of such business or businesses that is owned or acquired is what will be taken into account for purposes of the 80% of net assets test described above. If the business combination involves more than one target business, the 80% of net assets test will be based on the aggregate value of all of the target businesses.

AI Biotechnology LLC ("AI Biotechnology"), an affiliate of Access Industries, Inc., has indicated an interest to purchase up to an aggregate of $30,000,000 of our ordinary shares in a private placement that would occur concurrently with the consummation of our initial business combination. However, because indications of interest are not binding agreements or commitments to purchase, AI Biotechnology may ultimately determine to purchase more, fewer or no shares. We are also under no obligation to sell any shares to AI Biotechnology. As such, there can be no assurance that AI Biotechnology will acquire any shares in connection with our initial business combination or otherwise. Any investment by AI Biotechnology or its affiliated entities and persons would be made on terms and conditions determined at the time of the business combination and may be different from the terms and conditions on which shares are sold to other investors in any private placement. Furthermore, we are not under any obligation to sell any such shares. If we sell shares to the AI Biotechnology (or any other investor) in connection with our initial business combination, the equity interest of investors in this offering in the combined company may be diluted and the market prices for our securities may be adversely affected. In addition, if the per share trading price of our ordinary shares is greater than the price per share paid in the private placement, the private placement will result in value dilution to you, in addition to the immediate dilution that you will experience in connection with the consummation of this offering. See also "Dilution."

We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors, or completing the business combination through a joint venture or other form of shared ownership with our sponsor, officers or directors. In the event we seek to complete an initial business combination with a target that is affiliated (as defined in our articles) with our sponsor, officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm that is a member of FINRA or another independent entity that commonly renders valuation opinions that such an initial business combination is fair to our company from a financial point of view.

Members of our management team and our independent directors will directly or indirectly own founder shares and/or private placement shares following this offering and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. The low price that our sponsor, executive officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. In addition to their investments (directly or indirectly) in the founder shares and private placement shares, our sponsors, officers, directors and/or their affiliates may make loans or advances to us for working capital from time to time. If we are unable to complete our initial business combination within the completion window, the founder shares may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. Further, each of our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination.

Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. Our articles provide that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter (a) which may be a corporate opportunity for any director or officer, on the one hand, and us, on the other, or (b) the presentation of which would breach an existing legal obligation of a member of director, officer or sponsor to any other entity. The purpose for the surrender of corporate opportunities is to allow officers, directors or other representatives with multiple business affiliations to continue to serve as an officer of our company or on our board of directors. Our officers and directors may from time to time be presented with opportunities that could benefit both another business affiliation and us. In the absence of the "corporate opportunity" waiver in our articles, certain candidates would not be able to serve as an officer or director. We believe we substantially benefit from having representatives who bring significant, relevant and valuable experience to our management, and, as a result, the inclusion of the "corporate opportunity" waiver in our articles provide us with greater flexibility to attract and retain the officers and directors that we feel are the best candidates. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our initial business combination.

In addition, our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination.

Certain members of our sponsor and our officers and directors may have similar responsibilities in, or serve as directors, of other special purpose acquisition companies.

**OUR SPONSOR**

Our sponsor, JATT Ventures II L.P., is a Cayman Islands exempted limited partnership, which was formed to invest in us, and is acting by its general partner, JATT Ventures II Ltd. Although our sponsor is permitted to undertake any activities permitted under the Limited Liabilities Partnership Act (As Revised) and other applicable law, our sponsor's business is focused on investing in us and directly or indirectly providing office space and administrative services to members of our management team. As of the date of this prospectus, JATT Ventures II Ltd is the sole general partner of our sponsor, and our Chairman and Chief Executive Officer, Dr. Someit Sidhu is a limited partner of our sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd.

The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates:

---

| | | |
|:---|:---|:---|
| **Entity** | **Amount of Compensation to<br> be Received or Securities<br> Issued or to be Issued** | **Consideration<br> Paid or to be Paid** |
| JATT Ventures II L.P. | 1,725,000 ordinary shares (of which 225,000 shares are subject to forfeiture if the underwriters do not exercise their over-allotment option). If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor. | $25,000 (approximately $0.014 per share) |

---

---

| | | |
|:---|:---|:---|
| **Entity** | **Amount of Compensation to<br> be Received or Securities<br> Issued or to be Issued** | **Consideration<br> Paid or to be Paid** |
| JATT Ventures II L.P. | 300,000 private placement shares (or up to 309,000 private placement shares if the underwriters' over-allotment option is exercised in full) | $3,000,000 ($10.00 per share) (or up to $3,090,000 if the underwriters' over-allotment option is exercised in full) |
| JATT Ventures II L.P. and/or its affiliates or designees | $20,000 per month | Officer compensation and administrative services provided to members of our management team (the "Administrative Service Fee") |
| JATT Ventures II L.P. | Repayment in cash | Up to $300,000 under an unsecured, non-interest-bearing promissory note for offering-related and organizational expenses. The loan is due at the closing of this offering and are anticipated to be repaid upon completion of this offering. |
| JATT Ventures II L.P., our officers or directors, or affiliates thereof | Repayment in cash | Any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination |
| Dr. Someit Sidhu | Prior to closing of this offering, our Chief Executive Officer, Dr. Someit Sidhu will receive indirect interest in founder shares for his services through membership interests in our sponsor, representing 150,000 founder shares. | $2,100 in aggregate (approximately $0.014 per share) |
| Mr. Nicholas Fernandez | Prior to closing of this offering, our Chief Financial Officer, Mr. Nicholas Fernandez will receive indirect interest in founder shares for his services through membership interests in our sponsor, representing 50,000 founder shares. | $700 in aggregate (approximately $0.014 per share) |
| Independent directors | Prior to closing of this offering, each of our independent directors will receive indirect interest in founder shares for their board services through membership interests in our sponsor, representing 25,000 founder shares. | $1,400 in aggregate (approximately $0.014 per share) |

---

Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and material dilution upon the closing of this offering. See the sections titled "*Dilution*" and "*Risk Factors — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the business combination causes the trading price of our ordinary shares to materially decline.*"

Pursuant to a letter agreement to be entered with us, we have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor. Further, pursuant to such letter agreement, our initial shareholders have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (i) 180 days after the completion of our initial business combination and (ii) the date on which we complete a liquidation, merger, share exchange or other similar transaction after our initial business combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property; and our sponsor has agreed not to transfer, assign or sell any of its private placement shares until 30 days after the completion of our initial business combination; except, in each case, to certain permitted transferees and under certain circumstances as described herein under "*Principal Shareholders — Transfers of Founder Shares and Private Placement Shares*". Any permitted transferees will be subject to the same restrictions and other agreements of our initial shareholders with respect to any founder shares or private placement shares.

---

| | | | |
|:---|:---|:---|:---|
| **Subject Securities** | **Expiration Date** | **Persons Subject to<br> Restrictions** | **Exceptions to Transfer<br> Restrictions** |
| Founder Shares | With certain limited exceptions, the founder shares are not transferable, assignable or saleable until the earlier of (A) 180 days after the completion of our initial business combination and (B) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. | JATT Ventures II L.P. Dr. Someit Sidhu | Transfers of the founder shares are permitted (a) to our officers or directors, any affiliate or family member of any of our officers or directors, any members or partners of our sponsor or their affiliates, any affiliates of our sponsor, or any employees of such affiliates; (b) in the case of an individual, by gift to a member of such individual's immediate family or to a trust, the beneficiary of which is a member of such individual's immediate family, an affiliate of such individual or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or otherwise in connection with the consummation of our initial business combination at prices no greater than the price at which the securities were originally purchased; (f) in the event of our liquidation prior to the completion of an initial business combination; (g) by virtue of the laws of the Cayman Islands or our sponsor's limited partnership agreement upon dissolution of our sponsor; or (h) in the event of our liquidation, merger, capital stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property subsequent to the completion of an initial business combination; provided, however, that in the case of clauses (a) through (e) or (g), these permitted transferees must enter into a written agreement with the company agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreement (including provisions relating to voting, the trust account and liquidating distributions). |

---

---

| | | | |
|:---|:---|:---|:---|
| **Subject Securities** | **Expiration Date** | **Persons Subject to<br> Restrictions** | **Exceptions to Transfer<br> Restrictions** |
| Private Placement Shares | The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination. | JATT Ventures II L.P. | Same as above. |

---

Up to 225,000 of the founder shares will be surrendered by our sponsor to us for no consideration depending on the extent to which the underwriters' over-allotment option is exercised. In addition, although there are no current plans to do so, in order to facilitate our initial business combination or a PIPE financing or for any other reason determined by our sponsor in its sole discretion, our sponsor may surrender or forfeit, transfer or exchange our founder shares, including for no consideration, as well as subject any such securities to earn-outs or other restrictions, or otherwise amend the terms of any such securities or enter into any other arrangements with respect to any such securities.

The securities held by the sponsor are expected to only be distributed directly to the members of the sponsor in connection with or following the consummation of our initial business combination, provided that such members agree to become subject to the applicable transfer restrictions with respect to such securities. Indirect transfers of the securities held by the sponsor, such as to another limited partner of the sponsor or their affiliate or a new limited partner of the sponsor, may be permitted with the consent of Dr. Someit Sidhu, the sole general partner of our sponsor, so long as such transfer complies with the applicable transfer restrictions with respect to such securities.

Additionally, our initial business combination may be subject to regulatory review and approval requirements, including foreign investment regulations and review by government entities such as the Committee on Foreign Investment in the United States ("CFIUS"). Our initial shareholders, including our sponsor, will own approximately 20% of our issued and outstanding shares following this offering (excluding the private placement shares). Our sponsor is exclusively "controlled" for CFIUS purposes by Dr. Someit Sidhu, who is a citizen of the United Kingdom. As a result, we may be considered a "foreign person" under rules promulgated by CFIUS and may not be able to complete an initial business combination with a U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as CFIUS, or ultimately prohibited.. As such, an initial business combination with a U.S. business or foreign business with U.S. subsidiaries that we may wish to pursue may be subject to CFIUS review, or ultimately prohibited. As a result, the pool of potential targets with which we could complete an initial business combination may be limited. Please see "*Risk Factors — We may not be able to complete an initial business combination since such initial business combination may be subject to regulatory review and approval requirements, including foreign investment regulations and review by government entities such as the CFIUS, or may be ultimately prohibited*." for additional information.

**Corporate Information**

Our executive offices are located at 153 Central Avenue, C/O 56, Westfield, NJ 07091, and our telephone number is 201-688-0364.

We are a Cayman Islands exempted company. Exempted companies are Cayman Islands companies conducting business mainly outside the Cayman Islands and, as such, are exempted from complying with certain provisions of the Companies Act. As an exempted company, we have applied for and received a tax exemption undertaking from the Cayman Islands government that, in accordance with Section 6 of the Tax Concessions Act (As Revised) of the Cayman Islands, for a period of 30 years from the date of the undertaking, no law which is enacted in the Cayman Islands imposing any tax to be levied on profits, income, gains or appreciations will apply to us or our operations and, in addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax will be payable (i) on or in respect of our shares, debentures or other obligations or (ii) by way of the withholding in whole or in part of a payment of dividends or other distribution of income or capital by us to our shareholders or a payment of principal or interest or other sums due under a debenture or other obligation of us.

We are an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.

In addition, Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to "emerging growth company" will have the meaning associated with it in the JOBS Act.

Additionally, we are a "smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our ordinary shares held by non-affiliates is equal to or exceeds $250 million as of the prior June 30, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates is equal to or exceeds $700 million as of the prior June 30.

Prior to the date of this prospectus, we will file a Registration Statement on Form 8-A with the Securities and Exchange Commission (the "SEC") to voluntarily register our securities under Section 12 of the Exchange Act. As a result, we will be subject to the rules and regulations promulgated under the Exchange Act. We have no current intention of filing a Form 15 to suspend our reporting or other obligations under the Exchange Act prior or subsequent to the consummation of our initial business combination.

**THE OFFERING**

 

*In making your decision on whether to invest in our ordinary shares, you should take into account not only the backgrounds of the members of our management team, but also the special risks we face as a blank check company and the fact that this offering is not being conducted in compliance with Rule 419 promulgated under the Securities Act. You will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings. You should carefully consider these and the other risks set forth in the section below entitled "Risk Factors."*

 

 Prior to the initial investment in the company of $25,000 by the sponsor, the company had no assets, tangible or intangible. The per share price of the founder shares was determined by dividing the amount of cash contributed to the company by the number of founder shares issued. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 6,900,000 ordinary shares if the underwriters' over-allotment option is exercised in full, and therefore that such founder shares would represent approximately 20% of the issued and outstanding shares after this offering (excluding the private placement shares). Up to 225,000 of the founder shares will be surrendered for no consideration depending on the extent to which the underwriters' over-allotment option is not exercised. If we increase or decrease the size of this offering pursuant to Rule 462(b) under the Securities Act, we will effect a share capitalization or other appropriate mechanism immediately prior to the consummation of the offering in such amount as to maintain the number of founder shares at 20.0% of our issued and outstanding ordinary shares upon the consummation of this offering.

 The founder shares are identical to the ordinary shares being sold in this offering, except that:

(1) Assumes no exercise of the underwriters' over-allotment
option and 225,000 founder shares are surrendered to us for no consideration.

(2) Comprised of 6,000,000 ordinary shares, 1,500,000 founder
shares) and 300,000 private placement shares to be sold in the private placement that will close simultaneously with the closing of the
offering.

(3) Assumes surrender of all 225,000 founder shares. Up to 225,000
founder shares will be surrendered to us for no consideration depending on the extent to which the underwriters' over-allotment
option is exercised.

(4) Unlike certain other SPAC IPOs, investors in this offering
will not receive warrants that would become exercisable following completion of our initial business combination.

&nbsp;&nbsp;&nbsp;&nbsp;● our sponsor,
officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have agreed to (i) waive their
redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after
this offering in connection with the completion of our initial business combination; (ii) waive their redemption rights with respect
to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection
with a shareholder vote to approve an amendment to our articles (A) to modify the substance or timing of our obligation to allow
redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial
business combination within the completion window or (B) with respect to any other material provisions relating to shareholders'
rights or pre-initial business combination activity; (iii) waive their rights to liquidating distributions from the trust account
with respect to their founder shares and private placement shares if we fail to complete our initial business combination within the completion
window, although they will be entitled to liquidating distributions from assets outside the trust account with respect to any public
shares they hold if we fail to complete our initial business combination within the prescribed time frame and to liquidating distributions
from assets outside the trust account; and (iv) vote any founder shares held by them, any private placement shares held by them
and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor
of our initial business combination (except with respect to any such public shares which may not be voted in favor of approving the business
combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations
or guidance relating thereto). If we submit our initial business combination to our public shareholders for a vote, we will complete
our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law and our articles, being a
resolution passed by the affirmative vote of at least a simple majority of the holders of the shares present in person or represented
by proxy and entitled to vote thereon at a general meeting of the company. As a result, in addition to our initial shareholders'
founder shares and private placement shares, we would need 2,100,001, or approximately 35.0%, of the 6,000,000 public shares sold in
this offering to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming
all outstanding shares are voted and the over-allotment option is not exercised and the parties to the letter agreement do not acquire
any ordinary shares), and we will not need any public shares to be voted in favor of an initial business combination in order to have
our initial business combination approved (assuming only a quorum is present at the meeting and the over-allotment option is not exercised.

---

| | |
|:---|:---|
| **Transfer restrictions on founder shares:** | Our initial shareholders have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (i) 180 days after the completion of our initial business combination and (ii) the date on which we complete a liquidation, merger, share exchange or other similar transaction after our initial business combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, as described herein under "*Principal Shareholders — Transfers of Founder Shares and Private Placement Shares*". Any permitted transferees will be subject to the same restrictions and other agreements of our initial shareholders with respect to any founder shares. We refer to such transfer restrictions throughout this prospectus as the lock-up. |

---

---

| | |
|:---|:---|
| **Appointment of directors; voting:** | Except as set forth below, holders of record of our ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders. Unless specified in our articles or as required by the Companies Act or stock exchange rules, an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company is generally required to approve any matter voted on by our shareholders. Approval of certain actions require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company, and pursuant to our articles, such actions include amending our articles and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, meaning, following our initial business combination, the holders of more than 50% of our ordinary shares entitled to vote for the appointment of directors can elect all of the directors. |
|  | With respect to any other matter submitted to a vote of our shareholders, including any vote in connection with our initial business combination, except as required by law, holders of the founder shares and holders of our public shares will vote together as a single class, with each share entitling the holder to one vote. If we seek shareholder approval of our initial business combination, we will complete our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the holders of the shares present in person or by proxy and entitled to vote thereon at a general meeting of the company. In such case, our sponsor, officers, directors and advisors have agreed to vote their founder shares and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our initial business combination.<br>As a result, in addition to our initial shareholders' founder shares and private placement shares, we would need 2,100,001, or approximately 35.0%, of the 6,000,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming all outstanding shares are voted and the over-allotment option is not exercised and the parties to the letter agreement do not acquire any ordinary shares); and we will not need any public shares to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming only a quorum is present at the meeting and the over-allotment option is not exercised. |

---

---

| | |
|:---|:---|
| **Private placement shares:** | Our sponsor has committed, pursuant to a written agreement, to purchase an aggregate of 300,000 private placement shares (or 309,000 shares if the underwriters' over-allotment option is exercised in full), at a price of $10.00 per private placement share, or $3,000,000 in the aggregate (or $3,090,000 if the underwriters' over-allotment option is exercised in full), in a private placement that will close simultaneously with the closing of this offering. A portion of the purchase price of the private placement shares will be added to the proceeds from this offering to be held in the trust account such that at the time of closing of this such that at the time of closing of this offering $60,000,000 (or $69,000,000 if the underwriters exercise their over-allotment option in full) will be held in the trust account. The private placement shares will be identical to the shares sold in this offering except that (i) the private placement shares may not, subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after the completion of our initial business combination, and (ii) the private placement shares will be entitled to registration rights. |
|  | Our sponsor has agreed to (i) waive its redemption rights with respect to its private placement shares in connection with the completion of our initial business combination, (ii) waive its redemption rights with respect to its private placement shares in connection with a shareholder vote to approve an amendment to our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, (iii) waive its rights to liquidating distributions from the trust account with respect to their private placement shares if we fail to complete our initial business combination within the completion window, and (iv) vote any private placement shares held by it in favor of our initial business combination. |
| **Indication of interest** | AI Biotechnology has indicated an interest to purchase up to an aggregate of $30,000,000 of our ordinary shares in a private placement that would occur concurrently with the consummation of our initial business combination. However, because indications of interest are not binding agreements or commitments to purchase, AI Biotechnology may ultimately determine to purchase more, fewer or no shares. We are not under any obligation to sell any such shares. Such investment would be made on terms and conditions determined at the time of the business combination. |
| **Transfer restrictions on private placement shares:** | The private placement shares will not be transferable, assignable or saleable until 30 days after the completion of our initial business combination, except as described herein under "*Principal Shareholders — Transfers of Founder Shares and Private Placement Shares*." Any permitted transferees will be subject to the same restrictions and other agreements of our initial shareholders with respect to any private placement shares. |

---

---

| | |
|:---|:---|
| **Proceeds to be held in trust account:** | Nasdaq rules provide that at least 90% of the gross proceeds from this offering and the sale of the private placement shares be deposited in a trust account. Of the net proceeds we will receive from this offering and the sale of the private placement shares described in this prospectus, $60,000,000, or $69,000,000 if the underwriters' over-allotment option is exercised in full ($10.00 per share in either case), will be deposited into a segregated trust account located in the United States at JP Morgan Chase Bank, N.A. with Continental Stock Transfer & Trust Company acting as trustee, and held as cash or invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations, after deducting $600,000 in underwriting discounts and commissions payable upon the closing of this offering (or $690,000 if the underwriters' over-allotment option is exercised in full) and an aggregate of $2,400,000 to pay fees and expenses in connection with the closing of this offering and for working capital following the closing of this offering. The proceeds to be placed in the trust account include $1,800,000 (or up to $2,070,000 if the underwriters' over-allotment option is exercised in full) in deferred underwriting commissions.<br>Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our taxes, if any, the proceeds from this offering and the sale of the private placement shares will not be released from the trust account until the earliest of (i) the completion of our initial business combination, (ii) the redemption of our public shares if we are unable to complete our initial business combination within the completion window, subject to applicable law, or (iii) the redemption of our public shares properly submitted in connection with a shareholder vote to amend our articles to (A) modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity. The proceeds deposited in the trust account could become subject to the claims of our creditors, if any, which could have priority over the claims of our public shareholders. |
| **Ability to extend time to complete business combination** | We have until the date that is 24 months from the closing of this offering or until such earlier liquidation date as our board of directors may approve to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination within such 24-month period, we may seek shareholder approval to amend our articles to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of ordinary shares will be offered an opportunity to redeem their shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding ordinary shares, subject to the limitations and on the conditions described herein, regardless of whether they abstain, vote in favor of or vote against such extension. |

---

 Our initial shareholders will lose their entire investment in us if our initial business combination is not completed within the completion window unless we extend the amount of time we have to consummate an initial business combination by obtaining shareholder approval to amend our articles. While we do not currently intend to seek such an extension, we may elect to do so in the future. There is no limit on the number of extensions that we may seek; however, we do not expect to extend the time period to consummate our initial business combination beyond 36 months from the closing of this offering, in compliance with Nasdaq Rule IM-5101-2. If we do not or are unable to extend the time period to consummate our initial business combination, our sponsor's investment in our founder shares and private placement shares may be worthless. If we are unable to complete our initial business combination within the completion window and do not hold a shareholder vote to amend our articles to extend the amount of time we will have to consummate an initial business combination, we will redeem 100% of the ordinary shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest income to pay dissolution expenses), divided by the number of then issued and outstanding ordinary shares, subject to applicable law and certain conditions as further described herein.

---

| | |
|:---|:---|
| **Conditions to completing our initial business combination:** | Nasdaq rules require that we must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the trust account (excluding any deferred underwriters fees and taxes payable on the income earned on the trust account) at the time of the agreement to enter into the initial business combination. Our board of directors will make the determination as to the fair market value of our initial business combination. If our board of directors is not able to independently determine the fair market value of our initial business combination (including with the assistance of financial advisors), we will obtain an opinion from an independent investment banking firm which is a member of FINRA or another independent entity that commonly renders valuation opinions with respect to the satisfaction of such criteria. While we consider it likely that our board of directors will be able to make such independent determination of fair market value, it may be unable to do so if the board of directors is less familiar or experienced with the target company's business, there is a significant amount of uncertainty as to the value of the company's assets or prospects, including if such company is at an early stage of development, operations or growth, or if the anticipated transaction involves a complex financial analysis or other specialized skills and the board of directors determines that outside expertise would be helpful or necessary in conducting such analysis. Additionally, pursuant to Nasdaq rules, any initial business combination must be approved by a majority of our independent directors.<br>We will complete our initial business combination only if the post-transaction company in which our public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act. Even if the post-transaction company owns or acquires 50% or more of the voting securities of the target, our shareholders prior to our initial business combination may collectively own a minority interest in the post-business combination company, depending on valuations ascribed to the target and us in the business combination transaction. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock, shares or other equity interests of a target. In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our shareholders immediately prior to our initial business combination could own less than a majority of our issued and outstanding shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction company, the portion of such business or businesses that is owned or acquired is what will be taken into account for purposes of Nasdaq's 80% fair market value test, provided that in the event that the business combination involves more than one target business, the aggregate value of all of target business will be taken into account for purposes of the 80% fair market value test and we will treat the transactions together as our initial business combination for purposes of seeking shareholder approval or conducting a tender offer, as applicable. |

---

 Please see "*Proposed Business — Permitted Purchases of Our Securities*" for a description of how such persons will determine from which shareholders to seek to acquire securities.

 The purpose of any such purchases of shares could be to (1) increase the likelihood of obtaining shareholder approval of the business combination or (2) satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. Any such purchases of our ordinary shares may result in the completion of our initial business combination that may not otherwise have been possible. In addition, if such purchases are made, the public "float" of our ordinary shares may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our ordinary shares on a national securities exchange. Please see "*Risk Factors — If we seek shareholder approval of our initial business combination, sponsor, initial shareholders, directors, officers, advisors or their affiliates may elect to purchase public shares, which may influence a vote on a proposed business combination and reduce the public "float" of our securities."*

---

| | |
|:---|:---|
| **Redemption rights for public shareholders in connection with completion of our initial business combination:** | We will provide our public shareholders with the opportunity to redeem all or a portion of their public shares in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriter. There will be no redemption rights in connection with the completion of our initial business combination with respect to our private placement shares. Our sponsor, officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination. |
| **Manner of conducting redemptions:** | We will provide our public shareholders with the opportunity to redeem all or a portion of their public shares in connection with the completion of our initial business combination either (i) in connection with a general meeting called to approve the initial business combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether we will seek shareholder approval of a proposed initial business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirements.<br>Asset acquisitions and share purchases would not typically require shareholder approval while direct mergers with our company where we do not survive and any transactions where we issue more than 20% of our issued and outstanding ordinary shares or seek to amend our articles would require shareholder approval. So long as we obtain and maintain a listing for our securities on Nasdaq, we will be required to comply with Nasdaq's shareholder approval rules.<br>The requirement that we provide our public shareholders with the opportunity to redeem their public shares by one of the two methods listed above will be contained in provisions of our articles and will apply whether or not we maintain our registration under the Exchange Act or our listing on Nasdaq. Such provisions may be amended if approved by special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. |

---

 If we provide our public shareholders with the opportunity to redeem their public shares in connection with a general meeting, we will:

 If we seek shareholder approval, we will complete our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law and our articles, being the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. A quorum for such meeting will be present if the holders of one-third of issued and outstanding shares entitled to vote at the meeting are represented in person or by proxy. Our initial shareholders will count toward this quorum and, pursuant to the letter agreement, our sponsor, officers, directors and advisors have agreed to vote their founder shares, private placement shares and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our initial business combination. For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. As a result, in addition to our initial shareholders' founder shares and private placement shares, we would need 2,100,001, or approximately 35.0%, of the 6,000,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming all outstanding shares are voted, the private placement shares to be issued to our sponsor are voted in favor of the transaction and the over-allotment option is not exercised and the parties to the letter agreement do not acquire any ordinary shares). Assuming that only the holders of one-third of our issued and outstanding ordinary shares, representing a quorum under our articles, vote their shares at a general meeting of the company, we would not need any public shares to be voted in favor of an initial business combination in order to have our initial business combination approved. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. These quorum and voting thresholds, and the voting agreements of our initial shareholders, may make it more likely that we will consummate our initial business combination. Each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction or whether they do not vote or abstain from voting on the proposed transaction, or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction.

 If a shareholder vote is not required and we do not decide to hold a shareholder vote for business or other legal reasons, we will:

 In the event we conduct redemptions pursuant to the tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under the Exchange Act, and we will not be permitted to complete our initial business combination until the expiration of the tender offer period. In addition, the tender offer will be conditioned on public shareholders not tendering more than the number of shares we are permitted to redeem. If public shareholders tender more shares than we have offered to purchase, we will withdraw the tender offer and not complete such initial business combination. Upon the public announcement of our initial business combination, if we elect to conduct redemption pursuant to the tender offer rules, we or our sponsor will terminate any plan established in accordance with Rule 10b5-1 to purchase our ordinary shares in the open market, in order to comply with Rule 14e-5 under the Exchange Act.

 We intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to, at the holder's option, either deliver their share certificates to our transfer agent or deliver their shares to our transfer agent electronically using the Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) system, prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public shareholders to satisfy such delivery requirements. We believe that this will allow our transfer agent to efficiently process any redemptions without the need for further communication or action from the redeeming public shareholders, which could delay redemptions and result in additional administrative cost. If the proposed initial business combination is not approved and we continue to search for a target company, we will promptly return any certificates or shares delivered by public shareholders who elected to redeem their shares.

---

| | |
|:---|:---|
|  | Our proposed initial business combination may impose a minimum cash requirement for (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. In the event the aggregate cash consideration we would be required to pay for all ordinary shares that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the initial business combination or redeem any shares, and all ordinary shares submitted for redemption will be returned to the holders thereof. We may, however, raise funds through the issuance of equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop arrangements we may enter into following consummation of this offering, in order to, among other reasons, satisfy such net tangible assets or minimum cash requirements. |
| **Limitation on redemption rights of shareholders holding 20% or more of the shares sold in this offering if we hold shareholder vote:** | Notwithstanding the foregoing redemption rights, if we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our articles provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the shares sold in this offering without our prior consent.<br>We believe the restriction described above will discourage shareholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their ability to redeem their shares as a means to force us or our management to purchase their shares at a significant premium to the then-current market price or on other undesirable terms. Absent this provision, a public shareholder holding more than an aggregate of 20% of the shares sold in this offering could threaten to exercise its redemption rights against a business combination if such holder's shares are not purchased by us, our sponsor or our management at a premium to the then-current market price or on other undesirable terms. By limiting our shareholders' ability to redeem to no more than 20% of the shares sold in this offering, we believe we will limit the ability of a small group of shareholders to unreasonably attempt to block our ability to complete our initial business combination, particularly in connection with a business combination with a target that requires as a closing condition that we have a minimum net worth or a certain amount of cash. However, we would not be restricting our shareholders' ability to vote all of their shares (including all shares held by those shareholders that hold more than 20% of the shares sold in this offering) for or against our initial business combination. |

---

---

| | |
|:---|:---|
| **Release of funds in trust account in connection with the closing of our initial business combination:** | In connection with the completion of our initial business combination, the funds held in the trust account will be used to pay amounts due to any public shareholders who exercise their redemption rights as described above under "— *Redemption rights for public shareholders in connection with the completion of our initial business combination*," to pay the underwriters their deferred underwriting commissions, to pay all or a portion of the consideration payable to the target or owners of the target of our initial business combination and to pay other expenses associated with our initial business combination. If our initial business combination is paid for using equity or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination, we may use the balance of the cash released to us from the trust account following the closing for general corporate purposes, including for maintenance or expansion of operations of post-transaction businesses, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital. |
| **Redemption of public shares and distribution and liquidation if no initial business combination:** | Our articles provide that we will have only the completion window to complete our initial business combination. If we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and subject to the other requirements of applicable law.<br>Our sponsor, officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any founder shares and private placement shares held by them if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account. However, if our initial shareholders or management team acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the completion window.<br>The underwriters have agreed to waive its rights to its deferred underwriting commission held in the trust account in the event we do not complete our initial business combination within the completion window and, in such event, such amounts will be included with the funds held in the trust account that will be available to fund the redemption of our public shares. |

---

 In addition, we have agreed, pursuant to the services and indemnification agreement with our sponsor relating to the monthly payment for services outlined therein, that we will (i) indemnify our sponsor from any claims arising out of or relating to this offering or the company's operations or conduct of the company's business, (ii) in respect of any investment opportunities sourced by the sponsor and its respective affiliates, and/or (iii) any claim against our sponsor alleging any expressed or implied management or endorsement by our sponsor of any of the company's activities or any express or implied association between our sponsor, on the one hand, and the company or any of its other affiliates, on the other hand, which agreement will provide that the indemnified parties cannot access the funds held in our trust account.

As a result, our sponsor, officers and directors could have conflicts of interest in determining whether to present business combination opportunities to us or to any other special purpose acquisition company with which they may become involved. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination target. Our executive officers and our directors may have interests that differ from you in connection with the business combination, including the fact that they may lose their entire investment in us if our initial business combination is not completed, except to the extent they receive liquidating distributions from assets outside the trust account, and accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Additionally, the personal and financial interests of our directors and executive officers may influence their motivation in timely identifying and pursuing an initial business combination or completing our initial business combination. For example, our directors and executive officers may prioritize a prospective initial business combination with a shorter timeline to completion over another acquisition target which may be more difficult or time-intensive to consummate. Consequently, our directors' and executive officers' discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our shareholders' best interest, which could negatively impact the timing for a business combination.<br>In addition to the above, our officers and directors are not required to commit any specified amount of time to our affairs, and, accordingly, may have conflicts of interest in allocating management time among various business activities, including selecting a business combination target and monitoring the related due diligence. See "*Risk Factors — Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.*"<br>Additionally, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to any founder shares, private placement shares and any public shares held by them in connection with the consummation of our initial business combination. Further, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to any founder shares held by them if we are unable to complete our initial business combination within the completion window. With certain limited exceptions, the founder shares will not be transferable, assignable or salable by our sponsor or its permitted transferees until 180 days after the completion of our initial business combination. Since our sponsor and executive officers and directors may directly or indirectly own ordinary shares following this offering, our executive officers and directors may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window.<br>

---

| | |
|:---|:---|
|  | Our sponsor, members of our management team and board of directors will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Our sponsor paid a nominal aggregate purchase price of approximately $0.014 per share for the founder shares held by it. Accordingly, our management team, which owns direct or indirect interests in our sponsor, may be more willing to pursue a business combination with a riskier or less-established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares. <br>In the event our sponsor or members of our management team provide loans to us to finance transaction costs and/or incur expenses on our behalf in connection with an initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction as such loans may not be repaid and/or such expenses may not be reimbursed unless we consummate such business combination. <br>We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, executive officers or directors, or completing an initial business combination through a joint venture or other form of shared ownership with our sponsor, executive officers or directors; accordingly, such affiliated person(s) may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction as such affiliated person(s) would have interests different from our public shareholders and would likely not receive any financial benefit unless we consummated such business combination. In the event we seek to complete an initial business combination with a target that is an affiliate (as defined in our articles) of our sponsor, executive officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm which is a member of FINRA or another independent entity that commonly renders valuation opinions stating that the consideration to be paid by us in such an initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context. |
| **Indemnity by the sponsor in the event of liquidation without a business combination** | Our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us, or a prospective target business with which we have entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement (except for the Company's registered public accounting firm), reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our sponsor's only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination and redemptions could be reduced to less than $10.00 per public share. |

---

 We may also issue shares in private placement transactions (so-called PIPE transactions) in connection with our initial business combination, for instance in order to provide sufficient liquidity and capital to the post-business combination entity. As of the date of this prospectus, we have no commitments to issue any shares in connection with such a transaction. The price of the shares we may issue in such a transaction may be less, and potentially significantly less, than $10.00 per share or the market price for our shares at such time. Any such issuances of equity securities at a price that is less than $10.00 or the prevailing market price of our shares at that time could be structured to ensure a return on investment to the investors and could dilute the interests of our existing shareholders in a manner that would not ordinarily occur in a traditional initial public offering and could result in both a reduction in the trading price of our shares to the price at which we issue such equity securities and fluctuations in the net tangible book value per share of the combined company's securities following the completion of our initial business combination. We may also provide price protection or other incentives, or issue convertible securities such as preferred equity or convertible debt, and the exercise or conversion price of those securities may be fixed or adjustable, and may be less, and potentially significantly less, than $10.00 per share or the market price for our shares at such time. Such issuances could also result in additional transaction costs related to our initial business combination compared to a traditional initial public offering, including the placement fees associated with the engagement of a placement agent in connection with PIPE transactions. The issuance of additional ordinary or preference shares may significantly dilute the equity interest of investors in this offering and are likely to increase as the enterprise value of a prospective target company increases. We intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of this offering and the sale of the private placement shares, and, as a result, if the cash portion of the purchase price exceeds the amount available from the trust account, net of amounts needed to satisfy any redemptions by public shareholders, we may be required to seek additional financing to complete such proposed initial business combination. In order to facilitate our initial business combination or for any other reason determined by our sponsor in its sole discretion, our sponsor, in accordance with the terms of the letter agreement, may (i) surrender or forfeit, transfer or exchange, directly or indirectly, our founder shares, private placement shares or any of our other securities held by it, including for no consideration, in connection with a PIPE financing or otherwise, (ii) subject any such securities to earn-outs or other restrictions, and (iii) enter into any other arrangements with respect to any such securities. Although we have no commitments as of the date of this prospectus to issue any notes or other debt, or to otherwise incur debt following this offering, we may choose to incur substantial debt to complete our initial business combination. As such, no issuance of debt will affect the per share amount available for redemption from the trust account.

**SUMMARY OF RISK FACTORS**

An investment in our securities involves a high degree of risk. The occurrence of one or more of the events or circumstances described in the section titled "Risk Factors," alone or in combination with other events or circumstances, may materially adversely affect our business, financial condition and operating results. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. Such risks include, but are not limited to:

● We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.

● Our public shareholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we hold a vote, holders of our founder shares will participate in such vote, which means we may complete our initial business combination even though a majority of our public shareholders do not support such a combination.

● Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.

● If we seek shareholder approval of our initial business combination, our initial shareholders and management team have agreed to vote in favor of such initial business combination, regardless of how our public shareholders vote.

● The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target.

● The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares and the amount of deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us.

● The requirement that we complete our initial business combination within the completion window may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our shareholders.

● You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares, potentially at a loss.

● We may not be able to complete our initial business combination within the completion window, in which case we would redeem our public shares.

● If we seek shareholder approval of our initial business combination, our sponsor, initial shareholders, directors, officers, advisors or their affiliates may elect to purchase public shares from public shareholders, which may influence a vote on a proposed business combination and reduce the public "float" of our ordinary shares.

● Nasdaq may delist our ordinary shares from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions.

● If a shareholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed.

● You will not be entitled to protections normally afforded to investors of many other blank check companies.

● Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination and to negotiate attractive acquisition terms. If we have not completed our initial business combination within the completion window, our public shareholders may receive only their pro rata portion of the funds in the trust account that are available for distribution to public shareholders.

● If the net proceeds of this offering and the sale of the private placement shares not being held in the trust account are insufficient to allow us to operate for at least the duration of the completion window, it could limit the amount available to fund our search for a target business or businesses and complete our initial business combination, and we will depend on loans from our sponsor or management team to fund our search and to complete our initial business combination.

● Past performance by our management team and their affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, may not be indicative of future performance of an investment in the Company.

● The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination.

● Unlike some other similarly structured special purpose acquisition companies, our initial shareholders will receive additional ordinary shares if we issue certain shares to consummate an initial business combination.

● We may be a passive foreign investment company, or "PFIC," which could result in adverse U.S. federal income tax consequences to U.S. investors.

● We may transfer by way of continuation and reincorporate in another jurisdiction, which may result in taxes imposed on shareholders.

● Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. Federal courts may be limited.

● In recent years, the number of special purpose acquisition companies that have been formed has increased substantially, potentially resulting in more competition for attractive targets. This could increase the cost of our initial business combination and could even result in our inability to find a target or to consummate an initial business combination.

● The other risks and uncertainties discussed in "Risk Factors" and elsewhere in this prospectus.

**SUMMARY FINANCIAL DATA**

The following table summarizes the relevant financial data for our business and should be read with our financial statements, which are included in this prospectus. We have not had any significant operations to date, so only balance sheet data is presented.

---

| | | |
|:---|:---|:---|
|  | **February 13, 2026** | **February 13, 2026** |
|  | **Actual** | **As Adjusted** |
| **Balance Sheet Data:** |  |  |
| Working capital (deficit)<sup>(1)</sup> | $(28206) | $1449413 |
| Total assets<sup>(2)</sup> | 33699 | 61505413 |
| Total liabilities<sup>(3)</sup> | 28286 | 1856000 |
| Value of ordinary shares subject to possible redemption<sup>(4)</sup> |  | 60000000 |
| Shareholder's equity (deficit)<sup>(5)</sup> | 5413 | (350587) |

---

(1) The "as adjusted" calculation includes $1,500,000
of cash held outside the trust account, plus $5,413 of actual shareholders' equity on February 13, 2026, less $56,000 of over-allotment
liability.

(2) The "as adjusted" calculation equals $60,000,000
of cash held in trust from the proceeds of this offering and the sale of the private placement shares, plus $1,500,000 in cash held outside
the trust account, plus $5,413 of actual shareholders' equity on February 13, 2026.

(3) The "as adjusted" calculation equals $1,800,000
of deferred underwriting commissions, assuming the over-allotment option is not exercised, plus the over-allotment liability of $56,000.

(4) The "as adjusted" calculation equals 6,000,000
ordinary shares subject to possible redemption at $10.00 per share.

(5) Excludes 6,000,000 ordinary shares purchased in the public
market which are subject to conversion in connection with our initial business combination. The "as adjusted" calculation
equals the "as adjusted" total assets, less the "as adjusted" total liabilities, less the value of ordinary shares
that may be converted in connection with our initial business combination ($10.00 per share).

The "as adjusted" information gives effect to the sale of the ordinary shares in this offering, the sale of the private placement ordinary shares, and the payment of the estimated expenses of this offering and assumes no exercise of the underwriter's over-allotment option. The "as adjusted" total assets amount includes the $60,000,000 held in the trust account for the benefit of our public shareholders, which amount, less deferred underwriting commissions, will be available to us only upon the completion of our initial business combination within the completion window. The "as adjusted" working capital and "as adjusted" total assets include $1,800,000 being held in the trust account representing deferred underwriting commissions. The underwriters will not be entitled to any interest accrued on the deferred underwriting discounts and commissions.

**Risk Factors**

 

*An investment in our securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the other information contained in this prospectus, before making a decision to invest in our ordinary shares. If any of the following events occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline, and you could lose all or part of your investment.*

**Risks Relating to our Search for, Consummation of, or Inability to Consummate, a Business Combination**

 ****

***Our public shareholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we hold a vote, holders of our founder shares will participate in such vote, which means we may complete our initial business combination even though a majority of our public shareholders do not support such a combination.***

We may choose not to hold a shareholder vote to approve our initial business combination unless the business combination would require shareholder approval under applicable law or stock exchange listing requirements. Except as required by applicable law or stock exchange requirement, the decision as to whether we will seek shareholder approval of a proposed business combination or will allow shareholders to sell their shares to us in a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors, such as the timing of the transaction and whether the terms of the transaction would otherwise require us to seek shareholder approval. Even if we seek shareholder approval, the holders of our founder shares will participate in the vote on such approval. Accordingly, we may complete our initial business combination even if holders of a majority of our ordinary shares do not approve of the business combination we complete. Please see the section entitled "*Proposed Business — Shareholders May Not Have the Ability to Approve Our Initial Business Combination*" for additional information.

 ****

***Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.***

At the time of your investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of our initial business combination. Since our board of directors may complete a business combination without seeking shareholder approval, public shareholders may not have the right or opportunity to vote on the business combination, unless we seek such shareholder vote. Accordingly, your only opportunity to effect your investment decision regarding our initial business combination may be limited to exercising your redemption rights within the period of time (which will be at least 20 business days) set forth in our tender offer documents mailed to our public shareholders in which we describe our initial business combination. The amount of the deferred underwriting commissions payable to the underwriters will not be adjusted for any shares that are redeemed in connection with an initial business combination. The per-share amount we will distribute to shareholders who properly exercise their redemption rights will not be reduced by the deferred underwriting commission and after such redemptions, the per-share value of shares held by non-redeeming shareholders will reflect our obligation to pay the deferred underwriting commissions.

 ****

***If we seek shareholder approval of our initial business combination, our initial shareholders, management team and advisors have agreed to vote in favor of such initial business combination, regardless of how our public shareholders vote.***

Our initial shareholders will own, on an as-converted basis, approximately 20% of our issued and outstanding ordinary shares immediately following the completion of this offering (assuming our initial shareholders do not purchase any shares in this offering, and excluding the private placement shares).

Our initial shareholders, management team and advisors also may from time to time purchase ordinary shares prior to our initial business combination. Our articles provides that, if we seek shareholder approval of an initial business combination, such initial business combination will be approved if we receive approval pursuant to an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. As a result, in addition to our initial shareholders' founder shares and private placement shares, we would need 2,100,001, or approximately 35.0%, of the 6,000,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved, assuming all outstanding shares are voted, the over-allotment option is not exercised and the parties to the letter agreement do not acquire any ordinary shares. Assuming that only the holders of one-third of our issued and outstanding ordinary shares, representing a quorum under our articles, vote their ordinary shares at a general meeting of the company, we would not need any public shares to be voted in favor of an initial business combination in order to have our initial business combination approved. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. Accordingly, if we seek shareholder approval of our initial business combination, the agreement by our initial shareholders, management team and advisors to vote in favor of our initial business combination will increase the likelihood that an ordinary resolution will be passed, being the requisite shareholder approval for such initial business combination.

 ****

***The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target.***

We may seek to enter into a business combination transaction agreement with a minimum cash requirement for (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. If too many public shareholders exercise their redemption rights, we would not be able to meet such closing condition and, as a result, would not be able to proceed with the business combination. Consequently, if accepting all properly submitted redemption requests would not allow us to satisfy a closing condition as described above, we would not proceed with such redemption and the related business combination and may instead search for an alternate business combination. Prospective targets will be aware of these risks and, thus, may be reluctant to enter into a business combination transaction with us.

 ****

***The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares and the amount of deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us.***

At the time we enter into an agreement for our initial business combination, we will not know how many shareholders may exercise their redemption rights, and therefore will need to structure the transaction based on our expectations as to the number of shares that will be submitted for redemption. If our initial business combination agreement requires us to use a portion of the cash in the trust account to pay the purchase price, or requires us to have a minimum amount of cash at closing, we will need to reserve a portion of the cash in the trust account to meet such requirements, or arrange for third party financing. In addition, if a larger number of shares are submitted for redemption than we initially expected, we may need to restructure the transaction to reserve a greater portion of the cash in the trust account or arrange for third party financing. Raising additional third party financing may involve dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. In addition, the amount of the deferred underwriting compensation payable to the underwriters will not be adjusted for any shares that are redeemed in connection with an initial business combination. The per share amount we will distribute to shareholders who properly exercise their redemption rights will not be reduced by the deferred underwriting compensation and after such redemptions, the amount held in trust will continue to reflect our obligation to pay the entire deferred underwriting compensation. The above considerations may limit our ability to complete the most desirable business combination available to us or optimize our capital structure. As a result, our obligations to redeem public shares for which redemption is requested and to pay the deferred underwriting commissions may not allow us to complete the most desirable business combination or optimize our capital structure.

In addition, raising additional third-party financing may involve dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. The above considerations may limit our ability to complete the most desirable business combination available to us or optimize our capital structure and may result in substantial dilution from your purchase of our ordinary shares. The effect of this dilution will be greater for shareholders who do not redeem. The amount of the deferred underwriting compensation payable to the underwriters will not be adjusted for any shares that are redeemed in connection with an initial business combination, which may further dilute your investment. The per-share amount we will distribute to shareholders who properly exercise their redemption rights will not be reduced by the deferred underwriting compensation and after such redemptions, the per-share value of shares held by non-redeeming shareholders will reflect our obligation to pay the deferred underwriting compensation. We may not be able to generate sufficient value from the completion of our initial business combination in order to overcome the dilutive impact of these and other factors, and, accordingly, you may incur a net loss on your investment. Please see "— *Risks Relating to Our Securities — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the business combination causes the trading price of our ordinary shares to materially decline.*"

 ****

***The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares.***

If our initial business combination agreement requires us to use a portion of the cash in the trust account to pay the purchase price, or requires us to have a minimum amount of cash at closing, the probability that our initial business combination would be unsuccessful is increased. If our initial business combination is unsuccessful, you would not receive your pro rata portion of the funds in the trust account until we liquidate the trust account. If you are in need of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our shares may trade at a discount to the pro rata amount per share in the trust account. In either situation, you may suffer a material loss on your investment or lose the benefit of funds expected in connection with your exercise of redemption rights until we liquidate or you are able to sell your shares in the open market.

 ****

***The requirement that we complete our initial business combination within the completion window may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our shareholders.***

Any potential target business with which we enter into negotiations concerning a business combination will be aware that we must complete our initial business combination within the completion window. Consequently, such target business may obtain leverage over us in negotiating a business combination, knowing that if we do not complete our initial business combination with that particular target business, we may be unable to complete our initial business combination with any target business. This risk will increase as we get closer to the timeframe described above. In addition, we may have limited time to conduct due diligence and may enter into our initial business combination on terms that we would have rejected upon a more comprehensive investigation. The length of time it may take us to complete our diligence and negotiate a business combination may reduce the amount of time available for us to ultimately complete an initial business combination should such diligence or negotiations not lead to a consummated initial business combination.

 ****

***Our search for an initial business combination, and any target business with which we may ultimately consummate an initial business combination, may be materially adversely affected by current global geopolitical conditions resulting from the ongoing Russia-Ukraine conflict and conflicts in the Middle East and Southwest Asia.***

United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict, the recent escalation of the Israel-Hamas conflict, and the recent U.S./Israel-Iran conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization ("NATO") deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and conflicts in the Middle East and Southwest Asia, particularly the escalation of the Israel-Hamas, Israel-Iran conflicts, the recent U.S./Israel-Iran conflict, and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets. Any of the abovementioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the conflicts in the Middle East and Southwest Asia, particularly the escalation of the Israel-Hamas, Israel-Iran, and the recent U.S./Israel-Iran conflicts and subsequent sanctions or related actions, could adversely affect our search for an initial business combination and any target business with which we may ultimately consummate an initial business combination. The extent and duration of the ongoing conflicts, resulting sanctions and any related market disruptions are impossible to predict, but could be substantial, particularly if current or new sanctions continue for an extended period of time or if geopolitical tensions result in expanded military operations on a global scale. Any such disruptions may also have the effect of heightening many of the other risks described in this section. If these disruptions or other matters of global concern continue for an extensive period of time, our ability to consummate an initial business combination, or the operations of a target business with which we may ultimately consummate an initial business combination, may be materially adversely affected.

***We may engage our underwriters or one of its respective affiliates to provide additional services to us after this offering, which may include acting as M&A advisor in connection with an initial business combination or as placement agent in connection with a related financing transaction. Our underwriters are entitled to receive deferred underwriting commissions that will be released from the trust account only upon a completion of an initial business combination. These financial incentives may cause our underwriters to have potential conflicts of interest in rendering any such additional services to us after this offering, including, for example, in connection with the sourcing and consummation of an initial business combination.***

We may engage our underwriters or one of its affiliates to provide additional services to us after this offering, including, for example, identifying potential targets, providing M&A advisory services, acting as a placement agent in a private offering or arranging debt financing transactions. We may pay our underwriters or their affiliates fair and reasonable fees or other compensation that would be determined at that time in an arm's length negotiation; provided that no agreement will be entered into with our underwriters or their affiliates and no fees or other compensation for such services will be paid to our underwriters or their affiliates prior to the date that is 60 days from the date of this prospectus, unless such payment would not be deemed underwriters' compensation in connection with this offering.

The underwriters are also entitled to receive deferred underwriting commissions that are conditioned on the completion of an initial business combination. The underwriter's or its affiliates' financial interests tied to the consummation of a business combination transaction may give rise to potential conflicts of interest in providing any such additional services to us, including potential conflicts of interest in connection with the sourcing and consummation of an initial business combination. The underwriters are under no obligation to provide any further services to us in order to receive all or any part of the deferred underwriting commissions.

 ****

***We may not be able to complete our initial business combination within the completion window, in which case we would redeem our public shares.***

We may not be able to find a suitable target business and complete our initial business combination within the completion window. Our ability to complete our initial business combination may be negatively impacted by general market conditions, volatility in the capital and debt markets and the other risks described herein. If we have not completed our initial business combination within such time period, we will, as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment and completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidation distributions or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

Any redemption of public shareholders from the trust account will be effected automatically by function of our articles prior to any voluntary winding up. If we are required to wind-up, liquidate the trust account and distribute such amount therein, pro rata, to our public shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with the applicable provisions of the Companies Act. In that case, investors may be forced to wait beyond the duration of the completion window before the redemption proceeds of our trust account become available to them, and they receive the return of their pro rata portion of the proceeds from our trust account. We have no obligation to return funds to investors prior to the date of our redemption or liquidation unless we seek shareholder approval to amend our articles either to extend the date by which we must consummate our initial business combination or with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, or we consummate our initial business combination prior thereto and only then in cases where investors have sought to redeem their public shares. Only upon our redemption or any liquidation will public shareholders be entitled to distributions if we are unable to complete our initial business combination.

 ****

***We may decide not to extend the term we have to consummate our initial business combination, in which case we would redeem our public shares.***

We have until the date that is 24 months from the closing of this offering or until such earlier liquidation date as our board of directors may approve, to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination within such period, we may seek shareholder approval to amend our articles to extend the date by which we must consummate our initial business combination. However, we may decide not to seek to extend the date by which we must consummate our initial business combination. If we do not seek to extend the date by which we must consummate our initial business combination, and we are unable to consummate our initial business combination within the applicable time period, we will, as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares for a pro rata portion of the funds held in the trust account, subject to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

 ****

***If we seek shareholder approval of our initial business combination, our sponsor, initial shareholders, directors, officers, advisors and their affiliates may elect to purchase shares from public shareholders, which may influence a vote on a proposed business combination and reduce the public "float" of our ordinary shares.***

If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders directors, officers, advisors and their affiliates may purchase public shares or equity-linked securities in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination, although they are under no obligation or duty to do so. Any such price per share may be different than the amount per share a public shareholder would receive if it elected to redeem its shares in connection with our initial business combination. Such a purchase may include a contractual acknowledgment that such shareholder, although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights.

In the event that our sponsor, initial shareholders, directors, officers, advisors and their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares. It is intended that, if Rule 10b-18 would apply to purchases by sponsor, initial shareholders, directors, officers, advisors and their affiliates, then such purchases will comply with Rule 10b-18 under the Exchange Act, to the extent it applies, which provides a safe harbor for purchases made under certain conditions, including with respect to timing, pricing and volume of purchases.

Additionally, at any time at or prior to our initial business combination, subject to applicable securities laws (including with respect to material non-public information), our sponsor, initial shareholders, directors, officers, advisors and their affiliates may enter into transactions with investors and others to provide them with incentives to acquire public shares, vote their public shares in favor of our initial business combination or not redeem their public shares. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase public shares or rights in such transactions.

The purpose of any such transactions could be to increase the likelihood of obtaining shareholder approval of the business combination, or satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible.

In addition, if such purchases are made, the public "float" of our securities may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange. Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements.

Additionally, in the event our sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders, such purchases would be structured in compliance with the requirements of Rule 14e-5 under the Exchange Act including, in pertinent part, through adherence to the following:

● Our registration statement/proxy statement filed for our business combination transaction would disclose the possibility that our sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase public shares from public shareholders outside the redemption process, along with the purpose of such purchases;

● if our sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders, they would do so at a price no higher than the price offered through our redemption process;

● our registration statement/proxy statement filed for our business combination transaction would include a representation that any of our securities purchased by our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not be voted in favor of approving the business combination transaction;

● our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive such rights; and

● we would disclose in a Form 8-K, before our general meeting to approve the business combination transaction, the following material items:

● the amount of our securities purchased outside of the redemption offer by our sponsor, initial shareholders, directors, officers, advisors and their affiliates, along with the purchase price;

● the purpose of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates;

● the impact, if any, of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates on the likelihood that the business combination transaction will be approved;

● the identities of our security holders who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security holders) who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates; and

● the number of our securities for which we have received redemption requests pursuant to our redemption offer.

Please see "*Proposed Business — Permitted Purchases of Our Securities*" for a description of how such persons will determine from which shareholders to seek to acquire securities.

 ****

***If a shareholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed.***

We will comply with the proxy rules or tender offer rules, as applicable, when conducting redemptions in connection with our initial business combination. Despite our compliance with these rules, if a shareholder fails to receive our proxy materials or tender offer documents, as applicable, such shareholder may not become aware of the opportunity to redeem its shares. In addition, proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will describe the various procedures that must be complied with in order to validly tender or submit public shares for redemption. For example, we intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to, at the holder's option, either deliver their share certificates to our transfer agent, or to deliver their shares to our transfer agent electronically prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. In the event that a shareholder fails to comply with these or any other procedures disclosed in the proxy or tender offer materials, as applicable, its shares may not be redeemed. See the section of this prospectus entitled "*Proposed Business — Delivering Share Certificates in Connection with the Exercise of Redemption Rights*."

 ****

***You will not be entitled to protections normally afforded to investors of other blank check companies subject to Rule 419 of the Securities Act.***

Since the net proceeds of this offering and the sale of the private placement shares are intended to be used to complete one or more initial business combinations with a target business or businesses that has not been selected, we may be deemed to be a "blank check" company under the U.S. securities laws. However, because we will have net tangible assets in excess of $5,000,000 upon the completion of this offering and the sale of the private placement shares and will file a Current Report on Form 8-K, including an audited balance sheet demonstrating this fact, we are exempt from rules promulgated by the SEC to protect investors in blank check companies, such as Rule 419. Accordingly, investors will not be afforded the benefits or protections of those rules. Among other things, this means our shares will be immediately tradable and we will have a longer period of time to complete our respective business combinations than do companies subject to Rule 419.

Moreover, if this offering were subject to Rule 419, that rule would prohibit the release of any interest earned on funds held in the trust account to us unless and until the funds in the trust account were released to us or in connection with our completion of an initial business combination. For a more detailed comparison of our offering to offerings that comply with Rule 419, please see "*Proposed Business — Comparison of This Offering to Those of Blank Check Companies Subject to Rule 419*."

However, if we are not able to list our ordinary shares on Nasdaq or any other national stock exchange, we may be required to comply with the "penny stock rules" and this could negatively affect the market for our securities and our ability to complete an initial business combination.

 ****

***If we seek shareholder approval of our initial business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a "group" of shareholders are deemed to hold in excess of 20% of our ordinary shares, you may lose the ability to redeem all such shares in excess of 20% of our ordinary shares.***

If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our articles will provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a group (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 20% of the shares sold in this offering without our prior consent, which we refer to as the "Excess Shares." However, we would not be restricting our shareholders' ability to vote all of their shares (including Excess Shares) for or against our initial business combination.

Your inability to redeem the Excess Shares will reduce your influence over our ability to complete our initial business combination and you could suffer a material loss on your investment in us if you sell Excess Shares in open market transactions. Additionally, you will not receive redemption distributions with respect to the Excess Shares if we complete our initial business combination. And as a result, you will continue to hold that number of shares exceeding 20% and, in order to dispose of such shares, would be required to sell your shares in open market transactions, potentially at a loss.

***Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If we are unable to complete our initial business combination, our public shareholders may receive only their pro rata portion of the funds in the trust account that are available for distribution to public shareholders.***

We expect to encounter competition from other entities having a business objective similar to ours, including private investors (which may be individuals or investment partnerships), other blank check companies and other entities, domestic and international, competing for the types of businesses we intend to acquire. Many of these individuals and entities are well-established and have extensive experience in identifying and effecting, directly or indirectly, acquisitions of companies operating in or providing services to various industries. Many of these competitors possess similar or greater technical, human and other resources to ours or more local industry knowledge than we do and our financial resources will be relatively limited when contrasted with those of many of these competitors. While we believe there are numerous target businesses we could potentially acquire with the net proceeds of this offering and the sale of the private placement shares, our ability to compete with respect to the acquisition of certain target businesses that are sizable will be limited by our available financial resources. This inherent competitive limitation gives others an advantage in pursuing the acquisition of certain target businesses. Furthermore, we are obligated to offer holders of our public shares the right to redeem their shares for cash at the time of our initial business combination in conjunction with a shareholder vote or via a tender offer. Target companies will be aware that this may reduce the resources available to us for our initial business combination. Any of these obligations may place us at a competitive disadvantage in successfully negotiating a business combination.

In addition, in recent years, the number of SPACs that have been formed has increased substantially. Many potential targets for SPACs have already entered into an initial business combination, and there are still many SPACs preparing for an initial public offering, as well as many such companies currently in registration. As a result, at times, fewer attractive targets may be available to consummate an initial business combination. Because there are more SPACs seeking to enter into an initial business combination with available targets, the competition for available targets with attractive fundamentals or business models may increase, which could cause targets companies to demand improved financial terms. Attractive deals could also become scarcer for other reasons, such as economic or industry sector downturns, geopolitical tensions, or increases in the cost of additional capital needed to close business combinations or operate targets post-business combination. This could increase the cost of, delay or otherwise complicate or frustrate our ability to find and consummate an initial business combination, and may result in our inability to consummate an initial business combination on terms favorable to our investors altogether.

If we are unable to complete our initial business combination, our public shareholders may receive only their *pro rata* portion of the funds in the trust account that are available for distribution to public shareholders.

 ****

***If the net proceeds of this offering and the sale of the private placement shares not being held in the trust account are insufficient to allow us to operate for at least the next 24 months, it could limit the amount available to fund our search for a target business or businesses and complete our initial business combination, and we will depend on loans from our sponsor or management team to fund our search and to complete our initial business combination.***

Of the net proceeds of this offering, only $1,500,000 will be available to us initially outside the trust account to fund our working capital requirements. We believe that, upon closing of this offering, the funds available to us outside of the trust account will be sufficient to allow us to operate for at least the next 24 months; however, we cannot assure you that our estimate is accurate. Of the funds available to us, we could use a portion of the funds available to us to pay fees to consultants to assist us with our search for a target business. We could also use a portion of the funds as a down payment or to fund a "no-shop" provision (a provision in letters of intent or merger agreements designed to keep target businesses from "shopping" around for transactions with other companies or investors on terms more favorable to such target businesses) with respect to a particular proposed business combination, although we do not have any current intention to do so. If we entered into a letter of intent or merger agreement where we paid for the right to receive exclusivity from a target business and were subsequently required to forfeit such funds (whether as a result of our breach or otherwise), we might not have sufficient funds to continue searching for, or conduct due diligence with respect to, a target business.

In the event that our offering expenses exceed our estimate of $900,000 (not including the underwriter's discount), we may fund such excess with funds not to be held in the trust account. In such case, the amount of funds we intend to be held outside the trust account would decrease by a corresponding amount. The amount held in the trust account will not be impacted as a result of such increase or decrease. Conversely, in the event that the offering expenses are less than our estimate of $900,000 (not including the underwriter's discount), the amount of funds we intend to be held outside the trust account would increase by a corresponding amount. If we are required to seek additional capital, we would need to borrow funds from our sponsor, management team or other third parties to operate or may be forced to liquidate. Neither our sponsor, members of our management team nor any of their affiliates is under any obligation to advance funds to us in such circumstances. Any such advances would be repaid only from funds held outside the trust account or from funds released to us upon completion of our initial business combination. Up to $1,500,000 of such loans may be convertible into private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender. Prior to the completion of our initial business combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account. If we are unable to complete our initial business combination within the required time period because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. Consequently, our public shareholders may only receive an estimated $10.00 per share, or possibly less, on our redemption of our public shares.

 ****

***If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by shareholders may be less than $10.00 per share.***

Our placing of funds in the trust account may not protect those funds from third party claims against us. Although we will seek to have all vendors, service providers, prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public shareholders, such parties may not execute such agreements, or even if they execute such agreements they may not be prevented from bringing claims against the trust account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will consider whether competitive alternatives are reasonably available to us and will only enter into an agreement with such third party if management believes that such third party's engagement would be in the best interests of the company under the circumstances. WithumSmith+Brown, PC, our independent registered public accounting firm, and the underwriters of this offering will not execute agreements with us waiving such claims to the monies held in the trust account.

Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we are unable to complete our initial business combination within the prescribed timeframe, or upon the exercise of a redemption right in connection with our initial business combination, we will be required to provide for payment of claims of creditors that were not waived that may be brought against us within the 10 years following redemption.

Accordingly, the per-share redemption amount received by public shareholders could be less than the $10.00 per public share initially held in the trust account, due to claims of such creditors. Pursuant to the letter agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part, our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us (except for the Company's registered public accounting firm), or a prospective target business with which we have entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per public share due to reductions in the value of the trust assets, less taxes paid and payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses; *provided* that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our sponsor's only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination and redemptions could be reduced to less than $10.00 per public share. In such event, we may not be able to complete our initial business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

***Our directors may decide not to enforce the indemnification obligations of our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public shareholders.***

In the event that the proceeds in the trust account are reduced below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.00 per public share due to reductions in the value of the trust assets, in each case less taxes paid or payable (other than excise or similar taxes), and our sponsor asserts that it is unable to satisfy his obligations or that he has no indemnification obligations related to a particular claim, our independent directors would determine whether to take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment and subject to their fiduciary duties may choose not to do so in any particular instance if, for example, the cost of such legal action is deemed by the independent directors to be too high relative to the amount recoverable or if the independent directors determine that a favorable outcome is not likely. If our independent directors choose not to enforce these indemnification obligations, the amount of funds in the trust account available for distribution to our public shareholders may be reduced below $10.00 per public share.

 ****

***The securities in which we invest the funds held in the trust account could bear a negative rate of interest, which could reduce the interest income available for payment of taxes or reduce the value of the assets held in trust such that the per-share redemption amount received by public shareholders may be less than $10.00 per public share.***

The proceeds held in the trust account may be held in cash or invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations. While short-term U.S. government treasury obligations currently yield a positive rate of interest, they have briefly yielded negative interest rates in recent years. Central banks in Europe and Japan pursued interest rates below zero in recent years, and the Open Market Committee of the Federal Reserve has not ruled out the possibility that it may in the future adopt similar policies in the United States. In the event that we are unable to complete our initial business combination or make certain amendments to our articles, our public shareholders are entitled to receive their pro-rata share of the proceeds held in the trust account, plus any interest income (less taxes paid and payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses). Negative interest rates could reduce the value of the assets held in trust such that the per-share redemption amount received by public shareholders may be less than $10.00 per public share.

 ****

***If, after we distribute the proceeds in the trust account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, a bankruptcy or insolvency court may seek to recover such proceeds, and the members of our board of directors may be viewed as having breached their fiduciary duties to our creditors, thereby exposing the members of our board of directors and us to claims of punitive damages.***

If, after we distribute the proceeds in the trust account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a "preferential transfer" or a "fraudulent conveyance." As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by our shareholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims of punitive damages, by paying public shareholders from the trust account prior to addressing the claims of creditors.

***If, before distributing the proceeds in the trust account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders and the per-share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.***

If, before distributing the proceeds in the trust account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the trust account, the per-share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.

 ****

***If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination.***

If we are deemed to be an investment company under the Investment Company Act, our activities may be restricted, including:

● restrictions on the nature of our investments; and

● restrictions on the issuance of securities,

● each of which may make it difficult for us to complete our initial business combination. In addition, we may have imposed upon us burdensome requirements, including:

● registration as an investment company;

● adoption of a specific form of corporate structure; and

● reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations.

In order not to be regulated as an investment company under the Investment Company Act, unless we can qualify for an exclusion, we must ensure that we are engaged primarily in a business other than investing, reinvesting or trading of securities and that our activities do not include investing, reinvesting, owning, holding or trading "investment securities" constituting more than 40% of our assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. Our business will be to identify and complete a business combination and thereafter to operate the post-transaction business or assets for the long term. We do not intend to spend a considerable amount of time actively managing the assets in the trust account for the primary purpose of achieving investment returns. We do not plan to buy businesses or assets with a view to resale or profit from their resale. We do not plan to buy unrelated businesses or assets or to be a passive investor.

We do not believe that our anticipated principal activities will subject us to the Investment Company Act. To this end, the proceeds held in the trust account may only be held as cash or invested in U.S. "government securities" within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an "investment company" within the meaning of the Investment Company Act. This offering is not intended for persons who are seeking a return on investments in government securities or investment securities. The trust account is intended as a holding place for funds pending the earliest to occur of: (i) the completion of our initial business combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend our articles (A) to modify the substance or timing of our obligation to provide for the redemption of our public shares in connection with an initial business combination or to redeem 100% of our public shares if we have not consummated our initial business combination within the completion window or (B) with respect to any other provisions relating to shareholders' rights or pre-initial business combination activity; or (iii) absent an initial business combination within the completion window, our return of the funds held in the trust account to our public shareholders as part of our redemption of the public shares. If we do not invest the proceeds as discussed above, we may be deemed to be subject to the Investment Company Act.

Further, under the subjective test of a "investment company" pursuant to Section 3(a)(1)(A) of the Investment Company Act, even if the funds deposited in the trust account were invested in the assets discussed above (U.S. government securities or money market funds registered under the Investment Company Act), such assets, other than cash, are "securities" for purposes of the Investment Company Act and, therefore, nevertheless, there is a risk that we could be deemed an unregistered investment company and subject to the Investment Company Act at any time.

In the adopting release for the 2024 SPAC Rules (as defined below), the SEC provided guidance that a SPAC's potential status as an "investment company" depends on a variety of factors, such as a SPAC's duration, asset composition, business purpose and activities and "is a question of facts and circumstances" requiring individualized analysis. If we were deemed to be subject to compliance with and regulation under the Investment Company Act, we would be subject to additional regulatory burdens and expenses for which we have not allotted funds. Unless we are able to modify our activities so that we would not be deemed an investment company, we would either register as an investment company or wind down and abandon our efforts to complete an initial business combination and instead liquidate the Company. As a result, our public shareholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and would be unable to realize the potential benefits of an initial business combination, including the possible appreciation of the combined company's securities.

 ****

***To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, we may, at any time, instruct the trustee to liquidate the securities held in the trust account and instead to hold the funds in the trust account in cash until the earlier of the consummation of our initial business combination or our liquidation. As a result, following the liquidation of securities in the trust account, the interest earned on the funds held in the trust account may be materially reduced, which would reduce the dollar amount our public shareholders would receive upon any redemption or liquidation of the Company.***

We intend to initially hold the funds in the trust account as cash or in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds investing solely in U.S. government treasury obligations and meeting certain conditions under Rule 2a-7 under the Investment Company Act. U.S. government treasury obligations are considered "securities" for purposes of the Investment Company Act, while cash is not. As noted above, one of the factors the SEC identified as relevant to the determination of whether a SPAC which holds securities could potentially be deemed an "investment company" under the Investment Company Act is the SPAC's duration. To mitigate the risk of us being deemed to be an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus subject to regulation under the Investment Company Act, we may, at any time, instruct Continental Stock Transfer & Trust Company, the trustee with respect to the trust account, to liquidate the U.S. government treasury obligations or money market funds held in the trust account and thereafter to hold all funds in the trust account in cash until the earlier of consummation of our initial business combination or liquidation of the company. Following such liquidation, the rate of interest we receive on the funds held in the trust account may be materially decreased. However, interest previously earned on the funds held in the trust account still may be released to us to pay our taxes, if any, and certain other expenses as permitted. As a result, any decision to liquidate the securities held in the trust account and thereafter to hold all funds in the trust account in cash would reduce the dollar amount our public shareholders would receive upon any redemption or liquidation of the company.

 ****

***Changes in laws or regulations (including the adoption of policies by governing administrations), or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations.***

We are subject to laws and regulations enacted by national, regional and local governments. These governing bodies may seek to change laws and regulations, as well as adopt new policies, including tariffs and other economic policies, that could negatively impact us or target business with which we seek to consummate an initial business combination. We will also be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly and our efforts to comply with such new and evolving laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial business combination, and results of operations.

On January 24, 2024, the SEC issued final rules (the "2024 SPAC Rules"), effective as of July 1, 2024, that formally adopted some of the SEC's proposed rules for SPACs that were released on March 30, 2022. The 2024 SPAC Rules, among other items, impose additional disclosure requirements in initial public offerings by SPACs and business combination transactions involving SPACs and private operating companies; amend the financial statement requirements applicable to business combination transactions involving such companies; update and expand guidance regarding the general use of projections in SEC filings, as well as when projections are disclosed in connection with proposed business combination transactions; increase the potential liability of certain participants in proposed business combination transactions; and could impact the extent to which SPACs could become subject to regulation under the Investment Company Act. The 2024 SPAC Rules may materially adversely affect our business, including our ability to negotiate and complete, and the costs associated with, our initial business combination, and results of operations.

 ****

***We may not hold an annual general meeting until after the consummation of our initial business combination, which could delay the opportunity for our shareholders to appoint directors.***

In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual general meeting until no later than one year after our first fiscal year end following our listing on Nasdaq. There is no requirement under the Companies Act for us to hold annual or extraordinary general meetings to appoint directors. Until we hold an annual general meeting, public shareholders may not be afforded the opportunity to appoint directors and to discuss company affairs with management.

 ****

***Because we are neither limited to evaluating a target business in a particular industry sector nor have we selected any target businesses with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular target business's operations.***

Our efforts to identify a prospective initial business combination target will not be limited to a particular industry, sector or geographic region. While we may pursue an initial business combination opportunity in any industry or sector, we intend to capitalize on the ability of our management team to identify and acquire a business or businesses that can benefit from our management team's established global relationships and operating experience. Our management team has extensive experience in identifying and executing strategic investments globally and has done so successfully in a number of sectors, including the healthcare or healthcare-related industries sector. Our articles prohibits us from effectuating a business combination solely with another blank check company or similar company with nominal operations. Because we have not yet selected any specific target business with respect to a business combination, there is no basis to evaluate the possible merits or risks of any particular target business's operations, results of operations, cash flows, liquidity, financial condition or prospects.

To the extent we complete our initial business combination, we may be affected by numerous risks inherent in the business operations with which we combine. For example, if we combine with a financially unstable business or an entity lacking an established record of sales or earnings, we may be affected by the risks inherent in the business and operations of a financially unstable or a development stage entity. In recent years, a number of target businesses have underperformed financially post-business combination. There are no assurances that the target business with which we consummate our initial business combination will perform as anticipated. Although our officers and directors will endeavor to evaluate the risks inherent in a particular target business, we cannot assure you that we will properly ascertain or assess all of the significant risk factors or that we will have adequate time to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control or reduce the chances that those risks will adversely impact a target business. We also cannot assure you that an investment in our ordinary shares will ultimately prove to be more favorable to investors than a direct investment, if such opportunity were available, in a business combination target.

Accordingly, any shareholders who choose to remain shareholders following the business combination could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.

***We may seek business combination opportunities in industries or sectors that may be outside of our management's areas of expertise.***

We will consider a business combination outside of our management's areas of expertise if a business combination candidate is presented to us and we determine that such candidate offers an attractive business combination opportunity for our company. Although our management will endeavor to evaluate the risks inherent in any particular business combination candidate, we cannot assure you that we will adequately ascertain or assess all of the significant risk factors. We also cannot assure you that an investment in our ordinary shares will not ultimately prove to be less favorable to investors in this offering than a direct investment, if an opportunity were available, in a business combination candidate. In the event we elect to pursue a business combination outside of the areas of our management's expertise, our management's expertise may not be directly applicable to its evaluation or operation, and the information contained in this prospectus regarding the areas of our management's expertise would not be relevant to an understanding of the business that we elect to acquire. As a result, our management may not be able to ascertain or assess adequately all of the relevant risk factors. Accordingly, any shareholders who choose to remain shareholders following our initial business combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy for such reduction in value.

 ****

***Although we have identified general criteria and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.***

Although we have identified general criteria and guidelines for evaluating prospective target businesses, it is possible that a target business with which we enter into our initial business combination will not have all of these positive attributes. If we complete our initial business combination with a target that does not meet some or all of these guidelines, such combination may not be as successful as a combination with a business that does meet all of our general criteria and guidelines. In addition, if we announce a prospective business combination with a target that does not meet our general criteria and guidelines, a greater number of shareholders may exercise their redemption rights, which may make it difficult for us to meet any closing condition with a target business that requires us to have a minimum net worth or a certain amount of cash. In addition, if shareholder approval of the transaction is required by law, or we decide to obtain shareholder approval for business or other reasons, it may be more difficult for us to attain shareholder approval of our initial business combination if the target business does not meet our general criteria and guidelines. If we are unable to complete our initial business combination, our public shareholders may only receive their *pro rata* portion of the funds in the trust account that are available for distribution to public shareholders.

 ****

***We may not be required to obtain an opinion from an independent investment banking firm or from a valuation or appraisal firm, and consequently, you may have no assurance from an independent source that the consideration we are paying for the business is fair to our company and its shareholders from a financial point of view.***

Unless we complete our initial business combination with an affiliated (as defined in our articles) entity or our board of directors cannot independently determine the fair market value of the target business or businesses (including with the assistance of financial advisors), we are not required to obtain an opinion from an independent investment banking firm which is a member of FINRA or from another independent entity that commonly renders valuation opinions that the consideration we are paying is fair to our company and its shareholders from a financial point of view. If no opinion is obtained, our shareholders will be relying on the judgment of our board of directors, who will determine fair market value based on standards generally accepted by the financial community. Such standards used will be disclosed in our proxy materials or tender offer documents, as applicable, related to our initial business combination.

 ****

***We may issue additional ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. Any such issuances would dilute the interest of our shareholders and likely present other risks.***

Our articles authorizes the issuance of up to 200,000,000 ordinary shares, par value $0.0001 per share, and 1,000,000 preference shares, par value $0.0001 per share. Immediately after this offering, there will be 192,200,000 (assuming in that the underwriters have not exercised their over-allotment option and the forfeiture of 225,000 ordinary shares) authorized but unissued ordinary shares, available for issuance. Immediately after this offering, there will be no preference shares issued and outstanding.

We may issue a substantial number of additional ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. However, our articles provide, among other things, that prior to our initial business combination, we may not issue additional shares that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on any initial business combination. These provisions of our articles, like all provisions of our articles, may be amended with a shareholder vote. The issuance of additional ordinary or preference shares:

● may significantly dilute the equity interest of investors in this offering;

● may subordinate the rights of holders of ordinary shares if preference shares are issued with rights senior to those afforded our ordinary shares;

● could cause a change in control if a substantial number of ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and

● may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and

● may adversely affect prevailing market prices for our ordinary shares.

 ****

***The post-business combination company may issue shares to investors in connection with our initial business combination at a price which is less than $10.00 or the prevailing market price of our shares at that time, which could dilute the interests of our existing shareholders and add costs.***

In connection with our initial business combination, the post-business combination company may issue shares to investors in private placement transactions (so-called PIPE transactions) in order to complete our initial business combination and provide sufficient liquidity and capital to the post-business combination entity. The price of the shares we issue may be less, and potentially significantly less, than $10.00 per share or the market price for our shares at such time. Any such issuances of equity securities at a price that is less than $10.00 or the prevailing market price of our shares at that time could be structured to ensure a return on investment to the investors and could dilute the interests of our existing shareholders in a manner that would not ordinarily occur in a traditional initial public offering and could result in both a reduction in the trading price of our shares to the price at which we issue such equity securities and fluctuations in the net tangible book value per share of the combined company's securities following the completion of our initial business combination. We may also provide price protection or other incentives, or issue convertible securities such as preferred equity or convertible debt, and the exercise or conversion price of those securities may be fixed or adjustable, and may be less, and potentially significantly less, than $10.00 per share or the market price for our shares at such time. Such issuances could also result in additional transaction costs related to our initial business combination compared to a traditional initial public offering, including the placement fees associated with the engagement of a placement agent in connection with PIPE transactions.

 ****

***Resources could be wasted in researching business combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public shareholders may only receive their pro rata portion of the funds in the trust account that are available for distribution to public shareholders.***

We anticipate that the investigation of each specific target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require substantial management time and attention and substantial costs for accountants, attorneys, consultants and others. If we decide not to complete a specific initial business combination, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target business, we may fail to complete our initial business combination for any number of reasons including those beyond our control. Any such event will result in a loss to us of the related costs incurred which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public shareholders may only receive their *pro rata* portion of the funds in the trust account that are available for distribution to public shareholders.

***We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, officers, directors or existing holders which may raise potential conflicts of interest.***

In light of the involvement of our sponsor, its managing members, and our officers and directors with other entities, we may decide to acquire one or more businesses affiliated with or competitive with our sponsor, officers, directors and their respective affiliates or existing holders. Our directors also serve as officers and/or board members for other entities, including, without limitation, those described under "*Management — Conflicts of Interest*." Such entities may compete with us for business combination opportunities. Our sponsor, officers and directors are not currently aware of any specific opportunities for us to complete our initial business combination with any entities with which they are affiliated, and there have been no substantive discussions concerning a business combination with any such entity or entities. Although we will not be specifically focusing on, or targeting, any transaction with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met our criteria for a business combination as set forth in "*Effecting Our Initial Business Combination — Evaluation of a Target Business and Structuring of Our Initial Business Combination*" and such transaction was approved by a majority of our independent and disinterested directors. Despite our agreement to obtain an opinion from an independent investment banking firm which is a member of FINRA or another independent entity that commonly renders valuation opinions regarding the fairness to our company from a financial point of view of a business combination with one or more domestic or international businesses affiliated with our sponsor, officers, directors or existing holders, potential conflicts of interest still may exist and, as a result, the terms of the business combination may not be as advantageous to our public shareholders as they would be absent any conflicts of interest.

 ****

***Since our sponsor, officers and directors will lose their entire investment in us if our initial business combination is not completed (other than with respect to public shares they may acquire during or after this offering), a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.***

On February 12, 2026, our sponsor paid $25,000, or approximately $0.014 per share, to cover certain offering costs, in exchange for 1,725,000 founder shares. Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor.

Prior to the initial investment in the company of $25,000 by the sponsor, the company had no assets, tangible or intangible. The purchase price of the founder shares was determined by dividing the amount of cash contributed to the company by the number of founder shares issued. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 6,900,000 shares if the underwriters' over-allotment option is exercised in full, and therefore that such founder shares would represent approximately 20% of the outstanding shares after this offering. Up to 225,000 of the founder shares will be surrendered for no consideration depending on the extent to which the underwriter's over-allotment is exercised. The founder shares may be worthless if we do not complete an initial business combination. In addition, our sponsor has committed to purchase an aggregate of 300,000 private placement shares (or 309,000 shares if the underwriters' over-allotment option is exercised in full) for an aggregate purchase price of $3,000,000 (or $3,090,000 if the underwriters' over-allotment option is exercised in full), or $10.00 per share. The private placement shares may also be worthless if we do not complete our initial business combination. The personal and financial interests of our officers and directors may influence their motivation in identifying and selecting a target business combination, completing an initial business combination and influencing the operation of the business following the initial business combination. This risk may become more acute as the 24-month anniversary of the closing of this offering nears, which is the deadline for our completion of an initial business combination.

***We may issue notes or other debt securities, or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our shareholders' investment in us.***

Although we have no commitments as of the date of this prospectus to issue any notes or other debt securities, or to otherwise incur outstanding debt following this offering, we may choose to incur substantial debt to complete our initial business combination. The incurrence of debt could have a variety of negative effects, including:

● default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;

● acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

● our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;

● our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;

● using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for capital expenditures, acquisitions and other general corporate purposes;

● limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;

● increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and

● limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

 ****

***We may only be able to complete one business combination with the proceeds of this offering and the sale of the private placement shares, which will cause us to be solely dependent on a single business which may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.***

The net proceeds from this offering and the private placement of shares will provide us with $58,200,000 (or $66,930,000 if the underwriters' over-allotment option is exercised in full) that we may use to complete our initial business combination (after taking into account the $1,800,000, or $2,070,000 if the over-allotment option is exercised in full, of deferred underwriting commissions being held in the trust account payable at the closing of this offering, an estimated $1,500,000 of other offering expenses, and excluding approximately $1,500,000 held outside the trust account to fund our working capital requirements, and assuming no redemptions).

We may effectuate our initial business combination with a single target business or multiple target businesses simultaneously or within a short period of time. However, we may not be able to effectuate our initial business combination with more than one target business because of various factors, including the existence of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the SEC that present operating results and the financial condition of several target businesses as if they had been operated on a combined basis. By completing our initial business combination with only a single entity, our lack of diversification may subject us to numerous economic, competitive and regulatory developments. Further, we would not be able to diversify our operations or benefit from the possible spreading of risks or offsetting of losses, unlike other entities which may have the resources to complete several business combinations in different industries or different areas of a single industry. Accordingly, the prospects for our success may be:

● solely dependent upon the performance of a single business, property or asset; or

● dependent upon the development or market acceptance of a single or limited number of products, processes or services.

This lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to our initial business combination.

 ****

***We may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability.***

If we determine to simultaneously acquire several businesses that are owned by different sellers, we will need for each of such sellers to agree that our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make it more difficult for us, and delay our ability, to complete our initial business combination. With multiple business combinations, we could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations and services or products of the acquired companies in a single operating business. If we are unable to adequately address these risks, it could negatively impact our profitability and results of operations.

 ****

***We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all.***

In pursuing our business combination strategy, we may seek to effectuate our initial business combination with a privately held company. Very little public information generally exists about private companies, and we could be required to make our decision on whether to pursue a potential initial business combination on the basis of limited information, which may result in a business combination with a company that is not as profitable as we suspected, if at all.

 ****

***We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our shareholders do not agree.***

Our articles will not provide a specified maximum redemption threshold. Our proposed initial business combination may impose a minimum cash requirement for (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. As a result, we may be able to complete our initial business combination even though a substantial majority of our public shareholders do not agree with the transaction and have redeemed their shares or, if we seek shareholder approval of our initial business combination and do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, have entered into privately negotiated agreements to sell their shares to our sponsor, officers, directors, advisors or any of their affiliates. In the event the aggregate cash consideration we would be required to pay for all ordinary shares that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed business combination exceed the aggregate amount of cash available to us, we will not complete the business combination or redeem any shares, all ordinary shares submitted for redemption will be returned to the holders thereof, and we instead may search for an alternate business combination.

 ****

***In order to effectuate an initial business combination, special purpose acquisition companies have, in the recent past, amended various provisions of their charters and other governing instruments. We cannot assure you that we will not seek to amend our articles or governing instruments in a manner that will make it easier for us to complete our initial business combination that our shareholders may not support.***

In order to effectuate a business combination, special purpose acquisition companies have, in the recent past, amended various provisions of their charters and governing instruments. For example, special purpose acquisition companies have amended the definition of business combination, increased redemption thresholds and extended the time to consummate an initial business combination. Amending our articles requires a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. In addition, our articles requires us to provide our public shareholders with the opportunity to redeem their public shares for cash if we propose an amendment to our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity. To the extent any of such amendments would be deemed to fundamentally change the nature of the securities offered through this registration statement, we would register, or seek an exemption from registration for, the affected securities. We cannot assure you that we will not seek to amend our articles or extend the time to consummate an initial business combination in order to effectuate our initial business combination.

***The provisions of our articles that relate to our pre-business combination activity (and corresponding provisions of the agreement governing the release of funds from our trust account) may be amended with the approval of a special resolution passed by the affirmative vote of holders of a majority of not less than two-thirds of our ordinary shares which are represented in person or by proxy and are voted at a general meeting of the company (or 65% of our ordinary shares with respect to amendments to the trust agreement governing the release of funds from our trust account), which is a lower amendment threshold than that of some other special purpose acquisition companies. It may be easier for us, therefore, to amend our articles to facilitate the completion of an initial business combination that some of our shareholders may not support.***

Our articles provide that any of its provisions related to pre-business combination activity (including the requirement to deposit proceeds of this offering and the private placement of shares into the trust account and not release such amounts except in specified circumstances, and to provide redemption rights to public shareholders as described herein) may be amended if approved by special resolution, under Cayman Islands law and our articles being the affirmative vote of at least a two-thirds majority of the shareholders who attend either in person or by proxy and vote thereon at a general meeting of the company and corresponding provisions of the trust agreement governing the release of funds from our trust account may be amended if approved by holders of 65% of our ordinary shares which are represented in person or by proxy and are voted at a general meeting of the company. Our initial shareholders, who will collectively beneficially own approximately 20% of our ordinary shares upon the closing of this offering (excluding the private placement shares and assuming they do not purchase any shares in this offering), will participate in any vote to amend our articles and/or trust agreement and will have the discretion to vote in any manner they choose. As a result, we may be able to amend the provisions of our articles which govern our pre-business combination behavior more easily than some other special purpose acquisition companies, and this may increase our ability to complete a business combination with which you do not agree. Our shareholders may pursue remedies against us for any breach of our articles.

Our sponsor, officers, directors and director nominees have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, unless we provide our public shareholders with the opportunity to redeem their ordinary shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then outstanding public shares. Our shareholders are not parties to, or third-party beneficiaries of, these agreements and, as a result, will not have the ability to pursue remedies against our sponsor, officers, directors or director nominees for any breach of these agreements. As a result, in the event of a breach, our shareholders would need to pursue a shareholder derivative action, subject to applicable law.

 ****

***Certain agreements related to this offering may be amended without shareholder approval.***

Each of the agreements related to this offering to which we are a party, other than the investment management trust agreement, may be amended without shareholder approval. Such agreements are: the underwriting agreement; the letter agreement among us and our sponsor, officers and directors; the registration rights agreement among us and our initial shareholders; the private placement shares purchase agreement between us and our sponsor; and the administrative services agreement among us and our sponsor. These agreements contain various provisions that our public shareholders might deem to be material. For example, our letter agreement and the underwriting agreement contain certain lock-up provisions with respect to the founder shares and private placement shares held by our initial shareholders, sponsor, officers and directors. Amendments to such agreements would require the consent of the applicable parties thereto and would need to be approved by our board of directors, which may do so for a variety of reasons, including to facilitate our initial business combination. While we do not expect our board of directors to approve any amendment to any of these agreements prior to our initial business combination, it may be possible that our board of directors, in exercising its business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to any such agreement. Any amendment entered into in connection with the consummation of our initial business combination will be disclosed in our proxy materials or tender offer documents, as applicable, related to such initial business combination, and any other material amendment to any of our material agreements will be disclosed in a filing with the SEC. Any such amendments would not require approval from our shareholders, may result in the completion of our initial business combination that may not otherwise have been possible, and may have an adverse effect on the value of an investment in our securities. For example, amendments to the lock-up provision discussed above may result in our initial shareholders selling their securities earlier than they would otherwise be permitted, which may have an adverse effect on the price of our securities.

***We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a particular business combination.***

We have not selected any specific business combination target but intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of this offering and the sale of the private placement shares. As a result, if the cash portion of the purchase price exceeds the amount available from the trust account, net of amounts needed to satisfy any redemption by public shareholders, we may be required to seek additional financing to complete such proposed initial business combination. We cannot assure you that such financing will be available on acceptable terms, if at all. To the extent that additional financing proves to be unavailable when needed to complete our initial business combination, we would be compelled to either restructure the transaction or abandon that particular business combination and seek an alternative target business candidate. Further, we may be required to obtain additional financing in connection with the closing of our initial business combination for general corporate purposes, including for maintenance or expansion of operations of the post-transaction businesses, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, or to fund the purchase of other companies. If we are unable to complete our initial business combination, our public shareholders may only receive their *pro rata* portion of the funds in the trust account that are available for distribution to public shareholders. In addition, even if we do not need additional financing to complete our initial business combination, we may require such financing to fund the operations or growth of the target business. The failure to secure additional financing could have a material adverse effect on the continued development or growth of the target business. None of our officers, directors or shareholders is required to provide any financing to us in connection with or after our initial business combination.

 ****

***Our initial shareholders control a substantial interest in us and thus may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support.***

Upon closing of this offering, our initial shareholders will own approximately 20% of our issued and outstanding ordinary shares (excluding the private placement shares and assuming they do not purchase any shares in this offering). Accordingly, they may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support, including amendments to our articles. If our initial shareholders purchase any shares in this offering or if our initial shareholders purchase any additional ordinary shares in the aftermarket or in privately negotiated transactions, this would increase their control. Neither our initial shareholders nor, to our knowledge, any of our officers or directors, have any current intention to purchase additional securities, other than as disclosed in this prospectus. Factors that would be considered in making such additional purchases would include consideration of the current trading price of our ordinary shares.

 ****

***We may not be able to complete an initial business combination since such initial business combination may be subject to regulatory review and approval requirements, including foreign investment regulations and review by government entities such as the CFIUS, or may be ultimately prohibited.***

Our initial business combination may be subject to regulatory review and approval requirements by governmental entities, or ultimately prohibited. For example, CFIUS has authority to review direct or indirect foreign investments in U.S. companies. Among other things, CFIUS is empowered to require certain foreign investors to make mandatory filings, to charge filing fees related to such filings, and to self-initiate national security reviews of foreign direct and indirect investments in U.S. companies if the parties to that investment choose not to file voluntarily. In the case that CFIUS determines an investment to be a threat to national security, CFIUS has the power to unwind or place restrictions on the investment. Whether CFIUS has jurisdiction to review an acquisition or investment transaction depends on — among other factors — the nature and structure of the transaction, including the level of beneficial ownership interest and the nature of any information or governance rights involved. For example, investments that result in "control" of a U.S. business by a foreign person always are subject to CFIUS jurisdiction. CFIUS's expanded jurisdiction under the Foreign Investment Risk Review Modernization Act of 2018 and implementing regulations that became effective on February 13, 2020 further includes investments that do not result in control of a U.S. business by a foreign person but afford certain foreign investors certain information or governance rights in a U.S. business that has a nexus to "critical technologies," "critical infrastructure" and/or "sensitive personal data."

Our sponsor will own 20% of our issued and outstanding ordinary shares following this offering (excluding the private placement shares). Our sponsor is exclusively "controlled" for CFIUS purposes by Dr. Someit Sidhu, who is a citizen of the United Kingdom. As a result, we may be considered a "foreign person" under rules promulgated by CFIUS and may not be able to complete an initial business combination with a U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as CFIUS, or ultimately prohibited. As such, an initial business combination with a U.S. business or foreign business with U.S. subsidiaries that we may wish to pursue may be subject to CFIUS review. If a particular proposed initial business combination with a U.S. business falls within CFIUS's jurisdiction, we may determine that we are required to make a mandatory filing or that we will submit to CFIUS review on a voluntary basis, or to proceed with the transaction without submitting to CFIUS and risk CFIUS intervention, before or after closing the transaction. CFIUS may decide to block or delay our proposed initial business combination, impose conditions with respect to such initial business combination or request the President of the United States to order us to divest all or a portion of the U.S. target business of our initial business combination that we acquired without first obtaining CFIUS approval, which may limit the attractiveness of, delay or prevent us from pursuing certain target companies that we believe would otherwise be beneficial to us and our shareholders. As a result, the pool of potential targets with which we could complete an initial business combination may be limited and we may be adversely affected in terms of competing with other special purpose acquisition companies which do not have any foreign ownership issues. In addition, certain federally licensed businesses may be subject to rules or regulations that limit foreign ownership.

The process of government review, whether by CFIUS or otherwise, could be lengthy. Because we have only a limited time to complete our initial business combination, our failure to obtain any required approvals within the requisite time period may require us to liquidate. If we are unable to consummate our initial business combination within the applicable time period required under our articles, including as a result of extended regulatory review of a potential initial business combination, we will, as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares for a pro rata portion of the funds held in the trust account, subject to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. In such event, our shareholders will miss the opportunity to benefit from an investment in a target company and the appreciation in value of such investment.

 ****

***Because we must furnish our shareholders with target business financial statements, we may lose the ability to complete an otherwise advantageous initial business combination with some prospective target businesses.***

The federal proxy rules require that the proxy statement with respect to the vote on an initial business combination include historical and *pro forma* financial statement disclosure. We will include the same financial statement disclosure in connection with our tender offer documents, whether or not they are required under the tender offer rules. These financial statements may be required to be prepared in accordance with, or be reconciled to, accounting principles generally accepted in the United States of America ("GAAP") or international financial reporting standards as issued by the International Accounting Standards Board ("IFRS") depending on the circumstances and the historical financial statements may be required to be audited in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"). These financial statement requirements may limit the pool of potential target businesses we may acquire because some targets may be unable to provide such financial statements in time for us to disclose such statements in accordance with federal proxy rules and complete our initial business combination within the prescribed time frame.

 ****

***Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an initial business combination.***

Section 404 of the Sarbanes-Oxley Act requires that we evaluate and report on our system of internal controls beginning with our Annual Report on Form 10-K for the year ending December 31, 2026. Only in the event we are deemed to be a large accelerated filer or an accelerated filer, and no longer qualify as an emerging growth company, will we be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial reporting. Further, for as long as we remain an emerging growth company, we will not be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial reporting. The fact that we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared to other public companies because a target business with which we seek to complete our initial business combination may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal control of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such business combination.

 ****

***Our shareholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares.***

If we are forced to enter into an insolvent liquidation, any distributions received by shareholders could be viewed as an unlawful payment if it was proved that immediately following the date on which the distribution was made, we were unable to pay our debts as they fall due in the ordinary course of business. As a result, a liquidator could seek to recover some or all amounts received by our shareholders. Furthermore, our directors may be viewed as having breached their fiduciary duties to us or our creditors and/or may have acted in bad faith, thereby exposing themselves and our company to claims, by paying public shareholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons. We and our directors and officers who knowingly and willfully authorized or permitted any distribution to be paid out of our share premium account while we were unable to pay our debts as they fall due in the ordinary course of business would be guilty of an offence and may be liable to a fine of approximately $18,293 and to imprisonment for five years in the Cayman Islands.

 ****

***We may seek business combination opportunities with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our desired results.***

We may seek business combination opportunities with large, highly complex companies that we believe would benefit from operational improvements. While we intend to implement such improvements, to the extent that our efforts are delayed or we are unable to achieve the desired improvements, the business combination may not be as successful as we anticipate.

To the extent we complete our initial business combination with a large complex business or entity with a complex operating structure, we may also be affected by numerous risks inherent in the operations of the business with which we combine, which could delay or prevent us from implementing our strategy. Although our management team will endeavor to evaluate the risks inherent in a particular target business and its operations, we may not be able to properly ascertain or assess all of the significant risk factors until we complete our business combination. If we are not able to achieve our desired operational improvements, or the improvements take longer to implement than anticipated, we may not achieve the gains that we anticipate. Furthermore, some of these risks and complexities may be outside of our control and leave us with no ability to control or reduce the chances that those risks and complexities will adversely impact a target business. Such combination may not be as successful as a combination with a smaller, less complex organization.

**Risks Relating to the Post Business Combination Company**

 ****

***Subsequent to our completion of our initial business combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which could cause you to lose some or all of your investment.***

Even if we conduct due diligence on a target business with which we combine, we cannot assure you that this diligence will identify all material issues that may be present within a particular target business, that it would be possible to uncover all material issues through a customary amount of due diligence, or that factors outside of the target business and outside of our control will not later arise. As a result of these factors, we may be forced to later write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in our reporting losses. Even if our due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Even though these charges may be non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may cause us to violate net worth or other covenants to which we may be subject as a result of assuming pre-existing debt held by a target business or by virtue of our obtaining debt financing to partially finance the initial business combination or thereafter. Accordingly, any shareholders who choose to remain shareholders following the business combination could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.

 ****

***Resources could be wasted in researching business combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public shareholders may only receive their pro rata portion of the funds in the trust account that are available for distribution to public shareholders.***

We anticipate that the investigation of each specific target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require substantial management time and attention and substantial costs for accountants, attorneys and others. If we decide not to complete a specific initial business combination, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target business, we may fail to complete our initial business combination for any number of reasons including those beyond our control. Any such event will result in a loss to us of the related costs incurred which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public shareholders may only receive their *pro rata* portion of the funds in the trust account that are available for distribution to public shareholders.

 ****

***Our management may not be able to maintain control of a target business after our initial business combination. We cannot provide assurance that, upon loss of control of a target business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business.***

We may structure our initial business combination so that the post-transaction company in which our public shareholders own shares will own less than 100% of the equity interests or assets of a target business, but we will only complete such business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for us not to be required to register as an investment company under the Investment Company Act. We will not consider any transaction that does not meet such criteria. Even if the post-transaction company owns 50% or more of the voting securities of the target, our shareholders prior to the business combination may collectively own a minority interest in the post business combination company, depending on valuations ascribed to the target and us in the business combination. For example, we could pursue a transaction in which we issue a substantial number of new ordinary shares in exchange for all of the outstanding capital stock, shares or other equity interests of a target. In this case, we would acquire a 100% interest in the target. However, as a result of the issuance of a substantial number of new ordinary shares, our shareholders immediately prior to such transaction could own less than a majority of our issued and outstanding ordinary shares subsequent to such transaction. In addition, other minority shareholders may subsequently combine their holdings resulting in a single person or group obtaining a larger share of the company's shares than we initially acquired. Accordingly, this may make it more likely that our management will not be able to maintain control of the target business.

  ****

***We may have a limited ability to assess the management of a prospective target business and, as a result, may effect our initial business combination with a target business whose management may not have the skills, qualifications or abilities to manage a public company.***

When evaluating the desirability of effecting our initial business combination with a prospective target business, our ability to assess the target business's management may be limited due to a lack of time, resources or information. Our assessment of the capabilities of the target business's management, therefore, may prove to be incorrect and such management may lack the skills, qualifications or abilities we suspected. Should the target business's management not possess the skills, qualifications or abilities necessary to manage a public company, the operations and profitability of the post-combination business may be negatively impacted. Accordingly, any shareholders who choose to remain shareholders following the business combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.

 ****

***We may reincorporate in or transfer by way of continuation to another jurisdiction in connection with our initial business combination, and the laws of such jurisdiction may govern some or all of our future material agreements and we may not be able to enforce our legal rights.***

In connection with our initial business combination, we may relocate the home jurisdiction of our business from the Cayman Islands to another jurisdiction. If we determine to do this, the laws of such jurisdiction may govern some or all of our future material agreements. The system of laws and the enforcement of existing laws in such jurisdiction may not be as certain in implementation and interpretation as in the United States. The inability to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business, business opportunities or capital.

 ****

***We may transfer by way of continuation to another jurisdiction, which may result in taxes imposed on shareholders.***

We may, in connection with our initial business combination or otherwise and, to the extent applicable, subject to requisite shareholder approval by special resolution under the Companies Act and our articles, transfer by way of continuation to the jurisdiction in which the target company or business is located or in another jurisdiction. The transaction may require a shareholder to recognize taxable income in the jurisdiction in which the shareholder is a tax resident or in which its members are resident if it is a tax transparent entity (or may otherwise result in adverse tax consequences). We do not intend to make any cash distributions to shareholders to pay such taxes. Shareholders may be subject to withholding taxes or other taxes with respect to their ownership of our ordinary shares after the transfer by way of continuation.

 ****

***The officers and directors of an acquisition candidate may resign upon completion of our initial business combination. The loss of a business combination target's key personnel could negatively impact the operations and profitability of our post-combination business.***

The role of an acquisition candidate's key personnel upon the completion of our initial business combination cannot be ascertained at this time. Although we contemplate that certain members of an acquisition candidate's management team will remain associated with the acquisition candidate following our initial business combination, it is possible that members of the management of an acquisition candidate will not wish to remain in place.

***After our initial business combination, substantially all of our assets may be located in a foreign country and substantially all of our revenue will be derived from our operations in such country. Accordingly, our results of operations and prospects will be subject, to a significant extent, to the economic, political and legal policies, developments and conditions in the country in which we operate.***

The economic, political and social conditions, as well as government policies, of the country in which our operations are located could affect our business. Economic growth could be uneven, both geographically and among various sectors of the economy and such growth may not be sustained in the future. If in the future such country's economy experiences a downturn or grows at a slower rate than expected, there may be less demand for spending in certain industries. A decrease in demand for spending in certain industries could materially and adversely affect our ability to find an attractive target business with which to consummate our initial business combination and if we effect our initial business combination, the ability of that target business to become profitable.

 ****

***If our management following our initial business combination is unfamiliar with U.S. securities laws, they may have to expend time and resources becoming familiar with such laws, which could lead to various regulatory issues.***

Following our initial business combination, our management may resign from their positions as officers or directors of the company and the management of the target business at the time of the business combination will remain in place. Management of the target business may not be familiar with U.S. securities laws. If new management is unfamiliar with U.S. securities laws, they may have to expend time and resources becoming familiar with such laws. This could be expensive and time-consuming and could lead to various regulatory issues which may adversely affect our operations.

**Risks Relating to Acquiring and Operating a Business in Foreign Countries**

 ****

***If we effect our initial business combination with a company located outside of the United States, we would be subject to a variety of additional risks that may adversely affect us.***

If we pursue a target company with operations or opportunities outside of the United States for our initial business combination, we may face additional burdens in connection with investigating, agreeing to and completing such initial business combination, and if we effect such initial business combination, we would be subject to a variety of additional risks that may negatively impact our operations.

If we pursue a target a company with operations or opportunities outside of the United States for our initial business combination, we would be subject to risks associated with cross-border business combinations, including in connection with investigating, agreeing to and completing our initial business combination, conducting due diligence in a foreign jurisdiction, having such transaction approved by any local governments, regulators or agencies and changes in the purchase price based on fluctuations in foreign exchange rates.

If we effect our initial business combination with such a company, we would be subject to any special considerations or risks associated with companies operating in an international setting, including any of the following:

● costs and difficulties inherent in managing cross-border business operations;

● rules and regulations regarding currency redemption;

● complex corporate withholding taxes on individuals;

● laws governing the manner in which future business combinations may be effected;

● exchange listing and/or delisting requirements;

● tariffs and trade barriers;

● regulations related to customs and import/export matters;

● local or regional economic policies and market conditions;

● unexpected changes in regulatory requirements;

● challenges in managing and staffing international operations;

● longer payment cycles;

● tax issues, such as tax law changes and variations in tax laws as compared to the United States;

● currency fluctuations and exchange controls;

● rates of inflation;

● challenges in collecting accounts receivable;

● cultural and language differences;

● employment regulations;

● underdeveloped or unpredictable legal or regulatory systems;

● corruption;

● protection of intellectual property;

● social unrest, crime, strikes, riots and civil disturbances;

● regime changes and political upheaval;

● terrorist attacks, natural disasters, widespread health emergencies and wars; and

● deterioration of political relations with the United States.

We may not be able to adequately address these additional risks. If we were unable to do so, we may be unable to complete such initial business combination, or, if we complete such initial business combination, our operations might suffer, either of which may adversely impact our business, financial condition and results of operations.

 ****

***Exchange rate fluctuations and currency policies may cause a target business' ability to succeed in the international markets to be diminished.***

In the event we acquire a non-U.S. target, all revenues and income would likely be received in a foreign currency, and the dollar equivalent of our net assets and distributions, if any, could be adversely affected by reductions in the value of the local currency. The value of the currencies in our target regions fluctuate and are affected by, among other things, changes in political and economic conditions. Any change in the relative value of such currency against our reporting currency may affect the attractiveness of any target business or, following consummation of our initial business combination, our financial condition and results of operations. Additionally, if a currency appreciates in value against the dollar prior to the consummation of our initial business combination, the cost of a target business as measured in dollars will increase, which may make it less likely that we are able to consummate such transaction.

 ****

***If we acquire a non-U.S. target, our results of operations may be negatively impacted because of the costs and difficulties inherent in managing cross-border business operations.***

We may pursue a target company with operations or opportunities outside of the United States for our initial business combination. Managing a business, operations, personnel or assets in another country is challenging and costly. Any management that we may have (whether based abroad or in the U.S.) may be inexperienced in cross-border business practices and unaware of significant differences in accounting rules, legal regimes and labor practices. Even with a seasoned and experienced management team, the costs and difficulties inherent in managing cross-border business operations, personnel and assets can be significant (and much higher than in a purely domestic business) and may negatively impact our financial and operational performance.

 ****

***If social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval or policy changes or enactments occur in a country in which we may operate after we effect our initial business combination, it may result in a negative impact on our business.***

In the event we acquire a non-U.S. target, political events in another country may significantly affect our business, assets or operations. Social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval, and policy changes or enactments could negatively impact our business in a particular country.

***Many countries have difficult and unpredictable legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience, which may adversely impact our results of operations and financial condition.***

In the event we acquire a non-U.S. target, our ability to seek and enforce legal protections, including with respect to intellectual property and other property rights, or to defend ourselves with regard to legal actions taken against us in a given country, may be difficult or impossible, which could adversely impact our operations, assets or financial condition.

Rules and regulations in many countries are often ambiguous or open to differing interpretation by responsible individuals and agencies at the municipal, state, regional and federal levels. The attitudes and actions of such individuals and agencies are often difficult to predict and inconsistent.

Delay with respect to the enforcement of particular rules and regulations, including those relating to customs, tax, environmental and labor, could cause serious disruption to operations abroad and negatively impact our results.

 ****

***Because foreign law could govern almost all of our material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere, which could result in a significant loss of business, business opportunities or capital.***

In the event we acquire a non-U.S. target, foreign law could govern almost all of our material agreements. The target business may not be able to enforce any of its material agreements or enforce remedies for breaches of those agreements outside of such foreign jurisdiction's legal system. The system of laws and the enforcement of existing laws and contracts in such jurisdiction may not be as certain in implementation and interpretation as in the United States. As a result, the inability to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business and business opportunities.

 ****

***After our initial business combination, it is possible that a majority of our directors and officers will live outside the United States and all of our assets will be located outside the United States; therefore, investors may not be able to enforce federal securities laws or their other legal rights.***

It is possible that after our initial business combination, a majority of our directors and officers will reside outside of the United States and all of our assets will be located outside of the United States. As a result, it may be difficult, or in some cases not possible, for investors in the United States to enforce their legal rights, to effect service of process upon all of our directors or officers or to enforce judgments of United States courts predicated upon civil liabilities and criminal penalties on our directors and officers under United States laws.

 ****

***After our initial business combination, it is possible that substantially all of our assets may be located in a foreign country and substantially all of our revenue will be derived from our operations in such country. Accordingly, our results of operations and prospects will be subject, to a significant extent, to the economic, political and legal policies, developments and conditions in the country in which we operate.***

The economic, political and social conditions, as well as government policies, of the country in which our operations are located could affect our business. Economic growth could be uneven, both geographically and among various sectors of the economy and such growth may not be sustained in the future. If in the future such country's economy experiences a downturn or grows at a slower rate than expected, there may be less demand for spending in certain industries. A decrease in demand for spending in certain industries could materially and adversely affect our ability to find an attractive target business with which to consummate our initial business combination and if we effect our initial business combination, the ability of that target business to become profitable.

**Risks Relating to Our Sponsor and Management Team**

 ****

***We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate.***

Our operations are dependent upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success depends on the continued service of our officers and directors, at least until we have completed our initial business combination. In addition, our officers and directors are not required to commit any specified amount of time to our affairs and, accordingly, will have conflicts of interest in allocating their time among various business activities, including identifying potential business combinations and monitoring the related due diligence. We do not have an employment agreement with, or key-man insurance on the life of, any of our directors or officers. The unexpected loss of the services of one or more of our directors or officers could have a detrimental effect on us.

 ****

***Our ability to successfully effect our initial business combination and to be successful thereafter will be dependent upon the efforts of our key personnel, some of whom may join us following our initial business combination. The loss of key personnel could negatively impact the operations and profitability of our post-combination business.***

Our ability to successfully effect our initial business combination is dependent upon the efforts of our key personnel. The role of our key personnel in the target business, however, cannot presently be ascertained. Although some of our key personnel may remain with the target business in senior management or advisory positions following our initial business combination, it is likely that some or all of the management of the target business will remain in place. While we intend to closely scrutinize any individuals we engage after our initial business combination, we cannot assure you that our assessment of these individuals will prove to be correct. These individuals may be unfamiliar with the requirements of operating a company regulated by the SEC, which could cause us to have to expend time and resources helping them become familiar with such requirements.

 ****

***Our key personnel may negotiate employment or consulting agreements with a target business in connection with a particular business combination, and a particular business combination may be conditioned on the retention or resignation of such key personnel. These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular business combination is the most advantageous.***

Our key personnel may be able to remain with our company after the completion of our initial business combination only if they are able to negotiate employment or consulting agreements in connection with the business combination. Such negotiations would take place simultaneously with the negotiation of the business combination and could provide for such individuals to receive compensation in the form of cash payments and/or our securities for services they would render to us after the completion of the business combination. Such negotiations also could make such key personnel's retention or resignation a condition to any such agreement. The personal and financial interests of such individuals may influence their motivation in identifying and selecting a target business, subject to their fiduciary duties under Cayman Islands law.

 ****

***We may not have sufficient funds to satisfy indemnification claims of our sponsor, directors and officers.***

We have agreed to indemnify our sponsor and our officers and directors to the fullest extent permitted by law. However, our sponsor and our officers and directors have agreed to waive any right, title, interest or claim of any kind in or to any monies in the trust account and to not seek recourse against the trust account for any reason whatsoever. Accordingly, any indemnification provided will be able to be satisfied by us only if (i) we have sufficient funds outside of the trust account or (ii) we consummate an initial business combination. Our obligation to indemnify our sponsor and our officers and directors may discourage shareholders from bringing a lawsuit against our sponsor and our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our sponsor and our officers and directors, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.

 ****

***Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.***

Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in other business endeavors for which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs.

Our independent directors also serve as officers and board members for other entities. If our officers' and directors' other business affairs require them to devote substantial amounts of time to such affairs in excess of their current commitment levels, it could limit their ability to devote time to our affairs which may have a negative impact on our ability to complete our initial business combination. For a complete discussion of our officers' and directors' other business affairs, please see "*Management — Officers, Directors and Director Nominees*."

 ****

***Our officers and directors presently have, and any of them in the future may have additional, fiduciary or contractual obligations to other entities, including other blank check companies, and, accordingly, may have conflicts of interest in allocating their time and in determining to which entity a particular business opportunity should be presented.***

Following the completion of this offering and until we consummate our initial business combination, we intend to engage in the business of identifying and combining with one or more businesses. Our sponsor, its managing member, and our officers and directors are, or may in the future become, affiliated with entities (such as operating companies or investment vehicles) that are engaged in a similar business. We do not have employment contracts with our officers and directors that will limit their ability to work at other businesses. Each of our officers and directors presently has, and any of them in the future may have, additional fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entities. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in our favor and a potential target business may be presented to another entity prior to its presentation to us, subject to their fiduciary duties under Cayman Islands law. Our articles provide that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which may (a) be a corporate opportunity for any director or officer, on the one hand, and us, on the other, or (b) the presentation of which would breach an existing legal obligation of a member of director, officer or sponsor to any other entity. The purpose for the surrender of corporate opportunities is to allow officers, directors or other representatives with multiple business affiliations to continue to serve as an officer of our company or on our board of directors. Our officers and directors may from time to time be presented with opportunities that could benefit both another business affiliation and us. In the absence of the "corporate opportunity" waiver in our articles, certain candidates would not be able to serve as an officer or director. We believe we substantially benefit from having representatives who bring significant, relevant and valuable experience to our management, and, as a result, the inclusion of the "corporate opportunity" waiver in our articles provide us with greater flexibility to attract and retain the officers and directors that we feel are the best candidates. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our initial business combination.

In addition, our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies with acquisition objectives that are similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination.

For a complete discussion of our officers' and directors' business affiliations and the potential conflicts of interest that you should be aware of, please see "*Management — Officers, Directors and Director Nominee*s," "*Management — Conflicts of Interest*" and "*Certain Relationships and Related Party Transactions*."

 ****

***Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.***

We have not adopted a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into a business combination with a target business that is affiliated with our sponsor, our directors or officers, although we do not intend to do so. Nor do we have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours.

The personal and financial interests of our directors and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination. Consequently, our directors' and officers' discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our shareholders' best interest. If this were the case, it would be a breach of their fiduciary duties to us as a matter of Cayman Islands law and we or our shareholders might have a claim against such individuals for infringing on our shareholders' rights. See the section titled "*Description of Securities — Certain Differences in Corporate Law — Shareholder Suits*" for further information on the ability to bring such claims. However, we might not ultimately be successful in any claim we may make against them for such reason.

 ****

***Members of our management team and board of directors have significant experience as board members, officers or executives of other companies. As a result, certain of those persons have been, may be, or may become, involved in proceedings, investigations and litigation relating to the business affairs of the companies with which they were, are, or may in the future be, affiliated. This may have an adverse effect on us, which may impede our ability to consummate an initial business combination.***

During the course of their careers, members of our management team and board of directors have had significant experience as board members, officers or executives of other companies. As a result of their involvement and positions in these companies, certain persons were, are now, or may in the future become, involved in litigation, investigations or other proceedings relating to the business affairs of such companies or transactions entered into by such companies. Any such litigation, investigations or other proceedings may divert our management team's and board's attention and resources away from identifying and selecting a target business or businesses for our initial business combination and may negatively affect our reputation, which may impede our ability to complete an initial business combination.

 ****

***Members of our management team and affiliated companies may have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our business.***

Members of our management team have been (and intend to be) involved in a wide variety of businesses. Such involvement has, and may lead to, media coverage and public awareness. As a result, members of our management team and affiliated companies may have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our business. Any such claims or investigations may be detrimental to our reputation and could negatively affect our ability to identify and complete an initial business combination and may have an adverse effect on the price of our securities.

 ****

***Our letter agreement with our sponsor, officers, directors and advisors may be amended without shareholder approval.***

Our letter agreement with our sponsor, officers, directors and advisors contain provisions relating to transfer restrictions of our founder shares and private placement shares, indemnification of the trust account, waiver of redemption rights and participation in liquidating distributions from the trust account. The letter agreement may be amended without shareholder approval (although releasing the parties from the restriction not to transfer the founder shares for 185 days following the date of this prospectus will require the prior written consent of the underwriter). While we do not expect our board to approve any amendment to the letter agreement prior to our initial business combination, it may be possible that our board, in exercising its business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to the letter agreement. Any such amendments to the letter agreement would not require approval from our shareholders and may have an adverse effect on the value of an investment in our securities.

**Risks Relating to Our Securities**

 ****

***You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares, potentially at a loss.***

Our public shareholders will be entitled to receive funds from the trust account only upon the earlier to occur of: (i) in connection with our completion of an initial business combination, and then only in connection with those public shares that such shareholder properly elected to redeem, subject to the limitations described herein, (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend our articles not for the purpose of approving, or in conjunction with the consummation of, an initial business combination (A) to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, and the redemption of our public shares if we are unable to complete an initial business combination within the completion window, subject to applicable law and as further described herein. In addition, if we are unable to complete an initial business combination within the completion window, we will as promptly as reasonably possible but not more than ten business days thereafter, subject to lawfully available funds, redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 to pay dissolution expenses), divided by the number of then issued and outstanding public shares. In no other circumstances will a public shareholder have any right or interest of any kind in the trust account. Accordingly, to liquidate your investment, you may be forced to sell your public shares, potentially at a loss.

***If we are unable to consummate our initial business combination within the completion window from the closing of this offering, our public shareholders may be forced to wait beyond such completion window before redemption from our trust account.***

If we are unable to consummate our initial business combination within the completion window, the proceeds then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid and payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), will be used to fund the redemption of our public shares, as further described herein. Any redemption of public shareholders from the trust account will be effected automatically by function of our articles prior to any voluntary winding up. If we are required to wind-up, liquidate the trust account and distribute such amount therein, pro rata, to our public shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with the applicable provisions of the Companies Act. In that case, investors may be forced to wait beyond 24 months from the closing of this offering before the redemption proceeds of our trust account become available to them, and they receive the return of their pro rata portion of the proceeds from our trust account. We have no obligation to return funds to investors prior to the date of our redemption or liquidation unless we consummate our initial business combination prior thereto and only then in cases where investors have sought to redeem their ordinary shares. Only upon our redemption or any liquidation will public shareholders be entitled to distributions if we are unable to complete our initial business combination.

 ****

***Nasdaq may delist our ordinary shares from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions.***

We intend to apply to have our ordinary shares listed on Nasdaq. We expect that our ordinary shares will be listed on Nasdaq on or promptly after the date of this prospectus. Although after giving effect to this offering we expect to meet, on a *pro forma* basis, the minimum initial listing standards set forth in Nasdaq listing standards, we cannot assure you that our ordinary shares will be, or will continue to be, listed on Nasdaq in the future or prior to our initial business combination. In order to continue listing our securities on Nasdaq prior to our initial business combination, we must maintain certain financial, distribution and share price levels. Generally, following our initial public offering, we must maintain a minimum market value of listed securities (generally $50,000,000) and a minimum number of holders of our securities (generally 400 public holders). Additionally, in connection with our initial business combination, we will be required to demonstrate compliance with Nasdaq's initial listing requirements, which are more rigorous than Nasdaq's continued listing requirements, in order to continue to maintain the listing of our securities on Nasdaq. For instance, unless we decide to list on a different Nasdaq tier such as the Nasdaq Capital Market which has different initial listing requirements, our share price would generally be required to be at least $4.00 per share and we would be required to have a minimum of 400 round lot holders of our securities. We cannot assure you that we will be able to meet those initial listing requirements at that time.

If Nasdaq delists our ordinary shares from trading on its exchange and we are not able to list our ordinary shares on another national securities exchange, we expect our ordinary shares could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:

● a limited availability of market quotations for our ordinary shares;

● reduced liquidity for our ordinary shares;

● a determination that our ordinary shares are a "penny stock" which will require brokers trading in our ordinary shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our ordinary shares;

● a limited amount of news and analyst coverage; and

● a decreased ability to issue additional securities or obtain additional financing in the future.

The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as "covered securities." Because we expect that our ordinary shares will be listed on Nasdaq, our ordinary shares will qualify as covered securities under the statute. Although the states are preempted from regulating the sale of our ordinary shares, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. While we are not aware of a state having used these powers to prohibit or restrict the sale of securities issued by blank check companies, other than the State of Idaho, certain state securities regulators view blank check companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities of blank check companies in their states. Further, if we were no longer listed on Nasdaq, our securities would not qualify as covered securities under the statute and we would be subject to regulation in each state in which we offer our securities.

 ****

***The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the business combination causes the trading price of our ordinary shares to materially decline.***

We are offering our ordinary shares at an offering price of $10.00 per share and the amount in our trust account is initially anticipated to be $10.00 per public share, implying an initial value of $10.00 per public share. However, prior to this offering, our sponsor paid a nominal aggregate purchase price of $25,000 for 1,725,000 founder shares (including 225,000 founder shares subject to forfeiture by our sponsor if the over-allotment option is not exercised in full or in part by the underwriters), or approximately $0.014 per share. As a result, the value of your public shares may be significantly diluted upon the consummation of our initial business combination, when the founder shares are converted into public shares. Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor.

For example, the following table shows the dilutive effect of the founder shares on the implied value of the public shares upon the consummation of our initial business combination assuming that our equity value at that time is $58,200,000, which is the amount we would have for our initial business combination in the trust account assuming the underwriters' over-allotment option is not exercised, this offering is not upsized, no interest is earned on the funds held in the trust account, no public shares are redeemed in connection with our initial business combination, and all founder shares are held by our initial shareholders upon completion of our initial business combination. At such valuation, each of our ordinary shares would have an implied value of $7.46 per share upon consummation of our initial business combination, which is a 23.1% decrease as compared to the initial implied value per public share of $9.70.

---

| | |
|:---|:---|
| Public shares | 6000000.0 |
| Founder shares | 1500000.0 |
| Private placement shares | 300000.0 |
| Total shares | 7800000.0 |
| Total funds in trust available for initial business combination<sup>(1)</sup> | $58200000.0 |
| Public shareholders' investment per share | $10.0 |
| Sponsor's investment per ordinary share<sup>(2)</sup> | $0.2 |
| Initial implied value per public share | $9.7 |
| Implied value per share upon consummation of initial business combination<sup>(3)(4)</sup> | $7.46 |

---

(1) Does not take into account other potential impacts on our
valuation at the time of the business combination, such as the trading price of our public shares, the terms of the business combination
transaction (including any equity issued to or retained by, or cash or other consideration paid to, the target's shareholder or
other third parties), the business combination transaction costs (other than the payment of $1,800,000 of deferred underwriting commissions),
or the target's business itself, including its assets, liabilities, management and prospects. For instance, the potential dilution
experienced by holders of our ordinary shares may be mitigated if the business combination agreement is structured such that the potential
dilutive impact of the founder shares is borne by all shareholders in the pro forma company.

(2) The total investment in the equity of the company by the
sponsor consists of $25,000 paid by the sponsor for the founder shares. For purposes of this table, the full investment amount is ascribed
to the founder shares only.

(3) Note that redemptions of our public shares in connection
with our initial business combination would further reduce the implied value of our ordinary shares. For instance, in this example, if
50% of the public shares were redeemed in connection with our initial business combination, the implied value per ordinary share would
be $12.13.

(4) All founder shares would automatically convert into ordinary
shares upon completion of our initial business combination or earlier at the option of the holder.

Based on these assumptions, each ordinary share would have an implied value of $7.46 per share upon completion of our initial business combination, representing an approximately 23.1% decrease from the initial implied value of $9.70 per public share. While the implied value of $7.46 per ordinary share upon completion of our initial business combination would represent a dilution to our public shareholders, this would represent a significant increase in value for our sponsor relative to the price it paid for each founder share. At $7.46 per ordinary share, the 1,800,000 ordinary shares that the sponsor would own upon completion of our initial business combination would have an aggregate implied value of $13,428,000. As a result, even if the trading price of our ordinary shares significantly declines, the value of the founder shares held by our sponsor will be significantly greater than the amount our sponsor paid to purchase such shares. In addition, our sponsor could potentially recoup its entire investment in our company even if the trading price of our ordinary shares after the initial business combination is as low as $0.02 per share. As a result, our sponsor is likely to earn a substantial profit on its investment in us upon disposition of its ordinary shares even if the trading price of our ordinary shares declines after we complete our initial business combination. Our sponsor may therefore be economically incentivized to complete an initial business combination with a riskier, weaker-performing or less-established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares.

Additionally, our public shareholders may experience further dilution if we increase the size of this offering pursuant to Rule 462(b) under the Securities Act and we effect with our sponsor a share dividend or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding private placement shares).

 ****

***The grant of registration rights to our initial shareholders and holders of our private placement shares may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our ordinary shares.***

Pursuant to an agreement to be entered into concurrently with the issuance and sale of the securities in this offering, our initial shareholders and their permitted transferees can demand that we register the founder shares, holders of our private placement shares and their permitted transferees can demand that we register the private placement shares and the ordinary shares and holders of private placement shares that may be issued upon conversion of working capital loans may demand that we register such shares or the ordinary shares issuable upon exercise of such loans. We will bear the cost of registering these securities. The registration and availability of such a significant number of securities for trading in the public market may have an adverse effect on the market price of our ordinary shares. In addition, the existence of the registration rights may make our initial business combination more costly or difficult to conclude. This is because the shareholders of the target business may increase the equity stake they seek in the combined entity or ask for more cash consideration to offset the negative impact on the market price of our ordinary shares that is expected when the ordinary shares owned by our initial shareholders, holders of our private placement shares or holders of our working capital loans or their respective permitted transferees are registered.

 ****

***Our initial shareholders have paid an aggregate of $25,000, or approximately $0.014 per founder share and, accordingly, you will experience immediate and substantial dilution from the purchase of our ordinary shares.***

The difference between the public offering price per share and the *pro forma* net tangible book value per share of our ordinary shares after this offering constitutes the dilution to you and the other investors in this offering. Our initial shareholders acquired the founder shares at a nominal price, significantly contributing to this dilution. Upon closing of this offering you and the other public shareholders will incur an immediate and substantial dilution of approximately 101.90% (or $10.19 per share, assuming no exercise of the underwriter's over-allotment option), the difference between the *pro forma* net tangible book value per share after this offering of $(0.19) and the initial offering price of $10.00 per share.

***The determination of the offering price of our ordinary shares and the size of this offering is more arbitrary than the pricing of shares and size of an offering of an operating company in a particular industry. You may have less assurance, therefore, that the offering price of our shares properly reflects the value of such shares than you would have in a typical offering of an operating company.***

Prior to this offering there has been no public market for any of our ordinary shares. The public offering price of the shares was negotiated between us and the underwriter. In determining the size of this offering, management held customary organizational meetings with the representative of the underwriter, both prior to our inception and thereafter, with respect to the state of capital markets, generally, and the amount the underwriters believed it reasonably could raise on our behalf. Factors considered in determining the size of this offering, prices and terms of the ordinary shares include:

● the history and prospects of companies whose principal business is the acquisition of other companies;

● prior offerings of those companies;

● our prospects for acquiring an operating business at attractive values;

● a review of debt to equity ratios in leveraged transactions;

● our capital structure;

● an assessment of our management and their experience in identifying operating companies;

● general conditions of the securities markets at the time of this offering; and

● other factors as were deemed relevant.

Although these factors were considered, the determination of our offering size, price and terms of the shares is more arbitrary than the pricing of securities of an operating company in a particular industry since we have no historical operations or financial results.

 ****

***There is currently no market for our securities and a market for our securities may not develop, which would adversely affect the liquidity and price of our securities.***

There is currently no market for our securities. Shareholders therefore have no access to information about prior market history on which to base their investment decision. Following this offering, the price of our securities may vary significantly due to one or more potential business combinations and general market or economic conditions. Furthermore, an active trading market for our securities may never develop or, if developed, it may not be sustained. You may be unable to sell your securities unless a market can be established and sustained.

**General Risk Factors**

 ****

***We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.***

We are a blank check company incorporated under the laws of the Cayman Islands with no operating results, and we will not commence operations until obtaining funding through this offering. Because we lack an operating history, you have no basis upon which to evaluate our ability to achieve our business objective of completing our initial business combination. We have no plans, arrangements or understandings with any prospective target business concerning a business combination and may be unable to complete our initial business combination. If we fail to complete our initial business combination, we will never generate any operating revenues.

 ****

***Past performance by our management team, our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, may not be indicative of future performance of an investment in the Company.***

Information regarding our management team, our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, is presented for informational purposes only. Any past experience and performance by our management team, our advisors and their respective affiliates and the businesses with which they have been associated, is not a guarantee that we will be able to successfully identify a suitable candidate for our initial business combination, that we will be able to provide positive returns to our shareholders, or of any results with respect to any initial business combination we may consummate. You should not rely on the historical experiences of our management team, our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, as indicative of the future performance of an investment in us or as indicative of every prior investment by each of the members of our management team, our advisors or their respective affiliates. The market price of our securities may be influenced by numerous factors, many of which are beyond our and our management team's control, and our shareholders may experience losses on their investment in our securities.

 ****

***We may be a passive foreign investment company, or "PFIC," which could result in adverse U.S. federal income tax consequences to U.S. investors.***

If we are a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder (as defined in the section of this prospectus captioned "*Taxation — Certain U.S. Federal Income Tax Considerations — U.S. Holders*") of our ordinary shares, the U.S. Holder may be subject to adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. Our PFIC status for our current and subsequent taxable years may depend on whether we qualify for the PFIC startup exception (see the section of this prospectus captioned "*Taxation — Certain U.S. Federal Income Tax Considerations — U.S. Holders — Passive Foreign Investment Company Rules*"). Depending on our particular circumstances the application of the startup exception may be subject to uncertainty, and there cannot be any assurance that we will qualify for the startup exception. Our PFIC status for any taxable year, however, will not be determinable until after the end of such taxable year (and, in the case of the startup exemption, potentially not until after the two taxable years following our current taxable year). Accordingly, there can be no assurances with respect to our status as a PFIC for our current taxable year or any subsequent taxable year.

Moreover, if we determine we are a PFIC for any taxable year, upon written request, we will endeavor to provide to a U.S. Holder such information as the Internal Revenue Service (the "IRS") may require, including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain a "qualified electing fund" election, but there can be no assurance that we will timely provide such required information. We urge U.S. investors to consult their own tax advisors regarding the possible application of the PFIC rules. For a more detailed explanation of the tax consequences of PFIC classification to U.S. Holders, see the section of this prospectus captioned "*Taxation — Certain U.S. Federal Income Tax Considerations — U.S. Holders — Passive Foreign Investment Company Rules."*

 ****

***A 1% U.S. federal excise tax on stock buybacks could be imposed on redemptions of our stock if we were to become a "covered corporation" in the future.***

The Code generally imposes a 1% U.S. federal excise tax (the "Excise Tax") on certain repurchases of stock by "covered corporations" (which include publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign (i.e., non-U.S.) corporations). The Excise Tax is imposed on the repurchasing corporation itself, not its shareholders from which the stock is repurchased. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased. However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the Excise Tax. Although U.S. Treasury regulations clarify certain aspects of the Excise Tax, the interpretation and operation of other aspects of the Excise Tax remain unclear.

As a Cayman Islands exempted company, we are currently not a "covered corporation" for purposes of the Excise Tax. If we were to become a "covered corporation" in the future, whether in connection with the consummation of our initial business combination with a U.S. company (including if we were to redomicile as a U.S. corporation in connection therewith) or otherwise, whether and to what extent we would be subject to the Excise Tax on a redemption of our stock would depend on a number of factors, including (i) whether the redemption is treated as a repurchase of stock for purposes of the Excise Tax, (ii) the fair market value of the redemption treated as a repurchase of stock, (iii) the structure of our initial business combination, (iv) the nature and amount of any "PIPE" or other equity issuances (whether in connection with our initial business combination or otherwise) issued within the same taxable year of a redemption treated as a repurchase of stock and (v) the content of any future regulations and other guidance from the Treasury. As noted above, the Excise Tax would be payable by the repurchasing corporation, and not by the redeeming holder. The imposition of the Excise Tax on us as a result of redemptions by us could, however, reduce the amount of cash available to pay redemptions or reduce the cash available to the target business in connection with our initial business combination, which could cause investors in our securities who do not redeem or the other shareholders of the combined company to economically bear the impact of such Excise Tax. However, we will not use the proceeds placed in the trust account, or the interest earned on the proceeds placed in the trust account, to pay for possible excise tax or any other fees or taxes that may be levied on the company on any redemptions or share buybacks by the company pursuant to any current, pending or future rules or laws, including without limitation any Excise Tax, prior to the release of such funds from the trust account (a) following our initial business combination or (b) in the event that we do not complete our initial business combination within the completion window.

 ****

***An investment in this offering may result in uncertain U.S. federal income tax consequences.***

An investment in this offering may result in uncertain U.S. federal income tax consequences. For example, it is unclear whether the redemption rights with respect to our ordinary shares suspend the running of a U.S. Holder's (as defined in section titled "*Taxation — U.S. Federal Income Tax Considerations — U.S. Holders*") holding period for purposes of determining whether any gain or loss realized by such holder on the sale or exchange of ordinary shares is long-term capital gain or loss and for determining whether any dividend we pay would be considered "qualified dividend income" for U.S. federal income tax purposes. See the section titled "*Taxation — Certain U.S. Federal Income Tax Considerations*" for a summary of the U.S. federal income tax considerations of an investment in our securities. Prospective investors are urged to consult their tax advisors with respect to these and other tax consequences when acquiring, owning or disposing of our securities.

 ****

***Our initial business combination and our structure thereafter may not be tax-efficient to our shareholders. As a result of our business combination, our tax obligations may be more complex, burdensome and/or uncertain.***

Although we will attempt to structure our initial business combination in a tax-efficient manner, tax structuring considerations are complex, the relevant facts and law are uncertain and may change, and we may prioritize commercial and other considerations over tax considerations. For example, in connection with our initial business combination and subject to any requisite shareholder approval, we may structure our business combination in a manner that requires shareholders to recognize gain or income for tax purposes, effect a business combination with a target company in another jurisdiction, or reincorporate in a different jurisdiction (including, but not limited to, the jurisdiction in which the target company or business is located). We currently do not intend to make any cash distributions to shareholders to pay taxes in connection with our initial business combination or thereafter. Accordingly, a shareholder may need to satisfy any liability resulting from our initial business combination with cash from its own funds or by selling all or a portion of the shares received. In addition, shareholders may also be subject to additional income, withholding or other taxes with respect to their ownership of us after our initial business combination.

In addition, we may effect a business combination with a target company that has business operations outside of the United States, and possibly, business operations in multiple jurisdictions. If we effect such a business combination, we could be subject to significant income, withholding and other tax obligations in a number of jurisdictions with respect to income, operations and subsidiaries related to those jurisdictions. Due to the complexity of tax obligations and filings in other jurisdictions, we may have a heightened risk related to audits or examinations by U.S. federal, state and local and non-U.S. taxing authorities. This additional complexity and risk could have an adverse effect on our after-tax profitability and financial condition.

 ****

***We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.***

We are an "emerging growth company" within the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor internal controls attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, our shareholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our ordinary shares held by non-affiliates exceeds $700 million as of any June 30 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Additionally, we are a "smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our ordinary shares held by non-affiliates is equal to or exceeds $250 million as of the prior June 30, and (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates equals to or exceeds $700 million as of the prior June 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.

 ****

***Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited.***

We are an exempted company incorporated under the laws of the Cayman Islands. As a result, it may be difficult for investors to effect service of process within the United States upon our directors or officers, or enforce judgments obtained in the United States courts against our directors or officers.

Our corporate affairs will be governed by our articles, the Companies Act and the common law of the Cayman Islands. We will also be subject to the federal securities laws of the United States. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, the decisions of whose courts are of persuasive authority, but are not binding on a court in the Cayman Islands.

The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are different from what they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a different body of securities laws as compared to the United States, and certain states, such as Delaware, may have more fully developed and judicially interpreted bodies of corporate law. In addition, Cayman Islands companies may not have standing to initiate a shareholders derivative action in a federal court of the United States.

Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of the register of members of these companies. Our directors have discretion under our articles to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.

We have been advised by Appleby (Cayman) Ltd., our Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given, provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a U.S. company.

 ****

***Provisions in our articles may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our ordinary shares and could entrench management.***

Our articles contain provisions that may discourage unsolicited takeover proposals that shareholders may consider to be in their best interests. These provisions include a staggered board of directors and the ability of the board of directors to designate the terms of and issue new series of preference shares, which may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.

 ****

***Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.***

We depend on digital technologies, including information systems, infrastructure and cloud applications and services, including those of third parties with which we may deal. Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. As an early stage company without significant investments in data security protection, we may not be sufficiently protected against such occurrences. We may not have sufficient resources to adequately protect against, or to investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences, or a combination of them, could have adverse consequences on our business and lead to financial loss.

 ****

***Our articles provide that the courts of the Cayman Islands will be the exclusive forums for certain disputes between us and our shareholders, which could limit our shareholders' ability to obtain a favorable judicial forum for complaints against us or our directors, officers or employees.***

Our articles also provide that, without prejudice to any other rights or remedies that we may have, each of our shareholders acknowledges that damages alone would not be an adequate remedy for any breach of the selection of the courts of the Cayman Islands as exclusive forum and that accordingly we shall be entitled, without proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach of the selection of the courts of the Cayman Islands as exclusive forum.

This choice of forum provision may increase a shareholder's cost and limit the shareholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any of our shares or other securities, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies' charter documents has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable or unenforceable, and if a court were to find this provision in our articles to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could have adverse effect on our business and financial performance.

 ****

***Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination.***

The market for directors and officers liability insurance for special purpose acquisition companies has changed in ways adverse to us and our management team. Fewer insurance companies are offering quotes for directors and officers liability coverage, the premiums charged for such policies have generally increased and the terms of such policies have generally become less favorable. These trends may continue into the future.

The increased cost and decreased availability of directors and officers liability insurance could make it more difficult and more expensive for us to negotiate an initial business combination. In order to obtain directors and officers liability insurance or modify its coverage as a result of becoming a public company, the post-business combination entity might need to incur greater expense, accept less favorable terms or both. However, any failure to obtain adequate directors and officers liability insurance could have an adverse impact on the post-business combination's ability to attract and retain qualified officers and directors.

In addition, even after we were to complete an initial business combination, our directors and officers could still be subject to potential liability from claims arising from conduct alleged to have occurred prior to the initial business combination. As a result, in order to protect our directors and officers, the post-business combination entity may need to purchase additional insurance with respect to any such claims ("run-off insurance"). The need for run-off insurance would be an added expense for the post-business combination entity, and could interfere with or frustrate our ability to consummate an initial business combination on terms favorable to our investors.

 ****

***Recent increases in inflation in the United States and elsewhere could make it more difficult for us to complete our initial business combination.***

Recent increases in inflation in the United States and elsewhere may lead to increased price volatility for publicly traded securities, including ours, or other national, regional or international economic disruptions, any of which could make it more difficult for us to complete our initial business combination.

 ****

***We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of non-compliance.***

We are subject to rules and regulations by various governing bodies, including, for example, the SEC, which are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities.

Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed.

 ****

***We employ a mail forwarding service, which may delay or disrupt our ability to receive mail in a timely manner.***

Mail addressed to the Company and received at its registered office will be forwarded unopened to the forwarding address supplied by Company to be dealt with. None of the Company, its directors, officers, advisors or service providers (including the organization which provides registered office services in the Cayman Islands) will bear any responsibility for any delay howsoever caused in mail reaching the forwarding address, which may impair your ability to communicate with us.

**Cautionary Note Regarding Forward-Looking Statements**

Some of the statements contained in this prospectus may constitute "forward-looking statements" for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:

● our ability to select an appropriate target business or businesses;

● our ability to complete our initial business combination;

● our expectations around the performance of the prospective target business or businesses;

● our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;

● our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination;

● our potential ability to obtain additional financing to complete our initial business combination;

● our pool of prospective target businesses;

● our ability to consummate an initial business combination due to uncertainty and adverse impacts resulting from events outside of our control, such as increased geopolitical unrest, significant outbreaks of infectious diseases and increased volatility in the debt and equity markets;

● the ability of our officers and directors to generate a number of potential business combination opportunities;

● our public securities' potential liquidity and trading;

● the lack of a market for our securities;

● the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;

● the trust account not being subject to claims of third parties; or

● our financial performance following this offering.

The forward-looking statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "*Risk Factors*." Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

In addition, statements that contain "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. Although we believe that this information provides a reasonable basis for these statements, this information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

**Use of Proceeds**

We are offering 6,000,000 shares at an offering price of $10.00 per share. We estimate that the net proceeds of this offering together with the funds we will receive from the sale of the private placement shares will be used as set forth in the following table.

---

| | | |
|:---|:---|:---|
|  | **Without <br> Over-allotment <br> Option** | **Over-allotment <br> Option <br> Exercised** |
| **Gross proceeds** |  |  |
| Gross proceeds from shares offered to public<sup>(1)</sup> | $60000000 | $69000000 |
| Gross proceeds from private placement shares offered in the private <br> placement | 3000000 | 3090000 |
| Total gross proceeds | $63000000 | $72090000 |
| **Offering expenses**<sup>(2)</sup>** |  |  |
| Underwriting commissions (1.0% of gross proceeds from shares offered to public, excluding deferred portion) | $600000 | $690000 |
| Deferred underwriting commissions (3.0% of gross proceeds from shares offered to public)<sup>(3)</sup> | 1800000 | 2070000 |
| Initial trustee fee | 75000 | 75000 |
| Legal fees and expenses | 250000 | 250000 |
| Printing and engraving expenses | 35000 | 35000 |
| Accounting fees and expenses | 50000 | 50000 |
| Nasdaq filing fees | 75000 | 75000 |
| SEC Registration Fee | 9529 | 9529 |
| FINRA Registration Fee | 10850 | 10850 |
| Miscellaneous | 394621 | 394621 |
| Total offering expenses (other than underwriting commissions and deferred underwriting commissions) | $900000 | $900000 |
| Proceeds after offering expenses | $61500000 | $70500000 |
| Held in trust account<sup>(3)</sup> | $60000000 | $69000000 |
| % of public offering size | 100% | 100% |
| Not held in trust account | $1500000 | $1500000 |

---

The following table shows the use of the approximately $1,500,000 of net proceeds not held in the trust account:<sup>(4)</sup>

 

---

| | | |
|:---|:---|:---|
|  | **Amount** | **% of <br> Total** |
| Legal, accounting, due diligence and other expenses in connection with any business combination | $300000 | 20.0% |
| Due diligence, identification and research of prospective target business and reimbursement of out of pocket due diligence expenses to management | 200000 | 13.3% |
| Legal and accounting fees related to regulatory reporting obligations | 200000 | 13.3% |
| Payment for office space, utilities, administrative services and remote support services | 240000 | 16.0% |
| Directors and officers insurance | 300000 | 20.0% |
| CFO Compensation at closing of IPO | 36000 | 2.4% |
| Working capital and reserves (including finders' fees, consulting fees or other similar compensation, potential deposits, down payments or funding of a "no-shop" provision in connection with a particular business combination and liquidation obligations and reserves, if any) | 224000 | 15.0% |
| Total | $1500000 | 100.0% |

---

(1) Includes amounts payable to public shareholders who properly
redeem their shares in connection with our successful completion of our initial business combination.

(2) A portion of the offering expenses have been paid from the
proceeds of loans from our sponsor of up to $300,000 as described in this prospectus. These loans will be repaid upon completion of this
offering out of the $900,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting
commissions. In the event that offering expenses are less than set forth in this table, any such amounts will be used for post-closing
working capital expenses.

(3) The underwriters have agreed to defer underwriting commissions
of 3% of the gross proceeds of this offering. Upon and concurrently with the completion of our initial business combination, up to $1,800,000,
which constitutes the underwriters' deferred commissions (or up to $2,070,000 if the underwriters' over-allotment option
is exercised in full) will be paid to the underwriters from the funds held in the trust account. At our sole and absolute discretion,
up to $500,000 of this amount may be paid to third parties not participating in this offering that assist us in consummating our initial
business combination. See "*Underwriting*." The remaining funds, less amounts released to the trustee to pay redeeming
shareholders, will be released to us and can be used to pay all or a portion of the purchase price of the business or businesses with
which our initial business combination occurs or for general corporate purposes, including payment of principal or interest on indebtedness
incurred in connection with our initial business combination, to fund the purchases of other companies or for working capital. The underwriters
will not be entitled to any interest accrued on the deferred underwriting discounts and commissions.

(4) These expenses are estimates only. Our actual expenditures
for some or all of these items may differ from the estimates set forth herein. For example, we may incur greater legal and accounting
expenses than our current estimates in connection with negotiating and structuring our initial business combination based upon the level
of complexity of such business combination. In the event we identify a business combination target in a specific industry subject to
specific regulations, we may incur additional expenses associated with legal due diligence and the engagement of special legal counsel.
In addition, our staffing needs may vary and as a result, we may engage a number of consultants to assist with legal and financial due
diligence. We do not anticipate any change in our intended use of proceeds, other than fluctuations among the current categories of allocated
expenses, which fluctuations, to the extent they exceed current estimates for any specific category of expenses, would not be available
for our expenses. The amount in the table above does not include interest available to us from the trust account.

Nasdaq rules provide that at least 90% of the gross proceeds from this offering and the sale of the private placement shares be deposited in a trust account. Of the $63,000,000 in gross proceeds we receive from this offering and the sale of the private placement shares described in this prospectus (or $72,090,000 if the underwriters' over-allotment option is exercised in full), $60,000,000 ($10.00 per share) will be deposited into a trust account in the United States with Continental Stock Transfer & Trust Company acting as trustee (or $69,000,000 if the underwriters' over-allotment option is exercised in full ($10.00 per share)), after deducting $600,000 in underwriting discounts and commissions payable upon the closing of this offering (or $690,000 if the underwriters' over-allotment option is exercised in full) and an aggregate of $2,400,000 to pay fees and expenses in connection with the closing of this offering and for working capital following the closing of this offering. The proceeds held in the trust account will be held as cash or invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination and, may at any time be held as cash or cash items, including in demand deposit accounts at a bank. We will disclose in each quarterly and annual report filed with the SEC prior to our initial business combination whether the proceeds deposited in the trust account are invested in U.S. government treasury obligations or money market funds or a combination thereof or as cash or cash items, including in demand deposit accounts. We expect that the interest earned on the trust account will be sufficient to pay income taxes. We will not be permitted to withdraw any of the principal or interest held in the trust account, except for the withdrawal of interest to pay our taxes and up to $100,000 to pay dissolution expenses, as applicable, if any, until the earliest of (i) the completion of our initial business combination, (ii) the redemption of our public shares if we are unable to complete our initial business combination within the completion window, subject to applicable law, or (iii) the redemption of our public shares properly submitted in connection with a shareholder vote to approve an amendment to our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity.

The net proceeds released to us from the trust account upon the closing of our initial business combination may be used as consideration to pay the sellers of a target business with which we complete our initial business combination. If our initial business combination is paid for using equity or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination, we may use the balance of the cash released from the trust account following the closing for general corporate purposes, including for maintenance or expansion of operations of the post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital. There is no limitation on our ability to raise funds through the issuance of equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop arrangements we may enter into following consummation of this offering. However, our articles provides that, following this offering and prior to the consummation of our initial business combination, we will be prohibited from issuing additional securities that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on any initial business combination.

We believe that amounts not held in trust will be sufficient to pay the costs and expenses to which such proceeds are allocated that are payable prior to the closing of our initial business combination. However, if our estimate of the costs of undertaking in-depth due diligence and negotiating a business combination that are payable is less than the actual amount necessary to do so, we may be required to raise additional capital, the amount, availability and cost of which is currently unascertainable. If we are required to seek additional capital, we could seek such additional capital through loans or additional investments from our sponsor, members of our management team or any of their affiliates, but such persons are not under any obligation to advance funds to, or invest in, us.

We will pay our sponsor $20,000 per month for officer compensation and administrative services provided to members of our management team. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.

Mr. Nicholas Fernandez, our Chief Financial Officer, shall receive a lump-sum compensation of $35,714 from the sponsor at the closing of this offering for his service provided in relation to this offering. In addition, Mr. Fernandez will also receive $8,928 from the sponsor on a monthly basis out of the Administrative Services Fee, for his continued service as the Chief Financial Officer of the Company, from closing of this offering until completion of the Company's initial business combination. If the Company completes an initial business combination prior to the date that is 24 months from the closing of this offering, Mr. Fernandez shall receive at the completion of our initial business combination an additional amount such that the aggregate compensation Mr. Fernandez receives through closing of the business combination shall be no less than $250,000. Prior to the closing of this offering, our sponsor has agreed to loan us up to $300,000 to be used for a portion of the expenses of this offering. These loans are non-interest bearing, unsecured and are due at the closing of this offering. The loan will be repaid upon the closing of this offering out of the $900,000 of offering proceeds that has been allocated to the payment of offering expenses other than underwriting commissions.

In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete our initial business combination, we would repay such loaned amounts. In the event that our initial business combination does not close, we may use amounts held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used to repay such loaned amounts. Up to $1,500,000 of such loans may be convertible into private placement shares of the post business combination entity at a price of $10.00 per share at the option of the lender. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial business combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.

**Dividend Policy**

We have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of our initial business combination even if we have substantial assets outside the trust account. A Cayman Islands company may pay a dividend on its shares out of either profit, the share premium account, or other funds of the company available therefor, provided that in no circumstances may a dividend be paid if following such payment the company would be unable to pay its debts as they fall due in the ordinary course of business. The payment of cash dividends following the completion of our initial business combination will be within the discretion of our board of directors at such time and will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition at such time. There is no certainty we will be in a position to, or decide to, pay cash dividends after completing any business combination. If we increase or decrease the size of this offering pursuant to Rule 462(b) under the Securities Act, we will effect a share capitalization or other appropriate mechanism immediately prior to the consummation of this offering in such amount as to maintain the number of founder shares at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). Further, if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends following completion of our initial business combination may be limited by restrictive covenants we may agree to in connection therewith.

**Dilution**

The difference between the public offering price per ordinary share and Adjusted NTBVPS, on a pro forma basis to give effect to this offering and the issuance of the private placement shares, assuming no exercise of the over-allotment option and the exercise of the over-allotment option in full, constitutes dilution to investors in this offering. Adjusted NTBVPS is determined by dividing our net tangible book value, which is our total tangible assets less total liabilities (including the value of ordinary shares which may be redeemed for cash), as adjusted to reflect various potential redemption levels that may occur in connection with the closing of our initial business combination, by the number of outstanding ordinary shares.

Adjusted NTBVPS excludes the effect of the consummation of our initial business combination or any related transactions or expenses. The calculation of Adjusted NTBVPS assumes that no ordinary shares are issued to shareholders of our potential initial business combination target as consideration or issuable by the post-business combination company (for example, under an incentive plan or employee share purchase plan), no ordinary shares or convertible equity, equity-linked or debt securities are issued in connection with additional financing that we may seek in connection with our initial business combination, and no working capital loans are converted into private placement shares. The issuance of additional ordinary or preference shares may significantly dilute the equity interest of investors in this offering and are likely to increase as the enterprise value of a prospective target company increases. We intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of this offering and the sale of the private placement shares.

At February 13, 2026, our net tangible book deficit was $28,206, or approximately $(0.02) per ordinary share. The following table illustrates what the Adjusted NTBVPS at February 13, 2026, would have been to the public shareholders on a pro forma basis to give effect to this offering and the issuance of the private placement shares, assuming no exercise of the over-allotment option and exercise of the over-allotment option in full:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **No Redemptions** | **No Redemptions** | **25% of Maximum<br> Redemptions** | **25% of Maximum<br> Redemptions** | **50% of Maximum<br> Redemptions** | **50% of Maximum<br> Redemptions** | **75% of Maximum<br> Redemptions** | **75% of Maximum<br> Redemptions** | **Maximum<br> Redemptions** | **Maximum<br> Redemptions** |
|  | **No <br> Over-<br> Allotment** | **Full<br> Over-<br> Allotment** | **No <br> Over-<br> Allotment** | **Full<br> Over- <br> Allotment** | **No <br> Over- <br> Allotment** | **Full<br> Over- <br> Allotment** | **No <br> Over- <br> Allotment** | **Full<br> Over-<br> Allotment** | **No <br> Over-<br> Allotment** | **Full<br> Over-<br> Allotment** |
| Public offering price | $10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Net tangible book deficit before this offering | (0.02) | (0.02) | (0.02) | (0.02) | (0.02) | (0.02) | (0.02) | (0.02) | (0.02) | (0.02) |
| Increase (decrease) attributable to public shareholders | 7.67 | 7.68 | 7.11 | 7.12 | 6.20 | 6.21 | 4.46 | 4.46 | (0.17) | (0.26) |
| Pro forma net tangible book value (decrease) after this offering and the sale of the private placement shares | 7.65 | 7.66 | 7.09 | 7.10 | 6.18 | 6.19 | 4.44 | 4.44 | (0.19) | (0.28) |
| Dilution to public shareholders | $2.35 | 2.34 | 2.91 | 2.90 | 3.82 | 3.81 | 5.56 | 5.56 | 10.19 | 10.28 |
| Percentage of dilution to public shareholders | 23.50% | 23.40% | 29.10% | 29.00% | 38.20% | 38.10% | 55.60% | 55.60% | 101.90% | 102.80% |

---

For each of the redemption scenarios above, the NTBV was calculated as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **No Redemptions** | **No Redemptions** | **25% of Maximum <br> Redemptions** | **25% of Maximum <br> Redemptions** | **50% of Maximum <br> Redemptions** | **50% of Maximum <br> Redemptions** | **75% of Maximum <br> Redemptions** | **75% of Maximum <br> Redemptions** | **Maximum <br> Redemptions** | **Maximum <br> Redemptions** |
|  | **No <br> Over- <br> Allotment** | **Full <br> Over- <br> Allotment** | **No <br> Over- <br> Allotment** | **Full <br> Over- <br> Allotment** | **No <br> Over- <br> Allotment** | **Full <br> Over- <br> Allotment** | **No <br> Over- <br> Allotment** | **Full <br> Over- <br> Allotment** | **No <br> Over- <br> Allotment** | **Full <br> Over- <br> Allotment** |
| **Numerator:** | | | | | | | | | | |
| Net tangible book deficit before this offering | $(28206) | (28206) | (28206) | (28206) | (28206) | (28206) | (28206) | (28206) | (28206) | (28206) |
| Plus: Net proceeds from this offering and sale of the private placement shares<sup>(1)</sup> | 61500000 | 70500000 | 61500000 | 70500000 | 61500000 | 70500000 | 61500000 | 70500000 | 61500000 | 70500000 |
| Plus: Offering costs paid in advance, excluded from tangible book value before this offering | 33619 | 33619 | 33619 | 33619 | 33619 | 33619 | 33619 | 33619 | 33619 | 33619 |
| Less: Deferred underwriting fees | (1800000) | (2070000) | (1800000) | (2070000) | (1800000) | (2070000) | (1800000) | (2070000) | (1800000) | (2070000) |
| Less: Over-allotment liability<sup>(2)</sup> | (56000) |  | (56000) |  | (56000) |  | (56000) |  | (56000) |  |
| Less: Amounts paid for redemptions<sup>(3)</sup> |  |  | (15000000) | (17250000) | (30000000) | (34500000) | (45000000) | (51750000) | (60000000) | (69000000) |
|  | $59649413 | 68435413 | 44649413 | 51185413 | 29649413 | 33935413 | 14649413 | 16685413 | (350587) | (564587) |
| **Denominator:** |  |  |  |  |  |  |  |  |  |  |
| ordinary shares outstanding prior to this offering<sup>(4)</sup> | 1725000 | 1725000 | 1725000 | 1725000 | 1725000 | 1725000 | 1725000 | 1725000 | 1725000 | 1725000 |
| Less: ordinary shares forfeited if over-allotment is not exercised | (225000) |  | (225000) |  | (225000) |  | (225000) |  | (225000) |  |
| Plus: ordinary shares offered | 6000000 | 6900000 | 6000000 | 6900000 | 6000000 | 6900000 | 6000000 | 6900000 | 6000000 | 6900000 |
| Private placement <br> shares | 300000 | 309000 | 300000 | 309000 | 300000 | 309000 | 300000 | 309000 | 300000 | 309000 |
| Less: ordinary shares redeemed |  |  | (1500000) | (1725000) | (3000000) | (3450000) | (4500000) | (5175000) | (6000000) | (6900000) |
|  | 7800000 | 8934000 | 6300000 | 7209000 | 4800000 | 5484000 | 3300000 | 3759000 | 1800000 | 2034000 |

---

(1) Expenses applied against gross proceeds include offering
expenses of approximately $900,000 (not including $625,000 for director and officer liability insurance premiums to be paid upon closing
of this offering, which amount is not an offering expense to be capitalized) and underwriting commissions of $600,000. See "*Use of Proceeds*."

(2) Represents the value of 45-day over-allotment option
from the date of this offering granted to the underwriters to purchase an aggregate of up to 900,000 additional ordinary shares at the
initial public offering price less the underwriting commissions. The underwriters' over-allotment option is deemed to be a
freestanding financial instrument indexed on the shares subject to redemption and will be accounted for as a liability pursuant to ASC 480
if not fully exercised at the time of the initial public offering. The table above assumes that the option has either been fully exercised
or has expired with no exercise to purchase additional shares, thus the value of over-allotment liability in both scenario is $56,000.

(3) If we seek shareholder approval of our initial business combination
and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor,
initial shareholders, directors, executive officers, advisors or their affiliates may purchase shares in privately negotiated transactions
or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases
of our shares prior to the completion of our initial business combination, the number of ordinary shares subject to redemption will be
reduced by the amount of any such purchases, increasing the pro forma NTBV. See "*Proposed Business — Effecting Our Initial Business Combination — Permitted Purchases of Our Securities*."

(4) For purposes of presenting the maximum redemption scenario,
we have reduced our pro forma net tangible book value after this offering (assuming no exercise of the underwriters' option to
purchase additional shares) by $60,000,000 because holders of up to approximately 100% of our public shares may redeem their shares for
a pro rata share of the aggregate amount then on deposit in the trust account at a per share redemption price equal to the aggregate
amount then on deposit in the trust account, including interest earned on the funds held in the trust account less taxes paid or payable
(other than excise or similar taxes), divided by the number of then issued and outstanding public shares, subject to the limitations
and on the conditions described herein.

The following table sets forth information with respect to our initial shareholders and the public shareholders:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Purchased** | **Purchased** | **Total Consideration** | **Total Consideration** | |
|  | **Number** | **Percentage** | **Amount** | **Percentage** | **Average <br> Price Per**<br>**Share** |
| Initial shareholders<sup>(1)(2)</sup> | 1500000 | 19.23% | $25000 | 0.04% | 0.017 |
| Private placement shares | 300000 | 3.85% | $3000000 | 4.76% | 10.00 |
| Public shareholders | 6000000 | 76.92% | $60000000 | 95.20% | 10.00 |
|  | 7800000 | 100.0% | $63025000 | 100.0% |  |

---

(1) Assumes that 225,000 founder shares are surrendered to us
for no consideration after the closing of this offering in the event the underwriters do not exercise their over-allotment option.

In addition to the sources of potential dilution discussed herein, we note that there are additional possible sources of dilution and the extent of such dilution that non-redeeming public shareholders could experience in connection with the closing of the initial business combination may be uncertain, due to the uncertainty associated with the occurrence or the amount of securities that may be issued pursuant to such occurrence, including arising from: (i) the issuance of additional ordinary shares, including founder shares, upon the consummation of this offering if we increase the size of this offering, (ii) the issuance of additional founder shares, (iii) the issuance of additional securities as we may seek an initial business combination with a target company with an enterprise value greater than the net proceeds of the offering, (iv) any loans or additional investments from our sponsor, members of our management team or any of their affiliates or designees, including the issuance of shares upon conversion of working capital loans, (v) any ordinary shares, preferred shares or debt securities that may be issued to third parties pursuant to any equity financing or debt financing in connection with our initial business combination and (vi) the reservation and issuance of any securities under an employee incentive plan after completion of our initial business combination. For further discussions on potential sources of dilutions and potential risks associated thereof, see "*Risk Factors — We may issue additional ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination.*"

**Capitalization**

The following table sets forth our capitalization at February 13, 2026, and as adjusted to give effect to the filing of our articles, the sale of our ordinary shares in this offering and the sale of the private placement shares and the application of the estimated net proceeds derived from the sale of such securities, assuming no exercise by the underwriters of their over-allotment option:

---

| | | |
|:---|:---|:---|
|  | **February 13, 2026** | **February 13, 2026** |
|  | **Actual** | **As Adjusted** |
| Note payable to related party<sup>(1)</sup> | $13000 |  |
| Deferred underwriting commissions |  | 1800000 |
| Over-allotment liability<sup>(2)</sup> |  | 56000 |
| Ordinary shares, $0.0001 par value, 200,000,000 shares authorized; -0- and 6,000,000 shares subject to possible redemption, actual and as adjusted, respectively<sup>(3)</sup> |  | 60000000 |
| Preference shares, $0.0001 par value;1,000,000 shares authorized; none issued and outstanding, actual and as adjusted |  |  |
| Ordinary shares, $0.0001 par value, 200,000,000 shares authorized; 1,725,000 and 1,800,000 shares issued and outstanding (excluding -0- and 6,000,000 shares subject to possible redemption), actual and as adjusted, respectively | 173 | 180 |
| Additional paid-in capital | 24827 |  |
| Accumulated deficit | (19587) | (350767) |
| Total shareholders' equity (deficit) | $5413 | (350587) |
| Total capitalization | $18413 | 61505413 |

---

(1) Our sponsor has agreed to loan us up to $300,000 under an
unsecured promissory note to be used for a portion of the expenses of this offering. The "as adjusted" information gives
effect to the repayment of any loans received from our sponsor out of the proceeds from this offering and the sale of the private placement
shares. As of February 13, 2026, we have borrowed $13,000 under the promissory note with our sponsor.

(2) Represents the value of 45-day over-allotment option from
the date of this offering granted to the underwriter to purchase an aggregate of up to 900,000 additional ordinary shares at the initial
public offering price less the underwriting commissions. The over-allotment option is deemed to be a freestanding financial instrument
indexed on the contingently redeemable shares and will be accounted for as a liability pursuant to ASC 480.

(3) In connection with the completion of our initial business
combination, we will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price
equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation
of our initial business combination, including interest earned on the funds held in the trust account (less taxes paid or payable (other
than excise or similar taxes)), divided by the number of then outstanding public shares, subject to the limitations described herein
whereby a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting
in concert or as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from redeeming
its shares with respect to more than an aggregate of 20% of the shares sold in this offering without our prior consent.

(4) Actual share amount is prior to any forfeiture of founder
shares and as adjusted amount assumes no exercise of the underwriters' over-allotment option and forfeiture of an aggregate of
225,000 founder shares.

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview**

We are a blank check company incorporated on January 13, 2026 as a Cayman Islands exempted company with limited liability and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination in any business or industry. We intend to effectuate our initial business combination using cash from the proceeds of this offering and the private placement of the private placement shares, the proceeds of the sale of our shares in connection with our initial business combination (pursuant to forward purchase agreements or backstop agreements we may enter into following the consummation of this offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, other securities issuances, or a combination of the foregoing.

The issuance of additional shares in connection with a business combination to the owners of the target or other investors:

● may significantly dilute the equity interest of investors in this offering;

● may subordinate the rights of holders of ordinary shares if preference shares are issued with rights senior to those afforded our ordinary shares;

● could cause a change in control if a substantial number of our ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

● may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and

● may adversely affect prevailing market prices for our ordinary shares.

Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:

● default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;

● acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

● our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;

● our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;

● using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for expenses, capital expenditures, acquisitions and other general corporate purposes;

● limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;

● increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and

● limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

As indicated in the accompanying financial statements, at February 13, 2026, we had no cash and deferred offering costs of $33,619. Further, we expect to incur significant costs in the pursuit of our initial business combination. We cannot assure you that our plans to raise capital or to complete our initial business combination will be successful.

**Results of Operations and Known Trends or Future Events**

We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities and those necessary to prepare for this offering. Following this offering, we will not generate any operating revenues until after completion of our initial business combination. We will generate non-operating income in the form of interest income on cash and cash equivalents after this offering. There has been no significant change in our financial or trading position and no material adverse change has occurred since the date of our audited financial statements. After this offering, we expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. We expect our expenses to increase substantially after the closing of this offering.

**Liquidity and Capital Resources**

Our liquidity needs have been satisfied prior to the completion of this offering through $25,000 paid by the sponsor in exchange for the issuance of the founder shares to our sponsor and $300,000 in loans from our sponsor.

We estimate that the net proceeds from the sale of the ordinary shares in this offering and the sale of the private placement shares for an aggregate purchase price of $3,000,000 ($3,090,000 if the underwriters' over-allotment option is exercised in full), after deducting offering expenses of approximately $900,000 and underwriting commissions of $600,000 ($690,000 if the underwriters' over-allotment option is exercised in full) (excluding deferred underwriting commissions of $1,800,000, or $2,070,000 if the underwriters' over-allotment option is exercised in full), will be $61,500,000 (or $70,500,000 if the underwriters' over-allotment option is exercised in full). $60,000,000 (or $69,000,000 if the underwriters' over-allotment option is exercised in full) will be held in the trust account, which includes deferred underwriting commissions of $1,800,000 (or $2,070,000 if the underwriters' over-allotment option is exercised in full). The proceeds held in the trust account will initially be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that we hold investments in the trust account, we may, at any time (based on our management team's ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank. The remaining approximately $1,500,000 will not be held in the trust account. In the event that our offering expenses exceed our estimate of $900,000 (not including underwriter's discount), we may fund such excess with funds not to be held in the trust account. In such case, the amount of funds we intend to be held outside the trust account would decrease by a corresponding amount. Conversely, in the event that the offering expenses are less than our estimate of $900,000 (not including underwriter's discount), the amount of funds we intend to be held outside the trust account would increase by a corresponding amount.

We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account (excluding deferred underwriting commissions). We may withdraw interest to pay our taxes, if any. Our annual income tax obligations will depend on the amount of interest and other income earned on the amounts held in the trust account. We expect the interest earned on the amount in the trust account will be sufficient to pay our taxes. To the extent that our equity or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the trust account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

Prior to the completion of our initial business combination, we will have available to us the approximately $1,500,000 of proceeds held outside the trust account (assuming our offering expenses are as expected). We will use these funds to primarily identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.

We do not believe we will need to raise additional funds following this offering in order to meet the expenditures required for operating our business prior to our initial business combination. However, if our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial business combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our initial business combination. In order to fund working capital deficiencies or finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete our initial business combination, we would repay such loaned amounts. In the event that our initial business combination does not close, we may use amounts held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into private placement shares of the post business combination entity at a price of $10.00 per share at the option of the applicable lender. The terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial business combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.

We expect our primary liquidity requirements during that period to include approximately $500,000 for legal, accounting, due diligence, travel and other expenses associated with structuring, negotiating and documenting successful business combinations; $200,000 for legal and accounting fees related to regulatory reporting requirements; $240,000 for office space and administrative services; approximately $300,000 for directors' and officers' liability insurance; a payment of $36,000 to our Chief Financial Officer, and approximately $224,000 for general working capital that will be used for miscellaneous expenses and reserves.

These amounts are estimates and may differ materially from our actual expenses. In addition, we could use a portion of the funds not being placed in trust to pay commitment fees for financing, fees to consultants to assist us with our search for a target business or as a down payment or to fund a "no-shop" provision (a provision designed to keep target businesses from "shopping" around for transactions with other companies or investors on terms more favorable to such target businesses) with respect to a particular proposed business combination, although we do not have any current intention to do so. If we entered into an agreement where we paid for the right to receive exclusivity from a target business, the amount that would be used as a down payment or to fund a "no-shop" provision would be determined based on the terms of the specific business combination and the amount of our available funds at the time. Our forfeiture of such funds (whether as a result of our breach or otherwise) could result in our not having sufficient funds to continue searching for, or conducting due diligence with respect to, prospective target businesses.

Moreover, we may need to obtain additional financing to complete our initial business combination, either because the transaction requires more cash than is available from the proceeds held in our trust account or because we become obligated to redeem a significant number of our public shares upon completion of the business combination, in which case we may issue additional securities or incur debt in connection with such business combination. If we raise additional funds through equity or convertible debt issuances, our public shareholders may suffer significant dilution and these securities could have rights that rank senior to our public shares. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to our equity securities and could contain covenants that restrict our operations. In addition, we intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of this offering and the sale of the private placement shares, and, as a result, if the cash portion of the purchase price exceeds the amount available from the trust account, net of amounts needed to satisfy any redemptions by public shareholders, we may be required to seek additional financing to complete such proposed initial business combination. We may also obtain financing prior to the closing of our initial business combination to fund our working capital needs and transaction costs in connection with our search for and completion of our initial business combination. There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop agreements we may enter into following consummation of this offering. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our initial business combination. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to liquidate the trust account. In addition, following our initial business combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

**Controls and Procedures**

We are not currently required to maintain an effective system of internal controls as defined by Section 404 of the Sarbanes-Oxley Act. We will be required to comply with the internal control requirements of the Sarbanes-Oxley Act for the fiscal year ending December 31, 2026. Only in the event that we are deemed to be a large accelerated filer or an accelerated filer and no longer an emerging growth company would we be required to comply with the independent registered public accounting firm attestation requirement. Further, for as long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirement.

Prior to the closing of this offering, we have not completed an assessment, nor has our independent registered public accounting firm tested our systems, of internal controls. We expect to assess the internal controls of our target business or businesses prior to the completion of our initial business combination and, if necessary, to implement and test additional controls as we may determine are necessary in order to state that we maintain an effective system of internal controls. A target business may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding the adequacy of internal controls. Many small and mid-sized target businesses we may consider for our initial business combination may have internal controls that need improvement in areas such as:

● staffing for financial, accounting and external reporting areas, including segregation of duties;

● reconciliation of accounts;

● proper recording of expenses and liabilities in the period to which they relate;

● evidence of internal review and approval of accounting transactions;

● documentation of processes, assumptions and conclusions underlying significant estimates; and

● documentation of accounting policies and procedures.

Because it will take time, management involvement and perhaps outside resources to determine what internal control improvements are necessary for us to meet regulatory requirements and market expectations for our operation of a target business, we may incur significant expenses in meeting our public reporting responsibilities, particularly in the areas of designing, enhancing, or remediating internal and disclosure controls. Doing so effectively may also take longer than we expect, thus increasing our exposure to financial fraud or erroneous financing reporting.

Once our management's report on internal controls is complete, we will retain our independent registered public accounting firm to audit and render an opinion on such report when required by Section 404 of the Sarbanes-Oxley Act. The independent registered public accounting firm may identify additional issues concerning a target business's internal controls while performing their audit of internal control over financial reporting.

**Quantitative and Qualitative Disclosures about Market Risk**

The net proceeds of this offering and the sale of the private placement shares held in the trust account will initially be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that we hold investments in the trust account, we may, at any time (based on our management team's ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

**Related Party Transactions**

On February 13, 2026, our sponsor paid $25,000, or approximately $0.014 per share, to cover certain offering costs in exchange for 1,725,000 founder shares. Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor.

The number of founder shares issued and outstanding was determined based on the expectation that the total size of this offering would be a maximum of 6,900,000 ordinary shares if the underwriters' over-allotment option is exercised in full, and therefore that such founder shares would represent approximately 20% of the outstanding shares after this offering (not including the private placement shares). Up to 225,000 of the founder shares will be surrendered for no consideration depending on the extent to which the underwriters' over-allotment is exercised. If we increase or decrease the size of the offering, we will effect a share capitalization or a share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of this offering in such amount as to maintain the number of founder shares at 20.0% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares).

Our sponsor, JATT Ventures II L.P., has committed to purchase an aggregate of 300,000 ordinary shares (or 309,000 shares if the underwriters' over-allotment option is exercised in full), at a price of $10.00 per share in a private placement for an aggregate purchase price of $3,000,000 in the aggregate (or $3,090,000 if the underwriters' over-allotment option is exercised in full), that will close simultaneously with the closing of this offering. These ordinary shares, which we refer to as the private placement shares, are identical to the ordinary shares sold in this offering, subject to certain limited exceptions as described in this prospectus.

Prior to or in connection with the completion of our initial business combination, there may be payment by the company to our sponsor, officers or directors, advisors, or our or their affiliates, of a finder's fee, advisory fee, consulting fee or success fee for any services they render in order to effectuate the completion of our initial business, which, if made prior to the completion of our initial business combination, will be paid from funds held outside the trust account.

Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates.

We will reimburse our sponsor or an affiliate thereof in an amount equal to $20,000 per month for office compensation and administrative services made available to us. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.

Mr. Nicholas Fernandez, our Chief Financial Officer, shall receive a lump-sum compensation of $35,714 from the sponsor at the closing of this offering for his service provided in relation to this offering. In addition, Mr. Fernandez will also receive $8,928 from the sponsor on a monthly basis out of the Administrative Services Fee, for his continued service as the Chief Financial Officer of the Company, from closing of this offering until completion of the Company's initial business combination. If the Company completes an initial business combination prior to the date that is 24 months from the closing of this offering, Mr. Fernandez shall receive at the completion of our initial business combination an additional amount such that the aggregate compensation Mr. Fernandez receives through closing of the business combination shall be no less than $250,000.

Prior to the closing of this offering, our sponsor may loan us funds in an aggregate amount of up to $300,000 to be used for a portion of the expenses of this offering. These loans would be non-interest bearing, unsecured and are due at the earlier of the date on which the closing of this offering occurs or the date on which we determine not to conduct an initial public offering. As of February 13, 2026, we had $13,000 borrowed under the promissory note with our sponsor.

In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required on a non-interest basis. If we complete an initial business combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use amounts held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into private placement shares of the post business combination entity at a price of $10.00 per ordinary share at the option of the applicable lender. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial business combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.

Any of the foregoing payments to our sponsor, repayments of loans from our sponsor or repayments of working capital loans prior to our initial business combination will be made using funds held outside the trust account.

After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to our shareholders, to the extent then known, in the proxy solicitation or tender offer materials, as applicable, furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a general meeting held to consider our initial business combination, as applicable, as it will be up to the directors of the post-combination business to determine executive and director compensation.

We have entered into a registration rights agreement with respect to the founder shares and private placement shares, which is described under the heading "*Principal Shareholders — Registration Rights*."

**Off-Balance Sheet Arrangements; Commitments and Contractual Obligations; Quarterly Results**

As of February 13, 2026, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations. No unaudited quarterly operating data is included in this prospectus as we have not conducted any operations to date.

**JOBS Act**

The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We will qualify as an "emerging growth company" and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an "emerging growth company," we choose to rely on such exemptions we may not be required to, among other things, (i) provide an independent registered public accounting firm's attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the report of the independent registered public accounting firm providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO's compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of this offering or until we are no longer an "emerging growth company," whichever is earlier.

**Proposed Business**

**Introduction**

We are a blank check company incorporated on January 13, 2026, as a Cayman Islands exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value.

Our sponsor, JATT Ventures II L.P., is a Cayman Islands exempted limited partnership, which was formed to invest in us and is acting by its general partner, JATT Ventures II Ltd. Although our sponsor is permitted to undertake any activities permitted under the Limited Liabilities Partnership Act (As Revised) and other applicable law, our sponsor's business is focused on investing in us and directly or indirectly providing office space and administrative services to members of our management team. As of the date of this prospectus, JATT Ventures II Ltd is the sole general partner of our sponsor, and our Chairman and Chief Executive Officer, Dr. Someit Sidhu is a limited partner of our sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd.

**Prior SPAC Experience**

Our management team is comprised of industry leaders, who we believe are well positioned to identify and evaluate businesses that would benefit from our management team's skills and access to the public markets. We believe that our management team possesses extensive experience in operating and growing companies, has a deep network of contacts and brings a distinctive background that can have a transformative impact on a target business.

**JATT Acquisition Corp**

JATT Acquisition Corp ("JATT I") is a special purpose acquisition company incorporated for purposes similar to those of our company, which raised $138 million (including over-allotment) in an initial public offering of units in July 2021. JATT I was sponsored by JATT Ventures, L.P., the general partner of which is JATT Ventures Ltd. Dr. Someit Sidhu, our Chairman and Chief Executive Officer, is the limited partner of JATT Ventures, L.P. and the director and shareholder of JATT Ventures Ltd. Dr. Sidhu served as CEO and a director of JATT Acquisition Corp from its inception until JATT I completed its business combination with Zura Bio Limited ("Zura Bio") in March 2023. Mr. Verender S. Badial also served as the Chief Financial Officer of JATT I from closing of JATT I's IPO until the completion of its business combination with Zura Bio. Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura's pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura's lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. In connection with JATT I's shareholder proposal to amend its amended and restated memorandum and articles of association to extend the date by which JATT I was required to consummate a business combination, which was approved at an extraordinary general meeting held on January 12, 2023, the holders of 12,111,022 of JATT I's Class A ordinary shares, exercised their right to redeem their shares for cash at a redemption price of approximately $10.26 per share for an aggregate redemption amount of $124,226,450.64. In connection with the extraordinary general meeting to approve the business combination with Zura Bio, the holders of an additional 1,506,480 Class A ordinary shares exercised their right to redeem their shares for cash at a redemption price of approximately $10.26 per share for an aggregate redemption amount of $15,456,484.80. Prior to the Business Combination, holders of an aggregate of 13,617,502 Class A ordinary shares exercised their right to redeem their shares for cash for an aggregate redemption amount of $139,682,935.44. Following the closing, Zura Bio's Class A ordinary shares and warrants commenced trading on The Nasdaq Capital Market under the new trading symbols "ZURA" and "ZURAW," respectively, on March 21, 2023. On March 2, 2026, the closing sale price of ZURA was $6.67. As of March 2, 2026, the aggregate market capitalization of Zura Bio reflects a market value of approximately $641.4 million.

Past performance of our management team is not a guarantee that we will be able to identify a suitable target or consummate a successful business combination. You should not rely on the historical record of our management team's performance as indicative of our future performance. For additional information regarding our management team's experience, please see the section entitled "*Management*."

**Business Strategy**

We are a team of experienced life sciences executives, investors, physicians and entrepreneurs. Our business strategy is to leverage our network of relationships, therapeutic development experience and capital markets expertise to identify and complete our initial business combination with a company in the healthcare or healthcare-related industries, with a primary focus on biotechnology and broader life sciences. We intend to target a business that is well positioned to benefit from public-market access and from the operational, strategic and financing support of our management team and board.

Our selection process will draw upon the relationships, domain expertise and sourcing capabilities of our management team and directors across the United States, Europe and other key life sciences markets. We believe we are well positioned to identify a business combination partner that can benefit from our team's experience, including:

● Experience sourcing, structuring, financing and growing biopharmaceutical businesses and therapeutic assets;

● Experience identifying differentiated science and therapeutics targeting significant unmet medical needs;

● Experience evaluating and developing underappreciated assets and platforms within private companies, academic institutions and larger biopharmaceutical organizations, including through partnerships and licenses;

● Experience in capital formation, equity capital markets, strategic transactions and the transition from private to public ownership;

● Experience supporting companies through key development, financing, partnering and commercialization inflection points.

Our team is in regular contact with entrepreneurs, physicians, scientists, key opinion leaders, management teams, investors and investment bankers across the healthcare ecosystem. We believe this network should provide access to a meaningful volume of prospective targets, including companies evaluating crossover financings, strategic transactions or alternative paths to the public markets. Upon completion of this offering, we expect to use that network to define the parameters of our search and begin an active review of potential business combination opportunities.

**Business Combination Criteria**

Our acquisition strategy seeks to leverage our team's relationships, domain knowledge and inbound opportunities to source an attractive initial business combination.

Consistent with our business strategy, we have identified the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. We intend to identify and acquire a business that exhibits many, and perhaps all, of the following characteristics:

● Rigorous science and a differentiated therapeutic or technical rationale;

● Compelling preclinical or clinical data, or a platform with the potential to generate differentiated products addressing meaningful unmet medical needs;

● The potential for data-driven or technology-enabled approaches to improve development speed, decision-making or probability of success;

● Identifiable near- or medium-term milestones that could drive value creation through scientific, clinical, regulatory, strategic or commercial progress;

● Novel technology, know-how or assets protected by robust intellectual property or other durable competitive advantages;

● Platform or portfolio potential that can support repeatable value creation through additional pipeline development or expansion;

● A management team with the experience and judgment to develop, finance, partner and, where appropriate, commercialize its programs as a public company;

● An attractive valuation relative to the quality of the science, data, management team and development opportunity; and

● A business that would benefit from public ownership and access to incremental growth capital.

These criteria and guidelines are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general criteria and guidelines as well as other considerations, factors and criteria that our management may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet one or more of the above criteria and guidelines, we will disclose that fact in our shareholder communications related to our initial business combination.

**Our Management Team**

Our management team is led by Dr. Someit Sidhu, our Chairman and Chief Executive Officer, and Mr. Nicholas Fernandez, our Chief Financial Officer, each of whom has significant experience building, operating and investing in the life sciences and medical technology sectors globally. They will be supported by a team of investment professionals and support resources as further described below. We believe our management team has complementary skills and experience relevant to our business strategy, as well as significant expertise in identifying high quality companies seeking financing as a stepping stone to public markets. With significant exposure to such opportunities and deep experience in investing in both private and public life science markets, we expect to have access to a large volume of potential investment opportunities, which we believe represents a competitive advantage.

**Dr. Someit Sidhu** serves as our Chairman of the Board and Chief Executive Officer. Dr. Sidhu has broad expertise covering various topics in the life sciences industry, and is a strategy consultant and serial biotech entrepreneur in the industry. Dr. Sidhu is the founder of Khanda Therapeutics, and has served as its CEO and director since December 2025. Dr. Sidhu served as CEO and a director of JATT Acquisition Corp from its inception until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. From March 2023 to April 2024, Dr. Sidhu served as the CEO and director of Zura Bio, and has since continued to serve as director of Zura Bio. Dr. Sidhu was also a co-founder of Izana Bioscience and served as its CEO from November 2017 until its eventual sale to Roivant in June 2020. He is also Co-founder of Pathios Therapeutics and Akaza Bioscience and has served as its CEO from 2019 to 2021. Prior to these companies, Dr. Sidhu advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on Pharmaceutical R&D and Portfolio Strategy. Dr. Sidhu has also been serving as director of GSN Estate since September 2024 and as director of Invictus Bioscience since May 2016. Dr. Sidhu gained medical experience during his time in Cardiology and General Surgery after graduating from the Oxford Medical School where he was a Senior Mackinnon Scholar at Magdalen College. We believe Dr. Sidhu's extensive operational and investment experience in the life sciences industry gives him the qualifications, attributes and skills to serve as a director.

**Nicholas Fernandez** serves as our Chief Financial Officer. Mr. Fernandez has over 20 years of experience across operations, accounting and finance. Mr. Fernandez has been with Athanor Capital, a hedge fund, from December 2019 to December 2025, most recently serving as Chief Operating Officer and Chief Financial Officer. From April 2024 to November 2024, Mr. Fernandez served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of EcoBridge Capital Management. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jefferies LLC, a global bulge bracket investment bank, from February 2017 to April 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez has previously served as a director of Iris Acquisition Corp from May 2023 until its business combination with Liminatus Pharma, LLC in April 2025, and has been serving as a director of Liminatus Pharma, Inc., the post combination company since then. Mr. Fernandez has also been serving as the CFO of Amanat Acquisition Corp. since January 2026. Mr. Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr. Fernandez holds an active Certified Public Accountant License in the state of New York.

**Verender S. Badial** is a Director nominee. He has more than 20 years of experience as an investment banker and is currently Managing Director of Cryfield Investments, which he founded in 2015 and is responsible for the corporate finance services and capital fundraising activities. He also serves as Chief Executive Officer of ME Asset Management, a UK-based investment platform backed by Cryfield Investments. Mr. Badial has also served as the Chief Financial Officer of Zura Bio Limited from March 2023 to July 2025 and was previously JATT Acquisition Corp's chief financial officer since July 2021 until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. Between 1997 and 2015, Mr. Badial held executive functions in the Equity Capital Markets departments of Rothschild (ABN AMRO) and Societe Generale, allowing him to leverage rich experience in structuring and executing equity capital markets transactions as well as building up an extensive network. Mr. Badial also held the role of Managing Director with Rothschild (ABN AMRO) and Societe Generale within the investment banks and is experienced in both buy- and sell-side advisory transactions incorporating leveraged and structured equity and debt finance solutions with a key focus on financial sponsor portfolios in pharma and healthcare. Mr. Badial brings unique capabilities for the target identification and business combination processes based on his expertise from acquiring and funding numerous corporates, raising capital for M&A and IPOs coupled with significant expertise in analyzing potential financial or management improvements to operational businesses. Mr. Badial graduated with an honor's degree from the London School of Economics & Political Science. We believe Mr. Badial is qualified to serve on our board of directors because of his experience as a seasoned investment banker.

**Christopher Staral** is a Director nominee. Mr. Staral is the Founder, Managing Member, and Chief Investment Officer of Triple Helix Investments, where he brings a multidimensional background across science, public and private markets, and high-performance decision-making. Before launching Triple Helix, Mr. Staral founded and was CIO of Allostery Investments, a specialized, low-net biotech fund known for combining deep scientific research with sentiment and technical overlays, from July 2022 to August 2025. Mr. Staral previously worked as senior analyst of Laurion Capital Management, where he played a key role in building and helping lead Laurion Capital Management's private and long/short public biotech strategy, expanding the platform and driving investment across emerging and established therapeutic innovations. Prior to Laurion, Mr. Staral was an Investment Analyst at Mangrove Partners, focusing on high-conviction long and short opportunities within biotechnology. Mr. Staral began his finance career in sell-side equity research, first at Canaccord Genuity and later at Goldman Sachs. His path to investing was unconventional: raised in Minnesota and initially pursuing medicine, he ultimately gravitated to biotechnology investing because it combined his scientific interest in the complexity of human biology with the mark-to-market competition he thrived on — first as a world-class individual performer, and then by building and leading elite teams in highly competitive environments. Mr. Staral received his B.A. in Chemistry from Carleton College and attended the University of Minnesota Medical School. We believe Mr. Staral is qualified to serve on our board of directors because of his background in medicine and years of experience in finance.

**Dr. Arjun Goyal** is a Director nominee. Dr. Goyal is a life sciences investor and entrepreneur and the Founder and Managing Partner of Vianti Capital, a therapeutics-focused investment firm. Prior to founding Vianti, Dr. Goyal was a Co-Founder and Managing Director of Vida Ventures, a U.S.-based life sciences venture capital firm with over $1.7 billion in assets under management. He co-founded Vida in 2017 and departed the firm in December 2024 following multiple realized exits and the scaling of the platform. During his tenure, he served as the originating and lead partner on multiple investments, including Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck), Asklepios BioPharmaceutical (acquired by Bayer), Scorpion Therapeutics (acquired by Eli Lilly), Halda Therapeutics (acquired by Johnson & Johnson), Homology Medicines (NASDAQ: FIXX), Kinnate Therapeutics (NASDAQ: KNTE), Alterome Therapeutics, Quanta Therapeutics, and Third Arc Bio, with active governance involvement across multiple companies. Earlier in his career, from 2014 to 2017, Dr. Goyal was an investment professional at 5AM Ventures, a life sciences-focused venture firm. There, he co-led investments in companies including Aprea AB (NASDAQ: APRE), Spyryx, Pear Therapeutics, Portal Instruments, Entrada Therapeutics (NASDAQ: TRDA), and Homology Medicines (NASDAQ: FIXX), and served as a Board Observer across multiple portfolio companies. Dr. Goyal has also been serving as a director of Centessa Pharmaceuticals Plc since January 2021. Dr. Goyal trained as a physician and brings a combined clinical, scientific, and business background to his investment work. He earned his M.D. from the University of Melbourne, completed medical research training at the University of Oxford, received an M.Phil. in Bioscience Enterprise from the University of Cambridge as a Commonwealth Scholar and Gates Cambridge Scholar, and holds an MBA from Harvard Business School. He completed postgraduate medical training in Internal Medicine at the University of Sydney. He has received several professional recognitions, including the Advance Award for Technology & Entrepreneurship for Global Australians (2021) and selection as one of Australia's 25 Most Influential Global Game-Changers in Business (2026). He serves on the Board of Advisors for the MS/MBA Life Sciences Program at Harvard Business School, the American Australian Association Education Fellowship Committee, and the Investment Committee of the University of Melbourne Technology Endowment Fund. We believe Dr. Goyal is qualified to serve on our board of directors because of his experience as a life science investor.

**Dr. Jonathon Kluft** is a Director nominee. Dr. Kluft brings more than a decade of experience in biotechnology investing and investment analysis across a broad range of therapeutic areas. He currently serves as a consultant to Atika Capital Management, LLC, a healthcare, consumer and technology-focused hedge fund, and also engages in private investment activities. From April 2016 through June 2025, Dr. Kluft served as Vice President, Special Projects and, prior to that, Vice President, Investments (previously Business Development) at Roivant Sciences, where he was closely involved in the sourcing, evaluation and execution of transactions that resulted in the formation of several Roivant subsidiary companies, including Immunovant, Urovant, and Pulmovant, among others. Prior to joining Roivant, from January 2013 through April 2016, Dr. Kluft was an Analyst at Atika Capital, where he identified and presented equity investment recommendations primarily within the pharmaceutical and biotechnology sectors. Earlier in his career, Dr. Kluft served as an intern at Gilder, Gagnon, Howe & Co., an asset management firm, where he conducted due diligence on biotechnology companies. His background in biotechnology investing provides the Board with valuable perspective in evaluating potential acquisition opportunities, drug development programs and strategic transactions. Dr. Kluft received his M.D. from Columbia University College of Physicians and Surgeons in 2013 and his B.A. in Philosophy, Politics and Economics from the University of Pennsylvania in 2005. We believe Dr. Kluft is qualified to serve on our board of directors because of his decade of experience in biotechnology investing.

Our management team's efforts to seek a suitable business combination target will be complemented and augmented by the expertise and network of relationships of our independent director nominees. We believe that our access to and affiliation with our independent director nominees represent a competitive advantage. We also believe that our management team's expertise will be augmented by the other members of our board of directors, which will provide extensive experience in business and financial matters.

With respect to the foregoing experiences of our management team, past performance is not a guarantee (i) that we will be able to identify a suitable candidate for our initial business combination or (ii) of success with respect to any business combination we may consummate. You should not rely on the historical record of our management team's performance as indicative of our future performance. For more information on the experience and background of our management team, see the section entitled "*Management*."

**Initial Business Combination**

**Sourcing of Potential Business Combination Targets**

We believe our management team's significant operating and transaction experience and relationships will provide us with a substantial number of potential initial business combination targets. Over the course of their careers, the members of our management team have developed a broad network of contacts and corporate relationships around the world. This network has grown through the activities of our management team sourcing, acquiring and financing businesses, the reputation of our management team for integrity and fair dealing with sellers, financing sources and target management teams and the experience of our management team in executing transactions under varying economic and financial market conditions.

This network has provided our management team with a flow of referrals that has resulted in numerous transactions which were proprietary or where a limited group of investors were invited to participate in the sale process. We believe that the network of contacts and relationships of our management team will provide us important sources of investment opportunities. In addition, we anticipate that target business combination candidates will be brought to our attention from various unaffiliated sources, including investment market participants, private equity funds and large business enterprises seeking to divest non-core assets or divisions.

In evaluating a prospective target business, we expect to conduct a due diligence review which may encompass, among other things, meetings with incumbent management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as applicable, as well as a review of financial, operational, clinical, legal and other information about the target and its industry which will be made available to us. If we determine to move forward with a particular target, we will proceed to structure and negotiate the terms of the business combination transaction. The time required to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of, and negotiation with, a prospective target business with which our initial business combination is not ultimately completed will result in our incurring losses and will reduce the funds available for us to use to complete another initial business combination.

**Process and Structure**

We are not presently engaged in, and we will not engage in, any operations for an indefinite period of time following this offering. We intend to effectuate our initial business combination using cash from the proceeds of this offering and the private placement of the private placement shares, the proceeds of any sale of our shares in connection with our initial business combination (including pursuant to forward purchase agreements or backstop agreements we may enter into following the consummation of this offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, other securities issuances, or a combination of the foregoing. We may seek to complete our initial business combination with a company or business that may be financially unstable or in its early stage of development or growth, which would subject us to the numerous risks inherent in such companies and businesses.

We will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares in connection with the completion of our initial business combination either (i) in connection with a general meeting called to approve the business combination or (ii) without a shareholder vote by means of a tender offer. If we seek shareholder approval, we will complete our initial business combination only if we receive approval pursuant to an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company, however, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles. The decision as to whether we will seek shareholder approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirement.

We have until the date that is 24 months from the closing of this offering or until such earlier liquidation date as our board of directors may approve, to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination within such 24-month period, we may seek shareholder approval to amend our articles to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of ordinary shares will be offered an opportunity to redeem their shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding ordinary shares, subject to the limitations and on the conditions described herein, regardless of whether they abstain, vote in favor of or vote against such extension.

If we are unable to complete our initial business combination within the completion window, we will redeem 100% of the ordinary shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest income to pay dissolution expenses), divided by the number of then issued and outstanding ordinary shares, subject to applicable law and certain conditions as further described herein. We expect the pro rata redemption price to be approximately $10.00 per public share (regardless of whether the underwriters exercise their over-allotment option), without taking into account any interest or other income earned on such funds. However, we cannot assure you that we will in fact be able to distribute such amounts as a result of claims of creditors, which may take priority over the claims of our public shareholders.

Nasdaq rules require that we must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the trust account (excluding any deferred underwriters fees and taxes payable on the income earned on the trust account) at the time of the agreement to enter into the initial business combination. Our board of directors will make the determination as to the fair market value of our initial business combination. If our board of directors is not able to independently determine the fair market value of our initial business combination (including with the assistance of financial advisors), we will obtain an opinion from an independent investment banking firm which is a member of FINRA or an independent valuation or appraisal firm that regularly provides fairness opinions solely with respect to the satisfaction of such criteria. While we consider it likely that our board will be able to make such independent determination of fair market value, it may be unable to do so if the board is less familiar or experienced with the target company's business, there is a significant amount of uncertainty as to the value of the company's assets or prospects, including if such company is at an early stage of development, operations or growth, or if the anticipated transaction involves a complex financial analysis or other specialized skills and the board determines that outside expertise would be helpful or necessary in conducting such analysis. Additionally, pursuant to Nasdaq rules, any initial business combination must be approved by a majority of our independent directors.

We anticipate structuring our initial business combination so that the post-transaction company in which our public shareholders own shares will own or acquire 100% of the equity interests or assets of the target business or businesses. We may, however, structure our initial business combination such that the post transaction company owns or acquires less than 100% of such interests or assets of the target business in order to meet certain objectives of the target management team or shareholders or for other reasons, but we will only complete such business combination if the post transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. Even if the post transaction company owns or acquires 50% or more of the voting securities of the target, our shareholders prior to the business combination may collectively own a minority interest in the post transaction company, depending on valuations ascribed to the target and us in the business combination. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock, shares or other equity interests of a target. In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our shareholders immediately prior to our initial business combination could own less than a majority of our issued and outstanding shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post transaction company, the portion of such business or businesses that is owned or acquired is what will be taken into account for purposes of the 80% of net assets test described above. If the business combination involves more than one target business, the aggregate value of all of the target businesses will be taken into account for purposes of the 80% fair market value test.

AI Biotechnology, an affiliate of Access Industries, Inc., has indicated an interest to purchase up to an aggregate of $30,000,000 of our ordinary shares in a private placement that would occur concurrently with the consummation of our initial business combination. However, because indications of interest are not binding agreements or commitments to purchase, AI Biotechnology may ultimately determine to purchase more, fewer or no shares. We are also under no obligation to sell any shares to AI Biotechnology. As such, there can be no assurance that AI Biotechnology will acquire any shares in connection with our initial business combination or otherwise. Any investment by AI Biotechnology or its affiliated entities and persons would be made on terms and conditions determined at the time of the business combination and may be different from the terms and conditions on which shares are sold to other investors in any private placement. Furthermore, we are not under any obligation to sell any such shares. If we sell shares to the AI Biotechnology (or any other investor) in connection with our initial business combination, the equity interest of investors in this offering in the combined company may be diluted and the market prices for our securities may be adversely affected. In addition, if the per share trading price of our ordinary shares is greater than the price per share paid in the private placement, the private placement will result in value dilution to you, in addition to the immediate dilution that you will experience in connection with the consummation of this offering. See also "Dilution."

We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors, or completing the business combination through a joint venture or other form of shared ownership with our sponsor, officers or directors. In the event we seek to complete an initial business combination with a target that is affiliated (as defined in our articles) with our sponsor, officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm that is a member of FINRA or another independent entity that commonly renders valuation opinions that such an initial business combination is fair to our company from a financial point of view.

Members of our management team and our independent directors will directly or indirectly own founder shares and/or private placement shares following this offering and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. The low price that our sponsor, executive officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. In addition to their investments (directly or indirectly) in the founder shares and private placement shares, our sponsor, officers, directors and/or their affiliates may make loans or advances to us for working capital from time to time. If we are unable to complete our initial business combination within the completion window, the founder shares may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. Further, each of our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination.

Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. Our articles will provide that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which may (a) be a corporate opportunity for any director or officer, on the one hand, and us, on the other, or (b) the presentation of which would breach an existing legal obligation of a member of director, officer or sponsor to any other entity. The purpose for the surrender of corporate opportunities is to allow officers, directors or other representatives with multiple business affiliations to continue to serve as an officer of our company or on our board of directors. Our officers and directors may from time to time be presented with opportunities that could benefit both another business affiliation and us. In the absence of the "corporate opportunity" waiver in our articles, certain candidates would not be able to serve as an officer or director. We believe we substantially benefit from having representatives who bring significant, relevant and valuable experience to our management, and, as a result, the inclusion of the "corporate opportunity" waiver in our articles provide us with greater flexibility to attract and retain the officers and directors that we feel are the best candidates. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our initial business combination.

In addition, our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination target.

Prior to the date of this prospectus, we will file a Registration Statement on Form 8-A with the SEC to voluntarily register our securities under Section 12 of the Exchange Act. As a result, we will be subject to the rules and regulations promulgated under the Exchange Act. We have no current intention of filing a Form 15 to suspend our reporting or other obligations under the Exchange Act prior or subsequent to the consummation of our initial business combination.

**Status as a Public Company**

We believe our structure will make us an attractive business combination partner to target businesses. As an existing public company, we offer a target business an alternative to the traditional initial public offering through a merger or other business combination with us. In a business combination transaction with us, the owners of the target business may, for example, exchange their shares of stock or shares or other equity interests in the target business for our ordinary shares (or shares of a new holding company) or for a combination of our ordinary shares and cash, allowing us to tailor the consideration to the specific needs of the sellers. We believe target businesses will find this method a more expeditious and cost-effective method to becoming a public company than the typical initial public offering. The typical initial public offering process takes a significantly longer period of time than the typical business combination transaction process, and there are significant expenses, market and other uncertainties in the initial public offering process, including underwriting discounts and commissions, marketing and road show efforts that may not be present to the same extent in connection with a business combination with us.

Furthermore, once a proposed business combination is completed, the target business will have effectively become public, whereas an initial public offering is always subject to the underwriter's ability to complete the offering, as well as general market conditions, which could delay or prevent the offering from occurring or could have negative valuation consequences. Following an initial business combination, we believe the target business would then have greater access to capital, an additional means of providing management incentives consistent with shareholders' interests and the ability to use its shares as currency for acquisitions. Being a public company can offer further benefits by augmenting a company's profile among potential new customers and vendors and aid in attracting talented employees.

While we believe that our structure and our management team's backgrounds will make us an attractive business partner, some potential target businesses may view our status as a blank check company, such as our lack of an operating history and our ability to seek shareholder approval of any proposed initial business combination, negatively.

We are an "emerging growth company," as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

Additionally, we are a "smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our ordinary shares held by non-affiliates is equal to or exceeds $250 million as of the prior June 30, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates is equal to or exceeds $700 million as of the prior June 30.

**Financial Position**

With funds available for a business combination initially in the amount of $58,200,000 (assuming no redemptions), after payment of $1,800,000 of deferred underwriting fees (or $66,930,000 (assuming no redemptions) after payment of $2,070,000 of deferred underwriting fees if the underwriters' over-allotment option is exercised in full), we offer a target business a variety of options, such as creating a liquidity event for its owners, providing capital for the potential growth and expansion of its operations or strengthening its balance sheet by reducing its debt ratio. Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires. However, we have not taken any steps to secure third party financing and there can be no assurance it will be available to us.

**Our Sponsor**

Our sponsor, JATT Ventures II L.P., is a Cayman Islands exempted limited partnership, which was formed to invest in us and is acting by its general partner, JATT Ventures II Ltd. Although our sponsor is permitted to undertake any activities permitted under the Limited Liabilities Partnership Act (As Revised) and other applicable law, our sponsor's business is focused on investing in us and directly or indirectly providing office space and administrative services to members of our management team. As of the date of this prospectus, JATT Ventures II Ltd is the sole general partner of our sponsor, and our Chairman and Chief Executive Officer, Dr. Someit Sidhu is a limited partner of our sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd.

The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates:

---

| | | |
|:---|:---|:---|
| **Entity** | **Amount of Compensation to be<br> Received or Securities Issued or to be Issued** | **Consideration<br> Paid or to be Paid** |
| JATT Ventures II L.P. | 1,725,000 ordinary shares (of which 225,000) shares are subject to forfeiture if the underwriters do not exercise their over-allotment option). If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor. | $25,000 (approximately $0.014 per share) |
| JATT Ventures II L.P. | 300,000 private placement shares (or up to 309,000 private placement shares if the underwriters' over-allotment option is exercised in full) | $3,000,000 ($10.00 per share) (or up to $3,090,000 if the underwriters' over-allotment option is exercised in full) |
| JATT Ventures II L.P. and/or its affiliates or designees | $20,000 per month | Officer compensation and office space and administrative services provided to members of our management team |
| JATT Ventures II L.P. | Repayment in cash | Up to $300,000 under an unsecured, non-interest-bearing promissory note for offering-related and organizational expenses. The loan is due at the closing of this offering and are anticipated to be repaid upon completion of this offering. |

---

---

| | | |
|:---|:---|:---|
| **Entity** | **Amount of Compensation to be<br> Received or Securities Issued or to be Issued** | **Consideration<br> Paid or to be Paid** |
| JATT Ventures II L.P., our officers or directors, or affiliates thereof | Repayment in cash | Any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination |
| Dr. Someit Sidhu | Prior to closing of this offering, our Chief Executive Officer, Dr. Someit Sidhu will receive indirect interest in founder shares for his services through membership interests in our sponsor, representing 150,000 founder shares. | $2,100 in aggregate (approximately $0.014 per share) |
| Mr. Nicholas Fernandez | Prior to closing of this offering, our Chief Financial Officer, Mr. Nicholas Fernandez will receive indirect interest in founder shares for his services through membership interests in our sponsor, representing 50,000 founder shares. | $700 in aggregate (approximately $0.014 per share) |
| Independent directors | Prior to closing of this offering, each of our independent directors will receive indirect interest in founder shares for their board services through membership interests in our sponsor, representing 25,000 founder shares. | $1,400 in aggregate (approximately $0.014 per share) |

---

Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and material dilution upon the closing of this offering. Additionally, if we increase the size of the offering pursuant to Rule 462(b) under the Securities Act, we will effect with our sponsor a share dividend or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering. The issuance of additional ordinary shares may further dilute the equity interests of public shareholders. Further, our sponsor or an affiliate of our sponsor or certain of our officers and directors may loan us funds to finance transaction costs in connection with an intended initial business combination. Such loans may be convertible into private placement shares of the post-business combination entity at a price of $1.00 per share at the option of the lender, which may result in material dilution to our public shareholders. See the sections titled "*Dilution*" and "*Risk Factors — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the business combination causes the trading price of our ordinary shares to materially decline.*"

Pursuant to a letter agreement to be entered with us, we have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor. Further, pursuant to such letter agreement, our initial shareholders have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (i) 180 days after the completion of our initial business combination and (ii) the date on which we complete a liquidation, merger, share exchange or other similar transaction after our initial business combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property; and our sponsor has agreed not to transfer, assign or sell any of its private placement shares until 30 days after the completion of our initial business combination; except, in each case, to certain permitted transferees and under certain circumstances as described herein under "*Principal Shareholders — Transfers of Founder Shares and Private Placement Shares*". Any permitted transferees will be subject to the same restrictions and other agreements of our initial shareholders with respect to any founder shares or private placement shares.

Each of our sponsor and its affiliate(s), directors and officers has, pursuant to a letter agreement entered with us, agreed to certain restrictions on its ability to transfer, assign, or sell the founder shares and private placement shares, as summarized in the table below.

---

| | | | |
|:---|:---|:---|:---|
| **Subject Securities** | **Expiration Date** | **Persons Subject to<br> Restrictions** | **Exceptions to<br> Transfer Restrictions** |
| Founder Shares | With certain limited exceptions, the founder shares are not transferable, assignable or saleable until the earlier of (A) 180 days after the completion of our initial business combination and (B) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. | JATT Ventures II L.P. Dr. Someit Sidhu | Transfers of the founder shares are permitted (a) to our officers or directors, any affiliate or family member of any of our officers or directors, any members or partners of our sponsor or their affiliates, any affiliates of our sponsor, or any employees of such affiliates; (b) in the case of an individual, by gift to a member of such individual's immediate family or to a trust, the beneficiary of which is a member of such individual's immediate family, an affiliate of such individual or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or otherwise in connection with the consummation of our initial business combination at prices no greater than the price at which the securities were originally purchased; (f) in the event of our liquidation prior to the completion of an initial business combination; (g) by virtue of the laws of the Cayman Islands or our sponsor's limited partnership agreement upon dissolution of our sponsor; or (h) in the event of our liquidation, merger, capital stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property subsequent to the completion of an initial business combination; provided, however, that in the case of clauses (a) through (e) or (g), these permitted transferees must enter into a written agreement with the company agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreement (including provisions relating to voting, the trust account and liquidating distributions). |

---

---

| | | | |
|:---|:---|:---|:---|
| **Subject Securities** | **Expiration Date** | **Persons Subject to<br> Restrictions** | **Exceptions to<br> Transfer Restrictions** |
| Private Placement Shares | The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination. | JATT Ventures II L.P. | Same as above. |

---

Up to 225,000 of the founder shares will be surrendered by our sponsor to us for no consideration depending on the extent to which the underwriter' over-allotment option is exercised. In addition, although there are no current plans to do so, in order to facilitate our initial business combination or a PIPE financing or for any other reason determined by our sponsor in its sole discretion, our sponsor may surrender or forfeit, transfer or exchange our founder shares, including for no consideration, as well as subject any such securities to earn-outs or other restrictions, or otherwise amend the terms of any such securities or enter into any other arrangements with respect to any such securities.

The securities held by the sponsor are expected to only be distributed directly to the members of the sponsor in connection with or following the consummation of our initial business combination, provided that such members agree to become subject to the applicable transfer restrictions with respect to such securities. Indirect transfers of the securities held by the sponsor, such as to another limited partner of the sponsor or their affiliate or a new limited partner of the sponsor, may be permitted with the consent of Dr. Someit Sidhu, the sole general partner of our sponsor, so long as such transfer complies with the applicable transfer restrictions with respect to such securities.

Additionally, our initial business combination may be subject to regulatory review and approval requirements, including foreign investment regulations and review by government entities such as the Committee on Foreign Investment in the United States ("CFIUS"). Our initial shareholders, including our sponsor, will own approximately 20% of our issued and outstanding shares following this offering (excluding the private placement shares). Our sponsor is exclusively "controlled" for CFIUS purposes by Dr. Someit Sidhu, who is a citizen of the United Kingdom. As a result, we may be considered a "foreign person" under rules promulgated by CFIUS and may not be able to complete an initial business combination with a U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as CFIUS, or ultimately prohibited.. As such, an initial business combination with a U.S. business or foreign business with U.S. subsidiaries that we may wish to pursue may be subject to CFIUS review, or ultimately prohibited. As a result, the pool of potential targets with which we could complete an initial business combination may be limited. Please see "*Risk Factors — We may not be able to complete an initial business combination since such initial business combination may be subject to regulatory review and approval requirements, including foreign investment regulations and review by government entities such as the CFIUS, or may be ultimately prohibited*." for additional information.

**Effecting our Initial Business Combination**

**General**

We are not presently engaged in, and we will not engage in, any operations for an indefinite period of time following this offering. We intend to effectuate our initial business combination using cash from the proceeds of this offering and the private placement of the private placement shares, the proceeds of any sale of our shares in connection with our initial business combination (pursuant to forward purchase agreements or backstop agreements we may enter into following the consummation of this offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, other securities issuances, or a combination of the foregoing. We may seek to complete our initial business combination with a company or business that may be financially unstable or in its early stages of development or growth, which would subject us to the numerous risks inherent in such companies and businesses.

If our initial business combination is paid for using equity or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination or used for redemptions of our ordinary shares, we may use the balance of the cash released to us from the trust account following the closing for general corporate purposes, including for maintenance or expansion of operations of the post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies, or for working capital.

We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue an initial business combination target in any industry, we intend to focus our search on healthcare or healthcare-related industries. Accordingly, there is no current basis for investors in this offering to evaluate the possible merits or risks of the target business with which we may ultimately complete our initial business combination. Although our management will assess the risks inherent in a particular target business with which we may combine, we cannot assure you that this assessment will result in our identifying all risks that a target business may encounter. Furthermore, some of those risks may be outside of our control, meaning that we can do nothing to control or reduce the chances that those risks will adversely affect a target business.

We may seek to raise additional funds through a private offering of debt or equity securities in connection with the completion of our initial business combination and we may effectuate our initial business combination using the proceeds of such offering rather than using the amounts held in the trust account. In addition, we intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of this offering and the sale of the private placement shares, and, as a result, if the cash portion of the purchase price exceeds the amount available from the trust account, net of amounts needed to satisfy any redemptions by public shareholders, we may be required to seek additional financing to complete such proposed initial business combination. Subject to compliance with applicable securities laws, we would expect to complete such financing only simultaneously with the completion of our initial business combination. In the case of an initial business combination funded with assets other than the trust account assets, our proxy materials or tender offer documents disclosing the initial business combination would disclose the terms of the financing and, only if required by law, we would seek shareholder approval of such financing. There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop agreements we may enter into following consummation of this offering. At this time, we are not a party to any arrangement or understanding with any third party with respect to raising any additional funds through the sale of securities or otherwise. None of our sponsors, officers, directors or shareholders is required to provide any financing to us in connection with or after our initial business combination.

**Sources of Target Businesses**

We anticipate that target business candidates will be brought to our attention from various unaffiliated sources, including investment bankers and private investment funds. Target businesses may be brought to our attention by such unaffiliated sources as a result of being solicited by us through calls or mailings. These sources may also introduce us to target businesses in which they think we may be interested on an unsolicited basis, since many of these sources will have read this prospectus and know what types of businesses we are targeting. Our officers and directors, as well as their affiliates, may also bring to our attention target business candidates of which they become aware through their business contacts as a result of formal or informal inquiries or discussions they may have, as well as attending trade shows or conventions. In addition, we expect to receive a number of proprietary deal flow opportunities that would not otherwise necessarily be available to us as a result of the track record and business relationships of our officers and directors. While we do not presently anticipate engaging the services of professional firms or other individuals that specialize in business acquisitions on any formal basis, we may engage these firms or other individuals in the future, in which event we may pay a finder's fee, consulting fee or other compensation to be determined in an arm's length negotiation based on the terms of the transaction. We will engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management determines is in our best interest to pursue. Payment of a finder's fee is customarily tied to completion of a transaction, in which case any such fee will be paid out of the funds held in the trust account. In no event, however, will our sponsor or any of our existing officers or directors, or any entity with which they are affiliated, be paid any finder's fee, consulting fee or other compensation by the company prior to, or for any services they render in order to effectuate, the completion of our initial business combination (regardless of the type of transaction that it is). In addition, commencing on the date of this prospectus, we will pay our sponsor $20,000 per month for officer compensation and administrative services provided to members of our management team. We may also elect to make payment of customary fees to members of our board of directors for director service. Additionally, we are not limited from paying any finder's fees, reimbursement, consulting fee, monies in respect of any payment of a loan or other compensation paid by us to our sponsor, officers or directors, or any affiliate of our sponsor or officers prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is). Any such payments prior to our initial business combination will be made from funds held outside the trust account.

We are not prohibited from pursuing an initial business combination with a business combination target that is affiliated with our sponsor, officers or directors, or from completing the business combination through a joint venture or other form of shared ownership with our sponsor, officers or directors. In the event we seek to complete our initial business combination with a business combination target that is affiliated with our sponsor, officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm which is a member of FINRA or another independent entity that commonly renders valuation opinions, that such an initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context.

**Evaluation of a Target Business and Structuring of Our Initial Business Combination**

In evaluating a prospective target business, we expect to conduct a due diligence review which may encompass, among other things, meetings with incumbent management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as applicable, as well as a review of financial, operational, legal and other information which will be made available to us. If we determine to move forward with a particular target, we will proceed to structure and negotiate the terms of the business combination transaction.

The time required to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of, and negotiation with, a prospective target business with which our initial business combination is not ultimately completed will result in our incurring losses and will reduce the funds we can use to complete another business combination.

**Lack of Business Diversification**

For an indefinite period of time after the completion of our initial business combination, the prospects for our success may depend entirely on the future performance of a single business. Unlike other entities that have the resources to complete business combinations with multiple entities in one or several industries, it is probable that we will not have the resources to diversify our operations and mitigate the risks of being in a single line of business. By completing our initial business combination with only a single entity, our lack of diversification may: subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and cause us to depend on the marketing and sale of a single product or limited number of products or services.

**Limited Ability to Evaluate the Target's Management Team**

Although we intend to closely scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial business combination with that business, our assessment of the target business's management may not prove to be correct. In addition, the future management may not have the necessary skills, qualifications or abilities to manage a public company. Furthermore, the future role of members of our management team, if any, in the target business cannot presently be stated with any certainty. The determination as to whether any of the members of our management team will remain with the combined company will be made at the time of our initial business combination. While it is possible that one or more of our directors will remain associated in some capacity with us following our initial business combination, it is unlikely that any of them will devote their full efforts to our affairs subsequent to our initial business combination. Moreover, we cannot assure you that members of our management team will have significant experience or knowledge relating to the operations of the particular target business.

We cannot assure you that any of our key personnel will remain in senior management or advisory positions with the combined company. The determination as to whether any of our key personnel will remain with the combined company will be made at the time of our initial business combination.

Following a business combination, we may seek to recruit additional managers to supplement the incumbent management of the target business. We cannot assure you that we will have the ability to recruit additional managers, or that additional managers will have the requisite skills, knowledge or experience necessary to enhance the incumbent management.

**Shareholders May Not Have the Ability to Approve Our Initial Business Combination**

We may conduct redemptions without a shareholder vote pursuant to the tender offer rules of the SEC subject to the provisions of our articles. However, we will seek shareholder approval if it is required by law or applicable stock exchange rule, or we may decide to seek shareholder approval for business or other reasons.

Under Nasdaq's listing rules, shareholder approval would be required for our initial business combination if, for example:

● We issue ordinary shares that will be equal to or in excess of 20% of the number of our ordinary shares then outstanding (excluding the private placement shares and other than in a public offering);

● Any of our directors, officers or substantial shareholders (as defined by Nasdaq rules) has a 5% or greater interest earned on the trust account (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of ordinary shares could result in an increase in outstanding ordinary shares or voting power of 5% or more; or

● The issuance or potential issuance of ordinary shares will result in our undergoing a change of control.

The decision as to whether we will seek shareholder approval of a proposed business combination in those instances in which shareholder approval is not required by applicable law or stock exchange listing requirements will be made by us, solely in our discretion, and will be based on business and legal reasons, which include a variety of factors, including, but not limited to: (i) the timing of the transaction, including in the event we determine shareholder approval would require additional time and there is either not enough time to seek shareholder approval or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the company; (ii) the expected cost of holding a shareholder vote; (iii) the risk that the shareholders would fail to approve the proposed business combination; (iv) other time and budget constraints of the company; and (v) additional legal complexities of a proposed business combination that would be time-consuming and burdensome to present to shareholders.

**Permitted Purchases of Our Securities**

If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase public shares in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination, although they are under no obligation or duty to do so. Any such price per share may be different than the amount per share a public shareholder would receive if it elected to redeem its shares in connection with our initial business combination. Such a purchase may include a contractual acknowledgment that such shareholder, although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that our sponsor, initial shareholders, directors, officers, advisors and their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares. It is intended that, if Rule 10b-18 would apply to purchases by sponsor, initial shareholders, directors, officers, advisors and their affiliates, then such purchases will comply with Rule 10b-18 under the Exchange Act, to the extent it applies, which provides a safe harbor for purchases made under certain conditions, including with respect to timing, pricing and volume of purchases.

Additionally, at any time at or prior to our initial business combination, subject to applicable securities laws (including with respect to material non-public information), our sponsor, initial shareholders, directors, officers, advisors and their affiliates may enter into transactions with investors and others to provide them with incentives to acquire public shares, vote their public shares in favor of our initial business combination or not redeem their public shares. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase public shares in such transactions.

The purpose of any such transactions could be to (1) increase the likelihood of obtaining shareholder approval of the business combination or (2) satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible.

In addition, if such purchases are made, the public "float" of our securities may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.

Our sponsor, initial shareholders, directors, officers, advisors and their affiliates anticipate that they may identify the shareholders with whom our sponsor, initial shareholders, directors, officers, advisors and their affiliates may pursue privately negotiated transactions by either the shareholders contacting us directly or by our receipt of redemption requests submitted by shareholders (in the case of ordinary shares) following our mailing of proxy materials in connection with our initial business combination. To the extent that our sponsor, initial shareholders, directors, officers, advisors and their affiliates enter into a private transaction, they would identify and contact only potential selling or redeeming shareholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against our initial business combination, whether or not such shareholder has already submitted a proxy with respect to our initial business combination but only if such shares have not already been voted at the general meeting related to our initial business combination. Our sponsor, initial shareholders, directors, officers, advisors and their affiliates will select which shareholders to purchase shares from based on the negotiated price and number of shares and any other factors that they may deem relevant, and will be restricted from purchasing shares if such purchases do not comply with Regulation M under the Exchange Act and the other federal securities laws.

Our sponsor, initial shareholders, directors, officers, advisors and their affiliates will be restricted from making purchases of shares if the purchases would violate Section 9(a)(2) or Rule 10b-5 of the Exchange Act. Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements. Additionally, in the event our sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders, such purchases would be structured in compliance with the requirements of Rule 14e-5 under the Exchange Act including, in pertinent part, through adherence to the following:

● our registration statement/proxy statement filed for our business combination transaction would disclose the possibility that our sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase public shares from public shareholders outside the redemption process, along with the purpose of such purchases;

● if our sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders, they would do so at a price no higher than the price offered through our redemption process;

● our registration statement/proxy statement filed for our business combination transaction would include a representation that any of our securities purchased by our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not be voted in favor of approving the business combination transaction;

● our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive such rights; and

● we would disclose in a Form 8-K, before our general meeting to approve the business combination transaction, the following material items:

● the amount of our securities purchased outside of the redemption offer by our sponsor, initial shareholders, directors, officers, advisors and their affiliates, along with the purchase price;

● the purpose of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates;

● the impact, if any, of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates on the likelihood that the business combination transaction will be approved;

● the identities of our security holders who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security holders) who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates; and

● the number of our securities for which we have received redemption requests pursuant to our redemption offer.

Please see "*Risk Factors — If we seek shareholder approval of our initial business combination, our sponsor, initial shareholders, directors, officers, advisors and their affiliates may elect to purchase shares from public shareholders, which may influence a vote on a proposed business combination and reduce the public "float" of our ordinary shares.*"

**Redemption Rights for Public Shareholders in Connection with the Completion of Our Initial Business Combination**

We will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriter. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may hold in connection with the completion of our initial business combination.

**Limitation on Redemptions**

Our proposed initial business combination may impose a minimum cash requirement for (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. In the event the aggregate cash consideration we would be required to pay for all ordinary shares that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the initial business combination or redeem any shares, and all ordinary shares submitted for redemption will be returned to the holders thereof. We may, however, raise funds through the issuance of equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop arrangements we may enter into following consummation of this offering, in order to, among other reasons, satisfy such net tangible assets or minimum cash requirements.

**Manner of Conducting Redemptions**

We will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares in connection with the completion of our initial business combination either (i) in connection with a general meeting called to approve the business combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether we will seek shareholder approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirement or whether we were deemed to be a foreign private issuer (which would require a tender offer rather than seeking shareholder approval under SEC rules), as described above under the heading "— *Shareholders May Not Have the Ability to Approve Our Initial Business Combination*." Asset acquisitions and share purchases would not typically require shareholder approval while direct mergers with our company where we do not survive and any transactions where we issue more than 20% of our issued and outstanding ordinary shares (excluding the private placement shares) or seek to amend our articles would require shareholder approval. So long as we obtain and maintain a listing for our securities on Nasdaq, we will be required to comply with Nasdaq's shareholder approval rules.

The requirement that we provide our public shareholders with the opportunity to redeem their public shares by one of the two methods listed above will be contained in provisions of our articles and will apply whether or not we maintain our registration under the Exchange Act or our listing on Nasdaq. Such provisions may be amended if approved by special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote thereon on such matter at a general meeting of the company, so long as we offer redemption in connection with such amendment.

If we provide our public shareholders with the opportunity to redeem their public shares in connection with a general meeting, we will, pursuant to our articles:

● conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and

● file proxy materials with the SEC.

In the event that we seek shareholder approval of our initial business combination, we will distribute proxy materials and, in connection therewith, provide our public shareholders with the redemption rights described above upon completion of the initial business combination.

If we seek shareholder approval, we will complete our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company, however, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles. A quorum for such meeting will be present if the holders of one-third of issued and outstanding shares entitled to vote at the meeting are represented in person or by proxy. Our sponsor, officers, directors and advisors will count toward this quorum and, pursuant to the letter agreement, our sponsor, officers, directors and advisors have agreed to vote their founder shares, private placement shares and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our initial business combination. For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. As a result, in addition to our initial shareholders' founder shares and the private placement shares, we would need 2,100,001, or approximately 35.0%, of the 6,000,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming all outstanding shares are voted, the private placement shares to be issued to our sponsor are voted in favor of the transaction and the over-allotment option is not exercised and the parties to the letter agreement do not acquire any ordinary shares). Assuming that only the holders of one-third of our issued and outstanding ordinary shares, representing a quorum under our articles vote their shares at a general meeting of the company, we would not need any public shares to be voted in favor of an initial business combination in order to have our initial business combination approved. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. These quorum and voting thresholds, and the voting agreement of our sponsor, officers and directors, may make it more likely that we will consummate our initial business combination. Each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction.

If a shareholder vote is not required and we do not decide to hold a shareholder vote for business or other legal reasons, we will:

● conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and

● file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.

In the event we conduct redemptions pursuant to the tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under the Exchange Act, and we will not be permitted to complete our initial business combination until the expiration of the tender offer period. In addition, the tender offer will be conditioned on public shareholders not tendering more than the number of public shares we are permitted to redeem. If public shareholders tender more shares than we have offered to purchase, we will withdraw the tender offer and not complete the initial business combination.

Upon the public announcement of our initial business combination, if we elect to conduct redemption pursuant to the tender offer rules, we or our sponsor will terminate any plan established in accordance with Rule 10b5-1 to purchase our ordinary shares in the open market, in order to comply with Rule 14e-5 under the Exchange Act.

We intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to, at the holder's option, either deliver their share certificates to our transfer agent or deliver their shares to our transfer agent electronically using the Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) system, prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public shareholders to satisfy such delivery requirements. We believe that this will allow our transfer agent to efficiently process any redemptions without the need for further communication or action from the redeeming public shareholders, which could delay redemptions and result in additional administrative cost. If the proposed initial business combination is not approved and we continue to search for a target company, we will promptly return any certificates or shares delivered by public shareholders who elected to redeem their shares.

Our proposed initial business combination may impose a minimum cash requirement for (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. In the event the aggregate cash consideration we would be required to pay for all ordinary shares that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the initial business combination or redeem any shares, and all ordinary shares submitted for redemption will be returned to the holders thereof. We may, however, raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop arrangements we may enter into following consummation of this offering, in order to, among other reasons, satisfy such net tangible assets or minimum cash requirements.

**Limitation on Redemption Upon Completion of Our Initial Business Combination If We Seek Shareholder Approval**

If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our articles will provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares without our prior consent. We believe this restriction will discourage shareholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their ability to exercise their redemption rights against a proposed business combination as a means to force us or our management to purchase their shares at a significant premium to the then-current market price or on other undesirable terms. Absent this provision, a public shareholder holding more than an aggregate of 20% of the shares sold in this offering could threaten to exercise its redemption rights if such holder's shares are not purchased by us, our sponsor or our management at a premium to the then-current market price or on other undesirable terms. By limiting our shareholders' ability to redeem no more than 20% of the shares sold in this offering, we believe we will limit the ability of a small group of shareholders to unreasonably attempt to block our ability to complete our initial business combination, particularly in connection with a business combination with a target that requires as a closing condition that we have a minimum net worth or a certain amount of cash.

However, we would not be restricting our shareholders' ability to vote all of their shares (including Excess Shares) for or against our initial business combination.

**Delivering Share Certificates in Connection with the Exercise of Redemption Rights**

As described above, we intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to, at the holder's option, either deliver their share certificates to our transfer agent or deliver their shares (and share certificates (if any) and other redemption forms) to our transfer agent electronically using the Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) system, prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public shareholders to satisfy such delivery requirements. Accordingly, a public shareholder would have up to two business days prior to the scheduled vote on the initial business combination if we distribute proxy materials, or from the time we send out our tender offer materials until the close of the tender offer period, as applicable, to submit or tender its shares if it wishes to seek to exercise its redemption rights. In the event that a shareholder fails to comply with these or any other procedures disclosed in the proxy or tender offer materials, as applicable, its shares may not be redeemed. Given the relatively short exercise period, it is advisable for shareholders to use electronic delivery of their public shares.

There is a nominal cost associated with the above-referenced process and the act of certificating the shares or delivering them through the DWAC system. The transfer agent will typically charge the broker submitting or tendering shares a fee of approximately $100 and it would be up to the broker whether or not to pass this cost on to the redeeming holder. However, this fee would be incurred regardless of whether we require holders seeking to exercise redemption rights to deliver or tender (and share certificates (if any) and other redemption forms) their shares. The need to deliver or tender shares is a requirement of exercising redemption rights regardless of the timing of when such delivery must be effectuated.

Any request to redeem such shares, once made, may be withdrawn at any time up to the date set forth in the proxy materials or tender offer documents, as applicable. Furthermore, if a holder of a public share delivered its certificate in connection with an election of redemption rights and subsequently decides prior to the applicable date not to elect to exercise such rights, such holder may simply request that the transfer agent return the certificate (physically or electronically). It is anticipated that the funds to be distributed to holders of our public shares electing to redeem their shares will be distributed promptly after the completion of our initial business combination.

If our initial business combination is not approved or completed for any reason, then our public shareholders who elected to exercise their redemption rights would not be entitled to redeem their shares for the applicable pro rata share of the trust account. In such case, we will promptly return any certificates delivered by public holders who elected to redeem their shares.

If our initial proposed business combination is not completed, we may continue to try to complete a business combination with a different target until the end of the completion window.

**Redemption of Public Shares and Liquidation if No Initial Business Combination**

Our articles will provide that we will have only the duration of the completion window to complete our initial business combination. If we are unable to complete our initial business combination within the completion window, we will: (i) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidation or other distributions, if any) subject to our obligations under Cayman Islands law to provide for claims of creditors and subject to the other requirements of applicable law.

Our sponsor, officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any founder shares and private placement shares held by them if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account. However, if our sponsor or management team acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the allotted completion window.

Our sponsor, officers, directors and director nominees have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, unless we provide our public shareholders with the opportunity to redeem their public shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares.

We expect that all costs and expenses associated with implementing our plan of dissolution, as well as payments to any creditors, will be funded from amounts remaining out of the approximately $1,500,000 of proceeds held outside the trust account, although we cannot assure you that there will be sufficient funds for such purpose. However, if those funds are not sufficient to cover the costs and expenses associated with implementing our plan of dissolution, to the extent that there is any interest accrued in the trust account not required to pay income taxes on interest income earned on the trust account balance, we may request the trustee to release to us an additional amount of up to $100,000 of such accrued interest to pay those costs and expenses.

If we were to expend all of the net proceeds of this offering and the sale of the private placement shares, other than the proceeds deposited in the trust account, and without taking into account interest, if any, earned on the trust account and any tax payments or expenses for the dissolution of the trust, the per-share redemption amount received by shareholders upon our dissolution would be approximately $10.00. The proceeds deposited in the trust account could, however, become subject to the claims of our creditors which would have higher priority than the claims of our public shareholders. We cannot assure you that the actual per-share redemption amount received by shareholders will not be substantially less than $10.00. While we intend to pay such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors' claims.

Although we will seek to have all vendors, service providers, prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public shareholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account including but not limited to fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will consider whether competitive alternatives are reasonably available to us and will only enter into an agreement with such third party if management believes that such third party's engagement would be in the best interests of the company under the circumstances. Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. WithumSmith+Brown, PC, our independent registered public accounting firm, and the underwriters of this offering will not execute agreements with us waiving such claims to the monies held in the trust account. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. In order to protect the amounts held in the trust account, our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us (except for the Company's registered public accounting firm), or a prospective target business with which we have entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes paid and payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses; *provided* that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our sponsor's only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination and redemptions could be reduced to less than $10.00 per public share. In such event, we may not be able to complete our initial business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

In the event that the proceeds in the trust account are reduced below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, and our sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment may choose not to do so in any particular instance if, for example, the cost of such legal action is deemed by the independent directors to be too high relative to the amount recoverable or if the independent directors determine that a favorable outcome is not likely. Accordingly, we cannot assure you that due to claims of creditors the actual value of the per-share redemption price will not be less than $10.00 per share.

We will seek to reduce the possibility that our sponsor will have to indemnify the trust account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to monies held in the trust account. Our sponsor will also not be liable as to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. We will have access to up to approximately $1,500,000 from the proceeds of this offering with which to pay any such potential claims (including costs and expenses incurred in connection with our liquidation, currently estimated to be no more than approximately $100,000). In the event that we liquidate and it is subsequently determined that the reserve for claims and liabilities is insufficient, shareholders who received funds from our trust account could be liable for claims made by creditors. In the event that our offering expenses exceed our estimate of $900,000 (not including underwriter's discount), we may fund such excess with funds from the funds not to be held in the trust account. In such case, the amount of funds we intend to be held outside the trust account would decrease by a corresponding amount. Conversely, in the event that the offering expenses are less than our estimate of $900,000 (not including underwriter's discount), the amount of funds we intend to be held outside the trust account would increase by a corresponding amount.

If we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the trust account, we cannot assure you we will be able to return $10.00 per share to our public shareholders. Additionally, if we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a "preferential transfer" or a "fraudulent conveyance." As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by our shareholders. Furthermore, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or may have acted in bad faith, and thereby exposing itself and our company to claims of punitive damages, by paying public shareholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.

Our public shareholders will be entitled to receive funds from the trust account only (i) in the event of the redemption of our public shares if we do not complete our initial business combination within the completion window, (ii) in connection with a shareholder vote to amend our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity or (iii) if they redeem their respective shares for cash upon the completion of our initial business combination. In no other circumstances will a shareholder have any right or interest of any kind to or in the trust account. In the event we seek shareholder approval in connection with our initial business combination, a shareholder's voting in connection with the business combination alone will not result in a shareholder's redeeming its shares to us for an applicable pro rata share of the trust account. Such shareholder must have also exercised its redemption rights described above. These provisions of our articles, like all provisions of our articles, may be amended with a shareholder vote.

**Comparison of Redemption or Purchase Prices in Connection with Our Initial Business Combination and if We Fail to Complete Our Initial Business Combination.**

The following table compares the redemptions and other permitted purchases of public shares that may take place in connection with the completion of our initial business combination and if we are unable to complete our initial business combination within the completion window.

---

| | | | |
|:---|:---|:---|:---|
|  | **Redemptions in Connection <br> with our Initial Business <br> Combination** | **Other Permitted Purchases of <br> Public Shares by our Affiliates** | **Redemptions if we fail to <br> Complete an Initial Business <br> Combination** |
| **Calculation of redemption price** | Redemptions at the time of our initial business combination may be made pursuant to a tender offer or in connection with a shareholder vote. The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a shareholder vote. In either case, our public shareholders may redeem their public shares for cash equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitation that no redemptions will take place if all of the redemptions would cause to be unable to satisfy any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of terms of a proposed business combination. | If we seek shareholder approval of our initial business combination, our sponsor, initial shareholders, directors, officers, advisors or their affiliates may purchase shares in privately negotiated transactions or in the open market either prior to or following completion of our initial business combination. If our sponsor, initial shareholders, directors, officers, advisors or their affiliates were to purchase shares from public shareholders, they would do so at a price no higher than the price offered through our redemption process. If they engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules. | If we are unable to complete our initial business combination within the completion window, we will redeem all public shares at a per-share price, payable in cash, equal to the aggregate amount, then on deposit in the trust account (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares. |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Redemptions in Connection <br> with our Initial Business <br> Combination** | **Other Permitted Purchases of <br> Public Shares by our Affiliates** | **Redemptions if we fail to <br> Complete an Initial Business <br> Combination** |
| **Impact to remaining shareholders** | The redemptions in connection with our initial business combination will reduce the book value per share for our remaining shareholders, who will bear the burden of the deferred underwriting commissions and interest withdrawn in order to pay our taxes (to the extent not paid from amounts accrued as interest on the funds held in the trust account). | If the permitted purchases described above are made, there would be no impact to our remaining shareholders because the purchase price would not be paid by us. | The redemption of our public shares if we fail to complete our initial business combination will reduce the book value per share for the shares held by our initial shareholders, who will be our only remaining shareholders after such redemptions. |

---

**Comparison of This Offering to Those of Blank Check Companies Subject to Rule 419**

The following table compares the terms of this offering to the terms of an offering by a blank check company subject to the provisions of Rule 419. This comparison assumes that the gross proceeds, underwriting commissions and underwriting expenses of our offering would be identical to those of an offering undertaken by a company subject to Rule 419, and that the underwriters will not exercise their over-allotment option. None of the provisions of Rule 419 apply to our offering.

---

| | | |
|:---|:---|:---|
|  | **Terms of Our Offering** | **Terms Under a Rule 419 Offering** |
| **Escrow of offering proceeds** | $60,000,000 of the net proceeds of this offering and the sale of the private placement shares will be deposited into a trust account located in the United States with Continental Stock Transfer & Trust Company acting as trustee. | Approximately $51,030,000 of the offering proceeds, representing the gross proceeds of this offering, would be required to be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account (assuming our sponsor purchases 300,000 ordinary shares (or up to 309,000 ordinary shares if the underwriter's option to purchase additional shares is exercised in full) in this offering). |
| **Investment of net proceeds** | $60,000,000 of the net proceeds of this offering and the sale of the private placement shares held in trust will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. | Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States. |
| **Receipt of interest on escrowed funds** | Interest on proceeds from the trust account to be paid to shareholders is reduced by (i) any taxes paid or payable and (ii) in the event of our liquidation for failure to complete our initial business combination within the allotted time, up to $100,000 of net interest that may be released to us should we have no or insufficient working capital to fund the costs and expenses of our dissolution and liquidation. | Interest on funds in escrow account would be held for the sole benefit of investors, unless and only after the funds held in escrow were released to us in connection with our completion of a business combination. |

---

---

| | | |
|:---|:---|:---|
|  | **Terms of Our Offering** | **Terms Under a Rule 419 Offering** |
| **Limitation on fair value or net assets of target business** | Nasdaq rules require that we must complete one or more business combinations having an aggregate fair market value of at least 80% of our assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the income earned on the trust account) at the time of the agreement to enter into the initial business combination. | The fair value or net assets of a target business must represent at least 80% of the maximum offering proceeds. |
| **Trading of shares issued** | The ordinary shares are expected to begin trading on or promptly after the date of this prospectus. | No trading of the ordinary shares would be permitted until the completion of a business combination. During this period, the shares would be held in the escrow or trust account. |
| **Election to remain an investor** | We will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then outstanding public shares, in connection with the completion of our initial business combination, subject to the limitations and on the conditions described herein. We may not be required by law to hold a shareholder vote. If we are not required by law and do not 45<sup>th</sup> otherwise decide to hold a shareholder vote, we will, pursuant to our articles, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC's proxy rules. If, however, we hold a shareholder vote, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. Additionally, each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction, or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. | A prospectus containing information pertaining to the business combination required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of a post-effective amendment to the company's registration statement, to decide if he, she or it elects to remain a shareholder of the company or require the return of his, her or its investment. If the company has not received the notification by the end of the business day, funds and interest or dividends, if any, held in the trust or escrow account are automatically returned to the shareholder. Unless a sufficient number of investors elect to remain investors, all funds on deposit in the escrow account must be returned to all of the investors and none of the securities are issued. |

---

---

| | | |
|:---|:---|:---|
|  | **Terms of Our Offering** | **Terms Under a Rule 419 Offering** |
| **Business combination deadline** | If we are unable to complete our initial business combination within the completion window, we will redeem 100% of the public shares at per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and limitations and on the conditions described herein. We may seek shareholder approval to amend our articles by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension. | If an acquisition has not been completed within 18 months after the effective date of the company's registration statement, funds held in the trust or escrow account are returned to investors. |
| **Delivering share certificates in connection with the exercise of redemption rights** | We intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street name," to, at the holder's option, either deliver their shares (and share certificates (if any) and other redemption forms) to our transfer agent or tender or deliver their shares to our transfer agent electronically using the Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) system, prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public shareholders to satisfy such delivery requirements. Accordingly, a public shareholder would have up to two business days prior to the scheduled vote on the initial business combination if we distribute proxy materials, or from the time we send out our tender offer materials until the close of the tender offer period, as applicable, to deliver or tender its shares (and share certificates (if any) and other redemption forms) if it wishes to seek to exercise its redemption rights. | Many blank check companies provide that a shareholder can vote against a proposed business combination and check a box on the proxy card indicating that such shareholder is seeking to exercise its redemption rights.<br>After the business combination is approved, the company would contact such shareholder to arrange for delivery of its share certificates to verify ownership. |
| **Limitation on redemption rights of shareholders holding more than 20% of the shares sold in this offering if we hold a shareholder vote** | If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our articles will provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares without our prior consent. However, we would not restrict our shareholders' ability to vote all of their shares (including Excess Shares) for or against our initial business combination. | Many blank check companies provide no restrictions on the ability of shareholders to redeem shares based on the number of shares held by such shareholders in connection with an initial business combination. |

---

**Competition**

In identifying, evaluating and selecting a target business for our initial business combination, we may encounter competition from other entities having a business objective similar to ours, including other special purpose acquisition companies, private equity groups and leveraged buyout funds, public companies and operating businesses seeking strategic acquisitions. Many of these entities are well established and have extensive experience identifying and effecting business combinations directly or through affiliates. Moreover, many of these competitors possess similar or greater financial, technical, human and other resources than us. Our ability to acquire larger target businesses will be limited by our available financial resources. This inherent limitation gives others an advantage in pursuing the acquisition of a target business. Furthermore, our obligation to pay cash in connection with our public shareholders who exercise their redemption rights may reduce the resources available to us for our initial business combination, and the future dilution they potentially represent, may not be viewed favorably by certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully negotiating an initial business combination.

**Facilities**

We currently utilize office space at 153 Central Avenue, C/O 56, Westfield, NJ 07091 from our sponsor and the members of our management team as our executive offices. We consider our current office space adequate for our current operations. Subsequent to the closing of this offering, we will pay our sponsor or designees an aggregate of up to $20,000 per month for officer compensation and administrative services provided to us and members of our management team. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.

**Employees**

We currently have two officers: Dr. Someit Sidhu, our Chief Executive Officer, and Mr. Nicholas Fernandez, our Chief Financial Officer. These individuals are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial business combination and the stage of the business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial business combination.

**Periodic Reporting and Financial Information**

We will register our ordinary shares under the Exchange Act and have reporting obligations, including the requirement that we file annual, quarterly and current reports with the SEC. In accordance with the requirements of the Exchange Act, our annual reports will contain financial statements audited and reported on by our independent registered public accountants.

We will provide shareholders with audited financial statements of the prospective target business as part of the proxy solicitation materials or tender offer documents sent to shareholders to assist them in assessing the target business. In all likelihood, these financial statements will need to be prepared in accordance with, or reconciled to, GAAP or IFRS, depending on the circumstances, and the historical financial statements may be required to be audited in accordance with the standards of the PCAOB. These financial statement requirements may limit the pool of potential target businesses we may conduct an initial business combination with because some targets may be unable to provide such statements in time for us to disclose such statements in accordance with federal proxy rules and complete our initial business combination within the prescribed time frame. We cannot assure you that any particular target business identified by us as a potential business combination candidate will have financial statements prepared in accordance with the requirements outlined above, or that the potential target business will be able to prepare its financial statements in accordance with the requirements outlined above. To the extent that these requirements cannot be met, we may not be able to acquire the proposed target business. While this may limit the pool of potential business combination candidates, we do not believe that this limitation will be material.

We will be required to evaluate our internal control procedures for the fiscal year ending December 31, 2026 as required by the Sarbanes-Oxley Act. Only in the event we are deemed to be a large accelerated filer or an accelerated filer, and no longer qualify as an emerging growth company, will we be required to have our internal control procedures audited. A target business may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such business combination.

Prior to the date of this prospectus, we will file a Registration Statement on Form 8-A with the SEC to voluntarily register our securities under Section 12 of the Exchange Act. As a result, we will be subject to the rules and regulations promulgated under the Exchange Act. We have no current intention of filing a Form 15 to suspend our reporting or other obligations under the Exchange Act prior or subsequent to the consummation of our initial business combination.

We are a Cayman Islands exempted company. Exempted companies are Cayman Islands companies conducting business mainly outside the Cayman Islands and, as such, are exempted from complying with certain provisions of the Companies Act. As an exempted company, we have applied for and received a tax exemption undertaking from the Cayman Islands government that, in accordance with Section 6 of the Tax Concessions Act (As Revised) of the Cayman Islands, for a period of 30 years from the date of the undertaking, no law which is enacted in the Cayman Islands imposing any tax to be levied on profits, income, gains or appreciations will apply to us or our operations and, in addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax will be payable (i) on or in respect of our shares, debentures or other obligations or (ii) by way of the withholding in whole or in part of a payment of dividend or other distribution of income or capital by us to our shareholders or a payment of principal or interest or other sums due under a debenture or other obligation of us.

We are an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.

In addition, Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

Additionally, we are "smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our ordinary shares held by non-affiliates equals or exceeds $250 million as of the end of that year's second fiscal quarter, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates exceeds $700 million as of the end of that year's second fiscal quarter.

**Legal Proceedings**

There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacities as such.

**Management**

**Officers, Directors and Director Nominees**

Our officers, directors and director nominees are as follows:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Dr. Someit Sidhu | 37 | Chairman, Director, and Chief Executive Officer |
| Nicholas Fernandez | 42 | Chief Financial Officer |
| Verender S. Badial | 53 | Director Nominee |
| Christopher Staral | 38 | Director Nominee |
| Dr. Arjun Goyal | 45 | Director Nominee |
| Dr. Jonathon Kluft | 44 | Director Nominee |

---

**Dr. Someit Sidhu** serves as our Director, Chairman of the Board, and Chief Executive Officer. Dr. Sidhu has broad expertise covering various topics in the life sciences industry, and is a strategy consultant and serial biotech entrepreneur in the industry. Dr. Sidhu is the founder of Khanda Therapeutics, and has served as its CEO and director since December 2025. Dr. Sidhu served as CEO and a director of JATT Acquisition Corp from its inception until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. From March 2023 to April 2024, Dr. Sidhu served as the CEO and director of Zura Bio, and has since continued to serve as director of Zura Bio. Dr. Sidhu was also a co-founder of Izana Bioscience and served as its CEO from November 2017 until its eventual sale to Roivant in June 2020. He is also Co-founder of Pathios Therapeutics and Akaza Bioscience and has served as its CEO from 2019 to 2021. Prior to these companies, Dr. Sidhu advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on Pharmaceutical R&D and Portfolio Strategy. Dr. Sidhu has also been serving as director of GSN Estate since September 2024 and as director of Invictus Bioscience since May 2016. Dr. Sidhu gained medical experience during his time in Cardiology and General Surgery after graduating from the Oxford Medical School where he was a Senior Mackinnon Scholar at Magdalen College. We believe Dr. Sidhu's extensive operational and investment experience in the life sciences industry gives him the qualifications, attributes and skills to serve as a director.

**Nicholas Fernandez** serves as our Chief Financial Officer. Mr. Fernandez has over 20 years of experience across operations, accounting and finance. Mr. Fernandez has been with Athanor Capital, a hedge fund, from December 2019 to December 2025, most recently serving as Chief Operating Officer and Chief Financial Officer. From April 2024 to November 2024, Mr. Fernandez served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of EcoBridge Capital Management. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jefferies LLC, a global bulge bracket investment bank, from February 2017 to April 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez has previously served as a director of Iris Acquisition Corp from May 2023 until its business combination with Liminatus Pharma, LLC in April 2025, and has been serving as a director of Liminatus Pharma, Inc., the post combination company since then. Mr. Fernandez has also been serving as the CFO of Amanat Acquisition Corp. since January 2026. Mr. Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr. Fernandez holds an active Certified Public Accountant License in the state of New York.

**Verender S. Badial** is a Director nominee. He has more than 20 years of experience as an investment banker and is currently Managing Director of Cryfield Investments, which he founded in 2015 and is responsible for the corporate finance services and capital fundraising activities. He also serves as Chief Executive Officer of ME Asset Management, a UK-based investment platform backed by Cryfield Investments. Mr. Badial has also served as the Chief Financial Officer of Zura Bio Limited from March 2023 to July 2025, and was previously JATT Acquisition Corp's chief financial officer since July 2021 until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. Between 1997 and 2015, Mr. Badial held executive functions in the Equity Capital Markets departments of Rothschild (ABN AMRO) and Societe Generale, allowing him to leverage rich experience in structuring and executing equity capital markets transactions as well as building up an extensive network. Mr. Badial also held the role of Managing Director with Rothschild (ABN AMRO) and Societe Generale within the investment banks and is experienced in both buy- and sell-side advisory transactions incorporating leveraged and structured equity and debt finance solutions with a key focus on financial sponsor portfolios in pharma and healthcare. Mr. Badial brings unique capabilities for the target identification and business combination processes based on his expertise from acquiring and funding numerous corporates, raising capital for M&A and IPOs coupled with significant expertise in analyzing potential financial or management improvements to operational businesses. Mr. Badial graduated with an honor's degree from the London School of Economics & Political Science. We believe Mr. Badial is qualified to serve on our board of directors because of his experience as a seasoned investment banker.

**Christopher Staral** is a Director nominee. Mr. Staral is the Founder, Managing Member, and Chief Investment Officer of Triple Helix Investments, where he brings a multidimensional background across science, public and private markets, and high-performance decision-making. Before launching Triple Helix, Mr. Staral founded and was CIO of Allostery Investments, a specialized, low-net biotech fund known for combining deep scientific research with sentiment and technical overlays, from July 2022 to August 2025. Mr. Staral previously worked as senior analyst of Laurion Capital Management, where he played a key role in building and helping lead Laurion Capital Management's private and long/short public biotech strategy, expanding the platform and driving investment across emerging and established therapeutic innovations. Prior to Laurion, Mr. Staral was an Investment Analyst at Mangrove Partners, focusing on high-conviction long and short opportunities within biotechnology. Mr. Staral began his finance career in sell-side equity research, first at Canaccord Genuity and later at Goldman Sachs. His path to investing was unconventional: raised in Minnesota and initially pursuing medicine, he ultimately gravitated to biotechnology investing because it combined his scientific interest in the complexity of human biology with the mark-to-market competition he thrived on — first as a world-class individual performer, and then by building and leading elite teams in highly competitive environments. Mr. Staral received his B.A. in Chemistry from Carleton College and attended the University of Minnesota Medical School. We believe Mr. Staral is qualified to serve on our board of directors because of his background in medicine and years of experience in finance.

**Dr. Arjun Goyal** is a Director nominee. Dr. Goyal is a life sciences investor and entrepreneur and the Founder and Managing Partner of Vianti Capital, a therapeutics-focused investment firm. Prior to founding Vianti, Dr. Goyal was a Co-Founder and Managing Director of Vida Ventures, a U.S.-based life sciences venture capital firm with over $1.7 billion in assets under management. He co-founded Vida in 2017 and departed the firm in December 2024 following multiple realized exits and the scaling of the platform. During his tenure, he served as the originating and lead partner on multiple investments, including Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck), Asklepios BioPharmaceutical (acquired by Bayer), Scorpion Therapeutics (acquired by Eli Lilly), Halda Therapeutics (acquired by Johnson & Johnson), Homology Medicines (NASDAQ: FIXX), Kinnate Therapeutics (NASDAQ: KNTE), Alterome Therapeutics, Quanta Therapeutics, and Third Arc Bio, with active governance involvement across multiple companies. Earlier in his career, from 2014 to 2017, Dr. Goyal was an investment professional at 5AM Ventures, a life sciences-focused venture firm. There, he co-led investments in companies including Aprea AB (NASDAQ: APRE), Spyryx, Pear Therapeutics, Portal Instruments, Entrada Therapeutics (NASDAQ: TRDA), and Homology Medicines (NASDAQ: FIXX), and served as a Board Observer across multiple portfolio companies. Dr. Goyal has also been serving as a director of Centessa Pharmaceuticals Plc since January 2021. Dr. Goyal trained as a physician and brings a combined clinical, scientific, and business background to his investment work. He earned his M.D. from the University of Melbourne, completed medical research training at the University of Oxford, received an M.Phil. in Bioscience Enterprise from the University of Cambridge as a Commonwealth Scholar and Gates Cambridge Scholar, and holds an MBA from Harvard Business School. He completed postgraduate medical training in Internal Medicine at the University of Sydney. He has received several professional recognitions, including the Advance Award for Technology & Entrepreneurship for Global Australians (2021) and selection as one of Australia's 25 Most Influential Global Game-Changers in Business (2026). He serves on the Board of Advisors for the MS/MBA Life Sciences Program at Harvard Business School, the American Australian Association Education Fellowship Committee, and the Investment Committee of the University of Melbourne Technology Endowment Fund. We believe Dr. Goyal is qualified to serve on our board of directors because of his experience as a life science investor.

**Dr. Jonathon Kluft** is a Director nominee. Dr. Kluft brings more than a decade of experience in biotechnology investing and investment analysis across a broad range of therapeutic areas. He currently serves as a consultant to Atika Capital Management, LLC, a healthcare, consumer and technology-focused hedge fund, and also engages in private investment activities. From April 2016 through June 2025, Dr. Kluft served as Vice President, Special Projects and, prior to that, Vice President, Investments (previously Business Development) at Roivant Sciences, where he was closely involved in the sourcing, evaluation and execution of transactions that resulted in the formation of several Roivant subsidiary companies, including Immunovant, Urovant, and Pulmovant, among others. Prior to joining Roivant, from January 2013 through April 2016, Dr. Kluft was an Analyst at Atika Capital, where he identified and presented equity investment recommendations primarily within the pharmaceutical and biotechnology sectors. Earlier in his career, Dr. Kluft served as an intern at Gilder, Gagnon, Howe & Co., an asset management firm, where he conducted due diligence on biotechnology companies. His background in biotechnology investing provides the Board with valuable perspective in evaluating potential acquisition opportunities, drug development programs and strategic transactions. Dr. Kluft received his M.D. from Columbia University College of Physicians and Surgeons in 2013 and his B.A. in Philosophy, Politics and Economics from the University of Pennsylvania in 2005. We believe Dr. Kluft is qualified to serve on our board of directors because of his decade of experience in biotechnology investing.

**Number and Terms of Office of Officers and Directors**

Our board of directors will consist of five members. Prior to the completion of an initial business combination, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the directors present and voting at the meeting of our board of directors or by a majority of the holders of our insider shares. After completion of the business combination, subject to any other special rights applicable to the shareholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the directors present and voting at the meeting of our board of directors or by a majority of the holders of our ordinary shares. In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual general meeting until one year after our first fiscal year end following our listing on Nasdaq.

Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association.

**Director Independence**

Nasdaq rules require that a majority of our board of directors be independent within one year of our initial public offering. An "independent director" is defined generally as a person who, in the opinion of the company's board of directors, has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). Upon the commencement of trading of our ordinary shares on Nasdaq, we expect to have three "independent directors" as defined in Nasdaq rules and applicable SEC rules prior to completion of this offering. Our board of directors expects to determine that Verender S. Badial, Christopher Staral, Arjun Goyal and Jonathon Kluft are "independent directors" as defined in Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present.

**Officer and Director Compensation**

Upon the effective date of the registration statement of which this prospectus forms a part, we will into an Administrative Services Agreement pursuant to which we will agree to pay our sponsor $20,000 per month for the administrative services provided to members of our management team and services provided by Nicholas Fernandez, our Chief Financial Officer, in forming the Company and his services as the Chief Financial Officer of the Company. Mr. Fernandez shall receive a lump-sum compensation of $35,714 from the sponsor at the closing of this offering for his service provided in relation to this offering. In addition, Mr. Fernandez will also receive $8,928 from the sponsor on a monthly basis out of the Administrative Services Fee, for his continued service as the Chief Financial Officer of the Company, from closing of this offering until completion of the Company's initial business combination. If the Company completes an initial business combination prior to the date that is 24 months from the closing of this offering, Mr. Fernandez shall receive at the completion of our initial business combination an additional amount such that the aggregate compensation Mr. Fernandez receives through closing of the business combination shall be no less than $250,000. Except for Mr. Fernandez, none of our officers and directors have received any cash compensation for services rendered to us. Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor. We may elect to make payment of customary fees to members of our board of directors for director service. In addition, our sponsor, executive officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder's and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or any of their respective affiliates, prior to completion of our initial business combination.

After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed initial business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors.

We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management's motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment.

**Committees of the Board of Directors**

Upon the effective date of the registration statement of which this prospectus forms a part, our board of directors will have three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. Our audit committee, compensation committee, and nominating and corporate governance committee will be composed solely of independent directors. Subject to phase-in rules, the rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors, and the rules of Nasdaq require that the compensation committee and the nominating and corporate governance committee of a listed company be comprised solely of independent directors. Each committee will operate under a charter that will be approved by our board and will have the composition and responsibilities described below. The charter of each committee will be available on our website following the closing of this offering.

**Audit Committee**

Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Our audit committee will be composed of four independent directors as and when required by the rules of Nasdaq and Rule 10A of the Exchange Act. Verender S. Badial, Christopher Staral, Arjun Goyal, and Jonathon Kluft will serve as the members of the audit committee, and Verender S. Badial will chair the audit committee. Verender S. Badial, Christopher Staral, Arjun Goyal, and Jonathon Kluft are independent of and unaffiliated with our sponsor and our underwriter.

Each member of the audit committee is financially literate and our board of directors has determined that Verender S. Badial qualifies as an "audit committee financial expert" as defined in applicable SEC rules and has accounting or related financial management expertise.

We will adopt an audit committee charter, which will detail the principal functions of the audit committee, including:

● assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm's qualifications and independence, and (4) the performance of our internal audit function and independent registered public accounting firm; the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and any other independent registered public accounting firm engaged by us;

● pre-approving all audit and non-audit services to be provided by the independent registered public accounting firm or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; reviewing and discussing with the independent registered public accounting firm all relationships the firm has with us in order to evaluate their continued independence;

● setting clear policies for audit partner rotation in compliance with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (1) the registered public accounting firm's internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;

● meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the registered public accounting firm, including reviewing our specific disclosures under "Management's Discussion and Analysis of Financial Condition and Results of Operations"; reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and

● reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.

**Compensation Committee**

Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of directors. Verender S. Badial, Christopher Staral, Arjun Goyal, and Jonathon Kluft will serve as the member of the compensation committee, and Jonathon Kluft will chair the compensation committee. All members of our compensation committee are independent of and unaffiliated with our sponsor and our underwriter.

We will adopt a compensation committee charter, which will detail the principal functions of the compensation committee, including:

● reviewing and approving on an annual basis the corporate goals and objectives relevant to our chief executive officer's compensation, evaluating our chief executive officer's performance in light of such goals and objectives and determining and approving the remuneration (if any) of our chief executive officer's based on such evaluation;

● reviewing and making recommendations to our board of directors with respect to the compensation, and any incentive compensation and equity based plans that are subject to board approval of all of our other officers;

● reviewing our executive compensation policies and plans;

● implementing and administering our incentive compensation equity-based remuneration plans;

● assisting management in complying with our proxy statement and annual report disclosure requirements;

● approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;

● producing a report on executive compensation to be included in our annual proxy statement; and

● reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.

The charter will also provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.

**Nominating and Corporate Governance Committee**

Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a nominating and corporate governance committee of the board of directors. Verender S. Badial, Christopher Staral, Arjun Goyal, and Jonathon Kluft will serve as the member of the nominating and corporate governance committee, and Christopher Staral will chair the nominating and corporate governance committee. All members of our nominating and corporate governance committee are independent of and unaffiliated with our sponsor and our underwriter.

We will adopt a nominating and corporate governance committee charter, which will detail the purpose and responsibilities of the nominating and corporate governance committee, including:

● identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the board, and recommending to the board of directors candidates for nomination for election at the annual general meeting or to fill vacancies on the board of directors;

● developing and recommending to the board of directors and overseeing implementation of our corporate governance guidelines;

● coordinating and overseeing the annual self-evaluation of the board of directors, its committees, individual directors and management in the governance of the company; and

● reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary.

The charter will also provide that the nominating and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any search firm to be used to identify director candidates, and will be directly responsible for approving the search firm's fees and other retention terms.

We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the board of directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders. Prior to our initial business combination, holders of our public shares will not have the right to recommend director candidates for nomination to our board of directors.

**Compensation Committee Interlocks and Insider Participation**

None of our executive officers currently serves, or in the past year has served, as a member of the compensation committee of any entity that has one or more executive officers serving on our board of directors.

**Code of Business Conduct and Ethics**

Prior to the consummation of this offering, we will have adopted a Code of Business Conduct and Ethics applicable to our directors, officers and employees. We will file a copy of our Code of Business Conduct and Ethics as an exhibit to the registration statement of which this prospectus is a part. You will be able to review this document by accessing our public filings at the SEC's web site at *www.sec.gov*. In addition, a copy of the Code of Business Conduct and Ethics and the charters of the committees of our board of directors will be provided without charge upon request from us. See the section of this prospectus entitled "*Where You Can Find Additional Information*." If we make any amendments to our Code of Business Conduct and Ethics other than technical, administrative or other non-substantive amendments, or grant any waiver, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics applicable to our principal executive officer, principal financial officer principal accounting officer or controller or persons performing similar functions requiring disclosure under applicable SEC or Nasdaq rules, we will disclose the nature of such amendment or waiver on our website. The information included on our website is not incorporated by reference into this Form S-1 or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.

**Directors' Fiduciary Duties and Conflicts of Interest**

As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company. Accordingly, directors and officers owe the following fiduciary duties:

&nbsp;&nbsp;&nbsp;&nbsp;(i) duty to act in good faith in what the director or officer
believes to be in the best interests of the company as a whole;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) duty to exercise powers for the purposes for which those
powers were conferred and not for a collateral purpose;

&nbsp;&nbsp;&nbsp;&nbsp;(iii) directors should not improperly fetter the exercise of future
discretion;

&nbsp;&nbsp;&nbsp;&nbsp;(iv) duty to exercise authority for the purpose for which it is
conferred and a duty to exercise powers fairly as between different sections of shareholders;

&nbsp;&nbsp;&nbsp;&nbsp;(v) duty not to put themselves in a position in which there is
a conflict between their duty to the company and their personal interests; and

&nbsp;&nbsp;&nbsp;&nbsp;(vi) duty to exercise independent judgment.

In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge, skill and experience of that director.

As set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders provided that there is full disclosure by the directors. This can be done by way of permission granted in the memorandum and articles of association or alternatively by shareholder approval at general meetings.

Each of our executive officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our executive officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such entity, subject to their fiduciary duties under Cayman Islands law. Our articles will provide that we, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an executive officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which may (a) be a corporate opportunity for any director or officer, on the one hand, and us, on the other, or (b) the presentation of which would breach an existing legal obligation of a member of director, officer or sponsor to any other entity. The purpose for the surrender of corporate opportunities is to allow officers, directors or other representatives with multiple business affiliations to continue to serve as an officer of our company or on our board of directors. Our officers and directors may from time to time be presented with opportunities that could benefit both another business affiliation and us. In the absence of the "corporate opportunity" waiver in our articles, certain candidates would not be able to serve as an officer or director. We believe we substantially benefit from having representatives who bring significant, relevant and valuable experience to our management, and, as a result, the inclusion of the "corporate opportunity" waiver in our articles provide us with greater flexibility to attract and retain the officers and directors that we feel are the best candidates. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our initial business combination.

Below is a table summarizing the entities to which our executive officers and directors currently have fiduciary duties or contractual obligations:

---

| | | | |
|:---|:---|:---|:---|
| **Individual** | &nbsp;&nbsp;&nbsp;**Entity** | &nbsp;&nbsp;&nbsp;**Entity's Business** | &nbsp;&nbsp;&nbsp;**Affiliation** |
| Dr. Someit Sidhu | Zura Bio Limited | Biotechnology | Director |
|  | Khanda Therapeutics | Biotechnology | Founder, Chief Executive Officer, and Director |
|  | GSN Estate | Property Management | Director |
|  | Invictus Bioscience | Biotechnology | Director |
| Nicholas Fernandez | Liminatus Pharma, LLC | Biotechnology | Director |
|  | Iris Acquisition Corp | SPAC | Director |
|  | Amanat Acquisition Corp | SPAC | Chief Financial Officer |
| Verender S. Badial | Cryfield Investments Ltd | Investment Management | Managing Director |
|  | ME Asset Management Ltd | Asset Management | Chief Executive Officer |
| Christopher Staral | Triple Helix Investments, LLC. | Investment Management | Founder, Managing Member, and Chief Investment Officer |
| Dr. Arjun Goyal | Centessa Pharmaceuticals Plc | Biotechnology | Director |

---

In addition, our sponsor and members of our sponsor, officers and directors, and their affiliates and/or related parties may sponsor, form or participate in the formation of, or become an officer or director of, invest or otherwise become affiliated with, other blank check companies, including in connection with their initial business combinations, or may pursue other business or investment ventures, even prior to us entering into a definitive agreement for our initial business combination or completing our initial business combination. Any such companies, businesses or investments would present additional conflicts of interest in pursuing an initial business combination. Potential investors should also be aware of the following other potential conflicts of interest:

● Our executive officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs.

● Our initial shareholders purchased founder shares prior to the date of this prospectus and our sponsor will purchase private placement shares in a transaction that will close simultaneously with the closing of this offering. Our sponsor, officers, directors and advisors will entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and public shares in connection with the completion of our initial business combination. Additionally, our sponsor, officers, directors and advisors will agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares and private placement shares if we fail to complete our initial business combination within the prescribed time frame, although they will be entitled to liquidating distributions from assets outside the trust account. Furthermore, our sponsor, officers, directors and advisors have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (i) 180 days after the completion of our initial business combination or (ii) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property and our sponsor has agreed not to transfer, assign or sell any of its private placement shares until 30 days after the completion of our initial business combination. Because each of our officers and director nominees will own ordinary shares directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window.

● Our officers, directors and advisors will directly or indirectly own founder shares and/or private placement shares following this offering and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. The low price that our sponsor, officers, directors and advisors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. If we are unable to complete our initial business combination within the completion window, the founder shares may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. Further, each of our officers, directors and advisors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers, directors and advisors was included by a target business as a condition to any agreement with respect to our initial business combination.

We are not prohibited from pursuing an initial business combination with a business combination target that is affiliated with our sponsor, officers or directors or completing the business combination through a joint venture or other form of shared ownership with our sponsor, officers or directors. In the event we seek to complete our initial business combination with a business combination target that is affiliated with our sponsor, officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking which is a member of FINRA or another independent entity that commonly renders valuation opinions, that such initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context. Furthermore, in no event will our sponsor or any of our existing officers or directors, or any of their respective affiliates, be paid by the company any finder's fee, consulting fee or other compensation prior to, or for any services they render in order to effectuate, the completion of our initial business combination (regardless of the type of transaction that it is). However, commencing on the date the securities of the Company are first listed on Nasdaq, we will also pay our sponsor $20,000 per month for officer compensation and administrative services provided to members of our management team.

We cannot assure you that any of the above mentioned conflicts will be resolved in our favor.

In the event that we submit our initial business combination to our public shareholders for a vote, our sponsor, officers, directors and advisors have agreed to vote their founder shares, and they and the other members of our management team have agreed to vote their founder shares and any shares purchased during or after the offering in favor of our initial business combination.

**Limitation on Liability and Indemnification of Officers and Directors**

Cayman Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, fraud or the consequences of committing a crime. Our articles will provide that, subject to certain limitations, we may indemnify our officers and directors to the maximum extent permitted by law, including from any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect. We expect to purchase a policy of directors' and officers' liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.

Our officers and directors have agreed to waive any right, title, interest or claim of any kind in or to any monies in the trust account, and have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not seek recourse against the trust account for any reason whatsoever. Accordingly, any indemnification provided will only be able to be satisfied by us if (i) we have sufficient funds outside of the trust account or (ii) we consummate an initial business combination.

Our indemnification obligations may discourage shareholders from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.

We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

**Principal Shareholders**

The following table sets forth information regarding the beneficial ownership of our ordinary shares as of the date of this prospectus, and as adjusted to reflect the sale of our ordinary shares by this prospectus, and assuming no purchase of ordinary shares in this offering, by:

● each person known by us to be the beneficial owner of more than 5% of our issued and outstanding ordinary shares;

● each of our officers, directors and director nominees; and

● all our officers and directors as a group.

Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all of our ordinary shares beneficially owned by them.

On February 12, 2026, our sponsor paid $25,000, or approximately $0.014 per share, to cover certain offering costs, in exchange for 1,725,000 founder shares. Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor.

Prior to the initial investment in the company of $25,000 by the sponsor, the company had no assets, tangible or intangible. The purchase price of the founder shares was determined by dividing the amount of cash contributed to the company by the number of founder shares issued. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 6,900,000 shares if the underwriters' over-allotment option is exercised in full, and therefore that such founder shares would represent approximately 20% of the outstanding shares after this offering. Up to 225,000 of the founder shares will be surrendered for no consideration depending on the extent to which the underwriter's over-allotment is exercised. The post-offering percentages in the following table assume that the underwriters do not exercise their over-allotment option, that 225,000 founder shares have been surrendered to us for no consideration, that our sponsor does not purchase ordinary shares in this offering and that there are 7,800,000 ordinary shares issued and outstanding after this offering.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | | **Approximate Percentage of <br> Outstanding Ordinary Shares** | **Approximate Percentage of <br> Outstanding Ordinary Shares** |
| <br>**Name and address of the Beneficial Owner<sup>(1)</sup>** | **Ordinary <br> Shares <br> Beneficially <br> Owned**<br>**Before <br> Offering** | **Ordinary <br> Shares <br> Beneficially <br> Owned**<br>**After <br> Offering** | **Before <br> Offering** | **After <br> Offering<sup>(6)</sup>** |
| JATT Ventures II L.P.<sup>(2)(3)</sup> | 1725000 | 1475000 | 100% | 18.9% |
| Dr. Someit Sidhu<sup>(4)</sup> | 1725000 | 1625000 | 100% | 20.8% |
| Nicholas Fernandez<sup>(5)</sup> |  | 50000 |  | \* |
| Verender S. Badial<sup>(5)</sup> |  | 25000 |  | \* |
| Christopher Staral<sup>(5)</sup> |  | 25000 |  | \* |
| Dr. Arjun Goyal<sup>(5)</sup> |  | 25000 |  | \* |
| Dr. Jonathon Kluft<sup>(5)</sup> |  | 25000 |  | \* |
| All officers and directors as a group (6 persons) | 1725000 | 1775000 | 100% | 22.8% |

---

\* Less than one percent.

(1) Unless otherwise noted, the business address of each of the
following is 153 Central Avenue, C/O 56, Westfield, NJ 07091.

(2) Interests shown consist solely of founder shares and after
offering, founder shares and private placement shares.

(3) JATT Ventures II L.P., our sponsor, is the
 record holder of such shares. As of the date of this prospectus, JATT Ventures II Ltd
 is the sole general partner of our sponsor, and our Chairman and Chief Executive Officer,
 Dr. Someit Sidhu is a limited partner of our sponsor. Dr. Someit Sidhu is also
 the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment
 discretion with respect to the ordinary shares held of record by JATT Ventures II L.P. Dr. Someit
 Sidhu disclaims any beneficial ownership of the securities held by JATT Ventures II
 L.P. other than to the extent of any pecuniary interest she may have therein, directly or
 indirectly.

(4) Including indirect interest in 150,000 founder
 shares Dr. Someit Sidhu will receive prior to closing of this offering, which is represented
 by membership interests in our sponsor .

(5) For their services as directors and officers, each of the persons
 herein receives indirect interest in founder shares through membership interests in our sponsor.

(6) Assuming the underwriters will not exercise the
 over-allotment option, and 225,000 founder shares will be surrendered for no consideration.

Immediately after this offering, our initial shareholders will beneficially own 20.0% of the then issued and outstanding ordinary shares (excluding the private placement shares and assuming they do not purchase any shares in this offering). Because of this ownership block, our initial shareholders may be able to effectively influence the outcome of all other matters requiring approval by our shareholders, including amendments to our articles and approval of significant corporate transactions including our initial business combination.

Our sponsor has committed, pursuant to a written agreement, to purchase an aggregate of 300,000 private placement shares (or 309,000 shares if the underwriters' over-allotment option is exercised in full), at a price of $10.00 per share or $3,000,000 in the aggregate (or $3,090,000 if the underwriters' over-allotment option is exercised in full), in a private placement that will occur simultaneously with the closing of this offering.

The private placement shares may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder. A portion of the purchase price of the private placement shares will be added to the proceeds from this offering to be held in the trust account such that at the time of closing of this offering $60 million (or $69 million if the underwriters exercise their over-allotment option in full) will be held in the trust account. Our sponsor has entered into an agreement with us, pursuant to which it has agreed to waive its redemption rights with respect to private placement shares. Otherwise the private placement shares have terms and provisions that are identical to those of the shares being sold in this offering.

Our sponsor and our officers and directors are deemed to be our "promoters" as such term is defined under the federal securities laws.

**Transfers of Founder Shares and Private Placement Shares**

The founder shares and private placement shares are each subject to transfer restrictions pursuant to lock-up provisions in the agreement entered into by our sponsor and management team. Those lock-up provisions provide that (i) the founder shares are not transferable or saleable until the earlier of (A) 180 days after the completion of our initial business combination and (B) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property and (ii) the private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination.

**Registration Rights**

The holders of the (i) founder shares, which were issued in a private placement prior to the closing of this offering, (ii) private placement shares, which will be issued in a private placement simultaneously with the closing of this offering and (iii) private placement shares that may be issued upon conversion of working capital loans will have registration rights to require us to register a sale of any of our securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of this offering. Pursuant to the registration rights agreement and assuming the underwriters exercises their over-allotment option in full and $1,500,000 of working capital loans are converted into private placement shares, we will be obligated to register up to 2,184,000 ordinary shares. The number of ordinary shares includes (i) 1,725,000 founder shares, (ii) 309,000 private placement shares and (iii) 150,000 ordinary shares issued upon conversion of working capital loans. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain "piggyback" registration rights with respect to registration statements filed subsequent to our completion of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

**Certain Relationships and Related Party Transactions**

On February 13, 2026, our sponsor paid $25,000, or approximately $0.014 per share to cover certain offering costs, in exchange for 1,725,000 founder shares. Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering. Our management team may also purchase additional membership interests in our sponsor to receive indirect interest in ordinary shares held by our sponsor.

The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 6,900,000 ordinary shares if the underwriters' over-allotment option is exercised in full, and therefore that such founder shares would represent approximately 20% of the outstanding shares after this offering (excluding the private placement shares). Up to 225,000 of the founder shares will be surrendered for no consideration depending on the extent to which the underwriter's over-allotment is exercised. If we increase or decrease the size of the offering, we will effect a share capitalization or a share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our ordinary shares immediately prior to the consummation of this offering in such amount as to maintain the number of founder shares at 20.0% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares).

Our sponsor has committed to purchase an aggregate of 300,000 private placement shares (or 309,000 private placement shares if the underwriters' over-allotment option is exercised in full) at a price of $10.00 per share, or $3,090,000 in the aggregate (or $3,000,000 if the underwriters' over-allotment option is exercised in full), in a private placement that will close simultaneously with the closing of this offering.

The private placement shares may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder until 30 days after the completion of our initial business combination.

We currently utilize office space at 153 Central Avenue, C/O 56, Westfield, NJ 07091from our sponsor as our executive offices. Commencing on the date of this prospectus, we will pay our sponsor $20,000 per month for officer compensation and administrative services provided to members of our management team. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.

Mr. Fernandez shall receive a lump-sum compensation of $35,714 from the sponsor at the closing of this offering for his service provided in relation to this offering. In addition, Mr. Fernandez will also receive $8,928 from the sponsor on a monthly basis out of the Administrative Services Fee, for his continued service as the Chief Financial Officer of the Company, from closing of this offering until completion of the Company's initial business combination. If the Company completes an initial business combination prior to the date that is 24 months from the closing of this offering, Mr. Fernandez shall receive at the completion of our initial business combination an additional amount such that the aggregate compensation Mr. Fernandez receives through closing of the business combination shall be no less than $250,000.

Our sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates.

Prior to the closing of this offering, our sponsor may loan us up to $300,000 to be used for a portion of the expenses of this offering. These loans would be non-interest bearing, unsecured and are due at the closing of this offering.

In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required on a non-interest basis. If we complete an initial business combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into private placement shares of the post business combination entity at a price of $10.00 per share at the option of the lender. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial business combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.

We have until the date that is 24 months from the closing of this offering or until such earlier liquidation date as our board of directors may approve to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination within such 24-month period, we may seek shareholder approval to amend our articles to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of ordinary shares will be offered an opportunity to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding ordinary shares, subject to the limitations and on the conditions described herein, regardless of whether they abstain, vote in favor of or vote against such extension.

Any of the foregoing payments to our sponsor, repayments of loans from our sponsor or repayments of working capital loans prior to our initial business combination will be made using funds held outside the trust account.

After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to our shareholders, to the extent then known, in the proxy solicitation or tender offer materials, as applicable, furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a general meeting held to consider our initial business combination, as applicable, as it will be up to the directors of the post-combination business to determine executive and director compensation.

We have entered into a registration rights agreement with respect to the founder shares and private placement shares, which is described under the heading "*Principal Shareholders — Registration Rights*."

**Policy for Approval of Related Party Transactions**

The audit committee of our board of directors will adopt a policy setting forth the policies and procedures for its review and approval or ratification of "related party transactions." A "related party transaction" is any consummated or proposed transaction or series of transactions: (i) in which the company was or is to be a participant; (ii) the amount of which exceeds (or is reasonably expected to exceed) the lesser of $120,000 or 1% of the average of the company's total assets at year end for the prior two completed fiscal years in the aggregate over the duration of the transaction (without regard to profit or loss); and (iii) in which a "related party" had, has or will have a direct or indirect material interest. "Related parties" under this policy will include: (i) our directors, nominees for director or officers or any person who has served in such roles since the beginning of the most recent fiscal year, even if he or she does not currently serve in that role; (ii) any record or beneficial owner of more than 5% of any class of our voting securities; (iii) any immediate family member of any of the foregoing if the foregoing person is a natural person; and (iv) any other person who maybe a "related person" pursuant to Item 404 of Regulation S-K under the Exchange Act. Pursuant to the policy, the audit committee will consider (i) the relevant facts and circumstances of each related party transaction, including if the transaction is on terms comparable to those that could be obtained in arm's-length dealings with an unrelated third party, (ii) the extent of the related party's interest in the transaction, (iii) whether the transaction contravenes our code of ethics or other policies, (iv) whether the audit committee believes the relationship underlying the transaction to be in the best interests of the company and its shareholders and (v) if the related party is a director or an immediate family member of a director, the effect that the transaction may have on a director's status as an independent member of the board and on his or her eligibility to serve on the board's committees. Management will present to the audit committee each proposed related party transaction, including all relevant facts and circumstances relating thereto. Under the policy, we may consummate related party transactions only if our audit committee approves or ratifies the transaction in accordance with the guidelines set forth in the policy. The policy will not permit any director or officer to participate in the discussion of, or decision concerning, a related person transaction in which he or she is the related party.

**Description of Securities**

We are a Cayman Islands exempted company with limited liability (Company No. 429978) and our affairs are governed by our articles, the Companies Act and the common law of the Cayman Islands. Pursuant to our articles which will be adopted upon the consummation of this offering, we will be authorized to issue 200,000,000 ordinary shares of $0.0001 par value each, as well as 1,000,000 preference shares of $0.0001 par value each. The following description summarizes certain terms of our shares as set out more particularly in our articles. Because it is only a summary, it may not contain all the information that is important to you.

**Ordinary Shares**

Prior to the date of this prospectus, there were 1,725,000 ordinary shares outstanding, all of which were held of record by our initial shareholders, so that our initial shareholders will own approximately 20% of our issued and outstanding shares after this offering (excluding the private placement shares and assuming our initial shareholders do not purchase any shares in this offering). Up to 225,000 of the founder shares will be surrendered for no consideration depending on the extent to which the underwriter's over-allotment is exercised. Upon the closing of this offering, 7,800,000 ordinary shares will be outstanding (assuming no exercise of the underwriters' over-allotment option and the corresponding surrender for no consideration of 225,000 founder shares) including:

● 6,000,000 ordinary shares issued as part of this offering;

● 300,000 ordinary shares issues as private placement;

● 1,500,000 founder shares held by our initial shareholders.

Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders except as required by law. Unless otherwise specified in our articles, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, an ordinary resolution under Cayman Islands law and our articles which requires the affirmative vote of a majority of our ordinary shares that are represented in person or by proxy and are voted is required to approve any such matter voted on by our shareholders. Approval of certain actions will require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company, and pursuant to our articles; such actions include amending our articles and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares entitled to vote for the appointment of directors can appoint all of the directors. Our shareholders are entitled to receive rateable dividends when, as and if declared by the board of directors out of funds legally available therefor.

Because our articles authorize the issuance of up to 200,000,000 ordinary shares, if we were to enter into a business combination, we may (depending on the terms of such a business combination) be required to increase the number of ordinary shares which we are authorized to issue at the same time as our shareholders vote on the business combination to the extent we seek shareholder approval in connection with our initial business combination.

In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual general meeting until one year after our first fiscal year end following our listing on Nasdaq. There is no requirement under the Companies Act for us to hold annual or general meetings or appoint directors. We may not hold an annual general meeting to appoint new directors prior to the consummation of our initial business combination.

We will provide our public shareholders with the opportunity to redeem all or a portion of their public shares in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account described below as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriter. Our sponsor, officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and public shares in connection with the completion of our initial business combination. Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction with their initial business combinations and provide for related redemptions of public shares for cash upon completion of such initial business combinations even when a vote is not required by law, if a shareholder vote is not required by law and we do not decide to hold a shareholder vote for business or other legal reasons, we will, pursuant to our articles, conduct the redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents with the SEC prior to completing our initial business combination. Our articles require these tender offer documents to contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under the SEC's proxy rules. If, however, a shareholder approval of the transaction is required by law, or we decide to obtain shareholder approval for business or other reasons, we will, like many special purpose acquisition companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution under Cayman Islands law and our articles, which requires the affirmative vote of at least a two-thirds majority of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company. However, the participation of our sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions (as described in this prospectus), if any, could result in the approval of our initial business combination even if a majority of our public shareholders vote, or indicate their intention to vote, against such initial business combination. For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. A quorum for such meeting will consist of the holders present in person or by proxy of shares of issued and outstanding ordinary shares of the company representing one-third of all ordinary shares of the company entitled to vote at such meeting. Our articles require that at least five days' notice will be given of any general meeting.

If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our articles will provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a "group" (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to Excess Shares without our prior consent. However, we would not be restricting our shareholders' ability to vote all of their shares (including Excess Shares) for or against our initial business combination. Our shareholders' inability to redeem the Excess Shares will reduce their influence over our ability to complete our initial business combination, and such shareholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally, such shareholders will not receive redemption distributions with respect to the Excess Shares if we complete our initial business combination. And, as a result, such shareholders will continue to hold that number of shares exceeding 20% and, in order to dispose such shares would be required to sell their shares in open market transactions, potentially at a loss.

If we seek shareholder approval in connection with our initial business combination, our sponsor, officers, directors and advisors have agreed to vote their founder shares and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our initial business combination. As a result, in addition to our initial shareholders' founder shares and the private placement shares we would need 2,100,001, or approximately 35.0%, of the 6,000,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming all outstanding shares are voted, the over-allotment option is not exercised and the parties to the letter agreement do not acquire any ordinary shares). Assuming that only the holders of one-third of our issued and outstanding ordinary shares, representing a quorum under our articles, vote their shares at a general meeting of the company, we would not need any public shares to be voted in favor of an initial business combination in order to have our initial business combination approved. Additionally, each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction, or whether they do not vote or abstain from voting on the proposed transaction, or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction.

Pursuant to our articles, if we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and subject to the other requirements of applicable law. Our sponsor, officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares and private placement shares if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account. However, if our sponsor or management team acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the prescribed time period.

In the event of a liquidation, dissolution or winding up of the company after a business combination, our shareholders are entitled to share rateably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of shares, if any, having preference over the ordinary shares. Our shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that we will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, upon the completion of our initial business combination, subject to the limitations and on the conditions described herein.

**Founder Shares and Private Placement Shares**

The founder shares are ordinary shares being sold in this offering, and holders of founder shares and private placement shares have the same shareholder rights as public shareholders, except that (i) the founder shares and private placement shares are subject to certain transfer restrictions, as described in more detail below, (ii) the founder shares and private placement shares are entitled to registration rights; (iii) our sponsor, officers, directors and advisors have entered into a letter agreement with us, pursuant to which they have agreed to (A) waive their redemption rights with respect to their founder shares, private placement shares and public shares in connection with the completion of our initial business combination, (B) waive their redemption rights with respect to their founder shares, private placement shares and public shares in connection with a shareholder vote to approve an amendment to our articles (x) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (y) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, (C) waive their rights to liquidating distributions from the trust account with respect to their founder shares and private placement shares if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account with respect to any public shares they hold if we fail to complete our initial business combination within such time period and to liquidating distributions from assets outside the trust account and (D) vote any founder shares held by them, any private placement shares held by them and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our initial business combination (except with respect to any such public shares which may not be voted in favor of approving the business combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations or guidance relating thereto).

With certain limited exceptions, the founder shares are not transferable, assignable or saleable (except to our officers and directors and other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until the earlier of (A) 180 days after the completion of our initial business combination and (B) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. Up to 225,000 founder shares will be surrendered to us for no consideration depending on the exercise of the over-allotment option. With certain limited exceptions, the private placement shares are not transferable, assignable or saleable (except to our officers and directors and other persons or entities affiliated with our sponsor, each of whom will be subject to the same transfer restrictions) until 30 days after the completion of our initial business combinations.

**Register of Members**

Under the Company Act, we must keep a register of members and there will be entered therein:

● the names and addresses of the members, together with a statement of the shares held by each member which:

● distinguishes each share by its number (so long as the share has a number),

● confirms the amount paid or agreed to be considered as paid, on the shares of each member,

● confirms the number and category of shares held by each member, and

● confirms whether each relevant category of shares held by a member carries voting rights under the articles of association and if so, whether such voting rights are conditional;

● the date on which the name of any person was entered on the register as a member; and

● the date on which any person ceased to be a member.

Under the Companies Act, the register of members of our company is prima facie evidence of the matters set out therein (i.e. that is register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members will be deemed as a matter of the Companies Act to have legal title to the shares as set against its name in the register of members. Upon the closing of this public offering, the register of members will be immediately updated to reflect the issue of shares by us. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their name.

However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application for an order for rectification of the register of members were made in respect of our ordinary shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court.

**Preference Shares**

Our articles authorize us to issue 1,000,000 preference shares and provide that preference shares may be issued from time to time in one or more series or classes. Our board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series or class. Our board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the ordinary shares and could have anti-takeover effects. The ability of our board of directors to issue preference shares without shareholder approval could have the effect of, among other things, one or more of the following:

● Restricting dividends in the respect of the ordinary shares;

● Diluting the voting power of the ordinary shares or providing that holders of preference shares have the right to vote on matters as a class;

● Impairing the liquidation rights of the ordinary shares; or

● Delaying, deferring or preventing a change of control of us or the removal of existing management.

We have no preference shares outstanding at the date hereof. Although we do not currently intend to issue any preference shares, we cannot assure you that we will not do so in the future. No preference shares are being issued or registered in this offering.

**Dividends**

We have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of our initial business combination even if we have substantial assets outside the trust account. A Cayman Islands company may pay a dividend on its shares out of either profit, the share premium account or other funds of the company lawfully available therefor, provided that in no circumstances may a dividend be paid if following such payment the company would be unable to pay its debts as they fall due in the ordinary course of business. The payment of cash dividends following completion of our initial business combination will be within the discretion of our board of directors at such time and will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition at such time. There is no certainty we will be in a position to, or decide to, pay cash dividends after completing any business combination. If we increase or decrease the size of this offering pursuant to Rule 462(b) under the Securities Act, we will effect a share capitalization or other appropriate mechanism, immediately prior to the consummation of the offering in such amount as to maintain the number of founder shares at 20.0% of our issued and outstanding ordinary shares upon the consummation of this offering. Further, if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends following completion of our initial business combination may be limited by restrictive covenants we may agree to in connection therewith.

**Variation of Rights**

Under our articles, if the share capital is divided into more than one class of shares, the rights attached to any such class may, whether or not our company is being wound up, be varied without the consent of the holders of the issued shares of that class where such variation is considered by our board of directors not to have a material and adverse effect upon such rights; otherwise, any such variation shall be made only with the consent in writing of the holders of not less than two thirds of the issued shares of that class or with the approval of a resolution passed by a majority of not less than two thirds of the votes cast at a separate meeting of the holders of the shares of that class.

**Share Repurchase**

The Companies Act and the articles permit us to purchase our own shares, subject to certain restrictions. The board of directors may only exercise this power on behalf of the company, subject to the Companies Act, the articles and to any applicable requirements imposed from time to time by the SEC or by any recognized stock exchange on which our securities are listed.

**Liquidation**

On a winding-up or other return of capital, subject to any special rights attaching to any other class of shares, holders of ordinary shares will be entitled to participate in any surplus assets available for distribution in proportion to their shareholdings.

**Our Transfer Agent**

The transfer agent for our ordinary shares is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust Company in its roles as transfer agent, its agents and each of its shareholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to any gross negligence or intentional misconduct of the indemnified person or entity. Continental Stock Transfer & Trust Company has agreed that it has no right of set-off or any right, title, interest or claim of any kind to, or to any monies in, the trust account, and has irrevocably waived any right, title, interest or claim of any kind to, or to any monies in, the trust account that it may have now or in the future. Accordingly, any indemnification provided will only be able to be satisfied, or a claim will only be able to be pursued, solely against us and our assets outside the trust account and not against the any monies in the trust account or interest earned thereon.

**Certain Differences in Corporate Law**

Cayman Islands companies are governed by the Companies Act. The Companies Act is modeled on English Law but does not follow recent English Law statutory enactments, and differs from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of the material differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their shareholders.

*Mergers and Similar Arrangements.&nbsp;&nbsp;&nbsp;&nbsp;*In certain circumstances, the Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (a) "merger" means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (b) a "consolidation" means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company.

Where the merger or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of merger or consolidation containing certain prescribed information. That plan or merger or consolidation must then be authorized by (a) a special resolution (which requires the affirmative vote of a majority of at least two-thirds of the votes cast by the shareholders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company) of the shareholders of each company; and (b) such other authorization, if any, as may be specified in such constituent company's articles of association. No shareholder resolution is required for a merger between a parent company (i.e., a company that owns at least 90% of the issued shares of each class in a subsidiary company) and its subsidiary company, provided the parent company is the surviving entity and a copy of the plan of merger is given to every member of each subsidiary company to be merged unless that member agrees otherwise. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a declaration as to the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.

The consent of each holder of a fixed or floating security interest of a constituent company must be obtained, unless the court waives such requirement.

Where the merger or consolidation involves a foreign company, the procedure is similar, save that with respect to the foreign company, the directors of the Cayman Islands exempted company are required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i) that the merger or consolidation is permitted or not prohibited by the constitutional documents of the foreign company and by the laws of the jurisdiction in which the foreign company is incorporated, and that those laws and any requirements of those constitutional documents have been or will be complied with; (ii) that no petition or other similar proceeding has been filed and remains outstanding or order made or resolution adopted to wind up or liquidate the foreign company in any jurisdictions; (iii) that no receiver, trustee, administrator or other similar person has been appointed in any jurisdiction and is acting in respect of the foreign company, its affairs or its property or any part thereof; (iv) that no scheme, order, compromise or other similar arrangement has been entered into or made in any jurisdiction whereby the rights of creditors of the foreign company are and continue to be suspended or restricted; and (v) there is no other reason why it would be against the public interest to permit the merger or consolidation.

Where the surviving company is the Cayman Islands exempted company, the directors of the Cayman Islands exempted company are further required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i) that the foreign company is able to pay its debts as they fall due and that the merger or consolidated is bona fide and not intended to defraud unsecured creditors of the foreign company; (ii) that in respect of the transfer of any security interest granted by the foreign company to the surviving or consolidated company (a) consent or approval to the transfer has been obtained, released or waived; (b) the transfer is permitted by and has been approved in accordance with the constitutional documents of the foreign company; and (c) the laws of the jurisdiction of the foreign company with respect to the transfer have been or will be complied with; (iii) that the foreign company will, upon the merger or consolidation becoming effective, cease to be incorporated, registered or exist under the laws of the relevant foreign jurisdiction; and (iv) that there is no other reason why it would be against the public interest to permit the merger or consolidation.

Where the above procedures are adopted, the Companies Act provides for a right of dissenting shareholders to be paid a payment of the fair value of his shares upon their dissenting to the merger or consolidation if they follow a prescribed procedure. In essence, that procedure is as follows (a) the shareholder must give his written objection to the merger or consolidation to the constituent company before the vote on the merger or consolidation, including a statement that the shareholder proposes to demand payment for his shares if the merger or consolidation is authorized by the vote; (b) within 20 days following the date on which the merger or consolidation is approved by the shareholders, the constituent company who elects to dissent must give written notice to each shareholder who made a written objection; (c) a shareholder who elects to dissent must within 20 days following receipt of such notice from the constituent company, give the constituent company a written notice of their decision to dissent including, among other details, a demand for payment of the fair value of his shares; (d) within seven days following the date of the expiration of the period set out in paragraph (b) above or seven days following the date on which the plan of merger or consolidation is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to each dissenting shareholder to purchase his shares at a price that the company determines is the fair value and if the company and the shareholder agree on the price within 30 days following the date on which the offer was made, the company must pay the shareholder such amount; and (e) if the company and the shareholder fail to agree a price within such 30 day period, within 20 days following the date on which such 30 day period expires, the company (and any dissenting shareholder) must file a petition with the Grand Court of the Cayman Islands to determine the fair value and such petition by the company must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements as to the fair value of their shares have not been reached by the company. At the hearing of that petition, the court has the power to determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined to be the fair value. Any dissenting shareholder whose name appears on the list filed by the company may participate fully in all proceedings until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances, for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date or where the consideration for such shares to be contributed are shares of any company listed on a national securities exchange or shares of the surviving or consolidated company.

Moreover, Cayman Islands law has separate statutory provisions that facilitate the reconstruction or amalgamation of companies in certain circumstances, schemes of arrangement will generally be more suited for complex mergers or other transactions involving widely held companies, commonly referred to in the Cayman Islands as a "scheme of arrangement" which may be tantamount to a merger. In the event that a merger was sought pursuant to a scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures typically required to consummate a merger in the United States), the arrangement in question must be approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at an annual general meeting, or extraordinary general meeting summoned for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would have the right to express to the court the view that the transaction should not be approved, the court can be expected to approve the arrangement if it satisfies itself that:

● we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to majority vote have been complied with;

● the shareholders have been fairly represented at the meeting in question;

● the arrangement is such as a businessman would reasonably approve; and

● the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act or that would amount to a "fraud on the minority."

If a scheme of arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable to appraisal rights (providing rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily be available to dissenting shareholders of U.S. corporations.

 

*Squeeze-out Provisions.* When a takeover offer is made and accepted by holders of 90% of the shares to whom the offer relates is made within four months, the offeror may, within a two-month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed unless there is evidence of fraud, bad faith, collusion or inequitable treatment of the shareholders.

Further, transactions similar to a merger, reconstruction and/or an amalgamation may in some circumstances be achieved through means other than these statutory provisions, such as a share capital exchange, asset acquisition or control, or through contractual arrangements, of an operating business.

 

 

*Shareholders' Suits.* Appleby (Cayman) Ltd., our Cayman Islands legal counsel, is not aware of any reported class action having been brought in a Cayman Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, we will be the proper plaintiff in any claim based on a breach of duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder. However, based both on Cayman Islands authorities and on English authorities, which would in all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which:

● a company is acting, or proposing to act, illegally or beyond the scope of its authority;

● the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or

● those who control the company are perpetrating a "fraud on the minority."

A shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about to be infringed.

 

*Enforcement of Civil Liabilities.&nbsp;&nbsp;&nbsp;&nbsp;*The Cayman Islands has a different body of securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the Federal courts of the United States.

We have been advised by Appleby (Cayman) Ltd., our Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.

 

*Special Considerations for Exempted Companies.&nbsp;&nbsp;&nbsp;&nbsp;*We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company.

The requirements for an exempted company are similar for an ordinary company, except for the exemptions and privileges listed below:

● an exempted company does not have to file an annual return of its shareholders with the Registrar of Companies;

● an exempted company's register of members is not open to inspection and can be kept outside of the Cayman Islands;

● an exempted company does not have to hold an annual general meeting;

● an exempted company may issue shares with no nominal or par value;

● an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30 years in the first instance);

● an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;

● an exempted company may register as a limited duration company; and

● an exempted company may register as a segregated portfolio company.

"Limited liability" means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).

 

*Unanimous Action by Written Consent.* Our articles will provide that shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held.

 

*Amendment of Governing Documents.* As permitted by Cayman Islands law, our articles may only be amended by a special resolution of the members (requiring the affirmative vote of at least a two-thirds majority of the members present in person or by proxy at a general meeting where there is a quorum).

 

*Member Proposals.* An extraordinary general meeting may be called by our board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling extraordinary general meetings. The Companies Act provides shareholders with limited rights to requisition a general meeting and does not provide shareholders with any right to put any proposal before a general meeting. Our articles will provide for the ability of members to nominate candidates for election as directors or requisition an extraordinary general meeting under certain conditions, but will not otherwise allow members to bring business before a general meeting.

 

*General Meetings.* As a Cayman Islands exempted company, the company is not obliged by the Companies Act to call annual general meetings; however, our articles provide that in each year the company will hold an annual general meeting of shareholders, at a time determined by the board of directors, provided that our board of directors has the discretion whether to hold an annual general meeting in 2026. For the annual general meeting, the agenda will include, among other things, the presentation of the annual accounts and the report of the existing directors and the election of new directors. In addition, the agenda for an annual general meeting of shareholders will only include such items as have been included therein by the board of directors.

Also, we may, but are not required to (unless required by the laws of the Cayman Islands), hold other extraordinary general meetings during the year.

Neither our articles or the Companies Act provide members with rights to requisition a general meeting or provide member with any right to put any proposal before a general meeting.

 

*Cumulative Voting.* Cumulative voting potentially facilitates the representation of minority members on a board of directors since it permits the minority member to cast all the votes to which the member is entitled on a single director, which increases the member's voting power with respect to electing such director. As permitted under Cayman Islands law, our articles do not provide for cumulative voting.

 

*Dissolution.* Winding Up Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution (which requires the affirmative vote of at least a majority of members present in person or by proxy at a general meeting) of its members. The court has authority to order winding up in a number of specified circumstances, including where it is, in the opinion of the court, just and equitable to do so.

Our articles will provide that if our company is wound up, the liquidator may distribute the surplus assets available for distribution amongst the members in proportion to the par value of the ordinary shares held by them at the commencement of the winding up, subject to a deduction from those ordinary shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise.

 

 

*Rights of Non-Resident or Foreign Members.* There are no limitations imposed by our articles on the rights of non-resident or foreign members to hold or exercise voting rights on our shares. In addition, there are no provisions in our articles governing the ownership threshold above which member ownership must be disclosed.

 

*Directors' Power to Issue Shares.* Subject to applicable law, our board of directors has general and unconditional authority to issue or allot shares or grant options and warrants or otherwise deal with or dispose of any unissued shares in the company's capital without the approval of our shareholders (whether forming part of the original or any increased share capital), either at a premium or at par, with or without preferred, deferred, or other rights or restrictions, whether in regard to dividend, voting, return of capital or otherwise and to such persons, on such terms and conditions, and at such times as the directors may decide, but so that no share shall be issued at a discount, except in accordance with the provisions of the Companies Act. In accordance with the articles, we shall not issue bearer shares.

 

*Inspection of Books and Records.* Holders of shares have no general right under Cayman Islands law to inspect or obtain copies of our company's register of members or our company's corporate records. However, the board of directors may determine from time to time whether and to what extent our accounting records and books shall be open to inspection by shareholders who are not members of the board of directors.

**Amended and Restated Memorandum and Articles of Association**

The Business Combination Article of our articles contains provisions designed to provide certain rights and protections relating to this offering that will apply to us until the completion of our initial business combination. These provisions cannot be amended without a special resolution. As a matter of Cayman Islands law, a resolution is deemed to be a special resolution where it has been approved by either (i) at least a two-thirds majority (or any higher threshold specified in a company's articles of association) of the votes cast by the holders of the issued shares present in person or represented by proxy and entitled to vote on such matter at a general meeting of the company which notice specifying the intention to propose the resolution as a special resolution has been given; or (ii) if so authorized by a company's articles of association, by a unanimous written resolution of all of the company's shareholders. Our articles will provide that special resolutions must be approved either by at least a two-thirds majority of the votes cast by our shareholders who attend either in person or, where proxies are allowed, by proxy and are entitled to vote at a general meeting of the company (i.e., the lowest threshold permissible under Cayman Islands law), or by a unanimous written resolution of all of our shareholders.

Our initial shareholders, who will collectively beneficially own approximately 20% of our ordinary shares upon the closing of this offering (excluding private placement shares and assuming they do not purchase any shares in this offering), will participate in any vote to amend our articles and will have the discretion to vote in any manner they choose. Specifically, our articles will provide, among other things, that:

● If we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders' rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law;

● Prior to our initial business combination, we may not issue additional securities that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on our initial business combination;

● Although we do not intend to enter into a business combination with a target business that is affiliated with our sponsor, our directors or our officers, we are not prohibited from doing so. In the event we enter into such a transaction, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm which is a member of FINRA or another independent entity that commonly renders valuation opinions that such initial business combination is fair to our company from a financial point of view;

● If a shareholder vote on our initial business combination is not required by law and we do not decide to hold a shareholder vote for business or other legal reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act;

● If our shareholders approve an amendment to our articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity, we will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein; and

● We will not effectuate our initial business combination solely with another blank check company or a similar company with nominal operations.

The Companies Act permits a company incorporated in the Cayman Islands to amend its memorandum and articles of association with the approval of a special resolution. A company's articles of association may specify that the approval of a higher majority is required but, provided the approval of the required majority is obtained, any Cayman Islands exempted company may amend its memorandum and articles of association regardless of whether its memorandum and articles of association provides otherwise. Accordingly, although we could amend any of the provisions relating to our proposed offering, structure and business plan which are contained in our articles, we view all of these provisions as binding obligations to our shareholders and neither we, nor our officers or directors, will take any action to amend or waive any of these provisions unless we provide dissenting public shareholders with the opportunity to redeem their public shares.

**Anti-Money Laundering — Cayman Islands**

If any person in the Cayman Islands knows or suspects or has reasonable grounds for knowing or suspecting that another person is engaged in criminal conduct or money laundering or is involved with terrorism or proliferation financing or is the business combination partner of a financial sanction and the information for that knowledge or suspicion came to their attention in the course of business in the regulated sector, or other trade, profession, business or employment, the person will be required to report such knowledge or suspicion to (i) the Financial Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Act (As Revised) of the Cayman Islands if the disclosure relates to criminal conduct or money laundering or proliferation financing or is the business combination partner of a financial sanction, or (ii) a police officer of the rank of constable or higher, or the Financial Reporting Authority, pursuant to the Terrorism Act (As Revised) of the Cayman Islands, if the disclosure relates to involvement with terrorism or terrorist financing and property. Such a report shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise. We reserve the right to refuse to make any payment to a shareholder if our directors or officers suspect or are advised that the payment to such shareholder might result in a breach of applicable anti-money laundering, counter-terrorist financing, prevention of proliferation financing and financial sanctions or other laws or regulations by any person in any relevant jurisdiction, or if such refusal is considered necessary or appropriate to ensure our compliance with any such laws or regulations in any applicable jurisdiction.

Should a shareholder or its duly authorized delegates or agents be, or become (or is believed by the company or its affiliates ("Agents") to be or become) at any time while it owns or holds an interest in the company, (a) an individual or entity named on any sanctions list maintained by the United Kingdom (including as extended to the Cayman Islands by Orders in Council) or the Cayman Islands or any similar list maintained under applicable law or is otherwise subject to applicable sanctions in the Cayman Islands (a "Sanctions Subject") or (b) an entity owned or controlled directly or indirectly by a Sanctions Subject, as determined by the company in its sole discretion, then (i) the company or its Agents may immediately and without notice to the shareholder cease any further dealings with the shareholder or freeze any dealings with the interests or accounts of the shareholder (e.g., by prohibiting payments by or to the shareholder or restricting or suspending dealings with the interests or accounts) or freeze the assets of the company (including interests or accounts of other shareholders who are not Sanctions Subjects), until the relevant person ceases to be a Sanctions Subject or a license is obtained under applicable law to continue such dealings (a "Sanctioned Persons Event"), (ii) the company and its Agents may be required to report such action or failure to comply with information requests and to disclose the shareholder's identity (and/or the identity of the shareholder's beneficial owners and control persons) to the Cayman Islands Monetary Authority, the Cayman Islands Financial Reporting Authority, or other applicable governmental or regulatory authorities (without notifying the Subscriber that such information has been so provided) and (iii) the company and its Agents have no liability whatsoever for any liabilities, costs, expenses, damages and/or losses (including but not limited to any direct, indirect or consequential losses, loss of profit, loss of revenue, loss of reputation and all interest, penalties and legal costs and all other professional costs and expenses) incurred by the shareholder as a result of a Sanctioned Persons Event.

**Economic Substance — Cayman Islands**

The Cayman Islands, together with several other non-European Union jurisdictions, have introduced legislation aimed at addressing concerns raised by the Council of the European Union and the Organization for Economic Co-operation and Development (OECD) as to offshore structures engaged in certain activities which attract profits without real economic activity. The International Tax Co-operation (Economic Substance) Act (As Revised) (the "Substance Act") came into force in the Cayman Islands in January 2019, introducing certain economic substance requirements for in-scope Cayman Islands entities which are engaged in certain geographically mobile business activities ("relevant activities.") As we are a Cayman Islands exempted company, compliance obligations include filing annual notifications, in which need to state whether we are carrying out any relevant activities and if so, whether we have satisfied economic substance tests to the extent required under the Substance Act. It is anticipated that our Company will not be engaging in any "relevant activities" prior to the consummation of our initial business combination and will therefore not be required need to meet the economic substance requirements tests or will otherwise be subject to more limited substance requirements. Failure to satisfy applicable requirements may subject us to enforcement action (including administrative penalties) under the Substance Act.

**Cayman Islands Data Protection**

We have certain duties under the Data Protection Act (As Revised) of the Cayman Islands (the "Data Protection Act"), based on internationally accepted principles of data privacy.

**Privacy Notice**

**Introduction**

This privacy notice puts our shareholders on notice that through your investment in the company you will provide us with certain personal information, which constitutes "personal data" within the meaning of the Data Protection Act.

In the following discussion, the "company" refers to us and our affiliates and/or delegates, except where the context requires otherwise.

We are committed to processing personal data in accordance with the DPA. In our use of personal data, we will be characterized under the DPA as a "data controller," whilst certain of our service providers, affiliates, and delegates may act as "data processors" under the DPA. These service providers may process personal data for their own lawful purposes in connection with services provided to us. For the purposes of this Privacy Notice, "you" or "your" shall mean the subscriber and shall also include any individual connected to the subscriber.

By virtue of your investment in the company, we and certain of our service providers may collect, record, store, transfer, and otherwise process personal data by which individuals may be directly or indirectly identified. We may combine personal data that you provide to use with personal data that we collect from, or about you. This may include personal data collected in an online or offline context including from credit reference agencies and other available public databases or data sources, such as news outlines, websites and other media sources and international sanctions lists.

Your personal data will be processed fairly and for lawful purposes, including (a) where the processing is necessary for us to perform a contract to which you are a party or for taking pre-contractual steps at your request, (b) where the processing is necessary for compliance with any legal, tax, or regulatory obligation to which we are subject, (c) where the processing is for the purposes of legitimate interests pursued by us or by a service provider to whom the data are disclosed, or (d) where you otherwise consent to the processing of personal data for any other specific purpose. As a data controller, we will only use your personal data for the purposes for which we collected it. If we need to use your personal data for an unrelated purpose, we will contact you.

We anticipate that we will share your personal data with our service providers for the purposes set out in this privacy notice. We may also share relevant personal data where it is lawful to do so and necessary to comply with our contractual obligations or your instructions or where it is necessary or desirable to do so in connection with any regulatory reporting obligations. In exceptional circumstances, we will share your personal data with regulatory, prosecuting, and other governmental agencies or departments, and parties to litigation (whether pending or threatened), in any country or territory including to any other person where we have a public or legal duty to do so (e.g. to assist with detecting and preventing fraud, tax evasion, and financial crime or compliance with a court order).

Your personal data shall not be held by the company for longer than necessary with regard to the purposes of the data processing.

We will not sell your personal data. Any transfer of personal data outside of the Cayman Islands shall be in accordance with the requirements of the DPA. Where necessary, we will ensure that separate and appropriate legal agreements are put in place with the recipient of that data.

We will only transfer personal data in accordance with the requirements of the DPA, and will apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction, or damage to the personal data.

**Investor Data**

We will collect, use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately required to conduct our activities of on an ongoing basis or to comply with legal and regulatory obligations to which we are subject. We will only transfer personal data in accordance with the requirements of the Data Protection Act, and will apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or damage to the personal data.

In our use of this personal data, we will be characterized as a "data controller" for the purposes of the Data Protection Act, while our affiliates and service providers who may receive this personal data from us in the conduct of our activities may either act as our "data processors" for the purposes of the Data Protection Actor may process personal information for their own lawful purposes in connection with services provided to us.

We may also obtain personal data from other public sources. Personal data includes, without limitation, the following information relating to a shareholder and/or any individuals connected with a shareholder as an investor: name, residential address, email address, contact details, corporate contact information, signature, nationality, place of birth, date of birth, tax identification, credit history, correspondence records, passport number, bank account details, source of funds details and details relating to the shareholder's investment activity.

**Who this Affects**

If you are a natural person, this will affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation your investment in the Company, this will be relevant for those individuals and you should transmit the content of this Privacy Notice to such individuals or otherwise advise them of its content.

**How the Company May Use Your Personal Data**

The company, as the data controller, may collect, store and use personal data for lawful purposes, including, in particular:

&nbsp;&nbsp;&nbsp;&nbsp;(i) where this is necessary for the performance of our rights
and obligations under any purchase agreements;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) where this is necessary for compliance with a legal and regulatory
obligation to which we are subject (such as compliance with anti-money laundering and FATCA/CRS requirements); and/or

&nbsp;&nbsp;&nbsp;&nbsp;(iii) where this is necessary for the purposes of our legitimate
interests and such interests are not overridden by your interests, fundamental rights or freedoms.

Should we wish to use personal data for other specific purposes (including, if applicable, any purpose that requires your consent), we will contact you.

**Why We May Transfer Your Personal Data**

In certain circumstances, we may be legally obliged to share personal data and other information with respect to your shareholding with the relevant regulatory authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information with foreign authorities, including tax authorities.

We anticipate disclosing personal data to persons who provide services to us and their respective affiliates (which may include certain entities located outside the United States, the Cayman Islands or the European Economic Area), who will process your personal data on our behalf.

**The Data Protection Measures We Take**

Any transfer of personal data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in accordance with the requirements of the Data Protection Act.

We and our duly authorized affiliates and/or delegates shall apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal data.

We shall notify you of any personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those data subjects to whom the relevant personal data relates.

**Rights of Individual Data Subjects**

Individual data subjects have certain data protection rights, including the right to:

● be informed about the purposes for which your personal data are processed;

● access your personal data;

● stop direct marketing;

● restrict the processing of your personal data;

● have incomplete or inaccurate personal data corrected;

● ask us to stop processing your personal data;

● be informed of a personal data breach (unless the breach is unlikely to be prejudicial to you);

● complain to the Data Protection Ombudsman; and

● require us to delete your personal data in some limited circumstances.

If you do not wish to provide us with requested personal data or subsequently withdraw your consent, you may not be able to invest in the Company or remain invested in the Company as it will affect the Company' ability to manage your investment.

If you consider that your personal data has not been handled correctly, or you are not satisfied with our responses to any requests you have made regarding the use of your personal data, you have the right to complain to the Cayman Islands' Ombudsman. The Ombudsman can be contacted by calling +1 (345) 946-6283 or by email at info@ombudsman.ky or by accessing their website here: ombudsman.ky. The information on Ombudsman's website is not incorporated by reference in this prospectus, and you should not consider it a part of this prospectus.

**Certain Anti-Takeover Provisions of our Articles**

Our articles will contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids.

Our authorized but unissued ordinary shares and preference shares are available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved ordinary shares and preference shares could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

**Securities Eligible for Future Sale**

Immediately after this offering we will have 7,800,000 (or 8,934,000 if the underwriters' over-allotment option is exercised in full) ordinary shares outstanding. Of these shares, the ordinary shares sold in this offering (6,000,000 ordinary shares if the underwriters' over-allotment option is not exercised and 6,900,000 shares if the underwriters' over-allotment option is exercised in full) will be freely tradable without restriction or further registration under the Securities Act, except for any ordinary shares purchased by one of our affiliates within the meaning of Rule 144 under the Securities Act. All of the outstanding founder shares (1,500,000 founder shares if the underwriters' over-allotment option is not exercised and 1,725,000 founder shares if the underwriters' over-allotment option is exercised in full) and all of the outstanding private placement shares (300,000 shares if the underwriters' over-allotment option is not exercised and 225,000 shares if the underwriters' over-allotment option is exercised in full) will be restricted securities under Rule 144, in that they were issued in private transactions not involving a public offering.

**Rule 144**

Pursuant to Rule 144, a person who has beneficially owned restricted shares for at least six months would be entitled to sell their securities provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale.

Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of:

● 1% of the total number of ordinary shares then outstanding, which will equal 78,000 shares immediately after this offering (or 89,340 shares if the underwriters exercise in full their over-allotment option); or

● the average weekly reported trading volume of the ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

● Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.

**Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies**

Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:

● the issuer of the securities that was formerly a shell company has ceased to be a shell company;

● the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;

● the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12months (or such shorter period that the issuer was required to file such reports and materials), other than current reports on Form 8-K; and

● at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

As a result, our initial shareholders will be able to sell their founder shares and private placement shares, as applicable, pursuant to Rule 144 without registration one year after we have completed our initial business combination.

**Registration Rights**

The holders of the (i) founder shares, which were issued in a private placement prior to the closing of this offering, (ii) private placement shares, which will be issued in a private placement simultaneously with the closing of this offering and (iii) private placement shares that may be issued upon conversion of working capital loans will have registration rights to require us to register a sale of any of our securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of this offering. Pursuant to the registration rights agreement and assuming the underwriters exercises their over-allotment option in full and $1,500,000 of working capital loans are converted into private placement shares, we will be obligated to register up to 2,184,000 ordinary shares. The number of ordinary shares includes (i) 1,725,000 founder shares, (ii) 309,000 private placement shares and (iii) 150,000 ordinary shares issued upon conversion of working capital loans. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain "piggyback" registration rights with respect to registration statements filed subsequent to our completion of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

**Listing of Securities**

We intend to apply to have our ordinary shares listed on Nasdaq under the symbol "JATT" commencing on or promptly after the date of this prospectus.

**Taxation**

The following summary of certain Cayman Islands and United States federal income tax consequences of an investment in our ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in our ordinary shares, such as the tax consequences under state, local and other tax laws.

Prospective investors should consult their advisors on the possible tax consequences of investing in our ordinary shares under the laws of their country of citizenship, residence or domicile.

**Cayman Islands Tax Considerations**

The following is a discussion on certain Cayman Islands tax consequences of an investment in our ordinary shares. The discussion is a general summary of present law, which is subject to prospective and retroactive change. It is not intended as tax advice, does not consider any investor's particular circumstances, and does not consider tax consequences other than those arising under Cayman Islands law.

**Existing Cayman Islands Laws**

The Cayman Islands currently levies no taxes on individuals or companies based upon profits, income, gains, or appreciation and there is no taxation in the nature of inheritance tax, gift tax or estate duty. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or, after execution, brought within the jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on the issue of shares by, or any transfers of shares of, Cayman Islands companies (except those which hold interests in land in the Cayman Islands). There are no exchange control regulations or currency restrictions in the Cayman Islands.

Payments of dividends and capital in respect of our ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the securities, as the case may be, nor will gains derived from the disposal of the securities be subject to Cayman Islands income or corporate tax.

No stamp duty is payable in respect of the issue of our ordinary shares or on an instrument of transfer in respect of such shares. An instrument of transfer in respect of a share is stampable if executed in or, after execution, brought into the Cayman Islands or produced before a court of the Cayman Islands.

Our company has been incorporated under the laws of the Cayman Islands as an exempted company with limited liability and, as such, has applied for and received an undertaking from the Financial Secretary of the Cayman Islands in the following form on January 19, 2026:

**The Tax Concessions Act (As Revised)**

**Undertaking as to Tax Concessions**

In accordance with the Tax Concessions Act (As Revised) the following undertaking is hereby given to JATT II Acquisition Corp "the Company"

&nbsp;&nbsp;&nbsp;&nbsp;(a) That no law which is hereafter enacted in the Islands imposing
any tax to be levied on profits, income, gains or appreciations shall apply to the Company or its operations; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) In addition, that no tax to be levied on profits, income,
gains or appreciations or which is in the nature of estate duty or inheritance tax shall be payable:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) on or in respect of the shares, debentures or our other obligations;
or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) by way of the withholding in whole or part, of any relevant
payment as defined in the Tax Concessions Act (As Revised)

These concessions shall be for a period of THIRTY years from the 19<sup>th</sup> day of January 2026.

**Certain U.S. Federal Income Tax Considerations**

**General**

The following discussion summarizes certain United States federal income tax considerations generally applicable to the ownership and disposition of our ordinary shares that are purchased in this offering by U.S. Holders (as defined below) and Non-U.S. Holders (as defined below).

This discussion is limited to certain United States federal income tax considerations to beneficial owners of our ordinary shares who are initial purchasers of such ordinary shares pursuant to this offering and hold such ordinary shares as a capital asset within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended (the "Code"). This discussion assumes that any distributions made (or deemed made) by us on our ordinary shares and any consideration received (or deemed received) by a holder in consideration for the sale or other disposition of our ordinary shares will be in U.S. dollars.

This discussion does not address the United States federal income tax consequences to our founders, sponsors, officers or directors, or to holders of founder shares or private placement shares. This discussion is a summary only and does not describe all of the tax consequences that may be relevant to the acquisition, ownership and disposition of ordinary shares by a prospective investor in light of its particular circumstances, including, but not limited to, the alternative minimum tax, the Medicare tax on net investment income and the different consequences that may apply to investors that are subject to special rules under United States federal income tax laws, including, but not limited to:

● banks, financial institutions or financial services entities;

● broker-dealers;

● taxpayers that are subject to the mark-to-market tax accounting rules;

● tax-exempt entities;

● governments or agencies or instrumentalities thereof;

● insurance companies;

● grantor trusts;

● subchapter S corporations;

● personal holding companies;

● regulated investment companies;

● real estate investment trusts;

● expatriates or former long-term residents of the United States;

● persons that directly, indirectly, or constructively own five percent or more (by vote or value) of all classes of our shares;

● persons that acquired our ordinary shares pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation;

● persons that hold our ordinary shares as part of a straddle, constructive sale, hedge, wash sale, conversion or other integrated or similar transaction;

● U.S. Holders (as defined below) whose functional currency is not the U.S. dollar;

● controlled foreign corporations;

● passive foreign investment companies; and

● partnerships (including entities and arrangements classified as partnerships) for United States federal income tax purposes and any beneficial owners of such partnerships.

Moreover, the discussion below is based upon the provisions of the Code, the U.S. Treasury regulations promulgated thereunder (whether final, temporary, or proposed) and administrative and judicial interpretations thereof, all as of the date hereof, and such provisions may be repealed, revoked, modified or subject to differing interpretations, possibly on a retroactive basis, which may result in United States federal income tax consequences different from those discussed below. Furthermore, this discussion does not address any aspect of United States federal non-income tax laws, such as gift or estate tax laws, or state, local or non-United States tax laws.

We have not sought, and do not expect to seek, a ruling from the United States Internal Revenue Service ("IRS"), as to any United States federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion.

If a partnership (including any other entity or arrangement classified as a partnership) for United States federal income tax purposes is the beneficial owner of our ordinary shares, the United States federal income tax treatment of a partner, member or other beneficial owner in such partnership generally will depend on the status of the partner, member or other beneficial owner and the activities of the partnership. If you are a partner, member or other beneficial owner of a partnership holding our ordinary shares, you are urged to consult your own tax advisor regarding the tax consequences of the acquisition, ownership and disposition of our ordinary shares.

THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES. EACH PROSPECTIVE INVESTOR IN OUR ORDINARY SHARES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY UNITED STATES FEDERAL NON-INCOME, STATE AND LOCAL, AND NON-UNITED STATES TAX LAWS.

**U.S. Holders**

This section applies to you if you are a "U.S. Holder." A U.S. Holder is a beneficial owner of our ordinary shares who or that is, for United States federal income tax purposes:

● an individual who is a citizen or resident of the United States;

● a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia;

● an estate whose income is subject to United States federal income tax regardless of its source; or

● a trust, if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under Treasury Regulations to be treated as a United States person (as defined in the Code).

**Taxation of Distributions**

Subject to the passive foreign investment company ("PFIC"), rules discussed below, a U.S. Holder generally will be required to include in gross income as dividends in the year actually or constructively received by the U.S. Holder the amount of any distribution of cash or other property paid on our ordinary shares to the extent the distribution is paid out of our current or accumulated earnings and profits (as determined under United States federal income tax principles). Distributions in excess of such earnings and profits generally will be applied against and reduce the U.S. Holder's basis in its ordinary shares (but not below zero) and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of such ordinary shares (the treatment of which is described under "*— Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of ordinary shares*" below).

Dividends paid by us will be taxable to a corporate U.S. Holder at regular rates and will not be eligible for the dividends-received deduction generally allowed to domestic corporations in respect of dividends received from other domestic corporations. With respect to non-corporate U.S. Holders, dividends generally will be taxed at the preferential long-term capital gains rate applicable to "qualified dividend income" (see *"— Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of ordinary shares*" below) only if our ordinary shares are readily tradable on an established securities market in the United States (such as Nasdaq), we are not a PFIC in the taxable year in which the dividend was paid or in the previous year, and certain other requirements, including certain holding period requirements, are met. It is not clear, however, whether certain redemption rights described in this prospectus may suspend the running of the applicable holding period of the ordinary shares for this purpose. U.S. Holders should consult their tax advisors regarding the availability of such preferential rate for any dividends paid with respect to our ordinary shares.

**Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Ordinary Shares**

Subject to the PFIC rules discussed below, a U.S. Holder generally will recognize capital gain or loss on the sale or other taxable disposition of our ordinary shares (including a redemption of our ordinary shares (as described below) that is treated as a taxable disposition, including pursuant to our dissolution and liquidation if we do not consummate an initial business combination within the required time period). Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder's holding period for such ordinary shares exceeds one year. Long-term capital gain realized by a non-corporate U.S. Holder may be taxed at preferential rates of taxation. It is unclear, however, whether certain redemption rights described in this prospectus may suspend the running of the applicable holding period of the ordinary shares for this purpose. If the running of the holding period for the ordinary shares is suspended, then non-corporate U.S. Holders may not be able to satisfy the one-year holding period requirement for long-term capital gain treatment, in which case any gain on a sale or other taxable disposition of the ordinary shares would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. The deductibility of capital losses is subject to certain limitations.

The amount of gain or loss recognized by a U.S. Holder on a sale or other taxable disposition of its ordinary shares generally will be equal to the difference between (i) the sum of the amount of cash and the fair market value of any property received in such disposition and (ii) the U.S. Holder's adjusted tax basis in its ordinary shares so disposed of. A U.S. Holder's adjusted tax basis in its ordinary shares generally will equal the U.S. Holder's acquisition cost reduced by any prior distributions treated as a return of capital.

**Redemption of Ordinary Shares**

Subject to the PFIC rules discussed below, in the event that a U.S. Holder's ordinary shares are redeemed pursuant to the redemption provisions described in the section of this prospectus entitled "*Description of Securities — Ordinary Shares*" or if we purchase a U.S. Holder's ordinary shares in an open market transaction (such open market purchase of ordinary shares by us is referred to as a "redemption" for the remainder of this discussion), the treatment of the transaction for United States federal income tax purposes will depend on whether the redemption qualifies as a sale of the ordinary shares under Section 302 of the Code. If the redemption qualifies as a sale of ordinary shares, the U.S. Holder will be treated as described under "*— Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of ordinary shares*" above. If the redemption does not qualify as a sale of ordinary shares, the U.S. Holder will be treated as receiving a corporate distribution with the tax consequences described above under *"— Taxation of Distributions*." Whether a redemption qualifies for sale treatment will generally depend on the total number of our shares treated as held by the U.S. Holder (including any shares constructively owned by the U.S. Holder as described in the following paragraph) relative to all of our shares outstanding both before and after such redemption. A redemption of ordinary shares generally will be treated as a sale of the ordinary shares (rather than as a corporate distribution) if such redemption (i) is "substantially disproportionate" with respect to the U.S. Holder, (ii) results in a "complete termination" of the U.S. Holder's interest in us or (iii) is "not essentially equivalent to a dividend" with respect to the U.S. Holder. These tests are explained more fully below.

In determining whether any of the foregoing tests are satisfied, a U.S. Holder takes into account not only our shares actually owned by the U.S. Holder, but also our shares that are constructively owned by such holder. A U.S. Holder may constructively own, in addition to shares owned directly, shares owned by certain related individuals and entities in which the U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any shares the U.S. Holder has a right to acquire by exercise of an option. In order to meet the substantially disproportionate test, the percentage of our issued and outstanding voting shares actually and constructively owned by the U.S. Holder immediately following the redemption of ordinary shares must, among other requirements, be less than 80% of the percentage of our issued and outstanding voting shares actually and constructively owned by the U.S. Holder immediately before the redemption. There will be a complete termination of a U.S. Holder's interest if either (i) all of our shares actually and constructively owned by the U.S. Holder are redeemed or (ii) all of our shares actually owned by the U.S. Holder are redeemed and the U.S. Holder is eligible to waive, and effectively waives in accordance with specific rules, the attribution of shares owned by certain family members and the U.S. Holder does not constructively own any other shares of ours. The redemption of the ordinary shares will not be essentially equivalent to a dividend if such redemption results in a "meaningful reduction" of the U.S. Holder's proportionate interest in us. Whether the redemption will result in a meaningful reduction in a U.S. Holder's proportionate interest in us will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority shareholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a "meaningful reduction." A U.S. Holder should consult with its own tax advisors as to the tax consequences of a redemption of any ordinary shares.

If none of the foregoing tests are satisfied, then the redemption of any ordinary shares will be treated as a corporate distribution and the tax effects will be as described under "— *Taxation of Distributions*" above. After the application of those rules, any remaining tax basis of the U.S. Holder in the redeemed ordinary shares will be added to the U.S. Holder's adjusted tax basis in its remaining shares, or, if it has none, possibly to the U.S. Holder's adjusted tax basis in other shares constructively owned by it.

U.S. Holders who actually or constructively own five percent (or, if our ordinary shares are not then publicly traded, one percent) or more of our shares (by vote or value) may be subject to special reporting requirements with respect to a redemption of ordinary shares, and such holders are urged to consult with their own tax advisors with respect to their reporting requirements.

**Passive Foreign Investment Company Rules**

A foreign (i.e., non-U.S.) corporation will be classified as a PFIC for United States federal income tax purposes if either (i) at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii) at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes, among other things, dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of assets giving rise to passive income.

Because we are a blank check company, we may meet the PFIC asset or income test for our current taxable year. However, pursuant to a startup exception, a corporation will not be a PFIC for the first taxable year in which the corporation has gross income (the "startup year") if (1) no predecessor of the corporation was a PFIC; (2) the corporation satisfies the IRS that it will not be a PFIC for either of the first two taxable years following the startup year; and (3) the corporation is not in fact a PFIC for either of those years. The applicability of the startup exception to us is uncertain and will not be known until after the close of our current taxable year and, perhaps, until after the end of our two taxable years following our startup year. After the acquisition of a company or assets in a business combination, we may still meet one of the PFIC tests depending on the timing of the acquisition and the amount of our passive income and assets as well as the passive income and assets of the acquired business. If the company that we acquire in a business combination is a PFIC, then we will likely not qualify for the startup exception and will be a PFIC for our current taxable year. Our PFIC status for our current taxable year or any subsequent taxable year will not be determinable until after the end of such taxable year (and, in the case of the startup exception to our current taxable year, perhaps until after the end of our two taxable years following our startup year). Accordingly, there can be no assurance with respect to our status as a PFIC for our current taxable year or any future taxable year. In addition, our U.S. counsel expresses no opinion with respect to our PFIC status for our current or future taxable years.

Although our PFIC status is determined annually, a determination that our company is a PFIC for any taxable year generally will apply for subsequent years to a U.S. Holder who held ordinary shares while we were a PFIC, whether we meet the test for PFIC status in those subsequent years. If we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of our ordinary shares and the U.S. Holder did not make either a timely mark-to-market election or a qualified electing fund ("QEF") election (as discussed below) for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) ordinary shares, as described below, such U.S. Holder generally will be subject to special rules with respect to (i) any gain recognized by the U.S. Holder on the sale or other disposition of its ordinary shares (which may include gain realized by reason of transfers of ordinary shares that would otherwise qualify as nonrecognition transactions for United States federal income tax purposes) and (ii) any "excess distribution" made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of the ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter, the portion of such U.S. Holder's holding period for the ordinary shares that preceded the taxable year of the distribution) (together, the "excess distribution rules").

Under these excess distribution rules:

● the U.S. Holder's gain or excess distribution will be allocated ratably over the U.S. Holder's holding period for the ordinary shares;

● the amount allocated to the U.S. Holder's taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder's holding period before the first day of our first taxable year in which we are a PFIC, will be taxed as ordinary income;

● the amount allocated to each other taxable years (or portion thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder without regard to the U.S. Holder's other items of income and loss for such year; and

● an additional amount equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable year of the U.S. Holder.

In general, if we are a PFIC, a U.S. Holder may be able to avoid the excess distribution rules described above in respect to our ordinary shares by making a timely and valid QEF election (if eligible to do so) to include in income its pro rata share of our net capital gains (as long-term capital gain) and other earnings and profits (as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of the U.S. Holder in which or with which our taxable year ends. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge.

If a U.S. Holder makes a QEF election with respect to its ordinary shares in a year after our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) ordinary shares, then notwithstanding such QEF election, the excess distribution rules discussed above, adjusted to take into account the current income inclusions resulting from the QEF election, will continue to apply with respect to such U.S. Holder's ordinary shares, unless the U.S. Holder makes a purging election under the PFIC rules. Under one type of purging election, the U.S. Holder will be deemed to have sold such shares at their fair market value and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of such purging election, the U.S. Holder will have additional basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes of the PFIC rules, a new holding period in the ordinary shares. U.S. Holders are urged to consult their tax advisors as to the application of the rules governing purging elections to their particular circumstances.

The QEF election is made on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes a QEF election by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund), including the information provided in a PFIC annual information statement, to a timely filed United States federal income tax return for the tax year to which the election relates. Retroactive QEF elections generally may be made only by filing a protective statement with such return and if certain other conditions are met or with the consent of the IRS. U.S. Holders should consult their tax advisors regarding the availability and tax consequences of a QEF election under their particular circumstances.

In order to comply with the requirements of a QEF election, a U.S. Holder must receive a PFIC annual information statement from us. If we determine we are a PFIC for any taxable year, upon written request, we will endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain a QEF election, but there is no assurance that we will timely provide such required information. There is also no assurance that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided.

If a U.S. Holder has made a QEF election with respect to our ordinary shares, and the excess distribution rules discussed above do not apply to such shares (because of a timely QEF election for our first taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold) such shares or a purge of the PFIC taint pursuant to a purging election, as described above), any gain recognized on the sale of our ordinary shares generally will be taxable as capital gain and no additional interest charge will be imposed under the PFIC rules. As discussed above, if we are a PFIC for any taxable year, a U.S. Holder of our ordinary shares that has made a QEF election will be currently taxed on its pro rata share of our earnings and profits, whether or not distributed for such year. A subsequent distribution of such earnings and profits that were previously included in income generally should not be taxable when distributed to such U.S. Holder. The tax basis of a U.S. Holder's shares in a QEF will be increased by amounts that are included in income, and decreased by amounts distributed but not taxed as dividends, under the above rules. In addition, if we are not a PFIC for any taxable year, such U.S. Holder will not be subject to the QEF inclusion regime with respect to our ordinary shares for such a taxable year.

Alternatively, if a U.S. Holder, at the close of its taxable year, owns shares in a PFIC that are treated as marketable stock, the U.S. Holder may make a mark-to-market election with respect to such shares for such taxable year. If the U.S. Holder makes a valid mark-to-market election for the first taxable year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) ordinary shares and for which we are determined to be a PFIC, such U.S. Holder generally will not be subject to the excess distribution rules described above with respect to its ordinary shares. Instead, in general, the U.S. Holder will include as ordinary income in each taxable year the excess, if any, of the fair market value of its ordinary shares at the end of its taxable year over its adjusted basis in its ordinary shares. These amounts of ordinary income would not be eligible for the favorable tax rates applicable to qualified dividend income or long-term capital gains. The U.S. Holder also generally will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis in its ordinary shares over the fair market value of its ordinary shares at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder's basis in its ordinary shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of its ordinary shares will be treated as ordinary income and any further loss will be treated as ordinary loss (but only to the extent of the net amount of income previously included as a result of a mark-to-market election, and any loss in excess of such prior inclusions generally would be treated as capital loss).

The mark-to-market election is available only for stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission, including Nasdaq (on which we intend to list the ordinary shares), or on a foreign exchange or market that the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. If made, a mark-to-market election would be effective for the taxable year for which the election was made and for all subsequent taxable years unless the ordinary shares ceased to qualify as "marketable stock" for purposes of the PFIC rules or the IRS consented to the revocation of the election. U.S. Holders are urged to consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election in respect to our ordinary shares under their particular circumstances.

If we are a PFIC and, at any time, have a foreign subsidiary that is classified as a PFIC, U.S. Holders generally would be deemed to own a portion of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge under the excess distribution rules described above if we receive a distribution from, or dispose of all or part of our interest in, the lower-tier PFIC or the U.S. Holders otherwise were deemed to have disposed of an interest in the lower-tier PFIC. Upon written request, we will endeavor to cause any lower-tier PFIC to provide to a U.S. Holder the information that may be required to make or maintain a QEF election with respect to the lower-tier PFIC. There can be no assurance, however, that we will have timely knowledge of the status of any such lower-tier PFIC. In addition, we may not hold a controlling interest in any such lower-tier PFIC and thus there can be no assurance we will be able to cause the lower-tier PFIC to provide such required information. A mark-to-market election generally would not be available with respect to such lower-tier PFIC. U.S. Holders are urged to consult their tax advisors regarding the tax issues raised by lower-tier PFICs.

A U.S. Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder, may have to file an IRS Form 8621 (whether or not a QEF or mark-to-market election is made) and such other information as may be required by the U.S. Treasury Department. Failure to do so, if required, will extend the statute of limitations until such required information is furnished to the IRS.

The rules dealing with PFICs and with the QEF, purging, and mark-to-market elections are complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders of our ordinary shares should consult their own tax advisors concerning the application of the PFIC rules to our ordinary shares under their particular circumstances.

**Tax Reporting**

Certain U.S. Holders may be required to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a transfer of property (including cash) to us. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement, and the period of limitations on assessment and collection of United States federal income taxes will be extended in the event of a failure to comply. Furthermore, certain U.S. Holders who are individuals and certain entities will be required to report information with respect to such U.S. Holder's investment in "specified foreign financial assets" on IRS Form 8938 (Statement of Specified Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally include any financial account maintained with a non-U.S. financial institution and should also include the ordinary shares if they are not held in an account maintained with a U.S. financial institution. Persons who are required to report specified foreign financial assets and fail to do so may be subject to substantial penalties, and the period of limitations on assessment and collection of United States federal income taxes may be extended in the event of a failure to comply. Potential investors are urged to consult their tax advisors regarding the foreign financial asset and other reporting obligations and their application to an investment in our ordinary shares.

**Non-U.S. Holders**

This section applies to you if you are a "Non-U.S. Holder." As used herein, the term "Non-U.S. Holder" means a beneficial owner of our ordinary shares who or that is for United States federal income tax purposes:

● a non-resident alien individual (other than certain former citizens and residents of the United States subject to U.S. tax as expatriates);

● a foreign corporation; or

● an estate or trust that is not a U.S. Holder;

but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of the disposition of our ordinary shares. If you are such an individual, you should consult your tax advisor regarding the United States federal income tax consequences of the acquisition, ownership and disposition of our ordinary shares.

Dividends paid or deemed paid to a Non-U.S. Holder in respect of our ordinary shares generally will not be subject to United States federal income tax, unless the dividends are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such Non-U.S. Holder maintains in the United States). In addition, a Non-U.S. Holder generally will not be subject to United States federal income tax on any gain attributable to a sale or other disposition of our ordinary shares unless such gain is effectively connected with its conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such Non-U.S. Holder maintains in the United States).

Dividends and gains that are effectively connected with the Non-U.S. Holder's conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base in the United States) generally will be subject to United States federal income tax at the same regular United States federal income tax rates applicable to a comparable U.S. Holder and, in the case of a Non-U.S. Holder that is a corporation for United States federal income tax purposes, also may be subject to an additional branch profits tax at a 30% rate or a lower applicable tax treaty rate.

**Information Reporting and Backup Withholding**

Dividend payments with respect to our ordinary shares and proceeds from the sale, exchange or redemption of our ordinary shares may be subject to information reporting to the IRS and possible United States backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number on IRS Form W-9 and makes other required certifications, or who is otherwise exempt from backup withholding and establishes such exempt status. A Non-U.S. Holder generally will eliminate the requirement for information reporting and backup withholding by providing certification of its foreign status, under penalties of perjury, on a duly executed applicable IRS Form W-8 or by otherwise establishing an exemption.

Backup withholding is not an additional tax. Any amounts withheld as backup withholding may be credited against a holder's United States federal income tax liability, if any, and a holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules, by timely filing the appropriate claim for refund with the IRS and furnishing any required information.

**Underwriting**

Subject to the terms and conditions set forth in the underwriting agreement, dated as of the date of this prospectus, among us and Guggenheim Securities, LLC, as representative of the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of ordinary shares shown opposite its name below:

---

| | |
|:---|:---|
| **UNDERWRITER** | **NUMBER OF <br> ORDINARY <br> SHARES** |
| Guggenheim Securities, LLC |  |
| Total | 6000000 |

---

The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers' certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the ordinary shares if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities.

The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the ordinary shares as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the ordinary shares, that you will be able to sell any the ordinary shares that are held by you at a particular time or that the prices that you receive when you sell will be favorable.

The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority.

**Commission and Expenses**

The underwriters have advised us that they propose to offer the ordinary shares to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the representative. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus.

The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering.

Such amounts are shown assuming both no exercise and full exercise of the underwriters' over-allotment option.

---

| | | |
|:---|:---|:---|
|  | **PAID BY JATT II <br> ACQUISITION CORP** | **PAID BY JATT II <br> ACQUISITION CORP** |
|  | **NO <br> EXERCISE** | **FULL <br> EXERCISE** |
| Per Ordinary Share<sup>(1)</sup> | $0.40 | $0.40 |
| Total<sup>(1)</sup> | $2400000 | $2760000 |

---

(1) Includes $0.10 per share, or $600,000 in the aggregate (or
$690,000 if the underwriters' over-allotment option is exercised in full), payable to the underwriters upon the closing of this
offering. Also includes $0.30 per share, or $1,800,000 in the aggregate (or up to $2,070,000 in the aggregate if the underwriters'
over-allotment option is exercised in full) payable to the underwriters for deferred underwriting commissions to be placed in a trust
account located in the United States and released to the underwriters only upon the completion of an initial business combination.
The deferred commissions will be fully earned by the underwriters upon the payment of the purchase price for the ordinary shares purchased
by the underwriters on the closing of this offering and will be released to the underwriters only on and concurrently with completion
of an initial business combination. A portion of the deferred commissions is subject to reduction upon closing of an initial business
combination under certain circumstances.

If we do not complete our initial business combination within the completion window, the underwriters have agreed that (i) they will forfeit any rights or claims to their deferred underwriting commissions, including any accrued interest thereon, then in the trust account and (ii) the deferred underwriters' commissions will be distributed on a pro rata basis, together with any accrued interest thereon (which interest will be net of permitted withdrawals) to the public shareholders.

We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $900,000. We have agreed to reimburse the underwriters for its reasonable out-of-pocket expenses incurred in this offering not to exceed $25,000 (including, without limitation, travel, lodging and due diligence expenses and printing expenses) but excluding fees and disbursements of the underwriters' legal counsel, whether or not if this offering is consummated.

**Determination of Offering Price**

Prior to this offering, there has not been a public market for our ordinary shares. Consequently, the initial public offering price for our ordinary shares was determined by negotiations between us and the representative. Among the factors considered in these negotiations were the history and prospects of companies whose principal business is the acquisition of other companies, prior offerings of those companies, our management, our capital structure, and currently prevailing general conditions in equity securities markets, including current market valuations of publicly traded companies considered comparable to our company.

We offer no assurances that the initial public offering price will correspond to the price at which the ordinary shares will trade in the public market subsequent to the offering.

**Listing**

We have applied to have our ordinary shares listed on Nasdaq under the symbol "JATT."

**Stamp Taxes**

If you purchase ordinary shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.

**Option to Purchase Additional Ordinary Shares**

We have granted to the underwriters an option, exercisable for 45 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 900,000 ordinary shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions.

If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional ordinary shares proportionate to that underwriter's initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more ordinary shares than the total number set forth on the cover page of this prospectus.

**Contractual Transfer Restrictions in the Letter Agreement and Underwriting Agreement**

Our sponsor, officers and directors have agreed pursuant to the letter agreement with our sponsor, officers and directors not to transfer, assign or sell any founder shares they may hold until the earlier to occur of: (A) 180 days after the completion of our initial business combination and (B) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property; our sponsor has agreed not to transfer, assign or sell any of its private placement shares until 30 days after the completion of our initial business combination; except, in each case, to certain permitted transferees and under certain circumstances as described in this prospectus. Any permitted transferees will be subject to the same restrictions and other agreements of our sponsor and our management team. We refer to such transfer restrictions throughout this prospectus as the lock-up.

Further, pursuant to the underwriting agreement we have agreed that, for a period of 180 days from the date of this prospectus, we will not, without the prior written consent of Guggenheim Securities, LLC, as representative of the underwriters, offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, ordinary shares or any other securities convertible into, or exercisable, or exchangeable for, ordinary shares; provided, however, that we may (1) issue and sell the private placement shares, (2) issue and sell the additional ordinary shares to cover our underwriters' over-allotment option (if any), (3) register with the SEC pursuant to an agreement to be entered into concurrently with the issuance and sale of the securities in this offering, the resale of the founder shares, the private placement shares and ordinary shares issuable upon conversion of the founder shares and (4) issue securities in connection with an initial business combination. Guggenheim Securities, LLC, as representative of the underwriters, in their sole discretion, may release any of the securities subject to these restrictions at any time without notice. The foregoing shall not apply to the forfeiture of any founder shares pursuant to their terms or any transfer of founder shares to any current or future independent director of the company (as long as such current or future independent director is subject to the terms of the letter agreement, filed herewith, at the time of such transfer; and as long as, to the extent any Section 16 reporting obligation is triggered as a result of such transfer, any related Section 16 filing includes a practical explanation as to the nature of the transfer).

Our letter agreement contains a provision that also subjects our sponsor and our directors and officers to the restrictions of the underwriting agreement that are described in the foregoing paragraph. Pursuant to such provision in the letter agreement the sponsor and our officers and directors agree, subject to the same exceptions that are described in the foregoing and to certain limited exceptions as described in the letter agreement, that, for a period of 180 days from the date of this prospectus, they will not, without the prior written consent of Guggenheim Securities, LLC, as representative of the underwriters, offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, units, warrants, ordinary shares or any other securities convertible into, or exercisable, or exchangeable for, ordinary shares. The written consent of Guggenheim Securities, LLC, as representative of the underwriters, us, the sponsor and each of the directors and officers with respect to herself or himself, will be required in connection with a change, amendment, modification or waiver to the provision of the letter agreement described in the foregoing. For more information on the letter agreement and a summary of the transfer restrictions included therein and the exceptions to the transfer restrictions described above, also see "Proposed Business — Initial Business Combination" and "Risk Factors — Risks Relating to Our Sponsor and Management Team — Our letter agreement with our sponsor, officers, directors and advisors may be amended without shareholder approval."

**Stabilization**

The underwriters have advised us that they, pursuant to Regulation M under the Exchange Act, and certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the ordinary shares at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either "covered" short sales or "naked" short sales.

"Covered" short sales are sales made in an amount not greater than the underwriters' over-allotment option in this offering. The underwriters may close out any covered short position by either exercising their over-allotment option or purchasing ordinary shares in the open market. In determining the source of ordinary shares to close out the covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared to the price at which they may purchase ordinary shares through the over-allotment option.

"Naked" short sales are sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ordinary shares in the open market after pricing that could adversely affect investors who purchase in this offering.

A stabilizing bid is a bid for the purchase of ordinary shares on behalf of the underwriters for the purpose of fixing or maintaining the price of the ordinary shares. A syndicate covering transaction is the bid for or the purchase of ordinary shares on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters' purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the ordinary shares originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our ordinary shares. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.

The underwriters may also engage in passive market making transactions in our ordinary shares on Nasdaq in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of our ordinary shares in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker's bid, that bid must then be lowered when specified purchase limits are exceeded.

**Electronic Distribution**

A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters' web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.

**Other Activities and Relationships**

In addition to its role as underwriter, Guggenheim Securities, LLC may act as financial advisor in connection with any merger, reverse merger, scheme of arrangement or other form of business combination transaction we may undertake. The underwriting agreement does not obligate the underwriters to perform any services in connection with our initial business combination or to receive their deferred commissions, which will be fully earned by the underwriters upon the payment of the purchase price for the ordinary shares purchased by the underwriters on the closing of this offering and will be released to the underwriters only on and concurrently with completion of an initial business combination.

We may engage the underwriters, in our discretion, for example, to introduce us to potential target businesses, provided financial advisory services to us in connection with a business combination or assist us in raising additional capital in the future, including by acting as a placement agent in a private offering or underwriting or arranging debt financing. If any of the underwriters provide services to us after this offering, we may pay such underwriter fair and reasonable fees that would be determined at that time in an arm's length negotiation; provided that no agreement will be entered into with any of the underwriters and no fees for such services will be paid to any of the underwriters prior to the date that is 60 days from the date of this prospectus, unless such payment would not be deemed underwriters' compensation in connection with this offering. We may pay the underwriters of this offering or any entity with which they are affiliated, a finder's fee or other compensation for services rendered to us in connection with the completion of a business combination. Any fees we may pay the underwriters or their affiliates for services rendered to us after this offering may be contingent on the completion of a business combination and may include non-cash compensation. The underwriters or their affiliates that provide these services to us may have a potential conflict of interest given that the underwriters are entitled to the deferred portion of their underwriting compensation for this offering only if an initial business combination is completed within the specified timeframe.

The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.

In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

**Selling Restrictions**

 ****

***Canada***

 

*Resale Restrictions*

Any resale of the securities in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities.

Representations of Canadian Purchasers

By purchasing the securities in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that:

● the purchaser is entitled under applicable provincial securities laws to purchase the securities without the benefit of a prospectus qualified under those securities laws as it is an "accredited investor" as defined under National Instrument 45-106 — Prospectus Exemptions,

● the purchaser is a "permitted client" as defined in National Instrument 31-103 — Registration Requirements, Exemptions and Ongoing Registrant Obligations,

● where required by law, the purchaser is purchasing as principal and not as agent, and

● the purchaser has reviewed the text above under Resale Restrictions.

 

*Conflicts of Interest*

Canadian purchasers are hereby notified that the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument 33-105 — Underwriting Conflicts from having to provide certain conflict of interest disclosure in this document.

 

*Statutory Rights of Action*

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.

 

*Enforcement of Legal Rights*

All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.

 

*Taxation and Eligibility for Investment*

Canadian purchasers of the securities should consult their own legal and tax advisers with respect to the tax consequences of an investment in the securities in their particular circumstances and about the eligibility of the securities for investment by the purchaser under relevant Canadian legislation.

 ****

***Australia***

This prospectus is not a disclosure document for the purposes of Australia's Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities & Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia:

You confirm and warrant that you are either:

● a "sophisticated investor" under section 708(8)(a) or (b) of the Corporations Act;

● a "sophisticated investor" under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant's certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made;

● a person associated with the Company under Section 708(12) of the Corporations Act; or

● a "professional investor" within the meaning of section 708(11)(a) or (b) of the Corporations Act.

To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance.

You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act.

 ****

***European Economic Area***

In relation to each Member State of the European Economic Area (each a "Relevant State"), no ordinary shares have been offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in relation to the ordinary shares that has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of ordinary shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation:

&nbsp;&nbsp;&nbsp;&nbsp;(a) to any legal entity which is a qualified investor as defined
under the Prospectus Regulation;

&nbsp;&nbsp;&nbsp;&nbsp;(b) to fewer than 150 natural or legal persons (other than qualified
investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer;
or

&nbsp;&nbsp;&nbsp;&nbsp;(c) in any other circumstances falling within Article 1(4) of
the Prospectus Regulation, provided that no such offer of ordinary shares shall require the issuer or any underwriter to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

For the purposes of this provision, the expression an "offer to the public" in relation to any ordinary shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares to be offered so as to enable an investor to decide to purchase or subscribe for any ordinary shares, and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129.

 ****

***Hong Kong***

No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong ("SFO") and any rules made under that Ordinance; or in other circumstances which do not result in the document being a "prospectus" as defined in the Companies Ordinance (Cap. 32) of Hong Kong ("CO") or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the SFO and any rules made under that Ordinance.

This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions.

 ****

***Israel***

This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the ordinary shares is directed only at, (i) a limited number of persons in accordance with the Israeli Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and "qualified individuals," each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.

 ****

***Japan***

The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for reoffering or resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan.

 ****

***Singapore***

This prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

● a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

● a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 of the SFA except:

● to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;

● where no consideration is or will be given for the transfer;

● where the transfer is by operation of law;

● as specified in Section 276(7) of the SFA; or

● as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

 ****

***Switzerland***

The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this prospectus nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes ("CISA"). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.

***United Kingdom***

In relation to the United Kingdom, no ordinary shares have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the ordinary shares that either (i) has been approved by the Financial Conduct Authority or (ii) is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provision in Regulation 74 of the Prospectus (Amendment etc.) (EU exit) Regulations 2019, except that offers of ordinary shares may be made to the public in the United Kingdom at any time under the following exemptions under the UK Prospectus Regulation:

&nbsp;&nbsp;&nbsp;&nbsp;(a) to any legal entity which is a qualified investor as defined
in Article 2 of the UK Prospectus Regulation;

&nbsp;&nbsp;&nbsp;&nbsp;(b) to fewer than 150 natural or legal persons (other than qualified
investors as defined in Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriter for
any such offer; or

&nbsp;&nbsp;&nbsp;&nbsp;(c) in any other circumstances falling within section 86 of the
Financial Services and Markets Act 2000, as amended, (the "FSMA"), provided that no such offer of ordinary shares shall
require the issuer or any underwriter to publish a prospectus pursuant to section 85 of the FSMA or supplement a prospectus pursuant
to Article 23 of the UK Prospectus Regulation.

For the purposes of this provision, the expression an "offer to the public" in relation to any ordinary shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares to be offered so as to enable an investor to decide to purchase or subscribe for any ordinary shares, and the expression "UK Prospectus Regulation" means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

Each underwriter has represented and agreed that:

● it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of any ordinary shares in circumstances in which Section 21(1) of the FSMA does not apply to the issuer; and

● it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to any ordinary shares in, from or otherwise involving the United Kingdom.

 ****

***Cayman Islands***

This document does not constitute a public offer of, or an invitation to the public to purchase, ordinary shares in the company, whether by way of sale or subscription, in the Cayman Islands. Ordinary shares have not been offered or sold, and will not be offered or sold, directly or indirectly, in the Cayman Islands.

**Legal Matters**

Certain legal matters in connection with this offering relating to U.S. law will be passed upon for us by Loeb & Loeb LLP. Appleby (Cayman) Ltd. will pass upon the validity of the securities offered in this prospectus and certain other legal matters of Cayman Islands law. In connection with this offering, Davis Polk & Wardwell LLP is acting as counsel to the underwriters.

**Experts**

The financial statements of JATT II Acquisition Corp as of February 13, 2026, and for the period from January 13, 2026 (inception) through February 13, 2026, appearing in this prospectus have been audited by WithumSmith+Brown, PC, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere in this prospectus, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

**Where You Can Find Additional Information**

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information about us and our securities, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are materially complete but may not include a description of all aspects of such contracts, agreements or other documents, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.

Upon completion of this offering, we will be subject to the information requirements of the Exchange Act and will file annual, quarterly and current event reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC's website at *www.sec.gov.*

**JATT II ACQUISITION CORP**

**INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
|  | **Page** |
| **Financial Statements of JATT II Acquisition Corp:** |  |
| [Report of Independent Registered Public Accounting Firm](#f_001) | F-2 |
| [Balance Sheet as of February 13, 2026](#f_002) | F-3 |
| [Statement of Operations for the Period from January 13, 2026 (Inception) through February 13, 2026](#f_003) | F-4 |
| [Statement of Changes in Shareholder's Equity for the Period from January 13, 2026 (Inception) through February 13, 2026](#f_004) | F-5 |
| [Statement of Cash Flows for the Period from January 13, 2026 (Inception) through February 13, 2026](#f_005) | F-6 |
| [Notes to Financial Statements](#f_006) | F-7 |

---

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Shareholder and the Board of Directors of

JATT II Acquisition Corp.:

**Opinion on the Financial Statements**

We have audited the accompanying balance sheet of JATT II Acquisition Corp. (the "Company") as of February 13, 2026, and the related statements of operations, changes in shareholder's equity, and cash flows for the period from January 13, 2026 (inception) through February 13, 2026 and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of February 13, 2026, and the results of its operations and its cash flows for the period January 13, 2026 (inception) through February 13, 2026, in conformity with accounting principles generally accepted in the United States of America.

**Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company does not have sufficient cash and working capital to sustain its operations and the Company's ability to execute its business plan is dependent upon its completion of the proposed initial public offering described in Note 1 to the financial statements. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (the "PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company's auditor since 2026.

Whippany, New Jersey

March 13, 2026

**JATT II ACQUISITION CORP BALANCE SHEET FEBRUARY 13, 2026**

---

| | |
|:---|:---|
| **ASSETS** | |
| &nbsp;&nbsp;&nbsp;Current asset – prepaid expenses | $80 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | 33619 |
| **TOTAL ASSETS** | $**33699** |
| **LIABILITIES AND SHAREHOLDER'S EQUITY** |  |
| Current liabilities: |  |
| &nbsp;&nbsp;&nbsp;Accrued expenses | $6667 |
| &nbsp;&nbsp;&nbsp;Accrued offering costs | 8619 |
| &nbsp;&nbsp;&nbsp;Promissory note – related party | 13000 |
| **Total Current Liabilities** | **28286** |
| **Commitments and Contingencies (Note 6)** |  |
| **Shareholder's Equity** |  |
| &nbsp;&nbsp;&nbsp;Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 1,725,000 issued and outstanding<sup>(1)</sup> | 173 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 24827 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (19587) |
| **Total Shareholder's Equity** | **5413** |
| **TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY** | $**33699** |

---

(1) Includes an aggregate of up to 225,000 ordinary shares that
are subject to forfeiture depending on the extent to which the underwriter's over-allotment option is exercised (Note 5).

 

*The accompanying notes are an integral part of these financial statements.*

**JATT II ACQUISITION CORP STATEMENT OF OPERATIONS FOR THE PERIOD FROM JANUARY 13, 2026 (INCEPTION) THROUGH FEBRUARY 13, 2026**

---

| | |
|:---|:---|
| Formation, general and administrative expenses | $19587 |
| &nbsp;&nbsp;&nbsp;**Net loss** | $**(19587)** |
| Weighted average ordinary shares outstanding, basic and diluted<sup>(1)</sup> | 1500000 |
| **Basic and diluted net loss per ordinary share** | $**(0.01)** |

---

(1) Excludes an aggregate of up to 225,000 ordinary shares that
are subject to forfeiture depending on the extent to which the underwriter's over-allotment option is exercised (Note 5).

 

*The accompanying notes are an integral part of these financial statements.*

**JATT II ACQUISITION CORP STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY FOR THE PERIOD FROM JANUARY 13, 2026 (INCEPTION) THROUGH FEBRUARY 13, 2026**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Ordinary Shares** | **Ordinary Shares** | | | |
|  | **Shares** | **Amount** | **Additional<br> Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Total<br> Shareholder's**<br>**Equity** |
| **Balance at January 13, 2026 (inception)** |  | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;Issuance of ordinary shares to Sponsor<sup>(1)</sup> | 1725000 | 173 | 24827 |  | 25000 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  | (19587) | (19587) |
| **Balance at February 13, 2026** | **1725000** | $**173** | $**24827** | $**(19587)** | $**5413** |

---

(1) Includes an aggregate of up to 225,000 ordinary shares that
are subject to forfeiture depending on the extent to which the underwriter's over-allotment option is exercised (Note 5).

 

*The accompanying notes are an integral part of these financial statements.*

**JATT II ACQUISITION CORP STATEMENT OF CASH FLOWS FOR THE PERIOD FROM JANUARY 13, 2026 (INCEPTION) THROUGH FEBRUARY 13, 2026**

---

| | |
|:---|:---|
| **Cash Flows from Operating Activities:** | |
| Net loss | $(19587) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |
| Payment of formation, general and administrative expenses through the promissory note – related party | 12920 |
| Changes in operating liabilities: |  |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 6667 |
| &nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | **—** |
| **Net Change in Cash** | **—** |
| Cash – Beginning of period |  |
| **Cash – End of period** | $**—** |
| **Supplemental disclosure of non-cash investing and financing activities:** |  |
| Deferred offering costs included in accrued offering costs | $8619 |
| Prepaid expenses paid by Sponsor through promissory note-related party | $80 |
| Deferred offering costs paid by Sponsor in exchange for issuance of ordinary shares | $25000 |

---

 

*The accompanying notes are an integral part of these financial statements.*

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 1 — ORGANIZATION AND PLAN OF BUSINESS OPERATIONS**

JATT II Acquisition Corp (the "Company") is a blank check company incorporated as a Cayman Islands exempted company on January 13, 2026. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a "Business Combination"). The Company will have 24 months from the closing of this offering to complete the initial business combination (the "completion window"). The Company has not selected any specific business combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company.

As of February 13, 2026, the Company had not commenced any operations. All activity for the period from January 13, 2026 (inception) through February 13, 2026 relates to the Company's formation and the proposed initial public offering ("Proposed Public Offering"), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Proposed Public Offering. The Company has selected December 31 as its fiscal year end.

The Company's ability to commence operations is contingent upon obtaining adequate financial resources through a Proposed Public Offering of 6,000,000 Ordinary Shares (the "Public Shares") at $10.00 per Public Share (or 6,900,000 Public Shares if the underwriters' over-allotment option is exercised in full), which is discussed in Note 3, and the sale of 300,000 private placement shares (or 309,000 private placement shares if the underwriters' over-allotment option is exercised in full) (the "Private Placement Shares") at a price of $10.00 per Private Placement Share in a private placement to JATT Ventures II L.P. (the "Sponsor"), that will close simultaneously with the Proposed Public Offering.

The Company's management has broad discretion with respect to the specific application of the net proceeds of the Proposed Public Offering and the sale of the Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The rules of Nasdaq require that the Company must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the trust account) at the time of the agreement to enter into the initial business combination. The Company anticipates structuring the initial business combination so that the post transaction company in which the public shareholders own shares will own or acquire 100% of the equity interests or assets of the target business or businesses. The Company may, however, structure the initial business combination such that the post transaction company owns or acquires less than 100% of such interests or assets of the target business in order to meet certain objectives of the target management team or shareholders or for other reasons, but the Company will only complete such business combination if the post transaction company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the "Investment Company Act"). There is no assurance that the Company will be able to successfully effect a Business Combination. Upon the closing of the Proposed Public Offering, management has agreed that $10.00 per Share sold in the Proposed Public Offering, including proceeds of the sale of the Private Placement Shares, will be held in a trust account ("Trust Account") and held in cash or invested in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earliest of (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company's shareholders, as described below.

The Company will provide the holders of the public shares (the "Public Shareholders") with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i) in connection with a general meeting called to approve the Business Combination or (ii) without a shareholder vote by means of

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 1 — ORGANIZATION AND PLAN OF BUSINESS OPERATIONS** (cont.)

a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (initially anticipated to be $10.00 per Public Share), including interest (less taxes paid or payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The per-share amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). The Public Shares will be recorded at redemption value and classified as temporary equity upon the completion of the Proposed Public Offering, in accordance with Accounting Standards Codification ("ASC") Topic 480, "Distinguishing Liabilities from Equity."

Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a "group" (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company's prior written consent.

The Sponsor, officers, directors and advisors have entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to the founder shares, Private Placement Shares and any Public Shares they may acquire during or after this offering in connection with the completion of the initial Business Combination or an earlier redemption in connection with the commencement of the procedures to consummate the initial Business Combination if the Company determines that it is desirable to facilitate the completion of the initial Business Combination; (ii) waive their redemption rights with respect to the founder shares, Private Placement Shares and any Public Shares they may acquire during or after this offering in connection with a shareholder vote to approve an amendment to the articles (A) to modify the substance or timing of the obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the public shares if the Company has not consummated an initial Business Combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity; (iii) waive their rights to liquidating distributions from the Trust Account with respect to the founder shares and Private Placement Shares if the Company fails to complete the initial Business Combination within the completion window, although they will be entitled to liquidating distributions from assets outside the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame and to liquidating distributions from assets outside the Trust Account; and (iv) vote any founder shares held by them, any Private Placement Shares held by them and any Public Shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of the initial Business Combination. If the Company submits the initial business combination to the public shareholders for a vote, the Company will complete the initial business combination only if it is approved by an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the holders of the shares present in person or by proxy and entitled to vote thereon at a general meeting of the Company.

The Company will have until (i) the period ending on the date that is 24 months from the closing of the Proposed Public Offering, or such earlier liquidation as the Company's board of directors may approve, in which the Company must complete an initial business combination or (ii) such other time period in which the Company must complete an initial business combination pursuant to an amendment to the Company's Amended and Restated Memorandum and Articles of Association. (However, if the Company has not completed a Business Combination within the Completion Window, the Company will as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the trust account (less taxes paid or payable and up to $100,000 of interest to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares, which redemption will constitute full and complete payment for the public shares and completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidation or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and subject to the other requirements of applicable law.

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 1 — ORGANIZATION AND PLAN OF BUSINESS OPERATIONS** (cont.)

The Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to the Founder Shares it will receive if the Company fails to complete a Business Combination within the Completion Window. However, if the Sponsor or any of its respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Completion Window. The underwriter has agreed to waive its rights to its deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Completion Window, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Proposed Public Offering price per Share ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company's independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $10.00 per Public Share (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share, due to reductions in the value of trust assets, less taxes payable and up to $100,000 of interest to pay dissolution expenses, provided that this liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and as to any claims under the Company's indemnity of the underwriter of the Proposed Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company's independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

**Going Concern Consideration**

As of February 13, 2026, the Company had no cash and a working capital deficit of $28,206. The Company expects to continue to incur significant costs in pursuit of its acquisition plans. In connection with the Company's assessment of going concern considerations in accordance with Accounting Standards Codification ("ASC") 205-40, "Presentation of Financial Statements — Going Concern," the Company lacks the financial resources it needs to sustain operations for a reasonable period of time, which is considered to be one year from the date of the issuance of the financial statements. This condition raises substantial doubt about the Company's ability to continue as a going concern. Management plans to address this uncertainty through the Proposed Public Offering as discussed in Note 3. There is no assurance that the Company's plans to raise capital will be successful. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES**

 ****

***Basis of Presentation***

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC").

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES** (cont.)

***Emerging Growth Company***

The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 ****

***Use of Estimates***

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 ****

***Deferred Offering Costs***

The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin ("SAB") Topic 5A, "Expenses of Offering." Deferred offering costs consist principally of professional and registration fees that are related to the Proposed Public Offering. ASC 470-20, "Debt with Conversion and Other Options," addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Offering costs allocated to Public Shares will be charged to temporary equity and offering costs allocated to Private Placement Shares will be charged to shareholder's equity. Should the Proposed Public Offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations.

 ****

***Income Taxes***

ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company's management determined that the Cayman Islands is the Company's major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of February 13, 2026, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES** (cont.)

The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company's tax provision was zero for the period presented.

 ****

***Net Loss per Ordinary Share***

Net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares issued and outstanding during the period, excluding ordinary shares subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of 225,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriter's over-allotment option is exercised (see Note 5).

At February 13, 2026, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented.

 ****

***Concentration of Credit Risk***

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times may exceed the Federal Deposit Insurance Coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

 ****

***Fair Value of Financial Instruments***

The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, "Fair Value Measurement," approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature.

 ****

***Derivative Financial Instruments***

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, "Derivatives and Hedging". For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The underwriter's over-allotment option is deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and will be accounted for as a liability pursuant to ASC 480.

 ****

***Recent Accounting Standards***

In November 2023, the FASB issued ASU 2023-07, "Segment reporting (Topic 280): Improvements to Reportable Segment Disclosures" ("ASU 2023-07"). The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 on January 13, 2026, the date of its inception.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 3 — PROPOSED PUBLIC OFFERING**

Pursuant to the Proposed Public Offering, the Company will offer for sale up to 6,000,000 Public Shares (or 6,900,000 Public Shares if the underwriter's over-allotment option is exercised in full) at a purchase price of $10.00 per Public Share.

**NOTE 4 — PRIVATE PLACEMENT**

The Sponsor has committed to purchase an aggregate of 300,000 Private Placement Shares (or 309,000 Private Placement Shares if the underwriter's over-allotment option is exercised in full) at a price of $10.00 per Private Placement Share, for an aggregate purchase price of $3,000,000 (or $3,090,000 if the underwriter's over-allotment option is exercised in full), in a private placement that will occur simultaneously with the closing of the Proposed Public Offering. A portion of the proceeds from the Private Placement Shares will be added to the proceeds from the Proposed Public Offering to be held in the Trust Account.

**NOTE 5 — RELATED PARTY TRANSACTIONS**

 ****

***Founder Shares***

On February 13, 2026, Sponsor paid $25,000 to cover certain offering costs of the Company in consideration for 1,725,000 ordinary shares (the "Founder Shares"). The Founder Shares include an aggregate of up to 225,000 shares that are subject to forfeiture depending on the extent to which the underwriter's over-allotment option is exercised, so that the number of Founder Shares will equal, on an as-converted basis, approximately 20% of the Company's issued and outstanding ordinary shares after the Proposed Public Offering (assuming the Sponsor does not purchase any Public Shares in the Proposed Public Offering and excluding the Private Placement Shares). Prior to closing of this offering, our management team will receive indirect interest in founder shares through membership interests in our sponsor, including (i) to our Chief Executive Officer, Dr. Someit Sidhu 150,000 founder shares for his services, (ii) to our Chief Financial Officer, Mr. Nicholas Fernandez 50,000 founder shares for his services, (iii) to each of our independent directors 25,000 founder shares for their board services, and (iv) to an independent consultant 25,000 founder shares for his services in connection to this offering.

The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earliest of (A) 180 days after the completion of a Business Combination subsequent to a Business Combination and (B) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their Public ordinary shares for cash, securities or other property.

 ****

***Administrative Support Agreement***

The Company intends to enter into an agreement, commencing on the date that the securities are first listed on the Nasdaq through the earlier of the Company's consummation of a Business Combination and its liquidation, to pay the Sponsor or its affiliates, a total of $20,000 per month for officer compensation and administrative services.

 ****

***Promissory Note — Related Party***

On February 12, 2026, the Sponsor entered into an agreement to loan the Company an aggregate of up to $300,000 to be used for a portion of the expenses of the Proposed Public Offering. The loan is non-interest bearing, unsecured and due at the earlier of the closing of the Proposed Public Offering or the date on which the Company determines not to conduct a Proposed Public Offering. As of February 13, 2026, the Company had borrowed $13,000 under the promissory note.

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**NOTE 5 — RELATED PARTY TRANSACTIONS** (cont.)

***Related Party Loans***

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company's officers and directors may, but are not obligated to, loan the Company funds as may be required ("Working Capital Loans"). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender's discretion, up to $1,500,000 of such Working Capital Loans may be convertible into private placement shares of the post-Business Combination entity at a price of $10.00 per share. The shares would be identical to the Private Placement Shares. As of February 13, 2026, the Company had no outstanding borrowings under the Working Capital Loans.

**NOTE 6 — COMMITMENTS AND CONTINGENCIES**

 ****

***Registration Rights***

The holders of the Founder Shares, Private Placement Shares and any shares that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed before or on the effective date of the Proposed Public Offering. The holders of these securities will be entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain piggyback registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company's securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 ****

***Underwriting Agreement***

The Company will grant the underwriter a 45-day option to purchase up to 900,000 additional Public Shares to cover over-allotments at the Proposed Public Offering price, less the underwriting discounts and commissions.

The underwriter will be entitled to a cash underwriting discount of $0.10 per Public Share, or $600,000 in the aggregate (or $690,000 if the underwriter's over-allotment option is exercised in full), payable upon the closing of the Proposed Public Offering. In addition, the underwriter will be entitled to a deferred fee of $0.30 per Share, or $1,800,000 in the aggregate (or $2,070,000 in the aggregate if the underwriter's over-allotment option is exercised in full). The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

**NOTE 7 — SHAREHOLDER'S EQUITY**

 ****

***Preference Shares*** — The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company's board of directors. At February 13, 2026, there were no preference shares issued or outstanding.

 ****

***Ordinary Shares*** — The Company is authorized to issue 200,000,000 ordinary shares, with a par value of $0.0001 per share. At February 13, 2026, there were 1,725,000 ordinary shares issued and outstanding, of which an aggregate of up to 225,000 shares are subject to forfeiture depending on the extent to which the underwriter's over-allotment option is exercised, so that the number of ordinary shares will equal 20% of the Company's issued and outstanding ordinary shares after the Proposed Public Offering (assuming the Sponsor does not purchase any Public Shares in the Proposed Public Offering and excluding the Private Placement Shares).

The Founder Shares will automatically convert into ordinary shares at the time of a Business Combination or earlier at the option of the holders.

**JATT II ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS FEBRUARY 13, 2026**

**Note 8 — SEGMENT INFORMATION**

ASC Topic 280, "Segment Reporting," establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the Company's CODM, or group, in deciding how to allocate resources and assess performance.

The Company's CODM has been identified as the Chief Executive Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reporting segment.

The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the statement of operations as net income or loss. The measure of segment assets is reported on the balance sheet as total assets. When evaluating the Company's performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:

---

| | |
|:---|:---|
|  | **February 13, <br> 2026** |
| Deferred offering costs | $33619 |

---

---

| | |
|:---|:---|
|  | **For the <br> Period from <br> January 13, <br> 2026 <br> (Inception) <br> through <br> February 13, <br> 2026** |
| Formation, general and administrative expenses | $19587 |

---

Formation, general and administrative expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a Proposed Public Offering and eventually a Business Combination within the business combination period. The CODM also reviews formation, general and administrative expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. Formation, general and administrative expenses are the significant segment expenses regularly provided to the CODM.

**NOTE 9 — SUBSEQUENT EVENTS**

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to March 13, 2026, the date that the financial statements were available to be issued. Based upon this review, other than noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Through the date of this filing, the Company has drawn an additional $69,636 from the promissory note. The aggregate outstanding from the promissory note is $82,636.

**PART II**

**Information not Required in Prospectus**

**Item 13. Other Expenses of Issuance and Distribution.**

The estimated expenses payable by us in connection with the offering described in this registration statement (other than the underwriting discount and commissions) will be as follows:

---

| | |
|:---|:---|
| Initial trustee fee | $75000 |
| Legal fees and expenses | $250000 |
| Printing and engraving expenses | $35000 |
| Accounting fees and expenses | $50000 |
| Nasdaq filing fees | $75000 |
| SEC registration fee | 9529 |
| FINRA registration fee | 10850 |
| Miscellaneous | $394621 |
| Total | $900000 |

---

(1) This amount represents the approximate amount of annual directors'
and officers' liability insurance premiums the registrant anticipates paying following the completion of its initial public offering
and until it completes an initial business combination.

**Item 14. Indemnification of Directors and Officers.**

Cayman Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences of committing a crime. Our articles will provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect. We may purchase a policy of directors' and officers' liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.

Our officers and directors have agreed to waive any right, title, interest or claim of any kind in or to any monies in the trust account, and have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not seek recourse against the trust account for any reason whatsoever. Accordingly, any indemnification provided will only be able to be satisfied by us if (i) we have sufficient funds outside of the trust account or (ii) we consummate an initial business combination.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

**Item 15. Recent Sales of Unregistered Securities.**

On February 12, 2026, our sponsor paid $25,000, or approximately $0.014 per share, to cover certain offering costs, in exchange for 1,725,000 founder shares.

Such securities were issued in connection with our organization pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 6,900,000 ordinary shares if the underwriters' over-allotment option is exercised in full and therefore that such founder shares would represent 20% of the outstanding shares after this offering (excluding private placement shares). Up to 225,000 of these shares will be surrendered for no consideration depending on the extent to which the underwriter's over-allotment is exercised.

Such securities were issued in connection with our organization pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. Our sponsor is an accredited investor for purposes of Rule 501 of Regulation D.

Our sponsor has committed to purchase an aggregate of 300,000 private placement shares (or 309,000 private placement shares if the underwriters' over-allotment option is exercised in full), at a price of $10.00 per share, or $3,000,000 in the aggregate (or $3,090,000 if the underwriters' over-allotment option is exercised in full), in a private placement that will close simultaneously with the closing of this offering. This purchase will take place on a private placement basis simultaneously with the completion of our initial public offering. Any such issuances will be made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

No underwriting discounts or commissions were paid with respect to such sales.

**Item 16. Exhibits and Financial Statement Schedules.**

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1 | [Form of Underwriting Agreement.](ea028469001ex1-1.htm) |
| 3.1 | [Memorandum and Articles of Association.](ea028469001ex3-1.htm) |
| 3.2 | [Amendment to Memorandum and Articles of Association.](ea028469001ex3-2.htm) |
| 3.3 | [Form of Amended and Restated Memorandum and Articles of Association.](ea028469001ex3-3.htm) |
| 4.1 | [Specimen Ordinary Share Certificate.](ea028469001ex4-1.htm) |
| 5.1 | [Opinion of Appleby (Cayman) Ltd., Cayman Islands legal counsel to the Registrant.](ea028469001ex5-1.htm) |
| 10.1 | [Form of Letter Agreement among the Registrant, JATT Ventures II L.P. and each of the officers and directors of the Registrant.](ea028469001ex10-1.htm) |
| 10.2 | [Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant.](ea028469001ex10-2.htm) |
| 10.3 | [Form of Registration Rights Agreement among the Registrant, JATT Ventures II L.P. and the Holders signatory thereto.](ea028469001ex10-3.htm) |
| 10.4 | [Form of Private Placement Shares Purchase Agreement among the Registrant and JATT Ventures II L.P.](ea028469001ex10-4.htm) |
| 10.5 | [Form of Administrative Services and Indemnification Agreement.](ea028469001ex10-5.htm) |
| 10.6 | [Promissory Note issued to JATT Ventures II L.P.](ea028469001ex10-6.htm) |
| 10.7 | [Securities Subscription Agreement between JATT Ventures II L.P. and the Registrant.](ea028469001ex10-7.htm) |
| 10.8 | [Form of Indemnity Agreement](ea028469001ex10-8.htm) |
| 14.1 | [Form of Code of Business Conduct and Ethics.](ea028469001ex14-1.htm) |
| 23.1 | [Consent of WithumSmith+Brown, PC.](ea028469001ex23-1.htm) |
| 23.2 | [Consent of Appleby (Cayman) Ltd. (included on Exhibit 5.1).](ea028469001ex5-1.htm) |
| 24.1 | [Power of Attorney.](#poa_001) |
| 99.1 | [Form of Clawback Policy](ea028469001ex99-1.htm) |
| 99.2 | [Consent of Verender S. Badial.](ea028469001ex99-2.htm) |
| 99.3 | [Consent of Christopher Staral.](ea028469001ex99-3.htm) |
| 99.4 | [Consent of Arjun Goyal.](ea028469001ex99-4.htm) |
| 99.5 | [Consent of Jonathon Kluft.](ea028469001ex99-5.htm) |
| 99.6 | [Form of Charter of Audit Committee.](ea028469001ex99-6.htm) |
| 99.7 | [Form of Charter of Compensation Committee.](ea028469001ex99-7.htm) |
| 99.8 | [Form of Charter of Nominating and Governance Committee.](ea028469001ex99-8.htm) |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| 107\* | [Filing Fee Table.](https://www.sec.gov/ix?doc=/Archives/edgar/data/2112446/000121390026027726/ea027924201ex-fee.htm) |

---

\* Previously filed.

**Item 17. Undertakings.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned registrant hereby undertakes to provide to
the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names
as required by the underwriters to permit prompt delivery to each purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Insofar as indemnification for liabilities arising under
the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The undersigned registrant hereby undertakes that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) For purposes of determining any liability under the Securities
Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon
Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under
the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the purpose of determining any liability under the Securities
Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) For the purpose of determining liability under the Securities
Act of 1933 of any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as
part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than
prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is
part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) For the purpose of determining liability of a registrant under
the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes
that in a primary offering of securities of an undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any free writing prospectus relating to the offering prepared
by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the portion of any other free writing prospectus relating
to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned
registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) any other communication that is an offer in the offering
made by the undersigned registrant to the purchaser.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Westfield, New Jersey on the 2nd day of April, 2026.

---

| | |
|:---|:---|
| **JATT II ACQUISITION CORP** | **JATT II ACQUISITION CORP** |
| By: | /s/ Someit Sidhu |
|  | Someit Sidhu |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Position** | **Date** |
| /s/ Someit Sidhu | Chairman and Chief Executive Officer | April 2, 2026 |
| Someit Sidhu | (Principal Executive Officer) |  |
| /s/ Nicholas Fernandez | Chief Financial Officer and Chief Operating Officer | April 2, 2026 |
| Nicholas Fernandez | (Principal Financial and Accounting Officer) |  |

---

**AUTHORIZED REPRESENTATIVE**

Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement, solely in its capacity as the duly authorized representative of JATT II Acquisition Corp, in Westfield, New Jersey, on the 2nd day of April, 2026.

---

| | |
|:---|:---|
| By: | /s/ Nicholas Fernandez |
|  | Nicholas Fernandez |
|  | Chief Financial Officer |

---

## Exhibit 1.1

**Exhibit 1.1**

**6,000,000 Ordinary Shares<br> JATT II Acquisition Corp**

**<u>UNDERWRITING AGREEMENT</u>**

[●], 2026

Guggenheim Securities, LLC

330 Madison Avenue

New York, NY 10017

As representative (the "**Representative**") of the several Underwriters named in <u>Schedule I</u> hereto

Ladies and Gentlemen:

JATT II Acquisition Corp, a Cayman Islands exempted company (the "**Company**"), proposes to sell to you and, as applicable, to the several underwriters named in <u>Schedule I</u> hereto (collectively, the "**Underwriters**"), for whom you (the "**Representative**") are acting as representative, 6,000,000 ordinary shares, par value $0.0001 per share, of the Company (the "**Ordinary Shares**") (said Ordinary Shares to be issued and sold by the Company being hereinafter called the "**Underwritten Securities**"). The Company also proposes to grant to the Underwriters an option to purchase up to 900,000 additional Ordinary Shares to cover over-allotments, if any (the "**Option Securities**"; the Option Securities, together with the Underwritten Securities, being hereinafter called the "**Securities**"). To the extent there are no additional Underwriters listed on <u>Schedule I</u> other than you, the term Representative as used herein shall mean you, as Underwriter, and the term Underwriter shall mean either the singular or plural as the context requires. Certain capitalized terms used herein and not otherwise defined are defined in Section 21 hereof.

As used herein, the term "**Business Combination**" (as described more fully in the Registration Statement) shall mean a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

The Company has entered into an Investment Management Trust Agreement, effective as of [●], 2026, with Continental Stock Transfer & Trust Company ("**CST**"), as trustee, in substantially the form filed as Exhibit 10.2 to the Registration Statement (the "**Trust Agreement**"), pursuant to which certain proceeds from the sale of the Private Placement Shares (as defined below) and certain proceeds of the Offering will be deposited and held in a trust account (the "**Trust Account**") for the benefit of the Company, the Underwriters and the holders of the Underwritten Securities and the Option Securities, if and when issued.

The Company has entered into a Securities Subscription Agreement, dated as of February 13, 2026 (the "**Securities Subscription Agreement**"), with JATT Ventures II L.P., a Cayman Islands exempted limited partnership (the "**Sponsor**"), in substantially the form filed as Exhibit 10.7, pursuant to which the Sponsor purchased an aggregate of 1,725,000 Ordinary Shares of the Company (the "**Founder Shares**") for an aggregate purchase price of $25,000.

The Company has entered into a Private Placement Shares Purchase Agreement, effective as of [●], 2026 (the "**Private Placement Agreement**"), with the Sponsor, in substantially the form filed as Exhibit 10.4 to the Registration Statement, pursuant to which the Sponsor agreed to purchase 300,000 Ordinary Shares (or 309,000 Ordinary Shares if the Underwriters' over-allotment option is exercised in full) (the "**Private Placement Shares**") at a price of $10.00 per Private Placement Share.

The Company has entered into a Registration Rights Agreement, dated as of [●], 2026, with the Sponsor and the shareholders signatory thereto, in substantially the form filed as Exhibit 10.3 to the Registration Statement (the "**Registration Rights Agreement**"), pursuant to which the Company has granted certain registration rights in respect of the Founder Shares and Private Placement Shares as described in the Prospectus.

The Company has caused to be duly executed and delivered a letter agreement, dated [●], 2026, by and among the Sponsor and each of the Company's officers, directors and director nominees, in substantially the form filed as Exhibit 10.1 to the Registration Statement (the "**Letter Agreement**").

The Company has entered into an Administrative Services and Indemnification Agreement, dated as of [●], 2026, with an affiliate of the Sponsor, in substantially the form filed as Exhibit 10.8 to the Registration Statement (the "**Administrative Services Agreement**"), pursuant to which the Company will pay to such affiliate of the Sponsor an aggregate monthly fee of $20,000 for certain office space, utilities and secretarial and administrative support.

1. <u>REPRESENTATIONS AND WARRANTIES.</u>

The Company represents and warrants to, and agrees with, each Underwriter as set forth below in this Section 1.

(a) The Company has prepared and filed with the Commission the Registration Statement (file number 333-294294)
on Form S-1, including the related Preliminary Prospectus, for registration under the Act of the offering and sale of the Securities.
Such Registration Statement, including any amendments thereto filed prior to the Execution Time, has become effective. The Company has
filed one or more amendments thereto, including the related Preliminary Prospectus, each of which has previously been furnished to you.
The Company will file with the Commission the Prospectus in accordance with Rule 424(b). As filed, such Prospectus shall contain all information
required by the Act and, except to the extent the Representative shall agree in writing to a modification, shall be in all substantive
respects in the form furnished to you prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain
only such specific additional information and other changes (beyond that contained in the latest Preliminary Prospectus) as the Company
has advised you, prior to the Execution Time, will be included or made therein. The Company has complied to the Commission's satisfaction
with all requests of the Commission for additional or supplemental information.

(b) On the Effective Date, the Registration Statement did, and when the Prospectus is first filed in accordance
with Rule 424(b) and on the Closing Date (as defined herein) and on any date on which Option Securities are purchased, if such date is
not the Closing Date (a "**settlement date** "), the Prospectus (and any supplement thereto) will comply in all material
respects with the applicable requirements of the Act; on the Effective Date and at the Execution Time, the Registration Statement did
not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading; as of the Applicable
Time and on the Closing Date and any settlement date, any individual Written Testing-the-Waters Communication (as defined herein) did
not conflict with the information contained in the Registration Statement or the Statutory Prospectus, complied in all material respects
with the Act, when considered together with the Statutory Prospectus, and did not and will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading; and on the date of any filing pursuant to Rule 424(b) and on the Closing
Date and any settlement date, the Prospectus (together with any supplement thereto) will not include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; <u>provided</u>, <u>however</u>, that the Company makes no representations or warranties as to the information
contained in or omitted from the Registration Statement or the Prospectus (or any supplement thereto) in reliance upon and in conformity
with information furnished in writing to the Company by or on behalf of any Underwriter through the Representative specifically for inclusion
in the Registration Statement or the Prospectus (or any supplement thereto), it being understood and agreed that the only such information
furnished by any Underwriter consists of the information described as such in Section 8(b) hereof.

(c) The Statutory Prospectus, as of the Applicable Time and on the Closing Date and any settlement date, did
not and will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; <u>provided</u>, <u>however</u>, that the Company
makes no representations or warranties as to the information contained in or omitted from the Statutory Prospectus in reliance upon and
in conformity with written information furnished to the Company by or on behalf of any Underwriter through the Representative specifically
for use therein, it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of
the information described as such in Section 8(b) hereof.

(d) The Company has filed with the Commission a Form 8-A (file number 001-[•]) providing for the registration
under the Exchange Act of the Securities, which registration is currently effective on the date hereof. The Securities have been authorized
for listing, subject to official notice of issuance and evidence of satisfactory distribution, on the Nasdaq Global Market ()"**Nasdaq** "),
and the Company knows of no reason or set of facts that is likely to adversely affect such authorization.

(e) The Commission has not issued any order or, to the Company's knowledge, threatened to issue any
order preventing or suspending the effectiveness of the Registration Statement or the use of any Preliminary Prospectus, the Prospectus
or any part thereof, and has not instituted or, to the Company's knowledge, threatened to institute any proceedings with respect
to such an order.

(f) (i) At the time of filing the Registration Statement and (ii) as of the Execution Time (with such date
being used as the determination date for purposes of this clause (ii)), the Company was and is an Ineligible Issuer (as defined in Rule
405).

(g) The Company has not prepared or used a Free Writing Prospectus.

(h) The Company has been duly incorporated and is validly existing as an exempted company in the Cayman Islands
and is in good standing under the laws of the Cayman Islands with full corporate power and authority to own or lease, as the case may
be, and to operate its properties and conduct its business as described in the Statutory Prospectus and the Prospectus and to enter into
this Agreement, the Trust Agreement, the Securities Subscription Agreement, the Private Placement Agreement, the Registration Rights Agreement,
the Letter Agreement and the Administrative Services Agreement and to carry out the transactions contemplated hereby and thereby, and
is duly qualified to do business as a foreign corporation and is in good standing under the laws of each jurisdiction that requires such
qualification.

(i) There is no franchise, contract or other document of a character required to be described in the Registration
Statement or Prospectus, or to be filed as an exhibit thereto, which is not described or filed as required (and the Statutory Prospectus
contains in all material respects the same description of the foregoing matters contained in the Prospectus); and the statements in the
Statutory Prospectus and the Prospectus under the headings "**Principal Shareholders,**" "**Certain Relationships and Related Party Transactions,**" and "**Description of Securities**" insofar as such statements summarize legal
matters, agreements, documents or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements, documents
or proceedings. There are no business relationships or related party transactions involving the Company or any other person required by
the Act to be described in the Registration Statement or Prospectus that have not been described as required.

(j) The Company's authorized share capital is as set forth in the Statutory Prospectus, the Prospectus
and the Amended and Restated Memorandum and Articles of Association of the Company (the "**Amended and Restated Memorandum and Articles of Association** ").

(k) All issued and outstanding shares of the Company have been duly and validly authorized and issued and
are fully paid and non-assessable (meaning that the holder thereof shall not, solely by virtue of its status as a shareholder, be liable
for additional assessments or calls on such shares by the Company or its creditors (except in exceptional circumstances, such as involving
fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstance in which a court may be prepared
to pierce or lift the corporate veil)); and none of such shares were issued in violation of the preemptive rights of any holders of any
security of the Company or similar contractual rights granted by the Company. The offers and sales of the Founder Shares and Private Placement
Shares were at all relevant times either registered under the Act, the applicable state securities and blue sky laws or, based in part
on the representations and warranties of the purchasers of such Founder Shares and Private Placement Shares, exempt from such registration
requirements. The holders of outstanding shares or other securities of the Company are not entitled to preemptive or other rights to subscribe
for the Securities arising by operation of law or under the Amended and Restated Memorandum and Articles of Association; and, except as
set forth in the Statutory Prospectus and the Prospectus, no options, warrants or other rights to purchase, agreements or other obligations
to issue, or rights to convert any obligations into or exchange any securities for, shares of capital stock of or other ownership interests
in the Company are outstanding.

(l) The Securities have been duly authorized and reserved for issuance and when issued and delivered against
payment for the Securities by the Underwriters pursuant to this Agreement (including the registration of the share issuance in the Company's
register of members as fully paid), will be validly issued, fully paid and non-assessable (meaning that the holder thereof shall not,
solely by virtue of its status as a shareholder, be liable for additional assessments or calls on such shares by the Company or its creditors
(except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose
or other circumstance in which a court may be prepared to pierce or lift the corporate veil)).

(m) Except as set forth in the Statutory Prospectus, the Prospectus and the Amended and Restated Memorandum
and Articles of Association, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable
into securities of the Company have the right to require the Company to register any such securities of the Company under the Act or to
include any such securities in a registration statement to be filed by the Company.

(n) No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of,
any person or persons controlling, controlled by, or under common control with the Company from its inception through and including the
date hereof, except as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus.

(o) Neither the Company nor any of its affiliates has, prior to the date hereof, made any offer or sale of
any securities that are required to be "integrated" pursuant to the Act with the offer and sale of the Underwritten Securities
pursuant to the Registration Statement.

(p) The Founder Shares are duly authorized, validly issued, fully paid non-assessable (meaning that the holder
thereof shall not, solely by virtue of its status as a shareholder, be liable for additional assessments or calls on such shares by the
Company or its creditors (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or
an illegal or improper purpose or other circumstance in which a court may be prepared to pierce or lift the corporate veil)).

(q) The Private Placement Shares have been duly authorized and, when executed by the Company and countersigned,
and issued and delivered against payment for the Private Placement Shares by the Sponsor pursuant to the Private Placement Agreement (including
the registration of the share issuance in the Company's register of members as fully paid), will be validly issued, fully paid and
non-assessable (meaning that the holder thereof shall not, solely by virtue of its status as a shareholder, be liable for additional assessments
or calls on such shares by the Company or its creditors (except in exceptional circumstances, such as involving fraud, the establishment
of an agency relationship or an illegal or improper purpose or other circumstance in which a court may be prepared to pierce or lift the
corporate veil)).

(r) This Agreement has been duly authorized, executed and delivered by the Company and is a valid and binding
agreement of the Company, enforceable against the Company in accordance with its terms except as the enforceability thereof may be limited
by bankruptcy, insolvency, or similar laws affecting creditors' rights generally from time to time in effect and by equitable principles
of general applicability.

(s) The Trust Agreement has been duly authorized, executed and delivered by the Company, and is a valid and
binding agreement of the Company, enforceable against the Company, in accordance with its terms except as the enforceability thereof may
be limited by bankruptcy, insolvency, or similar laws affecting creditors' rights generally from time to time in effect and by equitable
principles of general applicability.

(t) The Securities Subscription Agreement has been duly authorized, executed and delivered by the Company
and the Sponsor, and is a valid and binding agreement of the Company and the Sponsor, enforceable against the Company and the Sponsor
in accordance with its terms except as the enforceability thereof may be limited by bankruptcy, insolvency, or similar laws affecting
creditors' rights generally from time to time in effect and by equitable principles of general applicability.

(u) The Private Placement Agreement has been duly authorized, executed and delivered by the Company, and is
a valid and binding agreement of the Company, enforceable against the Company and the Sponsor in accordance with its terms except as the
enforceability thereof may be limited by bankruptcy, insolvency, or similar laws affecting creditors' rights generally from time
to time in effect and by equitable principles of general applicability.

(v) [ *Intentionally omitted.* ]

(w) The Registration Rights Agreement has been duly authorized, executed and delivered by the Company and
is a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms except as the enforceability
thereof may be limited by bankruptcy, insolvency, or similar laws affecting creditors' rights generally from time to time in effect
and by equitable principles of general applicability.

(x) The Letter Agreement executed by the Company, the Sponsor and, to the Company's knowledge, each
executive officer, director and director nominee of the Company, has been duly authorized, executed and delivered by the Company, the
Sponsor and, to the Company's knowledge, each such executive officer, director and director nominee, respectively, and is a valid
and binding agreement of the Company, the Sponsor and, to the Company's knowledge, each such executive officer, director and director
nominee, respectively, enforceable against the Company, the Sponsor and, to the Company's knowledge, each such executive officer,
director and director nominee, respectively, in accordance with its terms except as the enforceability thereof may be limited by bankruptcy,
insolvency or similar laws affecting creditors' rights generally from time to time in effect and by equitable principles of general
applicability.

(y) The Administrative Services Agreement has been duly authorized, executed and delivered by the Company
and, assuming the due authorization, execution and delivery thereof by the affiliate of the Sponsor party thereto, is a valid and binding
agreement of the Company, enforceable against the Company in accordance with its terms except as the enforceability thereof may be limited
by bankruptcy, insolvency or similar laws affecting creditors' rights generally from time to time in effect and by equitable principles
of general applicability.

(z) The Company is not and, after giving effect to the offering and sale of the Securities and the application
of the proceeds thereof as described in the Statutory Prospectus and the Prospectus, will not be an "investment company" as
defined in the Investment Company Act of 1940, as amended.

(aa) No consent, approval, authorization, filing with or order of any court or governmental agency or body
is required in connection with the transactions contemplated herein or in the Trust Agreement, the Securities Subscription Agreement,
the Private Placement Agreement, the Registration Rights Agreement, the Letter Agreement or the Administrative Services Agreement, except
for the registration under the Act and the Exchange Act of the Securities and such as may be required under state securities or blue sky
laws of any jurisdiction in connection with the purchase and distribution of the Securities by the Underwriters in the manner contemplated
herein and in the Statutory Prospectus and the Prospectus.

(bb) The Company is not in violation or default of (i) any provision of its Amended and Restated Memorandum
and Articles of Association, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement
or other agreement, obligation, condition, covenant or instrument to which it is a party or bound or to which its property is subject,
or (iii) any (x) statute, law, rule, regulation, or (y) judgment, order or decree of any court, regulatory body, administrative agency,
governmental body, arbitrator or other authority having jurisdiction over the Company; except in the case of clauses (ii) and (iii) above
for any such conflict, breach or violation that would not, individually or in the aggregate, be reasonably expected to have a material
adverse effect on the financial condition, prospects, earnings, business or properties of the Company, taken as a whole, whether or not
arising from transactions in the ordinary course of business (a "**Material Adverse Effect** ").

(cc) Neither the issue and sale of the Securities nor the consummation of any other of the transactions herein
contemplated nor the fulfillment of the terms hereof or of the Trust Agreement, the Securities Subscription Agreement, the Private Placement
Agreement, the Registration Rights Agreement, the Letter Agreement or the Administrative Services Agreement will conflict with, result
in a breach or violation of, or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to,
(i) the Amended and Restated Memorandum and Articles of Association, (ii) the terms of any indenture, contract, lease, mortgage, deed
of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party
or bound or to which the Company's property is subject, or (iii) any statute, law, rule, or regulation, judgment, order or decree
applicable to the Company of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having
jurisdiction over the Company or any of its respective properties.

(dd) No holders of securities of the Company have rights to the registration of such securities under the Registration
Statement.

(ee) The historical financial statements, including the notes thereto and the supporting schedules, if any,
of the Company included in the Registration Statement, the Statutory Prospectus and the Prospectus present fairly the financial condition,
results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form with the applicable
accounting requirements of the Act and have been prepared in conformity with generally accepted accounting principles applied on a consistent
basis throughout the periods involved (except as otherwise noted therein). The Company is not party to any off-balance sheet transactions,
arrangements, obligations (including contingent obligations), or other relationships with unconsolidated entities or other persons that
may have a material current or future effect on the Company's financial condition, changes in financial condition, results of operations,
liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. The statistical, industry-related
and market-related data included in the Registration Statement, the Statutory Prospectus and the Prospectus are based on or derived from
sources that the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which
they are derived.

(ff) No action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or the Sponsor, or the property of either of them is pending or, to the knowledge of the Company, threatened
that (i) could reasonably be expected to have a material adverse effect on the performance of this Agreement or the consummation of any
of the transactions contemplated hereby by the Company or (ii) could reasonably be expected to have a Material Adverse Effect, except
as set forth in or contemplated in the Statutory Prospectus and the Prospectus (exclusive of any supplement thereto).

(gg) The Company owns or leases all such properties as are necessary to the conduct of its operations as presently
conducted.

(hh) WithumSmith+Brown, PC ()"**WithumSmith** "), who have certified certain financial statements
of the Company and delivered their report with respect to the audited financial statements and schedules included in the Registration
Statement, Statutory Prospectus and the Prospectus, is a registered public accounting firm that is independent with respect to the Company
within the meaning of the Act and the Exchange Act and the applicable published rules and regulations thereunder.

(ii) The Company maintains effective "disclosure controls and procedures" (as defined under Rule
13a-15(e) under the Exchange Act to the extent required by such rule).

(jj) Solely to the extent that the Sarbanes Oxley Act of 2002, as amended, and the rules and regulations promulgated
by the Commission thereunder (the "**Sarbanes Oxley Act**") have been applicable to the Company, there is and has been
no failure on the part of the Company to comply in all material respects with the applicable provisions of the Sarbanes Oxley Act.

(kk) There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of
the Company's officers or directors, in their capacities as such, to comply with (as and when applicable), and immediately following
the Effective Date the Company will be in compliance with, Nasdaq rules. Further, there is and has been no failure on the part of the
Company or, to the knowledge of the Company, any of the Company's officers or directors, in their capacities as such, to comply
with (as and when applicable), and immediately following the Effective Date the Company will be in compliance with, the phase-in requirements
and all other provisions of Nasdaq's corporate governance requirements set forth in the Nasdaq rules.

(ll) There are no transfer, stamp, issue, registration, documentary or other similar taxes, duties, fees or
charges under U.S. federal law or the laws of any state, or any political subdivision thereof, or under the laws of any non-U.S. jurisdiction,
required to be paid in connection with the execution and delivery of this Agreement or the issuance or sale by the Company of the Securities.

(mm) The Company has filed all tax returns (including U.S. federal, state and non-U.S.) that are required to
be filed by it or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse
Effect) through the date hereof and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against
it, to the extent that any of the foregoing is due and payable, except for any such tax, assessment, fine or penalty that is currently
being contested in good faith and for which adequate reserves required by generally accepted accounting principles have been created with
respect thereto or as would not have a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement,
Statutory Prospectus and the Prospectus (exclusive of any supplement thereto).

(nn) The Company possesses all licenses, certificates, permits and other authorizations issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct its business, and the Company has not received any notice of proceedings
relating to the revocation or modification of any such license, certificate, authorization or permit that, singly or in the aggregate,
if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, except as set forth in or contemplated
in the Statutory Prospectus and the Prospectus (exclusive of any supplement thereto).

(oo) None of the Company, the Sponsor or, to the knowledge of the Company, any director, director nominee,
officer, agent, employee, affiliate or other person associated with or acting on behalf of the Company: (i) has used any corporate funds
for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) has made any direct
or indirect unlawful contribution or payment to any official of, or candidate for, or any employee of, any federal, state or foreign office
from corporate funds; (iii) has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment; or (iv)
is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the OECD Convention on
Bribery of Foreign Public Officials in International Business Transactions, the Foreign Corrupt Practices Act of 1977, as amended, and
the rules and regulations thereunder (collectively, the "**FCPA**") or any similar law or regulation to which the Company,
any director, director nominee, officer, agent, employee, affiliate or other person associated with or acting on behalf of the Company
is subject. The Company, the Sponsor and, to the knowledge of the Company, its directors, director nominees, officers, agents, employees
and affiliates have each conducted the business of the Company and their own businesses on behalf of the Company in compliance with the
FCPA and any applicable similar law or regulation and have instituted and maintain policies and procedures designed to ensure, and which
are reasonably expected to continue to ensure, continued compliance therewith.

(pp) The operations of the Company are and have been conducted at all times in compliance with applicable financial
record-keeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening
America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the Currency and Foreign
Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of jurisdictions where the Company conducts business,
the applicable rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the "**Money Laundering Laws**") and no action, suit or proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws
is pending or, to the knowledge of the Company, threatened.

(qq) None of the Company, the Sponsor or, to the knowledge of the Company, any director, director nominee,
officer, agent or affiliate of the Company is currently subject to any sanctions administered by the Office of Foreign Assets Control
of the U.S. Treasury Department ()"**OFAC** "), the U.S. Department of State, the United Nations Security Council ()"**UNSC** "),
the European Union (the "**EU** "), His Majesty's Treasury ()"**HMT**") or any similar sanctions imposed
by any other body, governmental or other, to which any of such persons is subject (collectively, "**other economic sanctions** ");
and the Company will not directly or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any sanctions administered by OFAC or other economic sanctions.

(rr) Except as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, the Company
(i) does not have any material lending or other relationship with any bank or lending affiliate of any of the Underwriters and (ii) does
not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate of
any of the Underwriters.

(ss) All information contained in the questionnaires (the "**Questionnaires**") completed by
the Sponsor and, to the knowledge of the Company, the Company's officers, directors and director nominees and provided to the Representative,
is true and correct and the Company has not become aware of any information that would cause the information disclosed in the Questionnaires
completed by the Sponsor or the Company's officers, directors and director nominees to become inaccurate and incorrect.

(tt) Except as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, prior
to the date hereof, the Company has not selected any business combination target and has not, nor has anyone on its behalf, initiated
any substantive discussions, directly or indirectly, with any business combination target.

(uu) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material
Adverse Effect, and except as described in the Registration Statement, the Statutory Prospectus and the Prospectus, to the knowledge of
the Company, (i) there has been no security breach or other security compromise of or relating to any of the Company's information
technology and computer systems, networks, hardware, software, data, trade secrets, or equipment; and (ii) the Company is presently in
compliance with all applicable laws, regulations, contractual obligations and internal policies relating to data privacy and security
or personally identifiable information.

(vv) Except as described in the Registration Statement, the Statutory Prospectus and the Prospectus, there
are no claims, payments, arrangements, contracts, agreements or understandings relating to the payment of a brokerage commission or finder's,
consulting, origination or similar fee by the Company or the Sponsor with respect to the sale of the Securities hereunder or any other
arrangements, agreements, or understandings of the Company, the Sponsor or any officer or director of the Company, or their respective
affiliates, that may affect the Underwriters' compensation, as determined by the Financial Industry Regulatory Authority, Inc. ()"**FINRA** ").

(ww) Except as described in the Registration Statement, the Statutory Prospectus and the Prospectus, the Company
has not made any direct or indirect payments (in cash, securities or any other "item of value" as defined in Rule 5110(c)(3)
of FINRA's Conduct Rules): (i) to any person, as a finder's fee, consulting fee, or otherwise, in consideration of such person
raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) to any person
that, to the Company's knowledge, has been accepted by FINRA as a member of FINRA (a "**Member** "); or (iii) to any
person or entity that, to the Company's knowledge, has any direct or indirect affiliation or association with any Member, within
the twelve months prior to the Effective Date, other than payments to the Underwriters pursuant to this Agreement.

(xx) Except as described in the Registration Statement, the Statutory Prospectus and the Prospectus, during
the period beginning 180 days prior to the initial filing of the Registration Statement and ending on the Effective Date, no Member and/or
any person associated or affiliated with a Member has provided any investment banking, financial advisory and/or consulting services to
the Company.

(yy) Except as disclosed in the FINRA questionnaires provided to the Representative (the "**FINRA Questionnaires** "),
to the Company's knowledge no officer, director, or beneficial owner of any class of the Company's securities (whether debt
or equity, registered or unregistered, regardless of the time acquired or the source from which derived) (any such individual or entity,
a "**Company Affiliate**") is a Member or a person associated or affiliated with a Member.

(zz) Except as disclosed in the FINRA Questionnaires, to the Company's knowledge, no Company Affiliate
is an owner of shares or other securities of any Member (other than securities purchased on the open market).

(aaa) No Company Affiliate has made a subordinated loan to any Member.

(bbb) Except as described in the Registration Statement, the Statutory Prospectus and the Prospectus, no proceeds
from the sale of the Underwritten Securities (excluding underwriting compensation as disclosed in the Registration Statement, Statutory
Prospectus and the Prospectus) will be paid by the Company to any Member, or any persons associated or affiliated with a Member.

(ccc) The Company has not issued any warrants or other securities, or granted any options, directly or indirectly,
to anyone who is a potential underwriter in the Offering or a related person (as defined by FINRA rules) of such an underwriter within
the earliest of the 180-day period prior to the initial filing date and the initial confidential submission date of the Registration Statement.

(ddd) No person to whom securities of the Company have been privately issued within the 180-day period prior
to the initial filing date of the Registration Statement has to the Company's knowledge any relationship or affiliation or association
with any Member.

(eee) To the Company's knowledge, no Member intending to participate in the Offering has a conflict of
interest with the Company. For this purpose, a "conflict of interest" means, if at the time of the Member's participation
in the Offering, any of the following applies: (A) the securities are to be issued by the Member; (B) the Company controls, is controlled
by or is under common control with the Member or the Member's associated persons; (C) at least 5% of the net offering proceeds,
not including underwriting compensation, are intended to be: (i) used to reduce or retire the balance of a loan or credit facility extended
by the Member, its affiliates and its associated persons, in the aggregate; or (ii) otherwise directed to the Member, its affiliates and
its associated persons, in the aggregate; or (D) as a result of the Offering and any transactions contemplated at the time of the Offering:
(i) the Member will be an affiliate of the Company; (ii) the Member will become publicly owned; or (iii) the Company will become a Member
or form a broker-dealer subsidiary. "Member intending to participate in the Offering" includes any associated person of a
Member that is participating in the Offering, any members of such associated person's immediate family, and any affiliate of a Member
that is participating in the Offering.

(fff) The Company has not taken, directly or indirectly, any action designed to or that would constitute or
that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of the Securities.

(ggg) The Company does not own an interest in any corporation, partnership, limited liability company, joint
venture, trust or other entity.

(hhh) No relationship, direct or indirect, exists between or among any of the Company or any affiliate of the
Company, on the one hand, and any director, director nominee, officer, shareholder, special advisor, customer or supplier of the Company
or any affiliate of the Company, on the other hand, which is required by the Act or the Exchange Act to be described in the Registration
Statement, Statutory Prospectus or the Prospectus that is not described as required. There are no outstanding loans, advances (except
normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company to or for the benefit
of any of the officers, directors or director nominees of the Company or any of their respective family members, except as disclosed in
the Registration Statement, Statutory Prospectus and the Prospectus. The Company has not extended or maintained credit, arranged for the
extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any director or officer of the Company.

(iii) The Company has not offered, or caused the Underwriters to offer, the Underwritten Securities to any person
or entity with the intention of unlawfully influencing: (a) a customer or supplier of the Company or any affiliate of the Company to alter
the customer's or supplier's level or type of business with the Company or such affiliate or (b) a journalist or publication
to write or publish favorable information about the Company or any such affiliate.

(jjj) Upon delivery and payment for the Ordinary Shares on the Closing Date, the Company will not be subject
to Rule 419 under the Act and none of the Company's outstanding securities will be deemed to be a "penny stock" as defined
in Rule 3a51-1 under the Exchange Act.

(kkk) From the time of the initial confidential submission of the Registration Statement to the Commission (or,
if earlier, the first date on which the Company engaged, directly or through any person authorized to act on its behalf, in any Testing-the-Waters
Communication) through the Execution Time, the Company has been and is an "emerging growth company," as defined in Section
2(a) of the Act (an "**Emerging Growth Company** "). "**Testing-the-Waters Communication**" means any oral
or written communication with potential investors undertaken in reliance on Section 5(d) of the Act.

(lll) The Company (i) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters
Communications with the consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule
144A under the Act or institutions that are accredited investors within the meaning of Rule 501 under the Act and (ii) has not authorized
anyone other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has
been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters
Communications other than those listed on <u>Schedule III</u> hereto. "**Written Testing-the-Waters Communication**" means
any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Act.

(mmm) Except as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, under
current laws and regulations of the Cayman Islands and any political subdivision thereof, all dividends and other distributions declared
and payable on the Securities may be paid by the Company to the holder thereof in United States dollars and all such payments made to
holders thereof or therein who are non-residents of the Cayman Islands will not be subject to income, withholding or other taxes under
laws and regulations of the Cayman Islands or any political subdivision or taxing authority thereof or therein and will otherwise be free
and clear of any other tax, duty, withholding or deduction in the Cayman Islands or any political subdivision or taxing authority thereof
or therein and without the necessity of obtaining any governmental authorization in the Cayman Islands or any political subdivision or
taxing authority thereof or therein.

(nnn) Except as expressly set forth in that certain letter agreement, dated March 6, 2026, among the Company,
the Sponsor and the Representative, and as described in the Registration Statement, the Statutory Prospectus and the Prospectus, the Company
does not have any expectation, understanding or agreement with any Underwriter for such Underwriter to provide any additional services
to the Company after the consummation of the Offering relating to the initial Business Combination, the financing thereof or other related
transactions. Any Underwriter's provision of any such additional services in connection with the initial Business Combination will
require the Company's separate engagement of such Underwriter in connection with the initial Business Combination and the entry
into a related written engagement agreement between such Underwriter and the Company setting forth the terms and conditions of the additional
services to be provided by such Underwriter to the Company.

Any certificate signed by any officer of the Company and delivered to the Representative or counsel for the Underwriters in connection with the Offering shall be deemed a representation and warranty by the Company, as to matters covered thereby, to each Underwriter.

2. <u>PURCHASE AND SALE</u>

(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set
forth, the Company agrees to sell to each Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company,
at a purchase price of $9.90 per Underwritten Security, the amount of the Underwritten Securities set forth opposite such Underwriter's
name in <u>Schedule I</u> hereto.

(b) Subject to the terms and conditions and in reliance upon the representations and warranties herein set
forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to 900,000 Option Securities
at $9.90 per Option Security. Said option may be exercised only to cover over-allotments in the sale of the Underwritten Securities by
the Underwriters. Said option may be exercised in whole or in part at any time on or before the 45th day after the date of the Prospectus
upon written notice by the Representative to the Company setting forth the number of Option Securities as to which the several Underwriters
are exercising the option and the settlement date. The number of Option Securities to be purchased by each Underwriter shall be based
upon the same percentage of the total number of the Option Securities to be purchased by the several Underwriters as such Underwriter
is purchasing of the Underwritten Securities, subject to such adjustments as the Representative in its absolute discretion shall make
to eliminate any fractional shares.

(c) In addition to the discount from the public offering price represented by the purchase price set forth
in the first sentence of Section 2(a) of this Agreement, the Company hereby agrees to pay to the Underwriters a deferred discount of $0.30
per Ordinary Share (including both Underwritten Securities and Option Securities) purchased hereunder (the "**Deferred Discount** ").
The Underwriters agree that, at the Company's sole and absolute discretion, up to $500,000 of the Deferred Discount may be paid
to third parties not participating in this offering that assist the Company in consummating its initial Business Combination. The Underwriters
hereby agree that if no Business Combination is consummated within the time period provided in the Amended and Restated Memorandum and
Articles of Association and the funds held under the Trust Agreement are distributed to the holders of the Ordinary Shares included in
the Securities sold pursuant to this Agreement (the "**Public Shareholders** "), (i) the Underwriters will forfeit any rights
or claims to the Deferred Discount and (ii) the trustee under the Trust Agreement is authorized to distribute the Deferred Discount to
the Public Shareholders on a pro rata basis.

(d) Notwithstanding anything to the contrary in this Agreement, each Underwriter may at any time prior to
an initial Business Combination and in its sole and absolute discretion, by written notice to the Company, elect to forfeit any right
or claim to its Deferred Discount, in which case the Company agrees to instruct the trustee not to pay such Underwriter its Deferred Discount
upon the consummation of an initial Business Combination. For the avoidance of doubt, any such election by an Underwriter shall be without
prejudice to any right or claim of any other Underwriter to its respective portion of the Deferred Discount or to any other right such
Underwriter may have under this Agreement. In addition, for the avoidance of doubt, the obligations of the Underwriters under this Agreement
shall be fully satisfied upon the payment of the purchase price for the Ordinary Shares purchased by the Underwriters on the date of the
closing of the Offering without any further conditions.

3. <u>DELIVERY AND PAYMENT</u>

Delivery of and payment for the Underwritten Securities and the Option Securities (if the option provided for in Section 2(b) hereof shall have been exercised on or before the second Business Day prior to the Closing Date) shall be made at 9:00 a.m., New York City time, on [●], 2026, or at such time on such later date at least two Business Days after the foregoing date as the Representative shall designate, which date and time may be postponed by agreement between the Representative and the Company or as provided in Section 9 hereof (such date and time of delivery and payment for the Securities being herein called the "**Closing Date**"). Delivery of the Securities shall be made to the Representative for the respective accounts of the several Underwriters against payment by the several Underwriters through the Representative of the purchase price thereof by wire transfer payable in same-day funds to account specified by the Company and to the Trust Account as described below in this Section 3. Delivery of the Underwritten Securities and the Option Securities shall be made through the facilities of The Depository Trust Company ("**DTC**") unless the Representative shall otherwise instruct.

(a) Payment for the Underwritten Securities shall be made as follows: $57,600,000 of the net proceeds for
the Underwritten Securities (including $1,800,000 of Deferred Discount) shall be deposited in the Trust Account pursuant to the terms
of the Trust Agreement along with such portion of the gross proceeds from the sale of the Private Placement Shares (the "**Base Private Placement Portion**") in order for the Trust Account to equal the product of the number of Underwritten Securities sold
and the Public Offering price per Ordinary Share as set forth on the cover of the Prospectus upon delivery to the Representative of the
Underwritten Securities through the facilities of DTC or, if the Representative has otherwise instructed, upon delivery to the Representative
of certificates (in form and substance satisfactory to the Representative) representing the Underwritten Securities, in each case for
the account of the Underwriters. The Underwritten Securities shall be registered in such name or names and in such authorized denominations
as the Representative may request in writing at least two Business Days prior to the Closing Date. If delivery is not made through the
facilities of DTC, the Company will permit the Representative to examine and package the Underwritten Securities for delivery, at least
one Business Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Underwritten Securities except upon
tender of payment by the Representative for all the Underwritten Securities. Payment by the Underwriters for the Underwritten Securities
is contingent on the (i) payment by the Sponsor to the Company for the Private Placement Shares and (ii) deposit of the Base Private Placement
Portion by or at the direction of the Company into the Trust Account, in each case at least one Business Day prior to the Closing Date.

(b) Payment for the Option Securities shall be made as follows: $9.90 per Option Security (including $0.30
per Option Security of Deferred Discount) shall be deposited in the Trust Account pursuant to the terms of the Trust Agreement along with
such portion of the gross proceeds from the sale of the applicable number of over-allotment Private Placement Shares (the "**Over-Allotment Private Placement Portion**") in order for the Trust Account to equal the product of the number of Option Securities sold and
the Public Offering price per Ordinary Share as set forth on the cover of the Prospectus upon delivery to the Representative of the Option
Securities through the facilities of DTC or, if the Representative has otherwise instructed, upon delivery to the Representative of certificates
(in form and substance satisfactory to the Representative) representing the Option Securities (or through the facilities of DTC), in each
case for the account of the Underwriters. The Option Securities shall be registered in such name or names and in such authorized denominations
as the Representative may request in writing at least two Business Days prior to the Closing Date. If delivery is not made through the
facilities of DTC, the Company will permit the Representative to examine and package the Option Securities for delivery, at least one
Business Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Option Securities except upon tender
of payment by the Representative for all the Option Securities. Payment by the Underwriters for the Option Securities is contingent on
the (i) payment by the Sponsor to the Company for the applicable number of over-allotment Private Placement Shares and (ii) deposit of
the Over-Allotment Private Placement Portion by or at the direction of the Company into the Trust Account, in each case at least one Business
Day prior to the Closing Date.

If the option provided for in Section 2 hereof is exercised after the second Business Day prior to the Closing Date, the Company will deliver the Option Securities (at the expense of the Company) to the Representative, at 330 Madison Avenue, New York, NY 10017, on the date specified by the Representative (which shall be at least three Business Days after exercise of said option) for the respective accounts of the several Underwriters, against payment by the several Underwriters through the Representative of the purchase price thereof to the Trust Account as described above in Section 3(b). If settlement for the Option Securities occurs after the Closing Date, the Company will deliver to the Representative on the settlement date for the Option Securities, and the obligation of the Underwriters to purchase the Option Securities shall be conditioned upon receipt of, supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and letters delivered on the Closing Date pursuant to Section 6 hereof.

4. <u>OFFERING BY UNDERWRITERS</u>

It is understood that the several Underwriters propose to offer the Securities for sale to the public as set forth in the Prospectus (the "**Offering**").

5. <u>AGREEMENTS</u>

The Company agrees with the several Underwriters that:

(a) Prior to the termination of the Offering, the Company will not file any amendment to the Registration
Statement or supplement to the Prospectus or any Rule 462(b) Registration Statement unless the Company has furnished you a copy for your
review prior to filing and will not file any such proposed amendment, supplement or Rule 462(b) Registration Statement to which you reasonably
object. The Company will cause the Prospectus, properly completed, and any supplement thereto, to be filed in a form approved by the Representative
with the Commission pursuant to the applicable paragraph of Rule 424(b) within the time period prescribed and will provide evidence satisfactory
to the Representative of such timely filing. The Company will promptly advise the Representative (i) when the Prospectus, and any supplement
thereto, shall have been filed (if required) with the Commission pursuant to Rule 424(b) or when any Rule 462(b) Registration Statement
or any Written Testing-the-Waters Communication shall have been filed with the Commission, (ii) when, prior to termination of the Offering,
any amendment to the Registration Statement shall have been filed or become effective, (iii) of any request by the Commission or its staff
for any amendment of the Registration Statement, any Rule 462(b) Registration Statement or any Written Testing-the-Waters Communication
or for any supplement to the Prospectus or for any additional information, (iv) of the issuance by the Commission of any stop order suspending
the effectiveness of the Registration Statement or any order preventing or suspending the use of the Preliminary Prospectus, the Prospectus
or any Written Testing-the-Waters Communication, or of the institution of any proceedings for that purpose or pursuant to Section 8A of
the Act and (v) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Securities
for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company shall use its best efforts
to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration Statement
and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief
from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or a new registration
statement and using its best efforts to have such amendment or new registration statement declared effective as soon as practicable.

(b) If, at any time prior to the filing of the Prospectus pursuant to Rule 424(b), any event or development
occurs as a result of which the Statutory Prospectus would include any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein in the light of the circumstances under which they were made at such time not misleading,
the Company will (i) notify promptly the Representative so that any use of the Statutory Prospectus may cease until it is amended or supplemented;
(ii) amend or supplement the Statutory Prospectus to correct such statement or omission; and (iii) supply any amendment or supplement
to you in such quantities as you may reasonably request.

(c) If, at any time when a prospectus relating to the Securities is required to be delivered under the Act
(including in circumstances where such requirement may be satisfied pursuant to Rule 172), any event or development occurs as a result
of which the Prospectus as then supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein in the light of the circumstances under which they were made at such time not misleading,
or if it shall be necessary to amend the Registration Statement or supplement the Prospectus to comply with the Act or the rules thereunder,
the Company promptly will (i) notify the Representative of any such event; (ii) prepare and file with the Commission, subject to the second
sentence of paragraph (a) of this Section 5, an amendment or supplement that will correct such statement or omission or effect such compliance;
and (iii) supply any supplemented Prospectus to you in such quantities as you may reasonably request.

(d) As soon as practicable, the Company will make generally available to its security holders and to the Representative
an earnings statement or statements of the Company and its subsidiaries that will satisfy the provisions of Section 11(a) of the Act and
Rule 158; <u>provided</u>, that the Company will be deemed to have furnished such statements to its security holders and the Representative
to the extent they are filed on the Commission's Electronic Data Gathering, Analysis, and Retrieval system ()"**EDGAR** ")
or any successor system.

(e) The Company will not make any offer relating to the Ordinary Shares that constitutes or would constitute
a Free Writing Prospectus or a portion thereof required to be filed by the Company with the Commission or retained by the Company under
Rule 433 of the Act.

(f) The Company will furnish to the Representative and counsel for the Underwriters, without charge, signed
copies of the Registration Statement (including exhibits thereto) and to each other Underwriter a copy of the Registration Statement (without
exhibits thereto) and, so long as delivery of a prospectus by an Underwriter or dealer may be required by the Act (including in circumstances
where such requirement may be satisfied pursuant to Rule 172), as many copies of each Preliminary Prospectus, the Prospectus and any supplement
thereto as the Representative may reasonably request. The Company will pay the expenses of printing or other production of all documents
relating to the Offering.

(g) The Company will arrange, if necessary, for the qualification of the Securities for sale under the laws
of such jurisdictions as the Representative may designate and will maintain such qualifications in effect so long as required for the
distribution of the Securities; <u>provided</u>, <u>however</u>, that in no event shall the Company be obligated to qualify to do business
in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other
than those arising out of the offering or sale of the Securities, in any jurisdiction where it is not now so subject.

(h) The Company will not, without the prior written consent of the Representative, (x) offer, sell, contract
to sell, pledge or otherwise dispose of (or enter into any transaction that is designed to, or might reasonably be expected to, result
in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company
or any affiliate of the Company or any person in privity with the Company or any affiliate of the Company), directly or indirectly, including
the filing (or participation in the filing) of a registration statement with the Commission in respect of, or establish or increase a
put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act with
respect to, any other Ordinary Shares or any securities convertible into, or exercisable, or exchangeable for, Ordinary Shares or publicly
announce an intention to effect any such transaction during the period commencing on the date hereof and ending 180 days after the date
of this Agreement; <u>provided</u>, <u>however</u>, that the Company may (1) issue and sell the Private Placement Shares, (2) issue and
sell the Option Securities on exercise of the option provided for in Section 2 hereof, (3) register with the Commission pursuant to the
Registration Rights Agreement, in accordance with the terms of the Registration Rights Agreement, the resale of the securities covered
thereby, and (4) issue securities in connection with a Business Combination or (y) release the Sponsor or any officer, director or director
nominee from the 180-day lock-up contained in the Letter Agreement; <u>provided</u>, that the foregoing restrictions shall not apply to
the forfeiture of any Founder Shares pursuant to the terms of the Letter Agreement or any transfer of Founder Shares to a current or future
independent director of the Company (as long as such current or future independent director is subject to the terms of the Letter Agreement
with respect to such Founder Shares at the time of such transfer).

(i) The Company will not take, directly or indirectly, any action designed to or that would constitute or
that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of the Securities.

(j) The Company agrees to pay the costs and expenses relating to the following matters: (i) the preparation,
printing or reproduction and filing with the Commission of the Registration Statement (including financial statements and exhibits thereto),
each Preliminary Prospectus, the Prospectus and each amendment or supplement to any of them; (ii) the printing (or reproduction) and delivery
(including postage, air freight charges and charges for counting and packaging) of such copies of the Registration Statement, each Preliminary
Prospectus, the Prospectus and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use in
connection with the offering and sale of the Securities; (iii) the preparation, printing, authentication, issuance and delivery of certificates
for the Securities, including any stamp or transfer taxes (but, in no event, taxes imposed on the net income of an Underwriter) in connection
with the original issuance and sale of the Securities; (iv) the printing (or reproduction) and delivery of this Agreement and all other
agreements or documents printed (or reproduced) and delivered in connection with the Offering; (v) the registration of the Securities
under the Exchange Act and the listing of the Securities on Nasdaq; (vi) the printing and delivery of a preliminary blue sky memorandum,
any registration or qualification of the Securities for offer and sale under the securities or blue sky laws of the several states, and
any filings required to be made with FINRA (including filing fees and the reasonable and documented fees and expenses of counsel for the
Underwriters relating to such filings, memorandum, registration and qualification in an aggregate amount of up to $25,000); (vii) the
transportation and other expenses incurred by or on behalf of the Company (and not the Underwriters) in connection with presentations
to prospective purchasers of the Securities; (viii) the fees and expenses of the Company's accountants and the fees and expenses
of counsel for the Company; and (ix) all other costs and expenses incident to the performance by the Company of its obligations hereunder.

(k) For a period of at least five (5) years from the Effective Date or until such earlier time at which the
Liquidation occurs, the Company shall use its commercially reasonable efforts to maintain the registration of the Ordinary Shares (or
such other security into which such Ordinary Shares may be exchanged in connection with an initial Business Combination) under the Exchange
Act, except after giving effect to a going private transaction after the completion of a Business Combination. The Company will not deregister
the Ordinary Shares under the Exchange Act (except in connection with a going private transaction after the completion of a Business Combination)
without the prior consent of the Representative.

(l) The Company shall, on the date hereof, retain its independent registered public accounting firm to audit
the balance sheet of the Company as of the Closing Date (the "**Audited Balance Sheet**") reflecting the receipt by the
Company of the proceeds of the Offering on the Closing Date. As soon as the Audited Balance Sheet becomes available, the Company shall
promptly, but not later than four Business Days after the Closing Date, file a Current Report on Form 8-K with the Commission, which Report
shall contain the Audited Balance Sheet. Additionally, upon the Company's receipt of the proceeds from the exercise of all or any
portion of the option provided for in Section 2 hereof, the Company shall promptly, but not later than four Business Days after the receipt
of such proceeds, file a Current Report on Form 8-K with the Commission, which report shall disclose the Company's sale of the Option
Securities and its receipt of the proceeds therefrom.

(m) For a period of at least five (5) years from the Effective Date or until such earlier time at which the
Liquidation occurs or the Ordinary Shares cease to be publicly traded, the Company, at its expense, shall cause its regularly engaged
independent registered public accounting firm to review (but not audit) the Company's financial statements for each of the first
three fiscal quarters prior to the announcement of quarterly financial information, the filing of the Company's Form 10-Q quarterly
report and the mailing, if any, of quarterly financial information to shareholders.

(n) For a period of at least five (5) years from the Effective Date or until such earlier time at which the
Liquidation occurs, the Company shall, to the extent such information or documents are not otherwise publicly available, upon written
request from the Representative, furnish to the Representative copies of such financial statements and other periodic and special reports
as the Company from time to time furnishes generally to holders of any class of securities, and, to the extent such information or documents
are not otherwise publicly available, upon written request from the Representative promptly furnish to the Representative: (i) a copy
of such registration statements, financial statements and periodic and special reports as the Company shall be required to file with the
Commission and from time to time furnishes generally to holders of any such class of its securities; and (ii) such additional documents
and information with respect to the Company and the affairs of any future subsidiaries of the Company as the Representative may from time
to time reasonably request, all subject to the execution of a satisfactory confidentiality agreement. Any registration statements, financial
statements, periodic and special reports or other additional documents referred to in the preceding sentence filed on the Commission's
EDGAR website will be considered furnished for the purposes of this section.

(o) For a period of at least five (5) years from the Effective Date or until such earlier time at which the
Liquidation occurs or the Ordinary Shares cease to be publicly traded, the Company shall retain a transfer agent.

(p) In no event will the amounts payable by the Company for office space, utilities and secretarial and administrative
support exceed $20,000 per month in the aggregate until the earlier of the date of the consummation of the Business Combination or the
Liquidation.

(q) In the event the Company seeks to enter into a Business Combination with an entity that is affiliated
with the Sponsor and/or any directors or officers of the Company, the Company, or a committee of independent directors, will obtain an
opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions stating that
the consideration to be paid by the Company in such Business Combination is fair to the Company from a financial point of view.

(r) The Company will apply the net proceeds from the Offering and the sale of the Private Placement Shares
received by it in a manner consistent in all material respects with the applications described under the caption "**Use of Proceeds** "
in the Registration Statement, Statutory Prospectus and the Prospectus.

(s) For a period of 60 days following the Effective Date, in the event any person or entity (regardless of
any FINRA affiliation or association) is engaged to assist the Company in its search for a merger candidate or to provide any other merger
and acquisition services, or has provided or will provide any investment banking, financial, advisory and/or consulting services to the
Company, the Company agrees that it shall promptly provide to FINRA (via a FINRA submission), and to the Representative and its counsel,
a notification prior to entering into the agreement or transaction relating to a potential Business Combination including: (i) the identity
of the person or entity providing any such services; (ii) complete details of all such services and copies of all agreements governing
such services prior to entering into the agreement or transaction; and (iii) justification as to why the value received by any person
or entity for such services is not underwriting compensation for the Offering. The Company also agrees that proper disclosure of such
arrangement or potential arrangement will be made in the tender offer materials or proxy statement, as applicable, which the Company may
file in connection with the Business Combination for purposes of offering redemption of shares held by its shareholders or for soliciting
shareholder approval, as applicable.

(t) The Company shall advise FINRA, the Representative and its counsel, if it is aware that any 10% or greater
shareholder of the Company becomes an affiliate or associated person of a Member participating in the distribution of the Securities.

(u) The Company shall cause the proceeds of the Offering and certain of the proceeds from the sale of the
Private Placement Shares to be held in the Trust Account to initially be invested only in United States government treasury obligations
with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act
which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary
and for the sole purpose of facilitating the intended business combination, and may at any time be held as cash or cash items, including
in demand deposit accounts at a bank. The Company will otherwise conduct its business in a manner so that it will not become subject to
the Investment Company Act. Furthermore, once the Company consummates a Business Combination, it will not be required to register as an
investment company under the Investment Company Act.

(v) During the period prior to the Company's initial Business Combination or Liquidation, the Company
may instruct the trustee under the Trust Agreement to release interest from the Trust Account in such amounts necessary to pay the Company's
taxes; provided that such withdrawals may not be made from the principal held in the Trust Account (the "**Permitted Withdrawals** ").
Otherwise, all funds held in the Trust Account (including any interest income earned on the amounts held in the Trust Account (net of
Permitted Withdrawals)) will remain in the Trust Account until the earlier of the consummation of the Company's initial Business
Combination or the Liquidation; <u>provided</u>, <u>however</u>, that in the event of the Liquidation, up to $100,000 of interest income
may be released to the Company if the proceeds of the Offering held outside of the Trust Account are not sufficient to cover the costs
and expenses associated with the liquidation and dissolution of the Company.

(w) Prior to the consummation of a Business Combination or the Liquidation, the Company shall not issue any
Ordinary Shares, warrants or any options or other securities convertible into Ordinary Shares, or any shares of preferred stock, in each
case, that participate in any manner in the Trust Account or that vote as a class with the Ordinary Shares on a Business Combination.

(x) Prior to the consummation of a Business Combination or the Liquidation, the Company's audit committee
will review on a quarterly basis all payments made to the Sponsor, to the Company's officers or directors, or to the Company's
or any of such other persons' respective affiliates.

(y) The Company agrees that it shall use commercially reasonable efforts to prevent the Company from becoming
subject to Rule 419 prior to the consummation of any Business Combination, including, but not limited to, using commercially reasonable
efforts to prevent any of the Company's outstanding securities from being deemed to be a "penny stock" as defined in
Rule 3a51-1 under the Exchange Act during such period.

(z) To the extent required by Rule 13a-15(e) under the Exchange Act, the Company shall maintain "disclosure
controls and procedures" (as defined under Rule 13a-15(e) under the Exchange Act) and a system of internal accounting controls sufficient
to provide reasonable assurances that (i) transactions are executed in accordance with management's general or specific authorization,
(ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain
accountability for assets, (iii) access to assets is permitted only in accordance with management's general or specific authorization,
and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.

(aa) The Company will use commercially reasonable efforts to effect and, for a period of at least five (5)
years from the Effective Date or until such earlier time at which Liquidation occurs, maintain the listing of the Ordinary Shares on Nasdaq
(or another national securities exchange).

(bb) As soon as legally required to do so, the Company and its directors and officers, in their capacities
as such, shall take all actions necessary to comply with any applicable provisions of the Sarbanes-Oxley Act, including Section 402 related
to loans and Sections 302 and 906 related to certifications, and to comply with the Nasdaq Listing Rules.

(cc) The Company shall not take any action or omit to take any action that would cause the Company to be in
breach or violation of its Amended and Restated Memorandum and Articles of Association.

(dd) The Company shall seek to have all vendors, service providers (other than independent accountants), prospective
target businesses, lenders or other entities with which it does business enter into agreements waiving any right, title, interest or claim
of any kind in or to any monies held in the Trust Account for the benefit of the Public Shareholders. If any third party refuses to execute
an agreement waiving such claims to the monies held in the Trust Account, the Company will perform an analysis of the alternatives available
to it and will only enter into an agreement with a third party that has not executed a waiver if the Company's Chief Executive Officer
believes that such third party's engagement would be significantly more beneficial to the Company than any alternative.

(ee) The Company may consummate the initial Business Combination and conduct redemptions of Ordinary Shares
for cash upon consummation of such Business Combination without a shareholder vote pursuant to Rule 13e-4 and Regulation 14E under the
Exchange Act, including the filing of tender offer documents with the Commission. Such tender offer documents will contain substantially
the same financial and other information about the initial Business Combination and the redemption rights as is required under the Commission's
proxy rules and will provide each shareholder of the Company with the opportunity prior to the consummation of the initial Business Combination
to redeem the Ordinary Shares held by such shareholder for an amount of cash equal to (A) the aggregate amount then on deposit in the
Trust Account as of two business days prior to the consummation of the initial Business Combination, representing (x) certain of the proceeds
held in the Trust Account from the Offering and the sale of the Private Placement Shares and (y) any interest income earned on the funds
held in the Trust Account not previously released for Permitted Withdrawals, divided by (B) the total number of Ordinary Shares sold as
part of the Offering (the "**Public Shares**") then outstanding. If, however, a shareholder vote is required by law or
stock exchange listing requirement in connection with the initial Business Combination or the Company decides to hold a shareholder vote
for business or other legal reasons, the Company will submit such Business Combination to the Company's shareholders for their approval
(" **Business Combination Vote** "). With respect to the initial Business Combination Vote, if any, the Sponsor, and its
officers and directors, have agreed to vote all of their Founder Shares and any other Ordinary Shares purchased during or after the Offering
in favor of the Company's initial Business Combination. If the Company seeks shareholder approval of the initial Business Combination,
the Company will offer to each Public Shareholder holding Ordinary Shares the right to have its shares redeemed in conjunction with a
proxy solicitation pursuant to the proxy rules of the Commission at a per share redemption price (the "**Redemption Price** ")
equal to (I) the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial
Business Combination, representing (1) certain of the proceeds held in the Trust Account from the Offering and the sale of the Private
Placement Shares and (2) any interest income earned on the funds held in the Trust Account not previously released for Permitted Withdrawals,
divided by (II) the total number of Public Shares then outstanding. If the Company seeks shareholder approval of the initial Business
Combination, the Company may proceed with such Business Combination only if a majority of the outstanding Ordinary Shares voted by the
shareholders at a duly held shareholders meeting are voted to approve such Business Combination. If, after seeking and receiving such
shareholder approval, the Company elects to so proceed, it will redeem shares, at the Redemption Price, from those Public Shareholders
who affirmatively requested such redemption. Only Public Shareholders holding Ordinary Shares who properly exercise their redemption rights,
in accordance with the applicable tender offer or proxy materials related to such Business Combination and the Amended and Restated Memorandum
and Articles of Association, shall be entitled to receive distributions from the Trust Account in connection with an initial Business
Combination, and the Company shall pay no distributions with respect to any other holders of shares in the capital of the Company in connection
therewith. In the event that the Company does not effect a Business Combination by twenty-four (24) months from the closing of the Offering
or such earlier date as the directors may approve in accordance with the Amended and Restated Memorandum and Articles of Association,
or such later time as the shareholders of the Company may approve in accordance with the Amended and Restated Memorandum and Articles
of Association, or a resolution of the Company's shareholders is passed pursuant to the Companies Act (Revised) of the Cayman Islands
to commence the voluntary liquidation of the Company prior to the consummation of an initial Business Combination for any reason (the
" **Completion Window** "), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten (10) business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the Trust Account (including interest not previously released to the Company
for Permitted Withdrawals, and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding
Public Shares, which redemption will completely extinguish Public Shareholders' rights as shareholders (including the right to receive
further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the Company's remaining Shareholders and the Company's board of directors, liquidate and dissolve,
subject in each case to the Company's obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. Only Public Shareholders holding Ordinary Shares included in the Securities will be entitled to receive such
redemption amounts and the Company shall pay no such redemption amounts or any distributions in liquidation with respect to any other
shares of the Company. The Sponsor and the Company's officers and directors have agreed that they will not propose any amendment
to the Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company's obligation
to redeem 100% of the outstanding Public Shares if the Company has not consummated a Business Combination within the Completion Window
unless the Company offers to redeem the Public Shares in connection with such amendment, as described in the Statutory Prospectus and
Prospectus.

(ff) In the event that the Company desires or is required by an applicable law or regulation to cause an announcement
(" **Business Combination Announcement**") to be placed in The Wall Street Journal, The New York Times or any other news
or media publication or outlet or to be made via a public filing with the Commission announcing the consummation of the Business Combination
that indicates that the Underwriters were the underwriters in the Offering, the Company shall supply the Representative with a draft of
the Business Combination Announcement and provide the Representative with a reasonable advance opportunity to comment thereon, subject
to the agreement of the Underwriters to keep confidential such draft announcement in accordance with the Representative's standard
policies regarding confidential information.

(gg) Subject to the provisions of this paragraph, upon the consummation of the initial Business Combination,
the Company and the Representative will jointly direct the trustee to pay the Representative, on behalf of the Underwriters, the Deferred
Discount out of the proceeds of the Offering held in the Trust Account. The Underwriters shall have no claim to payment of any interest
earned on the portion of the proceeds held in the Trust Account representing the Deferred Discount. If the Company fails to consummate
its initial Business Combination within the Completion Window, the Deferred Discount will not be paid to the Representative and will,
instead, be included in the Liquidation distribution of the proceeds held in the Trust Account made to the Public Shareholders. In connection
with any such Liquidation, the Underwriters forfeit any rights or claims to the Deferred Discount.

(hh) The Company will endeavor in good faith, and in cooperation with the Representative, to qualify the Securities
for offering and sale under the securities laws of such jurisdictions as the Representative may reasonably designate; <u>provided</u> that no such qualification shall be required in any jurisdiction where, as a result thereof, the Company would be subject to service of
general process or to taxation as a foreign corporation doing business in such jurisdiction. Until the earliest of (i) the date on which
all Underwriters shall have ceased to engage in market-making activities in respect of the Securities, (ii) the date on which the Securities
are listed on Nasdaq (or any successor thereto), (iii) a going private transaction after the completion of a Business Combination, and
(iv) the date of the liquidation of the Company, in each jurisdiction where such qualification shall be effected, the Company will, unless
the Representative agrees that such action is not at the time necessary or advisable, use all reasonable efforts to file and make such
statements or reports at such times as are or may be required to qualify the Securities for offering and sale under the securities laws
of such jurisdiction.

(ii) If at any time following the distribution of any Written Testing-the-Waters Communication, there occurred
or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include any untrue
statement of a material fact or omitted or would omit to state any material fact necessary to make the statements therein in light of
the circumstances under which they were made at such time, not misleading, the Company will promptly (i) notify the Representative so
that use of the Written Testing-the-Waters Communication may cease until it is amended or supplemented; (ii) amend or supplement, at its
own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission; and (iii) supply
any amendment or supplement to the Representative in such quantities as may be reasonably requested.

(jj) The Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company
at any time prior to the later of completion of the distribution of the Securities within the meaning of the Act and completion of the
180-day restricted period referred to in Section 5(h) hereof.

(kk) [ *Intentionally omitted.* ]

(ll) Upon the earlier to occur of the expiration or termination of the Underwriters' over-allotment option,
the Company shall cancel or otherwise effect the forfeiture/surrender for no consideration of Founder Shares from the Sponsor in an aggregate
amount equal to the number of Founder Shares determined by multiplying (a) 1,725,000 by (b) a fraction, (i) the numerator of which is
900,000 minus the number of Option Securities purchased by the Underwriters upon the exercise of their over-allotment option, and (ii)
the denominator of which is 900,000. For the avoidance of doubt, if the Underwriters exercise their over-allotment option in full, the
Company shall not cancel or otherwise effect the forfeiture/surrender for no consideration of the Founder Shares pursuant to this subsection.

6. <u>CONDITIONS TO THE OBLIGATIONS OF THE UNDERWRITERS</u>

The obligations of the Underwriters to purchase the Underwritten Securities and the Option Securities, as the case may be, shall be subject to the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, the Closing Date and any settlement date pursuant to Section 3 hereof, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and to the following additional conditions:

(a) The Prospectus, and any supplement thereto, have been filed in the manner and within the time period required
by Rule 424(b); and no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use shall
have been issued and no proceedings for that purpose shall have been instituted or threatened.

(b) The Company shall have requested and caused Loeb & Loeb LLP, counsel for the Company, to have furnished
to the Representative its opinions and negative assurance letter, each dated the Closing Date or settlement date (as applicable) and addressed
to the Representative, in a form reasonably acceptable to the Representative.

(c) The Company shall have requested and caused Appleby (Cayman) Ltd., Cayman Islands counsel for the Company,
to have furnished to the Representative its opinions, dated the Closing Date and any settlement date, as applicable, and addressed to
the Representative, in form and substance reasonably acceptable to the Representative.

(d) The Representative shall have received from Davis Polk & Wardwell LLP, counsel for the Underwriters,
such opinion or opinions and negative assurance letter, each dated the Closing Date or settlement date (as applicable) and addressed to
the Representative, with respect to the issuance and sale of the Securities, the Registration Statement, the Statutory Prospectus, the
Prospectus (together with any supplement thereto) and other related matters as the Representative may reasonably require, and the Company
shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters.

(e) The Company shall have furnished to the Representative a certificate of the Company, signed by the Chief
Executive Officer and the principal financial or accounting officer of the Company, dated the Closing Date or settlement date (as applicable),
to the effect that the signers of such certificate have carefully examined the Registration Statement, each Preliminary Prospectus, the
Prospectus and any amendment or supplement thereto, and this Agreement and that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. the representations and warranties of the Company in this Agreement are true and correct on and as of
the Closing Date or settlement date (as applicable) with the same effect as if made on the Closing Date or settlement date (as applicable)
and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior
to the Closing Date or settlement date (as applicable);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its
use has been issued and no proceedings for that purpose have been instituted or, to the Company's knowledge, threatened; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. since the date of the most recent financial statements included in the Statutory Prospectus and the Prospectus
(exclusive of any supplement thereto), there has been no Material Adverse Effect, except as set forth in or contemplated by the Statutory
Prospectus and the Prospectus (exclusive of any supplement thereto).

(f) The Company shall have furnished to the Representative a certificate signed by a director or officer of
the Company, dated the Closing Date or settlement date (as applicable), certifying (i) that the Amended and Restated Memorandum and Articles
of Association is true and complete, has not been modified and is in full force and effect, (ii) that the resolutions relating to the
Offering contemplated by this agreement are in full force and effect and have not been modified, (iii) copies of all correspondence between
the Company or its counsel and the Commission, and (iv) as to the incumbency of the officers of the Company. The documents referred to
in such certificate shall be attached to such certificate.

(g) The Company shall have requested and caused WithumSmith to have furnished to the Representative, at the
Execution Time and at the Closing Date or settlement date (as applicable), letters, dated respectively as of the Execution Time and as
of the Closing Date or settlement date (as applicable), in form and substance satisfactory to the Representative, confirming that they
are a registered public accounting firm that is independent with respect to the Company within the meaning of the Act and the Exchange
Act and the applicable rules and regulations adopted by the Commission thereunder and that they have performed a review of the audited
financial statements of the Company for the period from January 13, 2026 (inception) through February 13, 2026, <u>provided</u>, <u>however</u>,
that the cutoff date shall not be more than two business days prior to such Execution Time or Closing Date or settlement date, as applicable,
and stating in effect that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. in their opinion the audited financial statements, the unaudited financial statements and any financial
statement schedules included in the Registration Statement, the Statutory Prospectus and the Prospectus and reported on by them comply
as to form in all material respects with the applicable accounting requirements of the Act and the related rules and regulations adopted
by the Commission; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. they have performed certain other specified procedures as a result of which they determined that certain
information of an accounting, financial or statistical nature (which is limited to accounting, financial or statistical information derived
from the general accounting records of the Company) set forth in the Registration Statement, the Statutory Prospectus and the Prospectus,
including the information set forth under the captions "**Dilution**" and "**Capitalization**" in the Statutory
Prospectus and the Prospectus, agrees with the accounting records of the Company, excluding any questions of legal interpretation.

References to the Prospectus in this paragraph (f) include any supplement thereto at the date of the letter.

(h) Subsequent to the Execution Time or, if earlier, the dates as of which information is given in the Registration
Statement (exclusive of any amendment thereof), the Statutory Prospectus and the Prospectus (exclusive of any supplement thereto), there
shall not have been any change or decrease specified in the letter or letters referred to in paragraph (g) of this Section 6 or any change,
or any development involving a prospective change, in or affecting the earnings, business, management, properties, assets, rights, operations,
condition (financial or otherwise) or prospects of the Company, whether or not arising from transactions in the ordinary course of business,
except as set forth in or contemplated in the Statutory Prospectus and the Prospectus (exclusive of any supplement thereto) the effect
of which, in any case referred to in clause (i) or (ii) in paragraph (g) above, is, in the sole judgment of the Representative, so material
and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by the
Registration Statement (exclusive of any amendment thereof), the Statutory Prospectus and the Prospectus (exclusive of any supplement
thereto).

(i) Prior to the Closing Date or settlement date (as applicable), the Company shall have furnished to the
Representative such further information, certificates and documents as the Representative may reasonably request.

(j) FINRA shall not have raised any objection with respect to the fairness or reasonableness of the underwriting
or other arrangements of the transactions contemplated hereby.

(k) The Securities shall be duly listed subject to notice of issuance on Nasdaq, satisfactory evidence of
which shall have been provided to the Representative.

(l) On the Effective Date, the Company shall have delivered to the Representative executed copies of the Trust
Agreement, the Securities Subscription Agreement, the Private Placement Agreement, the Registration Rights Agreement, the Letter Agreement
and the Administrative Services Agreement.

(m) [ *Intentionally omitted.* ]

(n) At least one Business Day prior to the Closing Date or settlement date (as applicable), the Company shall
have caused the applicable purchase price for the Private Placement Shares to be deposited into the Trust Account so that together with
the net proceeds for the Ordinary Shares (including the Deferred Discount), or with respect to the Optional Securities, the net proceeds
from the Optional Securities (including the Deferred Discount), the Trust Account would equal the product of the number of Ordinary Shares
sold and the public offering price per Ordinary Share as set forth on the cover of the Prospectus. Notwithstanding the foregoing, in no
event will the Company take any action that would result in the Company receiving proceeds from the sale of the Private Placement Shares
in excess of the sum of: (i) the amount required to satisfy the obligation in the immediately preceding sentence; (ii) the amount of the
discount from the public offering price represented by the purchase price set forth in Section 2(a) of this Agreement, and (iii) the amount
of money to be held by the Company outside of the Trust Account, as disclosed in the Registration Statement, the Statutory Prospectus
and the Prospectus.

(o) No order preventing or suspending the sale of the Ordinary Shares in any jurisdiction designated by the
Representative pursuant to Section 5(hh) hereof shall have been issued as of the Closing Date or settlement date (as applicable), and
no proceedings for that purpose shall have been instituted or shall have been threatened.

If any of the conditions specified in this Section 6 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Representative and counsel for the Underwriters, this Agreement and all obligations of the Underwriters hereunder may be canceled at, or at any time prior to, the Closing Date by the Representative. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed in writing.

The documents required to be delivered by this Section 6 shall be delivered at the office of Davis Polk & Wardwell LLP, counsel for the Underwriters, at 450 Lexington Avenue, New York, NY 10163, Attention: Derek Dostal and Robert Van de Mark, unless otherwise indicated herein, on the Closing Date or settlement date (as applicable).

7. <u>REIMBURSEMENT OF UNDERWRITERS' EXPENSES</u>

If the sale of the Securities provided for herein is not consummated because any condition to the obligations of the Underwriters set forth in Section 6 hereof is not satisfied, because of any termination pursuant to Section 10 hereof (other than clauses (ii), (iii) or (vi) thereof) or because of any refusal, inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof other than by reason of a default by any of the Underwriters, the Company will reimburse the Underwriters severally through the Representative on demand for all reasonable out-of-pocket expenses (including reasonable fees and disbursements of counsel, but, in no event, shall expenses exceed $25,000 or include taxes imposed on the net income of an Underwriter) that shall have been incurred by them in connection with the proposed purchase and sale of the Securities.

8. <u>INDEMNIFICATION AND CONTRIBUTION</u>

(a) The Company agrees to indemnify and hold harmless each Underwriter, the directors, officers, employees
and agents of each Underwriter, each person who controls any Underwriter within the meaning of either the Act or the Exchange Act and
each affiliate of each Underwriter against any and all losses, claims, damages or liabilities, joint or several, to which they or any
of them may become subject under the Act, the Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement
or alleged untrue statement of a material fact contained in (i) the Registration Statement for the registration of the Securities as originally
filed or in any amendment thereof, or in any Preliminary Prospectus, the Statutory Prospectus, the Prospectus, any "road show"
as defined in Rule 433(h) of the Act or any Written Testing-the-Waters Communication or in any amendment thereof or supplement thereto,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, and (ii) any materials or information, including roadshow materials, provided to investors
by, or with the approval of, the Company in connection with obtaining stockholder approval of the Business Combination, including any
road show or investor presentations made to investors by the Company (whether in person or electronically), or in any proxy statement,
prospectus (or any amendment or supplement thereto), any preliminary prospectus, or any Written Testing-the-Waters Communication, in each
case used in connection with the initial Business Combination, and agrees to reimburse each such indemnified party, as incurred, for any
legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability
or action; <u>provided</u>, <u>however</u>, that the Company will not be liable in any such case to the extent that any such loss, claim,
damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission
made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of any Underwriter through
the Representative specifically for inclusion therein, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described in the last sentence of Section 8(b) hereof. This indemnity agreement will be in addition
to any liability that the Company may otherwise have.

(b) Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of
its directors, each of its officers who signs the Registration Statement, and each person who controls the Company within the meaning
of either the Act or the Exchange Act, to the same extent as the foregoing indemnity from the Company to each Underwriter, but only with
reference to written information relating to such Underwriter furnished to the Company by or on behalf of such Underwriter through the
Representative specifically for inclusion in the documents referred to in the foregoing indemnity. This indemnity agreement will be in
addition to any liability that any Underwriter may otherwise have. The Company acknowledges that the following statements set forth under
the heading "Underwriting" in the Preliminary Prospectus, the Statutory Prospectus and the Prospectus constitute the only
information furnished in writing by or on behalf of the several Underwriters for inclusion in the documents referred to in the foregoing
indemnity: (x) the list of Underwriters and their respective roles and participation in the sale of the Securities, (y) the sentences
related to concessions and reallowances and the Underwriter's intention not to make sales to discretionary accounts, and (z) the
paragraphs related to stabilization, syndicate covering transactions and penalty bids.

(c) Promptly after receipt by an indemnified party under this Section 8 of notice of the commencement of any
action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 8,
notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party will not relieve
it from liability under paragraph (a) or (b) above unless and to the extent it did not otherwise learn of such action and such failure
results in the forfeiture by the indemnifying party of material rights and defenses and will not, in any event, relieve the indemnifying
party from any obligations to any indemnified party other than the indemnification obligation provided in paragraph (a) or (b) above.
The indemnifying party shall be entitled to appoint counsel of the indemnifying party's choice at the indemnifying party's
expense to represent the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall
not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as
set forth below); <u>provided</u>, <u>however</u>, that such counsel shall be satisfactory to the indemnified party. Notwithstanding the
indemnifying party's election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have
the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses
of such separate counsel if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party would present such
counsel with a conflict of interest, (ii) the actual or potential defendants in, or targets of, any such action include both the indemnified
party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available
to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party, (iii) the indemnifying
party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time
after notice of the institution of such action or (iv) the indemnifying party shall authorize the indemnified party to employ separate
counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written consent of the indemnified
parties (which consent shall not be unreasonably withheld, delayed or conditioned), settle or compromise or consent to the entry of any
judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution
may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless (i) such
settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising out of such claim,
action, suit or proceeding and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or
on behalf of any indemnified party. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of any proceeding effected
without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid
request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 45 days prior to such settlement
being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request
prior to the date of such settlement.

(d) In the event that the indemnity provided in paragraph (a) or (b) of this Section 8 is unavailable to or
insufficient to hold harmless an indemnified party for any reason, the Company and the Underwriters severally agree to contribute to the
aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating
or defending the same) (collectively "**Losses**") to which the Company and one or more of the Underwriters may be subject
in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and by the Underwriters
on the other from the Offering; <u>provided</u>, <u>however</u>, that in no case shall any Underwriter (except as may be provided in any
agreement among underwriters relating to the Offering) be responsible for any amount in excess of the underwriting discount or commission
applicable to the Securities purchased by such Underwriter hereunder. If the allocation provided by the immediately preceding sentence
is unavailable for any reason, the Company and the Underwriters severally shall contribute in such proportion as is appropriate to reflect
not only such relative benefits but also the relative fault of the Company on the one hand and of the Underwriters on the other in connection
with the statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. Benefits received
by the Company shall be deemed to be equal to the total net proceeds from the Offering (before deducting expenses) received by it, and
benefits received by the Underwriters shall be deemed to be equal to the total underwriting discounts and commissions, in each case as
set forth on the cover page of the Prospectus. Relative fault shall be determined by reference to, among other things, whether any untrue
or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
provided by the Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access
to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it
would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation that does not
take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph (d), no person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who
was not guilty of such fraudulent misrepresentation. For purposes of this Section 8, each person who controls an Underwriter within the
meaning of either the Act or the Exchange Act and each director, officer, employee and agent of an Underwriter shall have the same rights
to contribution as such Underwriter, and each person who controls the Company within the meaning of either the Act or the Exchange Act,
each officer of the Company who shall have signed the Registration Statement and each director of the Company shall have the same rights
to contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph (d).

(e) In any proceeding relating to the Registration Statement, the Preliminary Prospectus, the Statutory Prospectus,
any Written Testing-the-Waters Communication, the Prospectus or any supplement or amendment thereto, each party against whom contribution
may be sought under this Section 8 hereby consents to the exclusive jurisdiction of the federal courts of the United States of America
located in the City and County of New York, Borough of Manhattan and the courts of the State of New York located in the City and County
of New York, Borough of Manhattan (collectively, the "**Specified Courts** "), agrees that process issuing from such courts
may be served upon it by any other contributing party and consents to the service of such process and agrees that any other contributing
party may join it as an additional defendant in any such proceeding in which such other contributing party is a party.

(f) Any losses, claims, damages, liabilities or expenses for which an indemnified party is entitled to indemnification
or contribution under this Section 8 shall be paid by the indemnifying party to the indemnified party as such losses, claims, damages,
liabilities or expenses are incurred. The indemnity and contribution agreements contained in this Section 8 and the representations and
warranties of the Company set forth in this Agreement shall remain operative and in full force and effect, regardless of (i) any investigation
made by or on behalf of any Underwriter, its directors or officers or any person controlling any Underwriter, the Company, its directors
or officers or any persons controlling the Company, (ii) acceptance of any Securities and payment therefor hereunder, and (iii) any termination
of this Agreement. A successor to any Underwriter, its directors or officers or any person controlling any Underwriter, or to the Company,
its directors or officers, or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and
reimbursement agreements contained in this Section 8.

9. <u>DEFAULT BY AN UNDERWRITER</u>

If any one or more Underwriters shall fail to purchase and pay for any of the Securities agreed to be purchased by such Underwriter or Underwriters hereunder and such failure to purchase shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Underwriters shall be obligated severally to take up and pay for (in the respective proportions that the amount of Securities set forth opposite their names in <u>Schedule I</u> hereto bears to the aggregate amount of Securities set forth opposite the names of all the remaining Underwriters) the Securities that the defaulting Underwriter or Underwriters agreed but failed to purchase; <u>provided</u>, <u>however</u>, that in the event that the aggregate amount of Securities that the defaulting Underwriter or Underwriters agreed but failed to purchase shall exceed 10% of the Underwritten Securities, the remaining Underwriters shall have the right to purchase all, but shall not be under any obligation to purchase any, of the Securities. If within one Business Day after such default relating to more than 10% of the Underwritten Securities the remaining Underwriters do not arrange for the purchase of such Underwritten Securities, then the Company shall be entitled to a further period of one Business Day within which to procure another party or parties reasonably satisfactory to you to purchase said Underwritten Securities. In the event that neither the remaining Underwriters nor the Company purchase or arrange for the purchase of all of the Underwritten Securities to which a default relates as provided in this Section 9, this Agreement will terminate without liability to any nondefaulting Underwriter or the Company. In the event of a default by any Underwriter as set forth in this Section 9, the Closing Date shall be postponed for such period, not exceeding five Business Days, as the Representative shall determine in order that the required changes in the Registration Statement and the Prospectus or in any other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve any defaulting Underwriter of its liability, if any, to the Company and any nondefaulting Underwriter for damages occasioned by its default hereunder.

10. <u>TERMINATION</u>

This Agreement shall be subject to termination in the absolute discretion of the Representative, by notice given to the Company prior to delivery of and payment for the Securities, if at any time prior to such delivery and payment any of the following has occurred: (i) trading in the Company's Ordinary Shares shall have been suspended by the Commission, or trading in securities generally on the NYSE or Nasdaq Stock Market LLC shall have been suspended or limited or minimum prices shall have been established on such exchange or trading market, (ii) a banking moratorium shall have been declared either by Federal or New York State authorities, (iii) there shall have occurred any outbreak or escalation of hostilities, declaration by the United States of a national emergency or war, or other national or international calamity or crisis (including, without limitation, an act of terrorism) or change in economic or political conditions the effect of which on financial markets is such as to make it, in the sole judgment of the Representative, impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by the Statutory Prospectus or the Prospectus (exclusive of any supplement thereto), (iv) since the respective dates as of which information is given in the Registration Statement, the Statutory Prospectus and the Prospectus, any material adverse change or any development involving a prospective material adverse change in or affecting the earnings, business, management, properties, assets, rights, operations, condition (financial or otherwise) or prospects of the Company, whether or not arising in the ordinary course of business, (v) the enactment, publication, decree or other promulgation of any statute, regulation, rule or order of any court or other governmental authority which in your opinion materially and adversely affects or may materially and adversely affect the business or operations of the Company, or (vi) the taking of any action by any governmental body or agency in respect of its monetary or fiscal affairs which in your opinion has a material adverse effect on the securities markets in the United States.

11. <u>REPRESENTATIONS AND INDEMNITIES TO SURVIVE,</u>

The respective agreements, representations, warranties, indemnities and other statements of the Company or its officers and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of the officers, directors, employees, agents or controlling persons referred to in Section 8 hereof, and will survive delivery of and payment for the Securities. The provisions of Sections 7 and 8 hereof shall survive the termination or cancellation of this Agreement.

12. <u>NOTICES</u>

All communications hereunder will be in writing and effective only on receipt, and will be mailed, delivered or e-mailed.

If to the Representative:

Guggenheim Securities, LLC

330 Madison Avenue New York, New York 10017

Attention: Michael Jiang, Senior Managing Director

Email: michael.jiang@guggenheimpartners.com.

If to the Company:

JATT II Acquisition Corp<br> 153 Central Avenue

C/O 56

Westfield, NJ 07091<br> Attention: Nicholas Fernandez

Email: nicholas.fernandez@athanorcapital.com

Copy (which copy shall not constitute notice) to:

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attention: Giovanni Caruso, Esq

Email: gcaruso@loeb.com

13. <u>SUCCESSORS</u>

This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons referred to in Section 8 hereof, and no other person will have any right or obligation hereunder.

14. <u>NO FIDUCIARY DUTY</u>

The Company hereby acknowledges that (a) the purchase and sale of the Securities pursuant to this Agreement is an arm's-length commercial transaction between the Company, on the one hand, and the Underwriters and any affiliate through which any of them may be acting, on the other, (b) the Underwriters are each acting as principal and not as an agent or fiduciary of the Company and (c) the Company's engagement of the Underwriters in connection with the Offering and the process leading up to the Offering is as independent contractors and not in any other capacity. Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the Offering (irrespective of whether any of the Underwriters has advised or is currently advising the Company on related or other matters). The Company agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. None of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person.

15. <u>RECOGNITION OF THE U.S. SPECIAL RESOLUTION REGIMES.</u>

(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S.
Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement,
will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States.

(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter
becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against
such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

(c) For purposes of this Section 15: (A) a "**BHC Act Affiliate**" has the meaning assigned
to the term "affiliate" in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) "**Covered Entity** "
means any of the following: (i) a "covered entity" as that term is defined in, and interpreted in accordance with, 12 C.F.R.
§ 252.82(b); (ii) a "covered bank" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b);
or (iii) a "covered FSI" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) "**Default Right**" has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81,
47.2 or 382.1, as applicable; and (D) "U.S. Special Resolution Regime" means each of (i) the Federal Deposit Insurance Act
and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the
regulations promulgated thereunder.

16. <u>INTEGRATION</u>

This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitute the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersede all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof except as expressly set forth in that certain letter agreement, dated March 6, 2026, among the Company, the Sponsor and the Representative.

17. <u>APPLICABLE LAW</u>

This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed within the State of New York. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in the Specified Courts, and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party's address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

18. <u>WAIVER OF JURY TRIAL</u>

THE COMPANY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

19. <u>COUNTERPARTS; ELECTRONIC SIGNATURES.</u>

This Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement. Delivery of this Agreement by one party to the other may be made by facsimile, electronic mail (including any electronic signature complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. §§ 301-309), as amended from time to time, or other applicable law) or other transmission method, and the parties hereto agree that any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

20. <u>HEADINGS</u>

The section headings used herein are for convenience only and shall not affect the construction hereof.

21. <u>DEFINITIONS</u>

The terms that follow, when used in this Agreement, shall have the meanings indicated.

"**Act**" shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.

"**Applicable Time**" shall mean [●] p.m. (New York time) on the date of this Agreement.

"**Business Day**" shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated by law to close in New York City.

"**Commission**" shall mean the Securities and Exchange Commission.

"**Effective Date**" shall mean each date and time that the Registration Statement, any post-effective amendment or amendments thereto and any Rule 462(b) Registration Statement became or becomes effective.

"**Exchange Act**" shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.

"**Execution Time**" shall mean the date and time that this Agreement is executed and delivered by the parties hereto.

"**Free Writing Prospectus**" shall mean a free writing prospectus, as defined in Rule 405.

"**Liquidation**" shall mean the distributions of the Trust Account to the Public Shareholders in connection with the redemption of Ordinary Shares held by the Public Shareholders pursuant to the terms of the Amended and Restated Memorandum and Articles of Association if the Company fails to consummate a Business Combination.

"**Preliminary Prospectus**" shall mean any preliminary prospectus referred to in paragraph 1(a) above and any preliminary prospectus included in the Registration Statement at the Effective Date that omits Rule 430A Information.

"**Prospectus**" shall mean the prospectus relating to the Securities that is first filed pursuant to Rule 424(b) after the Execution Time.

"**Registration Statement**" shall mean the registration statements referred to in paragraph 1(a) above, including exhibits and financial statements and any prospectus and prospectus supplement relating to the Securities that is filed with the Commission pursuant to Rule 424(b) and deemed part of such registration statement pursuant to Rule 430A, as amended at the Execution Time and, in the event any post-effective amendment thereto or any Rule 462(b) Registration Statement becomes effective prior to the Closing Date, shall also mean such registration statement as so amended or such Rule 462(b) Registration Statement, as the case may be.

"**Rule 158**", "**Rule 172**", "**Rule 405**", "**Rule 419**", "**Rule 424(b)**", "**Rule 430A**", "**Rule 433**", "**Rule 433(h)**" and "**Rule 462(b)**" refer to such rules under the Act.

"**Rule 430A Information**" shall mean information with respect to the Securities and the offering thereof permitted to be omitted from the Registration Statement when it becomes effective pursuant to Rule 430A.

"**Rule 462(b) Registration Statement**" shall mean a registration statement and any amendments thereto filed pursuant to Rule 462(b) relating to the offering covered by the registration statement referred to in Section 1(a) hereof.

"**Statutory Prospectus**" shall mean (i) the Preliminary Prospectus dated [●], 2026, relating to the Securities and (ii) the Time of Delivery Information, if any, set forth on <u>Schedule II</u> hereto.

[*remainder of page intentionally left blank*]

If the foregoing is in accordance with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon it will become a binding agreement among the Company and the several Underwriters in accordance with its terms.

---

| |
|:---|
| Very truly yours, |
| **JATT II Acquisition Corp** |
| By: |
| Name: |
| Title: |

---

The foregoing Underwriting Agreement is hereby confirmed and accepted as of the date first above written.

---

| |
|:---|
| **Guggenheim Securities, LLC** |
| By: |
| Name: |
| Title: |

---

**Schedule I**

---

| | |
|:---|:---|
| <br>**Underwriters** | **Number of<br> Underwritten<br> Securities to<br> be Purchased** |
| Guggenheim Securities, LLC | 6000000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 6000000 |

---

**Schedule II**

**TIME OF DELIVERY INFORMATION**

Time of Delivery Information

1. The initial price to the public of the Securities: $10.00 per Ordinary Share.

2. Number of Underwritten Securities offered: 6,000,000.

3. The Company has granted an option to the Underwriters to purchase an aggregate of not more than 900,000 Option Securities.

**Schedule III**

**SCHEDULE OF WRITTEN TESTING-THE-WATERS COMMUNICATIONS**

Reference is made to the materials used in the testing the waters presentation made to potential investors by the Company, to the extent such materials are deemed to be a "written communication" within the meaning of Rule 405 under the Act.

## Exhibit 3.1

**Exhibit 3.1**

![](ea028469001_ex3-1img1.jpg)

**THE COMPANIES ACT (AS REVISED)**

**MEMORANDUM AND**

**ARTICLES OF ASSOCIATION**

**OF**

**JATT II ACQUISITION CORP**

*Auth Code: D35884473687* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

**THE COMPANIES ACT (AS REVISED)**

**MEMORANDUM OF ASSOCIATION**

**OF**

**JATT II ACQUISITION CORP**

1. The name of the Company is JATT II Acquisition Corp.

2. The registered office will be situated at the offices of Appleby Global Services (Cayman) Limited, 71
Fort Street, PO Box 500, George Town, Grand Cayman, Cayman Islands, KY1-1106 or at such other place in the Cayman Islands as the Directors
may from time to time decide.

3. The objects for which the Company is established are unrestricted and the Company shall have full power
and authority to carry out any object that is not prohibited by any law of the Cayman Islands.

4. The Company shall have and be capable of exercising all the powers of a natural person of full capacity
as provided by law.

5. The liability of the Members is limited to the amount, if any, unpaid on their shares.

6. The authorised share capital of the Company is US $22,100 divided into 200,000,000 Class A ordinary shares
of a par value of US$0.0001 each, 20,000,000 Class B ordinary shares of a par value US$0.0001 each and 1,000,000 preference shares of
a par value of US$0.0001 each.

7. The Company has power to register by way of continuation as a body corporate limited by shares under the
laws of any jurisdiction outside the Cayman Islands and to apply for deregistration in the Cayman Islands.

8. Capitalised terms that are not defined herein bear the same meaning given to them in the Articles of Association
of the Company.

---

| | |
|:---|:---|
| 1 of 2 |  |
|  | *Auth Code: D35884473687* |
|  | *www.verify.gov.ky* |

---

![](ea028469001_ex3-1img1.jpg)

The undersigned, whose name, address and description are set out below, wishes the Company to be incorporated as a company in the Cayman Islands in accordance with this Memorandum of Association, and agrees to take the number of shares in the capital of the Company as set out opposite the undersigned's name.

---

| | |
|:---|:---|
| **Name, Address and Description of** | **Number of Shares Taken by Subscriber** |
| **Subscriber** |  |
| AGS Nominees 1 Limited | One (1) |
| 71 Fort Street |  |
| PO Box 500 |  |
| George Town |  |
| Grand Cayman KY1-1106 |  |
| Cayman Islands |  |

---

---

| |
|:---|
| /s/ Isabel Mason |
| Subscriber: Isabel Mason |
| Date: 13 Jan 2026 |

---

---

| | |
|:---|:---|
| /s/ Chanel Cranston | /s/ Chanel Cranston |
| Signature of Witness | Signature of Witness |
| Name: | Chanel Cranston |
| 71 Fort Street | 71 Fort Street |
| PO Box 500 | PO Box 500 |
| George Town | George Town |
| Grand Cayman KY1-1106 | Grand Cayman KY1-1106 |
| Cayman Islands | Cayman Islands |

---

---

| | |
|:---|:---|
| Occupation: | Senior Corporate Administrator |
| Date: 13 Jan 2026 | Date: 13 Jan 2026 |

---

---

| | |
|:---|:---|
| 2 of 2 |  |
|  | *Auth Code: D35884473687* |
|  | *www.verify.gov.ky* |

---

---

| | |
|:---|:---|
| ![](ea028469001_ex3-1img2.jpg) | ![](ea028469001_ex3-1img1.jpg) |

---

---

| | | |
|:---|:---|:---|
| **CONTENTS** | **CONTENTS** | **CONTENTS** |
| 1. | Interpretation | 1 |
| 2. | Offices | 3 |
| 3. | Service Providers | 3 |
| 4. | Issue of Shares | 4 |
| 5. | Register of Members | 4 |
| 6. | Register of Beneficial Ownership | 4 |
| 7. | Record Date | 5 |
| 8. | Share Certificates | 5 |
| 9. | Transfer of Shares | 5 |
| 10. | Transmission of Shares | 6 |
| 11. | Redemption and Repurchase of Shares | 7 |
| 12. | Variation of Share Rights | 7 |
| 13. | Non-recognition of Trusts | 7 |
| 14. | Lien | 8 |
| 15. | Calls on Shares | 8 |
| 16. | Forfeiture of Shares | 9 |
| 17. | Increase of Capital | 10 |
| 18. | Alteration of Capital | 11 |
| 19. | General Meetings | 11 |
| 20. | Notice of General Meetings | 12 |
| 21. | Proceedings at General Meetings | 12 |
| 22. | Voting | 13 |
| 23. | Proxies and Corporate Representatives | 15 |
| 24. | Appointment and Removal of Directors | 16 |
| 25. | Resignation and Disqualification of Directors | 17 |
| 26. | Powers and Duties of Directors | 17 |
| 27. | Proceedings of Directors | 18 |

---

 *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

28. Directors' Interests 20

29. Delegation of Directors' Powers 21

30. Alternate Directors 21

31. Committees of Directors 22

32. Officers 22

33. Directors' Remuneration 22

34. Seals and Deeds 23

35. Dividends 23

36. Reserves 24

37. Capitalisation of Profits 25

38. Share Premium Account 25

39. Accounting Records 25

40. Financial Year End 26

41. Service of Notices and Documents 26

42. Winding Up 27

43. Indemnity 27

44. Continuation 28

45. Merger and Consolidation 29

46. Amendment of Memorandum and Articles 29

 *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

**THE COMPANIES ACT (AS REVISED)**

**ARTICLES OF ASSOCIATION**

**OF**

**JATT II ACQUISITION CORP**

1. **INTERPRETATION** 

1.1 Table A of the First Schedule to the Act shall not apply to the Company.

1.2 In these Articles, the following terms shall have the following meanings unless the context otherwise requires:

**Act**: the Companies Act (as revised) of the Cayman Islands;

**Articles**: these articles of association of the Company as amended, restated or supplemented from time to time by Special Resolution;

**Auditors**: the auditors for the time being of the Company (if any);

**Beneficial Owner**: has the same meaning as in the BOT Act;

**BOT Act**: the Beneficial Ownership Transparency Act of the Cayman Islands;

**clear days**: in relation to the period of a notice, that period excluding the day on which the notice is served (or deemed to be served) and the day for which it is given or on which it is to take effect;

**Company**: the above named company;

**Directors**: the directors for the time being of the Company;

**Electronic Record**: has the same meaning as in the Electronic Transactions Act (as revised) of the Cayman Islands;

**Indemnified Person**: any Director, officer or member of a committee duly constituted under these Articles and any liquidator, manager or trustee acting in relation to the affairs of the Company (including anyone previously acting in such capacity) and his heirs, executors, administrators, personal representatives or successors or assigns;

**Member**: has the same meaning as in the Act;

1 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

**Memorandum**: the memorandum of association of the Company for the time being;

**Month**: a calendar month;

**Ordinary Resolution**: a resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) passed by a simple majority of such Members as, being entitled to do so, vote in person or, where proxies
are allowed, by proxy at a general meeting of the Company and where a poll is taken regard shall be had in computing a majority to the
number of votes to which each Member is entitled; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) approved in writing by all of the Members entitled to vote at a general meeting of the Company in one
or more instruments each signed by one or more of the Members and the effective date of the resolution so adopted shall be the date on
which the instrument, or the last of such instruments, if more than one, is executed;

**Register of Beneficial Ownership**: the beneficial ownership register to be kept in accordance with the BOT Act;

**Register of Members**: the register of Members to be kept in accordance with the Act and includes every duplicate Register of Members;

**Registered Office**: the registered office for the time being of the Company in the Cayman Islands;

**Seal**: the common seal of the Company (if any) and includes every duplicate seal;

**Secretary**: the secretary for the time being of the Company and any person appointed to perform any of the duties of the secretary;

**Share**: a share in the capital of the Company and includes a fraction of a share, such fractional share being subject to and carrying the corresponding fraction of liabilities, limitations, privileges, qualifications, restrictions, rights and other attributes of a whole share of the same class of shares;

**Share Premium Account**: the share premium account established in accordance with these Articles and the Act;

**Special Resolution**: a resolution that is described as such in its terms:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) passed by a majority of not less than two thirds of such Members as, being entitled to do so, vote in
person or, where proxies are allowed, by proxy at a general meeting of the Company of which notice specifying the intention to propose
the resolution as a special resolution has been duly given and where a poll is taken regard shall be had in computing a majority to the
number of votes to which each Member is entitled; or

2 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) approved in writing by all of the Members entitled to vote at a general meeting of the Company in one
or more instruments each signed by one or more of the Members and the effective date of the resolution so adopted shall be the date on
which the instrument, or the last of such instruments, if more than one, is executed; and

**Subscriber**: the Subscriber to the Memorandum.

1.3 Words importing the singular number include the plural number and vice versa and words importing the masculine
gender include the feminine gender.

1.4 Words importing persons include corporations and any other legal or natural persons.

1.5 Any reference to writing includes all modes of representing or reproducing words in a visible and legible
form, including in the form of an Electronic Record.

1.6 The word **may** shall be construed as permissive and the word **shall** shall be construed as imperative.

1.7 Any phrase introduced by the **terms including, include, in particular** or any similar expression
shall be merely illustrative and shall not limit the sense of the words preceding those terms.

1.8 Where any provision of the Act is referred to, the reference is to that provision as modified by any subsequent
law for the time being in force.

1.9 Unless the context otherwise requires, words and expressions defined in the Act bear the same meanings
in these Articles.

1.10 References to days are to calendar days, unless otherwise specified.

1.11 Headings are used for convenience only and shall not affect the construction of these Articles.

2. OFFICES

2.1 The Registered Office of the Company shall be at such place in the Cayman Islands as the Directors shall
from time to time determine.

2.2 The Company, in addition to its Registered Office, may establish and maintain such other offices in the
Cayman Islands or elsewhere as the Directors may from time to time determine.

3. SERVICE PROVIDERS

3.1 The Directors may appoint any person to act as a service provider to the Company and may delegate to any
such service provider any of the functions, duties, powers and discretions available to them as Directors, upon such terms and conditions
(including as to the remuneration payable by the Company) and with such powers of sub-delegation,
but subject to such restrictions, as they think fit.

3 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

4. ISSUE OF SHARES

4.1 The Directors may (subject to the provisions of these Articles and the Act), without prejudice to any
rights attached to any existing Shares, offer, issue, allot, grant options over or otherwise dispose of the Shares with or without preferred,
deferred, qualified or other special rights or restrictions, whether in regard to dividends or other forms of distribution, voting, return
of capital or otherwise, and to such persons and on such terms and conditions and for such consideration, and at such times as they think
fit, provided no Share shall be issued at a discount (except in accordance with the provisions of the Act).

4.2 Any Share may, with the sanction of a Special Resolution, be issued on the terms that it is, or at the
option of the Company or the holder is liable, to be redeemed.

4.3 Notwithstanding the preceding Article, the Subscriber shall have the power to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) issue one Share to itself;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) transfer that Share by an instrument of transfer to any person; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) update the Register of Members in respect of the issue and transfer of that Share.

4.4 The Company shall not issue Shares to bearer.

4.5 The Company may, in accordance with the Act, issue fractions of Shares.

5. REGISTER OF MEMBERS

5.1 The Directors shall establish and maintain (or cause to be established and maintained) the Register of
Members at the Registered Office or at such other place determined by the Directors in the manner prescribed by the Act.

6. REGISTER OF BENEFICIAL OWNERSHIP

6.1 The Directors shall cause the Register of Beneficial Ownership to be established and maintained at the
Registered Office in the manner prescribed by law if and for as long as the Company is required by law to establish and maintain such
a register.

6.2 Every Member shall provide to the Company upon request written particulars of the beneficial ownership
of the Shares registered in such Member's name as the Company is required to collect for the Register of Beneficial Ownership and
shall advise the Company in writing in a timely manner of any changes in those particulars. If the Company is not provided with the information
required, a restrictions notice may be issued. Until a restrictions notice is withdrawn by the Registered Office or ceased by order of
the Grand Court of the Cayman Islands, the rights of the Member holding the affected Shares
to vote, transfer or otherwise deal with or receive any distribution (except in a liquidation of the Company) on the affected Shares under
the provisions of these Articles are suspended.

4 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

7. RECORD DATE

7.1 The Directors may fix in advance a date as the record date to determine the Members entitled to notice
of or to vote at a meeting of the Members and, for the purpose of determining the Members entitled to receive payment of any dividend,
the Directors may, at or within 90 days prior to the date of the declaration of such dividend, fix a subsequent date as the record date
for such determination.

7.2 If no such record date is fixed, the record date shall be the date on which notice of the meeting is sent
or the date on which the resolution of the Directors declaring such dividend is adopted, as the case may be. A determination of Members
entitled to vote at any meeting of Members in accordance with this Article, shall apply to any adjournment thereof.

8. SHARE CERTIFICATES

8.1 Every Member shall be entitled, without payment, to a certificate of the Company specifying the Share
or Shares held by him and the amount paid up thereon.

8.2 Notwithstanding the provisions of these Articles, the Directors may resolve not to issue share certificates
to Members of the Company.

8.3 The Company shall not be bound to issue more than one certificate for Shares held jointly by more than
one person, and delivery of a certificate to one joint holder shall be sufficient delivery to all.

8.4 If a share certificate is defaced, lost or destroyed, it may be replaced on payment of such fee (if any)
and on such terms (if any) as to evidence and indemnity, and on the payment of expenses of the Company in investigating such evidence
and preparing such indemnity as the Directors shall think fit and, in case of defacement, on delivery of the old certificate to the Company
for cancellation.

9. TRANSFER OF SHARES

9.1 The instrument of transfer of any Share shall be executed by or on behalf of the transferor (and, if the
Directors so determine, the transferee). The transferor shall be deemed to remain the holder of the Share until the name of the transferee
is entered in the Register of Members in respect of such Share. All instruments of transfer, once registered, may be retained by the Company.

9.2 Subject to any applicable restrictions contained in these Articles, Shares shall be transferred in any
usual or common form approved by the Directors.

5 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

9.3 The Directors may, in their absolute discretion and without assigning any reason therefore, decline to
register any transfer of any Share. The Directors may require reasonable evidence to show the right of the transferor to make the transfer.

9.4 If the Directors decline to register a transfer of Shares they shall send notice of the refusal to the
transferee within one month after the date on which the transfer was lodged with the Company.

9.5 The Directors may also suspend the registration of the transfers at such times and for such periods as
the Directors may from time to time determine.

10. TRANSMISSION OF SHARES

10.1 If a Member dies, the survivor or survivors (where he was a joint holder), and the legal personal representative
(where he was sole holder), shall be the only person recognised by the Company as having any title to the Share. The estate of a deceased
Member is not thereby released from any liability in respect of any Share held by him, whether solely or jointly. For the purpose of this
Article, legal personal representative means the person to whom probate or letters of administration has or have been granted in the Cayman
Islands or, if there is no such person, such other person as the Directors may in their absolute discretion determine to be the person
recognised by the Company for the purpose of this Article.

10.2 Any person becoming entitled to a Share in consequence of the death or bankruptcy of a Member or otherwise
by operation of applicable law may elect, upon such evidence being produced as may be required by the Directors as to his entitlement,
either be registered himself as a Member in respect of the Share or, instead of being registered himself, to make such transfer of the
Share as the deceased or bankrupt Member could have made.

10.3 If the person so becoming entitled elects to be registered himself, he shall deliver or send to the Company
a notice in writing signed by him stating that he so elects. If he shall elect to transfer the Shares, he shall signify his election by
signing an instrument of transfer of such Shares in favour of his transferee. All the limitations, restrictions and provisions of these
Articles relating to the right to transfer and the registration of transfers of Shares shall be applicable to any such notice or instrument
of transfer as aforesaid as if the death of the Member or other event giving rise to the transmission had not occurred and the notice
or instrument of transfer was an instrument of transfer signed by such Member.

10.4 A person becoming entitled to a Share in consequence of the death or bankruptcy of the Member (or otherwise
by operation of applicable law), upon such evidence being produced as may be required by the Directors as to his entitlement, shall be
entitled to the same dividends and other monies payable in respect of the Share as he would be entitled if he were the holder of such
Share. However, he shall not be entitled, until he becomes registered as the holder of such Share, to receive notices of or to attend
or vote at general meetings of the Company or (except as aforesaid) to exercise any other rights or privileges of a Member. The Directors
may at any time give notice requiring such person
to elect either to be registered himself or to transfer the Share and, if the notice is not complied with within sixty days, the Directors
may thereafter withhold payment of all dividends and other monies payable in respect of the Shares until the requirements of the notice
have been complied with.

6 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

11. REDEMPTION AND REPURCHASE OF SHARES

11.1 Subject to the provisions of the Act and the Memorandum, the Company may:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) purchase its own Shares (including any redeemable Shares) in such manner and on such terms as the Directors
may agree with the relevant Member unless following such purchase there would no longer be any issued Shares and may make payment for
such purchase or for any redemption of Shares in any manner authorised by the Act, including out of capital; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) reduce its share capital and any capital redemption reserve fund in any manner whatsoever.

12. VARIATION OF SHARE RIGHTS

12.1 If at any time the share capital is divided into different classes of Shares, all or any of the special
rights attached to any class of Shares (unless otherwise provided by the terms of issue of the Shares of that class) may be varied or
abrogated with the consent in writing of the holders of not less than two thirds of the issued Shares of that class or with the sanction
of a resolution passed by the holders of not less than two thirds of the issued Shares of that class as may be present in person or by
proxy at a separate general meeting of the holders of the Shares of that class. To any such separate general meeting, all of the provisions
of these Articles relating to general meetings shall mutatis mutandis apply, but so that the necessary quorum shall be any one or more
persons holding or representing by proxy not less than one third of the issued Shares of the class and that any holder of Shares of the
relevant class present in person or by proxy may demand a poll.

12.2 For the purpose of a separate class meeting, the Directors may treat two or more of all classes of Shares
as forming one class if they consider that such class of Shares would be affected in the same way by the proposals under consideration.

12.3 The rights conferred upon the holders of any Shares shall not, unless otherwise expressly provided in
the rights attaching to such Shares, be deemed to be altered by the creation or issue of further Shares ranking *pari passu* therewith.

13. NON-RECOGNITION OF TRUSTS

13.1 Except as required by the Act or these Articles, or under an order of a court of competent jurisdiction,
the Company shall not be bound by or compelled to recognise in any way, even when notice thereof is given to it, any equitable, contingent,
future or partial interest in any Share, or any other rights in respect of any Share other
than an absolute right to the entirety thereof in the registered holder.

7 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

14. LIEN

14.1 The Company shall have a first and paramount lien on every Share (not being a fully paid Share) for all
moneys (whether presently payable or not) called or payable at a date fixed by or in accordance with the terms of issue of such Share
in respect of that Share, and the Company shall also have a first and paramount lien on every Share (other than a fully paid up Share)
standing registered in the name of a Member, whether singly or jointly with any other person for all debts and liabilities of a Member
or his estate to the Company, whether the same shall have been incurred before or after notice to the Company of any interest of any person
other than such Member, and whether the time for the payment or discharge of the same shall have actually arrived or not, and notwithstanding
that the same are joint debts or liabilities of such Member or his estate and any other person, whether a Member or not. The Directors
may at any time, either generally or in any particular case, waive any lien that has arisen or declare any Share to be wholly or in part
exempt from the provisions of this Article. The Company's lien, if any, on a Share shall extend to all dividends payable thereon.

14.2 The Company may sell, in such manner as the Directors think fit, any Share on which the Company has a
lien, provided a sum in respect of which the lien exists is presently payable, and is not paid within fourteen days after a notice in
writing has been given to the registered holder for the time being of the Share, demanding payment of the sum presently payable and giving
notice of the intention to sell in default of such payment.

14.3 For giving effect to any such sale, the Directors may authorise any person to transfer the Share sold
to the purchaser thereof. The purchaser shall be registered as the holder of the Share comprised in any such transfer and he shall not
be bound to see to the application of the purchase money, nor shall his title to the Share be affected by any irregularity or invalidity
in the proceedings relating to the sale.

14.4 The net proceeds of such sale shall be applied in payment or discharge of the debt or liability in respect
of which the lien exists and as is presently payable, and any balance shall (subject to a like lien for debts or liabilities not presently
payable as existed upon the Shares prior to the sale) be paid to the person who was the registered holder of the Share immediately before
such sale.

15. CALLS ON SHARES

15.1 The Directors may from time to time make calls upon the Members in respect of any moneys unpaid on
 their Shares (whether in respect of the par value of the Shares or premium or otherwise and not, by the terms of issue thereof, made
 payable at a future date fixed by or in accordance with such terms of issue); and each Member shall (subject to the Company serving
 upon him at least 14 days' notice specifying the time or times and place of payment) pay to the Company at the time or times
 and place so specified the amount called on his Shares. A call may be revoked or postponed by the Directors wholly or in part as the
 Directors may determine. A call shall be deemed to have been made at the time when
the resolution of the Directors authorising the call was passed.

8 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

15.2 Payment of a call may be made by instalments on the direction of the Directors.

15.3 If a sum called in respect of a Share is not paid before or on the day appointed for payment thereof,
the person from whom the sum is due shall pay interest on the sum from the day payment is due to the time of the actual payment at such
rate as the Directors may determine, but the Directors may waive payment of such interest wholly or in part.

15.4 Any sum payable in respect of a Share on issue or allotment or at any fixed date, whether in respect of
the par value of the Share or premium or otherwise, shall be deemed to be a call and if it is not paid all the relevant provisions as
to payment of interest, forfeiture or otherwise of these Articles shall apply as if such sum had become due and payable by virtue of a
call duly made and notified.

15.5 The Directors may issue Shares with different terms as to the amount and times of payment of calls.

15.6 The joint holders of a Share shall be jointly and severally liable to pay calls in respect thereof.

15.7 The Directors may, if they think fit, receive from any Member willing to advance the same, all or any
part of the moneys uncalled and unpaid upon any Shares held by him; and may (until the amount would otherwise become payable) pay interest
at such rate (not exceeding six per cent without the sanction of the Company in general meeting) as may be agreed upon between the Member
paying the sum in advance and the Directors.

16. FORFEITURE OF SHARES

16.1 If a Member fails to pay any call or instalment of a call by the date it becomes due and payable, the
Directors may, at any time thereafter while such call or instalment remains unpaid, give notice to the Member requiring payment of the
unpaid portion of the call or instalment, together with any accrued interest and expenses incurred by the Company by reason of such non-payment.

16.2 The notice shall specify where and by what date (not being less than the expiration of 14 days'
from the date of the notice) payment is to be made and shall state that if it is not complied with the Shares in respect of which the
call was made will be liable to be forfeited. The Directors may accept the surrender of any Share liable to be forfeited hereunder and,
in such case, references to these Articles to forfeiture shall include surrender.

16.3 If such notice is not complied with, any Share in respect of which the notice was given may thereafter,
before the payment of all calls or instalments and interest due in respect thereof has been made, be forfeited by a resolution of the
Directors. Such forfeiture shall include all dividends declared, other distributions or other monies payable
in respect of the forfeited Shares and not paid before the forfeiture.

9 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

16.4 A forfeited Share may be sold, re-allotted or otherwise disposed of upon such terms and in such manner
as the Directors shall think fit, and at any time before a sale, re-allotment or disposition, the forfeiture may be cancelled on such
terms as the Directors think fit.

16.5 A person whose Shares have been forfeited shall cease to be a Member in respect of the forfeited Shares,
but shall remain liable to pay to the Company all moneys which at the date of forfeiture were presently payable by him in respect of the
Shares together with interest at such rate as the Directors may determine from the date of forfeiture until payment, but his liability
shall cease if and when the Company receives payment in full of all amounts due in respect of the Shares. The Company may enforce payment
without being under any obligation to make any allowance for the value of the Shares forfeited.

16.6 An affidavit in writing by a Director or Secretary of the Company that a Share has been duly forfeited
on a specified date, shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the Share.
The Company may receive the consideration, if any, given for the Share on any sale, re-allotment or disposition thereof and may authorise
some person to execute a transfer of the Share in favour of the person to whom the Share is sold, re-allotted or otherwise disposed of,
and he shall thereupon be registered as the holder of the Share, and shall not be bound to see to the application of the purchase money
(if any) nor shall his title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture,
sale, re-allotment or disposition of the Share.

16.7 The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which,
by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the par value of the Share, or by way of premium
or otherwise, as if the same had been made payable by virtue of a call duly made and notified to the Member.

17. INCREASE OF CAPITAL

17.1 The Company may from time to time by Ordinary Resolution increase its share capital by such sum, to be
divided into new Shares of such par value, and with such rights, priorities and privileges attached thereto as the resolution shall prescribe.

17.2 Subject to any directions given by the Company in a general meeting, all new Shares shall be at the disposal
of the Directors in accordance with these Articles.

17.3 The new Shares shall be subject to the same provisions of these Articles with reference to the payment
of calls, lien, forfeiture, transfer, transmission and otherwise, as the Shares in the original share capital.

10 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

18. ALTERATION OF CAPITAL

18.1 The Company may from time to time by Ordinary Resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) consolidate and divide all or any of its share capital into Shares of larger par value than its existing
Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) sub divide its existing Shares, or any of them, into Shares of smaller par value than is fixed by the
Memorandum, subject nevertheless to the provisions of section 13 of the Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) cancel any Shares which, at the date of the passing of the resolution, have not been taken or agreed to
be taken by any person; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) convert all or any paid up Shares into stock, and reconvert all or any stock into paid up Shares of any
denomination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.2 The Company may from time to time by Special Resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) divide its Shares into several classes and attach to such classes any preferential, deferred, or special
rights or restrictions in accordance with these Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) change the currency denomination of its share capital; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) reduce its share capital and any capital redemption reserve fund in any manner whatsoever.

19. GENERAL MEETINGS

19.1 The Directors may, whenever they think fit, convene an extraordinary general meeting. If at any time there
are not sufficient Directors capable of acting to form a quorum, any Director, or any one or more Members holding in the aggregate not
less than one third of the total issued share capital of the Company entitled to vote, may convene an extraordinary general meeting in
the same manner as nearly as possible as that in which meetings may be convened by the Directors.

19.2 The Directors shall, upon the requisition in writing of one or more Members holding in the aggregate not
less than one tenth of such paid up capital of the Company as at the date of the requisition carries the right of voting at general meetings,
convene an extraordinary general meeting. Any such requisition shall express the object of the meeting proposed to be called, and must
be signed by the requisitionists and deposited at the Registered Office, and may consist of several documents in like form, each signed
by one or more requisitionists.

19.3 If there are no Directors as at the date of the deposit of the Members' requisition or if the Directors
do not convene a general meeting within 21 days from the date of the deposit, the requisitionists or any or any of them or any other Member
or Members holding in the aggregate not less than one tenth of such paid
up capital of the Company as at the date of the requisition, may convene an extraordinary general meeting. A general meeting convened
by requisitionists shall be convened in the same manner as nearly as possible as that in which general meetings are to be convened by
the Directors.

11 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

20. NOTICE OF GENERAL MEETINGS

20.1 At least five clear days' notice shall be given of any general meeting. Every notice shall specify
the place, the day and the time of meeting and, in the case of special business, the general nature of the business to be conducted at
the general meeting, and shall be given in the manner provided in these Articles or in such other manner (if any) as may be prescribed
by the Company, to such persons as are entitled to receive such notices from the Company. A general meeting may be convened by such shorter
notice, or without notice, by a majority in number of the Members having the right to attend and vote at the meeting, being a majority
together holding not less than ninety-five percent in nominal value of the Shares giving that right.

20.2 The accidental omission to give notice of a meeting to, or the non-receipt of a notice of a meeting by,
any Member entitled to receive notice shall not invalidate the proceedings at any meeting.

21. PROCEEDINGS AT GENERAL MEETINGS

21.1 All business shall be deemed special that is transacted at an extraordinary general meeting.

21.2 No business shall be transacted at any general meeting unless a quorum of Members is present at the time
that the meeting proceeds to business, but the absence of a quorum shall not preclude the appointment, choice or election of a chairman,
which shall not be treated as part of the business of the Meeting. Save as herein otherwise provided, one or more Members holding in the
aggregate not less than one third of the total issued share capital of the Company present in person or by proxy and entitled to vote
shall be a quorum.

21.3 If within five minutes (or such longer time as the chairman of the meeting may determine to wait) after
the time appointed for the meeting, a quorum is not present, the meeting, if convened upon the requisition of Members, shall be dissolved.
In any other case, it shall stand adjourned to the same day in the next week, at the same time and place, and if at the adjourned meeting
a quorum is not present within half an hour from the time appointed for the meeting, the Members present shall be a quorum.

21.4 A meeting of the Members may be held by telephone, electronic or other communication facilities (including,
without limiting the generality of the foregoing, by telephone or video conferencing) by which all persons participating in the meeting
can communicate with each other simultaneously and instantaneously, and participation in such a general meeting shall constitute presence
in person at such meeting.

21.5 Any Director shall be entitled to attend and speak at any general meeting of the Company.

12 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

21.6 The chairman (if any) of the Board of Directors shall preside as chairman at every general meeting of
the Company. If there is no such chairman, or if at any meeting he is not present within five minutes after the time appointed for holding
the meeting or is unwilling to act as chairman, the Directors present shall choose one of their number to act or, if only one Director
is present, he shall preside as chairman if willing to act. If no Director is present, or if each of the Directors present declines to
take the chair, the Members present and entitled to vote shall elect one of their number to be chairman.

21.7 The chairman may, with the consent of a meeting at which a quorum is present (and shall if so directed
by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting
other than the business left unfinished at the meeting from which the adjournment took place. When a meeting is adjourned for ten days
or more, notice of the adjourned meeting shall be given as in the case of an original meeting. Save as aforesaid, it shall not be necessary
to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.

22. VOTING

22.1 Save where a Special Resolution or other greater majority is required by the Act or these Articles, any
question proposed for consideration at any general meeting shall be decided by an Ordinary Resolution.

22.2 At any general meeting, a resolution put to the vote of the meeting shall be decided on a show of hands,
unless (before or on the declaration of the result of the show of hands, or on the withdrawal of any other demand for a poll) a poll is
demanded by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the chairman of the meeting; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) at least three Members present in person or by proxy; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any Member or Members present in person or by proxy and holding collectively not less than one tenth of
the total voting rights of all the Members having the right to vote at such meeting; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a Member or Members present in person or by proxy holding Shares conferring the right to vote at such
meeting, being Shares on which an aggregate sum has been paid up equal to not less than one tenth of the total sum paid up on all such
Shares conferring such right.

22.3 Unless a poll is duly demanded and the demand is not withdrawn, a declaration by the chairman that a resolution
has, on a show of hands, been carried or carried unanimously, or by a particular majority, or lost and an entry to that effect in the
minutes of the proceedings of the Company shall be conclusive evidence of that fact, without proof of the number or proportion of the
votes recorded in favour of, or against, that resolution. The demand for a poll may be withdrawn by the person or any persons making it
at any time prior to the declaration of the result of the poll.

13 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

22.4 If a poll is duly demanded, it shall be taken in such manner as the chairman directs, and the result of
the poll shall be deemed to be the resolution of the meeting at which the poll was demanded.

22.5 In the case of an equality of votes at a general meeting, whether on a show of hands or on a poll, the
chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall not be entitled to a second or
casting vote and the resolution shall fail.

22.6 A poll demanded on the election of a chairman or on a question of adjournment shall be taken forthwith.
A poll demanded on any other question shall be taken in such manner and either forthwith or at such time later in the meeting as the chairman
of the meeting shall direct.

22.7 The demand for a poll shall not prevent the continuance of a meeting for the transaction of any business
other than the question on which the poll has been demanded and it may be withdrawn at any time before the close of the meeting or the
taking of the poll, whichever is the earlier.

22.8 On a poll votes may be cast either personally or by proxy.

22.9 A person entitled to more than one vote on a poll need not use all his votes or cast all the votes he
uses in the same way.

22.10 On a show of hands, every Member present in person or by proxy and entitled to vote shall have one vote.
On a poll, every Member present in person or by proxy and entitled to vote shall have one vote for each Share of which he is the registered
holder.

22.11 In the case of joint holders of a Share, the vote of the senior who tenders a vote, whether in person
or by proxy, shall be accepted to the exclusion of the votes of the other joint holders; and for this purpose seniority shall be determined
by the order in which the names stand in the Register of Members in respect of the joint holding.

22.12 A Member of unsound mind, or, in respect of whom an order has been made by any court having jurisdiction
in lunacy, may vote, whether on a show of hands or on a poll, by his receiver, committee, *curator bonis* or other person of similar
nature appointed by such court, and any such receiver, committee, curator bonis or other person may vote by proxy and may otherwise act
and be treated as such Member for the purpose of the general meetings.

22.13 No Member, unless the Directors otherwise determine, shall be entitled to vote at any general meeting,
unless all calls or other sums presently payable by him in respect of Shares in the Company have been paid.

22.14 No objection shall be raised as to the qualification of any voter or as to whether any votes have been
properly counted except at the general meeting or adjourned general meeting at which the vote objected to is given or tendered and every
vote not disallowed at the meeting shall be valid. Any objection made in due time and in accordance with these Articles shall be referred
to the chairman whose decision shall be final and conclusive.

14 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

23. PROXIES AND CORPORATE REPRESENTATIVES

23.1 Subject to these Articles, each Member entitled to attend and vote at a general meeting may attend and
vote at the general meeting:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) in person, or where a Member is a company or non-natural person, by a duly authorised corporate representative;
or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) by one or more proxies.

23.2 A proxy or corporate representative need not be a Member.

23.3 The instrument appointing a proxy shall be in writing under the hand of the Member or his duly authorised
attorney or, if the Member is a corporation, under the hand of its duly authorised representative.

23.4 An instrument appointing a proxy may be in any usual or common form (or such other form as the Directors
may approve) and may be expressed to be for a particular meeting or any adjournment thereof or may appoint a standing proxy until notice
of revocation is received at the Registered Office or at such place or places as the Directors may otherwise specify for the purpose.

23.5 Any corporation which is a Member of the Company may by resolution of its directors or other governing
body authorise such person as it thinks fit to act as its representative at any meeting of the Company or of any class of Members of the
Company, and the person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as
that corporation could exercise if it were an individual Member of the Company.

23.6 The instrument appointing a proxy or corporate representative, and the power of attorney (if any) under
which it is signed, together with such other evidence as to its due execution as the Directors may from time to time require, shall be
deposited at the Registered Office of the Company or at such other place as is specified for that purpose in the notice convening the
meeting or in any notice of any adjournment or, in either case or the case of a written resolution, in any document sent therewith, not
less than 24 hours (or such longer or shorter time as the Directors may determine) before the time for holding the meeting or adjourned
meeting at which the person named in the instrument proposes to vote.

23.7 In default of any of the provisions in these Articles to deposit any instrument of proxy or authorisation
at the Registered Office of the Company or at such other place as is specified for that purpose in the notice convening the meeting, the
instrument of proxy or authorisation shall not be treated as valid provided that the chairman of the meeting may in his discretion accept
an instrument of proxy or authorisation sent by email or fax upon receipt of email or fax confirmation that the signed original thereof
has been sent.

15 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

23.8 The operation of a standing proxy or authorisation shall be suspended at any general meeting or adjournment
thereof at which the Member is present in person or by specially appointed proxy. The Directors may require evidence as to the due execution
and continuing validity of any standing proxy or authorisation and the operation of any such standing proxy or authorisation shall be
deemed to be suspended until the Directors determine that they have received such satisfactory evidence.

23.9 In the case of a poll taken subsequently to the date of a meeting or adjourned meeting, the instrument
appointing the proxy or corporate representative referred to in these Articles shall be deposited at the Registered Office of the Company
or at such other place as is specified for that purpose in the notice convening the meeting before the time appointed for the taking of
the poll.

23.10 The instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a
poll, to speak at the meeting and to vote on any amendment of a written resolution or amendment of a resolution put to the meeting for
which it is given as the proxy thinks fit. The instrument of proxy or authorisation shall, unless the contrary is stated therein, be valid
as well for any adjournment of the meeting as for the meeting to which it relates.

23.11 A vote given in accordance with the terms of an instrument of proxy or authorisation shall be valid notwithstanding
the previous death or unsoundness of mind of the principal, or revocation of the proxy or of the corporate authority, unless notice in
writing of such death, unsoundness of mind or revocation was received by the Company at the Registered Office (or such other place as
may be specified for the delivery of instruments of proxy or authorisation in the notice convening the meeting or other documents sent
therewith) before the commencement of the general meeting, or adjourned meeting, at which the instrument or proxy is used.

23.12 In the case of a written resolution to be signed by a corporate representative, the instrument appointing
the corporate representative shall be deposited at the Registered Office of the Company or at such other place as is specified for that
purpose in the notice convening the meeting prior to the effective date of the written resolution.

23.13 Subject to the Act, the Directors may at their discretion waive any of the provisions of these Articles
relating to proxies or authorisations and, in particular, may accept such verbal or other assurances as they think fit as to the right
of any person to attend, speak and vote on behalf of any Member at general meetings or to sign written resolutions.

24. APPOINTMENT AND REMOVAL OF DIRECTORS

24.1 The names of the first Directors shall be determined in writing by the subscriber of the Memorandum.

24.2 The number of Directors shall be not less than one nor, unless the Members by Ordinary Resolution may
otherwise determine, more than ten. Directors shall serve for such term as the Members by Ordinary Resolution may determine, or in the absence
of such determination, until they are removed from office or are disqualified or resign under the terms of these Articles.

16 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

24.3 The Directors shall have the power at any time, and from time to time, to appoint any person to be a Director,
either to fill a vacancy or as an additional Director.

24.4 The Company may by Ordinary Resolution appoint and remove a Director or Directors.

24.5 No shareholding qualification shall be required for Directors unless otherwise required by the Company
by Ordinary Resolution.

25. RESIGNATION AND DISQUALIFICATION OF DIRECTORS

25.1 The office of Director shall *ipso facto* be vacated if the Director:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) resigns his office by notice in writing to the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) becomes of unsound mind and the Directors resolve that his office is vacated; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) becomes bankrupt under the laws of any country or makes any arrangement or composition with his creditors
generally; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) if he ceases to be a Director by virtue of, or becomes prohibited from being a Director by reason of, an
order made under any provisions of any law or enactment.

26. POWERS AND DUTIES OF DIRECTORS

26.1 The business of the Company shall be managed by the Directors, who may pay all expenses incurred in promoting
and registering the Company and may exercise all such powers of the Company as are not, by the Act or these Articles, required to be exercised
by the Company in general meeting, subject, nevertheless, to any clause of these Articles, to the provisions of the Act and to such regulations,
being not inconsistent with the aforesaid clauses or provisions, as may be prescribed by the Company in general meeting but no regulation
made by the Company in general meeting shall invalidate any prior act of the Directors which would have been valid if that regulation
had not been made.

26.2 The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its
undertaking, property and assets (present and future) and uncalled capital or any part thereof, to issue debentures, debenture stock and
other securities whenever money is borrowed or as security for any debt, liability or obligation of the Company or of any third party.

26.3 All cheques, promissory notes, drafts, bills of exchange and other instruments, whether negotiable or
not, and all receipts for moneys paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may
be, in such manner as the Directors shall from time to time by resolution determine.

17 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

26.4 The Directors on behalf of the Company may provide benefits, whether by the payment of gratuities or pensions
or otherwise, for any person including any Director or former Director who has held any executive office or employment with the Company
or any body corporate which is or has been a subsidiary or affiliate of the Company or a predecessor in the business of the Company or
of any such subsidiary or affiliate, and to any member of his family or any person who is or was dependent on him, and may contribute
to any fund and pay premiums for the purchase or provision of any such gratuity, pension or other benefit, or for the insurance of any
such person.

26.5 No document or deed otherwise duly executed and delivered by or on behalf of the Company shall be regarded
as invalid merely because at the date of delivery of the deed or document, the Director, Secretary or other officer or person who shall
have executed the same and/or affixed the Seal (if any) thereto as the case may be for and on behalf of the Company shall have ceased
to hold such office or to hold such authority on behalf of the Company.

26.6 The Directors may from time to time appoint one of their number to be a managing director, joint managing
director or an assistant managing director or to hold any other employment or executive office with the Company for such period and upon
such terms as the Directors may determine and may revoke or terminate any such appointments. Any such revocation or termination as aforesaid
shall be without prejudice to any claim for damages that such Director may have against the Company or the Company may have against such
Director for any breach of any contract of service between him and the Company which may be involved in such revocation or termination.
Any person so appointed shall receive such remuneration (if any) (whether by way of salary, commission, participation in profits or otherwise)
as the Directors may determine, and either in addition to or in lieu of his remuneration as a Director.

26.7 Notwithstanding any provision in these Articles to the contrary, a sole Director shall be entitled to
exercise all of the powers and functions of the Directors which may be imposed on them by Act or by these Articles.

27. PROCEEDINGS OF DIRECTORS

27.1 The Directors may meet together (either within or without the Cayman Islands) for the despatch of business,
adjourn and otherwise regulate their meetings and proceedings, as they think fit. Questions arising at any meeting shall be decided by
a majority of votes. In case of an equality of votes the chairman shall not have a second or casting vote and the motion shall be deemed
to have been lost.

27.2 A Director or alternate Director may, and the Secretary on the requisition of a Director or alternate
Director shall, at any time, summon a meeting of Directors by at least five days' notice in writing to every Director and alternate
Director which notice shall set forth the general nature of the business to be considered provided however that notice may be waived by
all the Directors (or their alternates) either at, before or retrospectively after the meeting is held provided further that notice or
waiver thereof may be given by email or fax.

18 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

27.3 The quorum for the transaction of the business of the Directors may be fixed by the Directors and unless
so fixed by the Directors, shall be two Directors, and shall be one if there is a sole Director. An alternate appointed by a Director
shall be counted in a quorum at a meeting at which the Director appointing him is not present provided always that where a Director is
acting in his own right and also as an alternate he is only counted once in the quorum. A Director who ceases to be a Director at a meeting
of the Directors may continue to be present and to act as a Director and be counted in the quorum until the termination of the meeting
provided no other Director objects and if otherwise a quorum of Directors would not be present.

27.4 The continuing Directors may act notwithstanding any vacancy in their body, but, if and so long as their
number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing Directors
may act for the purpose of increasing the number of Directors to that number, or of summoning a general meeting of the Company, but for
no other purpose.

27.5 The Directors may elect a chairman of their meetings and determine the period for which he is to hold
office; but if no such chairman is elected, or if at any meeting the chairman is not present within five minutes after the time appointed
for holding the same, the Directors present may choose one of their number to be chairman of the meeting.

27.6 A resolution in writing signed by all of the Directors or all of the members of a committee of Directors
for the time being entitled to receive notice of a meeting of the Directors (or by an alternate Director as provided in these Articles),
including a resolution signed in counterpart and/or sent or evidenced by way of signed fax or electronic transmission, shall be as valid
and effectual as if it had been passed at a meeting of the Directors or of a committee of Directors duly called and constituted.

27.7 To the extent permitted by law, a meeting of the Directors or a committee appointed by the Directors may
be held by means of such telephone, electronic or other communication facilities (including, without limiting the generality of the foregoing,
by telephone or by video conferencing) as permit all persons participating in the meeting to communicate with each other simultaneously
and instantaneously and participation in such a meeting shall constitute presence in person at such meeting. Such a meeting shall be deemed
to take place where the largest group of those Directors participating in the meeting is physically assembled, or, if there is no such
group, where the chairman of the meeting then is.

27.8 All acts done by any meeting of the Directors or of a committee of Directors, or by any person acting
as a Director shall, notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director
or person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such person had been duly appointed
and was qualified to be a Director.

27.9 The Directors shall cause minutes to be made and records kept for the purpose of recording:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all appointments of officers made by the Directors;

19 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the names of the Directors and other persons present at each meeting of the Directors and of any committee
of the Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) all resolutions and proceedings at all meetings of the Members of the Company or any class of Members
and of the Directors and of committees of Directors; and the chairman of all such meetings or of any meeting confirming the minutes thereof
shall sign the same.

28. DIRECTORS' INTERESTS

28.1 A Director may hold any other office or place of profit with the Company (except that of Auditor) in conjunction
with his office of Director for such period and upon such terms as to remuneration and otherwise as the Directors may determine.

28.2 A Director or officer may act by himself or his firm in a professional capacity for the Company (otherwise
than as Auditor), and he or his firm shall be entitled to remuneration for professional services as if he were not a Director or officer.

28.3 No Director or officer shall be disqualified from his office or prevented by such office from holding
any office or place of profit under the Company or under any company in which the Company shall be a Member or have any interest, or from
contracting with the Company, either as vendor, purchaser or otherwise, nor shall any such contract or any contract or transaction entered
into by or on behalf of the Company in which any Director or officer shall be in any way interested be or be liable to be avoided nor
shall any Director or officer so contracting, dealing or being so interested be liable to account to the Company for any profit realised
by any such contract or transaction by reason of such Director holding office or of the fiduciary relation thereby established.

28.4 A Director (or his alternate Director in his absence) shall be at liberty to vote in respect of any contract
or transaction in which he is interested provided that the nature of the interest of the Director in any such contract or transaction
shall be disclosed by him at or prior to its consideration and any vote thereon.

28.5 The nature of the interest of any Director or officer in any contract, dealing or transacting with or
affecting the Company shall be disclosed by him at or prior to its consideration and any vote thereon and a general notice that a Director
or officer is a shareholder of any specified firm or company and/or is to be regarded as interested in any transaction with such firm
or company shall be sufficient disclosure hereunder and after such general notice it shall not be necessary to give special notice relating
to any particular transaction.

20 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

29. DELEGATION OF DIRECTORS' POWERS

29.1 Directors may from time to time and at any time by power of attorney or otherwise appoint any company,
firm or person or fluctuating body of persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys
of the Company for such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the
Directors under these Articles) and for such period and subject to such conditions as they may think fit, and any such power of attorney
may contain such provisions for the protection and convenience of persons dealing with any such attorney and of such attorney as the Directors
may think fit and may also authorise any such attorney to delegate all or any of the powers, authorities and discretions vested in him.

29.2 The Directors may delegate any of the powers exercisable by them to a Managing Director, Director or any
other person or persons acting individually or jointly as they may from time to time by resolution appoint upon such terms and conditions
and with such restrictions as they may think fit, and may from time to time by resolution revoke, withdraw, alter or vary all or any such
powers.

30. ALTERNATE DIRECTORS

30.1 Any Director may by writing appoint any other Director, or other person willing to act, to be his alternate
and remove his alternate so appointed by him. Such appointment or removal shall be by notice to the Registered Office signed by the Director
making or revoking the appointment or in any other manner approved by the Directors, and shall be effective on the date the notice is
served and the alternate shall be notified of such appointment or revocation. Subject to the removal by the appointing Director, the alternate
shall continue in office until the date on which the Director who appointed him ceases to be a Director. An alternate may also be a Director
in his own right and may act as alternate to more than one Director.

30.2 An alternate shall be entitled to receive notice of all meetings of the Directors, attend, be counted
in the quorum, vote and act in the place of the Director who appointed him at every such meeting at which the appointing Director is not
personally present, and generally to perform all the functions of the Director who appointed him as a Director in his absence.

30.3 These Articles (except as regards powers to appoint an alternate and remuneration) apply equally to the
alternate as though he were the Director in his own right.

30.4 An alternate Director shall be deemed for all purposes to be a Director and shall alone be responsible
for his own acts and defaults and shall not be deemed to be the agent of the Director appointing him. The signature of an alternate to
any resolution in writing of the Directors or a committee thereof shall, unless the terms of the appointment provide to the contrary,
be as effective as the signature of each Director to whom he is alternate Director.

21 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

31. COMMITTEES OF DIRECTORS

31.1 The Directors may delegate any of their powers to committees consisting of such member or members of their
body as they think fit; any committee so formed shall, in the exercise of the powers so delegated, conform to any regulations that may
be imposed on it by the Directors.

31.2 A committee may elect a chairman of its meetings; if no such chairman is elected, or if at any meeting
the chairman is not present within five minutes after the time appointed for holding the same, the members present may choose one of their
number to be chairman of the meeting.

31.3 A committee may meet and adjourn as it thinks proper. Questions arising at any meeting shall be determined
by a majority of votes of the members present and in case of an equality of votes the chairman shall not have a second or casting vote
and the motion shall be deemed to have been lost.

32. OFFICERS

32.1 The Directors may appoint a Secretary and such other officers as they may from time to time consider necessary
upon such terms as to duration of office, remuneration and otherwise as they may think fit. Such Secretary or other officers need not
be Directors and in the case of the other officers may be ascribed such titles as the Directors may decide and the Directors may revoke
or terminate any such election or appointment. Any such revocation or termination shall be without prejudice to any claim for any damages
that such officer may have against the Company or the Company may have against such officer for any breach of any contract of service
between him and the Company which may be involved in such revocation or termination. Save as provided in the Act or these Articles, the
powers and duties of the officers of the Company shall be such (if any) as are determined from time to time by the Directors.

33. DIRECTORS' REMUNERATION

33.1 The remuneration to be paid to the Directors, if any, shall be determined by the Company in general meeting
or, in the absence of such a determination, by the Directors.

33.2 Each Director shall also be entitled to be paid his reasonable travelling, hotel and other expenses properly
incurred by him in connection with his attendance at meetings of the Directors, committees of the Directors or general meetings of the
Company, or otherwise in connection with the business of the Company, or to receive a fixed allowance in respect thereof as may be determined
by the Directors, or a combination partly of one such method and partly the other.

33.3 The Directors may by resolution approve additional remuneration to any Director for services which in
the opinion of the Directors go beyond the ordinary duties of a Director, and such extra remuneration shall be in addition to any remuneration
provided for, by or pursuant to any other Article.

22 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

34. SEALS AND DEEDS

34.1 The Directors may determine that the Company shall have a Seal, and if they so determine, shall provide
for the safe custody of the Seal. The Seal shall only be used by the authority of the Directors and in the presence of a Director or the
Secretary or such other person as the Directors may by resolution appoint for this purpose, and every instrument to which the Seal affixed
shall be signed by the relevant person. Notwithstanding the above, annual returns and notices filed under the Act may be executed either
as a deed or under Seal and in either case without the need for the authority of a resolution of the Directors.

34.2 The Company may maintain in any place or places outside the Cayman Islands a facsimile of any Seal and
such facsimile seal shall be affixed in the same way as if it were the Seal.

34.3 In accordance with the Act, the Company may execute any deed or other instrument (which would otherwise
be required to be executed under Seal) by the signature of such deed or instrument as a deed by a Director or by the Secretary of the
Company or by such other person as the Directors may appoint or by any other person or attorney on behalf of the Company appointed by
a deed or other instrument executed as a deed by a Director or the Secretary or such other person as aforesaid.

35. DIVIDENDS

35.1 The Directors may from time to time declare dividends to be paid to the Members according to their rights
and interests, including such interim dividends as appear to the Directors to be justified by the position of the Company. The Directors
may also pay any fixed cash dividend which is payable on any Shares of the Company half yearly or on such other dates, whenever the position
of the Company, in the opinion of the Directors, justifies such payment.

35.2 No dividend or other distribution shall be paid except out of the realised or unrealised profits of the
Company, out of the share premium account or as otherwise permitted by law.

35.3 Subject to the rights of Members, if any, entitled to Shares with special rights as to dividends, all
dividends shall be declared and paid according to the amount paid up on the Shares in respect of which the dividend is paid and any dividend
on any class of Shares not fully paid shall be declared and paid according to the amounts paid on the Shares of that class, but if and
so long as nothing is paid up on any of the Shares in the Company, dividends may be declared and paid according to the number of Shares.
No amount paid on a Share in advance of calls shall, while carrying interest, be treated for the purposes of this Article as paid on the
Share. Dividends may be apportioned and paid pro rata according to the amounts paid-up on the Shares during any portion or portions of
the period in respect of which the dividend is paid.

35.4 The Directors may deduct from any dividend, distribution or other monies payable to a Member by the Company
on or in respect of any Shares all sums of money (if any) presently payable by him to the Company on account of calls or otherwise in
respect of Shares of the Company.

23 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

35.5 If several persons are registered as joint holders of any Share, any of them may give effectual receipts
for any dividend or other money payable on or in respect of the Share.

35.6 Any dividend may be paid by cheque or warrant sent through the post to the address of the Member or person
entitled thereto in the Register of Members or, in the case of joint holders addressed to the holder whose name stands first in the Register
of Members in respect of the Shares at his registered address as appearing on the Register of Members or to such person and such address
as the Member or person entitled or such joint holders as the case may be may direct in writing. Every such cheque or warrant shall, unless
the holder or joint holders may in writing direct, be made payable to the order of the person to whom it is sent or to the order of the
holder or, in the case of joint holders, to the order of the holder whose name stands first in the Register of Members in respect of such
Shares, and shall be sent at his or their risk and payment of the cheque or warrant by the bank on which it is drawn shall constitute
a good discharge to the Company. Any one of two or more joint holders may give effectual receipts for any dividends, distributions or
other monies payable or property distributable in respect of the Shares held by such joint holders.

35.7 The Directors may declare that any dividend or distribution is paid wholly or partly by the distribution
of specific assets and, in particular, of paid up shares, debentures or debenture stock of any other company or in any one or more of
such ways, and where any difficulty arises in regard to such dividend or distribution, the Directors may settle the same as they think
expedient, and in particular may issue fractional Shares or ignore fractions altogether and may fix the value for dividend or distribution
of such specific assets or any part thereof and may determine that cash payments shall be made to any Members upon the basis of the value
so fixed in order to secure equality of distribution, and may vest any such specific assets in trustees as may seem expedient to the Directors.

35.8 No dividend or other distribution or other monies payable by the Company on or in respect of any Share
shall bear interest against the Company.

35.9 All unclaimed dividends or distributions may be invested or otherwise made use of by the Directors for
the benefit of the Company until claimed. Any dividend or distribution unclaimed by a Member six years after the dividend or distribution
payment date shall be forfeited and revert to the Company.

36. RESERVES

36.1 The Directors may, before declaring any dividend or distribution, set aside such sums as they think proper
as a reserve or reserves which shall, at the discretion of the Directors, be applicable for meeting contingencies, or for equalising dividends,
or for any other purpose of the Company, and pending such application may, in their discretion, be employed in the business of the Company
or be invested in such manner as the Directors may from time to time think fit. The Directors may also without placing the same to reserve
carry forward any sums which they think it prudent not to distribute.

24 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

37. CAPITALISATION OF PROFITS

37.1 The Directors may capitalise any sum standing to the credit of any of the Company's reserve accounts
which are available for distribution (including its Share Premium Account and capital redemption reserve fund, subject to the Act) or
any sum standing to the credit of the profit and loss account or otherwise available for distribution and to appropriate such sums to
Members in the proportions in which such sum would have been divisible amongst them had the same been a distribution of profits by way
of dividend and to apply such sum on their behalf in paying up in full unissued Shares for allotment and distribution credited as fully
paid-up to and amongst them in the proportion aforesaid.

37.2 Where any difficulty arises in regard to any distribution under the last preceding Article, the Directors
may settle the same as they think expedient and, in particular, may authorise any person to sell and transfer any fractions or may resolve
that the distribution should be as nearly as may be practicable in the correct proportion but not exactly so or may ignore fractions altogether,
and may determine that cash payments should be made to any Members in order to adjust the rights of all parties, as may seem expedient
to the Directors. The Directors may appoint any person to sign on behalf of the persons entitled to participate in the distribution any
contract necessary or desirable for giving effect thereto and such appointment shall be effective and binding upon the Members.

38. SHARE PREMIUM ACCOUNT

38.1 The Directors shall in accordance with the Act establish a Share Premium Account and shall carry to the
credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.

38.2 There shall be debited to any Share Premium Account on the redemption or purchase of a Share the difference
between the nominal value of such Share and the redemption or purchase price provided always that at the discretion of the Directors such
sum may be paid out of the profits of the Company or, if permitted by the Act, out of capital.

39. ACCOUNTING RECORDS

39.1 The Directors shall cause to be kept accounting records sufficient to give a true and fair view of the
state of the Company's affairs and to show and explain its transactions and otherwise in accordance with the Act.

39.2 The accounting records shall be kept at the Registered Office or at such other place or places as the
Directors think fit, and shall at all times be open to inspection by the Directors. No Member (who is not also a Director) shall have
any right to inspect any accounting record or book or document of the Company except as conferred by law or authorised by the Directors
or by the Members by Ordinary Resolution.

25 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

39.3 From time to time the Company in general meeting may determine (or revoke, alter or amend any such determination)
or, failing such determination, the Directors may determine (or revoke, alter or amend any such determination):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that the accounts of the Company be audited and the appointment of the Auditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that there be prepared and sent to each Member and other person entitled thereto a profit and loss account,
a balance sheet, group accounts and/or reports for such period and on such terms as they may determine; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) that there be laid before the Company in general meeting a copy of every balance sheet together with a
copy of the Auditor's report.

40. FINANCIAL YEAR END

The financial year end of the Company shall be 31 December in each calendar year or as otherwise determined by the Board of Directors.

41. SERVICE OF NOTICES AND DOCUMENTS

41.1 Notices or other documents or communications may be given to any Member by the Company either personally
or by sending it by courier, post, fax or email to him to his registered address, or (if he has no registered address) to the address,
if any, supplied by him to the Company for the giving of notices to him. Any notice shall be deemed to be effected:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if delivered personally or sent by courier, by properly addressing and prepaying a letter containing the
notice; and to have been effected, in the case of a notice of a meeting, when delivered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if sent by post, by properly addressing, prepaying, and posting a letter containing the notice (by airmail
if available) and to have been effected, in the case of a notice of a meeting, at the expiration of three days after it was posted; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) if sent by fax or email by properly addressing and sending such notice through the appropriate transmitting
medium and to have been effected on the day the same is sent.

41.2 A notice may be given by the Company to the joint holders of a Share by giving the notice to the joint
holder named first in the Register of Members in respect of the Share.

41.3 A notice may be given by the Company to the person entitled to a Share in consequence of the death or
bankruptcy of a Member by sending it through the post in a prepaid letter addressed to them by name, or by the title of representatives
of the deceased, or trustee of the bankrupt, or by any like description, at the address, if any, supplied for the purpose by the persons
claiming to be so entitled, or (until such an address has been so supplied) by giving the notice in any manner in which the same might
have been given if the death or bankruptcy had not occurred.

26 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

41.4 Notice of every general meeting shall be given in any manner hereinbefore authorised to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) every Member entitled to vote except those Members entitled to vote who (having no registered address)
have not supplied to the Company an address for the giving of notices to them; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) every person entitled to a Share in consequence of the death or bankruptcy of a Member, who, but for his
death or bankruptcy would be entitled to receive notice of the meeting.

41.5 No other persons shall be entitled to receive notices of general meeting.

42. WINDING UP

42.1 Subject to the rights attaching to any Shares, if the Company shall be wound up, the liquidator may, with
the sanction of a Special Resolution and any other sanction required by the Act or these Articles, divide amongst the Members in kind
the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may for such purpose
set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out
as between the Members or different classes of Members. The liquidator may, with the like sanction, vest the whole or any part of such
assets in trustees upon such trusts for the benefit of the contributories as the liquidator, with the like sanction, shall think fit,
but so that no Member shall be compelled to accept any asset upon which there is any liability.

42.2 If the Company shall be wound up and the assets available for distribution amongst the Members as such
shall be insufficient to repay the whole of the paid up capital, such assets shall be distributed so that, as nearly as may be, the losses
shall be borne by the Members in proportion to the capital paid up, or which ought to have been paid up, at the commencement of the winding
up, on the Shares held by them respectively. And if in a winding up the assets available for distribution amongst the Members shall be
more than sufficient to repay the whole of the capital paid up at the commencement of the winding up, the excess shall be distributed
amongst the Members in proportion to the capital paid up at the commencement of the winding up on the Shares held by them respectively.
This Article is to be without prejudice to the rights of the holders of Shares issued upon special terms and conditions.

43. INDEMNITY

43.1 Every Indemnified Person shall, in the absence of his own dishonesty, wilful default or fraud, be indemnified
and held harmless out of the assets of the Company against all liabilities, loss, damage, cost or expense (including but not limited to
liabilities under contract, tort and statute or any applicable foreign law or regulation and all reasonable legal and other costs and
expenses on a full indemnity basis properly payable) incurred or suffered by him by or by reason of any act done, conceived in or omitted
in the conduct of the Company's business or in the discharge of his duties and the indemnity contained in this Article shall extend
to any Indemnified Person acting in any office or trust in the reasonable belief that
he has been appointed or elected to such office or trust notwithstanding any defect in such appointment or election.

27 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

43.2 No Indemnified Person shall be liable to the Company for acts, defaults or omissions of any other Indemnified
Person.

43.3 Every Indemnified Person shall be indemnified out of the funds of the Company against all liabilities
incurred by him by or by reason of any act done, conceived in or omitted in the conduct of the Company's business or in the discharge
of his duties in defending any proceedings, whether civil or criminal, in which judgment is given in his favour, or in which he is acquitted,
or in connection with any application in which relief from liability is granted to him by the court.

43.4 To the extent that any Indemnified Person is entitled to claim an indemnity pursuant to these Articles
in respect of amounts paid or discharged by him, the relative indemnity shall take effect as an obligation of the Company to reimburse
the person making such payment or effecting such discharge.

43.5 Each Member and the Company agree to waive any claim or right of action he or it may at any time have,
whether individually or by or in the right of the Company, against any Indemnified Person on account of any act or omission of such Indemnified
Person in the performance of his duties for the Company; provided however, that such waiver shall not apply to any claims or rights of
action arising out of the dishonesty, wilful default or fraud of such Indemnified Person or to recover any gain, personal profit or advantage
to which such Indemnified Person is not legally entitled.

43.6 Expenses incurred in defending any civil or criminal action or proceeding for which indemnification is
required pursuant to these Articles shall be paid by the Company in advance of the final disposition of such action or proceeding upon
receipt of an undertaking by or on behalf of the Indemnified Person to repay such amount if it shall ultimately be determined that the
Indemnified Person is not entitled to be indemnified pursuant to these Articles. Each Member of the Company shall be deemed to have acknowledged
and agreed that the advances of funds may be made by the Company as aforesaid, and when made by the Company under this Article are made
to meet expenditures incurred for the purpose of enabling such Indemnified Person to properly perform his or her duties to the Company.

44. CONTINUATION

44.1 The Company shall have the power, subject to the provisions of the Act and with the approval of a Special
Resolution, to continue as a body incorporated under the laws of any jurisdiction outside of the Cayman Islands and to be de-registered
in the Cayman Islands.

28 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

![](ea028469001_ex3-1img1.jpg)

45. MERGER AND CONSOLIDATION

45.1 The Company shall have the power to merge or consolidate with one or more other constituent companies
(as defined in the Act) upon such terms as the Directors may determine and (to the extent required by the Act) with the approval of a
Special Resolution.

46. AMENDMENT OF MEMORANDUM AND ARTICLES

46.1 Subject to the provisions of the Act, the Company may from time to time by Special Resolution alter or
amend the Memorandum or these Articles in whole or in part provided that no such amendment shall affect the special rights attaching to
any class of Shares without the consent or sanction provided for in these Articles.

---

| | |
|:---|:---|
| **Name, Address and Description of** | **Number of Shares Taken by Subscriber** |
| **Subscriber** |  |
| AGS Nominees 1 Limited | One (1) Share |
| 71 Fort Street |  |
| PO Box 500 |  |
| George Town |  |
| Grand Cayman KY1-1106 |  |
| Cayman Islands |  |
|  | /s/ Isabel Mason |
|  | Subscriber: Isabel Mason |
|  | Date: 13 Jan 2026 |

---

---

| | |
|:---|:---|
| /s/ Chanel Cranston | /s/ Chanel Cranston |
| Signature of Witness | Signature of Witness |
| Chanel Cranston | Chanel Cranston |
| 71 Fort Street | 71 Fort Street |
| PO Box 500 | PO Box 500 |
| George Town | George Town |
| Grand Cayman KY1-1106 | Grand Cayman KY1-1106 |
| Cayman Islands | Cayman Islands |
| Occupation: | Senior Corporate Administrator |
| Date: 13 Jan 2026 | Date: 13 Jan 2026 |

---

29 of 29 <br> *Auth Code: G00828986585* <br> *www.verify.gov.ky*

## Exhibit 3.2

**Exhibit 3.2**

**THE COMPANIES ACT (AS REVISED)**

**THE AMENDMENT TO THE MEMORANDUM OF ASSOCIATION**

**BY WAY OF SPECIAL RESOLUTION DATED 12 FEBRUARY 2026**

**OF**

**JATT II ACQUISITION CORP**

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
|  | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

The undersigned, whose name, address and description are set out below, wishes the Company to be incorporated as a company in the Cayman Islands in accordance with this Memorandum of Association, and agrees to take the number of shares in the capital of the Company as set out opposite the undersigned's name.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
|  | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

**CONTENTS**

1. Interpretation 1

2. Offices 3

3. Service Providers 3

4. Issue of Shares 4

5. Register of Members 4

6. Register of Beneficial Ownership 4

7. Record Date 5

8. Share Certificates 5

9. Transfer of Shares 5

10. Transmission of Shares 6

11. Redemption and Repurchase of Shares 7

12. Variation of Share Rights 7

13. Non-recognition of Trusts 7

14. Lien 8

15. Calls on Shares 8

16. Forfeiture of Shares 9

17. Increase of Capital 10

18. Alteration of Capital 11

19. General Meetings 11

20. Notice of General Meetings 12

21. Proceedings at General Meetings 12

22. Voting 13

23. Proxies and Corporate Representatives 15

24. Appointment and Removal of Directors 16

25. Resignation and Disqualification of Directors 17

26. Powers and Duties of Directors 17

27. Proceedings of Directors 18

28. Directors' Interests 20

29. Delegation of Directors' Powers 21

30. Alternate Directors 21

31. Committees of Directors 22

32. Officers 22

33. Directors' Remuneration 22

34. Seals and Deeds 23

35. Dividends 23

36. Reserves 24

37. Capitalisation of Profits 25

38. Share Premium Account 25

39. Accounting Records 25

40. Financial Year End 26

41. Service of Notices and Documents 26

42. Winding Up 27

43. Indemnity 27

44. Continuation 28

45. Merger and Consolidation 29

46. Amendment of Memorandum and Articles 29

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| i | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

**THE COMPANIES ACT (AS REVISED)**

**ARTICLES OF ASSOCIATION**

**OF**

**JATT II ACQUISITION CORP**

**BY WAY OF SPECIAL RESOLUTION DATED 12 FEBRUARY 2026**

1. INTERPRETATION

1.1 Table A of the First Schedule to the Act shall not apply to the Company.

1.2 In these Articles, the following terms shall have the following meanings unless the context otherwise requires:

**Act**: the Companies Act (as revised) of the Cayman Islands;

**Articles**: these articles of association of the Company as amended, restated or supplemented from time to time by Special Resolution;

**Auditors**: the auditors for the time being of the Company (if any);

**Beneficial Owner**: has the same meaning as in the BOT Act;

**BOT Act**: the Beneficial Ownership Transparency Act of the Cayman Islands;

**clear days**: in relation to the period of a notice, that period excluding the day on which the notice is served (or deemed to be served) and the day for which it is given or on which it is to take effect;

**Company**: the above named company;

**Directors**: the directors for the time being of the Company;

**Electronic Record**: has the same meaning as in the Electronic Transactions Act (as revised) of the Cayman Islands;

**Indemnified Person**: any Director, officer or member of a committee duly constituted under these Articles and any liquidator, manager or trustee acting in relation to the affairs of the Company (including anyone previously acting in such capacity) and his heirs, executors, administrators, personal representatives or successors or assigns;

**Member**: has the same meaning as in the Act;

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 1 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

**Memorandum**: the memorandum of association of the Company for the time being;

**Month**: a calendar month;

**Ordinary Resolution**: a resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) passed by a simple majority of such Members as, being entitled to do so, vote in person or, where proxies
are allowed, by proxy at a general meeting of the Company and where a poll is taken regard shall be had in computing a majority to the
number of votes to which each Member is entitled; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) approved in writing by all of the Members entitled to vote at a general meeting of the Company in one
or more instruments each signed by one or more of the Members and the effective date of the resolution so adopted shall be the date on
which the instrument, or the last of such instruments, if more than one, is executed;

**Register of Beneficial Ownership**: the beneficial ownership register to be kept in accordance with the BOT Act;

**Register of Members**: the register of Members to be kept in accordance with the Act and includes every duplicate Register of Members;

**Registered Office**: the registered office for the time being of the Company in the Cayman Islands;

**Seal**: the common seal of the Company (if any) and includes every duplicate seal;

**Secretary**: the secretary for the time being of the Company and any person appointed to perform any of the duties of the secretary;

**Share**: a share in the capital of the Company and includes a fraction of a share, such fractional share being subject to and carrying the corresponding fraction of liabilities, limitations, privileges, qualifications, restrictions, rights and other attributes of a whole share of the same class of shares;

**Share Premium Account**: the share premium account established in accordance with these Articles and the Act;

**Special Resolution**: a resolution that is described as such in its terms:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) passed by a majority of not less than two thirds of such Members as, being entitled to do so, vote in
person or, where proxies are allowed, by proxy at a general meeting of the Company of which notice specifying the intention to propose
the resolution as a special resolution has been duly given and where a poll is taken regard shall be had in computing a majority to the
number of votes to which each Member is entitled; or

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 2 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) approved in writing by all of the Members entitled to vote at a general meeting of the Company in one
or more instruments each signed by one or more of the Members and the effective date of the resolution so adopted shall be the date on
which the instrument, or the last of such instruments, if more than one, is executed; and

**Subscriber**: the Subscriber to the Memorandum.

1.3 Words importing the singular number include the plural number and vice versa and words importing the masculine
gender include the feminine gender.

1.4 Words importing persons include corporations and any other legal or natural persons.

1.5 Any reference to writing includes all modes of representing or reproducing words in a visible and legible
form, including in the form of an Electronic Record.

1.6 The word **may** shall be construed as permissive and the word **shall** shall be construed as imperative.

1.7 Any phrase introduced by the **terms including, include, in particular** or any similar expression
shall be merely illustrative and shall not limit the sense of the words preceding those terms.

1.8 Where any provision of the Act is referred to, the reference is to that provision as modified by any subsequent
law for the time being in force.

1.9 Unless the context otherwise requires, words and expressions defined in the Act bear the same meanings
in these Articles.

1.10 References to days are to calendar days, unless otherwise specified.

1.11 Headings are used for convenience only and shall not affect the construction of these Articles.

2. OFFICES

2.1 The Registered Office of the Company shall be at such place in the Cayman Islands as the Directors shall
from time to time determine.

2.2 The Company, in addition to its Registered Office, may establish and maintain such other offices in the
Cayman Islands or elsewhere as the Directors may from time to time determine.

3. SERVICE PROVIDERS

3.1 The Directors may appoint any person to act as a service provider to the Company and may delegate to any
such service provider any of the functions, duties, powers and discretions available to them as Directors, upon such terms and conditions
(including as to the remuneration payable by the Company) and with such powers of sub-delegation,
but subject to such restrictions, as they think fit.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 3 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

4. ISSUE OF SHARES

4.1 The Directors may (subject to the provisions of these Articles and the Act), without prejudice to any
rights attached to any existing Shares, offer, issue, allot, grant options over or otherwise dispose of the Shares with or without preferred,
deferred, qualified or other special rights or restrictions, whether in regard to dividends or other forms of distribution, voting, return
of capital or otherwise, and to such persons and on such terms and conditions and for such consideration, and at such times as they think
fit, provided no Share shall be issued at a discount (except in accordance with the provisions of the Act).

4.2 Any Share may, with the sanction of a Special Resolution, be issued on the terms that it is, or at the
option of the Company or the holder is liable, to be redeemed.

4.3 Notwithstanding the preceding Article, the Subscriber shall have the power to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) issue one Share to itself;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) transfer that Share by an instrument of transfer to any person; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) update the Register of Members in respect of the issue and transfer of that Share.

4.4 The Company shall not issue Shares to bearer.

4.5 The Company may, in accordance with the Act, issue fractions of Shares.

5. REGISTER OF MEMBERS

5.1 The Directors shall establish and maintain (or cause to be established and maintained) the Register of
Members at the Registered Office or at such other place determined by the Directors in the manner prescribed by the Act.

6. REGISTER OF BENEFICIAL OWNERSHIP

6.1 The Directors shall cause the Register of Beneficial Ownership to be established and maintained at the
Registered Office in the manner prescribed by law if and for as long as the Company is required by law to establish and maintain such
a register.

6.2 Every Member shall provide to the Company upon request written particulars of the beneficial ownership
of the Shares registered in such Member's name as the Company is required to collect for the Register of Beneficial Ownership and
shall advise the Company in writing in a timely manner of any changes in those particulars. If the Company is not provided with the information
required, a restrictions notice may be issued. Until a restrictions notice is withdrawn by the Registered Office or ceased by order of
the Grand Court of the Cayman Islands, the rights of the Member holding the affected Shares
to vote, transfer or otherwise deal with or receive any distribution (except in a liquidation of the Company) on the affected Shares under
the provisions of these Articles are suspended.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 4 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

7. RECORD DATE

7.1 The Directors may fix in advance a date as the record date to determine the Members entitled to notice
of or to vote at a meeting of the Members and, for the purpose of determining the Members entitled to receive payment of any dividend,
the Directors may, at or within 90 days prior to the date of the declaration of such dividend, fix a subsequent date as the record date
for such determination.

7.2 If no such record date is fixed, the record date shall be the date on which notice of the meeting is sent
or the date on which the resolution of the Directors declaring such dividend is adopted, as the case may be. A determination of Members
entitled to vote at any meeting of Members in accordance with this Article, shall apply to any adjournment thereof.

8. SHARE CERTIFICATES

8.1 Every Member shall be entitled, without payment, to a certificate of the Company specifying the Share
or Shares held by him and the amount paid up thereon.

8.2 Notwithstanding the provisions of these Articles, the Directors may resolve not to issue share certificates
to Members of the Company.

8.3 The Company shall not be bound to issue more than one certificate for Shares held jointly by more than
one person, and delivery of a certificate to one joint holder shall be sufficient delivery to all.

8.4 If a share certificate is defaced, lost or destroyed, it may be replaced on payment of such fee (if any)
and on such terms (if any) as to evidence and indemnity, and on the payment of expenses of the Company in investigating such evidence
and preparing such indemnity as the Directors shall think fit and, in case of defacement, on delivery of the old certificate to the Company
for cancellation.

9. TRANSFER OF SHARES

9.1 The instrument of transfer of any Share shall be executed by or on behalf of the transferor (and, if the
Directors so determine, the transferee). The transferor shall be deemed to remain the holder of the Share until the name of the transferee
is entered in the Register of Members in respect of such Share. All instruments of transfer, once registered, may be retained by the Company.

9.2 Subject to any applicable restrictions contained in these Articles, Shares shall be transferred in any
usual or common form approved by the Directors.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 5 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

9.3 The Directors may, in their absolute discretion and without assigning any reason therefore, decline to
register any transfer of any Share. The Directors may require reasonable evidence to show the right of the transferor to make the transfer.

9.4 If the Directors decline to register a transfer of Shares they shall send notice of the refusal to the
transferee within one month after the date on which the transfer was lodged with the Company.

9.5 The Directors may also suspend the registration of the transfers at such times and for such periods as
the Directors may from time to time determine.

10. TRANSMISSION OF SHARES

10.1 If a Member dies, the survivor or survivors (where he was a joint holder), and the legal personal representative
(where he was sole holder), shall be the only person recognised by the Company as having any title to the Share. The estate of a deceased
Member is not thereby released from any liability in respect of any Share held by him, whether solely or jointly. For the purpose of this
Article, legal personal representative means the person to whom probate or letters of administration has or have been granted in the Cayman
Islands or, if there is no such person, such other person as the Directors may in their absolute discretion determine to be the person
recognised by the Company for the purpose of this Article.

10.2 Any person becoming entitled to a Share in consequence of the death or bankruptcy of a Member or otherwise
by operation of applicable law may elect, upon such evidence being produced as may be required by the Directors as to his entitlement,
either be registered himself as a Member in respect of the Share or, instead of being registered himself, to make such transfer of the
Share as the deceased or bankrupt Member could have made.

10.3 If the person so becoming entitled elects to be registered himself, he shall deliver or send to the Company
a notice in writing signed by him stating that he so elects. If he shall elect to transfer the Shares, he shall signify his election by
signing an instrument of transfer of such Shares in favour of his transferee. All the limitations, restrictions and provisions of these
Articles relating to the right to transfer and the registration of transfers of Shares shall be applicable to any such notice or instrument
of transfer as aforesaid as if the death of the Member or other event giving rise to the transmission had not occurred and the notice
or instrument of transfer was an instrument of transfer signed by such Member.

10.4 A person becoming entitled to a Share in consequence of the death or bankruptcy of the Member (or otherwise
by operation of applicable law), upon such evidence being produced as may be required by the Directors as to his entitlement, shall be
entitled to the same dividends and other monies payable in respect of the Share as he would be entitled if he were the holder of such
Share. However, he shall not be entitled, until he becomes registered as the holder of such Share, to receive notices of or to attend
or vote at general meetings of the Company or (except as aforesaid) to exercise any other rights or privileges of a Member. The Directors
may at any time give notice requiring such person
to elect either to be registered himself or to transfer the Share and, if the notice is not complied with within sixty days, the Directors
may thereafter withhold payment of all dividends and other monies payable in respect of the Shares until the requirements of the notice
have been complied with.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 6 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

11. REDEMPTION AND REPURCHASE OF SHARES

11.1 Subject to the provisions of the Act and the Memorandum, the Company may:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) purchase its own Shares (including any redeemable Shares) in such manner and on such terms as the Directors
may agree with the relevant Member unless following such purchase there would no longer be any issued Shares and may make payment for
such purchase or for any redemption of Shares in any manner authorised by the Act, including out of capital; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) reduce its share capital and any capital redemption reserve fund in any manner whatsoever.

12. VARIATION OF SHARE RIGHTS

12.1 If at any time the share capital is divided into different classes of Shares, all or any of the special
rights attached to any class of Shares (unless otherwise provided by the terms of issue of the Shares of that class) may be varied or
abrogated with the consent in writing of the holders of not less than two thirds of the issued Shares of that class or with the sanction
of a resolution passed by the holders of not less than two thirds of the issued Shares of that class as may be present in person or by
proxy at a separate general meeting of the holders of the Shares of that class. To any such separate general meeting, all of the provisions
of these Articles relating to general meetings shall mutatis mutandis apply, but so that the necessary quorum shall be any one or more
persons holding or representing by proxy not less than one third of the issued Shares of the class and that any holder of Shares of the
relevant class present in person or by proxy may demand a poll.

12.2 For the purpose of a separate class meeting, the Directors may treat two or more of all classes of Shares
as forming one class if they consider that such class of Shares would be affected in the same way by the proposals under consideration.

12.3 The rights conferred upon the holders of any Shares shall not, unless otherwise expressly provided in
the rights attaching to such Shares, be deemed to be altered by the creation or issue of further Shares ranking *pari passu* therewith.

13. NON-RECOGNITION OF TRUSTS

13.1 Except as required by the Act or these Articles, or under an order of a court of competent jurisdiction,
the Company shall not be bound by or compelled to recognise in any way, even when notice thereof is given to it, any equitable, contingent,
future or partial interest in any Share, or any other rights in respect of any Share other
than an absolute right to the entirety thereof in the registered holder.s

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 7 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

14. LIEN

14.1 The Company shall have a first and paramount lien on every Share (not being a fully paid Share) for all
moneys (whether presently payable or not) called or payable at a date fixed by or in accordance with the terms of issue of such Share
in respect of that Share, and the Company shall also have a first and paramount lien on every Share (other than a fully paid up Share)
standing registered in the name of a Member, whether singly or jointly with any other person for all debts and liabilities of a Member
or his estate to the Company, whether the same shall have been incurred before or after notice to the Company of any interest of any person
other than such Member, and whether the time for the payment or discharge of the same shall have actually arrived or not, and notwithstanding
that the same are joint debts or liabilities of such Member or his estate and any other person, whether a Member or not. The Directors
may at any time, either generally or in any particular case, waive any lien that has arisen or declare any Share to be wholly or in part
exempt from the provisions of this Article. The Company's lien, if any, on a Share shall extend to all dividends payable thereon.

14.2 The Company may sell, in such manner as the Directors think fit, any Share on which the Company has a
lien, provided a sum in respect of which the lien exists is presently payable, and is not paid within fourteen days after a notice in
writing has been given to the registered holder for the time being of the Share, demanding payment of the sum presently payable and giving
notice of the intention to sell in default of such payment.

14.3 For giving effect to any such sale, the Directors may authorise any person to transfer the Share sold
to the purchaser thereof. The purchaser shall be registered as the holder of the Share comprised in any such transfer and he shall not
be bound to see to the application of the purchase money, nor shall his title to the Share be affected by any irregularity or invalidity
in the proceedings relating to the sale.

14.4 The net proceeds of such sale shall be applied in payment or discharge of the debt or liability in respect
of which the lien exists and as is presently payable, and any balance shall (subject to a like lien for debts or liabilities not presently
payable as existed upon the Shares prior to the sale) be paid to the person who was the registered holder of the Share immediately before
such sale.

15. CALLS ON SHARES

15.1 The Directors may from time to time make calls upon the Members in respect of any moneys unpaid on
 their Shares (whether in respect of the par value of the Shares or premium or otherwise and not, by the terms of issue thereof, made
 payable at a future date fixed by or in accordance with such terms of issue); and each Member shall (subject to the Company serving
 upon him at least 14 days' notice specifying the time or times and place of payment) pay to the Company at the time or times
 and place so specified the amount called on his Shares. A call may be revoked or postponed by the Directors wholly or in part as the
 Directors may determine. A call shall be deemed to have been made at the time when
the resolution of the Directors authorising the call was passed.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 8 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

15.2 Payment of a call may be made by instalments on the direction of the Directors.

15.3 If a sum called in respect of a Share is not paid before or on the day appointed for payment thereof,
the person from whom the sum is due shall pay interest on the sum from the day payment is due to the time of the actual payment at such
rate as the Directors may determine, but the Directors may waive payment of such interest wholly or in part.

15.4 Any sum payable in respect of a Share on issue or allotment or at any fixed date, whether in respect of
the par value of the Share or premium or otherwise, shall be deemed to be a call and if it is not paid all the relevant provisions as
to payment of interest, forfeiture or otherwise of these Articles shall apply as if such sum had become due and payable by virtue of a
call duly made and notified.

15.5 The Directors may issue Shares with different terms as to the amount and times of payment of calls.

15.6 The joint holders of a Share shall be jointly and severally liable to pay calls in respect thereof.

15.7 The Directors may, if they think fit, receive from any Member willing to advance the same, all or any
part of the moneys uncalled and unpaid upon any Shares held by him; and may (until the amount would otherwise become payable) pay interest
at such rate (not exceeding six per cent without the sanction of the Company in general meeting) as may be agreed upon between the Member
paying the sum in advance and the Directors.

16. FORFEITURE OF SHARES

16.1 If a Member fails to pay any call or instalment of a call by the date it becomes due and payable, the
Directors may, at any time thereafter while such call or instalment remains unpaid, give notice to the Member requiring payment of the
unpaid portion of the call or instalment, together with any accrued interest and expenses incurred by the Company by reason of such non-payment.

16.2 The notice shall specify where and by what date (not being less than the expiration of 14 days'
from the date of the notice) payment is to be made and shall state that if it is not complied with the Shares in respect of which the
call was made will be liable to be forfeited. The Directors may accept the surrender of any Share liable to be forfeited hereunder and,
in such case, references to these Articles to forfeiture shall include surrender.

16.3 If such notice is not complied with, any Share in respect of which the notice was given may thereafter,
before the payment of all calls or instalments and interest due in respect thereof has been made, be forfeited by a resolution of the
Directors. Such forfeiture shall include all dividends declared, other distributions or other monies payable
in respect of the forfeited Shares and not paid before the forfeiture.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 9 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

16.4 A forfeited Share may be sold, re-allotted or otherwise disposed of upon such terms and in such manner
as the Directors shall think fit, and at any time before a sale, re-allotment or disposition, the forfeiture may be cancelled on such
terms as the Directors think fit.

16.5 A person whose Shares have been forfeited shall cease to be a Member in respect of the forfeited Shares,
but shall remain liable to pay to the Company all moneys which at the date of forfeiture were presently payable by him in respect of the
Shares together with interest at such rate as the Directors may determine from the date of forfeiture until payment, but his liability
shall cease if and when the Company receives payment in full of all amounts due in respect of the Shares. The Company may enforce payment
without being under any obligation to make any allowance for the value of the Shares forfeited.

16.6 An affidavit in writing by a Director or Secretary of the Company that a Share has been duly forfeited
on a specified date, shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the Share.
The Company may receive the consideration, if any, given for the Share on any sale, re-allotment or disposition thereof and may authorise
some person to execute a transfer of the Share in favour of the person to whom the Share is sold, re-allotted or otherwise disposed of,
and he shall thereupon be registered as the holder of the Share, and shall not be bound to see to the application of the purchase money
(if any) nor shall his title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture,
sale, re-allotment or disposition of the Share.

16.7 The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which,
by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the par value of the Share, or by way of premium
or otherwise, as if the same had been made payable by virtue of a call duly made and notified to the Member.

17. INCREASE OF CAPITAL

17.1 The Company may from time to time by Ordinary Resolution increase its share capital by such sum, to be
divided into new Shares of such par value, and with such rights, priorities and privileges attached thereto as the resolution shall prescribe.

17.2 Subject to any directions given by the Company in a general meeting, all new Shares shall be at the disposal
of the Directors in accordance with these Articles.

17.3 The new Shares shall be subject to the same provisions of these Articles with reference to the payment
of calls, lien, forfeiture, transfer, transmission and otherwise, as the Shares in the original share capital.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 10 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

18. ALTERATION OF CAPITAL

18.1 The Company may from time to time by Ordinary Resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) consolidate and divide all or any of its share capital into Shares of larger par value than its existing
Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) sub divide its existing Shares, or any of them, into Shares of smaller par value than is fixed by the
Memorandum, subject nevertheless to the provisions of section 13 of the Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) cancel any Shares which, at the date of the passing of the resolution, have not been taken or agreed to
be taken by any person; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) convert all or any paid up Shares into stock, and reconvert all or any stock into paid up Shares of any
denomination.

18.2 The Company may from time to time by Special Resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) divide its Shares into several classes and attach to such classes any preferential, deferred, or special
rights or restrictions in accordance with these Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) change the currency denomination of its share capital; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) reduce its share capital and any capital redemption reserve fund in any manner whatsoever.

19. GENERAL MEETINGS

19.1 The Directors may, whenever they think fit, convene an extraordinary general meeting. If at any time there
are not sufficient Directors capable of acting to form a quorum, any Director, or any one or more Members holding in the aggregate not
less than one third of the total issued share capital of the Company entitled to vote, may convene an extraordinary general meeting in
the same manner as nearly as possible as that in which meetings may be convened by the Directors.

19.2 The Directors shall, upon the requisition in writing of one or more Members holding in the aggregate not
less than one tenth of such paid up capital of the Company as at the date of the requisition carries the right of voting at general meetings,
convene an extraordinary general meeting. Any such requisition shall express the object of the meeting proposed to be called, and must
be signed by the requisitionists and deposited at the Registered Office, and may consist of several documents in like form, each signed
by one or more requisitionists.

19.3 If there are no Directors as at the date of the deposit of the Members' requisition or if the Directors
do not convene a general meeting within 21 days from the date of the deposit, the requisitionists or any or any of them or any other Member
or Members holding in the aggregate not less than one tenth of such paid
up capital of the Company as at the date of the requisition, may convene an extraordinary general meeting. A general meeting convened
by requisitionists shall be convened in the same manner as nearly as possible as that in which general meetings are to be convened by
the Directors.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 11 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

20. NOTICE OF GENERAL MEETINGS

20.1 At least five clear days' notice shall be given of any general meeting. Every notice shall specify
the place, the day and the time of meeting and, in the case of special business, the general nature of the business to be conducted at
the general meeting, and shall be given in the manner provided in these Articles or in such other manner (if any) as may be prescribed
by the Company, to such persons as are entitled to receive such notices from the Company. A general meeting may be convened by such shorter
notice, or without notice, by a majority in number of the Members having the right to attend and vote at the meeting, being a majority
together holding not less than ninety-five percent in nominal value of the Shares giving that right.

20.2 The accidental omission to give notice of a meeting to, or the non-receipt of a notice of a meeting by,
any Member entitled to receive notice shall not invalidate the proceedings at any meeting.

21. PROCEEDINGS AT GENERAL MEETINGS

21.1 All business shall be deemed special that is transacted at an extraordinary general meeting.

21.2 No business shall be transacted at any general meeting unless a quorum of Members is present at the time
that the meeting proceeds to business, but the absence of a quorum shall not preclude the appointment, choice or election of a chairman,
which shall not be treated as part of the business of the Meeting. Save as herein otherwise provided, one or more Members holding in the
aggregate not less than one third of the total issued share capital of the Company present in person or by proxy and entitled to vote
shall be a quorum.

21.3 If within five minutes (or such longer time as the chairman of the meeting may determine to wait) after
the time appointed for the meeting, a quorum is not present, the meeting, if convened upon the requisition of Members, shall be dissolved.
In any other case, it shall stand adjourned to the same day in the next week, at the same time and place, and if at the adjourned meeting
a quorum is not present within half an hour from the time appointed for the meeting, the Members present shall be a quorum.

21.4 A meeting of the Members may be held by telephone, electronic or other communication facilities (including,
without limiting the generality of the foregoing, by telephone or video conferencing) by which all persons participating in the meeting
can communicate with each other simultaneously and instantaneously, and participation in such a general meeting shall constitute presence
in person at such meeting.

21.5 Any Director shall be entitled to attend and speak at any general meeting of the Company.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 12 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

21.6 The chairman (if any) of the Board of Directors shall preside as chairman at every general meeting of
the Company. If there is no such chairman, or if at any meeting he is not present within five minutes after the time appointed for holding
the meeting or is unwilling to act as chairman, the Directors present shall choose one of their number to act or, if only one Director
is present, he shall preside as chairman if willing to act. If no Director is present, or if each of the Directors present declines to
take the chair, the Members present and entitled to vote shall elect one of their number to be chairman.

21.7 The chairman may, with the consent of a meeting at which a quorum is present (and shall if so directed
by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting
other than the business left unfinished at the meeting from which the adjournment took place. When a meeting is adjourned for ten days
or more, notice of the adjourned meeting shall be given as in the case of an original meeting. Save as aforesaid, it shall not be necessary
to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.

22. VOTING

22.1 Save where a Special Resolution or other greater majority is required by the Act or these Articles, any
question proposed for consideration at any general meeting shall be decided by an Ordinary Resolution.

22.2 At any general meeting, a resolution put to the vote of the meeting shall be decided on a show of hands,
unless (before or on the declaration of the result of the show of hands, or on the withdrawal of any other demand for a poll) a poll is
demanded by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the chairman of the meeting; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) at least three Members present in person or by proxy; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any Member or Members present in person or by proxy and holding collectively not less than one tenth of
the total voting rights of all the Members having the right to vote at such meeting; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a Member or Members present in person or by proxy holding Shares conferring the right to vote at such
meeting, being Shares on which an aggregate sum has been paid up equal to not less than one tenth of the total sum paid up on all such
Shares conferring such right.

22.3 Unless a poll is duly demanded and the demand is not withdrawn, a declaration by the chairman that a resolution
has, on a show of hands, been carried or carried unanimously, or by a particular majority, or lost and an entry to that effect in the
minutes of the proceedings of the Company shall be conclusive evidence of that fact, without proof of the number or proportion of the
votes recorded in favour of, or against, that resolution. The demand for a poll may be withdrawn by the person or any persons making it
at any time prior to the declaration of the result of the poll.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 13 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

22.4 If a poll is duly demanded, it shall be taken in such manner as the chairman directs, and the result of
the poll shall be deemed to be the resolution of the meeting at which the poll was demanded.

22.5 In the case of an equality of votes at a general meeting, whether on a show of hands or on a poll, the
chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall not be entitled to a second or
casting vote and the resolution shall fail.

22.6 A poll demanded on the election of a chairman or on a question of adjournment shall be taken forthwith.
A poll demanded on any other question shall be taken in such manner and either forthwith or at such time later in the meeting as the chairman
of the meeting shall direct.

22.7 The demand for a poll shall not prevent the continuance of a meeting for the transaction of any business
other than the question on which the poll has been demanded and it may be withdrawn at any time before the close of the meeting or the
taking of the poll, whichever is the earlier.

22.8 On a poll votes may be cast either personally or by proxy.

22.9 A person entitled to more than one vote on a poll need not use all his votes or cast all the votes he
uses in the same way.

22.10 On a show of hands, every Member present in person or by proxy and entitled to vote shall have one vote.
On a poll, every Member present in person or by proxy and entitled to vote shall have one vote for each Share of which he is the registered
holder.

22.11 In the case of joint holders of a Share, the vote of the senior who tenders a vote, whether in person
or by proxy, shall be accepted to the exclusion of the votes of the other joint holders; and for this purpose seniority shall be determined
by the order in which the names stand in the Register of Members in respect of the joint holding.

22.12 A Member of unsound mind, or, in respect of whom an order has been made by any court having jurisdiction
in lunacy, may vote, whether on a show of hands or on a poll, by his receiver, committee, *curator bonis* or other person of similar
nature appointed by such court, and any such receiver, committee, curator bonis or other person may vote by proxy and may otherwise act
and be treated as such Member for the purpose of the general meetings.

22.13 No Member, unless the Directors otherwise determine, shall be entitled to vote at any general meeting,
unless all calls or other sums presently payable by him in respect of Shares in the Company have been paid.

22.14 No objection shall be raised as to the qualification of any voter or as to whether any votes have been
properly counted except at the general meeting or adjourned general meeting at which the vote objected to is given or tendered and every
vote not disallowed at the meeting shall be valid. Any objection made in due time and in accordance with these Articles shall be referred
to the chairman whose decision shall be final and conclusive.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 14 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

23. PROXIES AND CORPORATE REPRESENTATIVES

23.1 Subject to these Articles, each Member entitled to attend and vote at a general meeting may attend and
vote at the general meeting:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) in person, or where a Member is a company or non-natural person, by a duly authorised corporate representative; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) by one or more proxies.

23.2 A proxy or corporate representative need not be a Member.

23.3 The instrument appointing a proxy shall be in writing under the hand of the Member or his duly authorised
attorney or, if the Member is a corporation, under the hand of its duly authorised representative.

23.4 An instrument appointing a proxy may be in any usual or common form (or such other form as the Directors
may approve) and may be expressed to be for a particular meeting or any adjournment thereof or may appoint a standing proxy until notice
of revocation is received at the Registered Office or at such place or places as the Directors may otherwise specify for the purpose.

23.5 Any corporation which is a Member of the Company may by resolution of its directors or other governing
body authorise such person as it thinks fit to act as its representative at any meeting of the Company or of any class of Members of the
Company, and the person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as
that corporation could exercise if it were an individual Member of the Company.

23.6 The instrument appointing a proxy or corporate representative, and the power of attorney (if any) under
which it is signed, together with such other evidence as to its due execution as the Directors may from time to time require, shall be
deposited at the Registered Office of the Company or at such other place as is specified for that purpose in the notice convening the
meeting or in any notice of any adjournment or, in either case or the case of a written resolution, in any document sent therewith, not
less than 24 hours (or such longer or shorter time as the Directors may determine) before the time for holding the meeting or adjourned
meeting at which the person named in the instrument proposes to vote.

23.7 In default of any of the provisions in these Articles to deposit any instrument of proxy or authorisation
at the Registered Office of the Company or at such other place as is specified for that purpose in the notice convening the meeting, the
instrument of proxy or authorisation shall not be treated as valid provided that the chairman of the meeting may in his discretion accept
an instrument of proxy or authorisation sent by email or fax upon receipt of email or fax confirmation that the signed original thereof
has been sent.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 15 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

23.8 The operation of a standing proxy or authorisation shall be suspended at any general meeting or adjournment
thereof at which the Member is present in person or by specially appointed proxy. The Directors may require evidence as to the due execution
and continuing validity of any standing proxy or authorisation and the operation of any such standing proxy or authorisation shall be
deemed to be suspended until the Directors determine that they have received such satisfactory evidence.

23.9 In the case of a poll taken subsequently to the date of a meeting or adjourned meeting, the instrument
appointing the proxy or corporate representative referred to in these Articles shall be deposited at the Registered Office of the Company
or at such other place as is specified for that purpose in the notice convening the meeting before the time appointed for the taking of
the poll.

23.10 The instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a
poll, to speak at the meeting and to vote on any amendment of a written resolution or amendment of a resolution put to the meeting for
which it is given as the proxy thinks fit. The instrument of proxy or authorisation shall, unless the contrary is stated therein, be valid
as well for any adjournment of the meeting as for the meeting to which it relates.

23.11 A vote given in accordance with the terms of an instrument of proxy or authorisation shall be valid notwithstanding
the previous death or unsoundness of mind of the principal, or revocation of the proxy or of the corporate authority, unless notice in
writing of such death, unsoundness of mind or revocation was received by the Company at the Registered Office (or such other place as
may be specified for the delivery of instruments of proxy or authorisation in the notice convening the meeting or other documents sent
therewith) before the commencement of the general meeting, or adjourned meeting, at which the instrument or proxy is used.

23.12 In the case of a written resolution to be signed by a corporate representative, the instrument appointing
the corporate representative shall be deposited at the Registered Office of the Company or at such other place as is specified for that
purpose in the notice convening the meeting prior to the effective date of the written resolution.

23.13 Subject to the Act, the Directors may at their discretion waive any of the provisions of these Articles
relating to proxies or authorisations and, in particular, may accept such verbal or other assurances as they think fit as to the right
of any person to attend, speak and vote on behalf of any Member at general meetings or to sign written resolutions.

24. APPOINTMENT AND REMOVAL OF DIRECTORS

24.1 The names of the first Directors shall be determined in writing by the subscriber of the Memorandum.

24.2 The number of Directors shall be not less than one nor, unless the Members by Ordinary Resolution may
otherwise determine, more than ten. Directors shall serve for such term as the Members by Ordinary Resolution may determine, or in the absence
of such determination, until they are removed from office or are disqualified or resign under the terms of these Articles.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 16 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

24.3 The Directors shall have the power at any time, and from time to time, to appoint any person to be a Director,
either to fill a vacancy or as an additional Director.

24.4 The Company may by Ordinary Resolution appoint and remove a Director or Directors.

24.5 No shareholding qualification shall be required for Directors unless otherwise required by the Company
by Ordinary Resolution.

25. RESIGNATION AND DISQUALIFICATION OF DIRECTORS

25.1 The office of Director shall *ipso facto* be vacated if the Director:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) resigns his office by notice in writing to the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) becomes of unsound mind and the Directors resolve that his office is vacated; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) becomes bankrupt under the laws of any country or makes any arrangement or composition with his creditors generally; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) if he ceases to be a Director by virtue of, or becomes prohibited from being a Director by reason of, an order made under any provisions
of any law or enactment.

26. POWERS AND DUTIES OF DIRECTORS

26.1 The business of the Company shall be managed by the Directors, who may pay all expenses incurred in promoting
and registering the Company and may exercise all such powers of the Company as are not, by the Act or these Articles, required to be exercised
by the Company in general meeting, subject, nevertheless, to any clause of these Articles, to the provisions of the Act and to such regulations,
being not inconsistent with the aforesaid clauses or provisions, as may be prescribed by the Company in general meeting but no regulation
made by the Company in general meeting shall invalidate any prior act of the Directors which would have been valid if that regulation
had not been made.

26.2 The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its
undertaking, property and assets (present and future) and uncalled capital or any part thereof, to issue debentures, debenture stock and
other securities whenever money is borrowed or as security for any debt, liability or obligation of the Company or of any third party.

26.3 All cheques, promissory notes, drafts, bills of exchange and other instruments, whether negotiable or
not, and all receipts for moneys paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may
be, in such manner as the Directors shall from time to time by resolution determine.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 17 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

26.4 The Directors on behalf of the Company may provide benefits, whether by the payment of gratuities or pensions
or otherwise, for any person including any Director or former Director who has held any executive office or employment with the Company
or any body corporate which is or has been a subsidiary or affiliate of the Company or a predecessor in the business of the Company or
of any such subsidiary or affiliate, and to any member of his family or any person who is or was dependent on him, and may contribute
to any fund and pay premiums for the purchase or provision of any such gratuity, pension or other benefit, or for the insurance of any
such person.

26.5 No document or deed otherwise duly executed and delivered by or on behalf of the Company shall be regarded
as invalid merely because at the date of delivery of the deed or document, the Director, Secretary or other officer or person who shall
have executed the same and/or affixed the Seal (if any) thereto as the case may be for and on behalf of the Company shall have ceased
to hold such office or to hold such authority on behalf of the Company.

26.6 The Directors may from time to time appoint one of their number to be a managing director, joint managing
director or an assistant managing director or to hold any other employment or executive office with the Company for such period and upon
such terms as the Directors may determine and may revoke or terminate any such appointments. Any such revocation or termination as aforesaid
shall be without prejudice to any claim for damages that such Director may have against the Company or the Company may have against such
Director for any breach of any contract of service between him and the Company which may be involved in such revocation or termination.
Any person so appointed shall receive such remuneration (if any) (whether by way of salary, commission, participation in profits or otherwise)
as the Directors may determine, and either in addition to or in lieu of his remuneration as a Director.

26.7 Notwithstanding any provision in these Articles to the contrary, a sole Director shall be entitled to
exercise all of the powers and functions of the Directors which may be imposed on them by Act or by these Articles.

27. PROCEEDINGS OF DIRECTORS

27.1 The Directors may meet together (either within or without the Cayman Islands) for the despatch of business,
adjourn and otherwise regulate their meetings and proceedings, as they think fit. Questions arising at any meeting shall be decided by
a majority of votes. In case of an equality of votes the chairman shall not have a second or casting vote and the motion shall be deemed
to have been lost.

27.2 A Director or alternate Director may, and the Secretary on the requisition of a Director or alternate
Director shall, at any time, summon a meeting of Directors by at least five days' notice in writing to every Director and alternate
Director which notice shall set forth the general nature of the business to be considered provided however that notice may be waived by
all the Directors (or their alternates) either at, before or retrospectively after the meeting is held provided further that notice or
waiver thereof may be given by email or fax.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 18 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

27.3 The quorum for the transaction of the business of the Directors may be fixed by the Directors and unless
so fixed by the Directors, shall be two Directors, and shall be one if there is a sole Director. An alternate appointed by a Director
shall be counted in a quorum at a meeting at which the Director appointing him is not present provided always that where a Director is
acting in his own right and also as an alternate he is only counted once in the quorum. A Director who ceases to be a Director at a meeting
of the Directors may continue to be present and to act as a Director and be counted in the quorum until the termination of the meeting
provided no other Director objects and if otherwise a quorum of Directors would not be present.

27.4 The continuing Directors may act notwithstanding any vacancy in their body, but, if and so long as their
number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing Directors
may act for the purpose of increasing the number of Directors to that number, or of summoning a general meeting of the Company, but for
no other purpose.

27.5 The Directors may elect a chairman of their meetings and determine the period for which he is to hold
office; but if no such chairman is elected, or if at any meeting the chairman is not present within five minutes after the time appointed
for holding the same, the Directors present may choose one of their number to be chairman of the meeting.

27.6 A resolution in writing signed by all of the Directors or all of the members of a committee of Directors
for the time being entitled to receive notice of a meeting of the Directors (or by an alternate Director as provided in these Articles),
including a resolution signed in counterpart and/or sent or evidenced by way of signed fax or electronic transmission, shall be as valid
and effectual as if it had been passed at a meeting of the Directors or of a committee of Directors duly called and constituted.

27.7 To the extent permitted by law, a meeting of the Directors or a committee appointed by the Directors may
be held by means of such telephone, electronic or other communication facilities (including, without limiting the generality of the foregoing,
by telephone or by video conferencing) as permit all persons participating in the meeting to communicate with each other simultaneously
and instantaneously and participation in such a meeting shall constitute presence in person at such meeting. Such a meeting shall be deemed
to take place where the largest group of those Directors participating in the meeting is physically assembled, or, if there is no such
group, where the chairman of the meeting then is.

27.8 All acts done by any meeting of the Directors or of a committee of Directors, or by any person acting
as a Director shall, notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director
or person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such person had been duly appointed
and was qualified to be a Director.

27.9 The Directors shall cause minutes to be made and records kept for the purpose of recording:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all appointments of officers made by the Directors;

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 19 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the names of the Directors and other persons present at each meeting of the Directors and of any committee
of the Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) all resolutions and proceedings at all meetings of the Members of the Company or any class of Members
and of the Directors and of committees of Directors; and the chairman of all such meetings or of any meeting confirming the minutes thereof
shall sign the same.

28. DIRECTORS' INTERESTS

28.1 A Director may hold any other office or place of profit with the Company (except that of Auditor) in conjunction
with his office of Director for such period and upon such terms as to remuneration and otherwise as the Directors may determine.

28.2 A Director or officer may act by himself or his firm in a professional capacity for the Company (otherwise
than as Auditor), and he or his firm shall be entitled to remuneration for professional services as if he were not a Director or officer.

28.3 No Director or officer shall be disqualified from his office or prevented by such office from holding
any office or place of profit under the Company or under any company in which the Company shall be a Member or have any interest, or from
contracting with the Company, either as vendor, purchaser or otherwise, nor shall any such contract or any contract or transaction entered
into by or on behalf of the Company in which any Director or officer shall be in any way interested be or be liable to be avoided nor
shall any Director or officer so contracting, dealing or being so interested be liable to account to the Company for any profit realised
by any such contract or transaction by reason of such Director holding office or of the fiduciary relation thereby established.

28.4 A Director (or his alternate Director in his absence) shall be at liberty to vote in respect of any contract
or transaction in which he is interested provided that the nature of the interest of the Director in any such contract or transaction
shall be disclosed by him at or prior to its consideration and any vote thereon.

28.5 The nature of the interest of any Director or officer in any contract, dealing or transacting with or
affecting the Company shall be disclosed by him at or prior to its consideration and any vote thereon and a general notice that a Director
or officer is a shareholder of any specified firm or company and/or is to be regarded as interested in any transaction with such firm
or company shall be sufficient disclosure hereunder and after such general notice it shall not be necessary to give special notice relating
to any particular transaction.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 20 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

29. DELEGATION OF DIRECTORS' POWERS

29.1 Directors may from time to time and at any time by power of attorney or otherwise appoint any company,
firm or person or fluctuating body of persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys
of the Company for such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the
Directors under these Articles) and for such period and subject to such conditions as they may think fit, and any such power of attorney
may contain such provisions for the protection and convenience of persons dealing with any such attorney and of such attorney as the Directors
may think fit and may also authorise any such attorney to delegate all or any of the powers, authorities and discretions vested in him.

29.2 The Directors may delegate any of the powers exercisable by them to a Managing Director, Director or any
other person or persons acting individually or jointly as they may from time to time by resolution appoint upon such terms and conditions
and with such restrictions as they may think fit, and may from time to time by resolution revoke, withdraw, alter or vary all or any such
powers.

30. ALTERNATE DIRECTORS

30.1 Any Director may by writing appoint any other Director, or other person willing to act, to be his alternate
and remove his alternate so appointed by him. Such appointment or removal shall be by notice to the Registered Office signed by the Director
making or revoking the appointment or in any other manner approved by the Directors, and shall be effective on the date the notice is
served and the alternate shall be notified of such appointment or revocation. Subject to the removal by the appointing Director, the alternate
shall continue in office until the date on which the Director who appointed him ceases to be a Director. An alternate may also be a Director
in his own right and may act as alternate to more than one Director.

30.2 An alternate shall be entitled to receive notice of all meetings of the Directors, attend, be counted
in the quorum, vote and act in the place of the Director who appointed him at every such meeting at which the appointing Director is not
personally present, and generally to perform all the functions of the Director who appointed him as a Director in his absence.

30.3 These Articles (except as regards powers to appoint an alternate and remuneration) apply equally to the
alternate as though he were the Director in his own right.

30.4 An alternate Director shall be deemed for all purposes to be a Director and shall alone be responsible
for his own acts and defaults and shall not be deemed to be the agent of the Director appointing him. The signature of an alternate to
any resolution in writing of the Directors or a committee thereof shall, unless the terms of the appointment provide to the contrary,
be as effective as the signature of each Director to whom he is alternate Director.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 21 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

31. COMMITTEES OF DIRECTORS

31.1 The Directors may delegate any of their powers to committees consisting of such member or members of their
body as they think fit; any committee so formed shall, in the exercise of the powers so delegated, conform to any regulations that may
be imposed on it by the Directors.

31.2 A committee may elect a chairman of its meetings; if no such chairman is elected, or if at any meeting
the chairman is not present within five minutes after the time appointed for holding the same, the members present may choose one of their
number to be chairman of the meeting.

31.3 A committee may meet and adjourn as it thinks proper. Questions arising at any meeting shall be determined
by a majority of votes of the members present and in case of an equality of votes the chairman shall not have a second or casting vote
and the motion shall be deemed to have been lost.

32. OFFICERS

32.1 The Directors may appoint a Secretary and such other officers as they may from time to time consider necessary
upon such terms as to duration of office, remuneration and otherwise as they may think fit. Such Secretary or other officers need not
be Directors and in the case of the other officers may be ascribed such titles as the Directors may decide and the Directors may revoke
or terminate any such election or appointment. Any such revocation or termination shall be without prejudice to any claim for any damages
that such officer may have against the Company or the Company may have against such officer for any breach of any contract of service
between him and the Company which may be involved in such revocation or termination. Save as provided in the Act or these Articles, the
powers and duties of the officers of the Company shall be such (if any) as are determined from time to time by the Directors.

33. DIRECTORS' REMUNERATION

33.1 The remuneration to be paid to the Directors, if any, shall be determined by the Company in general meeting
or, in the absence of such a determination, by the Directors.

33.2 Each Director shall also be entitled to be paid his reasonable travelling, hotel and other expenses properly
incurred by him in connection with his attendance at meetings of the Directors, committees of the Directors or general meetings of the
Company, or otherwise in connection with the business of the Company, or to receive a fixed allowance in respect thereof as may be determined
by the Directors, or a combination partly of one such method and partly the other.

33.3 The Directors may by resolution approve additional remuneration to any Director for services which in
the opinion of the Directors go beyond the ordinary duties of a Director, and such extra remuneration shall be in addition to any remuneration
provided for, by or pursuant to any other Article.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 22 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

34. SEALS AND DEEDS

34.1 The Directors may determine that the Company shall have a Seal, and if they so determine, shall provide
for the safe custody of the Seal. The Seal shall only be used by the authority of the Directors and in the presence of a Director or the
Secretary or such other person as the Directors may by resolution appoint for this purpose, and every instrument to which the Seal affixed
shall be signed by the relevant person. Notwithstanding the above, annual returns and notices filed under the Act may be executed either
as a deed or under Seal and in either case without the need for the authority of a resolution of the Directors.

34.2 The Company may maintain in any place or places outside the Cayman Islands a facsimile of any Seal and
such facsimile seal shall be affixed in the same way as if it were the Seal.

34.3 In accordance with the Act, the Company may execute any deed or other instrument (which would otherwise
be required to be executed under Seal) by the signature of such deed or instrument as a deed by a Director or by the Secretary of the
Company or by such other person as the Directors may appoint or by any other person or attorney on behalf of the Company appointed by
a deed or other instrument executed as a deed by a Director or the Secretary or such other person as aforesaid.

35. DIVIDENDS

35.1 The Directors may from time to time declare dividends to be paid to the Members according to their rights
and interests, including such interim dividends as appear to the Directors to be justified by the position of the Company. The Directors
may also pay any fixed cash dividend which is payable on any Shares of the Company half yearly or on such other dates, whenever the position
of the Company, in the opinion of the Directors, justifies such payment.

35.2 No dividend or other distribution shall be paid except out of the realised or unrealised profits of the
Company, out of the share premium account or as otherwise permitted by law.

35.3 Subject to the rights of Members, if any, entitled to Shares with special rights as to dividends, all
dividends shall be declared and paid according to the amount paid up on the Shares in respect of which the dividend is paid and any dividend
on any class of Shares not fully paid shall be declared and paid according to the amounts paid on the Shares of that class, but if and
so long as nothing is paid up on any of the Shares in the Company, dividends may be declared and paid according to the number of Shares.
No amount paid on a Share in advance of calls shall, while carrying interest, be treated for the purposes of this Article as paid on the
Share. Dividends may be apportioned and paid pro rata according to the amounts paid-up on the Shares during any portion or portions of
the period in respect of which the dividend is paid.

35.4 The Directors may deduct from any dividend, distribution or other monies payable to a Member by the Company
on or in respect of any Shares all sums of money (if any) presently payable by him to the Company on account of calls or otherwise in
respect of Shares of the Company.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 23 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

35.5 If several persons are registered as joint holders of any Share, any of them may give effectual receipts
for any dividend or other money payable on or in respect of the Share.

35.6 Any dividend may be paid by cheque or warrant sent through the post to the address of the Member or person
entitled thereto in the Register of Members or, in the case of joint holders addressed to the holder whose name stands first in the Register
of Members in respect of the Shares at his registered address as appearing on the Register of Members or to such person and such address
as the Member or person entitled or such joint holders as the case may be may direct in writing. Every such cheque or warrant shall, unless
the holder or joint holders may in writing direct, be made payable to the order of the person to whom it is sent or to the order of the
holder or, in the case of joint holders, to the order of the holder whose name stands first in the Register of Members in respect of such
Shares, and shall be sent at his or their risk and payment of the cheque or warrant by the bank on which it is drawn shall constitute
a good discharge to the Company. Any one of two or more joint holders may give effectual receipts for any dividends, distributions or
other monies payable or property distributable in respect of the Shares held by such joint holders.

35.7 The Directors may declare that any dividend or distribution is paid wholly or partly by the distribution
of specific assets and, in particular, of paid up shares, debentures or debenture stock of any other company or in any one or more of
such ways, and where any difficulty arises in regard to such dividend or distribution, the Directors may settle the same as they think
expedient, and in particular may issue fractional Shares or ignore fractions altogether and may fix the value for dividend or distribution
of such specific assets or any part thereof and may determine that cash payments shall be made to any Members upon the basis of the value
so fixed in order to secure equality of distribution, and may vest any such specific assets in trustees as may seem expedient to the Directors.

35.8 No dividend or other distribution or other monies payable by the Company on or in respect of any Share
shall bear interest against the Company.

35.9 All unclaimed dividends or distributions may be invested or otherwise made use of by the Directors for
the benefit of the Company until claimed. Any dividend or distribution unclaimed by a Member six years after the dividend or distribution
payment date shall be forfeited and revert to the Company.

36. RESERVES

36.1 The Directors may, before declaring any dividend or distribution, set aside such sums as they think proper
as a reserve or reserves which shall, at the discretion of the Directors, be applicable for meeting contingencies, or for equalising dividends,
or for any other purpose of the Company, and pending such application may, in their discretion, be employed in the business of the Company
or be invested in such manner as the Directors may from time to time think fit. The Directors may also without placing the same to reserve
carry forward any sums which they think it prudent not to distribute.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 24 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

37. CAPITALISATION OF PROFITS

37.1 The Directors may capitalise any sum standing to the credit of any of the Company's reserve accounts
which are available for distribution (including its Share Premium Account and capital redemption reserve fund, subject to the Act) or
any sum standing to the credit of the profit and loss account or otherwise available for distribution and to appropriate such sums to
Members in the proportions in which such sum would have been divisible amongst them had the same been a distribution of profits by way
of dividend and to apply such sum on their behalf in paying up in full unissued Shares for allotment and distribution credited as fully
paid-up to and amongst them in the proportion aforesaid.

37.2 Where any difficulty arises in regard to any distribution under the last preceding Article, the Directors
may settle the same as they think expedient and, in particular, may authorise any person to sell and transfer any fractions or may resolve
that the distribution should be as nearly as may be practicable in the correct proportion but not exactly so or may ignore fractions altogether,
and may determine that cash payments should be made to any Members in order to adjust the rights of all parties, as may seem expedient
to the Directors. The Directors may appoint any person to sign on behalf of the persons entitled to participate in the distribution any
contract necessary or desirable for giving effect thereto and such appointment shall be effective and binding upon the Members.

38. SHARE PREMIUM ACCOUNT

38.1 The Directors shall in accordance with the Act establish a Share Premium Account and shall carry to the
credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.

38.2 There shall be debited to any Share Premium Account on the redemption or purchase of a Share the difference
between the nominal value of such Share and the redemption or purchase price provided always that at the discretion of the Directors such
sum may be paid out of the profits of the Company or, if permitted by the Act, out of capital.

39. ACCOUNTING RECORDS

39.1 The Directors shall cause to be kept accounting records sufficient to give a true and fair view of the
state of the Company's affairs and to show and explain its transactions and otherwise in accordance with the Act.

39.2 The accounting records shall be kept at the Registered Office or at such other place or places as the
Directors think fit, and shall at all times be open to inspection by the Directors. No Member (who is not also a Director) shall have
any right to inspect any accounting record or book or document of the Company except as conferred by law or authorised by the Directors
or by the Members by Ordinary Resolution.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 25 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

39.3 From time to time the Company in general meeting may determine (or revoke, alter or amend any such determination)
or, failing such determination, the Directors may determine (or revoke, alter or amend any such determination):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that the accounts of the Company be audited and the appointment of the Auditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that there be prepared and sent to each Member and other person entitled thereto a profit and loss account,
a balance sheet, group accounts and/or reports for such period and on such terms as they may determine; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) that there be laid before the Company in general meeting a copy of every balance sheet together with a
copy of the Auditor's report.

40. FINANCIAL YEAR END

The financial year end of the Company shall be 31 December in each calendar year or as otherwise determined by the Board of Directors.

41. SERVICE OF NOTICES AND DOCUMENTS

41.1 Notices or other documents or communications may be given to any Member by the Company either personally
or by sending it by courier, post, fax or email to him to his registered address, or (if he has no registered address) to the address,
if any, supplied by him to the Company for the giving of notices to him. Any notice shall be deemed to be effected:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if delivered personally or sent by courier, by properly addressing and prepaying a letter containing the
notice; and to have been effected, in the case of a notice of a meeting, when delivered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if sent by post, by properly addressing, prepaying, and posting a letter containing the notice (by airmail
if available) and to have been effected, in the case of a notice of a meeting, at the expiration of three days after it was posted; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) if sent by fax or email by properly addressing and sending such notice through the appropriate transmitting
medium and to have been effected on the day the same is sent.

41.2 A notice may be given by the Company to the joint holders of a Share by giving the notice to the joint
holder named first in the Register of Members in respect of the Share.

41.3 A notice may be given by the Company to the person entitled to a Share in consequence of the death or
bankruptcy of a Member by sending it through the post in a prepaid letter addressed to them by name, or by the title of representatives
of the deceased, or trustee of the bankrupt, or by any like description, at the address, if any, supplied for the purpose by the persons
claiming to be so entitled, or (until such an address has been so supplied) by giving the notice in any manner in which the same might
have been given if the death or bankruptcy had not occurred.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 26 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

41.4 Notice of every general meeting shall be given in any manner hereinbefore authorised to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) every Member entitled to vote except those Members entitled to vote who (having no registered address)
have not supplied to the Company an address for the giving of notices to them; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) every person entitled to a Share in consequence of the death or bankruptcy of a Member, who, but for his
death or bankruptcy would be entitled to receive notice of the meeting.

41.5 No other persons shall be entitled to receive notices of general meeting.

42. WINDING UP

42.1 Subject to the rights attaching to any Shares, if the Company shall be wound up, the liquidator may, with
the sanction of a Special Resolution and any other sanction required by the Act or these Articles, divide amongst the Members in kind
the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may for such purpose
set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out
as between the Members or different classes of Members. The liquidator may, with the like sanction, vest the whole or any part of such
assets in trustees upon such trusts for the benefit of the contributories as the liquidator, with the like sanction, shall think fit,
but so that no Member shall be compelled to accept any asset upon which there is any liability.

42.2 If the Company shall be wound up and the assets available for distribution amongst the Members as such
shall be insufficient to repay the whole of the paid up capital, such assets shall be distributed so that, as nearly as may be, the losses
shall be borne by the Members in proportion to the capital paid up, or which ought to have been paid up, at the commencement of the winding
up, on the Shares held by them respectively. And if in a winding up the assets available for distribution amongst the Members shall be
more than sufficient to repay the whole of the capital paid up at the commencement of the winding up, the excess shall be distributed
amongst the Members in proportion to the capital paid up at the commencement of the winding up on the Shares held by them respectively.
This Article is to be without prejudice to the rights of the holders of Shares issued upon special terms and conditions.

43. INDEMNITY

43.1 Every Indemnified Person shall, in the absence of his own dishonesty, wilful default or fraud, be indemnified
and held harmless out of the assets of the Company against all liabilities, loss, damage, cost or expense (including but not limited to
liabilities under contract, tort and statute or any applicable foreign law or regulation and all reasonable legal and other costs and
expenses on a full indemnity basis properly payable) incurred or suffered by him by or by reason of any act done, conceived in or omitted
in the conduct of the Company's business or in the discharge of his duties and the indemnity contained in this Article shall extend
to any Indemnified Person acting in any office or trust in the reasonable belief that
he has been appointed or elected to such office or trust notwithstanding any defect in such appointment or election.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 27 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

43.2 No Indemnified Person shall be liable to the Company for acts, defaults or omissions of any other Indemnified
Person.

43.3 Every Indemnified Person shall be indemnified out of the funds of the Company against all liabilities
incurred by him by or by reason of any act done, conceived in or omitted in the conduct of the Company's business or in the discharge
of his duties in defending any proceedings, whether civil or criminal, in which judgment is given in his favour, or in which he is acquitted,
or in connection with any application in which relief from liability is granted to him by the court.

43.4 To the extent that any Indemnified Person is entitled to claim an indemnity pursuant to these Articles
in respect of amounts paid or discharged by him, the relative indemnity shall take effect as an obligation of the Company to reimburse
the person making such payment or effecting such discharge.

43.5 Each Member and the Company agree to waive any claim or right of action he or it may at any time have,
whether individually or by or in the right of the Company, against any Indemnified Person on account of any act or omission of such Indemnified
Person in the performance of his duties for the Company; provided however, that such waiver shall not apply to any claims or rights of
action arising out of the dishonesty, wilful default or fraud of such Indemnified Person or to recover any gain, personal profit or advantage
to which such Indemnified Person is not legally entitled.

43.6 Expenses incurred in defending any civil or criminal action or proceeding for which indemnification is
required pursuant to these Articles shall be paid by the Company in advance of the final disposition of such action or proceeding upon
receipt of an undertaking by or on behalf of the Indemnified Person to repay such amount if it shall ultimately be determined that the
Indemnified Person is not entitled to be indemnified pursuant to these Articles. Each Member of the Company shall be deemed to have acknowledged
and agreed that the advances of funds may be made by the Company as aforesaid, and when made by the Company under this Article are made
to meet expenditures incurred for the purpose of enabling such Indemnified Person to properly perform his or her duties to the Company.

44. CONTINUATION

44.1 The Company shall have the power, subject to the provisions of the Act and with the approval of a Special
Resolution, to continue as a body incorporated under the laws of any jurisdiction outside of the Cayman Islands and to be de-registered
in the Cayman Islands.

45. MERGER AND CONSOLIDATION

45.1 The Company shall have the power to merge or consolidate with one or more other constituent companies
(as defined in the Act) upon such terms as the Directors may determine and (to the extent required by the Act) with the approval of a
Special Resolution.

46. AMENDMENT OF MEMORANDUM AND ARTICLES

46.1 Subject to the provisions of the Act, the Company may from time to time by Special Resolution alter or
amend the Memorandum or these Articles in whole or in part provided that no such amendment shall affect the special rights attaching to
any class of Shares without the consent or sanction provided for in these Articles.

---

| | |
|:---|:---|
|  | ![](ea028469001_ex3-2img1.jpg) |
| 28 of 28 | *Filed: 11-Mar-2026 10:38 EST* |
| *www.verify.gov.ky File#: 429978* | *Auth Code: B32961520153* |

---

## Exhibit 3.3

**Exhibit 3.3**

---

| |
|:---|
| **THE COMPANIES ACT (AS REVISED)** |
| **OF THE CAYMAN ISLANDS** |
| **COMPANY LIMITED BY SHARES** |
| **AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION** |
| **OF** |
| **JATT II ACQUISITION CORP** |
| **(ADOPTED BY WAY OF SPECIAL RESOLUTION EFFECTIVE __ April, 2026)** |

---

**THE COMPANIES ACT (AS REVISED)**

**OF THE CAYMAN ISLANDS**

**COMPANY LIMITED BY SHARES**

**AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION**

**OF**

**JATT II ACQUISITION CORP**

**(ADOPTED BY WAY OF SPECIAL RESOLUTION EFFECTIVE ___ April, 2026)**

1. The name of the Company is JATT II Acquisition Corp.

2. The registered office of the Company will be situated at the offices of Appleby Global Services (Cayman)
Limited, Suite 210, 2nd Floor Windward III, Regatta Office Park, PO Box 500, Grand Cayman, Cayman Islands KY1-1106 or at such other place
in the Cayman Islands as the Directors may from time to time decide.

3. The objects for which the Company is established are unrestricted and the Company shall have full power
and authority to carry out any object that is not prohibited by the laws of the Cayman Islands.

4. The liability of each Member is limited to the amount, if any, unpaid on such Member's shares.

5. The share capital of the Company is US$20,100.00 divided into 200,000,000 ordinary shares of a par value
of US$0.0001 each, and 1,000,000 preference shares of a par value of US$0.0001 each.

6. The Company has power to register by way of continuation as a body corporate limited by shares under the
laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.

7. Capitalised terms that are not defined in this Amended and Restated Memorandum of Association bear the
respective meanings given to them in the Articles of Association of the Company.

**THE COMPANIES ACT (AS REVISED)**

**OF THE CAYMAN ISLANDS**

**COMPANY LIMITED BY SHARES**

**AMENDED AND RESTATED ARTICLES OF ASSOCIATION** 

**OF**

**JATT II ACQUISITION CORP**

**(ADOPTED BY WAY OF SPECIAL RESOLUTION EFFECTIVE ___ April, 2026)**

1. **INTERPRETATION** 

1.1 In these Articles, Table A in the First Schedule to the Statute does not apply and, unless there is something
in the subject or context inconsistent therewith:

**Affiliate**: means, with respect to a Person, any other person that, directly or indirectly, through one or more intermediaries, Controls, is Controlled by, or is under common Control with, such Person, and (a) in the case of a natural person, shall include such Person's spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law, whether by blood, marriage or adoption or anyone residing in such person's home, a trust for the benefit of any of the foregoing, or a corporation, a company, a partnership or other entity wholly or jointly owned by any of the foregoing and (b) in the case of an entity, shall include a corporation, a company, a partnership or other entity which directly, or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, such entity. The term Affiliated has meaning correlative to the foregoing;

**Applicable Law**: means, with respect to any Person, all applicable provisions of all constitutions, treaties, statutes, laws (including the common law), codes, rules, regulations, ordinances or orders of any Governmental Authority, and any orders, decisions, injunctions, judgments, awards and decrees of or agreements with any Governmental Authority;

**Articles**: means these amended and restated articles of association of the Company;

**Audit Committee**: means the audit committee of the board of Directors of the Company formed pursuant to the Articles, or any successor committee;

**Auditor**: means the Person for the time being performing the duties of auditor of the Company (if any);

**Business Combination**: means a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination involving the Company, with one or more businesses or assets (the target business), which Business Combination: (a) as long as the securities of the Company are listed on a Designated Stock Exchange, must occur with one or more target businesses or assets with a fair market value equal to at least 80 per cent of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting discount held in trust) at the time of signing the definitive agreement to enter into such Business Combination; and (b) must not be effectuated solely with another blank cheque company or a similar company with nominal operations;

**business day**: means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorised or obligated by law to close in New York City;

**Clearing House**: means a clearing house recognised by the laws of the jurisdiction in which the Shares (or depositary receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such jurisdiction;

**Company**: means the above named company;

**Company's Website**: means the website of the Company and/or its web-address or domain name (if any);

**Compensation Committee**: means the compensation committee of the board of Directors of the Company established pursuant to the Articles, or any successor committee;

**Control**: means with respect to a Person, the power or authority, whether exercised or not, to direct the business, management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; provided that such power or authority shall conclusively be presumed to exist upon possession of beneficial ownership or power to direct the vote of more than fifty per cent (50%) of the votes entitled to be cast at a meeting of the members or shareholders of such Person or power to control the composition of a majority of the board of directors of such Person. The terms Controlled and Controlling have meanings correlative to the foregoing;

**Designated Stock Exchange**: means any national securities exchange or automated system on which the Company's securities are listed for trading, including The Nasdaq Global Market;

**Directors**: means the directors for the time being of the Company;

**Dividend**: means any dividend (whether interim or final) resolved to be paid on Shares pursuant to the Articles;

**Electronic Communication**: means a communication sent by electronic means, including electronic posting to the Company's Website, transmission to any number, address or internet website (including the website of the United States Securities and Exchange Commission) or other electronic delivery methods as otherwise decided and approved by the Directors;

**Electronic Record**: has the same meaning as in the Electronic Transactions Act;

**Electronic Transactions Act**: means the Electronic Transactions Act (2003 Revision) of the Cayman Islands;

**Equity-linked Securities**: means any debt or equity securities that are convertible, exercisable or exchangeable for Ordinary Shares issued in a financing transaction in connection with a Business Combination, including but not limited to a private placement of equity or debt;

**Excise Tax**: means the 1% U.S. federal excise tax on share repurchases under Section 3401 of the U.S. Internal Revenue Code of 1986, as amended, enacted by the Inflation Reduction Act of 2022 of the United States;

**Founders**: means the Sponsor and all Members immediately prior to the consummation of the IPO;

**Governmental Authority**: means any nation or government or any province or state or any other political subdivision thereof, or any entity, authority or body exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including any court, tribunal, government authority, agency, department, board, commission or instrumentality or any political subdivision thereof, any court, tribunal or arbitrator, and any self-regulatory organization;

**Indemnified Person**: has the meaning ascribed to such term in Article 47.1;

**Independent Director**: has the same meaning as in the rules and regulations of the Designated Stock Exchange and/or the US Exchange Act, as the case may be;

**Initial Conversion Ratio**: has the meaning ascribed to such term in Article 17.1;

**IPO**: means the Company's initial public offering of securities;

**IPO Redemption**: has the meaning given to it in Article 52.4;

**Management**: has the meaning given to it in Article 53.1;

**Member**: has the same meaning as in the Statute;

**Memorandum**: means the amended and restated memorandum of association of the Company;

**Officer**: means a person appointed to hold an office in the Company;

**Ordinary Resolution**: means a resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) passed by a simple majority of the Members as, being entitled to do so, vote in person or, where proxies
are allowed, by proxy at a general meeting of the Company and where a poll is taken regard shall be had in computing a majority to the
number of votes to which each Member is entitled; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) approved in writing by all of the Members entitled to vote at a general meeting of the Company in one
or more instruments each signed by one or more of the Members;

**Ordinary Shares**: means an ordinary share of a par value of US$0.0001 in the share capital of the Company

**Over-Allotment Option**: means the option of the Underwriter to purchase up to an additional 15 per cent of the units issued in the IPO;

**Person**: means any individual, corporation, company, limited liability company, partnership, limited partnership, exempted limited partnership, proprietorship, association, joint venture, institution, public benefit corporation, exempted company, firm, trust, estate or other enterprise or entity (whether or not having a separate legal personality) or Governmental Authority or any of them as the context so requires, other than in respect of a Director or Officer of the Company in which circumstances Person shall mean any individual or entity permitted to act as such in accordance with the laws of the Cayman Islands;

**Preference Share**: means a preference share of a par value of US$0.0001 in the share capital of the Company;

**Public Share**: means an Ordinary Share issued as part of the units issued in the IPO;

**Redemption Notice**: means a notice in a form approved by the Company by which a holder of Public Shares is entitled to require the Company to redeem its Public Shares, subject to any conditions contained therein;

**Redemption Price**: has the meaning given to it in Article 52.4;

**Register of Members**: means the register of Members maintained in accordance with the Statute and includes (except where otherwise stated) any branch or duplicate register of Members;

**Registered Office**: means the registered office for the time being of the Company;

**Representative**: means a representative of the Underwriter;

**Seal**: means the common seal of the Company and includes every duplicate seal;

**SEC**: means the United States Securities and Exchange Commission;

**Share**: means an Ordinary Share or a Preference Share and includes a fraction of a share in the Company;

**Share Premium Account**: means the share premium account established in accordance with the Articles and the Statute;

**Special Resolution**: has the same meaning in the Statute, and includes a unanimous written resolution;

**Sponsor**: JATT Ventures II L.P.;

**Statute**: means the Companies Act (As Revised) of the Cayman Islands;

**Treasury Share**: means a Share held in the name of the Company as a treasury share in accordance with the Statute;

**Trust Account**: means the trust account established by the Company upon the consummation of its IPO and into which a certain amount of the net proceeds of the IPO, together with a certain amount of the proceeds of the private placement simultaneously with the closing date of the IPO, will be deposited;

**Underwriter**: means an underwriter of the IPO from time to time and any successor underwriter; and

**US Exchange Act**: means the United States Securities Exchange Act of 1934, as amended, or any similar U.S. federal statute and the rules and regulations of the SEC thereunder, all as the same shall be in effect at the time.

1.2 In these Articles:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) words importing the singular number include the plural number
and vice versa;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) words importing the masculine gender include the feminine gender;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) words importing persons include corporations and any other legal
or natural persons;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) "written" and "in writing" include all modes of representing or reproducing words
in visible form, including in the form of an Electronic Record;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) "shall" shall be construed as imperative and "may"
shall be construed as permissive;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) references to provisions of any law or regulation shall be construed as references to those provisions
as amended, modified, re-enacted or replaced;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) any phrase introduced by the terms "including", "include", "in particular"
or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) the term "and/or" is used herein to mean both "and" as well as "or."
The use of "and/or" in certain contexts in no respects qualifies or modifies the use of the terms "and" or "or"
in others. The term "or" shall not be interpreted to be exclusive and the term "and" shall not be interpreted
to require the conjunctive (in each case, unless the context otherwise requires);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) headings are inserted for reference only and shall be ignored
in construing the Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) any requirements as to delivery under the Articles include delivery in the form of an Electronic Record;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) any requirements as to execution or signature under the Articles including the execution of the Articles
themselves can be satisfied in the form of an electronic signature as defined in the Electronic Transactions Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) sections 8 and 19(3) of the Electronic Transactions Act shall
not apply;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) the term "clear days" in relation to the period of a notice means that period excluding the
day when the notice is received or deemed to be received and the day for which it is given or on which it is to take effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) the term "holder" in relation to a Share means a Person whose name is entered in the Register
of Members as the holder of such Share;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) reference to any determination by the Directors shall be construed as a determination by the Directors
in their sole and absolute discretion and shall be applicable either generally or in any particular case; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) reference to a dollar or dollars or USD or US$ or $ and to a cent or cents is reference to dollars and
cents of the United States of America.

2. **COMMENCEMENT OF BUSINESS** 

2.1 The business of the Company may be commenced as soon after incorporation of the Company as the Directors
shall see fit.

2.2 The Directors may pay, out of the capital or any other monies of the Company, all expenses incurred in
or about the formation and establishment of the Company, including the expenses of registration.

3. **ISSUE OF SHARES AND OTHER SECURITIES** 

3.1 Subject to the provisions, if any, in the Memorandum (and to any direction that may be given by the Company
in general meeting) and, where applicable, the rules and regulations of the Designated Stock Exchange, the SEC and/or any other competent
regulatory authority or otherwise under Applicable Law, and without prejudice to any rights attached to any existing Shares, the Directors
may allot, issue, grant options over or otherwise dispose of Shares (including fractions of a Share) with or without preferred, deferred
or other rights or restrictions, whether in regard to Dividends or other distributions, voting, return of capital or otherwise and to
such Persons, at such times and on such other terms as they think proper, and may also (subject to the Statute and the Articles) vary
such rights.

3.2 The Company may issue rights, options, warrants or convertible securities or securities of similar nature
conferring the right upon the holders thereof to subscribe for, purchase or receive any class of Shares or other securities in the Company,
upon such terms as the Directors may from time to time determine and for such purposes the Directors may reserve an appropriate number
of Shares for the time being unissued.

3.3 The Company may issue units of securities in the Company, which may be comprised of whole or fractional
Shares, rights, options, warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof
to subscribe for, purchase or receive any class of Shares or other securities in the Company, upon such terms as the Directors may from
time to time determine and for such purposes the Directors may reserve an appropriate number of Shares for the time being unissued. The
securities comprising any such units which are issued pursuant to the IPO can only be traded separately from one another on the 52nd day
following the date of the prospectus relating to the IPO (or, if such date is not a business day, the following business day) unless the
Representative(s) determines that an earlier date is acceptable, subject to the Company having filed a current report on Form 8-K with
the SEC and a press release announcing when such separate trading will begin. Prior to such date, the units can be traded, but the securities
comprising such units cannot be traded separately from one another.

3.4 The Company shall not issue Shares to bearer.

4. **REGISTER OF MEMBERS** 

4.1 The Company shall maintain or cause to be maintained the Register of Members in accordance with the Statute.

4.2 The Directors may determine that the Company shall maintain one or more branch registers of Members in
accordance with the Statute. The Directors may also determine which register of Members shall constitute the principal register and which
shall constitute the branch register or registers, and to vary such determination from time to time.

5. **CLOSING OF REGISTER OF MEMBERS OR FIXING RECORD DATE** 

5.1 For the purpose of determining Members entitled to notice of, or to vote at any meeting of Members or
any adjournment thereof, or Members entitled to receive payment of any Dividend or other distribution, or in order to make a determination
of Members for any other purpose, the Directors may, by any means in accordance with the requirements of the Designated Stock Exchange,
the SEC and/or any other competent regulatory authority or otherwise under Applicable Law, provide that the Register of Members shall
be closed for transfers for a stated period which shall not in any case exceed forty days.

5.2 In lieu of, or apart from, closing the Register of Members, the Directors may fix in advance or arrears
a date as the record date for any such determination of Members entitled to notice of, or to vote at any meeting of the Members or any
adjournment thereof, or for the purpose of determining the Members entitled to receive payment of any Dividend or other distribution,
or in order to make a determination of Members for any other purpose.

5.3 If the Register of Members is not so closed and no record date is fixed for the determination of Members
entitled to notice of, or to vote at, a meeting of Members or Members entitled to receive payment of a Dividend or other distribution,
the date on which notice of the meeting is sent or the date on which the resolution of the Directors resolving to pay such Dividend or
other distribution is passed, as the case may be, shall be the record date for such determination of Members. When a determination of
Members entitled to vote at any meeting of Members has been made as provided in this Article, such determination shall apply to any adjournment
thereof.

6. **CERTIFICATES FOR SHARES** 

6.1 A Member shall only be entitled to a share certificate if the Directors resolve that share certificates
shall be issued. Share certificates representing Shares, if any, shall be in such form as the Directors may determine. Share certificates
shall be signed by one or more Directors or other Person authorised by the Directors. The Directors may authorise certificates to be issued
with the authorised signature(s) affixed by mechanical process. All certificates for Shares shall be consecutively numbered or otherwise
identified and shall specify the Shares to which they relate. All certificates surrendered to the Company for transfer shall be cancelled
and, subject to the Articles, no new certificate shall be issued until the former certificate representing a like number of relevant Shares
shall have been surrendered and cancelled.

6.2 The Company shall not be bound to issue more than one certificate for Shares held jointly by more than
one Person and delivery of a certificate to one joint holder shall be a sufficient delivery to all of them.

6.3 If a share certificate is defaced, worn out, lost or destroyed, it may be renewed on such terms (if any)
as to evidence and indemnity and on the payment of such expenses reasonably incurred by the Company in investigating evidence, as the
Directors may prescribe, and (in the case of defacement or wearing out) upon delivery of the old certificate.

6.4 Every share certificate sent in accordance with the Articles will be sent at the risk of the Member or
other Person entitled to the certificate. The Company will not be responsible for any share certificate lost or delayed in the course
of delivery.

6.5 Share certificates shall be issued within the relevant time limit as prescribed by the Statute, if applicable,
or as the rules and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise
under Applicable Law may from time to time determine, whichever is shorter, after the allotment or, except in the case of a Share transfer
which the Company is for the time being entitled to refuse to register and does not register, after lodgement of a Share transfer with
the Company.

7. **TRANSFER OF SHARES** 

7.1 Subject to the terms of the Articles, any Member may transfer all or any of his Shares by an instrument
of transfer provided that such transfer complies with the rules and regulations of the Designated Stock Exchange, the SEC and/or any other
competent regulatory authority or otherwise under Applicable Law. If the Shares in question were issued in conjunction with rights, options
or warrants issued pursuant to the Articles on terms that one cannot be transferred without the other, the Directors shall refuse to register
the transfer of any such Share without evidence satisfactory to them of the like transfer of such option or warrant.

7.2 The instrument of transfer of any Share shall be in writing in the usual or common form or in a form prescribed
by the rules and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under
Applicable Law or in any other form approved by the Directors and shall be executed by or on behalf of the transferor (and if the Directors
so require, signed by or on behalf of the transferee) and may be under hand or, if the transferor or transferee is a Clearing House or
its nominee(s), by hand or by machine imprinted signature or by such other manner of execution as the Directors may approve from time
to time. The transferor shall be deemed to remain the holder of a Share until the name of the transferee is entered in the Register of
Members.

8. **REDEMPTION, REPURCHASE AND SURRENDER OF SHARES** 

8.1 Subject to the provisions of the Statute and the rules and regulations of the Designated Stock Exchange,
the SEC and/or any other competent regulatory authority or otherwise under Applicable Law, the Company may:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) issue Shares that are to be redeemed or are liable to be redeemed at the option of the Member or the Company
in such manner and upon such other terms as the Directors may determine before the issuance of the Shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) purchase its own Shares (including any redeemable Shares) in such manner and on such other terms as the
Directors may determine and agree with the relevant Member.

8.2 The Company may make a payment in respect of the redemption or purchase of its own Shares in any manner
permitted by the Statute, including out of capital.

8.3 With respect to redeeming or repurchasing the Shares:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Members who hold Public Shares are entitled to request the redemption of such Shares in the circumstances
described in Article 52;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Public Shares shall be repurchased by way of tender offer in the circumstances set out in Article 52;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Ordinary Shares held by the Sponsor shall be surrendered by the Sponsor for no consideration on a pro-rata
basis to the extent that the Over-Allotment Option is not exercised in full so that the Founders will own 20 per cent of the Company's
issued Shares after the IPO (exclusive of any securities purchased in private placement simultaneously with the IPO).

8.4 Subject to the provisions of the Statute, and, where applicable, the rules and regulations of the Designated
Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law, the Company may purchase its
own Shares (including any redeemable Shares) in such manner and on such other terms as the Directors may agree with the relevant Member.
For the avoidance of doubt, redemptions, repurchases and surrenders of Shares in the circumstances described in the Article above shall
not require further approval of the Members.

8.5 Any Share in respect of which notice of redemption has been given shall not be entitled to participate
in the profits of the Company in respect of the period after the date specified as the date of redemption in the Redemption Notice.

8.6 The redemption, purchase or surrender of any Share shall not be deemed to give rise to the redemption,
purchase or surrender of any other Share.

8.7 The Company may make a payment in respect of the redemption or purchase of its own Shares in any manner
permitted by the Statute, including out of capital.

8.8 The Directors may accept the surrender for no consideration of any fully paid Share (including any redeemable
share).

9. **TREASURY SHARES** 

9.1 The Directors may, prior to the purchase, redemption or surrender of any Share, determine that such Share
shall be held as a Treasury Share.

9.2 The Directors may determine to cancel a Treasury Share or transfer a Treasury Share on such terms as they
think proper (including, without limitation, for nil consideration).

10. **VARIATION OF SHARE RIGHTS** 

10.1 Subject to Article 3.1, if at any time the share capital of the Company is divided into different classes
of Shares, all or any of the rights attached to any class (unless otherwise provided by the terms of issue of the Shares of that class)
may, whether or not the Company is being wound up, be varied without the consent of the holders of the issued Shares of that class where
such variation is considered by the Directors not to have a material adverse effect upon such rights; otherwise, any such variation shall
be made only with the consent in writing of the holders of not less than two-thirds of the issued Shares of that class, or with the approval
of a resolution passed by a majority of not less than two-thirds of the votes cast at a separate meeting of the holders of the Shares
of that class. For the avoidance of doubt, the Directors reserve the right, notwithstanding that any such variation may not have a material
adverse effect, to obtain consent from the holders of Shares of the relevant class. To any such meeting all the provisions of the Articles
relating to general meetings shall apply mutatis mutandis, except that the necessary quorum shall be one or more Persons holding or representing
by proxy at least one-third of the issued Shares of the class (but so that if at any adjourned meeting of such holders a quorum as above
defined is not present, those Members who are present shall form a quorum) and that any holder of Shares of the class present in person
or by proxy may demand a poll.

10.2 For the purposes of a separate class meeting, the Directors may treat two or more or all the classes of
Shares as forming one class of Shares if the Directors consider that such class of Shares would be affected in the same way by the proposals
under consideration, but in any other case shall treat them as separate classes of Shares.

10.3 The rights conferred upon the holders of the Shares of any class issued with preferred or other rights
shall not, unless otherwise expressly provided by the terms of issue of the Shares of that class, be deemed to be varied by the creation
or issue of further Shares ranking pari passu therewith or Shares issued with preferred or other rights.

11. **COMMISSION ON SALES OF SHARES** 

The Company may, in so far as the Statute permits, pay a commission to any Person in consideration of his subscribing or agreeing to subscribe (whether absolutely or conditionally) or procuring or agreeing to procure subscriptions (whether absolutely or conditionally) for any Shares. Such commissions may be satisfied by the payment of cash and/or the issue of fully or partly paid-up Shares. The Company may also on any issue of Shares pay such brokerage as may be lawful.

12. **NON-RECOGNITION OF TRUSTS** 

The Company shall not be bound by or compelled to recognise in any way (even when notified) any equitable, contingent, future or partial interest in any Share, or (except only as is otherwise provided by the Articles or the Statute) any other rights in respect of any Share other than an absolute right to the entirety thereof in the holder.

13. **LIEN ON SHARES** 

13.1 The Company shall have a first and paramount lien on all Shares (whether fully paid-up or not) registered
in the name of a Member (whether solely or jointly with others) for all debts, liabilities or engagements to or with the Company (whether
presently payable or not) by such Member or his estate, either alone or jointly with any other Person, whether a Member or not, but the
Directors may at any time declare any Share to be wholly or in part exempt from the provisions of this Article. The registration of a
transfer of any such Share shall operate as a waiver of the Company's lien thereon. The Company's lien on a Share shall also extend to
any amount payable in respect of that Share.

13.2 The Company may sell, in such manner as the Directors think fit, any Shares on which the Company has a
lien, if a sum in respect of which the lien exists is presently payable, and is not paid within fourteen clear days after notice has been
received or deemed to have been received by the holder of the Shares, or to the Person entitled to it in consequence of the death or bankruptcy
of the holder, demanding payment and stating that if the notice is not complied with the Shares may be sold.

13.3 To give effect to any such sale the Directors may authorise any Person to execute an instrument of transfer
of the Shares sold to, or in accordance with the directions of, the purchaser. The purchaser or his nominee shall be registered as the
holder of the Shares comprised in any such transfer, and he shall not be bound to see to the application of the purchase money, nor shall
his title to the Shares be affected by any irregularity or invalidity in the sale or the exercise of the Company's power of sale under
the Articles.

13.4 The net proceeds of such sale after payment of costs, shall be applied in payment of such part of the
amount in respect of which the lien exists as is presently payable and any balance shall (subject to a like lien for sums not presently
payable as existed upon the Shares before the sale) be paid to the Person entitled to the Shares at the date of the sale.

14. **CALLS ON SHARES** 

14.1 Subject to the terms of the allotment and issue of any Shares, the Directors may make calls upon the Members
in respect of any monies unpaid on their Shares (whether in respect of par value or premium), and each Member shall (subject to receiving
at least fourteen clear days' notice specifying the time or times of payment) pay to the Company at the time or times so specified the
amount called on the Shares. A call may be revoked or postponed, in whole or in part, as the Directors may determine. A call may be required
to be paid by instalments. A Person upon whom a call is made shall remain liable for calls made upon him notwithstanding the subsequent
transfer of the Shares in respect of which the call was made.

14.2 A call shall be deemed to have been made at the time when the resolution of the Directors authorising
such call was passed.

14.3 The joint holders of a Share shall be jointly and severally
liable to pay all calls in respect thereof.

14.4 If a call remains unpaid after it has become due and payable, the Person from whom it is due shall pay
interest on the amount unpaid from the day it became due and payable until it is paid at such rate as the Directors may determine (and
in addition all expenses that have been incurred by the Company by reason of such non-payment), but the Directors may waive payment of
the interest or expenses wholly or in part.

14.5 An amount payable in respect of a Share on issue or allotment or at any fixed date, whether on account
of the par value of the Share or premium or otherwise, shall be deemed to be a call and if it is not paid all the provisions of the Articles
shall apply as if that amount had become due and payable by virtue of a call.

14.6 The Directors may issue Shares with different terms as to the amount and times of payment of calls, or
the interest to be paid.

14.7 The Directors may, if they think fit, receive an amount from any Member willing to advance all or any
part of the monies uncalled and unpaid upon any Shares held by him, and may (until the amount would otherwise become payable) pay interest
at such rate as may be agreed upon between the Directors and the Member paying such amount in advance.

14.8 No such amount paid in advance of calls shall entitle the Member paying such amount to any portion of
a Dividend or other distribution payable in respect of any period prior to the date upon which such amount would, but for such payment,
become payable.

15. **FORFEITURE OF SHARES** 

15.1 If a call or instalment of a call remains unpaid after it has become due and payable the Directors may
give to the Person from whom it is due not less than fourteen clear days' notice requiring payment of the amount unpaid together with
any interest which may have accrued and any expenses incurred by the Company by reason of such non-payment. The notice shall specify where
payment is to be made and shall state that if the notice is not complied with the Shares in respect of which the call was made will be
liable to be forfeited.

15.2 If the notice is not complied with, any Share in respect of which it was given may, before the payment
required by the notice has been made, be forfeited by a resolution of the Directors. Such forfeiture shall include all Dividends, other
distributions or other monies payable in respect of the forfeited Share and not paid before the forfeiture.

15.3 A forfeited Share may be sold, re-allotted or otherwise disposed of on such terms and in such manner as
the Directors think fit and at any time before a sale, re-allotment or disposition the forfeiture may be cancelled on such terms as the
Directors think fit. Where for the purposes of its disposal a forfeited Share is to be transferred to any Person the Directors may authorise
some Person to execute an instrument of transfer of the Share in favour of that Person.

15.4 A Person any of whose Shares have been forfeited shall cease to be a Member in respect of them and shall
surrender to the Company for cancellation the certificate for the Shares forfeited and shall remain liable to pay to the Company all monies
which at the date of forfeiture were payable by him to the Company in respect of those Shares together with interest at such rate as the
Directors may determine, but his liability shall cease if and when the Company shall have received payment in full of all monies due and
payable by him in respect of those Shares.

15.5 A certificate in writing under the hand of one Director or Officer of the Company that a Share has been
forfeited on a specified date shall be conclusive evidence of the facts stated in it as against all Persons claiming to be entitled to
the Share. The certificate shall (subject to the execution of an instrument of transfer) constitute a good title to the Share and the
Person to whom the Share is sold or otherwise disposed of shall not be bound to see to the application of the purchase money, if any,
nor shall his title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale
or disposal of the Share.

15.6 The provisions of the Articles as to forfeiture shall apply in the case of non-payment of any sum which,
by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the par value of the Share or by way of premium
as if it had been payable by virtue of a call duly made and notified.

16. **TRANSMISSION OF SHARES** 

16.1 If a Member dies, the survivor or survivors (where he was a joint holder), or his legal personal representatives
(where he was a sole holder), shall be the only Persons recognised by the Company as having any title to his Shares. The estate of a deceased
Member is not thereby released from any liability in respect of any Share, for which he was a joint or sole holder.

16.2 Any Person becoming entitled to a Share in consequence of the death or bankruptcy or liquidation or dissolution
of a Member (or in any other way than by transfer) may, upon such evidence being produced as may be required by the Directors, elect,
by a notice in writing sent by him to the Company, either to become the holder of such Share or to have some Person nominated by him registered
as the holder of such Share. If he elects to have another Person registered as the holder of such Share he shall sign an instrument of
transfer of that Share to that Person. The Directors shall, in either case, have the same right to decline or suspend registration as
they would have had in the case of a transfer of the Share by the relevant Member before his death or bankruptcy or liquidation or dissolution
or any other case than by transfer, as the case may be.

16.3 A Person becoming entitled to a Share by reason of the death or bankruptcy or liquidation or dissolution
of a Member (or in any other case than by transfer) shall be entitled to the same Dividends, other distributions and other advantages
to which he would be entitled if he were the holder of such Share. However, he shall not, before becoming a Member in respect of a Share,
be entitled in respect of it to exercise any right conferred by membership in relation to general meetings of the Company and the Directors
may at any time give notice requiring any such Person to elect either to be registered himself or to have some Person nominated by him
be registered as the holder of the Share (but the Directors shall, in either case, have the same right to decline or suspend registration
as they would have had in the case of a transfer of the Share by the relevant Member before his death or bankruptcy or liquidation or
dissolution or any other case than by transfer, as the case may be). If the notice is not complied with within ninety days of being received
or deemed to be received (as determined pursuant to the Articles) the Directors may thereafter withhold payment of all Dividends, other
distributions, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. **AMENDMENTS OF MEMORANDUM AND ARTICLES OF ASSOCIATION AND ALTERATION OF CAPITAL** 

17.1 The Company may by Ordinary Resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) increase its share capital by such sum as the Ordinary Resolution shall prescribe and with such rights,
priorities and privileges annexed thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) consolidate and divide all or any of its share capital into Shares of larger amount than its existing
Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) convert all or any of its paid-up Shares into stock, and reconvert that stock into paid- up Shares of
any denomination;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) by subdivision of its existing Shares or any of them divide the whole or any part of its share capital
into Shares of smaller amount than is fixed by the Memorandum or into Shares without par value; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) cancel any Shares that at the date of the passing of the Ordinary Resolution have not been taken or agreed
to be taken by any Person and diminish the amount of its share capital by the amount of the Shares so cancelled.

17.2 All new Shares created in accordance with the provisions of the preceding Article shall be subject to
the same provisions of the Articles with reference to the payment of calls, liens, transfer, transmission, forfeiture and otherwise as
the Shares in the original share capital.

17.3 Subject to the provisions of the Statute, the provisions of the Articles as regards the matters to be
dealt with by Ordinary Resolution, the Company may by Special Resolution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) change its name;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) alter or add to the Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) alter or add to the Memorandum with respect to any objects, powers or other matters specified therein;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) reduce its share capital or any capital redemption reserve fund.

18. **OFFICES AND PLACE OF BUSINESS** 

Subject to the provisions of the Statute, the Company may by resolution of the Directors change the location of its Registered Office. The Company may, in addition to its Registered Office, maintain such other offices or places of business as the Directors determine.

19. **GENERAL MEETINGS** 

20.1 All general meetings other than annual general meetings shall be called extraordinary general meetings.

20.2 The Company may, but shall not (unless required by the Statute or, for so long as any Shares are traded
on a Designated Stock Exchange) be obliged to, in each year hold a general meeting as its annual general meeting, and shall specify the
meeting as such in the notices calling it. Any annual general meeting shall be held at such time and place as the Directors shall appoint.
At these meetings the report of the Directors (if any) shall be presented.

20.3 The Directors or the chairman of the board of Directors may, whenever they think fit, call general meetings.

20.4 Members seeking to bring business before the annual general meeting or to nominate candidates for appointment
as Directors at the annual general meeting must deliver notice to the principal executive offices of the Company not less than one hundred
and twenty calendar days before the date of the Company's proxy statement released to Members in connection with the previous year's
annual general meeting or, if the Company did not hold an annual general meeting the previous year, or if the date of the current year's
annual general meeting has been changed by more than thirty days from the date of the previous year's annual general meeting, then
the deadline shall be set by the Directors with such deadline being a reasonable time before the Company begins to print and send its
related proxy materials.

21. **NOTICE OF GENERAL MEETINGS** 

21.1 At least five clear days' notice shall be given of any general meeting. Every notice shall specify the
place, the day and the hour of the meeting and the general nature of the business to be conducted at the general meeting and shall be
given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by the Company by Ordinary Resolution to
such Persons as are, under the Articles, entitled to receive such notices from the Company , provided that a general meeting of the Company
shall, whether or not the notice specified in this Article has been given and whether or not the provisions of the Articles regarding
general meetings have been complied with, be deemed to have been duly convened if it is so agreed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) in the case of an annual general meeting, by all of the Members entitled to attend and vote thereat; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) in the case of an extraordinary general meeting, by a majority in number of the Members having a right
to attend and vote at the meeting, together holding not less than ninety-five per cent in par value of the Shares giving that right.

21.2 The accidental omission to give notice of a general meeting to, or the non-receipt of notice of a general
meeting by, any Person entitled to receive such notice shall not invalidate the proceedings of that general meeting.

22. **PROCEEDINGS AT GENERAL MEETINGS** 

22.1 No business shall be transacted at any general meeting unless a quorum is present. Save as otherwise provided
by the Articles, one or more Members holding at least a majority of the paid up voting share capital of the Company present in person
or by proxy and entitled to vote at that meeting, or if a corporation or other non-natural person by its duly authorized representative
or proxy shall form a quorum.

22.2 A Person may participate at a general meeting by conference telephone, video, a virtual platform or other
communications equipment by means of which all the Persons participating in the meeting can communicate with each other. Participation
by a Person in a general meeting in this manner is treated as presence in person at that meeting.

22.3 A resolution (including a Special Resolution) in writing (in one or more counterparts) signed by or on
behalf of all of the Members for the time being entitled to receive notice of and to attend and vote at general meetings (or, being corporations
or other non-natural persons, signed by their duly authorised representatives) shall be as valid and effective as if the resolution had
been passed at a general meeting of the Company duly convened and held.

22.4 If a quorum is not present within half an hour from the time appointed for the meeting to commence, the
meeting shall stand adjourned to the same day in the next week at the same time and/or place or to such other day, time and/or place as
the Directors may determine, and if at the adjourned meeting a quorum is not present within half an hour from the time appointed for the
meeting to commence, the Members present shall be a quorum.

22.5 The Directors may, at any time prior to the time appointed for the meeting to commence, appoint any Person
to act as chairman of a general meeting of the Company or, if the Directors do not make any such appointment, the chairman, if any, of
the board of Directors shall preside as chairman at such general meeting. If there is no such chairman, or if he shall not be present
within fifteen minutes after the time appointed for the meeting to commence, or is unwilling to act, the Directors present shall elect
one of their number to be chairman of the meeting.

22.6 If no Director is willing to act as chairman or if no Director is present within fifteen minutes after
the time appointed for the meeting to commence, the Members present shall choose one of their number to be chairman of the meeting.

22.7 The chairman may, with the consent of a meeting at which a quorum is present (and shall if so directed
by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting
other than the business left unfinished at the meeting from which the adjournment took place.

22.8 When a general meeting is adjourned for thirty days or more, notice of the adjourned meeting shall be
given as in the case of an original meeting. Otherwise it shall not be necessary to give any such notice of an adjourned meeting. All
proxy forms submitted for the original general meeting shall remain valid for the postponed meeting. The Directors may postpone a general
meeting which has already been postponed.

22.9 A resolution put to the vote of the meeting shall be decided
on a poll.

22.10 If, prior to a Business Combination, a notice is issued in respect of a general meeting and the Directors,
in their absolute discretion, consider that it is impractical or undesirable for any reason to hold that general meeting at the place,
the day and the hour specified in the notice calling such general meeting, the Directors may postpone the general meeting to another place,
day and/or hour provided that notice of the place, the day and the hour of the rearranged general meeting is promptly given to all Members.
No business shall be transacted at any postponed meeting other than the business specified in the notice of the original meeting.

22.11 A poll shall be taken in such manner as the chairman directs, and the result of the poll shall be deemed
to be the resolution of the general meeting at which the poll was demanded.

22.12 In the case of an equality of votes the chairman of the general meeting shall be entitled to a second
or casting vote.

22.13 A poll on the election of a chairman or on a question of adjournment shall be taken forthwith. A poll
on any other question shall be taken at such date, time and place as the chairman of the general meeting directs, and any business other
than that upon which a poll has been demanded or is contingent thereon may proceed pending the taking of the poll.

23. **VOTES OF MEMBERS** 

23.1 Subject to any rights or restrictions attached to any Shares, every Member who being an individual is
present in person or by proxy or, if a corporation or other non-natural person is present by its duly authorised representative or by
proxy, shall have one vote for every Share of which he is the holder.

23.2 In the case of joint holders the vote of the senior holder who tenders a vote, whether in person or by
proxy (or, in the case of a corporation or other non-natural person, by its duly authorised representative or proxy), shall be accepted
to the exclusion of the votes of the other joint holders, and seniority shall be determined by the order in which the names of the holders
stand in the Register of Members.

23.3 A Member of unsound mind, or in respect of whom an order has been made by any court, having jurisdiction
in lunacy, may vote, whether on a show of hands or on a poll, by his committee, receiver, curator bonis, or other Person on such Member's
behalf appointed by that court, and any such committee, receiver, curator bonis or other Person may vote by proxy.

23.4 No Person shall be entitled to vote at any general meeting unless he is registered as a Member on the
record date for such meeting nor unless all calls or other monies then payable by him in respect of Shares have been paid.

23.5 No objection shall be raised as to the qualification of any voter except at the general meeting or adjourned
general meeting at which the vote objected to is given or tendered and every vote not disallowed at the meeting shall be valid. Any objection
made in due time in accordance with this Article shall be referred to the chairman whose decision shall be final and conclusive.

23.6 Votes may be cast either personally or by proxy (or in the case of a corporation or other non- natural
person by its duly authorised representative or proxy). A Member may appoint more than one proxy or the same proxy under one or more instruments
to attend and vote at a meeting. Where a Member appoints more than one proxy the instrument of proxy shall specify the number of Shares
in respect of which each proxy is entitled to exercise the related votes.

23.7 A Member holding more than one Share need not cast the votes in respect of his Shares in the same way
on any resolution and therefore may vote a Share or some or all such Shares either for or against a resolution and/or abstain from voting
a Share or some or all of the Shares and, subject to the terms of the instrument appointing him, a proxy appointed under one or more instruments
may vote a Share or some or all of the Shares in respect of which he is appointed either for or against a resolution and/or abstain from
voting a Share or some or all of the Shares in respect of which he is appointed.

24. **PROXIES** 

24.1 The instrument appointing a proxy shall be in writing and shall be executed under the hand of the appointor
or of his attorney duly authorised in writing, or, if the appointor is a corporation or other non-natural person, under the hand of its
duly authorised representative. A proxy need not be a Member.

24.2 The Directors may, in the notice convening any meeting or adjourned meeting, or in an instrument of proxy
sent out by the Company, specify the manner by which the instrument appointing a proxy shall be deposited and the place and the time (being
not later than the time appointed for the commencement of the meeting or adjourned meeting to which the proxy relates) at which the instrument
appointing a proxy shall be deposited. In the absence of any such direction from the Directors in the notice convening any meeting or
adjourned meeting or in an instrument of proxy sent out by the Company, the instrument appointing a proxy shall be deposited physically
at the Registered Office not less than 48 hours before the time appointed for the meeting or adjourned meeting to commence at which the
Person named in the instrument proposes to vote.

24.3 The chairman may in any event at his discretion declare that an instrument of proxy shall be deemed to
have been duly deposited. An instrument of proxy that is not deposited in the manner permitted, or which has not been declared to have
been duly deposited by the chairman, shall be invalid.

24.4 The instrument appointing a proxy may be in any usual or common form (or such other form as the Directors
may approve) and may be expressed to be for a particular meeting or any adjournment thereof or generally until revoked. An instrument
appointing a proxy shall be deemed to include the power to demand or join or concur in demanding a poll.

24.5 Votes given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the
previous death or insanity of the principal or revocation of the proxy or of the authority under which the proxy was executed, or the
transfer of the Share in respect of which the proxy is given unless notice in writing of such death, insanity, revocation or transfer
was received by the Company at the Registered Office before the commencement of the general meeting, or adjourned meeting at which it
is sought to use the proxy.

25. **CORPORATE MEMBERS** 

Any corporation or other non-natural person which is a Member may in accordance with its constitutional documents, or in the absence of such provision by resolution of its directors or other governing body, authorise such Person as it thinks fit to act as its representative at any meeting of the Company or of any class of Members, and the Person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as the corporation could exercise if it were an individual Member.

26. **CLEARING HOUSES** 

If a Clearing House (or its nominee(s)), being a corporation, is a Member it may authorise such Person or Persons as it thinks fit to act as its representative or representatives at any general meeting of the Company or at any meeting of any class of Members provided that, if more than one Person is so authorised, the authorisation shall specify the number and class of Shares in respect of which each such Person is so authorised. A Person so authorised pursuant to this Article shall be deemed to have been duly authorised without further evidence of the facts and be entitled to exercise the same powers on behalf of the clearing house (or its nominee(s)) which he represents as if such Person was the registered holder of such Shares held by the Clearing House (or its nominee(s)).

27. **SHARES THAT MAY NOT BE VOTED** 

Shares in the Company that are beneficially owned by the Company shall not be voted, directly or indirectly, at any meeting and shall not be counted in determining the total number of outstanding Shares at any given time.

28. **DIRECTORS** 

28.1 The Company may by Ordinary Resolution from time to time fix the maximum and minimum number of Directors
to be appointed but unless such numbers are fixed as aforesaid the minimum number of Directors shall be one and the maximum number of
Directors shall be unlimited.

29. **POWERS OF DIRECTORS** 

29.1 Subject to the provisions of the Statute, the Memorandum and the Articles and to any directions given
by Special Resolution, the business of the Company shall be managed by the Directors who may exercise all the powers of the Company. No
alteration of the Memorandum or Articles and no such direction shall invalidate any prior act of the Directors which would have been valid
if that alteration had not been made or that direction had not been given. A duly convened meeting of the Directors at which a quorum
is present may exercise all powers exercisable by the Directors.

29.2 All cheques, promissory notes, drafts, bills of exchange and other negotiable or transferable instruments
and all receipts for monies paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may be,
in such manner as the Directors shall determine by resolution.

29.3 The Directors on behalf of the Company may pay a gratuity or pension or allowance on retirement to any
Director who has held any other salaried office or place of profit with the Company or to his widow or dependants and may make contributions
to any fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance.

29.4 The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its
undertaking, property and assets (present and future) and uncalled capital or any part thereof and to issue debentures, debenture stock,
mortgages, bonds and other such securities whether outright or as security for any debt, liability or obligation of the Company or of
any third party.

29.5 The Directors shall have the authority to present a winding up petition on behalf of the Company without
the sanction of a resolution passed by the Company in general meeting.

30. **APPOINTMENT AND REMOVAL OF DIRECTORS** 

30.1 The Company may by Ordinary Resolution appoint any Person to be a Director or may by Ordinary Resolution
remove any Director. The Directors may appoint any Person to be a Director, either to fill a vacancy or as an additional Director, provided
that the appointment does not cause the number of Directors to exceed any number fixed by or in accordance with the Articles as the maximum
number of Directors.

30.2 At the time of or following the consummation of a Business Combination, the Company may by Ordinary Resolution
appoint any person to be a Director or may by Ordinary Resolution remove any Director.

31. **VACATION OF OFFICE OF DIRECTOR** 

The office of a Director shall be vacated if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Director gives notice in writing to the Company that he resigns the office of Director; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Director absents himself from three consecutive meetings of the board of Directors without special
leave of absence from the Directors, and the Directors pass a resolution that he has by reason of such absence vacated office; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Director dies, becomes bankrupt or makes any arrangement or composition with his creditors generally;
or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the Director is found to be or becomes of unsound mind; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) all of the other Directors (being not less than two in number) determine that he should be removed as
a Director, either by a resolution passed by all of the other Directors at a meeting of the Directors duly convened and held in accordance
with the Articles or by a resolution in writing signed by all of the other Directors; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the Director is removed from office pursuant to any other provision
of the Articles.

32. **PROCEEDINGS OF DIRECTORS** 

32.1 The quorum for the transaction of the business of the Directors may be fixed by the Directors, and unless
so fixed shall be a majority of the Directors then in office.

32.2 Subject to the provisions of the Articles, the Directors may regulate their proceedings as they think
fit. Questions arising at any meeting of the Directors shall be decided by a majority of votes. In the case of an equality of votes, the
chairman shall have a second or casting vote. A Director who is also an alternate Director shall be entitled in the absence of his appointor
to a separate vote on behalf of his appointor in addition to his or her own vote.

32.3 A Person may participate in a meeting of the Directors or any committee of Directors by conference telephone,
video, a virtual platform or other communications equipment by means of which all the Persons participating in the meeting can communicate
with each other at the same time. Participation by a Person in a meeting in this manner is treated as presence in person at that meeting.
Unless otherwise determined by the Directors the meeting shall be deemed to be held at the place where the chairman is located at the
start of the meeting.

32.4 A resolution in writing (in one or more counterparts) signed by all the Directors or all the members of
a committee of the Directors or, in the case of a resolution in writing relating to the removal of any Director or the vacation of office
by any Director, all of the Directors other than the Director who is the subject of such resolution (an alternate Director being entitled
to sign such a resolution on behalf of his appointor and if such alternate Director is also a Director, being entitled to sign such resolution
both on behalf of his appointer and in his capacity as a Director) shall be as valid and effectual as if it had been passed at a meeting
of the Directors, or committee of Directors as the case may be, duly convened and held.

32.5 A Director may, or other Officer of the Company on the direction of a Director, call a meeting of the
Directors by at least two days' notice in writing to every Director and alternate Director which notice shall set forth the general nature
of the business to be considered unless notice is waived by all the Directors (or their alternates) either at, before or after the meeting
is held. To any such notice of a meeting of the Directors all the provisions of the Articles relating to the giving of notices by the
Company to the Members shall apply mutatis mutandis.

32.6 The continuing Directors (or a sole continuing Director, as the case may be) may act notwithstanding any
vacancy in their body, but if and so long as their number is reduced below the number fixed by or pursuant to the Articles as the necessary
quorum of Directors the continuing Directors or Director may act for the purpose of increasing the number of Directors to be equal to
such fixed number, or of summoning a general meeting of the Company, but for no other purpose.

32.7 The Directors may elect a chairman of their board and determine the period for which he or she is to hold
office, but if no such chairman is elected, or if at any meeting the chairman is not present within five minutes after the time appointed
for the meeting to commence, the Directors present may choose one of their number to be chairman of the meeting.

32.8 Subject to any regulations imposed on it by the Directors, including where the Directors have designated
a chairman of the committee, a committee appointed by the Directors may elect a chairman of its meetings and determine the period for
which he is to hold office; but if no such chairman is elected, or if at any meeting the chairman is not present within five minutes after
the time appointed for the meeting to commence, the committee members present may choose one of their number to be chairman of the meeting.

32.9 A committee appointed by the Directors may meet and adjourn as it thinks proper. Subject to any regulations
imposed on it by the Directors, questions arising at any committee meeting shall be determined by a majority of votes of the committee
members present and in case of an equality of votes the chairman shall have a second or casting vote.

32.10 All acts done by any meeting of the Directors or of a committee of the Directors (including any Person
acting as an alternate Director) shall, notwithstanding that it is afterwards discovered that there was some defect in the appointment
of any Director or alternate Director, and/or that they or any of them were disqualified, and/or had vacated their office and/or were
not entitled to vote, be as valid as if every such Person had been duly appointed and/or not disqualified to be a Director or alternate
Director and/or had not vacated their office and/or had been entitled to vote, as the case may be.

32.11 A Director but not an alternate Director may be represented at any meetings of the board of Directors
by a proxy appointed in writing by him. The proxy shall count towards the quorum and the vote of the proxy shall for all purposes be deemed
to be that of the appointing Director.

33. **PRESUMPTION OF ASSENT** 

A Director or alternate Director who is present at a meeting of the board of Directors at which action on any Company matter is taken shall be presumed to have assented to the action taken unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent from such action with the Person acting as the chairman of the meeting before the adjournment thereof or shall forward such dissent by registered post to such Person immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director or alternate Director who voted in favour of such action.

34. **DIRECTORS' INTERESTS** 

34.1 A Director or alternate Director may hold any other office or place of profit under the Company (other
than the office of Auditor) in conjunction with his office of Director for such period and on such terms as to remuneration and otherwise
as the Directors may determine.

34.2 A Director or alternate Director may act by himself or by, through or on behalf of his firm, in a professional
capacity for the Company and he or his firm shall be entitled to remuneration for professional services as if he were not a Director or
alternate Director.

34.3 A Director or alternate Director may be or become a director or other Officer of or otherwise interested
in any company promoted by the Company or in which the Company may be interested as a shareholder, a contracting party or otherwise, and
no such Director or alternate Director shall be accountable to the Company for any remuneration or other benefits received by him as a
director or Officer of, or from his interest in, such other company.

34.4 No Person shall be disqualified from the office of Director or alternate Director or prevented by such
office from contracting with the Company, either as vendor, purchaser or otherwise, nor shall any such contract or any contract or transaction
entered into by or on behalf of the Company in which any Director or alternate Director shall be in any way interested be or be liable
to be avoided, nor shall any Director or alternate Director so contracting or being so interested be liable to account to the Company
for any profit realised by or arising in connection with any such contract or transaction by reason of such Director or alternate Director
holding office or of the fiduciary relationship thereby established. A Director (or his alternate Director in his absence) shall be at
liberty to vote in respect of any contract or transaction in which he is interested provided that the nature of the interest of any Director
or alternate Director in any such contract or transaction shall be disclosed by him at or prior to its consideration and any vote thereon.

34.5 A general notice that a Director or alternate Director is a shareholder, director, Officer or employee
of any specified firm or company and is to be regarded as interested in any transaction with such firm or company shall be sufficient
disclosure for the purposes of voting on a resolution in respect of a contract or transaction in which he has an interest, and after such
general notice it shall not be necessary to give special notice relating to any particular transaction.

35. **MINUTES** 

35.1 The Directors shall cause minutes to be made in books kept for the purpose of recording all appointments
of Officers made by the Directors, all proceedings at meetings of the Company or the holders of any class of Shares and of the Directors,
and of committees of the Directors, including the names of the Directors or alternate Directors present at each meeting.

36. **DELEGATION OF DIRECTORS' POWERS** 

36.1 The Directors may delegate any of their powers, authorities and discretions, including the power to sub-delegate,
to any committee consisting of one or more Directors (including, without limitation, the Audit Committee and the Compensation Committee);
any committee so formed shall in the exercise of the powers so delegated conform to any conditions that may be imposed on it by the Directors.
The Directors may also delegate to any managing director or any Director holding any other executive office such of their powers, authorities
and discretions as they consider desirable to be exercised by him provided that an alternate Director may not act as managing director
and the appointment of a managing director shall be revoked forthwith if he ceases to be a Director. Any such delegation may be made subject
to any conditions the Directors may impose and either collaterally with or to the exclusion of their own powers and any such delegation
may be revoked or altered by the Directors. Subject to any such conditions that may be imposed by the Directors, the proceedings of a
committee of Directors shall be governed by the Articles regulating the proceedings of Directors, so far as they are capable of applying.

36.2 The Directors may establish any committees, local boards or agencies or appoint any Person to be a manager
or agent for managing the affairs of the Company and may appoint any Person to be a member of such committees, local boards or agencies
and such Person need not be a Director or Officer of the Company. Any such appointment may be made subject to any conditions the Directors
may impose, and either collaterally with or to the exclusion of their own powers and any such appointment may be revoked or altered by
the Directors. Subject to any such conditions that may be imposed by the Directors, the proceedings of any such committee, local board
or agency shall be governed by the Articles regulating the proceedings of Directors, so far as they are capable of applying.

36.3 The Directors may adopt formal written charters for committees and, if so adopted, shall review and assess
the adequacy of such formal written charters on an annual basis. Each of these committees shall be empowered to do all things necessary
to exercise the rights of such committee set forth in the Articles and shall have such powers as the Directors may delegate pursuant to
the Articles and as required by the rules and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory
authority or otherwise under Applicable Law. Each of the Audit Committee and the Compensation Committee, if established, shall consist
of such number of Directors as the Directors shall from time to time determine (or such minimum number as may be required from time to
time by the rules and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise
under Applicable Law). For so long as any class of Shares is listed on the Designated Stock Exchange, the Audit Committee and the Compensation
Committee shall be made up of such number of Independent Directors as is required from time to time by the rules and regulations of the
Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law.

36.4 The Directors may by power of attorney or otherwise appoint any Person to be the agent of the Company
on such conditions as the Directors may determine, provided that the delegation is not to the exclusion of their own powers and may be
revoked by the Directors at any time.

36.5 The Directors may by power of attorney or otherwise appoint any company, firm, Person or body of Persons,
whether nominated directly or indirectly by the Directors, to be the attorney or authorised signatory of the Company for such purpose
and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Directors under the Articles) and
for such period and subject to such conditions as they may think fit, and any such powers of attorney or other appointment may contain
such provisions for the protection and convenience of Persons dealing with any such attorneys or authorised signatories as the Directors
may think fit and may also authorise any such attorney or authorised signatory to delegate all or any of the powers, authorities and discretions
vested in him.

36.6 The Directors may from time to time appoint any Person, whether or not a Director, to hold such office
in the Company as the Directors may think necessary for the administration of the Company (including, for the avoidance of doubt and without
limitation, a chairman, chief executive officer, president, chief operating officer, chief financial officer, vice-presidents, secretary,
assistant secretaries, treasurer or any other officers as may be determined by the Directors), for such term and at such remuneration
(whether by way of salary or commission or participation in profits or partly in one way and partly in another), and with such powers
and duties as the Directors may think fit. Any Person so appointed by the Directors may be removed by resolution of the Directors or by
the Company by Ordinary Resolution. An Officer of the Company may vacate his office at any time if he gives notice in writing to the Company
that he resigns his office.

37. **NO MINIMUM SHAREHOLDING** 

The Company in general meeting may fix a minimum shareholding required to be held by a Director, but unless and until such a shareholding qualification is fixed, a Director is not required to hold Shares.

38. **REMUNERATION OF DIRECTORS** 

38.1 The remuneration to be paid to the Directors, if any, shall be such remuneration as the Directors shall
determine. The Directors shall also be entitled to be paid all travelling, hotel and other expenses properly incurred by them in connection
with their attendance at meetings of Directors or committees of Directors, or general meetings of the Company, or separate meetings of
the holders of any class of Shares or debentures of the Company, or otherwise in connection with the business of the Company or the discharge
of their duties as a Director, or to receive a fixed allowance in respect thereof as may be determined by the Directors, or a combination
partly of one such method and partly the other.

38.2 The Directors may by resolution approve additional remuneration to any Director for any services which
in the opinion of the Directors go beyond his ordinary routine work as a Director. Any fees paid to a Director who is also counsel, attorney
or solicitor to the Company, or otherwise serves it in a professional capacity, shall be in addition to his remuneration as a Director.

39. **SEAL** 

39.1 The Company may, if the Directors so determine, have a Seal. The Seal shall only be used by the authority
of the Directors or of a committee of the Directors authorised by the Directors. Every instrument to which the Seal has been affixed shall
be signed by at least one Person who shall be either a Director or Officer of the Company or other Person appointed by the Directors for
the purpose.

39.2 The Company may have for use in any place or places outside the Cayman Islands a duplicate Seal or Seals
each of which shall be a facsimile of the common Seal of the Company and, if the Directors so determine, with the addition on its face
of the name of every place where it is to be used.

39.3 A Director or Officer, representative or attorney of the Company may without further authority of the
Directors affix the Seal over his signature alone to any document of the Company required to be authenticated by him under seal or to
be filed with the Registrar of Companies in the Cayman Islands or elsewhere wheresoever.

40. **DIVIDENDS, DISTRIBUTIONS AND RESERVE** 

40.1 Subject to the Statute and this Article and except as otherwise provided by the rights attached to any
Shares, the Directors may resolve to pay Dividends and other distributions on Shares in issue and authorise payment of the Dividends or
other distributions out of the funds of the Company lawfully available therefor. A Dividend shall be deemed to be an interim Dividend
unless the terms of the resolution pursuant to which the Directors resolve to pay such Dividend specifically state that such Dividend
shall be a final Dividend. No Dividend or other distribution shall be paid except out of the realised or unrealised profits of the Company,
out of the Share Premium Account or as otherwise permitted by law.

40.2 Except as otherwise provided by the rights attached to any Shares, all Dividends and other distributions
shall be paid according to the par value of the Shares that a Member holds. If any Share is issued on terms providing that it shall rank
for Dividend as from a particular date, that Share shall rank for Dividend accordingly.

40.3 The Directors may deduct from any Dividend or other distribution payable to any Member all sums of money
(if any) then payable by him to the Company on account of calls or otherwise.

40.4 The Directors may resolve that any Dividend or other distribution be paid wholly or partly by the distribution
of specific assets and in particular (but without limitation) by the distribution of shares, debentures, or securities of any other company
or in any one or more of such ways and where any difficulty arises in regard to such distribution, the Directors may settle the same as
they think expedient and in particular may issue fractional Shares and may fix the value for distribution of such specific assets or any
part thereof and may determine that cash payments shall be made to any Members upon the basis of the value so fixed in order to adjust
the rights of all Members and may vest any such specific assets in trustees in such manner as may seem expedient to the Directors.

40.5 Except as otherwise provided by the rights attached to any Shares, Dividends and other distributions may
be paid in any currency. The Directors may determine the basis of conversion for any currency conversions that may be required and how
any costs involved are to be met.

40.6 The Directors may, before resolving to pay any Dividend or other distribution, set aside such sums as
they think proper as a reserve or reserves which shall, at the discretion of the Directors, be applicable for any purpose of the Company
and pending such application may, at the discretion of the Directors, be employed in the business of the Company.

40.7 Any Dividend, other distribution, interest or other monies payable in cash in respect of Shares may be
paid by wire transfer to the holder or by cheque or warrant sent through the post directed to the registered address of the holder or,
in the case of joint holders, to the registered address of the holder who is first named on the Register of Members or to such Person
and to such address as such holder or joint holders may in writing direct. Every such cheque or warrant shall be made payable to the order
of the Person to whom it is sent. Any one of two or more joint holders may give effectual receipts for any Dividends, other distributions,
bonuses, or other monies payable in respect of the Share held by them as joint holders.

40.8 No Dividend or other distribution shall bear interest against
the Company.

40.9 Any Dividend or other distribution which cannot be paid to a Member and/or which remains unclaimed after
six months from the date on which such Dividend or other distribution becomes payable may, in the discretion of the Directors, be paid
into a separate account in the Company's name, provided that the Company shall not be constituted as a trustee in respect of that account
and the Dividend or other distribution shall remain as a debt due to the Member. Any Dividend or other distribution which remains unclaimed
after a period of six years from the date on which such Dividend or other distribution becomes payable shall be forfeited and shall revert
to the Company.

41. **CAPITALISATION** 

The Directors may at any time capitalise any sum standing to the credit of any of the Company's reserve accounts or funds (including the Share Premium Account and capital redemption reserve fund) or any sum standing to the credit of the profit and loss account or otherwise available for distribution; appropriate such sum to Members in the proportions in which such sum would have been divisible amongst such Members had the same been a distribution of profits by way of Dividend or other distribution; and apply such sum on their behalf in paying up in full unissued Shares for allotment and distribution credited as fully paid-up to and amongst them in the proportion aforesaid. In such event the Directors shall do all acts and things required to give effect to such capitalisation, with full power given to the Directors to make such provisions as they think fit in the case of Shares becoming distributable in fractions (including provisions whereby the benefit of fractional entitlements accrue to the Company rather than to the Members concerned). The Directors may authorise any Person to enter on behalf of all of the Members interested into an agreement with the Company providing for such capitalisation and matters incidental or relating thereto and any agreement made under such authority shall be effective and binding on all such Members and the Company.

42. **SHARE PREMIUM ACCOUNT** 

42.1 The Directors shall in accordance with the Statute establish a Share Premium Account and shall carry to
the credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.

42.2 There shall be debited to any Share Premium Account on the redemption or purchase of a Share the difference
between the nominal value of such Share and the redemption or purchase price provided always that at the determination of the Directors
such sum may be paid out of the profits of the Company or, if permitted by the Statute, out of capital.

43. **BOOKS OF ACCOUNT** 

43.1 The Directors shall cause proper books of account (including, where applicable, material underlying documentation
including contracts and invoices) to be kept with respect to all sums of money received and expended by the Company and the matters in
respect of which the receipt or expenditure takes place, all sales and purchases of goods by the Company and the assets and liabilities
of the Company. Such books of account must be retained for a minimum period of five years from the date on which they are prepared. Proper
books shall not be deemed to be kept if there are not kept such books of account as are necessary to give a true and fair view of the
state of the Company's affairs and to explain its transactions.

43.2 The Directors shall determine whether and to what extent and at what times and places and under what conditions
or regulations the accounts and books of the Company or any of them shall be open to the inspection of Members not being Directors and
no Member (not being a Director) shall have any right of inspecting any account or book or document of the Company except as conferred
by Statute or authorised by the Directors or by the Company in general meeting.

43.3 The Directors may cause to be prepared and to be laid before the Company in general meeting profit and
loss accounts, balance sheets, group accounts (if any) and such other reports and accounts as may be required by law.

44. **AUDIT** 

44.1 The Directors may appoint an Auditor of the Company who shall hold office on such terms as the Directors
determine.

44.2 If the office of Auditor becomes vacant by resignation or death of the Auditor, or by his becoming incapable
of acting by reason of illness or other disability at a time when his services are required, the Directors shall fill the vacancy.

44.3 Every Auditor of the Company shall have a right of access at all times to the books and accounts and vouchers
of the Company and shall be entitled to require from the Directors and Officers of the Company such information and explanation as may
be necessary for the performance of the duties of the Auditor.

44.4 Auditors shall, if so required by the Directors, make a report on the accounts of the Company during their
tenure of office at the next annual general meeting following their appointment in the case of a company which is registered with the
Registrar of Companies as an ordinary company, and at the next extraordinary general meeting following their appointment in the case of
a company which is registered with the Registrar of Companies as an exempted company, and at any other time during their term of office,
upon request of the Directors or any general meeting of the Company.

44.5 Without prejudice to the freedom of the Directors to establish any other committee, if any of the Shares
(or depositary receipts therefor) are listed or quoted on a Designated Stock Exchange, and if required by the rules and regulations of
the Designated Stock Exchange, the SEC and/or any other compentent regulatory authority or otherwise under Applicable Law, the Directors
shall establish and maintain an Audit Committee as a committee of the board of Directors and shall adopt a formal written audit committee
charter and review and assess the adequacy of the formal written charter on an annual basis. The composition and responsibilities of the
Audit Committee shall comply with the rules and regulations of the SEC and the Designated Stock Exchange and/or any other competent regulatory
authority or otherwise under Applicable Law. The Audit Committee (if one exists) shall meet at least once every financial quarter, or
more frequently as circumstances dictate.

44.6 If any of the Shares (or depositary receipts therefor) are listed or quoted on a Designated Stock Exchange,
the Company shall conduct an appropriate review of all related party transactions on an ongoing basis and shall utilise the Audit Committee
for the review and approval of potential conflicts of interest.

44.7 The remuneration of the Auditor shall be fixed by the Audit Committee (if one exists) or otherwise by
the Directors.

44.8 Any payment made to members of the Audit Committee (if one exists) shall require the review and approval
of the Directors, with any Director interested in such payment abstaining from such review and approval.

45. **NOTICES** 

45.1 Notices shall be in writing and may be given by the Company to any Member either personally or by sending
it by courier, post, cable, telex, fax or e-mail to him or to his address as shown in the Register of Members (or where the notice is
given by e-mail by sending it to the e-mail address provided by such Member). For so long as any of the Shares are traded on a Designated
Stock Exchange, notice must also be served in accordance with the requirements of the Designated Stock Exchange. Notice may also be served
by Electronic Communication in accordance with the rules and regulations of the Designated Stock Exchange, the SEC and/or any other competent
regulatory authority or by placing it on the Company's Website.

45.2 Where a notice is sent by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) courier, service of the notice shall be deemed to be effected by delivery of the notice to a courier company,
and shall be deemed to have been received on the third day (not including Saturdays or Sundays or public holidays) following the day on
which the notice was delivered to the courier;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) post, service of the notice shall be deemed to be effected by properly addressing, pre paying and posting
a letter containing the notice, and shall be deemed to have been received on the fifth day (not including Saturdays or Sundays or public
holidays in the Cayman Islands) following the day on which the notice was posted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) cable, telex or fax, service of the notice shall be deemed to be effected by properly addressing and sending
such notice and shall be deemed to have been received on the same day that it was transmitted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) e-mail service shall be deemed to be effected by transmitting the e-mail to the e-mail address provided
by the intended recipient and shall be deemed to have been received on the same day that it was sent, and it shall not be necessary for
the receipt of the e-mail to be acknowledged by the recipient; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) placing it on the Company's Website, service of the notice shall be deemed to have been effected
one hour after the notice or document was placed on the Company's Website.

45.3 A notice may be given by the Company to the Person or Persons which the Company has been advised are entitled
to a Share or Shares in consequence of the death or bankruptcy of a Member in the same manner as other notices which are required to be
given under the Articles and shall be addressed to them by name, or by the title of representatives of the deceased, or trustee of the
bankrupt, or by any like description at the address supplied for that purpose by the Persons claiming to be so entitled, or at the option
of the Company by giving the notice in any manner in which the same might have been given if the death or bankruptcy had not occurred.

45.4 Notice of every general meeting shall be given in any manner authorised by the Articles to every holder
of Shares carrying an entitlement to receive such notice on the record date for such meeting except that in the case of joint holders
the notice shall be sufficient if given to the joint holder first named in the Register of Members and every Person upon whom the ownership
of a Share devolves by reason of his being a legal personal representative or a trustee in bankruptcy of a Member where the Member but
for his death or bankruptcy would be entitled to receive notice of the meeting, and no other Person shall be entitled to receive notices
of general meetings.

46. **WINDING UP** 

46.1 If the Company shall be wound up, the liquidator shall apply the assets of the Company in satisfaction
of creditors' claims in such manner and order as such liquidator thinks fit. Subject to the rights attaching to any Shares, in a winding
up:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if the assets available for distribution amongst the Members shall be insufficient to repay the whole
of the Company's issued share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the
Members in proportion to the par value of the Shares held by them; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if the assets available for distribution amongst the Members shall be more than sufficient to repay the
whole of the Company's issued share capital at the commencement of the winding up, the surplus shall be distributed amongst the Members
in proportion to the par value of the Shares held by them at the commencement of the winding up subject to a deduction from those Shares
in respect of which there are monies due, of all monies payable to the Company for unpaid calls or otherwise.

46.2 If the Company shall be wound up the liquidator may, subject to the rights attaching to any Shares and
with the approval of a Special Resolution of the Company and any other approval required by the Statute, divide amongst the Members in
kind the whole or any part of the assets of the Company (whether such assets shall consist of property of the same kind or not) and may
for that purpose value any assets and determine how the division shall be carried out as between the Members or different classes of Members.
The liquidator may, with the like approval, vest the whole or any part of such assets in trustees upon such trusts for the benefit of
the Members as the liquidator, with the like approval, shall think fit, but so that no Member shall be compelled to accept any asset upon
which there is a liability.

47. **INDEMNITY AND INSURANCE** 

47.1 Every Director and Officer (which for the avoidance of doubt, shall not include auditors of the Company),
together with every former Director and former Officer (each an "**Indemnified Person**") shall be indemnified out of the
assets of the Company against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses,
whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other than such
liability (if any) that they may incur by reason of their own actual fraud, wilful neglect or wilful default. No Indemnified Person shall
be liable to the Company for any loss or damage incurred by the Company as a result (whether direct or indirect) of the carrying out of
their functions unless that liability arises through the actual fraud, wilful neglect or wilful default of such Indemnified Person. No
person shall be found to have committed actual fraud, wilful neglect or wilful default under this Article unless or until a court of competent
jurisdiction shall have made a finding to that effect.

47.2 The Company shall advance to each Indemnified Person reasonable attorneys' fees and other costs and expenses
incurred in connection with the defence of any action, suit, proceeding or investigation involving such Indemnified Person for which indemnity
will or could be sought. In connection with any advance of any expenses hereunder, the Indemnified Person shall execute an undertaking
to repay the advanced amount to the Company if it shall be determined by final judgment or other final adjudication that such Indemnified
Person was not entitled to indemnification pursuant to this Article. If it shall be determined by a final judgment or other final adjudication
that such Indemnified Person was not entitled to indemnification with respect to such judgment, costs or expenses, then such party shall
not be indemnified with respect to such judgment, costs or expenses and any advancement shall be returned to the Company (without interest)
by the Indemnified Person.

47.3 The Directors, on behalf of the Company, may purchase and maintain insurance for the benefit of any Director
or Officer of the Company against any liability which, by virtue of any rule of law, would otherwise attach to such Person in respect
of any negligence, default, breach of duty or breach of trust of which such Person may be guilty in relation to the Company.

48. **FINANCIAL YEAR** 

Unless the Directors otherwise prescribe, the financial year of the Company shall end on 31st December in each year and, following the year of incorporation, shall begin on 1st January in each year.

49. **TRANSFER BY WAY OF CONTINUATION** 

49.1 If the Company is exempted as defined in the Statute, it shall, subject to the provisions of the Statute
and with the approval of a Special Resolution, have the power to register by way of continuation as a body corporate under the laws of
any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.

49.2 At the time of or following the consummation of a Business Combination, if the Company is exempted as
defined in the Statute, it shall, subject to the provisions of the Statute and with the approval of a Special Resolution, have the power
to register by way of continuation as a body corporate under the laws of any jurisdiction outside the Cayman Islands and to be deregistered
in the Cayman Islands.

50. **MERGERS AND CONSOLIDATIONS** 

The Company shall have the power to merge or consolidate with one or more other constituent companies (as defined in the Statute) upon such terms as the Directors may determine and (to the extent required by the Statute) with the approval of a Special Resolution.

51. **DISCLOSURE** 

The Directors, Officers of the Company or any authorised service providers (including the registered office agent of the Company), shall be entitled to disclose to any regulatory or judicial authority, or to any Designated Stock Exchange on which the Shares may from time to time be listed, any information regarding the affairs of the Company including, without limitation, information contained in the Register of Members and books of the Company.

52. **BUSINESS COMBINATION** 

52.1 Notwithstanding any other provision of the Articles, this Article shall apply during the period commencing
upon the adoption of the Articles and terminating upon the first to occur of the consummation of a Business Combination and the full distribution
of the Trust Account pursuant to this Article. In the event of a conflict between this Article and any other Articles, the provisions
of this Article shall prevail.

52.2 Prior to the consummation of any Business Combination, the Company
shall either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) submit such Business Combination to the Members for approval by way of an Ordinary Resolution; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) provide Members with the opportunity to have their Shares repurchased by means of a tender offer for a
per-Share repurchase price payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business
days prior to the consummation of such Business Combination, including interest earned on the Trust Account (less taxes paid or payable
(other than Excise Tax or similar taxes), divided by the number of then issued Public Shares. Such obligation to repurchase Shares is
subject to the completion of the proposed Business Combination to which it relates.

52.3 If the Company initiates any tender offer in accordance with Rule 13e-4 and Regulation 14E of the US Exchange
Act in connection with a proposed Business Combination, it shall file tender offer documents with the SEC prior to completing such Business
Combination which contain substantially the same financial and other information about such Business Combination and the redemption rights
as is required under Regulation 14A of the US Exchange Act. If, alternatively, the Company holds a general meeting to approve a proposed
Business Combination, the Company will conduct any redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of
the US Exchange Act, and not pursuant to the tender offer rules, and file proxy materials with the SEC.

52.4 Any Member holding Public Shares who is not the Sponsor, a Founder, Officer or Director may, in connection
with any vote on a Business Combination, elect to have their Public Shares redeemed for cash, in accordance with any applicable requirements
provided for in the related proxy materials (the "**IPO Redemption** "), provided that no such Member acting together with
any Affiliate of his or any other person with whom he is acting in concert or as a partnership, limited partnership, syndicate, or other
group for the purposes of acquiring, holding, or disposing of Shares may exercise this redemption right with respect to more than 15 per
cent of the Public Shares in the aggregate without the prior consent of the Company and provided further that any beneficial holder of
Public Shares on whose behalf a redemption right is being exercised must identify itself to the Company in connection with any redemption
election in order to validly redeem such Public Shares. If so demanded, the Company shall pay any such redeeming Member, regardless of
whether he is voting for or against such proposed Business Combination, a per-Share redemption price payable in cash, equal to the aggregate
amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the Business Combination,
including interest earned on the Trust Account (such interest shall be net of taxes payable) and not previously released to the Company
to pay its taxes, divided by the number of then issued Public Shares (such redemption price being referred to herein as the "**Redemption Price** "), but only in the event that the applicable proposed Business Combination is approved and consummated.

52.5 A Member may not withdraw a Redemption Notice once submitted to the Company unless the Directors determine
(in their sole discretion) to permit the withdrawal of such redemption request (which they may do in whole or in part).

52.6 In the event that the Company does not consummate a Business Combination within 24 months from the consummation
of the IPO, or such later time as the Members may approve in accordance with the Articles, the Company shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) cease all operations except for the purpose of winding up;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares,
at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on
the funds held in the Trust Account (less taxes paid or payable (other than Excise Tax or similar taxes) and up to $100,000 of interest
to pay dissolution expenses) will be used to fund the redemption of the Public Shares in issue, which redemption will completely extinguish
public Members' rights as Members (including the right to receive further liquidation distributions, if any); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) as promptly as reasonably possible following such redemption, subject to the approval of the Company's
remaining Members and the Directors, liquidate and dissolve,

subject in each case to its obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of Applicable Law.

52.7 In the event that any amendment is made to the Articles:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) to modify the substance or timing of the Company's obligation to allow redemption in connection with a
Business Combination or redeem 100 per cent of the Public Shares if the Company does not consummate a Business Combination within 24 months
after the date of the closing of the IPO, or such later time as the Members may approve in accordance with the Articles, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) with respect to any other provision relating to Members' rights or pre-Business Combination activity,
of the Articles relating to the rights of holders of Ordinary Shares,

each holder of Public Shares who is not the Sponsor, a Founder, Officer or Director shall be provided with the opportunity to redeem their Public Shares upon the approval or effectiveness of any such amendment at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, divided by the number of then outstanding Public Shares.

52.8 A holder of Public Shares shall be entitled to receive distributions from the Trust Account only in the
event of an IPO Redemption, a repurchase of Shares by means of a tender offer pursuant to this Article, or a distribution of the Trust
Account pursuant to this Article. In no other circumstance shall a holder of Public Shares have any right or interest of any kind in the
Trust Account.

52.9 After the issue of Public Shares, and prior to the consummation of a Business Combination, the Company
shall not issue additional Shares or any other securities that would entitle the holders thereof to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) receive funds from the Trust Account; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) vote as a class with Public Shares on a Business Combination.

52.10 As long as the securities of the Company are listed on a Designated Stock Exchange, the Company must complete
one or more Business Combinations having an aggregate fair market value of at least 80 per cent of the assets held in the Trust Account
(net of amounts previously disbursed to the Company's management for taxes or working capital and excluding the amount of deferred
underwriting discounts held in the Trust Account) at the time of the Company's signing a definitive agreement in connection with
a Business Combination. A Business Combination must not be effectuated with another blank cheque company or a similar company with nominal
operations.

52.11 A Director may vote in respect of a Business Combination in which such Director has a conflict of interest
with respect to the evaluation of such Business Combination. Such Director must disclose such interest or conflict to the other Directors.

52.12 The Company may enter into a Business Combination with a target business that is Affiliated with the Sponsor,
a Founder, a Director or an Officer. In the event the Company seeks to consummate a Business Combination with a target that is Affiliated
with the Sponsor, a Founder, a Director or an Officer, the Company, or a committee of Independent Directors, will obtain an opinion from
an independent investment banking firm or another valuation or appraisal firm that regularly renders fairness opinions on the type of
target business the Company is seeking to acquire that is a member of the United States Financial Industry Regulatory Authority or an
independent accounting firm that such a Business Combination is fair to the Company from a financial point of view.

52.13 A Business Combination must be approved by a majority of the board of Directors and a majority of the
Independent Directors.

53. **BUSINESS OPPORTUNITIES** 

53.1 To the fullest extent permitted by Applicable Law, no individual serving as a Director or an officer ()"**Management** ")
shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same
or similar business activities or lines of business as the Company. To the fullest extent permitted by Applicable Law, the Company renounces
any interest or expectancy of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter
which may be a corporate opportunity for Management, on the one hand, and the Company, on the other. Except to the extent expressly assumed
by contract, to the fullest extent permitted by Applicable Law, Management shall have no duty to communicate or offer any such corporate
opportunity to the Company and shall not be liable to the Company or its Members for breach of any fiduciary duty as a Member, Director
and/or officer solely by reason of the fact that such party pursues or acquires such corporate opportunity for itself, himself or herself,
directs such corporate opportunity to another person, or does not communicate information regarding such corporate opportunity to the
Company.

53.2 Except as provided elsewhere in this Article, the Company hereby renounces any interest or expectancy
of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate
opportunity for both the Company and Management, about which a Director and/or officer who is also a member of Management acquires knowledge.

53.3 To the extent a court might hold that the conduct of any activity related to a corporate opportunity that
is renounced in this Article to be a breach of duty to the Company or its Members, the Company hereby waives, to the fullest extent permitted
by Applicable Law, any and all claims and causes of action that the Company may have for such activities. To the fullest extent permitted
by Applicable Law, the provisions of this Article apply equally to activities conducted in the future and that have been conducted in
the past.

54. **EXCLUSIVE JURISDICTION AND FORUM** 

54.1 Unless the Company consents in writing to the selection of an alternative forum, the courts of the Cayman
Islands shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with the Memorandum, the Articles
or otherwise related in any way to each Member's shareholding in the Company, including but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any derivative action or proceeding brought on behalf of the
Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any action asserting a claim of breach of any fiduciary or other duty owed by any current or former Director,
Officer or other employee of the Company to the Company

or the Members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any action asserting a claim arising pursuant to any provision of the Statute, the Memorandum or the Articles;
or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) any action asserting a claim against the Company governed by
the "Internal Affairs Doctrine" (as such concept is recognized under the laws of the United States of America).

54.2 Each Member irrevocably submits to the exclusive jurisdiction
of the courts of the Cayman Islands over all such claims or disputes.

54.3 Without prejudice to any other rights or remedies that the Company may have, each Member acknowledges
that damages alone would not be an adequate remedy for any breach of the selection of the courts of the Cayman Islands as exclusive forum
and that accordingly the Company shall be entitled, without proof of special damages, to the remedies of injunction, specific performance
or other equitable relief for any threatened or actual breach of the selection of the courts of the Cayman Islands as exclusive forum.

54.4 This Article 55 shall not apply to any action or suits brought

which the federal district courts of the United States of America are, as a matter of the laws of the United States, the sole and exclusive
forum for determination of such a claim.

## Exhibit 4.1

**Exhibit 4.1**

**SHARES**

**NUMBER<br> C-**<br> SEE REVERESE FPR CERTAIN DEFINITIONS

**CUSIP**

**G50765 109**

**JATT II ACQUISITION CORP<br> ORDINARY SHARES**

THIS CERTIFIES THAT is the owner of ordinary shares, par value $0.0001 per share (each, an "*Ordinary Share*"), of JATT II Acquisition Corp, a Cayman Islands exempted company (the "*Company*"), transferable on the books of the Company in person or by duly authorized attorney upon surrender of this certificate properly endorsed, subject to the amended and restated memorandum and articles of association of the Company, as may be amended from time to time (the "**Memorandum and Articles**").

This certificate is not valid unless countersigned by the Transfer Agent and registered by the Registrar of the Company.

Witness the facsimile signature of a duly authorized signatory of the Company.

<u> Authorized Signatory</u> <u>Transfer Agent</u>

**JATT II Acquisition Corp**

The Company will furnish without charge to each shareholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of equity or series thereof of the Company and the qualifications, limitations, or restrictions of such preferences and/or rights. This certificate and the shares represented thereby are issued and shall be held subject to all the provisions of the Memorandum and Articles and resolutions of the Board of Directors providing for the issue of securities (copies of which may be obtained from the secretary of the Company), to all of which the holder of this certificate by acceptance hereof assents.

The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations:

---

| | | | |
|:---|:---|:---|:---|
| TEN<br> COM | as tenants in common | UNIF GIFT MIN ACT | – ________ Custodian ________<br>(Cust) (Minor) |
| TEN<br> ENT | as tenants by the entities |  | Under Uniform Gifts to Minors Act |
| JT TEN | as joint tenants with right of survivorship and not as tenants in common |  | (State) |

---

Additional abbreviations may also be used though not in the above list.

 

*For value received, hereby sells, assigns and transfers unto*

(PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER(S) OF ASSIGNEE(S)) (PLEASE PRINT OR TYPEWRITE NAME(S) AND ADDRESS(ES), INCLUDING ZIP CODE, OF ASSIGNEE(S))

 

*Ordinary Shares represented by the within certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said Ordinary Shares on the books of the within named Company with full power of substitution in the premises.*

 

*Dated*

 

---

| | | |
|:---|:---|:---|
| Signature(s) Guaranteed: | **Notice:** | The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever. |

---

THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)).

As more fully described in, and subject to the terms and conditions described in, the Company's final prospectus for its initial public offering dated , the holder(s) of this certificate shall be entitled to receive a pro-rata portion of certain funds held in the trust account established in connection with the Company's initial public offering in the event that (i) the Company redeems the Ordinary Shares sold in its initial public offering and liquidates because it does not consummate an initial business combination within the time period set forth in the Company's Amended and Restated Memorandum and Articles of Association, as the same may be amended from time to time, or (ii) if the holder(s) properly redeem for cash his, her or its respective Ordinary Shares represented by this certificate in connection with (x) a tender offer (or proxy solicitation, solely in the event the Company seeks shareholder approval of the proposed initial business combination) setting forth the details of a proposed initial business combination or (y) a shareholder vote to amend the Company's Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company's obligation to allow redemption in connection with the Company's initial business combination or to redeem 100% of the Ordinary Shares if it does not consummate an initial business combination within the time set forth in the Company's Amended and Restated Memorandum and Articles of Association, as the same may be amended from time to time or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial Business Combination activity. In no other circumstances shall the holder(s) have any right or interest of any kind in or to the trust account.

## Exhibit 5.1

**Exhibit 5.1**

![](ea028469001_ex5-1img1.jpg)

---

| | |
|:---|:---|
| **JATT II Acquisition Corp** | **JATT II Acquisition Corp** |
| Suite 210, 2nd Floor, Windward III | Suite 210, 2nd Floor, Windward III |
| Regatta Office Park | Regatta Office Park |
| PO Box 500 | PO Box 500 |
| Grand Cayman, KY1-1106 | Grand Cayman, KY1-1106 |
| Cayman Islands | 2 April 2026 |

---

---

| | |
|:---|:---|
|  | **JATT II Acquisition Corp** |
| Cayman Office<br>&nbsp;&nbsp;&nbsp;&nbsp;Appleby (Cayman) Ltd.<br> 9<sup>th</sup> Floor, 60 Nexus Way<br> Camana Bay<br> PO Box 190<br> Grand Cayman KY1-1104<br> Cayman Islands<br>Tel +1 345 949 4900 applebyglobal.com | We have acted as counsel as to Cayman Islands law to **JATT II Acquisition Corp** (the "**Company**") in connection with the Company's registration statement on Form S-1, including all amendments or supplements thereto, filed with the United States Securities and Exchange Commission (the "**Commission**") under the United States Securities Act of 1933, as amended (the "**Act**") (including its exhibits, the "**Registration Statement**") for the purposes of, registering with the Commission under the Act, the offering and sale to the public of: up to 6,900,000 ordinary shares (including up to 900,000 ordinary shares which may be issued if the underwriters option to purchase additional shares is exercised in full, which the several underwriters for whom Guggenheim Securities, LLC is acting as representative ("**Representative**"), will have a 45-day option to purchase from the Company to cover over-allotments, if any) at an offering price of US$10.00 per share, each share consisting of one ordinary share of a par value of US$0.0001 of the Company ("**Ordinary Shares**"). |
|  | This opinion letter is given in accordance with the terms of the Legal Matters section of the Registration Statement. |

---

---

| | |
|:---|:---|
| **1.** | **Documents Reviewed** |
| We have reviewed originals, copies, drafts or conformed copies of the following documents: | We have reviewed originals, copies, drafts or conformed copies of the following documents: |
| 1.1 | The certificate of incorporation dated 13 January 2026, the memorandum and articles of association of the Company as registered or adopted on 13 January 2026, the amendment to the memorandum of association dated 12 February 2026, and the amended and restated memorandum and articles of association as adopted at the time the Registration Statement becomes effective (together, the "**Memorandum and Articles**"). |
| 1.2 | The written resolutions of the board of directors of the Company dated 12 February 2026, 25 March 2026 and resolutions to be adopted on or about the date the Registration Statement becomes effective and the corporate records of the Company maintained at its registered office in the Cayman Islands. |
| 1.3 | The written resolutions of the shareholders dated 12 February 2026. |
| 1.4 | A certificate of good standing with respect to the Company issued by the Registrar of Companies (the "**Certificate of Good Standing**"). |

---

Bermuda ■ British Virgin Islands ■ Cayman Islands ■ Guernsey ■ Hong Kong ■ Isle of Man ■ Jersey ■ Mauritius ■ Seychelles ■ Shanghai

![](ea028469001_ex5-1img1.jpg)

---

| | |
|:---|:---|
| 1.5 | The Registration Statement. |
| 1.6 | A draft of the form of the ordinary share certificate representing the Ordinary Shares (the "**Ordinary Share Certificate**"). |
| 1.7 | A draft of the underwriting agreement between the Company and the Representative. |
| The documents listed in paragraphs 1.5 to 1.7 inclusive above shall be referred to collectively herein as the "**Documents**". | The documents listed in paragraphs 1.5 to 1.7 inclusive above shall be referred to collectively herein as the "**Documents**". |
| 2 | **Assumptions** |
| The following opinions are given only as to, and based on, circumstances and matters of fact existing and known to us on the date of this opinion letter. These opinions only relate to the laws of the Cayman Islands which are in force on the date of this opinion letter. In giving the following opinions, we have relied (without further verification) upon the completeness and accuracy, as at the date of this opinion letter, and the Certificate of Good Standing. We have also relied upon the following assumptions, which we have not independently verified: | The following opinions are given only as to, and based on, circumstances and matters of fact existing and known to us on the date of this opinion letter. These opinions only relate to the laws of the Cayman Islands which are in force on the date of this opinion letter. In giving the following opinions, we have relied (without further verification) upon the completeness and accuracy, as at the date of this opinion letter, and the Certificate of Good Standing. We have also relied upon the following assumptions, which we have not independently verified: |
| 2.1 | The choice of laws of the State of New York as the governing law of the Documents has been made in good faith and would be regarded as a valid and binding selection which will be upheld by the courts of the State of New York and any other relevant jurisdiction (other than the Cayman Islands) as a matter of the State of New York and all other relevant laws (other than the laws of the Cayman Islands). |
| 2.2 | Copies of documents, conformed copies or drafts of documents provided to us are true and complete copies of, or in the final forms of, the originals. |
| 2.3 | All signatures, initials and seals are genuine. |
| 2.4 | No invitation has been or will be made by or on behalf of the Company to the public in the Cayman Islands to subscribe for any of the Ordinary Shares. |
| 2.5 | No monies paid to or for the account of any party under the Documents or any property received or disposed of by any party to the Documents in each case in connection with the Documents or the consummation of the transactions contemplated thereby represent or will represent proceeds of criminal conduct or criminal property or terrorist property (as defined in the Proceeds of Crime Act (As Revised) and the Terrorism Act (As Revised), respectively). |
| 2.6 | There is nothing under any law (other than the laws of the Cayman Islands) which would or might affect the opinions set out below. Specifically, we have made no independent investigation of the laws of New York. |
| Save as aforesaid we have not been instructed to undertake and have not undertaken any further enquiry or due diligence in relation to the transaction the subject of this opinion letter. | Save as aforesaid we have not been instructed to undertake and have not undertaken any further enquiry or due diligence in relation to the transaction the subject of this opinion letter. |

---

2 <br> Bermuda ■ British Virgin Islands ■ Cayman Islands ■ Guernsey ■ Hong Kong ■ Isle of Man ■ Jersey ■ Mauritius ■ Seychelles ■ Shanghai

![](ea028469001_ex5-1img1.jpg)

---

| | |
|:---|:---|
| 3 | **OPINIONS** |
| Based upon, and subject to, the foregoing assumptions and the qualifications set out below, and having regard to such legal considerations as we deem relevant, we are of the opinion that: | Based upon, and subject to, the foregoing assumptions and the qualifications set out below, and having regard to such legal considerations as we deem relevant, we are of the opinion that: |

---

---

| | |
|:---|:---|
| 3.1 | The Company has been duly incorporated as an exempted company with limited liability and is validly existing and in good standing with the Registrar of Companies under the laws of the Cayman Islands. |
| 3.2 | The Ordinary Shares to be offered and issued by the Company as contemplated by the Registration Statement have been duly authorised for issue, and when issued by the Company against payment in full of the consideration as set out in the Registration Statement and in accordance with the terms set out in the Registration Statement, such Ordinary Shares will be validly issued, fully paid and non-assessable. As a matter of Cayman Islands law, a share is only issued when it has been entered in the register of members (shareholders). |
| 3.3 | The execution, delivery and performance of the Ordinary Share Certificate have been authorised by and on behalf of the Company and, once the Ordinary Share Certificate have been executed and delivered by any director or officer of the Company, the Ordinary Share Certificate will be duly executed and delivered on behalf of the Company and will constitute the legal, valid and binding obligations of the Company enforceable in accordance with their terms. |
| 4 | **QUALIFICATIONS** |
| The opinions expressed above are subject to the following qualifications: | The opinions expressed above are subject to the following qualifications: |
| 4.1 | The obligations assumed by the Company under the Documents will not necessarily be enforceable in all circumstances in accordance with their terms. In particular: |
| (a) | enforcement may be limited by bankruptcy, insolvency, liquidation, reorganisation, readjustment of debts or moratorium or other laws of general application relating to protecting or affecting the rights of creditors; |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) enforcement may be limited by general principles of equity. For example, equitable remedies such as specific performance may not be available, inter alia, where damages are considered to be an adequate remedy;

(c) where obligations are to be performed in a jurisdiction outside the Cayman Islands, they may not be enforceable in the Cayman Islands to the extent that performance would be illegal under the laws of that jurisdiction; and

(d) some claims may become barred under relevant statutes of limitation or may be or become subject to defences of set off, counterclaim, estoppel and similar defences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 To maintain the Company in good standing with the Registrar of Companies under the laws of the Cayman Islands, annual filing fees must be paid and returns made to the Registrar of Companies within the time frame prescribed by law.

4.3 Under Cayman Islands law, the register of members (shareholders) is prima facie evidence of title to shares and this register would not record a third-party interest in such shares. However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not reflect the correct legal position. As far as we are aware, such applications are rarely made in the Cayman Islands and for the purposes of the opinion given in paragraph 3.2, there are no circumstances or matters of fact known to us on the date of this opinion letter which would properly form the basis for an application for an order for rectification of the register of members of the Company, but if such an application were made in respect of the Ordinary Shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court.

3 <br> Bermuda ■ British Virgin Islands ■ Cayman Islands ■ Guernsey ■ Hong Kong ■ Isle of Man ■ Jersey ■ Mauritius ■ Seychelles ■ Shanghai

![](ea028469001_ex5-1img1.jpg)

---

| | |
|:---|:---|
| 4.4 | In this opinion letter the phrase "non-assessable" means, with respect to the issuance of shares, that a shareholder shall not, in respect of the relevant shares and in the absence of a contractual arrangement, or an obligation pursuant to the Memorandum and Articles, to the contrary, have any obligation to make further contributions to the Company's assets (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil). |
| We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement and to the references to our firm under the headings "*Legal Matters*", "*Risk Factors*", "*Shareholders' Suits*" and "*Enforcement of Civil Liabilities*" in the prospectus included in the Registration Statement. In providing our consent, we do not thereby admit that we are in the category of persons whose consent is required under section 7 of the Act or the Rules and Regulations of the Commission thereunder. | We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement and to the references to our firm under the headings "*Legal Matters*", "*Risk Factors*", "*Shareholders' Suits*" and "*Enforcement of Civil Liabilities*" in the prospectus included in the Registration Statement. In providing our consent, we do not thereby admit that we are in the category of persons whose consent is required under section 7 of the Act or the Rules and Regulations of the Commission thereunder. |
| We offer no opinion: (i) as to any laws other than the laws of the Cayman Islands, and we have not, for the purposes of this opinion, made any investigation of the laws of any other jurisdiction, and we express no opinion as to the enforceability, meaning, validity, or effect of references in the Documents to statutes, rules, regulations, codes or judicial authority of any jurisdiction other than the Cayman Islands; or (ii) except to the extent that this opinion expressly provides otherwise, as to the commercial terms of, or the validity, enforceability or effect of the documents reviewed (or as to how the commercial terms of such documents reflect the intentions of the parties), the accuracy of representations, the fulfilment of warranties or conditions, the occurrence of events of default or terminating events or the existence of any conflicts or inconsistencies among the documents and any other agreements into which the Company may have entered or any other documents. | We offer no opinion: (i) as to any laws other than the laws of the Cayman Islands, and we have not, for the purposes of this opinion, made any investigation of the laws of any other jurisdiction, and we express no opinion as to the enforceability, meaning, validity, or effect of references in the Documents to statutes, rules, regulations, codes or judicial authority of any jurisdiction other than the Cayman Islands; or (ii) except to the extent that this opinion expressly provides otherwise, as to the commercial terms of, or the validity, enforceability or effect of the documents reviewed (or as to how the commercial terms of such documents reflect the intentions of the parties), the accuracy of representations, the fulfilment of warranties or conditions, the occurrence of events of default or terminating events or the existence of any conflicts or inconsistencies among the documents and any other agreements into which the Company may have entered or any other documents. |
| The opinions in this opinion letter are strictly limited to the matters contained in the opinions section above and do not extend to any other matters. We have not been asked to review and we therefore have not reviewed any of the ancillary documents relating to the Documents and express no opinion or observation upon the terms of any such document. | The opinions in this opinion letter are strictly limited to the matters contained in the opinions section above and do not extend to any other matters. We have not been asked to review and we therefore have not reviewed any of the ancillary documents relating to the Documents and express no opinion or observation upon the terms of any such document. |
| This opinion letter is addressed to you and may be relied upon by you, your counsel and purchasers of Ordinary Shares pursuant to the Registration Statement. This opinion letter is limited to the matters detailed herein and is not to be read as an opinion with respect to any other matter. | This opinion letter is addressed to you and may be relied upon by you, your counsel and purchasers of Ordinary Shares pursuant to the Registration Statement. This opinion letter is limited to the matters detailed herein and is not to be read as an opinion with respect to any other matter. |
| Yours faithfully | Yours faithfully |
| /s/ Appleby (Cayman) Ltd. | /s/ Appleby (Cayman) Ltd. |
| **Appleby (Cayman) Ltd.** | **Appleby (Cayman) Ltd.** |

---

4 <br> Bermuda ■ British Virgin Islands ■ Cayman Islands ■ Guernsey ■ Hong Kong ■ Isle of Man ■ Jersey ■ Mauritius ■ Seychelles ■ Shanghai

## Exhibit 10.1

**Exhibit 10.1**

[●], 2026

JATT II Acquisition Corp

153 Central Avenue

C/O 56

Westfield, NJ 07091

Re: <u>Initial Public Offering</u>

Ladies and Gentlemen:

This letter (this "***Letter Agreement***") is being delivered to you in accordance with the Underwriting Agreement (the "***Underwriting Agreement***") entered into by and between JATT II Acquisition Corp, a Cayman Islands exempted company (the "***Company***") and Guggenheim Securities, LLC, as representative (the "***Representative***") of the underwriters named therein (the "***Underwriters***"), relating to an underwritten initial public offering (the "***Public Offering***") of up to 6,900,000 of the Company's ordinary shares, par value $0.0001 per share (including up to 900,000 shares that may be purchased to cover over-allotments, if any) (the "***Ordinary Shares***"). The Ordinary Shares will be sold in the Public Offering pursuant to a registration statement on Form S-1 and prospectus (the "***Prospectus***") filed by the Company with the U.S. Securities and Exchange Commission (the "***Commission***") and the Company has applied to have the Ordinary Shares listed on The Nasdaq Global Market. Certain capitalized terms used herein are defined in paragraph 11 hereof.

In order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the Public Offering and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of JATT Ventures II L.P. (the "***Sponsor***") and the undersigned individuals, each of whom is a member of the Company's board of directors and/or management team, or independent consultant (each of the undersigned individuals, an "***Insider***" and collectively, the "***Insiders***"), hereby agrees with the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. It is acknowledged and agreed that the Company shall not
enter into a definitive agreement regarding a proposed Business Combination without the prior consent of the Sponsor. The Sponsor and
each Insider agrees that if the Company seeks shareholder approval of a proposed Business Combination, then in connection with such proposed
Business Combination, it, he or she shall (i) vote any Ordinary Shares (as defined below) owned by it, him or her in favor of any proposed
Business Combination (except with respect to any such Offering Shares (as defined below) which may not be voted in favor of approving
the Business Combination in accordance with the requirements of Rule 14e-5 under the Exchange Act (as defined below) and any Commission
interpretations or guidance relating thereto) and (ii) not redeem any Ordinary Shares owned by it, him or her in connection with such
shareholder approval. If the Company seeks to consummate a proposed Business Combination by engaging in a tender offer, the Sponsor and
each Insider agrees that it, he or she will not sell or tender to the Company any Ordinary Shares owned by it, him or her in connection
therewith.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Sponsor and each Insider hereby agrees that in the event
that the Company fails to consummate a Business Combination within 24 months from the closing of the Public Offering, or such later period
approved by the Company's shareholders in accordance with the Company's amended and restated memorandum and articles of association
(as it may be amended from time to time, the "  ***Charter*** "), the Sponsor and each Insider shall take all reasonable
steps to cause the Company to, as promptly as reasonably possible but not more than ten (10) business days thereafter, redeem 100% of
the Ordinary Shares in the Public Offering (the "  ***Offering Shares*** "), at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account (as defined below), including interest earned on the funds held in
the Trust Account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution
expenses), divided by the number of then issued and outstanding Offering Shares, which redemption will constitute full and complete payment
for the Offering Shares and completely extinguish all Public Shareholders' (as defined below) rights as shareholders (including
the right to receive further liquidating or other distributions, if any), subject to the Company's obligations under Cayman Islands
law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. The Sponsor and each Insider
agrees to not propose any amendment to the Charter (A) to modify the substance or timing of the Company's obligation to allow redemption
in connection with a Business Combination or to redeem 100% of the Offering Shares if the Company does not complete a Business Combination
within the required time period set forth in the Charter or (B) with respect to any other material provisions relating to shareholders'
rights or pre-initial Business Combination activity, unless the Company provides its Public Shareholders with the opportunity to redeem
their Offering Shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on
deposit in the Trust Account, including interest earned on the funds held in the Trust Account (net of taxes paid or payable (other than
excise or similar taxes)), divided by the number of then issued and outstanding Offering Shares.

The Sponsor and each Insider acknowledges that it, he or she has no right, title, interest or claim of any kind in or to any monies held in the Trust Account with respect to the Founder Shares held by it, him or her. The Sponsor and each Insider hereby further waives, with respect to any Ordinary Shares held by it, him or her, if any, any redemption rights it, he or she may have in connection with (a) the consummation of a Business Combination, including, without limitation, any such rights available in the context of a shareholder vote to approve such Business Combination, or (b) a shareholder vote to approve an amendment to the Charter (A) to modify the substance or timing of the Company's obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Offering Shares if the Company has not consummated a Business Combination within the time period set forth in the Charter or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial Business Combination activity or in the context of a tender offer made by the Company to purchase Offering Shares (although the Sponsor, the Insiders and their respective affiliates shall be entitled to redemption and liquidation rights with respect to any Offering Shares it or they hold if the Company fails to consummate a Business Combination within the time period set forth in the Charter).

&nbsp;&nbsp;&nbsp;&nbsp;3. During the period commencing on the effective date of the
Underwriting Agreement and ending 180 days after such date, the Sponsor and each Insider shall not, without the prior written consent
of the Representative, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise
dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease
a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "  ***Exchange Act*** "), and the rules and regulations of the Commission promulgated thereunder, with respect to Ordinary Shares (including,
but not limited to, Founder Shares) or any securities convertible into, or exercisable, or exchangeable for, Ordinary Shares owned by
it, him or her, (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of Ordinary Shares (including, but not limited to, Founder Shares) or any securities convertible into, or exercisable, or
exchangeable for, Ordinary Shares owned by it, him or her, whether any such transaction is to be settled by delivery of such securities,
in cash or otherwise, or (iii) publicly announce any intention to effect any transaction specified in clause (i) or (ii). The provisions
of this paragraph will not apply to any transfer permitted under paragraph 7(c) hereof or if the release or waiver is effected solely
to permit a transfer not for consideration and the transferee has agreed in writing to be bound by the same terms described in this Letter
Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

&nbsp;&nbsp;&nbsp;&nbsp;4. In the event of the liquidation of the Trust Account upon
the failure of the Company to consummate its initial Business Combination within the time period set forth in the Charter, the Sponsor
(the "  ***Indemnitor***") agrees to indemnify and hold harmless the Company against any and all loss, liability, claim,
damage and expense whatsoever (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, whether pending or threatened) to which the Company may become subject as a result of
any claim by (i) any third party for services rendered or products sold to the Company (except for the Company's independent auditors)
or (ii) any prospective target business with which the Company has entered into a written letter of intent, confidentiality or other
similar agreement, in connection with an extension of the timeframe for the Company to consummate a Business Combination or Business
Combination agreement (a "  ***Target*** "); <u>provided</u>, <u>however</u>, that such indemnification of the Company
by the Indemnitor (x) shall apply only to the extent necessary to ensure that such claims by a third party or a Target do not reduce
the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Offering Share and (ii) the actual amount per Offering
Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Offering Share is then
held in the Trust Account due to reductions in the value of the trust assets, less taxes payable, (y) shall not apply to any claims by
a third party or a Target which executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such
waiver is enforceable) and (z) shall not apply to any claims under the Company's indemnity of the Underwriters against certain
liabilities, including liabilities under the Securities Act of 1933, as amended. The Indemnitor shall have the right to defend against
any such claim with counsel of its choice reasonably satisfactory to the Company if, within 15 days following written receipt of notice
of the claim to the Indemnitor, the Indemnitor notifies the Company in writing that it shall undertake such defense.

&nbsp;&nbsp;&nbsp;&nbsp;5. To the extent that the Underwriters do not exercise their
over-allotment option to purchase up to an additional 900,000 Ordinary Shares within 45 days from the date of the Prospectus (and as
further described in the Prospectus), the Sponsor agrees to forfeit, at no cost, a number of Founder Shares equal to 225,000 multiplied
by a fraction, (i) the numerator of which is 900,000 minus the number of Ordinary Shares purchased by the Underwriters upon the exercise
of their over-allotment option, and (ii) the denominator of which is 900,000. The forfeiture will be adjusted to the extent that the
over-allotment option is not exercised in full by the Underwriters so that the Founder Shares will represent an aggregate of 20.0% of
the Company's issued and outstanding Ordinary Shares after the Public Offering (not including the Private Placement Shares (as
defined below)). The Initial Shareholders further agree that to the extent that the size of the Public Offering is increased or decreased,
the Company will purchase or sell Ordinary Shares or effect a share repurchase or share capitalization, as applicable, immediately prior
to the consummation of the Public Offering in such amount as to maintain the number of Founder Shares at 20.0% of its issued and outstanding
Ordinary Shares upon the consummation of the Public Offering (not including the Private Placement Shares). In connection with such increase
or decrease in the size of the Public Offering, then (A) the references to 900,000 in the numerator and denominator of the formula in
the first sentence of this paragraph shall be changed to a number equal to 15% of the number of Ordinary Shares issued in the Public
Offering and (B) the reference to 225,000 in the formula set forth in the first sentence of this paragraph shall be adjusted to such
number of Founder Shares that the Sponsor would have to surrender to the Company in order for the number of Founder Shares to equal an
aggregate of 20.0% of the Company's issued and outstanding Ordinary Shares after the Public Offering (not including Private Placement
Shares).

&nbsp;&nbsp;&nbsp;&nbsp;6. The Sponsor and each Insider hereby agrees and acknowledges
that: (i) the Underwriters and the Company would be irreparably injured in the event of a breach by such Sponsor or an Insider of its,
his or her obligations under paragraphs 1, 2, 3, 4, 5, 7(a), 7(b), and 9, as applicable, of this Letter Agreement, (ii) monetary damages
may not be an adequate remedy for such breach and (iii) the non-breaching party shall be entitled to injunctive relief, in addition to
any other remedy that such party may have in law or in equity, in the event of such breach.

&nbsp;&nbsp;&nbsp;&nbsp;7. (a) The Sponsor and each Insider agrees that it, he or she
shall not Transfer any Founder Shares (or any Ordinary Shares issuable upon conversion thereof) until the earlier of (A) 180 days after
the completion of the Company's initial Business Combination and (B) subsequent to the Business Combination, the date on which
the Company completes a liquidation, merger, amalgamation, capital stock exchange, reorganization or other similar transaction that results
in all of the Company's Public Shareholders having the right to exchange their Ordinary Shares for cash, securities or other property
(the "  ***Founder Shares Lock-up Period*** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Sponsor and each Insider agrees that it, he or she shall not Transfer any Private Placement Shares, until 30 days after the completion of a Business Combination (the "***Private Placement Shares Lock-up Period***", together with the Founder Shares Lock-up Period, the "***Lock-up Periods***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding the provisions set forth in paragraphs 7(a) and 7(b), Transfers of the Founder Shares (or any Ordinary Shares issuable upon conversion thereof) or Private Placement Shares that are held by the Sponsor, any Insider or any of their permitted transferees (that have complied with this paragraph 7(c)), are permitted (a) to the Company's officers or directors, any affiliate or family member of any of the Company's officers or directors, any members or partners of the Sponsor or their affiliates, any affiliates of the Sponsor, or any employees of such affiliates; (b) in the case of an individual, by gift to a member of such individual's immediate family or to a trust, the beneficiary of which is a member of such individual's immediate family, an affiliate of such individual or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or otherwise in connection with the consummation of an initial Business Combination at prices no greater than the price at which the securities were originally purchased; (f) in the event of the Company's liquidation prior to the completion of an initial Business Combination; (g) by virtue of the laws of the Cayman Islands or the Sponsor's limited liability company agreement upon dissolution of the Sponsor; or (h) in the event of the Company's liquidation, merger, capital stock exchange or other similar transaction which results in all of the Company's shareholders having the right to exchange their Ordinary Shares for cash, securities or other property subsequent to the Company's completion of an initial Business Combination; provided, however, that in the case of clauses (a) through (e) or (g), these permitted transferees must enter into a written agreement with the Company agreeing to be bound by the transfer restrictions herein and the other restrictions contained in this Agreement (including provisions relating to voting, the Trust Account and liquidating distributions).

&nbsp;&nbsp;&nbsp;&nbsp;8. The Sponsor and each Insider represents and warrants that
it, he or she has never been suspended or expelled from membership in any securities or commodities exchange or association or had a
securities or commodities license or registration denied, suspended or revoked. Each Insider's biographical information furnished
to the Company (including any such information included in the Prospectus) is true and accurate in all respects and does not omit any
material information with respect to the Insider's background. The Sponsor and each Insider's questionnaire furnished to
the Company is true and accurate in all respects. The Sponsor and each Insider represents and warrants that: it, he or she is not subject
to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from
any act or practice relating to the offering of securities in any jurisdiction; it, he or she has never been convicted of, or pleaded
guilty to, any crime (i) involving fraud, (ii) relating to any financial transaction or handling of funds of another person, or (iii)
pertaining to any dealings in any securities and it, he or she is not currently a defendant in any such criminal proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;9. [Reserved.]

&nbsp;&nbsp;&nbsp;&nbsp;10. The Sponsor and each Insider has full right and power, without
violating any agreement to which it is bound (including, without limitation, any non-competition or non-solicitation agreement with any
employer or former employer), to enter into this Letter Agreement and, as applicable, to serve as an officer and/or director on the board
of directors of the Company and hereby consents to being named in the Prospectus as an officer and/or director of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;11. As used herein, (i) "  ***Business Combination*** "
shall mean a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, involving the
Company and one or more businesses; (ii) "  ***Founder Shares***" shall mean the 1,725,000 Ordinary Shares issued and
outstanding (up to 225,000 of which are subject to complete or partial forfeiture if the over-allotment option is not exercised by the
Underwriters); (iii) "  ***Initial Shareholders***" shall mean the Sponsor and any Insider that holds Founder Shares;
(iv) "  ***Private Placement Shares***" shall mean the 300,000 Ordinary Shares (or 309,000 Ordinary Shares if the over-allotment
option is exercised in full) that the Sponsor has agreed to purchase for an aggregate purchase price of $3,000,000 (or $3,090,000 if
the over-allotment option is exercised in full), or $10.00 per share, in a private placement that shall occur simultaneously with the
consummation of the Public Offering; (v) "  ***Shares***" shall mean the Private Placement Shares and public shares;
(vi) "  ***Public Shareholders***" shall mean the holders of securities issued in the Public Offering; (vii) "  ***Trust Account***" shall mean the trust fund into which a portion of the net proceeds of the Public Offering and the sale of the
Private Placement Shares shall be deposited; and (viii) "  ***Transfer***" shall mean the (a) sale of, offer to sell,
contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of,
directly or indirectly, or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call
equivalent position within the meaning of Section 16 of the Exchange Act, and the rules and regulations of the Commission promulgated
thereunder with respect to, any security, (b) entry into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities,
in cash or otherwise, or (c) public announcement of any intention to effect any transaction specified in clause (a) or (b).

&nbsp;&nbsp;&nbsp;&nbsp;12. The Company will maintain an insurance policy or policies
providing directors' and officers' liability insurance, and each Director shall be covered by such policy or policies, in
accordance with its or their terms.

&nbsp;&nbsp;&nbsp;&nbsp;13. This Letter Agreement constitutes the entire agreement and
understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements, or representations
by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions
contemplated hereby. This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error)
as to any particular provision, except by a written instrument executed by all parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;14. No party hereto may assign either this Letter Agreement or
any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported assignment
in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the
purported assignee. This Letter Agreement shall be binding on the Sponsor and each Insider and their respective successors, heirs and
assigns and permitted transferees.

&nbsp;&nbsp;&nbsp;&nbsp;15. Nothing in this Letter Agreement shall be construed to confer
upon, or give to, any person or entity other than the parties hereto any right, remedy or claim under or by reason of this Letter Agreement
or of any covenant, condition, stipulation, promise or agreement hereof. All covenants, conditions, stipulations, promises and agreements
contained in this Letter Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors, heirs, personal
representatives and assigns and permitted transferees.

&nbsp;&nbsp;&nbsp;&nbsp;16. This Letter Agreement may be executed in any number of original
or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts
shall together constitute but one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;17. This Letter Agreement shall be deemed severable, and the
invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Letter Agreement
or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto
intend that there shall be added as a part of this Letter Agreement a provision as similar in terms to such invalid or unenforceable
provision as may be possible and be valid and enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;18. This Letter Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York. The parties hereto (i) all agree that any action, proceeding,
claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in the courts of New
York City, in the State of New York, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive
and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.

&nbsp;&nbsp;&nbsp;&nbsp;19. Any notice, consent or request to be given in connection
with any of the terms or provisions of this Letter Agreement shall be in writing and shall be sent by express mail or similar private
courier service, by certified mail (return receipt requested), by hand delivery or e-mail transmission.

&nbsp;&nbsp;&nbsp;&nbsp;20. This Letter Agreement shall terminate on the earlier of (i)
the expiration of the Lock-up Periods or (ii) the liquidation of the Company; provided that this Letter Agreement shall earlier terminate
in the event that the Public Offering is not consummated and closed by December 31, 2026; provided further that paragraph 4 of this Letter
Agreement shall survive such liquidation.

[Signature Page Follows]

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **JATT Ventures II L.P.** | **JATT Ventures II L.P.** |
| (acting by its general partner, JATT Ventures II Ltd) | (acting by its general partner, JATT Ventures II Ltd) |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Director |
| By: |  |
| Name: | Someit Sidhu |
| By: |  |
| Name: | Nicholas Fernandez |
| By: |  |
| Name: | Verender S. Badial |
| By: |  |
| Name: | Christopher Staral |
| By: |  |
| Name: | Arjun Goyal |
| By: |  |
| Name: | Jonathon Kluft |
| By: |  |
| Name: | Brad Middlekauff |

---

---

| | |
|:---|:---|
| Acknowledged and Agreed: | Acknowledged and Agreed: |
| **JATT II Acquisition Corp** | **JATT II Acquisition Corp** |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Chief Executive Officer |

---

*[Signature Page to Letter Agreement]*

## Exhibit 10.2

**Exhibit 10.2**

**INVESTMENT MANAGEMENT TRUST AGREEMENT**

This Investment Management Trust Agreement (this "***Agreement***") is made effective as of [•], 2026 by and between JATT II Acquisition Corp, a Cayman Islands exempted company (the "***Company***"), and Continental Stock Transfer & Trust Company, a New York corporation (the "***Trustee***").

WHEREAS, the Company's registration statement on Form S-1, File No. 333-294294 (the "***Registration Statement***") and prospectus (the "***Prospectus***") for the initial public offering (the "***Offering***") of the Company's Ordinary Shares, par value $0.0001 per share (the "***Ordinary Shares***") has been declared effective as of the date hereof by the U.S. Securities and Exchange Commission; and

WHEREAS, the Company has entered into an Underwriting Agreement (the "***Underwriting Agreement***") with Guggenheim Securities, LLC, as representative of the underwriters named therein (the "***Underwriters***"); and

WHEREAS, as described in the Prospectus, $60,000,000 of the gross proceeds of the Offering and sale of the Private Placement Shares (as defined in the Underwriting Agreement) (or $69,000,000 if the Underwriters' over-allotment option is exercised in full) will be delivered to the Trustee to be deposited and held in a segregated trust account located at all times in the United States (the "***Trust Account***") for the benefit of the Company and the holders of the Ordinary Shares issued in the Offering as hereinafter provided (the amount to be delivered to the Trustee (and any interest subsequently earned thereon) is referred to herein as the "***Property***," the shareholders for whose benefit the Trustee shall hold the Property will be referred to as the "***Public Shareholders***," and the Public Shareholders and the Company will be referred to together as the "***Beneficiaries***"); and

WHEREAS, pursuant to the Underwriting Agreement, a portion of the Property equal to $1,800,000, or $2,070,000 if the Underwriters' over-allotment option is exercised in full, is attributable to deferred underwriting discounts and commissions that will be payable by the Company to the Underwriters upon and concurrently with the consummation of the Business Combination (as defined below) (the "***Deferred Discount***") and at the Company's sole and absolute discretion, up to $500,000 of this amount may be paid to third parties not participating in the Company's Offering that assist the Company in consummating the Business Combination; and

WHEREAS, the Company and the Trustee desire to enter into this Agreement to set forth the terms and conditions pursuant to which the Trustee shall hold the Property.

NOW THEREFORE, IT IS AGREED:

1. <u>Agreements and Covenants of Trustee</u>. The Trustee hereby agrees and covenants to:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Hold the Property in trust for the Beneficiaries in accordance
with the terms of this Agreement in the Trust Account established by the Trustee in the United States at JPMorgan Chase Bank, N.A. (or
at another U.S. chartered commercial bank with consolidated assets of $100 billion or more) and at a brokerage institution selected by
the Trustee that is reasonably satisfactory to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Manage, supervise and administer the Trust Account subject
to the terms and conditions set forth herein;

&nbsp;&nbsp;&nbsp;&nbsp;(c) In a timely manner, upon the written instruction of the Company,
(i) hold the Property as uninvested cash, (ii) deposit the Property into an interest bearing or non-interest bearing demand deposit account
at a U.S. chartered commercial bank with consolidated assets of $100 billion or more selected by the Trustee that is satisfactory to
the Company, or (iii) invest and reinvest the Property in United States government securities within the meaning of Section 2(a)(16)
of the Investment Company Act of 1940, as amended (the "Investment Company Act"), having a maturity of 185 days or less,
or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule 2a-7 promulgated under the Investment
Company Act (or any successor rule), which invest only in direct U.S. government treasury obligations; the Trustee may not invest in
any other securities or assets; it being understood that the Trust Account will earn no interest while account funds are uninvested awaiting
the Company's instructions hereunder and while the account funds are invested or uninvested, the Trustee may earn bank credits
or other consideration during such periods;

&nbsp;&nbsp;&nbsp;&nbsp;(d) Collect and receive, when due, all interest or other income
arising from the Property, which shall become part of the "Property," as such term is used herein;

&nbsp;&nbsp;&nbsp;&nbsp;(e) Promptly notify the Company and the Underwriters of all communications
received by the Trustee with respect to any Property requiring action by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(f) Supply any necessary information or documents as may be requested
by the Company (or its authorized agents) in connection with the Company's preparation of the tax returns relating to assets held
in the Trust Account or in connection with the preparation of the Company's financial statements or completion of the audit of
the Company's financial statements by the Company's auditors;

&nbsp;&nbsp;&nbsp;&nbsp;(g) Participate in any plan or proceeding for protecting or enforcing
any right or interest arising from the Property if, as and when instructed by the Company to do so;

&nbsp;&nbsp;&nbsp;&nbsp;(h) Render to the Company monthly written statements of the activities
of, and amounts in, the Trust Account reflecting all receipts and disbursements of the Trust Account;

&nbsp;&nbsp;&nbsp;&nbsp;(i) Commence liquidation of the Trust Account only after and
promptly after (x) receipt of, and only in accordance with the terms of, a letter from the Company ("  ***Termination Letter*** ")
in a form substantially similar to that attached hereto as either <u>Exhibit A</u> or <u>Exhibit B</u>, as applicable, signed on behalf
of the Company by its Chief Executive Officer, Chief Financial Officer, President, Executive Vice President, Vice President, Secretary
or Chairman of the board of directors of the Company (the "  ***Board***") or other authorized officer of the Company
, and, in the case of <u>Exhibit A</u>, acknowledged and agreed to by the Underwriters, and complete the liquidation of the Trust Account
and distribute the Property in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes paid or
payable and up to $100,000 of interest to pay dissolution expenses), only as directed in the Termination Letter and the other documents
referred to therein, or (y) upon the date which is the later of (1) 24 months after the closing of the Offering and (2) such later date
as may be approved by the Company's shareholders in accordance with the Company's amended and restated memorandum and articles
of association, (as may be amended and/or restated from time to time, the "  ***Articles***") or (z) upon the end of
a 30-day cure period after the date any additional amount of funds were required to be deposited in the Trust Account as a condition
of any extension of such date approved by the Company's shareholders but were not deposited, if a Termination Letter has not been
received by the Trustee prior to such date, in which case the Trust Account shall be liquidated in accordance with the procedures set
forth in the Termination Letter attached as <u>Exhibit B</u> and the Property in the Trust Account, including interest earned on the
funds held in the Trust Account (less taxes paid or payable and up to $100,000 of interest to pay dissolution expenses), shall be distributed
to the Public Shareholders of record as of such date;

&nbsp;&nbsp;&nbsp;&nbsp;(j) Upon written request from the Company, which may be given from time to time in a form substantially
 similar to that attached hereto as <u>Exhibit C</u> (a "  ***Tax Payment Withdrawal Instruction*** "), withdraw
 from the Trust Account and distribute to the Company the amount of interest earned on the Property requested by the Company to cover
 any tax obligation owed by the Company as a result of assets of the Company or interest or other income earned on the Property,
 which amount shall be delivered directly to the Company by electronic funds transfer or other method of prompt payment, and the
 Company shall forward such payment to the relevant taxing authority so long as there is no reduction in the principal amount per
 share initially deposited in the Trust Account plus any additional amounts, calculated on a per share basis, required to be
 deposited for an extension of the last date to complete a business combination as a condition of any extension of such date approved
 by the Company's shareholders; provided, however, that to the extent there is not sufficient cash in the Trust Account to pay such
 tax obligation, the Trustee shall liquidate such assets held in the Trust Account as shall be designated by the Company in writing
 to make such distribution (it being acknowledged and agreed that any such amount in excess of interest income earned on the Property
 shall not be payable from the Trust Account). The written request of the Company referenced above shall constitute presumptive
 evidence that the Company is entitled to said funds, and the Trustee shall have no responsibility to look beyond said request;

&nbsp;&nbsp;&nbsp;&nbsp;(k) Upon written request from the Company, which may be given
from time to time in a form substantially similar to that attached hereto as <u>Exhibit D</u> (a "  ***Shareholder Redemption Withdrawal Instruction*** "), the Trustee shall distribute to the Public Shareholders on behalf of the Company the amount requested
by the Company to be used to redeem Ordinary Shares from Public Shareholders properly submitted in connection with a shareholder vote
to approve an amendment to the Company's Articles (A) to modify the substance or timing of the Company's obligation to allow
redemption in connection with the Company's initial business combination or to redeem 100% of the Ordinary Shares sold in the Offering
(the "  ***public shares***") if the Company has not consummated an initial Business Combination within such time as
is described in the Articles or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial
Business Combination activity. The written request of the Company referenced above shall constitute presumptive evidence that the Company
is entitled to distribute said funds, and the Trustee shall have no responsibility to look beyond said request; and

&nbsp;&nbsp;&nbsp;&nbsp;(l) Not make any withdrawals or distributions from the Trust
Account other than pursuant to <u>Section 1(i)</u>, <u>(j)</u> or <u>(k)</u> above.

2. <u>Agreements and Covenants of the Company</u>. The Company hereby agrees and covenants to:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Give all instructions to the Trustee hereunder in writing,
signed by the Company's Chairman of the Board, Chief Executive Officer, Chief Financial Officer, President, Executive Vice President,
Vice President or Secretary. In addition, except with respect to its duties under <u>Sections 1(i)</u>, <u>1(j)</u> and <u>1(k)</u> hereof,
the Trustee shall be entitled to rely on, and shall be protected in relying on, any verbal or telephonic advice or instruction which
it, in good faith and with reasonable care, believes to be given by any one of the persons authorized above to give written instructions,
provided that the Company shall promptly confirm such instructions in writing;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Subject to Section <u>4 hereof</u>, hold the Trustee harmless
and indemnify the Trustee from and against any and all expenses, including reasonable counsel fees and disbursements, or losses suffered
by the Trustee in connection with any action taken by it hereunder and in connection with any action, suit or other proceeding brought
against the Trustee involving any claim, or in connection with any claim or demand, which in any way arises out of or relates to this
Agreement, the services of the Trustee hereunder, or the Property or any interest earned on the Property, except for expenses and losses
resulting from the Trustee's gross negligence, fraud or willful misconduct. Promptly after the receipt by the Trustee of notice
of demand or claim or the commencement of any action, suit or proceeding, pursuant to which the Trustee intends to seek indemnification
under this <u>Section 2(b)</u>, it shall notify the Company in writing of such claim (hereinafter referred to as the "  ***Indemnified Claim*** "). The Trustee shall have the right to conduct and manage the defense against such Indemnified Claim; <u>provided</u> that the Trustee shall obtain the consent of the Company with respect to the selection of counsel, which consent shall not be unreasonably
withheld. The Trustee may not agree to settle any Indemnified Claim without the prior written consent of the Company, which such consent
shall not be unreasonably withheld. The Company may participate in such action with its own counsel;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Pay the Trustee the fees set forth on <u>Schedule A</u> hereto,
including an initial acceptance fee, annual administration fee, and transaction processing fee which fees shall be subject to modification
by the parties from time to time. It is expressly understood that the Property shall not be used to pay such fees unless and until it
is distributed to the Company pursuant to <u>Sections 1(i)</u> through <u>1(j)</u> hereof. The Company shall pay the Trustee the initial
acceptance fee and the first annual administration fee at the consummation of the Offering. The Company shall not be responsible for
any other fees or charges of the Trustee except as set forth in this <u>Section 2(c)</u>, Schedule A and as may be provided in <u>Section 2(b)</u> hereof;

&nbsp;&nbsp;&nbsp;&nbsp;(d) In connection with any vote of the Company's shareholders
regarding a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company
and one or more businesses (the "  ***Business Combination*** "), provide to the Trustee an affidavit or certificate
of the inspector of elections for the shareholder meeting verifying the vote of such shareholders regarding such Business Combination;

&nbsp;&nbsp;&nbsp;&nbsp;(e) Provide the Underwriters with a copy of any Termination Letter(s),
Tax Payment Withdrawal Instruction(s), Shareholder Redemption Withdrawal Instruction(s), and/or any other correspondence that is sent
to the Trustee with respect to any proposed withdrawal from the Trust Account promptly after it issues the same;

&nbsp;&nbsp;&nbsp;&nbsp;(f) Unless otherwise agreed between the Company and the Underwriters,
ensure that any Instruction Letter (as defined in <u>Exhibit A</u>) delivered in connection with a Termination Letter in the form of <u>Exhibit A</u> expressly provides that the Deferred Discount is paid directly to the account or accounts directed by the Underwriters
prior to any transfer of the funds held in the Trust Account to the Company or any other person;

&nbsp;&nbsp;&nbsp;&nbsp;(g) Instruct the Trustee to make only those distributions that
are permitted under this Agreement, and refrain from instructing the Trustee to make any distributions that are not permitted under this
Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;(h) Within four (4) business days after the Underwriters exercise
the over-allotment option (or any unexercised portion thereof) or such over-allotment option expires, provide the Trustee with a notice
in writing of the total amount of the Deferred Discount.

3. <u>Limitations of Liability</u>. The Trustee shall have no responsibility or liability to:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Imply obligations, perform duties, inquire or otherwise be
subject to the provisions of any agreement or document other than this Agreement and that which is expressly set forth herein;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Take any action with respect to the Property, other than
as directed in <u>Section 1</u> hereof, and the Trustee shall have no liability to any third party except for liability arising out of
the Trustee's gross negligence, fraud or willful misconduct;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Institute any proceeding for the collection of any principal
and income arising from, or institute, appear in or defend any proceeding of any kind with respect to, any of the Property unless and
until it shall have received instructions from the Company given as provided herein to do so and the Company shall have advanced or guaranteed
to it funds sufficient to pay any expenses incident thereto;

&nbsp;&nbsp;&nbsp;&nbsp;(d) Refund any depreciation in principal of any Property;

&nbsp;&nbsp;&nbsp;&nbsp;(e) Assume that the authority of any person designated by the
Company to give instructions hereunder shall not be continuing unless provided otherwise in such designation, or unless the Company shall
have delivered a written revocation of such authority to the Trustee;

&nbsp;&nbsp;&nbsp;&nbsp;(f) The other parties hereto or to anyone else for any action
taken or omitted by it, or any action suffered by it to be taken or omitted, in good faith and in the Trustee's best judgment,
except for the Trustee's gross negligence, fraud or willful misconduct. The Trustee may rely conclusively and shall be protected
in acting upon any order, notice, demand, certificate, opinion or advice of counsel (including counsel chosen by the Trustee, which counsel
may be the Company's counsel), statement, instrument, report or other paper or document (not only as to its due execution and the
validity and effectiveness of its provisions, but also as to the truth and acceptability of any information therein contained) which
the Trustee believes, in good faith and with reasonable care, to be genuine and to be signed or presented by the proper person or persons.
The Trustee shall not be bound by any notice or demand, or any waiver, modification, termination or rescission of this Agreement or any
of the terms hereof, unless evidenced by a written instrument delivered to the Trustee, signed by the proper party or parties and, if
the duties or rights of the Trustee are affected, unless it shall give its prior written consent thereto;

&nbsp;&nbsp;&nbsp;&nbsp;(g) Verify the accuracy of the information contained in the Registration
Statement;

&nbsp;&nbsp;&nbsp;&nbsp;(h) Provide any assurance that any Business Combination entered
into by the Company or any other action taken by the Company is as contemplated by the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;(i) File information returns with respect to the Trust Account
with any local, state or federal taxing authority or provide periodic written statements to the Company documenting the taxes payable
by the Company, if any, relating to any interest income earned on the Property;

&nbsp;&nbsp;&nbsp;&nbsp;(j) Prepare, execute and file tax reports, income or other tax
returns and pay any taxes with respect to any income generated by, and activities relating to, the Trust Account, regardless of whether
such tax is payable by the Trust Account or the Company, including, but not limited to, tax obligations, except pursuant to <u>Section 1(j)</u> hereof; or

&nbsp;&nbsp;&nbsp;&nbsp;(k) Verify calculations, qualify or otherwise approve the Company's
written requests for distributions pursuant to <u>Sections 1(i)</u>, <u>1(j)</u> or <u>1(k)</u> hereof.

4. <u>Trust Account Waiver</u>. The Trustee has no right of set-off or any right, title, interest or claim of any kind ("  ***Claim***") to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it may have now or in the future. In the event the Trustee has any Claim against the Company under this Agreement, including, without limitation, under Section 2(b) or Section 2(c) hereof, the Trustee shall pursue such Claim solely against the Company and its assets outside the Trust Account and not against the Property or any monies in the Trust Account.

5. <u>Termination</u>. This Agreement shall terminate as follows:

&nbsp;&nbsp;&nbsp;&nbsp;(a) If the Trustee gives written notice to the Company that it
desires to resign under this Agreement, the Company shall use its reasonable efforts to locate a successor trustee, pending which the
Trustee shall continue to act in accordance with this Agreement. At such time that the Company notifies the Trustee that a successor
trustee has been appointed and has agreed to become subject to the terms of this Agreement, the Trustee shall transfer the management
of the Trust Account to the successor trustee, including but not limited to the transfer of copies of the reports and statements relating
to the Trust Account, whereupon this Agreement shall terminate; <u>provided</u>, <u>however</u>, that in the event that the Company does
not locate a successor trustee within ninety (90) days of receipt of the resignation notice from the Trustee, the Trustee may submit
an application to have the Property deposited with any court in the State of New York or with the United States District Court for the
Southern District of New York and upon such deposit, the Trustee shall be immune from any liability whatsoever; or

&nbsp;&nbsp;&nbsp;&nbsp;(b) At such time that the Trustee has completed the liquidation
of the Trust Account and its obligations in accordance with the provisions of <u>Section 1(i)</u> hereof and distributed the Property
in accordance with the provisions of the Termination Letter, this Agreement shall terminate except with respect to <u>Section 2(b)</u>.

6. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company and the Trustee each acknowledge that the Trustee
will follow the security procedures set forth below with respect to funds transferred from the Trust Account. The Company and the Trustee
will each restrict access to confidential information relating to such security procedures to authorized persons. Each party must notify
the other party immediately if it has reason to believe unauthorized persons may have obtained access to such confidential information,
or of any change in its authorized personnel. In executing funds transfers, the Trustee shall rely upon all information supplied to it
by the Company, including, account names, account numbers, and all other identifying information relating to a Beneficiary, Beneficiary's
bank or intermediary bank. Except for any liability arising out of the Trustee's gross negligence, fraud or willful misconduct,
the Trustee shall not be liable for any loss, liability or expense resulting from any error in the information or transmission of the
funds.

&nbsp;&nbsp;&nbsp;&nbsp;(b) This Agreement shall be governed by and construed and enforced
in accordance with the internal laws of the State of New York. This Agreement may be executed in several original or facsimile counterparts,
each one of which shall constitute an original, and together shall constitute but one instrument.

&nbsp;&nbsp;&nbsp;&nbsp;(c) This Agreement contains the entire agreement and understanding
of the parties hereto with respect to the subject matter hereof. Except for <u>Section 1(i)</u>, <u>1(j)</u> and <u>1(k)</u> hereof (which
sections may not be modified, amended or deleted without the affirmative vote of two-thirds of the then outstanding Ordinary Shares of
the Company, which are represented in person or by proxy and are voted at a general meeting of the Company, voting together as a single
class; <u>provided that</u> no such amendment will affect any Public Shareholder who has properly elected to redeem his or her Ordinary
Shares in connection with a shareholder vote to amend this Agreement (A) to modify the substance or timing of the Company's obligation
to allow redemption in connection with the Company's initial business combination or to redeem 100% of its public shares if the
Company does not complete its initial Business Combination within the time frame specified in the Articles or (B) with respect to any
other material provisions relating to shareholders' rights or pre-initial Business Combination activity), this Agreement or any
provision hereof may only be changed, amended or modified (other than to correct a typographical error) by a writing signed by each of
the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The parties to this Agreement agree and acknowledge that
the Company has no obligation to deposit any funds held outside of the Trust Account into the Trust Account for the benefit of the Beneficiaries
following the deposit of the Property in connection with the consummation of the Offering. Holders of Public Shares have no rights to
any funds held by the Company outside of the Trust Account upon or following their redemption pursuant to the Articles or this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The parties hereto consent to the jurisdiction and venue
of any state or federal court located in the City of New York, State of New York, for purposes of resolving any disputes hereunder. AS
TO ANY CLAIM, CROSS-CLAIM OR COUNTERCLAIM IN ANY WAY RELATING TO THIS AGREEMENT, EACH PARTY WAIVES THE RIGHT TO TRIAL BY JURY.

&nbsp;&nbsp;&nbsp;&nbsp;(f) Any notice, consent or request to be given in connection
with any of the terms or provisions of this Agreement shall be in writing and shall be sent by express mail or similar private courier
service, by certified mail (return receipt requested), by hand delivery or by electronic mail:

if to the Trustee, to:

Continental Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, NY 10004

Attn: Francis Wolf & Celeste Gonzalez

Email: fwolf@continentalstock.com

Email: cgonzalez@continentalstock.com

Tel: (212) 845-3233; (212) 845-3248

if to the Company, to:

JATT II Acquisition Corp<br> 153 Central Avenue

C/O 56

Westfield, NJ 07091<br> Attention: Nicholas Fernandez

Email: nicholas.fernandez@athanorcapital.com

In each case, with copies (which copy shall not constitute notice) to:

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attention: Giovanni Caruso, Esq

Email: gcaruso@loeb.com

and

Guggenheim Securities, LLC

330 Madison Avenue New York, New York 10017

Attention: Michael Jiang, Senior Managing Director

Email: michael.jiang@guggenheimpartners.com.

and

Davis Polk & Wardwell LLP

450 Lexington Avenue

New York, NY 10017

Attn: Derek Dostal

Email: derek.dostal@davispolk.com

&nbsp;&nbsp;&nbsp;&nbsp;(g) Each of the Company and the Trustee hereby represents that
it has the full right and power and has been duly authorized to enter into this Agreement and to perform its respective obligations as
contemplated hereunder. The Trustee acknowledges and agrees that it shall not make any claims or proceed against the Trust Account, including
by way of set-off, and shall not be entitled to any funds in the Trust Account under any circumstance.

&nbsp;&nbsp;&nbsp;&nbsp;(h) This Agreement is the joint product of the Trustee and the
Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not
be construed for or against any party hereto.

&nbsp;&nbsp;&nbsp;&nbsp;(i) This Agreement may be executed in any number of counterparts,
each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Delivery
of a signed counterpart of this Agreement by facsimile or electronic transmission shall constitute valid and sufficient delivery thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(j) Each of the Company and the Trustee hereby acknowledges and
agrees that the Underwriters are a third-party beneficiaries of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(k) Except as specified herein, no party to this Agreement may
assign its rights or delegate its obligations hereunder to any other person or entity without the prior written consent of the other.

 

*[Signature Page Follows]*

**IN WITNESS WHEREOF**, the parties have duly executed this Investment Management Trust Agreement as of the date first written above.

**CONTINENTAL STOCK TRANSFER & TRUST COMPANY**, as Trustee

By:   <br> Name: Francis Wolf <br> Title: Vice President

**JATT II Acquisition Corp**

By:   <br> Name: Someit Sidhu <br> Title: Chief Executive Officer

*[Signature Page to Investment Management Trust Agreement]*

**SCHEDULE A**

---

| | | |
|:---|:---|:---|
| **Fee Item** | **Time and method of payment** | **Amount** |
| Initial set-up fee | Initial closing of Offering by wire transfer. | $2000 |
| Trustee administration fee | Payable annually. First year fee payable, at initial closing of Offering by wire transfer, thereafter by wire transfer or check. | $8000 |
| Transaction processing fee for disbursements to Company under <u>Section 1</u> | Billed to Company following disbursement made to Company under <u>Section 1</u> | $150 |
| Paying Agent services as required pursuant to <u>Section 1(i), 1(j) and 1(k)</u> | Billed to Company upon delivery of service pursuant to <u>Section 1(i), 1(j) and 1(k)</u> | Prevailing rates |

---

Schedule A-1

**EXHIBIT A<br> [Letterhead of Company]<br> [Insert date]**

Continental Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

Attn: Francis Wolf and Celeste Gonzalez

Re: <u>Trust Account - Termination Letter</u>

Dear Mr. Wolf and Ms. Gonzalez:

Pursuant to <u>Section 1(i)</u> of the Investment Management Trust Agreement between JATT II Acquisition Corp (the "***Company***") and Continental Stock Transfer & Trust Company ("***Trustee***"), dated as of [\*], 2026 (the "***Trust Agreement***"), this is to advise you that the Company has entered into an agreement with ___________ (the "***Target Business***") to consummate a business combination with Target Business (the "***Business Combination***") on or about **[insert date]**. The Company shall notify you at least seventy-two (72) hours in advance of the actual date (or such shorter period as you may agree) of the consummation of the Business Combination (the "***Consummation Date***"). Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.

In accordance with the terms of the Trust Agreement, the Company hereby authorizes you to commence to liquidate all of the assets of the Trust Account, and to transfer the proceeds to a segregated account held by you on behalf of the Beneficiaries to the effect that, on the Consummation Date, all of the funds held in the Trust Operating Account will be immediately available for transfer to the account or accounts that the Company shall direct on the Consummation Date (including as directed to it by the Underwriters (with respect to the Deferred Discount)).

On the Consummation Date (i) counsel for the Company shall deliver to you written notification that the Business Combination has been consummated, or will be consummated concurrently with your transfer of funds to the accounts as directed by the Company (the "***Notification***"), and (ii) the Company shall deliver to you (a) a certificate by the Chief Executive Officer, Chief Financial Officer or Chief Legal Officer, which verifies that the Business Combination has been approved by a vote of the Company's shareholders, if a vote is held and (b) a joint written instruction signed by the Company and the Underwriters with respect to the transfer of the funds held in the Trust Operating Account, including payment of amounts owed to public shareholders who have properly exercised their redemption rights and payment of the Deferred Discount directly to the account or accounts directed by the Underwriters from the Trust Account (the "***Instruction Letter***"). You are hereby directed and authorized to transfer the funds held in the Trust Account immediately upon your receipt of the Notification and the Instruction Letter, in accordance with the terms of the Instruction Letter. In the event that certain deposits held in the Trust Account may not be liquidated by the Consummation Date without penalty, you will notify the Company in writing of the same and the Company shall direct you as to whether such funds should remain in the Trust Account and be distributed after the Consummation Date to the Company. Upon the distribution of all the funds, net of any payments necessary for reasonable unreimbursed expenses related to liquidating the Trust Account, your obligations under the Trust Agreement shall be terminated.

In the event that the Business Combination is not consummated on the Consummation Date described in the notice thereof and the Company has not notified you on or before the original Consummation Date of a new Consummation Date, then upon receipt by the Trustee of written instructions from the Company, the funds held in the Trust Account shall be reinvested as provided in Section 1(c) of the Trust Agreement on the business day immediately following the Consummation Date as set forth in such notice as soon thereafter as possible.

Exhibit A-1

Very truly yours,

JATT II Acquisition Corp

By:   <br> Name: <br> Title:

Agreed and acknowledged by:

Guggenheim Securities, LLC

By:   <br> Name: <br> Title:

Exhibit A-2

**EXHIBIT B<br> [Letterhead of Company]<br> [Insert date]**

Continental Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

Attn: Francis Wolf and Celeste Gonzalez

Re: <u>Trust Account - Termination Letter</u>

Dear Mr. Wolf and Ms. Gonzalez:

Pursuant to Section 1(i) of the Investment Management Trust Agreement between JATT II Acquisition Corp (the "***Company***") and Continental Stock Transfer & Trust Company (the "***Trustee***"), dated as of [\*], 2026 (the "***Trust Agreement***"), this is to advise you that the Company has been unable to effect a business combination with a Target Business (the "***Business Combination***") within the time frame specified in the Articles or on such earlier date as determined by the Company's Board of Directors, [the Company's Board of Directors has determined to terminate the period in which the Company must consummate a Business Combination on [●]], as described in the Company's Prospectus relating to the Offering. Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.

In accordance with the terms of the Trust Agreement, the Company hereby authorizes you to liquidate all of the assets in the Trust Account and to transfer the total proceeds into a segregated account held by you on behalf of the Beneficiaries to await distribution to the Public Shareholders, less taxes payable or owed and up to $100,000 to cover dissolution expenses of the Company. In accordance with the terms of the Trust Agreement, you are hereby directed and authorized to transfer (via wire transfer) such amount for dissolution expenses of $____ promptly upon your receipt of this letter to the Company's operating account at:

[WIRE INSTRUCTION INFORMATION]

The Company has selected __________<sup>1</sup> as the effective date for the purpose of determining when the Public Shareholders will be entitled to receive their share of the liquidation proceeds. You agree to be the Paying Agent of record and, in your separate capacity as Paying Agent, agree to distribute said funds directly to the Company's Public Shareholders in accordance with the terms of the Trust Agreement and the Articles. Upon the distribution of all the funds, net of any payments necessary for reasonable unreimbursed expenses related to liquidating the Trust Account, your obligations under the Trust Agreement shall be terminated, except to the extent otherwise provided in Section 1(i) of the Trust Agreement.

Very truly yours,

JATT II Acquisition Corp

By:   <br> Name: <br> Title:

cc: Guggenheim Securities, LLC

<sup>1</sup> 24 months after the closing date of the Offering, such earlier date as the Company's board of directors may approve, or such later date as the Company's shareholders may approve.

Exhibit B-1

**EXHIBIT C<br> [Letterhead of Company]<br> [Insert date]**

Continental Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

Attn: Francis Wolf and Celeste Gonzalez

---

| | |
|:---|:---|
| Re: | <u>Trust Account - Tax Payment Withdrawal Instruction</u> |

---

Dear Mr. Wolf and Ms. Gonzalez:

Pursuant to Section 1(j) of the Investment Management Trust Agreement between JATT II Acquisition Corp (the "***Company***") and Continental Stock Transfer & Trust Company (the "***Trustee***"), dated as of [\*], 2026 (the "***Trust Agreement***"), the Company hereby requests that you deliver to the Company $_______ of the interest income earned on the Property as of the date hereof. Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.

The Company needs such funds to pay for the tax obligations. In accordance with the terms of the Trust Agreement, you are hereby directed and authorized to transfer (via wire transfer) such funds promptly upon your receipt of this letter to the Company's operating account at:

**[WIRE INSTRUCTION INFORMATION]**

Very truly yours,

JATT II Acquisition Corp

By:   <br> Name: <br> Title:

cc: Guggenheim Securities, LLC

Exhibit C-1

**EXHIBIT D<br> [Letterhead of Company]<br> [Insert date]**

Continental Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

Attn: Francis Wolf & Celeste Gonzalez

---

| | |
|:---|:---|
| Re: | <u>Trust Account - Shareholder Redemption Withdrawal Instruction</u> |

---

Dear Mr. Wolf and Ms. Gonzalez:

Pursuant to Section 1(k) of the Investment Management Trust Agreement between JATT II Acquisition Corp (the "***Company***") and Continental Stock Transfer & Trust Company (the "***Trustee***"), dated as of [\*], 2026 (the "***Trust Agreement***"), the Company hereby requests that you deliver to the redeeming Public Shareholders of the Company $____ of the principal and interest income earned on the Property as of the date hereof to a segregated account held by you on behalf of the Beneficiaries for distribution to the Public Shareholders who have requested redemption of their Ordinary Shares. Capitalized terms used but not defined herein shall have the meanings set forth in the Trust Agreement.

The Company needs such funds to pay its Public Shareholders who have properly elected to have their Ordinary Shares redeemed by the Company in connection with a shareholder vote to approve an amendment to the Articles (A) to modify the substance or timing of the Company's obligation to allow redemption in connection with the Company's initial business combination or to redeem 100% of its public Ordinary Shares if the Company has not consummated an initial Business Combination within such time as is described in the Articles or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial Business Combination activity. As such, you are hereby directed and authorized to transfer (via wire transfer) such funds to the redeeming Shareholders promptly upon your receipt of this letter in accordance with your customary procedures.

Very truly yours,

JATT II Acquisition Corp

By:   <br> Name: <br> Title:

cc: Guggenheim Securities, LLC

Exhibit D-2

## Exhibit 10.3

**Exhibit 10.3**

**REGISTRATION RIGHTS AGREEMENT**

THIS REGISTRATION RIGHTS AGREEMENT (this "***Agreement***"), dated as of [•], 2026, is made and entered into by and between JATT II Acquisition Corp, a Cayman Islands exempted company (the "***Company***"), JATT Ventures II L.P., a Cayman Islands exempted limited partnership (the "***Sponsor***") and each of the undersigned parties listed on the signature page hereto under "Holders" (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to <u>Section 5.2</u> of this Agreement, a "***Holder***" and collectively the "***Holders***").

**RECITALS**

**WHEREAS**, the Company has 1,725,000 the ("***Founder Shares***")ordinary shares of the Company, par value $0.0001 per share (the "***Ordinary Shares***"), issued and outstanding, up to 225,000 of which will be surrendered to the Company for no consideration depending on the extent to which the underwriters of the Company's initial public offering exercise their over-allotment option;

**WHEREAS**, on the date hereof, the Company and the Sponsor entered into that certain Private Placement Shares Purchase Agreement (the "***Private Placement Shares Purchase Agreement***"), pursuant to which the Sponsor agreed to purchase an aggregate of 300,000 Ordinary Shares (or up to 309,000 Ordinary Shares to the extent that the over-allotment option in connection with the Company's initial public offering is exercised in full) (the "***Private Placement Shares***") in a private placement transaction occurring simultaneously with the closing of the Company's initial public offering;

**WHEREAS**, in order to finance the Company's transaction costs in connection with its search for and consummation of an initial Business Combination (as defined below), the Sponsor, its affiliates or any of the Company's officers and directors may loan to the Company funds as the Company may require, of which up to $1,500,000 of such loans may be convertible into Ordinary Shares equivalent to Private Placement Shares ("***Working Capital Shares***") at a price of $10.00 per share at the option of the lender; and

**WHEREAS**, the Company and the Holders desire to enter into this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement.

**NOW**, **THEREFORE**, in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

**Article I<br> Definitions**

1.1 <u>Definitions</u>. The terms defined in this *<u>Article I</u>* shall, for all purposes of this Agreement, have the respective meanings set forth below:

"***Adverse Disclosure***" shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Chief Executive Officer or principal financial officer of the Company, after consultation with counsel to the Company, (i) would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances under which they were made) not misleading, (ii) would not be required to be made at such time if the Registration Statement were not being filed, and (iii) the Company has a bona fide business purpose for not making such information public.

"***Agreement***" shall have the meaning given in the Preamble.

"***Board***" shall mean the Board of Directors of the Company.

"***Business Combination***" shall mean any merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses, involving the Company.

"***Commission***" shall mean the United States Securities and Exchange Commission.

"***Company***" shall have the meaning given in the Preamble.

"***Demand Registration***" shall have the meaning given in subsection 2.1.1.

"***Demanding Holder***" shall have the meaning given in subsection 2.1.1.

"***Exchange Act***" shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.

"***Form S-1***" shall have the meaning given in subsection 2.1.1.

"***Form S-3***" shall have the meaning given in subsection 2.3.

"***Founder Shares***" shall have the meaning given in the Recitals hereto.

"***Founder Shares Lock-up Period***" shall mean, with respect to the Founder Shares and any Ordinary Shares issuable upon conversion thereof, the period ending on the earlier of (A) 180 days after the completion of the Company's initial Business Combination and (B) subsequent to the completion of the Business Combination, the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company's shareholders having the right to exchange their Ordinary Shares for cash, securities or other property.

"***Holders***" shall have the meaning given in the Preamble.

"***Insider Letter***" shall mean that certain letter agreement, dated as of the date hereof, by and among the Company, the Sponsor and each of the Company's officers and directors.

"***Maximum Number of Securities***" shall have the meaning given in subsection 2.1.4.

"***Misstatement***" shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus (in the light of the circumstances under which they were made) not misleading.

"***Ordinary Shares***" shall have the meaning given in the Recitals hereto.

"***Permitted Transferees***" shall mean any person or entity to whom a Holder of Registrable Securities is permitted to transfer such Registrable Securities prior to the expiration of the Founder Shares Lock-up Period, Private Placement Lock-up Period or any other lock-up period, as the case may be, under the Insider Letter, the Private Placement Shares Purchase Agreement, this Agreement and any other applicable agreement between such Holder and the Company, and to any transferee thereafter.

"***Piggyback Registration***" shall have the meaning given in subsection 2.2.1.

"***Private Placement Lock-up Period***" shall mean, with respect to Private Placement Shares that are held by the initial purchasers of such Private Placement Shares or their Permitted Transferees, the period ending 30 days after the completion of the Company's initial Business Combination.

"***Private Placement Shares***" shall have the meaning given in the Recitals hereto.

"***Private Placement Shares Purchase Agreement***" shall have the meaning given in the Recitals hereto.

"***Pro Rata***" shall have the meaning given in <u>subsection 2.1.4</u>.

"***Prospectus***" shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended by any and all post-effective amendments and including all material incorporated by reference in such prospectus.

"***Registrable Security***" shall mean (a) the Founder Shares, (b) the Private Placement Shares, (c) any outstanding Ordinary Shares or any other equity security (including the Ordinary Shares issued or issuable upon the conversion of any other equity security) of the Company held by a Holder as of the date of this Agreement or acquired by a Holder prior to the consummation of the Business Combination, (d) any equity securities (including the Ordinary Shares issued or issuable upon the exercise of any such equity security) of the Company issuable upon conversion of any working capital loans in an amount up to $1,500,000 made to the Company by a Holder, (e) any equity securities (including the Ordinary Shares issued or issuable upon the exercise of any such equity security) of the Company held by a Holder on or after the date of the Business Combination to the extent that such securities are "restricted securities" (as defined in Rule 144) or are otherwise held by an "affiliate" (as defined in Rule 144) of the Company and (f) any other equity security of the Company issued or issuable with respect to any such Ordinary Share by way of a share capitalization or share sub-division or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization; <u>provided</u>, <u>however</u>, that, as to any particular Registrable Security, such securities shall cease to be Registrable Securities when: (A) a Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (B) such securities shall have been otherwise transferred, new certificates for such securities not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities Act; (C) such securities shall have ceased to be outstanding; (D) such securities may be sold without registration pursuant to Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission) (but with no volume or other restrictions or limitations including as to manner or timing of sale or current public information requirements); or (E) such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction.

"***Registration***" shall mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective.

"***Registration Expenses***" shall mean the out-of-pocket expenses of a Registration, including, without limitation, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) all registration and filing fees (including fees with respect
to filings required to be made with the Financial Industry Regulatory Authority, Inc.) and any securities exchange on which the Ordinary
Shares are then listed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) fees and expenses of compliance with securities or blue sky
laws (including reasonable fees and disbursements of counsel for the Underwriters in connection with blue sky qualifications of Registrable
Securities);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) printing, messenger, telephone and delivery expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) reasonable fees and disbursements of counsel for the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) reasonable fees and disbursements of all independent registered
public accountants of the Company incurred specifically in connection with such Registration; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F) reasonable fees and expenses of one (1) legal counsel selected
by the majority-in-interest of the Demanding Holders initiating a Demand Registration to be registered for offer and sale in the applicable
Registration.

"***Registration Statement***" shall mean any registration statement that covers the Registrable Securities pursuant to the provisions of this Agreement, including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to such registration statement, and all exhibits to and all material incorporated by reference in such registration statement.

"***Requesting Holder***" shall have the meaning given in <u>subsection 2.1.1</u>.

"***Securities Act***" shall mean the Securities Act of 1933, as amended from time to time.

"***Shelf***" shall have the meaning given in subsection 2.3.1.

"***Sponsor***" shall have the meaning given in the Recitals hereto.

"***Subsequent Shelf Registration***" shall have the meaning given in subsection 2.3.2.

 ****

***"Takedown Requesting Holder"*** shall have the meaning given in subsection 2.3.3.

"***Underwriter***" shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such dealer's market-making activities.

"***Underwritten Registration***" or "***Underwritten Offering***" shall mean a Registration in which securities of the Company are sold to an Underwriter in a firm commitment underwriting for distribution to the public.

 ****

***"Underwritten Shelf Takedown"*** shall have the meaning given in subsection 2.3.3.

"***Working Capital Shares***" shall have the meaning given in the Recitals hereto.

**Article II<br> registrations**

2.1 Demand Registration.

&nbsp;&nbsp;&nbsp;&nbsp;2.1.1 <u>Request for Registration</u>. Subject to the provisions
of <u>subsection 2.1.4</u> and <u>Section 2.4</u> hereof, at any time and from time to time on or after the date the Company consummates
the Business Combination, the Holders of at least fifteen percent (15%) of the then-outstanding number of Registrable Securities (the
"  ***Demanding Holders***") may make a written demand for Registration under the Securities Act of all or part of
their Registrable Securities, which written demand shall describe the amount and type of securities to be included in such Registration
and the intended method(s) of distribution thereof (such written demand a "  ***Demand Registration*** "). The Company
shall, within ten (10) days of the Company's receipt of the Demand Registration, notify, in writing, all other Holders of Registrable
Securities of such demand, and each Holder of Registrable Securities who thereafter wishes to include all or a portion of such Holder's
Registrable Securities in a Registration pursuant to a Demand Registration (each such Holder that includes all or a portion of such Holder's
Registrable Securities in such Registration, a "  ***Requesting Holder***") shall so notify the Company, in writing,
within five (5) days after the receipt by the Holder of the notice from the Company. Upon receipt by the Company of any such written
notification from a Requesting Holder(s) to the Company, such Requesting Holder(s) shall be entitled to have their Registrable Securities
included in a Registration pursuant to a Demand Registration and the Company shall effect, as soon thereafter as practicable, but not
more than forty five (45) days immediately after the Company's receipt of the Demand Registration, the Registration of all Registrable
Securities requested by the Demanding Holders and Requesting Holders pursuant to such Demand Registration. Under no circumstances shall
the Company be obligated to effect more than an aggregate of three (3) Registrations pursuant to a Demand Registration under this <u>subsection 2.1.1</u> with respect to any or all Registrable Securities; provided, however, that a Registration shall not be counted for such purposes
unless a Form S-1 or any similar long-form registration statement that may be available at such time ("  ***Form S-1*** ")
has become effective and all of the Registrable Securities requested by the Requesting Holders to be registered on behalf of the Requesting
Holders in such Form S-1 Registration have been sold, in accordance with <u>Section 3.1</u> of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;2.1.2 <u>Effective Registration</u>. Notwithstanding the provisions
of <u>subsection 2.1.1</u> above or any other part of this Agreement, a Registration pursuant to a Demand Registration shall not count
as a Registration unless and until (i) the Registration Statement filed with the Commission with respect to a Registration pursuant to
a Demand Registration has been declared effective by the Commission and (ii) the Company has complied with all of its obligations under
this Agreement with respect thereto; <u>provided</u>, <u>further</u>, that if, after such Registration Statement has been declared effective,
an offering of Registrable Securities in a Registration pursuant to a Demand Registration is subsequently interfered with by any stop
order or injunction of the Commission, federal or state court or any other governmental agency the Registration Statement with respect
to such Registration shall be deemed not to have been declared effective, unless and until, (i) such stop order or injunction is removed,
rescinded or otherwise terminated, and (ii) a majority-in-interest of the Demanding Holders initiating such Demand Registration thereafter
affirmatively elect to continue with such Registration and accordingly notify the Company in writing, but in no event later than five
(5) days, of such election; and <u>provided</u>, <u>further</u>, that the Company shall not be obligated or required to file another
Registration Statement until the Registration Statement that has been previously filed with respect to a Registration pursuant to a Demand
Registration becomes effective or is subsequently terminated.

&nbsp;&nbsp;&nbsp;&nbsp;2.1.3 <u>Underwritten Offering</u>. Subject to the provisions of <u>subsection 2.1.4</u> and <u>Section 2.4</u> hereof, if a majority-in-interest of the Demanding Holders so advise the Company as part
of their Demand Registration that the offering of the Registrable Securities pursuant to such Demand Registration shall be in the form
of an Underwritten Offering, then the right of such Demanding Holder or Requesting Holder (if any) to include its Registrable Securities
in such Registration shall be conditioned upon such Holder's participation in such Underwritten Offering and the inclusion of such
Holder's Registrable Securities in such Underwritten Offering to the extent provided herein. All such Holders proposing to distribute
their Registrable Securities through an Underwritten Offering under this <u>subsection 2.1.3</u> shall enter into an underwriting agreement
in customary form with the Underwriter(s) selected for such Underwritten Offering by the majority-in-interest of the Demanding Holders
initiating the Demand Registration.

&nbsp;&nbsp;&nbsp;&nbsp;2.1.4 <u>Reduction of Underwritten Offering</u>. If the managing
Underwriter or Underwriters in an Underwritten Registration pursuant to a Demand Registration, in good faith, advises the Company, the
Demanding Holders and the Requesting Holders (if any) in writing that the dollar amount or number of Registrable Securities that the
Demanding Holders and the Requesting Holders (if any) desire to sell, taken together with all other Ordinary Shares or other equity securities
that the Company desires to sell and the Ordinary Shares, if any, as to which a Registration has been requested pursuant to separate
written contractual piggy-back registration rights held by any other shareholders who desire to sell, exceeds the maximum dollar amount
or maximum number of equity securities that can be sold in the Underwritten Offering without adversely affecting the proposed offering
price, the timing, the distribution method, or the probability of success of such offering (such maximum dollar amount or maximum number
of such securities, as applicable, the "  ***Maximum Number of Securities*** "), then the Company shall include in such
Underwritten Offering, as follows: (i) first, the Registrable Securities of the Demanding Holders and the Requesting Holders (if any)
(pro rata based on the respective number of Registrable Securities that each Demanding Holder and Requesting Holder (if any) has requested
be included in such Underwritten Registration and the aggregate number of Registrable Securities that the Demanding Holders and Requesting
Holders have requested be included in such Underwritten Registration (such proportion is referred to herein as "  ***Pro Rata*** "))
that can be sold without exceeding the Maximum Number of Securities; (ii) second, to the extent that the Maximum Number of Securities
has not been reached under the foregoing clause (i), the Registrable Securities of Holders (Pro Rata, based on the respective number
of Registrable Securities that each Holder has so requested) exercising their rights to register their Registrable Securities pursuant
to <u>subsection 2.2.1</u> hereof, without exceeding the Maximum Number of Securities; and (iii) third, to the extent that the Maximum
Number of Securities has not been reached under the foregoing clauses (i) and (ii), the Ordinary Shares or other equity securities that
the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (iv) fourth, to the extent that
the Maximum Number of Securities has not been reached under the foregoing clauses (i), (ii) and (iii), the Ordinary Shares or other equity
securities of other persons or entities that the Company is obligated to register in a Registration pursuant to separate written contractual
arrangements with such persons and that can be sold without exceeding the Maximum Number of Securities.

&nbsp;&nbsp;&nbsp;&nbsp;2.1.5 <u>Demand Registration Withdrawal</u>. A majority-in-interest
of the Demanding Holders initiating a Demand Registration or a majority-in-interest of the Requesting Holders (if any), pursuant to a
Registration under <u>subsection 2.1.1</u> hereof shall have the right to withdraw from a Registration pursuant to such Demand Registration
for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of their intention
to withdraw from such Registration prior to the effectiveness of the Registration Statement filed with the Commission with respect to
the Registration of their Registrable Securities pursuant to such Demand Registration. Notwithstanding anything to the contrary in this
Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with a Registration pursuant to a Demand
Registration prior to its withdrawal under this <u>subsection 2.1.5</u>.

2.2 Piggyback Registration.

&nbsp;&nbsp;&nbsp;&nbsp;2.2.1 <u>Piggyback Rights</u>. If, at any time on or after the
date the Company consummates a Business Combination, the Company proposes to file a Registration Statement under the Securities Act with
respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into
equity securities, for its own account or for the account of shareholders of the Company (or by the Company and by the shareholders of
the Company including, without limitation, pursuant to <u>Section 2.1</u> hereof), other than a Registration Statement (i) filed in connection
with any employee share option or other benefit plan, (ii) for an exchange offer or offering of securities solely to the Company's
existing shareholders, (iii) for an offering of debt that is convertible into equity securities of the Company or (iv) for a dividend
reinvestment plan, then the Company shall give written notice of such proposed filing to all of the Holders of Registrable Securities
as soon as practicable but not less than ten (10) days before the anticipated filing date of such Registration Statement, which notice
shall (A) describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the
name of the proposed managing Underwriter or Underwriters, if any, in such offering, and (B) offer to all of the Holders of Registrable
Securities the opportunity to register the sale of such number of Registrable Securities as such Holders may request in writing within
five (5) days after receipt of such written notice (such Registration a "  ***Piggyback Registration*** "). The Company
shall, in good faith, cause such Registrable Securities to be included in such Piggyback Registration and shall use its best efforts
to cause the managing Underwriter or Underwriters of a proposed Underwritten Offering to permit the Registrable Securities requested
by the Holders pursuant to this <u>subsection 2.2.1</u> to be included in a Piggyback Registration on the same terms and conditions as
any similar securities of the Company included in such Registration and to permit the sale or other disposition of such Registrable Securities
in accordance with the intended method(s) of distribution thereof. All such Holders proposing to distribute their Registrable Securities
through an Underwritten Offering under this <u>subsection 2.2.1</u> shall enter into an underwriting agreement in customary form with
the Underwriter(s) selected for such Underwritten Offering by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;2.2.2 <u>Reduction of Piggyback Registration</u>. If the managing
Underwriter or Underwriters in an Underwritten Registration that is to be a Piggyback Registration, in good faith, advises the Company
and the Holders of Registrable Securities participating in the Piggyback Registration in writing that the dollar amount or number of
the Ordinary Shares that the Company desires to sell, taken together with (i) the Ordinary Shares, if any, as to which Registration has
been demanded pursuant to separate written contractual arrangements with persons or entities other than the Holders of Registrable Securities
hereunder (ii) the Registrable Securities as to which registration has been requested pursuant to <u>Section 2.2</u> hereof, and (iii)
the Ordinary Shares, if any, as to which Registration has been requested pursuant to separate written contractual piggy-back registration
rights of other shareholders of the Company, exceeds the Maximum Number of Securities, then:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If the Registration is undertaken for the Company's
account, the Company shall include in any such Registration (A) first, the Ordinary Shares or other equity securities that the Company
desires to sell, which can be sold without exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum Number
of Securities has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register
their Registrable Securities pursuant to <u>subsection 2.2.1</u> hereof (pro rata based on the respective number of Registrable Securities
that such Holder has requested be included in such Registration), which can be sold without exceeding the Maximum Number of Securities;
and (C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), the
Ordinary Shares, if any, as to which Registration has been requested pursuant to written contractual piggy-back registration rights of
other shareholders of the Company, which can be sold without exceeding the Maximum Number of Securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If the Registration is pursuant to a request by persons or
entities other than the Holders of Registrable Securities, then the Company shall include in any such Registration (A) first, the Ordinary
Shares or other equity securities, if any, of such requesting persons or entities, other than the Holders of Registrable Securities,
which can be sold without exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum Number of Securities
has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their
Registrable Securities pursuant to <u>subsection 2.2.1</u> hereof, pro rata based on the number of Registrable Securities that each Holder
has requested be included in such Registration and the aggregate number of Registrable Securities that the Holders have requested to
be included in such Registration, which can be sold without exceeding the Maximum Number of Securities; (C) third, to the extent that
the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), the Ordinary Shares or other equity securities
that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (D) fourth, to the extent
that the Maximum Number of Securities has not been reached under the foregoing clauses (A), (B) and (C), the Ordinary Shares or other
equity securities for the account of other persons or entities that the Company is obligated to register pursuant to separate written
contractual arrangements with such persons or entities, which can be sold without exceeding the Maximum Number of Securities.

&nbsp;&nbsp;&nbsp;&nbsp;2.2.3 Any Holder of Registrable Securities shall have the right
to withdraw from a Piggyback Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter
or Underwriters (if any) of his, her or its intention to withdraw from such Piggyback Registration prior to the effectiveness of the
Registration Statement filed with the Commission with respect to such Piggyback Registration. The Company (whether on its own good faith
determination or as the result of a request for withdrawal by persons pursuant to separate written contractual obligations) may withdraw
a Registration Statement filed with the Commission in connection with a Piggyback Registration at any time prior to the effectiveness
of such Registration Statement. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the
Registration Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under this <u>subsection 2.2.3</u>.

&nbsp;&nbsp;&nbsp;&nbsp;2.2.4 <u>Unlimited Piggyback Registration Rights</u>. For purposes
of clarity, any Registration effected pursuant to <u>Section 2.2</u> hereof shall not be counted as a Registration pursuant to a Demand
Registration effected under <u>Section 2.1</u> hereof.

2.3 <u>Shelf Registration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;2.3.1 The Holders of Registrable Securities may at any time, and
from time to time, request in writing that the Company, pursuant to Rule 415 under the Securities Act (or any successor rule promulgated
thereafter by the Commission), register the resale of any or all of their Registrable Securities on Form S-3 or any similar short form
registration statement that may be available at such time ("  ***Form S-3*** "), or if the Company is ineligible to
use Form S-3, on Form S-1; a registration statement filed pursuant to this subsection 2.3.1 (a "  ***Shelf***") shall
provide for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally available
to, and requested by, any Holder. Within five (5) days of the Company's receipt of a written request from a Holder or Holders of
Registrable Securities for a Registration on a Shelf, the Company shall promptly give written notice of the proposed Registration to
all other Holders of Registrable Securities, and each Holder of Registrable Securities who thereafter wishes to include all or a portion
of such Holder's Registrable Securities in such Registration on a Shelf shall so notify the Company, in writing, within ten (10)
days after the receipt by the Holder of the notice from the Company. As soon as practicable thereafter, but not more than twelve (12)
days after the Company's initial receipt of such written request for a Registration on Form S-3, the Company shall register all
or such portion of such Holder's Registrable Securities as are specified in such written request, together with all or such portion
of Registrable Securities of any other Holder or Holders joining in such request as are specified in the written notification given by
such Holder or Holders; <u>provided</u>, <u>however</u>, that the Company shall not be obligated to effect any such Registration pursuant
to <u>this subsection 2.3.1 if</u> the Holders of Registrable Securities, together with the Holders of any other equity securities of
the Company entitled to inclusion in such Registration, propose to sell the Registrable Securities and such other equity securities (if
any) at any aggregate price to the public of less than $10,000,000. The Company shall maintain each Shelf in accordance with the terms
hereof, and shall prepare and file with the SEC such amendments, including post-effective amendments, and supplements as may be necessary
to keep such Shelf continuously effective, available for use and in compliance with the provisions of the Securities Act until such time
as there are no longer any Registrable Securities included on such Shelf. In the event the Company files a Shelf on Form S-1, the Company
shall use its commercially reasonable efforts to convert the Form S-1 to a Form S-3 as soon as practicable after the Company is eligible
to use Form S-3.

&nbsp;&nbsp;&nbsp;&nbsp;2.3.2 If any Shelf ceases to be effective under the Securities
Act for any reason at any time while Registrable Securities included thereon are still outstanding, the Company shall use its commercially
reasonable efforts to as promptly as is reasonably practicable cause such Shelf to again become effective under the Securities Act (including
obtaining the prompt withdrawal of any order suspending the effectiveness of such Shelf), and shall use its commercially reasonable efforts
to as promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order
suspending the effectiveness of such Shelf or file an additional registration statement (a "  ***Subsequent Shelf Registration*** ")
registering the resale of all Registrable Securities including on such Shelf, and pursuant to any method or combination of methods legally
available to, and requested by, any Holder. If a Subsequent Shelf Registration is filed, the Company shall use its commercially reasonable
efforts to (i) cause such Subsequent Shelf Registration to become effective under the Securities Act as promptly as is reasonably practicable
after the filing thereof and (ii) keep such Subsequent Shelf Registration continuously effective, available for use and in compliance
with the provisions of the Securities Act until such time as there are no longer any Registrable Securities included thereon. Any such
Subsequent Shelf Registration shall be on Form S-3 to the extent that the Company is eligible to use such form. Otherwise, such Subsequent
Shelf Registration shall be on another appropriate form. In the event that any Holder holds Registrable Securities that are not registered
for resale on a delayed or continuous basis, the Company, upon request of a Holder shall promptly use its commercially reasonable efforts
to cause the resale of such Registrable Securities to be covered by either, at the Company's option, a Shelf (including by means
of a post-effective amendment) or a Subsequent Shelf Registration and cause the same to become effective as soon as practicable after
such filing and such Shelf or Subsequent Shelf Registration shall be subject to the terms hereof; provided, however, the Company shall
only be required to cause such Registrable Securities to be so covered once annually after inquiry of the Holders.

&nbsp;&nbsp;&nbsp;&nbsp;2.3.3 At any time and from time to time after a Shelf has been
declared effective by the Commission, the Sponsor and Holders may request to sell all or any portion of its Registrable Securities in
an underwritten offering that is registered pursuant to the Shelf (each, an "  ***Underwritten Shelf Takedown*** ");
provided that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include securities
with a total offering price (including piggyback securities and before deduction of underwriting discounts) reasonably expected to exceed,
in the aggregate, $10,000,000. All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company at
least 48 hours prior to the public announcement of such Underwritten Shelf Takedown, which shall specify the approximate number of Registrable
Securities proposed to be sold in the Underwritten Shelf Takedown and the expected price range (net of underwriting discounts and commissions)
of such Underwritten Shelf Takedown. The Company shall include in any Underwritten Shelf Takedown the securities requested to be included
by any holder (each a "  ***Takedown Requesting Holder***") at least 24 hours prior to the public announcement of such
Underwritten Shelf Takedown pursuant to written contractual piggyback registration rights of such holder (including to those set forth
herein). The Sponsor and Holders shall have the right to select the underwriter(s) for such offering (which shall consist of one or more
reputable nationally recognized investment banks), subject to the Company's prior approval which shall not be unreasonably withheld,
conditioned or delayed. For purposes of clarity, any Registration effected pursuant to this <u>subsection 2.3.3</u> shall not be counted
as a Registration pursuant to a Demand Registration effected under <u>Section 2.1</u> hereof.

&nbsp;&nbsp;&nbsp;&nbsp;2.3.4 If the managing Underwriter or Underwriters in an Underwritten Shelf Takedown, in good faith, advises the Company, the Sponsor, Holders and the Takedown Requesting Holders (if any) in writing that the dollar amount or number of Registrable Securities that the Sponsor and the Takedown Requesting Holders (if any) desire to sell, taken together with all other Ordinary Shares or other equity securities that the Company desires to sell, exceeds the Maximum Number of Securities, then the Company shall include in such Underwritten Shelf Takedown, as follows: (i) first, the Registrable Securities of the Sponsor and the Holders that can be sold without exceeding the Maximum Number of Securities, determined Pro Rata based on the respective number of Registrable Securities that each such Holder has so requested to be included in such Underwritten Shelf Takedown; (ii) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i), the Ordinary Shares or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (iii) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i) and (ii), the Ordinary Shares or other equity securities of the Takedown Requesting Holders, if any, that can be sold without exceeding the Maximum Number of Securities, determined Pro Rata based on the respective number of Registrable Securities that each Takedown Requesting Holder has so requested to be included in such Underwritten Shelf Takedown.

&nbsp;&nbsp;&nbsp;&nbsp;2.3.5 The Sponsor and Holders shall have the right to withdraw
from an Underwritten Shelf Takedown for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters
(if any) of its intention to withdraw from such Underwritten Shelf Takedown prior to the public announcement of such Underwritten Shelf
Takedown. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses
incurred in connection with an Underwritten Shelf Takedown prior to a withdrawal under this <u>subsection 2.3.5</u>.

2.4 <u>Restrictions on Registration Rights</u>. If (A) during
the period starting with the date sixty (60) days prior to the Company's good faith estimate of the date of the filing of, and
ending on a date one hundred and twenty (120) days after the effective date of, a Company initiated Registration and provided that the
Company has delivered written notice to the Holders prior to receipt of a Demand Registration pursuant to <u>subsection 2.1.1</u> hereof
and it continues to actively employ, in good faith, all reasonable efforts to cause the applicable Registration Statement to become effective;
(B) the Holders have requested an Underwritten Registration and the Company and the Holders are unable to obtain the commitment of underwriters
to firmly underwrite the offer; or (C) in the good faith judgment of the Board such Registration would be seriously detrimental to the
Company and the Board concludes as a result that it is essential to defer the filing of such Registration Statement at such time, then
in each case the Company shall furnish to such Holders a certificate signed by the Chairperson of the Board stating that in the good
faith judgment of the Board it would be seriously detrimental to the Company for such Registration Statement to be filed in the near
future and that it is therefore essential to defer the filing of such Registration Statement. In such event, the Company shall have the
right to defer such filing for a period of not more than thirty (30) days; <u>provided</u>, <u>however</u>, that the Company shall not
defer its obligation in this manner more than once in any 12-month period.

2.5 <u>Legends.</u> In connection with any sale or other disposition
of the Registrable Securities by a Holder pursuant to Rule 144 promulgated under the Securities Act (or any successor rule promulgated
thereafter by the Commission) and upon compliance by the Holder with the requirements of this Section 2.5, if requested by the Holder,
the Company shall cause the transfer agent for the Registrable Securities (the "  ***Transfer Agent***") to remove
any restrictive legends related to the book entry account holding such Registrable Securities and make a new, unlegended entry for such
book entry shares sold or disposed of without restrictive legends within two (2) trading days of any such request therefor from the Holder;
provided that the Company and the Transfer Agent have timely received from the Holder customary representations and other documentation
reasonably acceptable to the Company and the Transfer Agent in connection therewith. Subject to receipt from the Holder by the Company
and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent
in connection therewith, the Holder may request that the Company remove any legend from the book entry position evidencing its Registrable
Securities and the Company will, if required by the Transfer Agent, use its commercially reasonable efforts cause an opinion of the Company's
counsel be provided, in a form reasonably acceptable to the Transfer Agent, to the effect that the removal of such restrictive legends
in such circumstances may be effected under the Securities Act, following the earliest of such time as such Registrable Securities (i)
are subject to or have been or are about to be sold pursuant to an effective registration statement or (ii) have been or are about to
be sold pursuant to Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission). If
restrictive legends are no longer required for such Registrable Securities pursuant to the foregoing, the Company shall, in accordance
with the provisions of this section and within two (2) trading days of any request therefor from the Holder accompanied by such customary
and reasonably acceptable representations and other documentation referred to above establishing that restrictive legends are no longer
required, deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such
book entry shares. The Company shall be responsible for the fees of its Transfer Agent, its legal counsel and all DTC fees associated
with such issuance.

**Article III<br> COMPANY PROCEDURES**

3.1 <u>General Procedures</u>. If at any time on or after the date the Company consummates a Business Combination the Company is required to effect the Registration of Registrable Securities, the Company shall use its best efforts to effect such Registration to permit the sale of such Registrable Securities in accordance with the intended plan of distribution thereof, and pursuant thereto the Company shall, as expeditiously as possible:

&nbsp;&nbsp;&nbsp;&nbsp;3.1.1 prepare and file with the Commission as soon as practicable
a Registration Statement with respect to such Registrable Securities and use its reasonable best efforts to cause such Registration Statement
to become effective and remain effective until all Registrable Securities covered by such Registration Statement have been sold;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.2 prepare and file with the Commission such amendments and
post-effective amendments to the Registration Statement, and such supplements to the Prospectus, as may be requested by the Holders or
any Underwriter of Registrable Securities or as may be required by the rules, regulations or instructions applicable to the registration
form used by the Company or by the Securities Act or rules and regulations thereunder to keep the Registration Statement effective until
all Registrable Securities covered by such Registration Statement are sold in accordance with the intended plan of distribution set forth
in such Registration Statement or supplement to the Prospectus;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.3 prior to filing a Registration Statement or Prospectus, or
any amendment or supplement thereto, furnish without charge to the Underwriters, if any, and the Holders of Registrable Securities included
in such Registration, and such Holders' and Underwriters' legal counsel, copies of such Registration Statement as proposed
to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto and documents
incorporated by reference therein), the Prospectus included in such Registration Statement (including each preliminary Prospectus), and
such other documents as the Underwriters and the Holders of Registrable Securities included in such Registration or the legal counsel
for any such Holders and Underwriters may request in order to facilitate the disposition of the Registrable Securities owned by such
Holders;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.4 prior to any public offering of Registrable Securities, use
its best efforts to (i) register or qualify the Registrable Securities covered by the Registration Statement under such securities or
"blue sky" laws of such jurisdictions in the United States as the Holders of Registrable Securities included in such Registration
Statement (in light of their intended plan of distribution) may request and (ii) take such action necessary to cause such Registrable
Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may be necessary
by virtue of the business and operations of the Company and do any and all other acts and things that may be necessary or advisable to
enable the Holders of Registrable Securities included in such Registration Statement to consummate the disposition of such Registrable
Securities in such jurisdictions; <u>provided</u>, <u>however</u>, that the Company shall not be required to qualify generally to do
business in any jurisdiction where it would not otherwise be required to qualify or take any action to which it would be subject to general
service of process or taxation in any such jurisdiction where it is not then otherwise so subject;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.5 cause all such Registrable Securities to be listed on each
securities exchange or automated quotation system on which similar securities issued by the Company are then listed;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.6 provide a transfer agent and registrar for all such Registrable
Securities no later than the effective date of such Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.7 advise each seller of such Registrable Securities, promptly
after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission suspending the effectiveness
of such Registration Statement or the initiation or threatening of any proceeding for such purpose and promptly use its reasonable best
efforts to prevent the issuance of any stop order or to obtain its withdrawal if such stop order should be issued;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.8 at least five (5) days prior to the filing of any Registration
Statement or Prospectus or any amendment or supplement to such Registration Statement or Prospectus furnish a copy thereof to each seller
of such Registrable Securities and its counsel, including, without limitation, providing copies promptly upon receipt of any comment
letters received with respect to any such Registration Statement or Prospectus;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.9 notify the Holders at any time when a Prospectus relating
to such Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result of which
the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement, and then to correct such Misstatement
as set forth in <u>Section 3.4</u> hereof;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.10 permit a representative of the Holders (such representative
to be selected by a majority of the participating Holders), the Underwriters, if any, and any attorney or accountant retained by such
Holders or Underwriter to participate, at each such person's own expense, in the preparation of the Registration Statement, and
cause the Company's officers, directors and employees to supply all information reasonably requested by any such representative,
Underwriter, attorney or accountant in connection with the Registration; <u>provided</u>, <u>however</u>, that such representatives or
Underwriters enter into a confidentiality agreement, in form and substance reasonably satisfactory to the Company, prior to the release
or disclosure of any such information; and <u>provided further</u>, the Company may not include the name of any Holder or Underwriter
or any information regarding any Holder or Underwriter in any Registration Statement or Prospectus, any amendment or supplement to such
Registration Statement or Prospectus, any document that is to be incorporated by reference into such Registration Statement or Prospectus,
or any response to any comment letter, without the prior written consent of such Holder or Underwriter and providing each such Holder
or Underwriter a reasonable amount of time to review and comment on such applicable document, which comments the Company shall include
unless contrary to applicable law;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.11 obtain a "cold comfort" letter from the Company's
independent registered public accountants in the event of an Underwritten Registration which the participating Holders may rely on, in
customary form and covering such matters of the type customarily covered by "cold comfort" letters as the managing Underwriter
may reasonably request, and reasonably satisfactory to a majority-in-interest of the participating Holders;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.12 on the date the Registrable Securities are delivered for
sale pursuant to such Registration, obtain an opinion, dated such date, of counsel representing the Company for the purposes of such
Registration, addressed to the Holders, the placement agent or sales agent, if any, and the Underwriters, if any, covering such legal
matters with respect to the Registration in respect of which such opinion is being given as the Holders, placement agent, sales agent,
or Underwriter may reasonably request and as are customarily included in such opinions and negative assurance letters, and reasonably
satisfactory to a majority in interest of the participating Holders;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.13 in the event of any Underwritten Offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary form, with the managing Underwriter of such offering;

&nbsp;&nbsp;&nbsp;&nbsp;3.1.14 make available to its security holders, as soon as reasonably
practicable, an earnings statement covering the period of at least twelve (12) months beginning with the first day of the Company's
first full calendar quarter after the effective date of the Registration Statement which satisfies the provisions of <u>Section 11(a)</u> of the Securities Act and Rule 158 thereunder (or any successor rule promulgated thereafter by the Commission);

&nbsp;&nbsp;&nbsp;&nbsp;3.1.15 if the Registration involves the Registration of Registrable
Securities involving gross proceeds in excess of $25,000,000, use its reasonable efforts to make available senior executives of the Company
to participate in customary "road show" presentations that may be reasonably requested by the Underwriter in any Underwritten
Offering; and

&nbsp;&nbsp;&nbsp;&nbsp;3.1.16 otherwise, in good faith, cooperate reasonably with, and
take such customary actions as may reasonably be requested by the Holders, in connection with such Registration.

3.2 <u>Registration Expenses</u>. The Registration Expenses of all Registrations shall be borne by the Company. It is acknowledged by the Holders that the Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters' commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in the definition of "Registration Expenses," all reasonable fees and expenses of any legal counsel representing the Holders.

3.3 <u>Requirements for Participation in Underwritten Offerings</u>. No person may participate in any Underwritten Offering for equity securities of the Company pursuant to a Registration initiated by the Company hereunder unless such person (i) agrees to sell such person's securities on the basis provided in any underwriting arrangements approved by the Company and (ii) completes and executes all customary questionnaires, powers of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably required under the terms of such underwriting arrangements.

3.4 <u>Suspension of Sales; Adverse Disclosure</u>. Upon receipt of written notice from the Company that a Registration Statement or Prospectus contains a Misstatement, each of the Holders shall forthwith discontinue disposition of Registrable Securities until he, she or it has received copies of a supplemented or amended Prospectus correcting the Misstatement (it being understood that the Company hereby covenants to prepare and file such supplement or amendment as soon as practicable after the time of such notice), or until he, she or it is advised in writing by the Company that the use of the Prospectus may be resumed. If the filing, initial effectiveness or continued use of a Registration Statement in respect of any Registration at any time would require the Company to make an Adverse Disclosure or would require the inclusion in such Registration Statement of financial statements that are unavailable to the Company for reasons beyond the Company's control, the Company may, upon giving prompt written notice of such action to the Holders, delay the filing or initial effectiveness of, or suspend use of, such Registration Statement for the shortest period of time, but in no event more than thirty (30) days, determined in good faith by the Company to be necessary for such purpose. In the event the Company exercises its rights under the preceding sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus relating to any Registration in connection with any sale or offer to sell Registrable Securities. The Company shall immediately notify the Holders of the expiration of any period during which it exercised its rights under this <u>Section 3.4</u>.

3.5 <u>Reporting Obligations</u>. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to <u>Sections 13(a)</u> or <u>15(d)</u> of the Exchange Act and to promptly furnish the Holders with true and complete copies of all such filings. The Company further covenants that it shall take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to sell Ordinary Shares held by such Holder without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission), including providing any legal opinions. Upon the request of any Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer as to whether it has complied with such requirements.

**Article IV<br> indemnification and contribution**

4.1 <u>Indemnification.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;4.1.1 The Company agrees to indemnify, to the extent permitted
by law, each Holder of Registrable Securities, its officers and directors and each person who controls such Holder (within the meaning
of the Securities Act) against all losses, claims, damages, liabilities and expenses (including attorneys' fees) caused by any
untrue or alleged untrue statement of material fact contained in any Registration Statement, Prospectus or preliminary Prospectus or
any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein not misleading, except insofar as the same are caused by or contained in any information furnished in
writing to the Company by such Holder expressly for use therein. The Company shall indemnify the Underwriters, their officers and directors
and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in the foregoing
with respect to the indemnification of the Holder.

&nbsp;&nbsp;&nbsp;&nbsp;4.1.2 In connection with any Registration Statement in which a
Holder of Registrable Securities is participating, such Holder shall furnish to the Company in writing such information and affidavits
as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus and, to the extent permitted
by law, shall indemnify the Company, its directors and officers and agents and each person who controls the Company (within the meaning
of the Securities Act) against any losses, claims, damages, liabilities and expenses (including without limitation reasonable attorneys'
fees) resulting from any untrue statement of material fact contained in the Registration Statement, Prospectus or preliminary Prospectus
or any amendment thereof or supplement thereto or any omission of a material fact required to be stated therein or necessary to make
the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information
or affidavit so furnished in writing by such Holder expressly for use therein; <u>provided</u>, <u>however</u>, that the obligation to
indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability of each such Holder
of Registrable Securities shall be in proportion to and limited to the net proceeds received by such Holder from the sale of Registrable
Securities pursuant to such Registration Statement. The Holders of Registrable Securities shall indemnify the Underwriters, their officers,
directors and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in
the foregoing with respect to indemnification of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;4.1.3 Any person entitled to indemnification herein shall (i) give
prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure
to give prompt notice shall not impair any person's right to indemnification hereunder to the extent such failure has not materially
prejudiced the indemnifying party) and (ii) unless in such indemnified party's reasonable judgment a conflict of interest between
such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall
not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not be unreasonably
withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay
the fees and expenses of more than one counsel (plus local counsel) for all parties indemnified by such indemnifying party with respect
to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party
and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified
party, consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money
(and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect
to such claim or litigation.

&nbsp;&nbsp;&nbsp;&nbsp;4.1.4 The indemnification provided for under this Agreement shall
remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer, director
or controlling person of such indemnified party and shall survive the transfer of securities. The Company and each Holder of Registrable
Securities participating in an offering also agrees to make such provisions as are reasonably requested by any indemnified party for
contribution to such party in the event the Company's or such Holder's indemnification is unavailable for any reason.

&nbsp;&nbsp;&nbsp;&nbsp;4.1.5 If the indemnification provided under <u>Section 4.1</u> hereof from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party in respect of any losses, claims,
damages, liabilities and expenses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall
contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses
in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any
other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference
to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified
party, and the indemnifying party's and indemnified party's relative intent, knowledge, access to information and opportunity
to correct or prevent such action; <u>provided</u>, <u>however</u>, that the liability of any Holder under this <u>subsection 4.1.5</u> shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability. The amount
paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the
limitations set forth in <u>subsections 4.1.1</u>, <u>4.1.2</u> and <u>4.1.3</u> above, any legal or other fees, charges or expenses
reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree that it would not be just
and equitable if contribution pursuant to this <u>subsection 4.1.5</u> were determined by pro rata allocation or by any other method
of allocation, which does not take account of the equitable considerations referred to in this <u>subsection 4.1.5</u>. No person guilty
of fraudulent misrepresentation (within the meaning of <u>Section 11(f)</u> of the Securities Act) shall be entitled to contribution
pursuant to this <u>subsection 4.1.5</u> from any person who was not guilty of such fraudulent misrepresentation.

4.2 <u>Waiver of Medallion Guaranty</u>. The Company agrees to
use commercially reasonable efforts to enter into an indemnification agreement in customary form, in favor of Continental Stock Transfer
& Trust Company (or any successor transfer agent or warrant agent of the Company) in connection with the waiver of any requirement
to provide a medallion guarantee in connection with any Transfer of any equity securities of the Company by the Sponsor, the Representative
or any of their Permitted Transferees.

**Article V<br> MISCELLANEOUS**

5.1 <u>Notices</u>. Any notice or communication under this Agreement must be in writing and given by (i) deposit in the United States mail, addressed to the party to be notified, postage prepaid and registered or certified with return receipt requested, (ii) delivery in person or by courier service providing evidence of delivery, or (iii) transmission by hand delivery, electronic mail, telecopy, telegram or facsimile. Each notice or communication that is mailed, delivered, or transmitted in the manner described above shall be deemed sufficiently given, served, sent, and received, in the case of mailed notices, on the third business day following the date on which it is mailed and, in the case of notices delivered by courier service, hand delivery, electronic mail, telecopy, telegram or facsimile, at such time as it is delivered to the addressee (with the delivery receipt or the affidavit of messenger) or at such time as delivery is refused by the addressee upon presentation. Any notice or communication under this Agreement must be addressed, if to the Company, to: 153 Central Avenue, C/O 56, Westfield, NJ 07091, and, if to any Holder, at such Holder's address or contact information as set forth in the Company's books and records. Any party may change its address for notice at any time and from time to time by written notice to the other parties hereto, and such change of address shall become effective thirty (30) days after delivery of such notice as provided in this <u>Section 5.1</u>.

5.2 <u>Assignment; No Third-Party Beneficiaries.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;5.2.1 This Agreement and the rights, duties and obligations of
the Company hereunder may not be assigned or delegated by the Company in whole or in part.

&nbsp;&nbsp;&nbsp;&nbsp;5.2.2 Prior to the expiration of the Founder Shares Lock-up Period
or the Private Placement Lock-up Period, as the case may be, no Holder may assign or delegate such Holder's rights, duties or obligations
under this Agreement, in whole or in part, except in connection with a transfer of Registrable Securities by such Holder to a Permitted
Transferee but only if such Permitted Transferee agrees to become bound by the transfer restrictions set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;5.2.3 This Agreement and the provisions hereof shall be binding
upon and shall inure to the benefit of each of the parties and its successors and the permitted assigns of the Holders, which shall include
Permitted Transferees.

&nbsp;&nbsp;&nbsp;&nbsp;5.2.4 This Agreement shall not confer any rights or benefits on
any persons that are not parties hereto, other than as expressly set forth in this Agreement and <u>Section 5.2</u> hereof.

&nbsp;&nbsp;&nbsp;&nbsp;5.2.5 No assignment by any party hereto of such party's rights, duties and obligations hereunder shall be binding upon or obligate the Company unless and until the Company shall have received (i) written notice of such assignment as provided in <u>Section 5.1</u> hereof and (ii) the written agreement of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and provisions of this Agreement (which may be accomplished by an addendum or certificate of joinder to this Agreement). Any transfer or assignment made other than as provided in this <u>Section 5.2</u> shall be null and void.

5.3 <u>Counterparts</u>. This Agreement may be executed in multiple counterparts (including facsimile or PDF counterparts), each of which shall be deemed an original, and all of which together shall constitute the same instrument, but only one of which need be produced.

5.4 <u>Governing Law; Venue</u>. NOTWITHSTANDING THE PLACE WHERE THIS AGREEMENT MAY BE EXECUTED BY ANY OF THE PARTIES HERETO, THE PARTIES EXPRESSLY AGREE THAT THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED UNDER THE LAWS OF THE STATE OF NEW YORK AS APPLIED TO AGREEMENTS AMONG NEW YORK RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN NEW YORK, WITHOUT REGARD TO THE CONFLICT OF LAW PROVISIONS OF SUCH JURISDICTION. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OR THE COURTS OF THE STATE OF NEW YORK IN EACH CASE LOCATED IN THE CITY OF NEW YORK, AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.

5.5 <u>Amendments and Modifications</u>. Upon the written consent of the Company and the Holders of at least a majority in interest of the Registrable Securities at the time in question, compliance with any of the provisions, covenants and conditions set forth in this Agreement may be waived, or any of such provisions, covenants or conditions may be amended or modified; <u>provided</u>, <u>however</u>, that notwithstanding the foregoing, any amendment hereto or waiver hereof that adversely affects one Holder, solely in his, her or its capacity as a holder of the capital shares of the Company, in a manner that is materially different from the other Holders (in such capacity) shall require the consent of the Holder so affected. No course of dealing between any Holder or the Company and any other party hereto or any failure or delay on the part of a Holder or the Company in exercising any rights or remedies under this Agreement shall operate as a waiver of any rights or remedies of any Holder or the Company. No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as a waiver or preclude the exercise of any other rights or remedies hereunder or thereunder by such party.

5.6 <u>Other Registration Rights</u>. The Company represents and warrants that no person, other than a Holder of Registrable Securities, has any right to require the Company to register any securities of the Company for sale or to include such securities of the Company in any Registration filed by the Company for the sale of securities for its own account or for the account of any other person. Further, the Company represents and warrants that this Agreement supersedes any other registration rights agreement or agreement with similar terms and conditions and in the event of a conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.

5.7 <u>Term</u>. This Agreement shall terminate upon the earlier of (i) the tenth anniversary of the date of this Agreement or (ii) the date as of which (A) all of the Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the applicable period referred to in Section 4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated thereafter by the Commission)) or (B) the Holders of all Registrable Securities are permitted to sell the Registrable Securities without registration pursuant to Rule 144 (or any similar provision) under the Securities Act with no volume or other restrictions or limitations. The provisions of <u>Section 3.5</u> and *<u>Article IV</u>* hereof shall survive any termination.

 

*[Signature Page Follows]*

**IN WITNESS WHEREOF**, the undersigned have caused this Agreement to be executed as of the date first written above.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| **JATT II Acquisition Corp** | **JATT II Acquisition Corp** |
| a Cayman Islands exempted company | a Cayman Islands exempted company |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| **HOLDERS** | **HOLDERS** |
| **JATT Ventures II L.P.** | **JATT Ventures II L.P.** |
| (acting by its general partner, JATT Ventures II Ltd) | (acting by its general partner, JATT Ventures II Ltd) |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Director |

---

*[Signature Page to Registration Rights Agreement]*

## Exhibit 10.4

**Exhibit 10.4**

**PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT**

THIS PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT, dated as of [•], 2026, (as it may from time to time be amended, this "***Agreement***"), is entered into by and between JATT II Acquisition Corp, a Cayman Islands exempted company (the "***Company***"), and JATT Ventures II L.P., a Cayman Islands exempted limited partnership (the "***Purchaser***").

WHEREAS, the Company intends to consummate an initial public offering (the "***Public Offering***") of shares of the Company's Ordinary Shares, par value $0.0001 per share (the "***Shares***"). The Purchaser has agreed to purchase an aggregate of 300,000 Shares (or 309,000 in the aggregate if the over-allotment option in connection with the Public Offering is exercised in full) (the "***Private Placement Shares***").

NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows:

<u>AGREEMENT</u>

**Section 1. Authorization, Purchase and Sale; Terms of the Private Placement Shares**.

&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Authorization of the Private Placement Shares</u>. The
Company has duly authorized the issuance and sale of the Private Placement Shares to the Purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Purchase and Sale of the Private Placement Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) On the date of the consummation of the Public Offering or
on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the "  ***Initial Closing Date*** "),
the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, an aggregate of 300,000 Private
Placement Shares at a price of $10.00 per share for an aggregate purchase price of $3,000,000 (the "  ***Purchase Price*** "),
which shall be paid by wire transfer of immediately available funds to the Company at least one business day prior to the Initial Closing
Date in accordance with the Company's wiring instructions. On the Initial Closing Date, upon the payment by the Purchaser of the
Purchase Price, the Company, at its option, shall deliver a certificate evidencing the Private Placement Shares purchased by the Purchaser
on such date duly registered in the Purchaser's name to the Purchaser, or effect such delivery in book-entry form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) On the date of the consummation of the closing of the over-allotment
option in connection with the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company
(each such date, an "  ***Over-Allotment Closing Date*** ", and each Over-Allotment Closing Date (if any) and the Initial
Closing Date being sometimes referred to herein as a "  ***Closing Date*** "), the Company shall issue and sell to the
Purchaser, and the Purchaser shall purchase from the Company, up to an aggregate of 9,000 additional Private Placement Shares at a price
of $10.00 per share for an aggregate purchase price of up to $90,000 (if the over-allotment option in connection with the Public Offering
is exercised in full) (the "  ***Over-Allotment Purchase Price*** "). The Purchaser shall pay the Over-Allotment Purchase
Price by wire transfer of immediately available funds to the Company at least one business day prior to the Over-Allotment Closing Date
in accordance with the Company's wiring instructions. On the Over-Allotment Closing Date, upon the payment by the Purchaser of
the Over-Allotment Purchase Price, the Company shall, at its option, deliver a certificate evidencing the Private Placement Shares purchased
by the Purchaser on such date duly registered in the Purchaser's name to the Purchaser, or effect such delivery in book-entry form.

&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Terms of the Private Placement Shares.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Private Placement Shares shall be subject to a letter
agreement, dated as of the date hereof, by and among the Purchaser, the Company and certain of the Company's directors and officers
(a "  ***Letter Agreement*** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) At the time of the Initial Closing Date, the Company and the
Purchaser shall enter into a registration rights agreement (the "  ***Registration Rights Agreement***") pursuant to
which the Company will grant certain registration rights to the Purchaser relating to the Private Placement Shares.

**Section 2. Representations and Warranties of the Company.** As a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Shares, the Company hereby represents and warrants to the Purchaser (which representations and warranties shall survive the Closing Date) that:

&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Incorporation and Corporate Power</u>. The Company is
an exempted company duly incorporated, validly existing and in good standing under the laws of the Cayman Islands and is qualified to
do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on
the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority
necessary to carry out the transactions contemplated by this Agreement and the Letter Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Authorization; No Breach</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The execution, delivery and performance of this Agreement
and the Private Placement Shares have been duly authorized by the Company as of the Closing Date. This Agreement constitutes the valid
and binding obligation of the Company, enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The execution and delivery by the Company of this Agreement
and the Private Placement Shares, the issuance and sale of the Private Placement Shares and the fulfillment of, and compliance with,
the respective terms hereof and thereof by the Company, do not and will not as of the Closing Date (a) conflict with or result in a breach
of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest,
charge or encumbrance upon the Company's equity or assets under, (d) result in a violation of, or (e) require any authorization,
consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental
body or agency pursuant to the Amended and Restated Memorandum and Articles of Association of the Company in effect on the date hereof
or as may be amended prior to completion of the contemplated Public Offering, or any material law, statute, rule or regulation to which
the Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except for any filings required
after the date hereof under federal or state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Title to Securities</u>. Upon issuance in accordance with,
and payment pursuant to, the terms hereof, the Private Placement Shares will be duly and validly issued, fully paid and nonassessable.
Upon issuance in accordance with, and payment pursuant to, the terms hereof, and upon registration in the Company's register of
members, the Purchaser will have good title to the Private Placement Shares, free and clear of all liens, claims and encumbrances of
any kind, other than (i) transfer restrictions hereunder and under the other agreements contemplated hereby, (ii) transfer restrictions
under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of the Purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Governmental Consents</u>. No permit, consent, approval
or authorization of, or declaration to or filing with, any governmental authority is required in connection with the execution, delivery
and performance by the Company of this Agreement or the consummation by the Company of any other transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;E. <u>Regulation D Qualification</u>. Neither the Company nor,
to its knowledge, any of its affiliates, members, officers, directors or beneficial shareholders of 20% or more of its outstanding securities,
has experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D under the Securities Act of 1933, as amended
(the "  ***Securities Act*** ").

**Section 3. Representations and Warranties of the Purchaser.** As a material inducement to the Company to enter into this Agreement and issue and sell the Private Placement Shares to the Purchaser, the Purchaser hereby represents and warrants to the Company (which representations and warranties shall survive each Closing Date) that:

&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Organization and Requisite Authority</u>. The Purchaser
possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Authorization; No Breach</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) This Agreement constitutes a valid and binding obligation
of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other laws of general applicability relating to or affecting creditors' rights and to general equitable principles
(whether considered in a proceeding in equity or law).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The execution and delivery by the Purchaser of this Agreement
and the fulfillment of and compliance with the terms hereof by the Purchaser does not and shall not as of each Closing Date conflict
with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement, instrument, order, judgment or decree
to which the Purchaser is subject.

&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Investment Representations</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Purchaser is acquiring the Private Placement Shares (the
"  ***Securities*** "), for the Purchaser's own account, for investment purposes only and not with a view towards,
or for resale in connection with, any public sale or distribution thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Purchaser is an "accredited investor" as such
term is defined in Rule 501(a)(3) of Regulation D, and the Purchaser has not experienced a disqualifying event as enumerated pursuant
to Rule 506(d) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Purchaser understands that the Securities are being offered
and will be sold to it in reliance on specific exemptions from the registration requirements of the United States federal and state securities
laws and that the Company is relying upon the truth and accuracy of, and the Purchaser's compliance with, the representations and
warranties of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser
to acquire such Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) The Purchaser did not decide to enter into this Agreement
as a result of any general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D under the Securities
Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) The Purchaser has been furnished with all materials relating
to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been
requested by the Purchaser. The Purchaser has been afforded the opportunity to ask questions of the executive officers and directors
of the Company. The Purchaser understands that its investment in the Securities involves a high degree of risk and it has sought such
accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the acquisition
of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) The Purchaser understands that no United States federal or
state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities
or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon or endorsed
the merits of the offering of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) The Purchaser understands that: (a) the Securities have not
been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned
or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption therefrom; and (b) except as specifically
set forth in the Registration Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities
under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. While the
Purchaser understands that Rule 144 is not available for the resale of securities initially issued by shell companies (other than business
combination related shell companies) or issuers that have been at any time previously a shell company, the Purchaser understands that
Rule 144 includes an exception to this prohibition if the following conditions are met: (i) the issuer of the securities that was formerly
a shell company has ceased to be a shell company; (ii) the issuer of the securities is subject to the reporting requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "  ***Exchange Act*** "); (iii) the issuer of the
securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such
shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and (iv) at least one year
has elapsed from the time that the issuer filed current Form 10 type information with the U.S. Securities and Exchange Commission (the
"  ***SEC***") reflecting its status as an entity that is not a shell company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) The Purchaser has such knowledge and experience in financial
and business matters, knows of the high degree of risk associated with investments in the securities of companies in the development
stage such as the Company, is capable of evaluating the merits and risks of an investment in the Securities and is able to bear the economic
risk of an investment in the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate
means of providing for its current financial needs and contingencies and will have no current or anticipated future needs for liquidity
which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investment in the Securities.

**Section 4. Conditions of the Purchaser's Obligations.** The obligation of the Purchaser to purchase and pay for the Private Placement Shares is subject to the fulfillment, on or before each Closing Date, of each of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Representations and Warranties</u>. The representations
and warranties of the Company contained in Section 2 hereof shall be true and correct at and as of such Closing Date as though then made.

&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Performance</u>. The Company shall have performed and
complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with
by it on or before such Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;C. <u>No Injunction</u>. No litigation, statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental
authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which
prohibits the consummation of any of the transactions contemplated by this Agreement or the Letter Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Letter Agreement and Registration Rights Agreement</u>.
The Company shall have entered into the Letter Agreement and the Registration Rights Agreement, each on terms satisfactory to the Purchaser.

**Section 5. Conditions of the Company's Obligations.** The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before each Closing Date, of each of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Representations and Warranties</u>. The representations
and warranties of the Purchaser contained in Section 3 hereof shall be true and correct at and as of such Closing Date as though then
made.

&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Performance</u>. The Purchaser shall have performed and
complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with
by the Purchaser on or before such Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Corporate Consents</u>. The Company shall have obtained
the consent of its Board of Directors authorizing the execution, delivery and performance of this Agreement and the Letter Agreement
and the issuance and sale of the Private Placement Shares hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;D. <u>No Injunction</u>. No litigation, statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental
authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby, which
prohibits the consummation of any of the transactions contemplated by this Agreement or the Letter Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;E. <u>Letter Agreement</u>. The Company shall have entered into
the Letter Agreement on terms satisfactory to the Company.

**Section 6. Termination.** This Agreement may be terminated at any time after June 30, 2026 upon the election by either the Company or the Purchaser upon written notice to the other party if the closing of the Public Offering does not occur prior to such date.

**Section 7. Survival of Representations and Warranties.** All of the representations and warranties contained herein shall survive each Closing Date.

**Section 8. Definitions.** Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms in the registration statement on Form S-1 the Company has filed with the SEC under the Securities Act.

**Section 9. Miscellaneous**.

&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Successors and Assigns</u>. Except as otherwise expressly
provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and
inure to the benefit of the respective successors of the parties hereto whether so expressed or not. Notwithstanding the foregoing or
anything to the contrary herein, the parties may not assign this Agreement, other than assignments by the Purchaser to affiliates thereof
(including, without limitation one or more of its members).

&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Severability</u>. Whenever possible, each provision of
this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition
or invalidity, without invalidating the remainder of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Counterparts</u>. This Agreement may be executed simultaneously
in two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together
shall constitute one and the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Descriptive Headings; Interpretation</u>. The descriptive
headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. The use of the
word "including" in this Agreement shall be by way of example rather than by limitation.

&nbsp;&nbsp;&nbsp;&nbsp;E. <u>Governing Law</u>. This Agreement shall be deemed to be
a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with the internal laws
of the State of New York.

&nbsp;&nbsp;&nbsp;&nbsp;F. <u>Amendments</u>. This Agreement may not be amended, modified
or waived as to any particular provision, except by a written instrument executed by all parties hereto.

[*Signature Page Follows*]

**IN WITNESS WHEREOF**, the parties hereto have executed this Agreement to be effective as of the date first set forth above.

---

| | |
|:---|:---|
| **COMPANY** | **COMPANY** |
| **JATT II Acquisition Corp** | **JATT II Acquisition Corp** |
| a Cayman Islands exempted company | a Cayman Islands exempted company |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Chief Executive Officer |
| **PURCHASER** | **PURCHASER** |
| **JATT Ventures II L.P.** | **JATT Ventures II L.P.** |
| (acting by its general partner, JATT Ventures II Ltd) | (acting by its general partner, JATT Ventures II Ltd) |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Director |

---

[*Signature Page to Private Placement Shares Purchase Agreement*]

## Exhibit 10.5

**Exhibit 10.5**

**JATT II Acquisition Corp** 

153 Central Avenue

C/O 56

Westfield, NJ 07091

[●] , 2026

JATT Ventures II L.P.

153 Central Avenue

C/O 56

Westfield, NJ 07091

Re: <u>Administrative Services and Indemnification Agreement</u>

Ladies and Gentlemen:

This letter agreement (this "***Agreement***") by and between JATT II Acquisition Corp (the "***Company***") and JATT Ventures II L.P. (the "***Sponsor***"), dated as of the date hereof, will confirm our agreement that, commencing on the date the securities of the Company are first listed on the Nasdaq Global Market (the "***Listing Date***"), pursuant to a Registration Statement on Form S-1 and prospectus filed with the U.S. Securities and Exchange Commission (the "***Registration Statement***") and continuing until the earlier of the consummation by the Company of an initial business combination ("***Business Combination***") or the Company's liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the "***Termination Date***"):

&nbsp;&nbsp;&nbsp;&nbsp;1. The Sponsor shall make available, or cause to be made available,
to the Company, at 153 Central Avenue, C/O 56, Westfield, NJ 07091 (or any successor location), officer compensation and administrative
services as may be reasonably required by the Company. In exchange therefor, the Company shall pay the Sponsor $20,000 per month on the
Listing Date and continuing monthly thereafter until the Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Company agrees to indemnify and hold harmless the Sponsor,
its directors, officers, employees, principals, managers, partners, members, shareholders, equityholders, control persons, affiliates,
agents, advisors, consultants and representatives (the "Indemnitees") from any claims, losses, liabilities, obligations,
causes of action, proceedings (whether pending or threatened), investigations, damages, awards, settlements, judgments, decrees, fees,
costs, penalties, amounts paid in settlement or expenses (including interest, assessments and other charges in connection therewith and
reasonable fees and disbursements of attorneys and other professional advisors and costs of suit) arising out of or relating to any pending
or threatened claim, action, suit, proceeding or investigation against any of them or in which any of them may be a participant or may
otherwise be involved (including as a witness) that arises out of or relates to (i) the Offering or the Company's operations or
conduct of its business (including, for the avoidance of doubt, a Business Combination), or (ii) any claim against the Sponsor alleging
any expressed or implied management or endorsement by the Sponsor of any activities of the Company or any express or implied association
between the Sponsor, on the one hand, and the Company or any of its affiliates, on the other hand. The Indemnitee will promptly notify
the Company in writing of any indemnified claim, provided that failure or delay to give such notice shall not relieve the Company of
its indemnification obligations hereunder. The Company will, at its expense, undertake the defense of such claim with attorneys of its
own choosing reasonably satisfactory in all respects to such Indemnitee, subject to the right of such Indemnitee to undertake such defense
as hereinafter provided. An Indemnitee may participate in such defense with counsel of such Indemnitee's choosing at the expense
of the Company. In the event that the Company does not undertake the defense of any claim within a reasonable time after such Indemnitee
has given the notice thereof, or in the event that such Indemnitee shall in good faith determine that the defense of any claim by the
Company is inadequate or may conflict with the interest of any Indemnitee, such Indemnitee may, at the expense of the Company and after
giving notice to the Company of such action, undertake the defense of the claim and compromise or settle the claim, all for the account
of and at the risk of the Company. The Company shall pay all costs and expenses (including, without limitation, attorneys' fees
and costs of experts) incurred by the Indemnitee in connection with Indemnitee's defense of any such claim promptly (and in any
event within 10 days) after receipt of any statement therefor. In the defense of any claim against an Indemnitee, the Company shall not,
except with the prior written consent of such Indemnitee, consent to entry of any judgment or enter into any settlement that includes
any injunctive or other non-monetary relief or any payment of money by such Indemnitee, or that does not include as an unconditional
term thereof the giving by the person or persons asserting such claim to such Indemnitee of an unconditional release from all liability
on any of the matters that are the subject of such Claim and an acknowledgement that such Indemnitee denies all wrongdoing in connection
with such matters. The Company shall not be obligated to indemnify an Indemnitee against amounts paid in settlement of a claim if such
settlement is effected by such Indemnitee without the prior written consent of the Company, which shall not be unreasonably withheld
or delayed. If the indemnification provided for in this paragraph is for any reason not available to an Indemnitee as a matter of law
in respect of any losses, claims, damages or liabilities referred to herein, then, in lieu of indemnifying such Indemnitee therefor,
the Company shall contribute to the amount paid or payable by such Indemnitee as a result of such losses, claims, damages or liabilities
(and expenses relating thereto) (a) in such proportion as is appropriate to reflect the relative benefits to the Indemnitee, on the one
hand, and the Company, on the other hand, of the subject matter of this Agreement or (b) if the allocation provided by clause (a) above
is not available, in such proportion as is appropriate to reflect not only the relative benefits referred to in such clause (a) but also
the relative fault of each of such Indemnitee and the Company, as well as any other relevant equitable considerations. Notwithstanding
anything to the contrary set forth herein or otherwise, the Company acknowledges and agrees that each Indemnitee shall be an express
third-party beneficiary of the provisions of this paragraph 2 and any related provision hereof that is or may extend rights to such Indemnitee.
For the avoidance of doubt, the Company's indemnification obligations contained in this paragraph 2 shall survive the Company's
consummation of a Business Combination.

&nbsp;&nbsp;&nbsp;&nbsp;3. The Sponsor hereby irrevocably waives any and all right,
title, interest, causes of action and claims of any kind as a result of, or arising out of, this Agreement (each, a "  ***Claim*** ")
in or to, and any and all right to seek payment of any amounts due to it out of, the trust account established for the benefit of the
public shareholders of the Company and into which substantially all of the proceeds of the Company's initial public offering will
be deposited (the "  ***Trust Account*** "), and hereby irrevocably waives any Claim it may have in the future as a
result of, or arising out of, this Agreement, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any
monies or other assets in the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim
against the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever.

This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby.

This Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by the parties hereto.

No party hereto may assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee.

This Agreement shall be governed by and construed in accordance with the laws of the State of New York for agreements made and to be wholly performed within such state, without regards to the conflicts of laws principles thereof.

[*Signature Page Follows*]

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **JATT II Acquisition Corp** | **JATT II Acquisition Corp** |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| AGREED AND ACCEPTED BY: | AGREED AND ACCEPTED BY: |
| **JATT Ventures II L.P.** | **JATT Ventures II L.P.** |
| (acting by its general partner, JATT Ventures II Ltd) | (acting by its general partner, JATT Ventures II Ltd) |
| By: |  |
| Name: | Someit Sidhu |
| Title: | Director |

---

[*Signature Page to Administrative Services and Indemnification Agreement*]

## Exhibit 10.6

**Exhibit 10.6**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount: $300,000.00 | Dated as of February 12, 2026 |

---

JATT II Acquisition Corp, a Cayman Islands exempted company (the "**Maker**") promises to pay to the order of JATT Ventures II L.P., or its assigns or successors in interest (the "**Payee**") the principal sum of Three Hundred Thousand Dollars ($300,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Principal.** The principal balance of this Promissory Note (this "**Note**") shall be payable promptly after (i) the date on
 which the Maker consummates an initial public offering of its securities or (ii) the date on which the Maker determines not to conduct
 an initial public offering of its securities. The principal balance may be prepaid at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under
 this Note, including (without limitation) reasonable attorney's fees, then to the payment in full of any late charges (if any)
 and finally to the reduction of the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Events of Default.** The following shall constitute an event of default ()"**Event of Default** "):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Failure to Make Required Payments.** Failure by Maker to pay the principal of this Note within five (5) business days following the date
 when due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Voluntary Liquidation, Etc.** The commencement by Maker of a proceeding relating to its bankruptcy, insolvency, reorganization, rehabilitation or other
 similar action, or the consent by it to the appointment of, or taking possession by, a receiver, liquidator, assignee, trustee, custodian,
 sequestrator (or other similar official) for Maker or for any substantial part of its property, or the making by it of any assignment
 for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate
 action by Maker in furtherance of any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Involuntary Bankruptcy, Etc.** The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of maker in an involuntary
 case under any applicable bankruptcy, insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian,
 trustee, sequestrator (or similar official) for Maker or for any substantial part of its property, or ordering the winding-up or
 liquidation of the affairs of Maker, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive
 days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon the occurrence of
 an Event of Default specified in Section 4(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately
 and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable thereunder, shall become immediately
 due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything
 contained herein or in the documents evidencing the same to the contrary notwithstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon the occurrence of
 an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of this Note, and all other sums payable with
 regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Waivers.** Maker and
 all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest,
 and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under
 the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property,
 real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution,
 or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any
 real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may
 be sold upon any such writ in whole or in part in any order desired by Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Unconditional Liability.** Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment
 of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall
 not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee,
 and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to
 the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties
 hereto without notice to Maker or affecting Maker's liability hereunder.

8. **Notices.** Any notice
 called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt requested, (ii) personally delivered,
 or (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted delivery, in
 each case to the following addresses or to such other address as either party may designate by notice in accordance with this Section:

If to Maker:

<br> JATT II Acquisition Corp

153 Central Avenue

C/O 56

Westfield, NJ 07091

If to Payee:

JATT Ventures II L.P.

c/o Appleby Global Services (Cayman) Limited

71 Fort Street, PO Box 500, George Town

Grand Cayman, Cayman Islands, KY1-1106

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date reflected on a signed delivery receipt, or (iii) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Construction.** THIS
 NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **Jurisdiction.** The
 courts of New York have exclusive jurisdiction to settle any dispute arising out of or in connection with this agreement (including
 a dispute relating to any non-contractual obligations arising out of or in connection with this agreement) and the parties submit
 to the exclusive jurisdiction of the courts of New York.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **Severability.** Any
 provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
 to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition
 or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **Trust Waiver.** Notwithstanding
 anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind ()"**Claim** ")
 in or to any amounts contained in the trust account in which the proceeds of the initial public offering (the "**IPO** ")
 conducted by the Maker and the proceeds of the sale of securities in a private placement to occur prior to the effectiveness of the
 IPO, as described in greater detail in the registration statement and prospectus to be filed with the Securities and Exchange Commission
 in connection with the IPO, will be placed, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any
 Claim from the trust account or any distribution therefrom for any reason whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **Amendment; Waiver.** Any
 amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

14. **Assignment.** No assignment
 or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise)
 without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. **Further Assurance.** The
 Maker shall, at its own cost and expense, execute and do (or procure to be executed and done by any other necessary party) all such
 deeds, documents, acts and things as the Payee may from time to time require as may be necessary to give full effect to this Promissory
 Note.

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | |
|:---|:---|
| JATT II Acquisition Corp | JATT II Acquisition Corp |
| By: | /s/ Nicholas Fernandez |
| Name: | Nicholas Fernandez |
| Title: | Chief Financial Officer |

---

## Exhibit 10.7

**Exhibit 10.7**

SECURITIES SUBSCRIPTION AGREEMENT

JATT II Acquisition Corp

RE: Securities Subscription Agreement

Ladies and Gentlemen:

This agreement (the "Agreement") is entered into as of February 12, 2026 by and between JATT Ventures II Ltd, an exempted company incorporated in the Cayman Islands with limited liability, acting on behalf of JATT Ventures II L.P. (the "Subscriber" or "you") as the general partner of the Subscriber, and JATT II Acquisition Corp, an exempted company incorporated in the Cayman Islands with limited liability (the "Company," "we" or "us"). Pursuant to the terms hereof, the Company hereby accepts the offer the Subscriber has made to purchase 1,725,000 [Class B] ordinary shares, $0.0001 par value per share (the "Shares"), up to 225,000 of which are subject to forfeiture by you if the underwriters of the initial public offering ("IPO") of [Class A] ordinary shares of the Company, do not fully exercise their over-allotment option (the "Over-allotment Option"). The Company and the Subscriber's agreements regarding such Shares are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Purchase of Securities</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Purchase of Shares</u>. For the sum of $25,000.00 (the "Purchase Price"), which the Company acknowledges receiving in cash, the Company hereby issues the Shares to the Subscriber, and the Subscriber hereby purchases the Shares from the Company, subject to forfeiture, on the terms and subject to the conditions set forth in this Agreement. Concurrently with the Subscriber's execution of this Agreement, the Company shall, at its option, deliver to the Subscriber a certificate registered in the Subscriber's name representing the shares (the "Original Certificate"), or effect such delivery in book-entry form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Representations, Warranties and Agreements</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Subscriber's Representations, Warranties and Agreements</u>. To induce the Company to issue the Shares to the Subscriber, the Subscriber hereby represents and warrants to the Company and agrees with the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1 <u>No Government Recommendation or Approval</u>. The Subscriber understands that no federal or state agency has passed upon or made any recommendation or endorsement of the offering of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.2 <u>No Conflicts</u>. The execution, delivery and performance of this Agreement and the consummation by the Subscriber of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the formation and governing documents of the Subscriber, (ii) any agreement, indenture or instrument to which the Subscriber is a party or (iii) any law, statute, rule or regulation to which the Subscriber is subject, or any agreement, order, judgment or decree to which the Subscriber is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.3 <u>Organization and Authority</u>. The Subscriber is a Delaware limited liability company, validly existing and in good standing under the laws of the State of Delaware and possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement. Upon execution and delivery by you, this Agreement is a legal, valid and binding agreement of Subscriber, enforceable against Subscriber in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance or similar laws affecting the enforcement of creditors' rights generally and subject to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.4 <u>Experience, Financial Capability and Suitability</u>. Subscriber is: (i) sophisticated in financial matters and is able to evaluate the risks and benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an indefinite period of time because the Shares have not been registered under the Securities Act (as defined below) and therefore cannot be sold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. Subscriber must bear the economic risk of this investment until the Shares are sold pursuant to: (i) an effective registration statement under the Securities Act or (ii) an exemption from registration available with respect to such sale. Subscriber is able to bear the economic risks of an investment in the Shares and to afford a complete loss of Subscriber's investment in the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.5 <u>Access to Information; Independent Investigation</u>. Prior to the execution of this Agreement, the Subscriber has had the opportunity to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as the finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to verify the accuracy of all information so obtained. In determining whether to make this investment, Subscriber has relied solely on Subscriber's own knowledge and understanding of the Company and its business based upon Subscriber's own due diligence investigation and the information furnished pursuant to this paragraph. Subscriber understands that no person has been authorized to give any information or to make any representations which were not furnished pursuant to this Section 2 and Subscriber has not relied on any other representations or information in making its investment decision, whether written or oral, relating to the Company, its operations and/or its prospects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.6 <u>Regulation D Offering</u>. Subscriber represents that it is an "accredited investor" as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the "Securities Act") and acknowledges the sale contemplated hereby is being made in reliance on a private placement exemption to "accredited investors" within the meaning of Section 501(a) of Regulation D under the Securities Act or similar exemptions under state law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.7 <u>Investment Purposes</u>. The Subscriber is purchasing the Shares solely for investment purposes, for the Subscriber's own account and not for the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof. The Subscriber did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502 under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.8 <u>Restrictions on Transfer; Shell Company</u>. Subscriber understands the Shares are being offered in a transaction not involving a public offering within the meaning of the Securities Act. Subscriber understands the Shares will be "restricted securities" within the meaning of Rule 144(a)(3) under the Securities Act, and Subscriber understands that the certificates or book-entries representing the Shares will contain a legend in respect of such restrictions. If in the future the Subscriber decides to offer, resell, pledge or otherwise transfer the Shares, such Shares may be offered, resold, pledged or otherwise transferred only pursuant to: (i) registration under the Securities Act, or (ii) an available exemption from registration. Subscriber agrees that if any transfer of its Shares or any interest therein is proposed to be made, as a condition precedent to any such transfer, Subscriber may be required to deliver to the Company an opinion of counsel satisfactory to the Company. Absent registration or an exemption, the Subscriber agrees not to resell the Shares. Subscriber further acknowledges that because the Company is a shell company, Rule 144 may not be available to the Subscriber for the resale of the Shares until one year following consummation of the initial business combination of the Company, despite technical compliance with the requirements of Rule 144 and the release or waiver of any contractual transfer restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.9 <u>No Governmental Consents</u>. No governmental, administrative or other third party consents or approvals are required, necessary or appropriate on the part of Subscriber in connection with the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Company's Representations, Warranties and Agreements</u>. To induce the Subscriber to purchase the Shares, the Company hereby represents and warrants to the Subscriber and agrees with the Subscriber as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.1 <u>Organization and Corporate Power</u>. The Company is a Cayman Islands exempted company and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.2 <u>No Conflicts</u>. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the governing documents of the Company, (ii) any agreement, indenture or instrument to which the Company is a party or (iii) any law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.3 <u>Title to Securities</u>. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Shares will be duly and validly issued, fully paid and non-assessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Subscriber will have or receive good title to the Shares, free and clear of all liens, claims and encumbrances of any kind, other than (a) transfer restrictions hereunder and other agreements to which the Shares may be subject which have been notified to the Subscriber in writing, (b) transfer restrictions under federal and state securities laws, and (c) liens, claims or encumbrances imposed due to the actions of the Subscriber.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.4 <u>No Adverse Actions</u>. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Company which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement or (ii) question the validity or legality of any transactions or seeks to recover damages or to obtain other relief in connection with any transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Forfeiture of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Partial or No Exercise of the Over-allotment Option</u>. In the event the Over-allotment Option granted to the underwriters of the IPO is not exercised in full, the Subscriber acknowledges and agrees that it (or, if applicable, it and any transferees of Shares) shall forfeit any and all rights to such number of Shares (up to an aggregate of 225,000 Shares and pro rata based upon the percentage of the Over-allotment Option exercised) such that immediately following such forfeiture, the Subscriber (and all other initial shareholders prior to the IPO, if any) will own an aggregate number of Shares, not including Shares issuable upon exercise of any warrants or any Ordinary Shares purchased by Subscriber in the IPO or in the aftermarket equal to approximately 20.0% of the issued and outstanding ordinary shares of the Company immediately following the IPO.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Termination of Rights as Shareholder</u>. If any of the Shares are forfeited in accordance with this Section 3, then after such time the Subscriber (or successor in interest), shall no longer have any rights as a holder of such forfeited Shares, and the Company shall take such action as is appropriate to cancel such forfeited Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>Share Certificates</u>. In the event an adjustment to the Original Certificates, if any, is required pursuant to this Section 3, then the Subscriber shall return such Original Certificates to the Company or its designated agent as soon as practicable upon its receipt of notice from the Company advising Subscriber of such adjustment, following which a new certificate (the "New Certificate"), if any, shall be issued in such amount representing the adjusted number of Shares held by the Subscriber. The New Certificate, if any, shall be returned to the Subscriber as soon as practicable. Any such adjustment for any uncertificated securities held by the Subscriber shall be made in book-entry form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Waiver of Liquidation Distributions; Redemption Rights</u>. In connection with the Shares purchased pursuant to this Agreement, the Subscriber hereby waives any and all right, title, interest or claim of any kind in or to any distributions by the Company from the trust account which will be established for the benefit of the Company's public shareholders and into which substantially all of the proceeds of the IPO will be deposited (the "Trust Account"), in the event of a liquidation of the Company upon the Company's failure to timely complete an initial business combination. For purposes of clarity, in the event the Subscriber purchases Shares in the IPO or in the aftermarket, any additional Shares so purchased shall be eligible to receive any liquidating distributions by the Company. However, in no event will the Subscriber have the right to redeem any Shares into funds held in the Trust Account upon the successful completion of an initial business combination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Restrictions on Transfer</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Securities Law Restrictions</u>. In addition to any restrictions to be contained in that certain letter agreement (commonly known as an "Insider Letter") to be dated as of the closing of the IPO by and between Subscriber and the Company, Subscriber agrees not to sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior thereto (a) a registration statement on the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed to be transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company, that such registration is not required because such transaction is exempt from registration under the Securities Act and the rules promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Lock-up</u>. Subscriber acknowledges that the Shares will be subject to lock-up provisions (the "Lock-up") contained in the Insider Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>Restrictive Legends</u>. Any certificates representing the Shares shall have endorsed thereon legends substantially as follows:

"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL, IS AVAILABLE."

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCKUP AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED DURING THE TERM OF THE LOCKUP."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <u>Additional Shares or Substituted Securities</u>. In the event of the declaration of a share dividend, the declaration of an extraordinary dividend payable in a form other than Shares, a spin-off, a share split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company's outstanding Shares without receipt of consideration, any new, substituted or additional securities or other property which are by reason of such transaction distributed with respect to any Shares subject to this Section 5 or into which such Shares thereby become convertible shall immediately be subject to this Section 5 and Section 3. Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of Shares subject to this Section 5 and Section 3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <u>Registration Rights</u>. Subscriber acknowledges that the Shares are being purchased pursuant to an exemption from the registration requirements of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant to a registration rights agreement to be entered into with the Company prior to the closing of the IPO.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Other Agreements</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Further Assurances</u>. Subscriber agrees to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Notices</u>. All notices, statements or other documents which are required or contemplated by this Agreement shall be: (i) in writing and delivered personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>Entire Agreement</u>. This Agreement, together with the Insider Letter and the registration rights agreement, each substantially in the form to be filed as an exhibit to the Registration Statement on Form S-1 associated with the Company's IPO, embodies the entire agreement and understanding between the Subscriber and the Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <u>Modifications and Amendments</u>. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by all parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Waivers and Consents</u>. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <u>Assignment</u>. The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written consent of the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <u>Benefit</u>. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <u>Governing Law</u>. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of New York applicable to contracts wholly performed within the borders of such state, without giving effect to the conflict of law principles thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <u>Severability</u>. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <u>No Waiver of Rights, Powers and Remedies</u>. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.11 <u>Survival of Representations and Warranties</u>. All representations and warranties made by the parties hereto in this Agreement or in any other agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof and any investigations made by or on behalf of the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.12 <u>No Broker or Finder</u>. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial consultant has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as to create any liability on the other. Each of the parties hereto agrees to indemnify and save the other harmless from any claim or demand for commission or other compensation by any broker, finder, financial consultant or similar agent claiming to have been employed by or on behalf of such party and to bear the cost of legal expenses incurred in defending against any such claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.13 <u>Headings and Captions</u>. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.14 <u>Counterparts</u>. This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.15 <u>Construction</u>. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. The words "include," "includes," and "including" will be deemed to be followed by "without limitation." Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires. The words "this Agreement," "herein," "hereof," "hereby," "hereunder," and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.16 <u>Mutual Drafting</u>. This Agreement is the joint product of the Subscriber and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Voting and Tender of Shares</u>. Subscriber agrees to vote the Shares in favor of an initial business combination that the Company negotiates and submits for approval to the Company's shareholders and shall not seek redemption with respect to such Shares. Additionally, the Subscriber agrees not to tender any Shares in connection with a tender offer presented to the Company's shareholders in connection with an initial business combination negotiated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Indemnification</u>. Each party shall indemnify the other against any loss, cost or damages (including reasonable attorney's fees and expenses) incurred as a result of such party's breach of any representation, warranty, covenant or agreement in this Agreement.

[Signature Page Follows]

If the foregoing accurately sets forth our understanding and agreement, please sign the enclosed copy of this Agreement and return it to us.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| JATT II Acquisition Corp | JATT II Acquisition Corp |
| By: | /s/ Someit Sidhu |
| Name: | Someit Sidhu |
| Title: | Director |
| Accepted and agreed as of the date first written above. | Accepted and agreed as of the date first written above. |
| JATT VENTURES II L.P. | JATT VENTURES II L.P. |
| (acting by its general partner, JATT Ventures II Ltd) | (acting by its general partner, JATT Ventures II Ltd) |
| By: | /s/ Someit Sidhu |
| Name: | Someit Sidhu |
| Title: | Director |

---

## Exhibit 10.8

**Exhibit 10.8**

**INDEMNITY AGREEMENT**

THIS INDEMNITY AGREEMENT (this "***Agreement***") is made as of [●], by and between JATT II Acquisition Corp, a Cayman Islands exempted company (the "***Company***"), and [●] ("***Indemnitee***").

**RECITALS**

**WHEREAS**, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

**WHEREAS**, the board of directors of the Company (the "***Board***") has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries, if any, from certain liabilities;

**WHEREAS**, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself;

**WHEREAS**, the amended and restated memorandum and articles of association of the Company (the "***Charter***") require indemnification of the officers and directors of the Company, Indemnitee may also be entitled to indemnification pursuant to applicable Cayman Islands law and the Charter provides that the indemnification provisions set forth therein are not exclusive, and thereby contemplates that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights;

**WHEREAS**, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

**WHEREAS**, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company's shareholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

**WHEREAS**, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law and the Charter so that they will serve or continue to serve the Company free from undue concern that they will not be so protected against liabilities;

**WHEREAS**, this Agreement is a supplement to and in furtherance of the Charter and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and

**WHEREAS**, Indemnitee may not be willing to serve as an officer or director, advisor or in another capacity, without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified;

**NOW, THEREFORE**, in consideration of the premises and the covenants contained herein and subject to the provisions of the letter agreement dated as of [●] by and among the Company, Indemnitee and the other parties thereto, the Company and Indemnitee do hereby covenant and agree as follows:

**<u>TERMS AND CONDITIONS</u>**

1. **SERVICES TO THE COMPANY**. Indemnitee will serve or
continue to serve as an officer, director, advisor, key employee or in any other capacity of the Company, as applicable, for so long
as Indemnitee is duly elected, appointed or retained or until Indemnitee tenders his or her resignation or until Indemnitee is removed.
The foregoing notwithstanding, this Agreement shall continue in full force and effect as provided in Section 17. This Agreement, however,
shall not impose any obligation on Indemnitee or the Company to continue Indemnitee's service to the Company beyond any period
otherwise required by law or by other agreements or commitments of the parties, if any.

2. **DEFINITIONS**. As used in this Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;(a) The term "  ***agent***" shall mean any
person who is or was a director, officer or employee of the Company or a subsidiary of the Company or other person authorized by the
Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other
official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of,
for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The terms "  ***Beneficial Owner***" and
"  ***Beneficial Ownership***" shall have the meanings set forth in Rule 13d-3 promulgated under the Exchange Act (as
defined below) as in effect on the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The term "  ***Cayman Court***" shall mean
the courts of the Cayman Islands.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The term "  ***Change in Control***" shall
mean the occurrence of the earliest to occur after the date of this Agreement of any of the following events:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Acquisition of Shares by Third Party</u>. Other than an
affiliate of JATT Ventures II L.P. (the "  ***Sponsor*** "), any Person (as defined below) is or becomes the Beneficial
Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of
the Company's then outstanding securities entitled to vote generally in the election of directors, unless (1) the change in the
relative Beneficial Ownership of the Company's securities by any Person results solely from a reduction in the aggregate number
of outstanding shares entitled to vote generally in the election of directors, or (2) such acquisition was approved in advance by the
Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part (iii) of this definition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Change in Board of Directors</u>. Individuals who, as of
the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by the Company's
shareholders was approved by a vote of at least two thirds of the directors then still in office who were directors on the date hereof
or whose election or nomination for election was previously so approved (collectively, the "  ***Continuing Directors*** "),
cease for any reason to constitute at least a majority of the members of the Board;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Corporate Transactions</u>. The effective date of a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more
businesses (a "  ***Business Combination*** "), in each case, unless, following such Business Combination: (1) all or
substantially all of the individuals and entities who were the Beneficial Owners of securities entitled to vote generally in the election
of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 51% of the combined voting
power of the then outstanding securities of the Company entitled to vote generally in the election of directors resulting from such Business
Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially
all of the Company's assets either directly or through one or more Subsidiaries (as defined below)) in substantially the same proportions
as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of directors;
(2) other than an affiliate of the Sponsor, no Person (excluding any corporation resulting from such Business Combination) is the Beneficial
Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding securities entitled to vote generally
in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business Combination;
and (3) at least a majority of the Board of Directors of the corporation resulting from such Business Combination were Continuing Directors
at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Liquidation</u>. The approval by the shareholders of the
Company of a complete liquidation of the Company or an agreement or series of agreements for the sale or disposition by the Company of
all or substantially all of the Company's assets, other than factoring the Company's current receivables or escrows due (or,
if such approval is not required, the decision by the Board to proceed with such a liquidation, sale, or disposition in one transaction
or a series of related transactions); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Other Events</u>. There occurs any other event of a nature
that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or any successor rule) (or a response
to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company
is then subject to such reporting requirement.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The term "  ***Companies Act***" shall
mean the Companies Act (As revised) of the Cayman Islands, as amended from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;(f) The term "  ***Corporate Status***" describes
the status of a person who is or was a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of
the Company or of any other Enterprise (as defined below) which such person is or was serving at the request of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(g) The term "  ***Disinterested Director*** "
shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect of which indemnification
is sought by Indemnitee.

&nbsp;&nbsp;&nbsp;&nbsp;(h) The term "  ***Enterprise***" shall mean
the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation
or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture,
trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer,
trustee, general partner, managing member, fiduciary, employee or agent.

&nbsp;&nbsp;&nbsp;&nbsp;(i) The term "  ***Exchange Act***" shall mean
the Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;(j) The term "  ***Expenses***" shall include
all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all reasonable attorneys'
fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators
and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission
charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing
to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating in,
a Proceeding (as defined below), including reasonable compensation for time spent by Indemnitee for which he or she is not otherwise
compensated by the Company or any third party. Expenses also shall include Expenses incurred in connection with any appeal resulting
from any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to
any cost bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement
by Indemnitee or the amount of judgments or fines against Indemnitee.

&nbsp;&nbsp;&nbsp;&nbsp;(k) The term "Independent Counsel" shall mean a law
firm or a member of a law firm with significant experience in matters of corporate law and neither presently is, nor in the past five
years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect
to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements); or (ii) any
other party to the Proceeding (as defined below) giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing,
the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's
rights under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(l) The term "  ***Person***" shall have the
meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however, that "Person"
shall exclude: (i) the Company; (ii) any Subsidiaries (as defined below) of the Company; (iii) any employment benefit plan of the Company
or of a Subsidiary (as defined below) of the Company or of any corporation owned, directly or indirectly, by the shareholders of the
Company in substantially the same proportions as their ownership of shares of the Company; and (iv) any trustee or other fiduciary holding
securities under an employee benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of a corporation owned
directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of shares of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(m) The term "  ***Proceeding***" shall include
any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry,
administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise
and whether of a civil (including intentional or unintentional tort claims), criminal, administrative or investigative or related nature,
in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director
or officer of the Company, by reason of any action (or failure to act) taken by him or her or of any action (or failure to act) on his
or her part while acting as a director or officer of the Company, or by reason of the fact that he or she is or was serving at the request
of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of any other Enterprise,
in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement,
or advancement of expenses can be provided under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(n) The term "  ***Serving at the request of the Company*** "
shall include any service as a director, officer, employee, agent or fiduciary of the Company which imposes duties on, or involves services
by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan, its participants or beneficiaries;
and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants
and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner "  ***not opposed to the best interests of the Company***" as referred to in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(o) The term "  ***Subsidiary*** ," with respect
to any Person, shall mean any corporation, limited liability company, partnership, joint venture, trust or other entity of which a majority
of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person.

&nbsp;&nbsp;&nbsp;&nbsp;(p) The phrase "  ***to the fullest extent permitted by applicable law***" shall include, but not be limited to: (a) to the fullest extent authorized or permitted by the provisions
of applicable Cayman Islands law that authorizes or contemplates additional indemnification by agreement, or the corresponding provision
of any amendment to or replacement of applicable Cayman Islands law, and (b) to the fullest extent authorized or permitted by any amendments
to or replacements of applicable Cayman Islands law adopted after the date of this Agreement that increase the extent to which a company
may indemnify its officers and directors.

3. **INDEMNITY IN THIRD-PARTY PROCEEDINGS**. To the fullest extent permitted by applicable law and the Charter, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this <u>Section 3</u> if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee's Corporate Status. Pursuant to this <u>Section 3</u>, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually, and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful; *provided*, in no event shall Indemnitee be entitled to be indemnified, held harmless or advanced any amounts hereunder in respect of any Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (if any) that Indemnitee may incur by reason of his or her own actual fraud or willful default or willful neglect. Indemnitee shall not be found to have committed actual fraud, willful default or willful neglect for any purpose of this Agreement unless or until a court of competent jurisdiction shall have made a finding to that effect.

4. **INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY**. To the fullest extent permitted by applicable law and the Charter, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this <u>Section 4</u> if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee's Corporate Status. Pursuant to this <u>Section 4,</u> Indemnitee shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification, hold harmless or exoneration for Expenses shall be made under this <u>Section 4</u> in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which the Proceeding was brought or the Cayman Court shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration.

5. **INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL**. Notwithstanding any other provisions of this Agreement except for <u>Section 27</u>, to the extent that Indemnitee was or is, by reason of Indemnitee's Corporate Status, a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted by applicable law and the Charter, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law and the Charter, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter. If Indemnitee is not wholly successful in such Proceeding, the Company also shall, to the fullest extent permitted by applicable law and the Charter, indemnify, hold harmless and exonerate Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which Indemnitee was successful. For purposes of this <u>Section 5</u> and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

6. **INDEMNIFICATION FOR EXPENSES OF A WITNESS**. Notwithstanding any other provision of this Agreement except for <u>Section 27</u>, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness or deponent in any Proceeding to which Indemnitee is not a party or threatened to be made a party, he or she shall, to the fullest extent permitted by applicable law and the Charter, be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

7. **ADDITIONAL INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS**. Notwithstanding any limitation in <u>Sections 3</u>, <u>4</u>, or <u>5</u> and except for <u>Section 27</u>, the Company shall, to the fullest extent permitted by applicable law and the Charter, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding. No indemnification, hold harmless or exoneration rights shall be available under this <u>Section 7</u> on account of Indemnitee's conduct which constitutes a breach of Indemnitee's duty of loyalty to the Company or its shareholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law.

8. **CONTRIBUTION IN THE EVENT OF JOINT LIABILITY**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) To the fullest extent permissible under applicable law, if
the indemnification, hold harmless and/or exoneration rights provided for in this Agreement are unavailable to Indemnitee in whole or
in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or exonerating Indemnitee, shall pay, in the
first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities, fines, penalties, amounts paid or to be
paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee to contribute to such payment,
and the Company hereby waives and relinquishes any right of contribution it may have at any time against Indemnitee.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall not enter into any settlement of any Proceeding
in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for
a full and final release of all claims asserted against Indemnitee.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company hereby agrees to fully indemnify, hold harmless
and exonerate Indemnitee from any claims for contribution which may be brought by officers, directors or employees of the Company other
than Indemnitee who may be jointly liable with Indemnitee.

9. **EXCLUSIONS**. Notwithstanding any provision in this Agreement except for <u>Section 27</u>, the Company shall not be obligated under this Agreement to make any indemnification, advance expenses, hold harmless or exoneration payment in connection with any claim made against Indemnitee:

&nbsp;&nbsp;&nbsp;&nbsp;(a) for which payment has actually been received by or on behalf
of Indemnitee under any insurance policy or other indemnity or advancement provision or otherwise, except with respect to any excess
beyond the amount actually received under any insurance policy, contract, agreement, other indemnity or advancement provision or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;(b) for an accounting of profits made from the purchase and sale
(or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (or any successor
rule) or similar provisions of state statutory law or common law; or

&nbsp;&nbsp;&nbsp;&nbsp;(c) except as otherwise provided in <u>Sections 14(e)-(f)</u> hereof, prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including
any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other
indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company
provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers vested in the Company
under applicable law. Indemnitee shall seek payments or advances from the Company only to the extent that such payments or advances are
unavailable from any insurance policy of the Company covering Indemnitee.

10. **ADVANCES OF EXPENSES; DEFENSE OF CLAIM**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Notwithstanding any provision of this Agreement to the contrary
except for <u>Section 27</u>, and to the fullest extent not prohibited by applicable law and the Charter, the Company shall pay the Expenses
incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection with any
Proceeding within ten (10) days after the receipt by the Company of a statement or statements requesting such advances from time to time,
prior to the final disposition of any Proceeding. Advances shall, to the fullest extent permitted by law, be unsecured and interest free.
Advances shall, to the fullest extent permitted by law, be made without regard to Indemnitee's ability to repay the Expenses and
without regard to Indemnitee's ultimate entitlement to be indemnified, held harmless or exonerated under the other provisions of
this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing a Proceeding to enforce this right of advancement,
including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. To the fullest extent
required by applicable law, such payments of Expenses in advance of the final disposition of the Proceeding shall be made only upon the
Company's receipt of an undertaking, by or on behalf of Indemnitee, to repay the advanced amounts to the extent that it is ultimately
determined that Indemnitee is not entitled to be indemnified, held harmless or exonerated by the Company under the provisions of this
Agreement, the Charter, applicable law or otherwise. If it shall be determined by a final judgment or other final adjudication that Indemnitee
was not so entitled to indemnification, any advancement shall be returned to the Company (without interest) by the Indemnitee. This <u>Section 10(a)</u> shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration payment is excluded
pursuant to <u>Section 9</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company will be entitled to participate in the Proceeding
at its own expense.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall not settle any action, claim or Proceeding
(in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on Indemnitee without Indemnitee's
prior written consent.

11. **PROCEDURE FOR NOTIFICATION AND APPLICATION FOR INDEMNIFICATION**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Indemnitee agrees to notify promptly the Company in writing
upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding,
claim, issue or matter therein which may be subject to indemnification, hold harmless or exoneration rights, or advancement of Expenses
covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have
to Indemnitee under this Agreement, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Indemnitee may deliver to the Company a written application
to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement. Such application(s) may be delivered from time
to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion. Following such a written application for indemnification
by Indemnitee, Indemnitee's entitlement to indemnification shall be determined according to <u>Section 12(a)</u> of this Agreement.

12. **PROCEDURE UPON APPLICATION FOR INDEMNIFICATION**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) A determination, if required by applicable law, with respect
to Indemnitee's entitlement to indemnification shall be made in the specific case by one of the following methods: (i) if no Change
in Control has occurred, (x) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (y) by a
committee of Disinterested Directors, even though less than a quorum of the Board, or (z) if there are no Disinterested Directors, or
if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered
to Indemnitee; or (ii) if a Change in Control has occurred, by Independent Counsel in a written opinion to the Board, a copy of which
shall be delivered to Indemnitee. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee
is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied. If
it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such
determination. Indemnitee shall reasonably cooperate with the person, persons or entity making such determination with respect to Indemnitee's
entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation
or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably
necessary to such determination. Any costs or Expenses (including reasonable attorneys' fees and disbursements) incurred by Indemnitee
in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination
as to Indemnitee's entitlement to indemnification) and the Company hereby agrees to indemnify and hold Indemnitee harmless therefrom.

&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event the determination of entitlement to indemnification
is to be made by Independent Counsel pursuant to <u>Section 12(a)</u> hereof, the Independent Counsel shall be selected as provided in
this <u>Section 12(b)</u>. The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection
be made by the Board), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel
so selected and certifying that the Independent Counsel so selected meets the requirements of "Independent Counsel" as defined
in <u>Section 2</u> of this Agreement. If the Independent Counsel is selected by the Board, the Company shall give written notice to
Indemnitee advising him or her of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so
selected meets the requirements of "Independent Counsel" as defined in <u>Section 2</u> of this Agreement. In either event,
Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been received,
deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection
may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of "Independent Counsel"
as defined in <u>Section 2</u> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.
Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and
substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn
or a court of competent jurisdiction has determined that such objection is without merit. If, within twenty (20) days after submission
by Indemnitee of a written request for indemnification pursuant to <u>Section 11(a)</u> hereof, no Independent Counsel shall have been
selected and not objected to, either the Company or Indemnitee may petition the Cayman Court for resolution of any objection which shall
have been made by the Company or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent
Counsel of a person selected by the Cayman Court, and the person with respect to whom all objections are so resolved or the person so
appointed shall act as Independent Counsel under <u>Section 12(a)</u> hereof. Upon the due commencement of any judicial proceeding or
arbitration pursuant to <u>Section 14(a)</u> of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility
in such capacity (subject to the applicable standards of professional conduct then prevailing).

&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company agrees to pay the reasonable fees and expenses
of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses, claims, liabilities
and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

13. **PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) In making a determination with respect to entitlement to
indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification
under this Agreement if Indemnitee has submitted a request for indemnification in accordance with <u>Section 11(b)</u> of this Agreement,
and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity
of any determination contrary to that presumption. Neither the failure of the Company (including by the Disinterested Directors or Independent
Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper
in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including
by the Disinterested Directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense
to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

&nbsp;&nbsp;&nbsp;&nbsp;(b) If the person, persons or entity empowered or selected under <u>Section 12</u> of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination
within thirty (30) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification
shall, to the fullest extent permitted by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification,
absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement
not materially misleading, in connection with the request for indemnification, or (ii) a final judicial determination that any or all
such indemnification is expressly prohibited under applicable law or the Charter; provided, however, that such 30-day period may be extended
for a reasonable time, not to exceed an additional fifteen (15) days, if the person, persons or entity making the determination with
respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation
and/or information relating thereto.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The termination of any Proceeding or of any claim, issue
or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except
as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a
presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to
the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee's
conduct was unlawful.

&nbsp;&nbsp;&nbsp;&nbsp;(d) For purposes of any determination of good faith, Indemnitee
shall be deemed to have acted in good faith if Indemnitee's action is based on the records or books of account of the Enterprise,
including financial statements, or on information supplied to Indemnitee by the directors, trustees, general partners, managers or managing
members of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee
of the Board or any director, trustee, general partner, manager or managing member of the Enterprise, or on information or records given
or reports made to the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing
member of the Enterprise, by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise,
its Board, any committee of the Board or any director, trustee, general partner, manager or managing member. The provisions of this <u>Section 13(d)</u> shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found
to have met the applicable standard of conduct set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The knowledge and/or actions, or failure to act, of any other
director, officer, trustee, partner, manager, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to
Indemnitee for purposes of determining the right to indemnification under this Agreement.

14. **REMEDIES OF INDEMNITEE**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that (i) a determination is made pursuant to <u>Section 12</u> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses,
to the fullest extent permitted by applicable law, is not timely made pursuant to <u>Section 10</u> of this Agreement, (iii) no determination
of entitlement to indemnification shall have been made pursuant to <u>Section 12(a)</u> of this Agreement within thirty (30) days after
receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to <u>Sections 5</u>, <u>6</u>, <u>7</u> or the last sentence of <u>Section 12(a)</u> of this Agreement within ten (10) days after receipt by the Company of
a written request therefor, (v) a contribution payment is not made in a timely manner pursuant to <u>Section 8</u> of this Agreement,
(vi) payment of indemnification pursuant to <u>Sections 3</u> or <u>4</u> of this Agreement is not made within ten (10) days after a
determination has been made that Indemnitee is entitled to indemnification, or (vii) payment to Indemnitee pursuant to any hold harmless
or exoneration rights under this Agreement or otherwise is not made within ten (10) days after receipt by the Company of a written request
therefor, Indemnitee shall be entitled to an adjudication by the Cayman Court to such indemnification, hold harmless, exoneration, contribution
or advancement rights. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single
arbitrator pursuant to the Commercial Arbitration Rules and Mediation Procedures of the American Arbitration Association. Except as set
forth herein, the provisions of Cayman Islands law (without regard to its conflict of laws rules) shall apply to any such arbitration.
The Company shall not oppose Indemnitee's right to seek any such adjudication or award in arbitration.

&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event that a determination shall have been made pursuant
to <u>Section 12(a)</u> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration
commenced pursuant to this <u>Section 14</u> shall be conducted in all respects as a de novo trial, or arbitration, on the merits and
Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant
to this <u>Section 14</u>, Indemnitee shall be presumed to be entitled to be indemnified, held harmless, exonerated to receive advances
of Expenses under this Agreement and the Company shall have the burden of proving Indemnitee is not entitled to be indemnified, held
harmless, exonerated and to receive advances of Expenses, as the case may be, and the Company may not refer to or introduce into evidence
any determination pursuant to <u>Section 12(a)</u> of this Agreement adverse to Indemnitee for any purpose. If Indemnitee commences a
judicial proceeding or arbitration pursuant to this <u>Section 14</u>, Indemnitee shall not be required to reimburse the Company for
any advances pursuant to <u>Section 10</u> until a final determination is made with respect to Indemnitee's entitlement to indemnification
(as to which all rights of appeal have been exhausted or lapsed).

&nbsp;&nbsp;&nbsp;&nbsp;(c) If a determination shall have been made pursuant to <u>Section 12(a)</u> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial
proceeding or arbitration commenced pursuant to this <u>Section 14</u>, absent (i) a misstatement by Indemnitee of a material fact, or
an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request
for indemnification, or (ii) a prohibition of such indemnification under applicable law or the Charter.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall be precluded from asserting in any judicial
proceeding or arbitration commenced pursuant to this <u>Section 14</u> that the procedures and presumptions of this Agreement are not
valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the
provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company shall indemnify and hold harmless Indemnitee
to the fullest extent permitted by applicable law or the Charter against all Expenses and, if requested by Indemnitee, shall (within
ten (10) days after the Company's receipt of such written request) pay to Indemnitee, to the fullest extent permitted by applicable
law or the Charter, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought
by Indemnitee (i) to enforce his or her rights under, or to recover damages for breach of, this Agreement or any other indemnification,
hold harmless, exoneration, advancement or contribution agreement or provision of the Charter now or hereafter in effect; or (ii) for
recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of the outcome and
whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration right, advancement,
contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by Indemnitee
in good faith).

&nbsp;&nbsp;&nbsp;&nbsp;(f) Interest shall be paid by the Company to Indemnitee at the
legal rate under New York law for amounts which the Company indemnifies, holds harmless or exonerates, or is obliged to indemnify, hold
harmless or exonerate for the period commencing with the date on which Indemnitee requests indemnification, to be held harmless, exonerated,
contribution, reimbursement or advancement of any Expenses and ending with the date on which such payment is made to Indemnitee by the
Company.

15. **SECURITY**. Notwithstanding anything herein to the contrary, but subject to <u>Section 27</u>, to the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company's obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.

16. **NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) The rights of Indemnitee as provided by this Agreement shall
not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, any agreement,
a vote of shareholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision
hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any Proceeding (regardless of when such Proceeding
is first threatened, commenced or completed) or claim, issue or matter therein arising out of, or related to, any action taken or omitted
by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in applicable
law, whether by statute or judicial decision, permits greater indemnification, hold harmless or exoneration rights or advancement of
Expenses than would be afforded currently under the Charter or this Agreement, then this Agreement (without any further action by the
parties hereto) shall automatically be deemed to be amended to require that the Company indemnify Indemnitee to the fullest extent permitted
by law. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy
shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity
or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion
or employment of any other right or remedy.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The Companies Act and the Charter permit the Company to purchase
and maintain insurance or furnish similar protection or make other arrangements including, but not limited to, providing a trust fund,
letter of credit, or surety bond ("  ***Indemnification Arrangements***") on behalf of Indemnitee against any liability
asserted against him or her or incurred by or on behalf of him or her or in such capacity as a director, officer, employee or agent of
the Company, or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or her against
such liability under the provisions of this Agreement or under the Companies Act, as it may then be in effect. The purchase, establishment,
and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company
or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company
and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties thereto under
any such Indemnification Arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;(c) To the extent that the Company maintains an insurance policy
or policies providing liability insurance for directors, officers, trustees, partners, managing members, fiduciaries, employees, or agents
of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such
policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer,
trustee, partner, managing member, fiduciary, employee or agent under such policy or policies. If, at the time the Company receives notice
from any source of a Proceeding as to which Indemnitee is a party or a participant (as a witness, deponent or otherwise), the Company
has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance
with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause
such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such
policies.

&nbsp;&nbsp;&nbsp;&nbsp;(d) In the event of any payment under this Agreement, the Company,
to the fullest extent permitted by law, shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee,
who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are
necessary to enable the Company to bring suit to enforce such rights.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company's obligation to indemnify, hold harmless,
exonerate or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee,
partner, managing member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually
received as indemnification, hold harmless or exoneration payments or advancement of expenses from such Enterprise. Notwithstanding any
other provision of this Agreement to the contrary except for <u>Section 27</u>, (i) Indemnitee shall have no obligation to reduce, offset,
allocate, pursue or apportion any indemnification, hold harmless, exoneration, advancement, contribution or insurance coverage among
multiple parties possessing such duties to Indemnitee prior to the Company's satisfaction and performance of all its obligations
under this Agreement, and (ii) the Company shall perform fully its obligations under this Agreement without regard to whether Indemnitee
holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or insurance coverage rights
against any person or entity other than the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(f) To the extent Indemnitee has rights to indemnification, advancement
of expenses and/or insurance provided by the Sponsor or its affiliates (other than the Company) as applicable, (i) the Company shall
be the indemnitor of first resort (*i.e.*, that its obligations to Indemnitee are primary and any obligation of the Sponsor or its
respective affiliates, as applicable, to advance expenses or to provide indemnification for the same expenses or liabilities incurred
by Indemnitee are secondary), (ii) the Company shall be required to advance the full amount of expenses incurred by Indemnitee and shall
be liable for the full amount of all claims, liabilities, damages, losses, costs and expenses (including amounts paid in satisfaction
of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable expenses of investigating
or defending against any claim or alleged claim) to the extent legally permitted and as required by the terms of this Agreement, the
Company's organizational documents or other agreement, without regard to any rights Indemnitee may have against the Sponsor or
its affiliates, as applicable, and (iii) the Company irrevocably waives, relinquishes and releases the Sponsor and its affiliates, as
applicable, from any and all claims against them for contribution, subrogation or any other recovery of any kind in respect thereof.
No advancement or payment by the Sponsor or its affiliates, as applicable, on behalf of Indemnitee with respect to any claim for which
Indemnitee has sought indemnification from the Company shall affect the foregoing, and the Sponsor and its affiliates, as applicable,
shall have a right of contribution and be subrogated to the extent of such advancement or payment to all of the rights of recovery of
Indemnitee against the Company.

17. **DURATION OF AGREEMENT**. All agreements and obligations
of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director,
officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust,
employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long
as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee
pursuant to <u>Section 14</u> of this Agreement) by reason of his or her Corporate Status, whether or not he is acting in any such capacity
at the time any liability or expense is incurred for which indemnification or advancement can be provided under this Agreement.

18. **SEVERABILITY**. If any provision or provisions of this
Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability
of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this
Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable)
shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision
or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent
of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each
portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable,
that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

19. **ENFORCEMENT AND BINDING EFFECT**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company expressly confirms and agrees that it has entered
into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer or
key employee of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, officer
or key employee of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Without limiting any of the rights of Indemnitee under the
Charter as they may be amended from time to time, this Agreement constitutes the entire agreement between the parties hereto with respect
to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto
with respect to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The indemnification, hold harmless, exoneration and advancement
of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and
their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to
all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director,
officer, employee or agent of the Company or director or officer of any other Enterprise at the Company's request, and shall inure
to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall require and cause any successor (whether
direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business
and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to
perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession
had taken place.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company and Indemnitee agree herein that a monetary remedy
for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such
breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may, to the fullest extent permitted
by law, enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without any necessity
of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not
be precluded from seeking or obtaining any other relief to which he or she may be entitled. The Company and Indemnitee further agree
that Indemnitee shall, to the fullest extent permitted by law, be entitled to such specific performance and injunctive relief, including
temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking
in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee
by a court of competent jurisdiction, and the Company hereby waives any such requirement of such a bond or undertaking to the fullest
extent permitted by law.

20. **MODIFICATION AND WAIVER**. No supplement, modification
or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions
of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute
a continuing waiver.

21. **NOTICES**. All notices, requests, demands and other
communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) if delivered by hand and receipted
for by the party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with
postage prepaid, on the third (3rd) business day after the date on which it is so mailed, or (iii) if by electronic mail, on the first
business day after the date on which it is so emailed:

&nbsp;&nbsp;&nbsp;&nbsp;(a) If to Indemnitee, at the address indicated on the signature
page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(b) If to the Company, to:

JATT II Acquisition Corp<br> 153 Central Avenue

C/O 56

Westfield, NJ 07091<br> Attention: Nicholas Fernandez

Email: nicholas.fernandez@athanorcapital.com

In each case, with copies (which copy shall not constitute notice) to:

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attention: Giovanni Caruso, Esq

Email: gcaruso@loeb.com

or to any other address as may have been furnished to Indemnitee in writing by the Company.

22. **APPLICABLE LAW AND CONSENT TO JURISDICTION**. This Agreement
and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State
of New York, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to <u>Section 14(a)</u> of this Agreement, to the fullest extent permitted by law, the Company and Indemnitee hereby irrevocably and unconditionally:
(a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Cayman Court
and not in any state or federal court in the United States of America or any court in any other country; (b) consent to submit to the
exclusive jurisdiction of the Cayman Court for purposes of any action or proceeding arising out of or in connection with this Agreement;
(c) waive any objection to the laying of venue of any such action or proceeding in the Cayman Court; and (d) waive, and agree not to
plead or to make, any claim that any such action or proceeding brought in the Cayman Court has been brought in an improper or inconvenient
forum, or is subject (in whole or in part) to a jury trial.

23. **IDENTICAL COUNTERPARTS**. This Agreement may be executed
in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute
one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced
to evidence the existence of this Agreement.

24. **MISCELLANEOUS**. Use of the masculine pronoun shall
be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for
convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

25. **PERIOD OF LIMITATIONS**. No legal action shall be brought
and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee's spouse, heirs, executors
or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim
or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within
such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action
such shorter period shall govern.

26. **ADDITIONAL ACTS**. If for the validation of any of the
provisions in this Agreement any act, resolution, approval or other procedure is required to the fullest extent permitted by law, the
Company undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that will enable
the Company to fulfill its obligations under this Agreement.

27. **WAIVER OF CLAIMS TO TRUST ACCOUNT**. Notwithstanding
anything contained herein to the contrary, Indemnitee hereby agrees that it does not have any right, title, interest or claim of any
kind (each, a "  ***Claim***") in or to any monies in the trust account established in connection with the Company's
initial public offering for the benefit of the Company and holders of shares issued in such offering (the "  ***Trust Account*** "),
and hereby waives any Claim it may have in the future as a result of, or arising out of, any services provided to the Company and will
not seek recourse against such Trust Account for any reason whatsoever. Accordingly, Indemnitee acknowledges and agrees that any indemnification
provided hereto will only be able to be satisfied by the Company if (i) the Company has sufficient funds outside of the Trust Account
to satisfy its obligations hereunder or (ii) the Company consummates an initial business combination.

28. **MAINTENANCE OF INSURANCE**. The Company shall use commercially
reasonable efforts to obtain and maintain in effect during the entire period for which the Company is obligated to indemnify the Indemnitee
under this Agreement, one or more policies of insurance with reputable insurance companies to provide the officers/directors of the Company
with coverage for losses from wrongful acts and omissions and to ensure the Company's performance of its indemnification obligations
under this Agreement. The Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum
extent of the coverage available for any such director or officer under such policy or policies. In all such insurance policies, the
Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee with the same rights and benefits as are accorded
to the most favorably insured of the Company's directors and officers.

[*Signature Page Follows*]

**IN WITNESS WHEREOF**, the parties hereto have caused this Indemnity Agreement to be signed as of the day and year first above written.

---

| | | |
|:---|:---|:---|
| **JATT II Acquisition Corp** | **JATT II Acquisition Corp** | **JATT II Acquisition Corp** |
| By: |  |  |
|  | Name: | Someit Sidhu |
|  | Title: | Chief Executive Officer |
| **INDEMNITEE** | **INDEMNITEE** | **INDEMNITEE** |
| By: |  |  |
|  | Name: |  |
| Address: | Address: |  |

---

[*Signature Page to Indemnity Agreement*]

## Exhibit 14.1

**Exhibit 14.1**

**JATT II ACQUISITION CORP<br> FORM OF CODE OF BUSINESS CONDUCT AND ETHICS<br> Effective [●]**

**I. <u>Introduction</u>**

The Board of Directors (the "***Board***") of JATT II Acquisition Corp has adopted this code of business conduct and ethics (this "***Code***"), as amended from time to time by the Board and which is applicable to all of the Company's directors, officers and employees (to the extent that employees are hired in the future) (each a "***person***," as used herein) of the Company (as defined below), to:

● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

● promote the full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the U.S. Securities and Exchange Commission (the "SEC"), as well as in other public communications made by or on behalf of the Company;

● promote compliance with applicable governmental laws, rules and regulations;

● deter wrongdoing; and

● require prompt internal reporting of breaches of, and accountability for adherence to, this Code.

This Code may be amended or modified by the Board. In this Code, references to the "Company" mean JATT II Acquisition Corp and, in appropriate context, the Company's subsidiaries, if any.

**II. <u>HONEST, ETHICAL AND FAIR CONDUCT</u>**

Each person owes a duty to the Company to act with integrity. Integrity requires, among other things, being honest, fair and candid. Deceit, dishonesty and subordination of principle are inconsistent with integrity. Service to the Company should never be subordinated to personal gain or advantage.

Each person must:

● Act with integrity, including being honest and candid while still maintaining the confidentiality of the Company's information where required or when in the Company's interests;

● Observe all applicable governmental laws, rules and regulations;

● Comply with the requirements of applicable accounting and auditing standards, as well as Company policies, in order to maintain a high standard of accuracy and completeness in the Company's financial records and other business-related information and data;

● Adhere to a high standard of business ethics and not seek competitive advantage through unlawful or unethical business practices;

● Deal fairly with the Company's customers, suppliers, competitors and employees;

● Refrain from taking advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice;

● Protect the assets of the Company and ensure their proper use;

● Subject to, and except as permitted by, the Company's amended and restated memorandum and articles of association, as it may be amended from time to time (the "charter"), not (i) take for themselves corporate or business opportunities that are discovered through the use of corporate property, information or position, (ii) use corporate property, information or position for personal gain and (iii) compete with the Company; and

● Avoid conflicts of interest, wherever possible, except as may be allowed under guidelines or resolutions approved by the Board (or the appropriate committee of the Board), as disclosed in the Company's public filings with the SEC or as permitted by the charter. Anything that would be a conflict for a person subject to this Code also will be a conflict for a member of his or her immediate family or any other close relative. Examples of conflict of interest situations include, but are not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o any significant ownership interest in any supplier or customer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o any consulting or employment relationship with any supplier
or customer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o the receipt of any money, non-nominal gifts or excessive
entertainment from any entity with which the Company has current or prospective business dealings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o selling anything to the Company or buying anything from the
Company, except on the same terms and conditions as comparable officers or directors are permitted to so purchase or sell;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o any other financial transaction, arrangement or relationship
(including any indebtedness or guarantee of indebtedness) involving the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o any other circumstance, event, relationship or situation
in which the personal interest of a person subject to this Code interferes — or even appears to interfere — with the interests
of the Company as a whole.

**III. <u>Disclosure</u>**

The Company strives to ensure that the contents of and the disclosures in the reports and documents that the Company files with the SEC and other public communications shall be full, fair, accurate, timely and understandable in accordance with applicable disclosure standards, including standards of materiality, where appropriate. Each person must:

● not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company's independent registered public accountants, governmental regulators, self-regulating organizations and other governmental officials, as appropriate; and

● in relation to his or her area of responsibility, properly review and critically analyze proposed disclosure for accuracy and completeness.

In addition to the foregoing, the Chief Executive Officer and Chief Financial Officer of the Company and each subsidiary of the Company (or persons performing similar functions), and each other person that typically is involved in the financial reporting of the Company, must familiarize himself or herself with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company.

Each person must promptly bring to the attention of the Chairperson of the Board (the "***Chairperson***") any information he or she may have concerning (a) significant deficiencies in the design or operation of internal and/or disclosure controls that could adversely affect the Company's ability to record, process, summarize and report financial data or (b) any fraud that involves management or other employees who have a significant role in the Company's financial reporting, disclosures or internal controls.

**IV. <u>Compliance</u>**

It is the Company's obligation and policy to comply with all applicable governmental laws, rules and regulations. It is the personal responsibility of each person to, and each person must, adhere to the standards and restrictions imposed by those laws, rules and regulations, including those relating to accounting and auditing matters.

**V. <u>Reporting and Accountability</u>**

The Board is responsible for applying this Code to specific situations in which questions are presented to it and has the authority to interpret this Code in any particular situation. Any person who becomes aware of any existing or potential breach of this Code is required to notify the Chairperson promptly. Failure to do so is, in and of itself, a breach of this Code.

Specifically, each person must:

● Notify the Chairperson promptly of any existing or potential violation of this Code; and

● Not retaliate against any other person for reports of potential violations that are made in good faith.

The Company will follow the following procedures in investigating and enforcing this Code and in reporting on this Code:

● The Board will take all appropriate action to investigate any breaches reported to it; and

● Upon determination by the Board that a breach has occurred, the Board (by majority decision) will take or authorize such disciplinary or preventive action as it deems appropriate, after consultation with the Company's internal or external legal counsel, up to and including dismissal or, in the event of criminal or other serious violations of law, notification of the SEC or other appropriate law enforcement authorities.

No person following the above procedure shall, as a result of following such procedure, be subject by the Company or any officer or employee thereof to discharge, demotion, suspension, threat, harassment or, in any manner, discrimination against such person in terms and conditions of employment.

**VI. <u>Waivers and Amendments</u>**

Any waiver (defined below) or implicit waiver (defined below) from a provision of this Code for the principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, or any amendment (as defined below) to this Code is required to be disclosed in a Current Report on Form 8-K filed with the SEC. In lieu of filing a Current Report on Form 8-K to report any such waivers or amendments, the Company may provide such information on its website and keep such information on the website for at least 12 months and disclose the website address as well as any intention to provide such disclosures in this manner in its most recently filed Annual Report on Form 10-K.

A "***waiver***" means the approval by the Board of a material departure from a provision of this Code. An "***implicit waiver***" means the Company's failure to take action within a reasonable period of time regarding a material departure from a provision of this Code that has been made known to an executive officer of the Company. An "***amendment***" means any amendment to this Code other than minor technical, administrative or other non-substantive amendments hereto.

All persons should note that it is not the Company's intention to grant or to permit waivers from the requirements of this Code. The Company expects full compliance with this Code.

**VII. <u>INSIDER TRADING AND DISSEMINATION OF INSIDE INFORMATION</u>**

Each person shall comply with the Company's Policy Regarding Insider Trading and Dissemination of Inside Information.

**VIII. <u>FINANCIAL STATEMENTS AND OTHER RECORDS</u>**

All of the Company's books, records, accounts and financial statements must be maintained in reasonable detail, must appropriately reflect the Company's transactions and must both conform to applicable legal requirements and to the Company's system of internal controls. Unrecorded or "off the books" funds or assets should not be maintained unless permitted by applicable law or regulation. Records should always be retained or destroyed according to the Company's record retention policies. In accordance with those policies, in the event of litigation or governmental investigation, please consult the Board or the Company's internal or external legal counsel.

**IX. <u>IMPROPER INFLUENCE ON CONDUCT OF AUDITS</u>**

No director, officer or employee, or any other person acting under the direction thereof, shall directly or indirectly take any action to coerce, manipulate, mislead or fraudulently influence any public or certified public accountant engaged in the performance of an audit or review of the financial statements of the Company or take any action that such person knows or should know that if successful could result in rendering the Company's financial statements materially misleading. Any person who believes such improper influence is being exerted should report such action to such person's supervisor, or if that is impractical under the circumstances, to any of the Company's directors.

Types of conduct that could constitute improper influence include, but are not limited to, directly or indirectly:

● Offering or paying bribes or other financial incentives, including future employment or contracts for non-audit services;

● Providing an auditor with an inaccurate or misleading legal analysis;

● Threatening to cancel or canceling existing non-audit or audit engagements if the auditor objects to the Company's accounting;

● Seeking to have a partner removed from the audit engagement because the partner objects to the Company's accounting;

● Blackmailing; and

● Making physical threats.

**X. <u>ANTI-CORRUPTION LAWS</u>**

The Company complies with the anti-corruption laws of the countries in which it does business, including the U.S. Foreign Corrupt Practices Act. To the extent prohibited by applicable law, directors, officers and employees will not directly or indirectly give anything of value to government officials, including employees of state-owned enterprises or foreign political candidates. These requirements apply both to Company employees and agents, such as third party sales representatives, no matter where they are doing business. If you are authorized to engage agents, you are responsible for ensuring they are reputable and for obtaining a written agreement to uphold the Company's standards in this area.

**XI. <u>VIOLATIONS</u>**

Violation of this Code is grounds for disciplinary action up to and including termination of employment. Such action is in addition to any civil or criminal liability which might be imposed by any court or regulatory agency.

**XII. <u>OTHER POLICIES AND PROCEDURES</u>**

Any other policy or procedure set out by the Company in writing or made generally known to employees, officers or directors of the Company prior to the effective date hereof or hereafter are separate requirements and remain in full force and effect.

**XIII. <u>INQUIRIES</u>**

All inquiries and questions in relation to this Code or its applicability to particular people or situations should be addressed to the Chair of the Audit Committee of the Board, or such other compliance officer as shall be designated from time to time by the Board.

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Amendment No. 1 to Form S-1 of our report dated March 13, 2026, relating to the financial statements of JATT II Acquisition Corp. as of February 13, 2026, and for the period from January 13, 2026 (inception) through February 13, 2026, (which includes an explanatory paragraph about the Company's ability to continue as a going concern) which is contained in that Prospectus. We also consent to the reference to our firm under the caption "Experts" in the Prospectus.

/s/ WithumSmith+Brown, PC

Whippany, New Jersey

April 2, 2026

## Exhibit 99.1

**Exhibit 99.1**

**JATT II ACQUISITION CORP** 

**POLICY FOR THE<br> RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION**

Effective as of [●], 2026

A. OVERVIEW

In accordance with the applicable rules of The Nasdaq Stock Market (the ***"Nasdaq Rules"***), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***") ("***Rule 10D-1***"), the Board of Directors (the "***Board***") of JATT II Acquisition Corp (the "***Company***") has adopted this Policy (the "***Policy***") to provide for the recovery of erroneously awarded Incentive-based Compensation from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.

B. RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) In the event of an Accounting Restatement, the Company will reasonably promptly recover the Erroneously Awarded Compensation Received in accordance with Nasdaq Rules and Rule 10D-1 as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) After an Accounting Restatement, the Compensation Committee
(if composed entirely of independent directors, or in the absence of such a committee, a majority of independent directors serving on
the Board) (the "  ***Committee***") shall determine the amount of any Erroneously Awarded Compensation Received by
each Executive Officer and shall promptly notify each Executive Officer with a written notice containing the amount of any Erroneously
Awarded Compensation and a demand for repayment or return of such compensation, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) For Incentive-based Compensation based on (or derived from)
the Company's stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical
recalculation directly from the information in the applicable Accounting Restatement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. The amount to be repaid or returned shall be determined by
the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company's stock price or total
shareholder return upon which the Incentive-based Compensation was Received; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. The Company shall maintain documentation of the determination
of such reasonable estimate and provide the relevant documentation as required to the Nasdaq.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Committee shall have discretion to determine the appropriate
means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances. Notwithstanding the foregoing,
except as set forth in Section B(2) below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded
Compensation in satisfaction of an Executive Officer's obligations hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To the extent that the Executive Officer has already reimbursed
the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or
applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously Awarded Compensation
that is subject to recovery under this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) To the extent that an Executive Officer fails to repay all
Erroneously Awarded Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover such
Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall be required to reimburse
the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded
Compensation in accordance with the immediately preceding sentence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee (which, as specified above, is composed entirely of independent directors or in the absence of such a committee, a majority of the independent directors serving on the Board) determines that recovery would be impracticable *and* any of the following two conditions are met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Committee has determined that the direct expenses paid
to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making this determination, the Company
must make a reasonable attempt to recover the Erroneously Awarded Compensation, documented such attempt(s) and provided such documentation
to Nasdaq; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Recovery would likely cause an otherwise tax-qualified retirement
plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13)
or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.

C. DISCLOSURE REQUIREMENTS

The Company shall file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission ("***SEC***") filings and rules.

D. PROHIBITION OF INDEMNIFICATION

The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company's enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or awarded to an Executive Officer from the application of this Policy or that waives the Company's right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).

E. ADMINISTRATION AND INTERPRETATION

This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.

The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy and for the Company's compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith.

F. AMENDMENT; TERMINATION

The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or Nasdaq rule.

G. OTHER RECOVERY RIGHTS

This Policy shall be binding and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or Nasdaq, their beneficiaries, heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.

H. DEFINITIONS

For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) "***Accounting Restatement***" means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a "Big R" restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a "little r" restatement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) "***Clawback Eligible Incentive Compensation***" means all Incentive-based Compensation Received by an Executive Officer (i) on or after the effective date of the applicable Nasdaq rules, (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Clawback Period (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) "***Clawback Period***" means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date (as defined below), and if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) "***Erroneously Awarded Compensation***" means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) "***Executive Officer***" means each individual who is currently or was previously designated as an "officer" of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) "***Financial Reporting Measures***" means measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company's financial statements or included in a filing with the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) "***Incentive-based Compensation***" means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) "***Nasdaq***" means The Nasdaq Stock Market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9) "***Received***" means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10) "***Restatement Date***" means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

**Exhibit A**

**ATTESTATION AND ACKNOWLEDGEMENT OF POLICY FOR THE RECOVERY OF<br> ERRONEOUSLY AWARDED COMPENSATION**

By my signature below, I acknowledge and agree that:

● I have received and read the attached Policy for the Recovery of Erroneously Awarded Compensation of JATT II Acquisition Corp (this "  ***Policy*** ").

● I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy.

● I hereby waive any right to the indemnification, insurance or advancement of expenses by the Company with respect to any Erroneously Awarded Compensation in accordance with Section D of this Policy.

---

| |
|:---|
| Signature: |
| Printed Name: |
| Date: |

---

*Signature Page to Policy for The Recovery of Erroneously Awarded Compensation*

## Exhibit 99.2

**Exhibit 99.2**

**Consent to be Named as a Director Nominee**

In connection with the filing by JATT II Acquisition Corp of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "***Securities Act***"), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of JATT II Acquisition Corp in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.

Dated: March 30, 2026

---

| | |
|:---|:---|
| By: | /s/ Verender S. Badial |
| Name: | Verender S. Badial |

---

## Exhibit 99.3

**Exhibit 99.3**

**Consent to be Named as a Director Nominee**

In connection with the filing by JATT II Acquisition Corp of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "***Securities Act***"), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of JATT II Acquisition Corp in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.

Dated: March 30, 2026

---

| | |
|:---|:---|
| By: | /s/ Christopher Staral |
| Name: | Christopher Staral |

---

## Exhibit 99.4

**Exhibit 99.4**

**Consent to be Named as a Director Nominee**

In connection with the filing by JATT II Acquisition Corp of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "***Securities Act***"), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of JATT II Acquisition Corp in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.

Dated: March 30, 2026

---

| | |
|:---|:---|
| By: | /s/ Arjun Goyal |
| Name: | Arjun Goyal |

---

## Exhibit 99.5

**Exhibit 99.5**

**Consent to be Named as a Director Nominee**

In connection with the filing by JATT II Acquisition Corp of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "***Securities Act***"), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of JATT II Acquisition Corp in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.

Dated: March 30, 2026

---

| | |
|:---|:---|
| By: | /s/ Jonathon Kluft |
| Name: | Jonathon Kluft |

---

## Exhibit 99.6

**Exhibit 99.6**

**JATT II ACQUISITION CORP** 

**FORM OF AUDIT COMMITTEE CHARTER**

**Effective [●], 2026**

**I.**  **<u>Purposes</u>** 

The Audit Committee (the "***Committee***") is appointed by the Board of Directors (the "***Board***") of JATT II Acquisition Corp (the "***Company***") to assist the Board in its oversight of the accounting and financial reporting processes of the Company and the Company's compliance with legal and regulatory requirements. To assist the Board in fulfilling its responsibilities, the Committee shall: (A) oversee: (i) audits of the financial statements of the Company; (ii) the integrity of the Company's financial statements; (iii) the Company's processes relating to risk management and the conduct and systems of internal control over financial reporting and disclosure controls and procedures; (iv) the qualifications, engagement, compensation, independence and performance of the Company's independent auditor, and the auditor's conduct of the annual audit of the Company's financial statements and any other services provided to the Company; and (v) the performance of the Company's internal audit function, if any; and (B) produce the annual report of the Committee required by the rules of the U.S. Securities and Exchange Commission (the "***SEC***").

**II.**  **<u>Committee Membership</u>** 

**A.**  ***Composition*** 

The Committee shall consist of at least three members of the Board, subject to applicable phase-in schedules of the Nasdaq Stock Market ("***Nasdaq***"). Except as otherwise directed by the Board, a director selected as a Committee member shall continue to be a member for as long as he or she remains a director or until his or her earlier resignation or removal from the Committee. Any member may be removed from the Committee by the Board, with or without cause, at any time. Any vacancy on the Committee shall be filled by majority vote of the Board. No member of the Committee shall be removed except by majority vote of the Board.

**B.**  ***Chair*** 

The Chair of the Committee shall be appointed from among the Committee members by, and serve at the pleasure of, the Board, shall preside at meetings of the Committee and shall have authority to convene meetings, set agendas for meetings, and determine the Committee's information needs, except as otherwise provided by the Board or the Committee, provided that if the Board does not so designate a chairperson, the members of the Committee, by a majority vote, may designate a chairperson. In the absence of the Chair at a duly convened meeting, the Committee shall select a temporary substitute from among its members to serve as chair of the meeting.

**C.**  ***Independence*** 

Each member of the Committee shall be an "independent" director in accordance with applicable listing standards of Nasdaq and Rule 10A-3 under the United States Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), subject to any exceptions or cure periods that are applicable pursuant to the foregoing requirements and the phase-in schedules permitted under the rules of Nasdaq under which the Committee is required to have only one independent member at the time of listing, a majority of independent members within 90 days of listing and all independent members within one year of listing. Any action duly taken by the Committee shall be valid and effective, whether or not the members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership provided herein.

**D.**  ***Financial Literacy*** 

Each member of the Committee shall in the judgment of the Board have the ability to read and understand fundamental financial statements and otherwise meet the financial literacy requirements of Nasdaq. At least one member shall be an "audit committee financial expert" as such term is defined under applicable SEC rules.

**E.**  ***Service on Multiple Audit Committees*** 

No member of the Committee may serve on the audit committee of more than three public companies, including the Company, unless the Board has determined that such simultaneous service would not impair the ability of such member to effectively serve on the Committee.

**III.**  **<u>Authority</u>** 

In discharging its role, the Committee is empowered to inquire into any matter that it considers appropriate to carry out its responsibilities, with access to all books, records, facilities and personnel of the Company, and, subject to the direction of the Board, the Committee is authorized and delegated the authority to act on behalf of the Board with respect to any matter it determines to be necessary or appropriate to the accomplishment of its purposes.

The Committee shall have authority to retain, direct and oversee the activities of, and to terminate the engagement of, the Company's independent auditor and any other accounting firm retained by the Committee to prepare or issue any other audit report or to perform any other audit, review or attest services and any legal counsel, accounting or other advisor or consultant hired to assist the Committee, all of whom shall be accountable to the Committee.

The Company shall provide the Committee with appropriate funding, as determined by the Committee, for the payment of (a) compensation to any registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company; (b) compensation to any independent counsel or other advisers retained by the Committee in carrying out its duties; and (c) ordinary administrative expenses of the Committee that are necessary or appropriate in carrying out its duties.

**IV.**  **<u>Committee Meetings</u>** 

The Committee shall meet on a regularly scheduled basis at least four times per year and additionally as circumstances dictate.

The Committee shall establish its own schedule of meetings. The Committee may also act by unanimous written consent of its members.

Notice of meetings shall be given to all Committee members or may be waived, in the same manner as required for meetings of the Board. Meetings of the Committee may be held by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear and speak with each other. A majority of the members of the Committee shall constitute a quorum for a meeting and the affirmative vote of a majority of members present at a meeting at which a quorum is present shall constitute the action of the Committee. The Committee shall otherwise establish its own rules of procedure.

The Committee shall meet in executive session separately with each of the independent auditor, the internal auditor, if any, and with senior management, at least quarterly. At the end of each of the Committee's regularly scheduled meetings, and more frequently as deemed necessary, the Committee shall meet in private session with only the Committee members.

**V.**  **<u>Delegation</u>** 

The Committee, by resolution approved by a majority of the Committee, may form and delegate any of its responsibilities to a subcommittee so long as such subcommittee is solely comprised of one or more members of the Committee and such delegation is not otherwise inconsistent with law and applicable rules and regulations of the SEC and Nasdaq.

**VI.**  **<u>Key Responsibilities</u>** 

The Committee relies on the expertise and knowledge of management, the internal auditors, if any, and the independent auditor in carrying out its oversight responsibilities. Management is responsible for the preparation, presentation, and integrity of the Company's financial statements, for the appropriateness of the accounting principles and reporting policies that are used by the Company, and for establishing and maintaining effective internal control over financial reporting. The independent auditor is responsible for auditing the Company's financial statements and, if applicable, the Company's internal control over financial reporting, and for reviewing the Company's unaudited interim financial statements.

The responsibilities set forth in this charter do not reflect or create any duty or obligation of the Committee to plan or conduct any audit; to determine or certify that the Company's financial statements are complete, accurate, fairly presented or in accordance with generally accepted accounting principles ("***GAAP***") or applicable law; to guarantee or otherwise certify as to the independent auditor's reports; to conduct investigations; or to assure compliance with laws and regulations or the Company's code of ethics, internal policies, procedures and controls. The following responsibilities are set forth as a guide for fulfilling the Committee's purposes in such manner as the Committee determines is appropriate.

**A.**  ***Oversight of the Independent Auditor*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  ***Independent Auditor Retention*** . The Committee
is solely and directly responsible for the appointment, evaluation, compensation, retention and, if appropriate, replacement of the independent
auditor. The Committee may, in its discretion, seek shareholder ratification of the public accounting firm selected to be the Company's
independent auditor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  ***Independence*** . The Committee shall assess at
least annually the independent auditor's independence. In connection with this assessment, the Committee shall ensure the receipt
of and review formal written statements from the independent auditor delineating all relationships between the auditor and the Company,
consistent with applicable requirements of the Public Company Accounting Oversight Board ("  ***PCAOB***") regarding
the independent auditor's communications with the Committee concerning independence. The Committee shall engage in an active dialogue
with the independent auditor concerning any disclosed relationships or services that may impact the objectivity and independence of the
auditor and take, or recommend that the Board take, appropriate action to oversee and ensure the independence of the auditor.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  ***Quality and Performance*** . The Committee shall
evaluate at least annually the qualifications and performance of the independent auditor, including the lead partner. The evaluation
will include obtaining a written report from the independent auditor describing the firm's internal quality control procedures;
any material issues raised by the most recent internal quality control review, PCAOB inspection, or other PCAOB review of the firm, by
a peer review of the firm or by any inquiry or investigation by governmental or professional authorities within the past five years,
respecting one or more independent audit or audits carried out by the firm, and any steps taken to address any such issues; and all relationships
between the independent registered public accounting firm and us to assess the independent registered public accounting firm's
independence.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  ***General Oversight*** . The independent auditor
reports directly to the Committee. The Committee is responsible for oversight of the work of the independent auditor, including resolution
of disagreements between management and the independent auditor regarding financial reporting. In connection with its oversight responsibility,
the Committee shall consider the independent auditor's communications regarding, among other things, critical accounting policies
and practices, all alternative accounting treatments within GAAP related to items material to the financial statements that have been
discussed with management, including the ramifications of the alternative treatments and the treatment preferred by the independent auditor,
and all material written communications between the independent auditor and management, and shall review the effect or potential effect
of any regulatory regime, accounting initiatives or off-balance sheet structures on the Company's financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  ***Audit Oversight*** . The Committee shall establish
with the independent auditor an understanding of the terms of the audit engagement, the role of the auditor with respect to the Company's
financial statements and coordination of audit efforts to ensure completeness of coverage, reduction of redundant efforts, the effective
use of audit resources, and the use of accounting firms other than the appointed auditors of the Company. The Committee shall review
the scope of the annual audit or interim review (including the level of involvement with unaudited quarterly or other interim-period
information), and discuss the results, including, without limitation, the independent auditor's report and all matters required
to be communicated to the Committee by the independent auditor in accordance with applicable auditing standards.

The Committee shall discuss with the independent auditor, before the issuance of the audit report, the overall audit strategy, including the timing of the audit, significant risks the auditor identified and significant changes to the planned audit strategy or identified risks. The Committee shall review with the independent auditor any audit problems or difficulties encountered during the course of the audit work and management's response, including any restrictions on the scope of the independent auditor's activities or access to required records, data and information, any difficult or contentious matters for which the auditor consulted outside the engagement team (for example, the audit firm's national office), any significant disagreements with management, and any other matters arising from the audit that are significant to the oversight of the Company's financial reporting process.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  ***Auditor Rotation*** . The Committee shall consider
whether, in addition to assuring the regular rotation of the lead audit partner as required by law, in the interest of assuring continuing
independence of an independent auditor, the Company should regularly rotate the firm appointed as the Company's independent auditor.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)  ***Pre-Approval of Auditor Services*** . The Committee
is exclusively authorized and directed to consider and, in its discretion, approve in advance any services (including the fees and material
terms thereof) proposed to be carried out for the Company by the independent auditor or by any other firm proposed to be engaged by the
Company as its independent auditor. In connection with approval of any permissible tax services and services related to internal control
over financial reporting, the Committee shall discuss with the independent auditor the potential effects of such services on the independence
of the auditor.

**B.**  ***Financial Statements and Other Financial Disclosures*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  ***Quality and Integrity of Financial Statements*** .
The Committee shall review and discuss with management and the independent auditor: the critical accounting policies and practices used
by the Company, and any significant changes in the selection or application of the Company's accounting and auditing principles
and practices as suggested by the Company's independent auditor, internal auditors, if any, or management; the accounting treatment
to be applied in respect of significant new transactions or other significant events not in the ordinary course of the Company's
business; other policies and procedures adopted by the Company to fulfill its responsibilities regarding the presentation of financial
statements in accordance with GAAP and applicable rules and regulations of the SEC, including the proper explanation and reconciliation
of any non-GAAP measures presented; and any issues that arise with respect to the quality or integrity of the Company's financial
statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  ***Audited Financial Statements*** . The Committee
shall review and discuss with management and the independent auditor, before the issuance of the audit report, the financial statements
and related notes and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" proposed
to be included in the Company's Annual Report on Form 10-K. In this connection, the Committee shall review and discuss with management
and the independent auditor the analyses prepared by management setting forth significant financial reporting issues and judgments made
in connection with the preparation of the financial statements (including analyses of the effects of alternative GAAP methods on the
financial statements), and such other matters for which discussion shall be required by applicable auditing and related PCAOB standards.
The Committee shall make a recommendation to the Board as to whether such financial statements should be included in the Company's
Annual Report on Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  ***Audit Committee Report*** . The Committee shall
annually prepare an audit committee report for inclusion where necessary in the proxy statement relating to the annual meeting of shareholders
and/or annual report of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  ***Quarterly Financial Statements*** . The Committee
shall review and discuss with management and the independent auditor the quarterly financial statements and related notes and the "Management's
Discussion and Analysis of Financial Condition and Results of Operations" proposed to be included in the Company's Quarterly
Reports on Form 10-Q, together with the analyses prepared by management setting forth significant financial reporting issues and judgments
made in connection with the preparation of the financial statements, and such other matters for which discussion shall be required by
applicable auditing standards and related PCAOB standards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  ***Earnings Releases and Other Financial Information*** .
The Committee shall discuss with management and the independent auditor and, prior to issuance, review and approve the Company's
earnings releases, including the financial information, use of any "pro forma" or "adjusted" non-GAAP information,
and earnings guidance (if such is provided) to be disclosed in such releases. The Committee shall also discuss with management other
significant financial information to be provided to analysts or rating agencies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  ***Payments*** . The Committee shall review on a quarterly
basis all payments made to the Company's sponsor, officers or directors, or to the Company's or their affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)  ***Restatements*** . The Committee shall, after review
and discussion of any relevant analyses with management and the independent auditor, recommend whether any previously issued financial
statements covering one or more years or interim periods for which the registrant is required to provide financial statements under Regulation
S-X should no longer be relied upon because of an error in such financial statements as addressed in FASB ASC Topic 250, Accounting Changes
and Error Corrections, as may be modified, supplemented or succeeded financial statements are required to be restated.

**C.**  ***Controls and Procedures*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  ***Oversight*** . The Committee shall provide oversight
of management's design and maintenance of the Company's internal control over financial reporting and disclosure controls
and procedures. Prior to the filing of the Company's Annual Report on Form 10-K, the Committee shall review with the independent
auditor, management and the head of the internal audit function, if any: the Company's annual assessment and report and the independent
auditor's report on the effectiveness of the Company's internal control over financial reporting, to the extent then applicable;
any "material weakness" or "significant deficiency" in the design or operation of internal control over financial
reporting, any steps taken to resolve any such control deficiencies and the adequacy of disclosures about changes in internal control
over financial reporting; and any related significant findings and recommendations of the independent auditor or internal audit function,
if any, together with management's responses (including, in the case of the independent auditor, any concerns regarding matters
within the scope of, and compliance with, Section 10A of the Exchange Act).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  ***Certifications*** . The Committee shall review
and discuss with management and the independent auditor the certifications and any related disclosures made by the Company's Chief
Executive Officer and Chief Financial Officer in the Company's periodic reports about the results of their evaluation of the effectiveness
of disclosure controls and procedures and any significant deficiencies or material weaknesses in the design or operation of internal
control over financial reporting, and any fraud involving management or other employees who have a significant role in the Company's
internal control over financial reporting, prior to the filing of the Company's Annual Reports on Form 10-K and Quarterly Reports
on Form 10-Q.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  ***Internal Audit Function*** . At least annually,
the Committee shall review with the independent auditor the responsibilities, budget, staffing, effectiveness and performance of the
internal audit function, if any, including the structure, qualification and activities of the internal audit function and the scope of
internal audit responsibilities in relation to the independent auditor's duties. The Committee shall review and assess the annual
internal audit plan, if any, the process used to develop the plan, and the status of activities, significant findings, recommendations
and management's response. The Committee shall recommend for Board approval all matters related to responsibilities, budget and
staffing of the internal audit function, if any. The Committee shall recommend for Board approval the appointment and, if appropriate,
replacement of the senior internal audit executive.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  ***Hiring Policies*** . The Committee shall establish
clear policies regarding the hiring of employees and former employees of the Company's independent auditor.

**D.**  ***Risk Management, Compliance and Ethics*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  ***Risk Management*** . The Committee shall review
and discuss with management, the head of the internal audit function, if any, and the independent auditor any significant risks or exposures
and the Company's policies and processes with respect to risk assessment and risk management, and shall assess the steps management
has taken to monitor and control such risks, except with respect to those risks for which oversight has been assigned to other committees
of the Board or retained by the Board. The Committee shall review the Company's annual disclosures concerning the role of the Board
in the risk oversight of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  ***Legal and Regulatory Compliance*** . The Committee
shall review and assess with the Chairman, Co-Chairman or Co-Executive Chairman of the Board or outside counsel, as appropriate, legal
and regulatory matters that may have a material impact on the Company's financial statements or accounting policies. The Committee
shall also review and recommend for Board approval the code of ethics and any other appropriate compliance policies, and will review
requests for waivers under the code of ethics sought with respect to any executive officer or director. The Committee shall review annually
with the Chairman, Co-Chairman or Co-Executive Chairman of the Board or outside counsel, as appropriate, the scope, implementation and
effectiveness of the ethics and compliance program, and any significant deviations by officers and employees from the code of ethics
or other compliance policies, and other matters pertaining to the integrity of management.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  ***Procedures for Complaints*** . The Committee shall
establish "whistleblowing" procedures for (a) the receipt, retention and treatment of complaints received by the Company
regarding accounting, internal accounting controls or auditing matters and (b) the confidential, anonymous submission by the Company's
employees of concerns regarding questionable accounting or auditing matters. The Committee shall review any such significant complaints
or concerns.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  ***Review and Approval of Swap Transactions*** . The
Committee shall at least annually review and approve the Company's decision to enter into swaps and other derivative transactions
that are exempt from exchange-execution and clearance requirements under "end-user exception" regulations, and review and
discuss with management applicable Company policies governing the Company's use of swaps subject to the end-user exception.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  ***Related Person Transactions*** . The Committee
shall review and, if appropriate, approve or ratify any related person transactions and other significant conflicts of interest, in each
case in accordance with the Company's Code of Ethics and Related Party Transactions Policy.

**E.**  ***Self-Evaluation and Reporting*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  ***Self-Evaluation and Charter Review*** . The Committee
shall conduct an annual self-evaluation of the performance of the Committee, including its effectiveness and compliance with this charter,
and recommend to the Board such amendments of this charter as the Committee deems appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  ***Reporting*** . The Committee shall report regularly
to the Board on Committee findings and recommendations and any other matters the Committee deems appropriate or the Board requests, and
maintain minutes or other records of Committee meetings and activities.

The Committee shall undertake such other responsibilities or tasks as the Board may delegate or assign to the Committee from time to time.

## Exhibit 99.7

**Exhibit 99.7** 

**JATT II ACQUISITION CORP** 

**FORM OF COMPENSATION COMMITTEE CHARTER**

**Effective [●], 2026**

**I.**  **<u>Purposes</u>** 

The Compensation Committee (the "***Committee***") is appointed by the Board of Directors (the "***Board***") of JATT II Acquisition Corp (the "***Company***") to: (A) assist the Board in overseeing the Company's employee compensation policies and practices, including (i) determining and approving the compensation of the Company's Chief Executive Officer ("***CEO***") and the Company's other executive officers, and (ii) reviewing and approving incentive compensation and equity compensation policies and programs, and exercising discretion in the administration of such programs; and (B) produce the annual report of the Committee required by the rules of the U.S. Securities and Exchange Commission ("***SEC***").

**II.**  **<u>Committee Membership</u>** 

**A.**  ***Composition*** 

The Committee shall consist of two or more members of the Board. Except as otherwise directed by the Board, a director selected as a Committee member shall continue to be a member for as long as he or she remains a director or until his or her earlier resignation or removal from the Committee. Any member may be removed from the Committee by the Board, with or without cause, at any time. Any vacancy on the Committee shall be filled by a majority vote of the Board. No member of the Committee shall be removed except by majority vote of the Board.

**B.**  ***Chair*** 

The Chair of the Committee shall be appointed from among the Committee members by, and serve at the pleasure of, the Board, shall preside at meetings of the Committee and shall have authority to convene meetings, set agendas for meetings, and determine the Committee's information needs, except as otherwise provided by the Board or the Committee, provided that if the Board does not so designate a chairperson, the members of the Committee, by a majority vote, may designate a chairperson. In the absence of the Chair at a duly convened meeting, the Committee shall select a temporary substitute from among its members to serve as chair of the meeting.

**C.**  ***Independence*** 

Each member of the Committee shall be an "independent" director in accordance with the applicable listing standards of the Nasdaq Stock Market ("***Nasdaq***"), including standards specifically applicable to compensation committee members, subject to any exceptions or cure schedules that are applicable pursuant to the foregoing requirements and the phase-in periods permitted under the rules of Nasdaq under which the Committee is required to have only one independent member at the time of listing, a majority of independent members within 90 days of listing and all independent members within one year of listing. Any action duly taken by the Committee shall be valid and effective, whether or not the members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership provided herein.

**III.**  **<u>Authority</u>** 

In discharging its role, the Committee is empowered to inquire into any matter that it considers appropriate to carry out its responsibilities, with access to all books, records, facilities and personnel of the Company, and, subject to the direction of the Board, the Committee is authorized and delegated the authority to act on behalf of the Board with respect to any matter necessary or appropriate to the accomplishment of its purposes.

The Committee shall have the sole discretion to retain or obtain advice from, oversee and terminate any compensation consultant, legal counsel or other adviser to the Committee and be directly responsible for the appointment, compensation and oversight of any work of such adviser retained by the Committee, and the Company will provide appropriate funding (as determined by the Committee) for the payment of reasonable compensation to any such adviser.

**IV.**  **<u>Committee Meetings</u>** 

The Committee shall meet as often as necessary to carry out its responsibilities, which, following the Company's initial business combination, shall be at least quarterly.

The Committee shall establish its own schedule of meetings. The Committee may also act by unanimous written consent of its members.

Notice of meetings shall be given to all Committee members or may be waived, in the same manner as required for meetings of the Board. Meetings of the Committee may be held by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear and speak with each other. A majority of the members of the Committee shall constitute a quorum for a meeting and the affirmative vote of a majority of members present at a meeting at which a quorum is present shall constitute the action of the Committee. The Committee shall otherwise establish its own rules of procedure.

**V.**  **<u>Delegation</u>** 

The Committee, by resolution approved by a majority of the Committee, may form and delegate any of its responsibilities to a subcommittee so long as such subcommittee is solely comprised of one or more members of the Committee and such delegation is not otherwise inconsistent with law and applicable rules and regulations of the SEC and Nasdaq.

In addition, the Committee may, by resolution approved by a majority of the Committee, delegate to management the administration of the Company's incentive compensation and equity-based compensation plans, to the extent permitted by law and as may be permitted by such plans and subject to such rules, policies and guidelines (including limits on the aggregate awards that may be made pursuant to such delegation) as the Committee shall approve, provided that, consistent with Section VI below, the Committee shall determine and approve the awards made under such plan to any executive officer and any other member of senior management as the Committee shall designate and shall at least annually review the awards made to such other members of senior management as the Committee shall designate.

**VI.**  **<u>Key Responsibilities</u>** 

The following responsibilities are set forth as a guide for fulfilling the Committee's purposes in such manner as the Committee determines is appropriate:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) establish and review the objectives of the Company's
management compensation programs and its basic compensation policies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) review and approve corporate goals and objectives relevant
to the compensation of the CEO and other executive officers, including annual and long-term performance goals and objectives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) review and approve, subject to such further action of the
Board as the Board shall determine, any employment, compensation, benefit or severance agreement with any executive officer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) evaluate at least annually the performance of the CEO and
other executive officers against corporate goals and objectives including the annual performance objectives and, based on this evaluation,
determine and approve, subject to such further action of the Board as the Board shall determine, the compensation (including any awards
under any equity-based compensation or non-equity-based incentive compensation plan of the Company and any material perquisites) for
the executive officers based on this evaluation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) determine and approve the compensation level (including any
awards under any equity-based compensation or non-equity-based incentive compensation plan of the Company and any material perquisites)
for other members of senior management of the Company as the Committee or the Board may from time to time determine to be appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) review at least annually the compensation of other employees
as the Committee determines to be appropriate (including any awards under any equity-based compensation or non-equity-based incentive
compensation plan of the Company and any material perquisites);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) review on a periodic basis the Company's management
compensation programs, including any management incentive compensation plans as well as plans and policies pertaining to perquisites,
to determine whether they are appropriate, properly coordinated and achieve their intended purpose(s), and recommend to the Board any
appropriate modifications or new plans, programs or policies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) review, approve and recommend to the Board the adoption of
any equity-based compensation plan for employees of or consultants to the Company and any modification of any such plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) administer the Company's equity-based compensation
plans for employees of and consultants to the Company as provided by the terms of such plans, including authorizing all awards made pursuant
to such plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) review, approve and recommend to the Board the adoption of
any non-equity-based incentive compensation plan for employees of or consultants to the Company and any material modification of any
such plan and review at least annually the awards made pursuant to such plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) review, approve and recommend to the Board the adoption of
any employee retirement plan, and other material employee benefit plan, and any material modification of any such plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) review at least annually (a) the Company's compensation
policies and practices for executives, management employees and employees generally to assess whether such policies and practices could
lead to excessive risk taking behavior and (b) the manner in which any risks arising out of the Company's compensation policies
and practices are monitored and mitigated and adjustments necessary to address changes in the Company's risk profile;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) with respect to any compensation consultant who has been
engaged to make determinations or recommendations on the amount or form of executive or director compensation: (a) annually, or from
time to time as the Committee deems appropriate, assess whether the work of any such compensation consultant (whether retained by the
compensation committee or management) has raised any conflicts of interest; and (b) review the engagement and the nature of any additional
services provided by such compensation consultant to the Committee or to management, as well as all remuneration provided to such consultant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) annually, or from time to time as the Committee deems appropriate
and prior to retention of any advisers to the Committee, assess the independence of compensation consultants, legal and other advisers
to the Committee, taking into consideration all relevant factors the Committee deems appropriate to such adviser's independence,
including factors specified in the listing standards of Nasdaq;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) review and discuss with management the Compensation Discussion
and Analysis disclosure required by SEC regulations and determine whether to recommend to the Board, as part of a report of the Committee
to the Board, that such disclosure be included in the Company's Annual Report on Form 10-K and any proxy statement for the election
of directors; as part of this review, the Committee shall consider the results of the most recent shareholder advisory vote on executive
compensation ("say-on-pay" vote) required by Section 14A of the Exchange Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) at least every six years or more frequently as appropriate,
make a recommendation to the Board regarding the frequency with which the Company will conduct a say-on-pay vote;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) review the form and amount of director compensation at least
annually, and make recommendations thereon to the Board;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) oversee and monitor other compensation related policies and
practices of the Company, including: (i) the Company's share ownership guidelines for directors and executive officers; (ii) compliance
by management with rules regarding equity-based compensation plans for employees and consultants pursuant to the terms of such plans,
and the guidelines for issuance of awards as the Board or Committee may establish; (iii) the Company's recoupment policy and procedures;
and (iv) all special perquisites, special cash payments and other special compensation and benefit arrangements for the Company's
offers and employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) oversee shareholder communications relating to executive
compensation and review and make recommendations with respect to shareholder proposals related to compensation matters;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) conduct an annual self-evaluation of the performance of the
Committee, including its effectiveness and compliance with this charter, and recommend to the Board such amendments of this charter as
the Committee deems appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) report regularly to the Board on Committee findings and recommendations
and any other matters the Committee deems appropriate or the Board requests, and maintain minutes or other records of Committee meetings
and activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) from and after the completion of the Company's initial
business combination, in consultation with the CEO, annually report to the Board on succession planning, which shall include emergency
CEO succession, CEO succession in the ordinary course and succession for other members of senior management, working with the entire
Board to evaluate potential successors to the CEO; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) undertake such other responsibilities or tasks as the Board
may delegate or assign to the Committee from time to time.

## Exhibit 99.8

**Exhibit 99.8**

**JATT II ACQUISITION CORP** 

**FORM OF NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER**

**Effective [●], 2026**

**I.**  **<u>Introduction</u>** 

The Nominating and Corporate Governance Committee (the "***Committee***") is appointed by the Board of Directors (the "***Board***") of JATT II Acquisition Corp (the "***Company***") to: (i) identify and screen individuals qualified to serve as directors and recommend to the Board candidates for nomination for election at the annual meeting of shareholders or to fill Board vacancies; (ii) develop, recommend to the Board and review the Company's Corporate Governance Guidelines; (iii) coordinate and oversee the annual self-evaluation of the Board, its committees, individual directors and management in the governance of the Company; and (iv) review on a regular basis the overall corporate governance of the Company and recommend improvements for approval by the Board where appropriate.

**II.**  **<u>Committee Membership</u>** 

**A.** Composition

The Committee shall consist of two or more members of the Board. Except as otherwise directed by the Board, a director selected as a Committee member shall continue to be a member for as long as he or she remains a director or until his or her earlier resignation or removal from the Committee. Any member may be removed from the Committee by the Board, with or without cause, at any time.

**B.**  ***Chair*** 

The Chair of the Committee shall be appointed from among the Committee members by, and serve at the pleasure of, the Board, shall preside at meetings of the Committee and shall have authority to convene meetings, set agendas for meetings, and determine the Committee's information needs, except as otherwise provided by the Board or the Committee. In the absence of the Chair at a duly convened meeting, the Committee shall select a temporary substitute from among its members to serve as chair of the meeting. The Chair of the Committee shall serve as "Administrator" of the Company's Policy Regarding Insider Trading and Dissemination of Inside Information in the circumstances and to the extent described therein.

**C.**  ***Independence*** 

Each member of the Committee shall be an "independent" director in accordance with the applicable listing standards of Nasdaq ("***Nasdaq***") and the Company's Corporate Governance Guidelines, subject to any exceptions or cure periods that are applicable pursuant to the foregoing requirements and the phase-in periods permitted under the rules of Nasdaq under which the Committee is required to have only one independent member at the time of listing, a majority of independent members within 90 days of listing and all independent members within one year of listing. Any action duly taken by the Committee shall be valid and effective, whether or not the members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership provided herein.

**III.**  **<u>Authority</u>** 

In discharging its role, the Committee is empowered to inquire into any matter it considers appropriate to carry out its responsibilities, with access to all books, records, facilities and personnel of the Company, and, subject to the direction of the Board, the Committee is authorized and delegated the authority to act on behalf of the Board with respect to any matter necessary or appropriate to the accomplishment of its purposes.

The Committee shall have the sole discretion to retain or obtain advice from, oversee and terminate any director search or recruitment consultant, legal counsel or other adviser to the Committee and be directly responsible for the appointment, compensation and oversight of any work of such adviser retained by the Committee, and the Company will provide appropriate funding (as determined by the Committee) for the payment of reasonable compensation to any such adviser.

**IV.**  **<u>Committee Meetings</u>** 

The Committee shall meet as often as necessary to carry out its responsibilities, which, following the Company's initial business combination, shall be at least quarterly.

The Committee shall establish its own schedule of meetings. The Committee may also act by unanimous written consent of its members.

Notice of meetings shall be given to all Committee members or may be waived, in the same manner as required for meetings of the Board. Meetings of the Committee may be held by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear and speak with each other. A majority of the members of the Committee shall constitute a quorum for a meeting and the affirmative vote of a majority of members present at a meeting at which a quorum is present shall constitute the action of the Committee. The Committee shall otherwise establish its own rules of procedure.

**V.**  **<u>Delegation</u>** 

The Committee, by resolution approved by a majority of the Committee, may form and delegate any of its responsibilities to a subcommittee so long as such subcommittee is solely comprised of one or more members of the Committee and such delegation is not otherwise inconsistent with law and applicable rules and regulations of the U.S. Securities and Exchange Commission and Nasdaq.

**VI.**  **<u>Key Responsibilities</u>** 

The following responsibilities are set forth as a guide for fulfilling the Committee's purposes in such manner as the Committee determines is appropriate:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) recommend to the Board for approval, review the effectiveness
of, recommend modifications as appropriate to, and review Company disclosures concerning: (a) the Company's policies and procedures
for identifying and screening Board nominee candidates; (b) the process and criteria (including experience, qualifications, attributes,
diversity or skills in light of the Company's business and structure) used to evaluate Board membership and director independence;
and (c) any policies with regard to diversity on the Board;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) identify and screen director candidates (including incumbent
directors for potential renomination and candidates recommended by shareholders in accordance with the Company's policies as set
forth in its proxy statement) consistent with criteria approved by the Board, and recommend to the Board candidates for: (a) nomination
for election or re-election by the shareholders; and (b) any Board vacancies that are to be filled by the Board subject to any rights
regarding the selection of directors by holders of preferred stock and any other contractual or other commitments of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) oversee the Company's policies and procedures with respect
to the consideration of director candidates recommended by shareholders, including the submission of any proxy access nominees by shareholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) review Company disclosures concerning the specific experience,
qualifications, attributes or skills that led to the conclusion that each director and nominee should serve as a director in light of
the Company's business and structure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) review annually the relationships between directors, the Company
and members of management and recommend to the Board whether each director qualifies as "independent" under the Board's
definition of "independence" and the applicable rules of Nasdaq and the Company's Corporate Governance Guidelines;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) assess the appropriateness of a director continuing to serve
on the Board upon a substantial change in the director's principal occupation or business association from the position such director
held when originally invited to join the Board, and recommend to the Board any action to be taken with respect thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) assess annually whether the composition of the Board as a
whole reflects the appropriate balance of independence, sound judgment, business specialization, technical skills, diversity and other
desired qualities, and recommend any appropriate changes to the Board;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) (i) review the Board's leadership structure in light
of the specific characteristics or circumstances of the Company and recommend any changes to the Board for approval; (ii) discuss in
coordination with the Audit Committee the effect on the Board's leadership structure of the Board's role in the risk oversight
of the Company; and (iii) review and approve Company disclosures relating to Board leadership;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) review periodically the committee structure of the Board and
recommend to the Board the appointment of directors to Board committees and assignment of committee chairs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) review periodically the size of the Board and recommend to
the Board any appropriate changes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) coordinate with management to develop an appropriate director
orientation program and identify continuing education opportunities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) coordinate and oversee the annual self-evaluation of the role
and performance of the Board, its committees, individual directors and management in the governance of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) develop and recommend to the Board, review the effectiveness
of, and recommend modifications as appropriate to, the Corporate Governance Guidelines and other governance policies of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) review and address conflicts of interest of directors and
executive officers, and the manner in which any such conflicts are to be monitored;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) review on a periodic basis, and as necessary when specific
issues arise, relations with the Company's shareholders and advise the Board on effective and appropriate shareholder communications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) review emerging corporate governance issues and practices,
including proxy advisory firm policies and recommendations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) conduct an annual self-evaluation of the performance of the
Committee, including its effectiveness and compliance with this charter, and recommend to the Board such amendments of this charter as
the Committee deems appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) report regularly to the Board on Committee findings, recommendations
and any other matters the Committee deems appropriate or the Board requests, and maintain minutes or other records of Committee meetings
and activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) review all determinations and interpretations under the Company's
Policy Regarding Insider Trading and Dissemination of Inside Information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) undertake such other responsibilities as the Board may delegate
or assign to the Committee from time to time.

\*\*\*\*\*